

IW 7545714

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

**UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office**

September 09, 2015

**THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF THE FILE WRAPPER AND CONTENTS
OF:**

APPLICATION NUMBER: 08/416,673

FILING DATE: April 07, 1995

PATENT NUMBER: 5,665,772

ISSUE DATE: September 09, 1997

**By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office**




M. Tarver
M. TARVER
Certifying Officer

Replaced by Article 34
 Reclon or April 1995

CLAIMS

1. A compound of Formula I



(I)

X is (H,H) or O;

Y is (H,OH) or O;

R¹ and R² are independently selected from

H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl,
 hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl,
 aminoalkyl, alkylaminoalkyl, alkoxy-carbonylaminoalkyl, acylaminoalkyl,

arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, caralkoxyalkyl, and $(R^3)_3Si$ where each R^3 is independently selected from H, methyl, ethyl, isopropyl, *t*-butyl, and phenyl; wherein "alk-" or "alkyl" refers to C_{1-6} alkyl, branched or linear, preferably C_{1-3} alkyl, in which the carbon chain may be optionally interrupted by an ether (-O-) linkage; and

R^4 is methyl or R^4 and R^1 together form C_{2-6} alkylene;

provided that R^1 and R^2 are not both H; and

provided that where R^1 is carbalkoxyalkyl or $(R^3)_3Si$, X and Y are not both O.

2. Compounds according to claim 1 selected from the following:

1. 40-O-Benzyl-rapamycin
2. 40-O-(4'-Hydroxymethyl)benzyl-rapamycin
3. 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin
4. 40-O-Allyl-rapamycin
5. 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin
6. (2'E, 4'S)-40-O-(4',5'-Dihydroxypent-2'-en-1'-yl)-rapamycin
7. 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin
8. 40-O-(2-Hydroxy)ethyl-rapamycin
9. 40-O-(3-Hydroxy)propyl-rapamycin
10. 40-O-(6-Hydroxy)hexyl-rapamycin
11. 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin
12. 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin
13. 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin
14. 40-O-(2-Acetoxy)ethyl-rapamycin
15. 40-O-(2-Nicotinoyloxy)ethyl-rapamycin
16. 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin

- 39 -

17. 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin
 18. 40-O-[2-(N-Methyl-N'-piperaziny)acetoxy]ethyl-rapamycin
 19. 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin
 20. (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin
 21. 28-O-Methyl-rapamycin
 22. 40-O-(2-Aminoethyl)-rapamycin
 23. 40-O-(2-Acetaminoethyl)-rapamycin
 24. 40-O-(2-Nicotinamidoethyl)-rapamycin
 25. 40-O-(2-(N-Methyl-imidazo-2'-ylcarbethoxamido)ethyl)-rapamycin
 26. 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin
 27. 40-O-(2-Tolylsulfonamidoethyl)-rapamycin
 28. 40-O-[2-(4',5'-Dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin
3. Compounds according to claim 1 where X and Y are both O, R² is H, R⁴ is methyl, and R¹ is other than H.
 4. 40-O-(2-Hydroxy)ethyl-rapamycin.
 5. Compounds according to any one of claims 1 through 4 obtained or obtainable by (i) reacting a rapamycin, deoxorapamycin, or dihydrorapamycin (optionally in O-protected form) with an organic radical attached to a leaving group under suitable acidic or neutral reaction conditions, and (ii) optionally reducing the product..
 6. A compound according to any one of claims 1-5 for use as a pharmaceutical.
 7. A pharmaceutical composition comprising a compound according to any one of claims 1-5 together with a pharmaceutically acceptable diluent or carrier.
 8. Use of a compound according to claims 1-5 in the manufacture of a medicament for

- 40 -

treating or preventing any of the following conditions:

- Replaced by Article 34*
- (i) autoimmune disease,
 - (ii) allograft rejection,
 - (iii) graft vs. host disease,
 - (iv) asthma,
 - (v) multidrug resistance,
 - (vi) tumors or hyperproliferative disorders, or
 - (vii) fungal infections,
 - (viii) inflammation,
 - (ix) infection by pathogens having Mip or Mip-like factors, or
 - (x) ~~overdose of macrophilin binding immunosuppressants.~~

9. Novel products, processes, and utilities substantially as described herein.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 498/18, C07F 7/18 A61K 31/435 // C07D 498/18 C07D 311:00, 273:00, 221:00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/09010 (43) International Publication Date: 28 April 1994 (28.04.94)</p>
<p>(21) International Application Number: PCT/EP93/02604 (22) International Filing Date: 24 September 1993 (24.09.93) (30) Priority data: 9221220.8 9 October 1992 (09.10.92) GB (71) Applicant (for AT only): SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT). (71) Applicant (for DE only): SANDOZ-PATENT-GMBH [DE/ DE]; Humboldtstrasse 3, D-79539 Lörrach (DE). (71) Applicant (for all designated States except AT DE US): SAN- DOZ LTD. [CH/CH]; Lichtstrasse 35, CH-4002 Basle (CH).</p>	<p>(72) Inventors; and (75) Inventors/Applicants (for US only) : COTTENS, Sylvain [CH/CH]; In den Reben 12, CH-4108 Witterswil (CH). SEDRANI, Richard [LU/CH]; Herrengrabenweg 15, CH-4054 Basle (CH). (74) Common Representative: SANDOZ LTD.; Patents & Trademarks Div., Lichtstrasse 35, CH-4002 Basle (CH). (81) Designated States: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RO, RU, SK, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.</p>	

(54) Title: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

(57) Abstract

Novel O-alkylated derivatives of rapamycin of formula (I), especially 40-O-alkylated derivatives, are found to have pharmaceutical utility, particularly as immunosuppressants.



**DECLARATION AND POWER OF ATTORNEY
FOR UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and

I believe that I am the original, first and sole inventor (if only one name is listed below)
or an original, first and joint inventor (if more than one name is listed below) of the subject
matter which is claimed and for which a United States patent is sought on the invention
entitled

O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY
AS IMMUNOSUPPRESSANTS

the specification of which

is attached hereto.

was filed on _____ 19 ____ as application Serial No. 0/

and, if these brackets contain an X , was amended on _____ 19 ____

was filed as Patent Cooperation Treaty international application No. PCT/EP93/02604

on September 24 _____, 19 93 ____, if these brackets contain an X , was
amended under Patent Cooperation Treaty Article 19 on _____, 19 ____

and, if these brackets contain an X , was amended on _____, 19 ____

entered the national stage in the United States and was accorded Serial No.

on _____, 19 ____, and if these brackets contain an X

was amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified
specification including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose all information which is known by me to be material
to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim the benefit under Title 35, United States Code, §119 of any foreign
application(s) for patent or inventor's certificate indicated below and of any Patent
Cooperation Treaty international application(s) designating at least one country other than the
United States indicated below and have also identified any foreign application(s) for

patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

<u>Country:</u>	<u>Number:</u>	<u>Filing Date:</u>	<u>Priority Claimed:</u>
<u>Great Britain</u>	<u>9221220.8</u>	<u>October 9, 1992</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and of any Patent Cooperation Treaty international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

<u>Application</u>	<u>Status (Pending,</u>
<u>Serial No.</u>	<u>Abandoned, Patented)</u>
<u>none</u>	_____
_____	_____
_____	_____
_____	_____

I hereby appoint the following:

ROBERT S. HONOR
THOMAS O. MCGOVERN
MELVYN M. KASSENOFF
JOSEPH J. BOROVIAN
DIANE E. FURMAN
CARL W. BATTLE
ANDREW N. PARFOMAK
JOHN L. CHIATALAS
CAROL A. LOESCHORN
MICHAEL P. MORRIS
THOMAS C. DOYLE

Reg. No. 22,801
Reg. No. 25,741
Reg. No. 26,389
Reg. No. 26,631
Reg. No. 31,104
Reg. No. 30,731
Reg. No. 32,431
Reg. No. 31,818
Reg. No. 35,590
Reg. No. 34,513
Reg. No. 22,340 //

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademarks Office connected therewith. Please address all communications to ROBERT S. HONOR, SANDOZ CORPORATION, 59 Route 10, East Hanover, New Jersey 07936-1080, whose telephone number is 201-503-8485.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statement may jeopardize the validity of the application or any patent issuing thereon.

Sole inventor or first joint inventor:

Full name : Sylvain Cottens 1-00
Signature : *Sylvain Cottens*
Date : March 13, 1995
Citizenship : Switzerland
Residence : In den Reben 12, CH-4108 Witterswil,
Switzerland CHX
P.O. Address: same as above

IMPORTANT: Before this declaration is signed, the patent application (the specificateion, the claims and this declarations) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Second joint inventor,
if any:

Full name : Richard Sedrani 2-00
Signature : Richard Sedrani
Date : March 13 1935
Citizenship : Luxembourg
Residence : Herrenggrabenweg 15, CH-4054 Basle,
Switzerland CHX
P.O. Address : same as above

Third joint inventor,
if any:

Full name : _____
Signature : _____
Date : _____
Citizenship : _____
Residence : _____
P.O. Address: _____

Fourth joint inventor,
if any:

Full name : _____
Signature : _____
Date : _____
Citizenship : _____
Residence : _____
P.O. Address: _____

Fifth joint inventor
if any:

Full name : _____
Signature : _____
Date : _____
Citizenship : _____
Residence : _____
P.O. Address: _____

DO/EO BIBLIOGRAPHIC DATA ENTRY

SERIAL NUMBER: 08 / 416673 RECEIPT DATE: 04 / 07 / 95
IA NUMBER: PCT/ EP93 / 02604 IA FILING DATE: 09 / 24 / 93
FAMILY NAME: COTTENS DELAY WAIVED (Y/N): N
GIVEN NAME: SYLVAIN DEMAND RECEIVED (Y/N): Y
PRIORITY CLAIMED (Y/N): Y PRIORITY DATE: 10 / 09 / 92
NO BASIC FEE (Y/N): N US DESIGNATED ONLY (Y/N): N
ATTORNEY DOCKET NUMBER: 100-7932/PCT COUNTRY: EPX
CORRESPONDENTS NAME/ADDRESS:
ROBERT S. HONOR
SANDOZ PATENT DEPT
59 ROUTE 10
E. HANOVER, N.J. 07936-1080

APPLICATION TITLES:
O-ALKLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS
IMMUNOSUPPRESSANTS

OK TO UPDATE? (Y OR N) Y

BAR CODE LABEL



U.S. PATENT APPLICATION

SERIAL NUMBER

08/416,673

FILING DATE

04/07/95

CLASS

514

GROUP ART UNIT

1205

APPLICANT

SYLVAIN COTTENS, WITERSWIL, SWITZERLAND; RICHARD SEDRANI, BASLE, SWITZERLAND.

****CONTINUING DATA*******

VERIFIED THIS APPLN IS A 371 OF PCT/EP93/02604 09/24/93

****FOREIGN/PCT APPLICATIONS*******

VERIFIED GREAT BRITAIN 9221220.8 10/09/92

STATE DR
COUNTRY

CHX

SHEETS
DRAWING

0

TOTAL
CLAIMS

8

INDEPENDENT
CLAIMS

1

FILING FEE
RECEIVED

\$1,090.00

ATTORNEY DOCKET NO.

100-7932/PCT

ADDRESS

ROBERT S HONOR
SANDOZ CORPORATION
59 ROUTE 10
EAST HANOVER NJ 07936-1080

TITLE

O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

This is to certify that annexed hereto is a true copy from the records of the United States Patent and Trademark Office of the application which is identified above.

By authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

Date

Certifying Officer

PATENT APPLICATION SERIAL NO. 08/416673

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

MS19049 04/12/95 08416673
19039 05/22/95 08416673
19040 05/22/95 08416673

19-0134 190 960
19-0134 190 960
19-0134 190 970

980.00CH
980.00CR
980.00CH

OK Refund
\$ 130.00 Rg

SE18086 05/30/95 08416673

19-0134 180 970

130.00CR

MS19046 10/23/95 08416673

19-0134 190 968

110.00CH

PTO-1556
(5/87)

PATENT APPLICATION DETERMINATION RECORD

Effective October 1, 1994

Application or Docket Number

100-7932/FEI

CLAIMS AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA
BASIC FEE		
TOTAL CLAIMS	21 // minus 20 = *	
INDEPENDENT CLAIMS		minus 3 = *
MULTIPLE DEPENDENT CLAIM PRESENT y		

* If the difference in column 1 is less than zero, enter "0" in column 2

SMALL ENTITY

OTHER THAN SMALL ENTITY

RATE	FEE
	365.00
x\$11=	
x38=	
+120=	
TOTAL	

RATE	FEE
	850
	730.00
x\$22=	
x76=	
+240=	240
TOTAL	850

CLAIMS AS AMENDED - PART II

AMENDMENT A	(Column 1)	(Column 2)	(Column 3)	(Column 4)	(Column 5)
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	*	Minus	**	=	
Independent	*	Minus	***	=	
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM					

SMALL ENTITY

OTHER THAN SMALL ENTITY

RATE	ADDITIONAL FEE
x\$11=	
x38=	
+120=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
x\$22=	
x76=	
+240=	
TOTAL ADDIT. FEE	

AMENDMENT B	(Column 1)	(Column 2)	(Column 3)	(Column 4)	(Column 5)
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	*	Minus	**	=	
Independent	*	Minus	***	=	
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM					

RATE	ADDITIONAL FEE
x\$11=	
x38=	
+120=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
x\$22=	
x76=	
+240=	
TOTAL ADDIT. FEE	

AMENDMENT C	(Column 1)	(Column 2)	(Column 3)	(Column 4)	(Column 5)
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	*	Minus	**	=	
Independent	*	Minus	***	=	
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM					

RATE	ADDITIONAL FEE
x\$11=	
x38=	
+120=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
x\$22=	
x76=	
+240=	
TOTAL ADDIT. FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20."
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3."
 The Highest Number Previously Paid For (Total or Independent) is the highest number found in the appropriate box in column 1.


*Insert
 A1
 A1*

O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNO-SUPPRESSANTS

This invention comprises novel alkylated derivatives of rapamycin having pharmaceutical utility, especially as immunosuppressants.

Rapamycin is a known macrolide antibiotic produced by Streptomyces hygroscopicus, having the structure depicted in Formula A:

70020x




See, e.g., McAlpine, J.B., et al., J. Antibiotics (1991) 44: 688; Schreiber, S.L., et al., J. Am. Chem. Soc. (1991) 113: 7433; US Patent No. 3 929 992. Rapamycin is an extremely

potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable bioavailability as well as its high toxicity. Moreover, rapamycin is highly insoluble, making it difficult to formulate stable galenic compositions.

It has now surprisingly been discovered that certain novel derivatives of rapamycin (the Novel Compounds) have an improved pharmacologic profile over rapamycin, exhibit greater stability and bioavailability, and allow for greater ease in producing galenic formulations. The Novel Compounds are alkylated derivatives of rapamycin having the structure of Formula I:

70030X



wherein

3

-3-

X is (H,H) or O;

Y is (H,OH) or O;

R¹ and R² are independently selected from

H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxy-carbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, carbalkoxyalkyl, and (R³)₃Si where each R³ is independently selected from H, methyl, ethyl, isopropyl, i-butyl, and phenyl; wherein "alk-" or "alkyl" refers to C₁₋₆ alkyl, branched or linear preferably C₁₋₃ alkyl, in which the carbon chain may be optionally interrupted by an ether (-O-) linkage; and

R⁴ is methyl, or R⁴ and R¹ together form C₂₋₆ alkylene;

provided that R¹ and R² are not both H; and

provided that where R¹ is (R³)₃Si or carbalkoxyalkyl, X and Y are not both O.

Preferred Novel Compounds include the following:

1. 40-O-Benzyl-rapamycin
2. 40-O-(4'-Hydroxymethyl)benzyl-rapamycin
3. 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin
4. 40-O-Allyl-rapamycin
5. 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin
6. (2'E, 4'S)-40-O-(4',5'-Dihydroxypent-2'-en-1'-yl)-rapamycin
7. 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin
8. 40-O-(2-Hydroxy)ethyl-rapamycin

- 4 -

9. 40-O-(3-Hydroxy)propyl-rapamycin
10. 40-O-(6-Hydroxy)hexyl-rapamycin
11. 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin
12. 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin
13. 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin
14. 40-O-(2-Acetoxy)ethyl-rapamycin
15. 40-O-(2-Nicotinoyloxy)ethyl-rapamycin
16. 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin
17. 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin
18. 40-O-[2-(N-Methyl-N'-piperazinyloxy)acetoxy]ethyl-rapamycin
19. 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin
20. (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin
21. 28-O-Methyl-rapamycin
22. 40-O-(2-Aminoethyl)-rapamycin
23. 40-O-(2-Acetaminoethyl)-rapamycin
24. 40-O-(2-Nicotinamidoethyl)-rapamycin
25. 40-O-(2-(N-Methyl-imidazo-2'-ylcarbathoxamido)ethyl)-rapamycin
26. 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin
27. 40-O-(2-Tolylsulfonamidoethyl)-rapamycin
28. 40-O-[2-(4',5'-Dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin

The Novel Compounds for immunosuppressive use are preferably the 40-O-substituted rapamycins where X and Y are both O, R² is H, R⁴ is methyl, and R¹ is other than H; most preferably where R¹ is selected from hydroxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl, and aminoalkyl; especially 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-(2-acetaminoethyl)-rapamycin).

Preferably, O-substitution at C40 or O,O-disubstitution at C28 and C40 is performed

- 5 -

according to the following general process: Rapamycin (or dihydro or deoxorapamycin) is reacted with an organic radical attached to a leaving group (e.g., RX where R is the organic radical, e.g., an alkyl, allyl, or benzyl moiety, which is desired as the O-substituent, and X is the leaving group, e.g., $\text{CCl}_3\text{C}(\text{NH})\text{O}$ or CF_3SO_3) under suitable reaction conditions, preferably acidic or neutral conditions, e.g., in the presence of an acid like trifluoromethanesulfonic acid, camphorsulfonic acid, p-toluenesulfonic acid or their respective pyridinium or substituted pyridinium salts when X is $\text{CCl}_3\text{C}(\text{NH})\text{O}$ or in the presence of a base like pyridine, a substituted pyridine, diisopropylethylamine or pentamethylpiperidine when X is CF_3SO_3 . O-substitutions at C28 only are accomplished in the same manner, but with prior protection at C40. Further modifications are possible. For example, where the substituent is allyl, the isolated, monosubstituted double bond of the allyl moiety is highly amenable to further modification.

The 9-deoxorapamycin compounds are preferably produced by reducing a rapamycin using hydrogen sulfide, by reacting rapamycin with diphenyldiselenide and tributylphosphine or by other suitable reduction reaction.

The 26-dihydro-rapamycins are preferably produced by reducing rapamycins or 9-deoxorapamycins from keto to hydroxy at C26 by a mild reduction reaction, such as a borohydride reduction reaction.

The Novel Compounds are particularly useful for the following conditions:

- a) Treatment and prevention of organ or tissue transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants. They are also indicated for the prevention of graft-versus-host disease, such as following bone marrow transplantation.
- b) Treatment and prevention of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an etiology including an autoimmune

6

- 6 -

component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases. Specific autoimmune diseases for which the compounds of the invention may be employed include, autoimmune hematological disorders (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis and Crohn's disease) endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy) and juvenile dermatomyositis.

- c) Treatment and prevention of asthma.
- d) Treatment of multi-drug resistance (MDR). The Novel Compounds suppress P-glycoproteins (Pgp), which are the membrane transport molecules associated with MDR. MDR is particularly problematic in cancer patients and AIDS patients who will not respond to conventional chemotherapy because the medication is pumped out of the cells by Pgp. The Novel Compounds are therefore useful for enhancing the efficacy of other chemotherapeutic agents in the treatment and control of multidrug resistant conditions such as multidrug resistant cancer or multidrug resistant AIDS.
- e) Treatment of proliferative disorders, e.g. tumors, hyperproliferative skin disorder and the like.
- f) Treatment of fungal infections.
- g) Treatment and prevention of inflammation, especially in potentiating the action of steroids.
- h) Treatment and prevention of infection, especially infection by pathogens having Mip or Mip-like factors.
- i) Treatment of overdoses of FK-506, rapamycin, immunosuppressive Novel

- 7 -

Compounds, and other macrophilin binding immunosuppressants.

The invention thus provides the Novel Compounds described herein, for use as novel intermediates or as pharmaceuticals, methods of treating or preventing the above-described disorders by administering an effective amount of a Novel Compound to a patient in need thereof, use of a Novel Compound in the manufacture of a medicament for treatment or prevention of the above-described disorders, and pharmaceutical compositions comprising a Novel Compound in combination or association with a pharmaceutically acceptable diluent or carrier.

Most of the Novel Compounds described herein are highly immunosuppressive, especially those Novel Compounds which are O-substituted at C40, and these Novel Compounds are particularly useful in indications a and b, but not in indication i. Those of the Novel Compounds which are less immunosuppressive, especially those which are O-substituted at C28 only, are particularly useful in indications h and i, but are less preferred in indications a or b.

The Novel Compounds are utilized by administration of a pharmaceutically effective dose in pharmaceutically acceptable form to a subject in need of treatment. Appropriate dosages of the Novel Compounds will of course vary, e.g. depending on the condition to be treated (for example the disease type or the nature of resistance), the effect desired and the mode of administration.

In general however satisfactory results are obtained on administration orally at dosages on the order of from 0.05 to 5 or up to 10mg/kg/day, e.g. on the order of from 0.1 to 2 or up to 7.5 mg/kg/day administered once or, in divided doses 2 to 4x per day, or on administration parenterally, e.g. intravenously, for example by i.v. drip or infusion, at dosages on the order of from 0.01 to 2.5 up to 5 mg/kg/day, e.g. on the order of from 0.05 or 0.1 up to 1.0 mg/kg/day. Suitable daily dosages for patients are thus on the order of 500

- 8 -

mg p.o., e.g. on the order of from 5 to 100 mg p.o., or on the order of from 0.5 to 125 up to 250 mg i.v., e.g. on the order of from 2.5 to 50 mg i.v..

Alternatively and even preferably, dosaging is arranged in patient specific manner to provide pre-determined trough blood levels, e.g. as determined by RIA technique. Thus patient dosaging may be adjusted so as to achieve regular on-going trough blood levels as measured by RIA on the order of from 50 or 150 up to 500 or 1000ng/ml, i.e. analogously to methods of dosaging currently employed for Ciclosporin immunosuppressive therapy.

The Novel Compounds may be administered as the sole active ingredient or together with other drugs. For example, in immunosuppressive applications such as prevention and treatment of graft vs. host disease, transplant rejection, or autoimmune disease, the Novel Compounds may be used in combination with Ciclosporin, FK-506, or their immunosuppressive derivatives; corticosteroids; azathioprene; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to CD3, CD4, CD25, CD28, or CD45; and/or other immunomodulatory compounds. For anti-inflammatory applications, the Novel Compounds can be used together with anti-inflammatory agents, e.g., corticosteroids. For anti-infective applications, the Novel Compounds can be used in combination with other anti-infective agents, e.g., anti-viral drugs or antibiotics.

The Novel Compounds are administered by any conventional route, in particular enterally, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectable solutions or suspensions. Suitable unit dosage forms for oral administration comprise, e.g. from 1 to 50 mg of a compound of the invention, usually 1 to 10 mg. Pharmaceutical compositions comprising the novel compounds may be prepared analogously to pharmaceutical compositions comprising rapamycin, e.g., as described in EPA 0 041 795, which would be evident to one skilled in the art.

9

The pharmacological activity of the Novel Compounds are demonstrated in, e.g., the following tests:

1. Mixed lymphocyte reaction (MLR)

The Mixed Lymphocyte Reaction was originally developed in connection with allografts, to assess the tissue compatibility between potential organ donors and recipients, and is one of the best established models of immune reaction in vitro. A murine model MLR, e.g., as described by T.Meo in "Immunological Methods", L. Lefkovits and B. Peris, Eds., Academic Press, N.Y. pp. 227-239 (1979), is used to demonstrate the immunosuppressive effect of the Novel Compounds. Spleen cells (0.5×10^6) from Balb/c mice (female, 8-10 weeks) are co-incubated for 5 days with 0.5×10^6 irradiated (2000 rads) or mitomycin C treated spleen cells from CBA mice (female, 8-10 weeks). The irradiated allogeneic cells induce a proliferative response in the Balb/c spleen cells which can be measured by labeled precursor incorporation into the DNA. Since the stimulator cells are irradiated (or mitomycin C treated) they do not respond to the Balb/c cells with proliferation but do retain their antigenicity. The antiproliferative effect of the Novel Compounds on the Balb/c cells is measured at various dilutions and the concentration resulting in 50% inhibition of cell proliferation (IC_{50}) is calculated. The inhibitory capacity of the test sample may be compared to rapamycin and expressed as a relative IC_{50} (i.e. IC_{50} test sample/ IC_{50} rapamycin).

2. IL-6 mediated proliferation

The capacity of the Novel Compounds to interfere with growth factor associated signalling pathways is assessed using an interleukin-6 (IL-6)-dependent mouse hybridoma cell line. The assay is performed in 96-well microtiter plates. 5000 cells/well are cultivated in serum-free medium (as described by M. H. Schreier and R. Tees in Immunological Methods, I. Lefkovits and B. Pernis, eds., Academic Press 1981, Vol. II, pp. 263-275), supplemented with 1 ng recombinant IL-6/ml. Following a 66 hour incubation in the absence or presence of a test sample, cells are pulsed with 1 μ Ci (3-H)-thymidine/well for

- 10 -

another 6 hours, harvested and counted by liquid scintillation. (3-H)-thymidine incorporation into DNA correlates with the increase in cell number and is thus a measure of cell proliferation. A dilution series of the test sample allows the calculation of the concentration resulting in 50% inhibition of cell proliferation (IC_{50}). The inhibitory capacity of the test sample may be compared to rapamycin and expressed as a relative IC_{50} (i.e. IC_{50} test sample/ IC_{50} rapamycin).

3. Macrophilin binding assay

Rapamycin and the structurally related immunosuppressant, FK-506, are both known to bind in vivo to macrophilin-12 (also known as FK-506 binding protein or FKBP-12), and this binding is thought to be related to the immunosuppressive activity of these compounds. The Novel Compounds also bind strongly to macrophilin-12, as is demonstrated in a competitive binding assay.

In this assay, FK-506 coupled to BSA is used to coat microtiter wells. Biotinylated recombinant human macrophilin-12 (biot-MAP) is allowed to bind in the presence or absence of a test sample to the immobilized FK-506. After washing (to remove non-specifically bound macrophilin), bound biot-MAP is assessed by incubation with a streptavidin-alkaline phosphatase conjugate, followed by washing and subsequent addition of p-nitrophenyl phosphate as a substrate. The read-out is the OD at 405nm. Binding of a test sample to biot-MAP results in a decrease in the amount of biot-MAP bound to the FK-506 and thus in a decrease in the OD405. A dilution series of the test sample allows determination of the concentration resulting in 50% inhibition of the biot-MAP binding to the immobilized FK-506 (IC_{50}). The inhibitory capacity of a test sample is compared to the IC_{50} of free FK-506 as a standard and expressed as a relative IC_{50} (i.e., IC_{50} -test sample/ IC_{50} -free FK-506).

4. Localized Graft-Versus-Host (GvH) Reaction

In vivo efficacy of the Novel Compounds is proved in a suitable animal model, as

- 11 -

described, e.g., in Ford et al, TRANSPLANTATION 10 (1970) 258. Spleen cells (1×10^7) from 6 week old female Wistar/Furth (WF) rats are injected subcutaneously on day 0 into the left hind-paw of female (F344 x WF) F_1 rats weighing about 100g. Animals are treated for 4 consecutive days and the popliteal lymph nodes are removed and weighed on day 7. The difference in weight between the two lymph nodes is taken as the parameter for evaluating the reaction.

5. Kidney Allograft Reaction in Rat

One kidney from a female fisher 344 rat is transplanted onto the renal vessel of a unilaterally (left side) nephrectomized WF recipient rat using an end-to-end anastomosis. Ureteric anastomosis is also end-to-end. Treatment commences on the day of transplantation and is continued for 14 days. A contralateral nephrectomy is done seven days after transplantation, leaving the recipient relying on the performance of the donor kidney. Survival of the graft recipient is taken as the parameter for a functional graft.

6. Experimentally Induced Allergic Encephalomyelitis (EAE) in Rats

Efficacy of the Novel Compounds in EAE is measured, e.g., by the procedure described in Levine & Wenk, AMER J PATH 47 (1965) 61; McFarlin et al, J IMMUNOL 113 (1974) 712; Borel, TRANSPLANT. & CLIN. IMMUNOL 13 (1981) 3. EAE is a widely accepted model for multiple sclerosis. Male Wistar rats are injected in the hind paws with a mixture of bovine spinal cord and complete Freund's adjuvant. Symptoms of the disease (paralysis of the tail and both hind legs) usually develop within 16 days. The number of diseased animals as well as the time of onset of the disease are recorded.

7. Freund's Adjuvant Arthritis

Efficacy against experimentally induced arthritis is shown using the procedure described, e.g., in Winter & Nuss, ARTHRITIS & RHEUMATISM 9 (1966) 394; Billingham & Davies, HANDBOOK OF EXPERIMENTAL PHARMACOL (Vane & Ferreira Eds, Springer-Verlag, Berlin) 50/II (1979) 108-144. OFA and Wistar rats (male or

12

- 12 -

female, 150g body weight) are injected i.c. at the base of the tail or in the hind paw with 0.1 ml of mineral oil containing 0.6 mg of lyophilized heat-killed *Mycobacterium smegmatis*. In the developing arthritis model, treatment is started immediately after the injection of the adjuvant (days 1 - 18); in the established arthritis model treatment is started on day 14, when the secondary inflammation is well developed (days 14-20). At the end of the experiment, the swelling of the joints is measured by means of a micro-caliper. ED₅₀ is the oral dose in mg/kg which reduces the swelling (primary or secondary) to half of that of the controls.

8. Antitumor and MDR activity

The antitumor activity of the Novel Compounds and their ability to enhance the performance of antitumor agents by alleviating multidrug resistance is demonstrated, e.g., by administration of an anticancer agent, e.g., colchicine or etoposide, to multidrug resistant cells and drug sensitive cells in vitro or to animals having multidrug resistant or drug sensitive tumors or infections, with and without co-administration of the Novel Compounds to be tested, and by administration of the Novel Compound alone.

Such in vitro testing is performed employing any appropriate drug resistant cell line and control (parental) cell line, generated, e.g. as described by Ling et al., *J. Cell. Physiol.* 83, 103-116 (1974) and Bech-Hansen et al. *J. Cell. Physiol.* 88, 23-32 (1976). Particular clones chosen are the multi-drug resistant (e.g. colchicine resistant) line CHR (subclone C5S3.2) and the parental, sensitive line AUX B1 (subclone AB1 S11).

In vivo anti-tumor and anti-MDR activity is shown, e.g., in mice injected with multidrug resistant and drug sensitive cancer cells. Ehrlich ascites carcinoma (EA) sub-lines resistant to drug substance DR, VC, AM, ET, TE or CC are developed by sequential transfer of EA cells to subsequent generations of BALB/c host mice in accordance with the methods described by Slater et al., *J. Clin. Invest.*, 70, 1131 (1982).

13

- 13 -

Equivalent results may be obtained employing the Novel Compounds test models of comparable design, e.g. *in vitro*, or employing test animals infected with drug-resistant and drug sensitive viral strains, antibiotic (e.g. penicillin) resistant and sensitive bacterial strains, anti-mycotic resistant and sensitive fungal strains as well as drug resistant protozoal strains, e.g. Plasmodial strains, for example naturally occurring sub-strains of *Plasmodium falciparum* exhibiting acquired chemotherapeutic, anti-malarial drug resistance.

9. FKBP binding

Certain of the Novel Compounds are not immunosuppressive, particularly those which are O-substituted at C28 only, such as 28-O-methyl-rapamycin. This can be shown in standard *in vitro* assays in comparison to FK506 and rapamycin. FK506, for example, is known to be a potent inhibitor of IL-2 transcription, as can be shown in an IL-2 reporter gene assay. Rapamycin, although not active in the IL-2 reporter gene assay, strongly inhibits IL-6 dependent T-cell proliferation. Both compounds are very potent inhibitors of the mixed lymphocyte reaction. Nonimmunosuppressivity can also be shown in the *in vivo* models 1-7 above. Even those Novel Compounds which are not immunosuppressive, however, bind to macrophilin, which confers certain utilities in which nonimmunosuppressivity is an advantage.

Those of the Novel Compounds which bind strongly to macrophilin and are not themselves immunosuppressive can be used in the treatment of overdoses of macrophilin-binding immunosuppressants, such as FK506, rapamycin, and the immunosuppressive Novel Compounds.

10. Steroid potentiation

The macrophilin binding activity of the Novel Compounds also makes them useful in enhancing or potentiating the action of corticosteroids. Combined treatment with the compounds of the invention and a corticosteroid, such as dexamethasone, results in greatly enhanced steroidal activity. This can be shown, e.g., in the murine mammary tumor virus-

14

- 14 -

chloramphenicol acetyltransferase (MMTV-CAT) reporter gene assay, e.g., as described in Ning, et al., *J. Biol. Chem.* (1993) **268**: 6073. This synergistic effect allows reduced doses of corticosteroids, thereby reducing the risk of side effects in some cases.

11. Mip and Mip-like factor inhibition

Additionally, the Novel Compounds bind to and block a variety of Mip (macrophage infectivity potentiator) and Mip-like factors, which are structurally similar to macrophilin. Mip and Mip-like factors are virulence factors produced by a wide variety of pathogens, including those of the genera Chlamidia, e.g., Chlamidia trachomatis; Neisseria, e.g., Neisseria meningitidis; and Legionella, e.g., Legionella pneumophilia; and also by the obligately parasitic members of the order Rickettsiales. These factors play a critical role in the establishment of intracellular infection. The efficacy of the Novel Compounds in reducing the infectivity of pathogens which produce Mip or Mip-like factors can be shown by comparing infectivity of the pathogens in cells culture in the presence and absence of the macrolides, e.g., using the methods described in Lundemose, et al., *Mol. Microbiol.* (1993) **7**: 777. The nonimmunosuppressive compounds of the invention are preferred for use in this indication for the reason that they are not immunosuppressive, thus they do not compromise the body's natural immune defenses against the pathogens.

The Novel Compounds are also useful in assays to detect the presence or amount of macrophilin-binding compounds, e.g., in competitive assays for diagnostic or screening purposes. Thus, in another embodiment, the invention provides for use of the Novel Compounds as a screening tool to determine the presence of macrophilin-binding compounds in a test solution, e.g., blood, blood serum, or test broth to be screened. Preferably, a Novel Compound is immobilized in microtiter wells and then allowed to bind in the presence and absence of a test solution to labelled macrophilin-12 (FKBP-12). Alternatively, the FKBP-12 immobilized in microtiter wells and allowed to bind in the presence and absence of a test solution to a Novel Compound which has been labelled, e.g., fluoro-, enzymatically- or radio-labelled, e.g., a Novel Compound which has been O-substituted at C40 and/or C28

15

- 15 -

with a labelling group. The plates are washed and the amount of bound labelled compound is measured. The amount of macrophilin-binding substance in the test solution is roughly inversely proportional to the amount of bound labelled compound. For quantitative analysis, a standard binding curve is made using known concentrations of macrophilin bind compound.

16

- 16 -

EXAMPLES:

In the following examples, characteristic spectroscopic data is given to facilitate identification. Peaks which do not differ significantly from rapamycin are not included. Biological data is expressed as a relative IC₅₀, compared to rapamycin in the case of the mixed lymphocyte reaction (MLR) and IL-6 dependent proliferation (IL-6 dep. prol.) assays, and to FK-506 in the macrophilin binding assay (MBA). A higher IC₅₀ correlates with lower binding affinity.

Example 1: 40-O-Benzyl-rapamycin

To a stirred solution of 183 mg (0.200 mmol) of rapamycin in 2.1 mL of 2:1 cyclohexane-methylene chloride is added 75 μ L (0.402 mmol) of benzyl-trichloroacetimidate, followed by 2.6 μ L (29 μ mol 15 mol%) of trifluoromethanesulfonic acid whereupon the mixture turned immediately yellow. After 3h the mixture is diluted with ethyl acetate and quenched with 10% aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted twice with ethyl acetate. The combined organic solution is washed with 10% aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (50:50 hexane-ethyl acetate) to afford 40-O-benzyl-rapamycin as a white amorphous solid: ¹H NMR (CDCl₃) δ 0.73 (1H, dd), 1.65 (3H, s), 1.73 (3H, s), 3.12 (4H, s and m), 3.33 (3H, s), 3.49 (3H, s), 4.15 (1H, bd), 4.65 (1H, d), 4.71 (1H, d), 7.22-7.38 (5H, m); MS (FAB) m/z 1026 ([M+Na]⁺), 972 ([M-OCH₃]⁺), 954 ([M-(OCH₃+H₂O)]⁺).

MBA (rel. IC ₅₀)	1.8
IL-6 dep. prol. (rel. IC ₅₀)	10
MLR (rel. IC ₅₀)	110

Example 2: 40-O-(4'-Hydroxymethyl)benzyl-rapamycin

a) 40-O-[4'-(t-Butyldimethylsilyl)oxymethyl]benzyl-rapamycin

To a stirred, cooled (-78°C) solution of 345 μ L (2.0 mmol) of triflic anhydride in 5 mL of methylene chloride is added a solution of 504 mg (2.0 mmol) of 4-(t-

70170X

17

- 17 -

butyldimethylsilyl)oxymethyl-benzyl alcohol and 820 mg (4.0 mmol) of 2,6-di-*t*-butyl-4-methyl-pyridine in 5 mL of methylene chloride. The resulting mixture is warmed to -20°C and stirring is continued at this temperature for 0.5h. The mixture is then cooled back to -78°C and a solution of 914 mg (1.0 mmol) of rapamycin in 5 mL of methylene chloride is added. This mixture is allowed to warm to room temperature overnight and is then quenched with 10% aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted with ethyl acetate. The combined organic solution is washed with saturated brine, dried over sodium sulfate, filtered under reduced pressure and concentrated. The residue is purified by column chromatography on silica gel (50:50 hexane-ethyl acetate) to afford 40-O-[4'-(*t*-butyldimethylsilyl)oxymethyl]benzyl-rapamycin a white foam: MS (FAB) m/z 1170 ($[M+Na]^+$), 1098 ($[M-(OCH_3+H_2O)]^+$).

b) 40-O-(4'-Hydroxymethyl)benzyl-rapamycin

To a stirred, cooled (0°C) solution of 98 mg (0.093 mmol) of the compound obtained in example 2 in 2 mL of acetonitrile is added 0.2 mL of HF-pyridine. The resulting mixture is stirred for 2h and quenched with aqueous sodium bicarbonate, then extracted with ethyl acetate. The organic solution is washed with brine, dried over sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (20:80 hexane-ethyl acetate) to afford the title compound as a white foam: 1H NMR ($CDCl_3$) δ 0.73 (1H, dd), 1.65 (3H, s), 1.74 (3H, s), 3.22 (1H, m), 4.67 (4H, m), 7.35 (4H, m); MS (FAB) m/z 1056 ($[M+Na]^+$), 1002 ($[M-OCH_3]^+$), 984 ($[M-(OCH_3+H_2O)]^+$), 966 ($[M-(OCH_3+2H_2O)]^+$), 934 ($[M-(OCH_3+CH_3OH+2H_2O)]^+$).

70180X

MBA (rel. IC50)	2.7
IL-6 dep. prol. (rel. IC50)	3.9
MLR (rel. IC50)	3

Example 3: 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin

a) 40-O-[4'-(2,2-Dimethyl-1,3-dioxolan-4-yl)]benzyl-rapamycin

In 10 mL of 1:1 cyclohexane-methylene chloride is dissolved 452 mg (1.24 mmol) of 4-(2,2-dimethyl-1,3-dioxolan-4-yl)benzyl trichloroacetimidate, followed by 0.14 mL (0.64

18

- 18 -

mmol) of 2,6-di-*t*-butylpyridine and 56 μ L (0.64 mmol) of trifluoromethanesulfonic acid. To this mixture is added a solution of 587 mg (0.64 mmol) of rapamycin in 2 mL of methylene chloride. The reaction is stirred overnight at room temperature and quenched with aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted twice with ethyl acetate. The combined organic solution is washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (50:50 hexane-ethyl acetate) to give 40-O-[4'-(2,2-Dimethyl-1,3-dioxolan-4-yl)]benzyl-rapamycin as a white, amorphous solid: $^1\text{H NMR}$ (CDCl_3) δ 0.73 (1H, dd), 1.48 (3H, s), 1.55 (3H, s), 1.65 (3H, s), 1.74 (3H, s), 3.67 (3H, m), 4.28 (1H, dd), 4.62 (1H, d), 4.69 (1H, d), 5.06 (1H, dd), 7.33 (4H, m); MS (FAB) m/z 1126 ($[\text{M}+\text{Na}]^+$), 1072 ($[\text{M}-\text{OCH}_3]^+$), 1054 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 1014 ($[\text{M}-(\text{OCH}_3+\text{CH}_3\text{COCH}_3)]^+$), 996 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O}+\text{CH}_3\text{COCH}_3)]^+$), 978 ($[\text{M}-(\text{OCH}_3+2\text{H}_2\text{O}+\text{CH}_3\text{COCH}_3)]^+$).

b) 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin

To a solution of 90.7 mg (0.08 mmol) of 40-O-[4'-(2,2-Dimethyl-1,3-dioxolan-4-yl)]benzyl-rapamycin in 4 mL of methanol is added 1 mL of 1N aqueous HCl. After 2h the mixture is quenched with aqueous sodium bicarbonate and extracted twice with ethyl acetate. The organic solution is washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue is purified by column chromatography on silica gel (ethyl acetate) and the title compound is obtained as a white foam: $^1\text{H NMR}$ (CDCl_3) δ 0.73 (1H, dd), 1.65 (3H, s), 1.74 (3H, s), 3.70 (4H, m), 4.63 (1H, d), 4.69 (1H, d), 4.80 (1H, dd), 7.33 (4H, m); MS (FAB) m/z 1086 ($[\text{M}+\text{Na}]^+$), 1032 ($[\text{M}-\text{OCH}_3]^+$), 1014 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 996 ($[\text{M}-(\text{OCH}_3+2\text{H}_2\text{O})]^+$).

MBA (rel. IC50)	0.92
IL-6 dep. prol. (rel. IC50)	10.5
MLR (rel. IC50)	22

Example 4: 40-O-Allyl-rapamycin

To a stirred, cooled (-78°C) solution of 0.33 mL (2.01 mmol) of triflic anhydride in 10 mL of methylene chloride is slowly added a solution of 0.14 mL (2.06 mmol) of allyl

70190x

19

- 19 -

alcohol and 0.42 g (2.04 mmol) of 2,6-di-*t*-butyl-4-methyl-pyridine in 5 mL of methylene chloride. The resulting greenish solution is stirred for 1.5h and a solution of 915 mg (1.00 mmol) of rapamycin and 0.42 g (2.04 mmol) of 2,6-di-*t*-butyl-4-methyl-pyridine in 5 mL of methylene chloride is added. Stirring is continued for 0.5h at -78°C and then the mixture is warmed to room temperature. After one more hour the mixture is quenched with aqueous sodium bicarbonate and the layers are separated. The aqueous layer is extracted twice with ethyl acetate. The combined organic solution is washed with aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The resulting green oil is purified by column chromatography on silica gel (60:40 hexane-ethyl acetate) to afford the title compound as a colorless, amorphous solid: ¹H NMR (CDCl₃) δ 0.72 (1H, dd), 1.65 (3H, s), 1.74 (3H, s), 3.05 (1H, m), 4.13 (2H, bd), 5.14 (2H, m), 5.27 (2H, m), 5.92 (2H, m); MS (FAB) m/z 976 ([M+Na]⁺), 922 ([M-OCH₃]⁺), 904 ([M-(OCH₃+H₂O)]⁺), 886 ([M-(OCH₃+2H₂O)]⁺), 872 ([M-(2CH₃OH+OH)]⁺), 854 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	1
IL-6 dep. prol. (rel. IC50)	8
MLR (rel. IC50)	260

Example 5: 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin

To a stirred, cooled (-78°C) solution of 0.64 g (4.00 mmol) of E-(4S)-4,5-O,O-isopropylidene-pent-2-en-1,4,5-triol and 1.26 g (6.00 mmol) of 2,6-di-*t*-butyl-4-methyl-pyridine in 20 mL of methylene chloride is added 0.82 mL (5.00 mmol) of triflic anhydride. The resulting mixture is stirred at this temperature for 2h and a solution of 1.82 g (2.00 mmol) of rapamycin and 1.26 g (6.00 mmol) of 2,6-di-*t*-butyl-4-methyl-pyridine in 5 mL of methylene chloride is added. The mixture is allowed to gradually warm to room temperature overnight and is then quenched with aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted three times with ethyl acetate. The organic solution is washed with aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel

- 20 -

(40:60 hexane-ethyl acetate) to afford the title compound as a white solid: $^1\text{H NMR}$ (CDCl_3) δ 0.72 (1H, dd), 1.38 (3H, s), 1.42 (3H, s), 1.65 (3H, s), 1.73 (3H, s), 3.06 (1H, m), 3.58 (2H, m), 4.08 (1H, dd), 4.15 (2H, m), 4.52 (1H, bdd), 5.72 (1H, m), 5.88 (1H, m); MS (FAB) m/z 1076 ($[\text{M}+\text{Na}]^+$), 1022 ($[\text{M}-\text{OCH}_3]^+$), 1004 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 964 ($[\text{M}-(\text{OCH}_3+\text{CH}_3\text{COCH}_3)]^+$), 946 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O}+\text{CH}_3\text{COCH}_3)]^+$), 946 ($[\text{M}-(\text{OCH}_3+2\text{H}_2\text{O}+\text{CH}_3\text{COCH}_3)]^+$).

10210x

MBA (rel. IC50)	0.64
IL-6 dep. prol. (rel. IC50)	11
MLR (rel. IC50)	8

Example 6: (2'E, 4'S)-40-O-(4',5'-Dihydroxypent-2'-en-1'-yl)-rapamycin

The conditions described in example 3, step b) applied to the compound obtained in the previous example, followed by purification through column chromatography on silica gel (95:5 ethyl acetate-methanol) afford the title compound as a white foam: $^1\text{H NMR}$ (CDCl_3) δ 0.68 (1H, dd), 3.04 (1H, m), 4.18 (5H, m), 5.75 (1H, dd), 5.88 (1H, m); MS (FAB) m/z 1036 ($[\text{M}+\text{Na}]^+$), 1013 (M^+), 995 ($[\text{M}-\text{H}_2\text{O}]^+$), 982 ($[\text{M}-\text{OCH}_3]^+$), 964 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 946 ($[\text{M}-(\text{OCH}_3+2\text{H}_2\text{O})]^+$), 832 ($[\text{M}-(2\text{CH}_3\text{OH}+\text{OH})]^+$), 914 ($[\text{M}-(\text{OCH}_3+\text{CH}_3\text{OH}+2\text{H}_2\text{O})]^+$).

MBA (rel. IC50)	1.7
IL-6 dep. prol. (rel. IC50)	12
MLR (rel. IC50)	3.5

Example 7: 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin

a) 40-O-[2-(t-Butyldimethylsilyl)oxy]ethoxycarbonylmethyl-rapamycin

To a stirred solution of 2.74 g (3.00 mmol) of rapamycin and 30 mg (0.06 mmol) of dirhodium tetraacetate dihydrate in 30 mL of methylene chloride is added a solution of 0.38 mL (3.60 mmol) of 2-(t-butyldimethylsilyl)oxyethyl diazoacetate in 10 mL of methylene chloride over 5h. After the addition is complete stirring is continued for one more hour, then the reaction is quenched with 1N aq. HCl. The layers are separated and the aqueous layer is

- 21 -

extracted with ethyl acetate. The combined organic solution is washed with aq. sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (40:60 hexane-ethyl acetate) yielding 40-O-[2-(t-butyldimethylsilyl)oxy]ethoxycarbonylmethyl-rapamycin: $^1\text{H NMR}$ (CDCl_3) δ 0.06 (6H, s), 0.68 (1H, dd), 0.88 (9H, s), 1.64 (3H, s), 1.73 (3H, s), 3.12 (5H, s and m), 3.81 (2H, dd), 4.19 (2H, dd), 4.32 (2H, s); MS (FAB) m/z 1152 ($[\text{M}+\text{Na}]^+$), 1080 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$).

b) 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin

To a stirred, cooled (0°C) solution of 81 mg (0.07 mmol) of 40-O-[2-(t-butyldimethylsilyl)oxy]ethoxycarbonylmethyl-rapamycin in 1.5 mL of acetonitrile is added 0.15 mL of HF-pyridine. After 2h the reaction is quenched with aq. sodium bicarbonate. The mixture is extracted with ethyl acetate. The organic solution is washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by PTLC (ethyl acetate) to afford the title compound as a white solid: $^1\text{H NMR}$ (CDCl_3) δ 0.70 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 3.13 (5H, s and m), 3.85 (3H, m), 4.25 (5H, m); MS (FAB) m/z 1038 ($[\text{M}+\text{Na}]^+$), 984 ($[\text{M}-\text{OCH}_3]^+$), 966 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 948 ($[\text{M}-(\text{OCH}_3+2\text{H}_2\text{O})]^+$).

MBA (rel. IC50)	4
IL-6 dep. prol. (rel. IC50)	9.7
MLR (rel. IC50)	2.1

Example 8: 40-O-(2-Hydroxy)ethyl-rapamycin

a) 40-O-[2-(t-Butyldimethylsilyl)oxy]ethyl-rapamycin

A solution of 9.14 g (10 mmol) of rapamycin and 4.70 mL (40 mmol) of 2,6-lutidine in 30 mL of toluene is warmed to 60°C and a solution of 6.17 g (20 mmol) of 2-(t-butyldimethylsilyl)oxyethyl triflate and 2.35 mL (20 mmol) of 2,6-lutidine in 20 mL of toluene is added. This mixture is stirred for 1.5h. Then two batches of a solution of 3.08 g (10 mmol) of triflate and 1.2 mL (10 mmol) of 2,6-lutidine in 10 mL of toluene are added in a 1.5h interval. After addition of the last batch, stirring is continued at 60°C for 2h and the resulting brown suspension is filtered. The filtrate is diluted with ethyl acetate and washed

70220x

22

- 22 -

with aq. sodium bicarbonate and brine. The organic solution is dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (40:60 hexane-ethyl acetate) to afford 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl-rapamycin as a white solid: $^1\text{H NMR}$ (CDCl_3) δ 0.06 (6H, s), 0.72 (1H, dd), 0.90 (9H, s), 1.65 (3H, s), 1.75 (3H, s), 3.02 (1H, m), 3.63 (3H, m), 3.72 (3H, m); MS (FAB) m/z 1094 ($[\text{M}+\text{Na}]^+$), 1022 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$).

b) 40-O-(2-Hydroxy)ethyl-rapamycin

To a stirred, cooled (0°C) solution of 4.5 g (4.2 mmol) of 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl-rapamycin in 20 mL of methanol is added 2 mL of 1N HCl. This solution is stirred for 2h and neutralized with aq. sodium bicarbonate. The mixture is extracted with three portions of ethyl acetate. The organic solution is washed with aq. sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica gel (ethyl acetate) gave the title compound as a white solid: $^1\text{H NMR}$ (CDCl_3) δ 0.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 3.13 (5H, s and m), 3.52-3.91 (8H, m); MS (FAB) m/z 980 ($[\text{M}+\text{Na}]^+$), 926 ($[\text{M}-\text{OCH}_3]^+$), 908 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 890 ($[\text{M}-(\text{OCH}_3+2\text{H}_2\text{O})]^+$), 876 ($[\text{M}-(2\text{CH}_3\text{OH}+\text{OH})]^+$), 858 ($[\text{M}-(\text{OCH}_3+\text{CH}_3\text{OH}+2\text{H}_2\text{O})]^+$).

MBA (rel. IC50)	2.2
IL-6 dep. prol. (rel. IC50)	2.8
MLR (rel. IC50)	3.4

Example 9: 40-O-(3-Hydroxy)propyl-rapamycin

a) 40-O-[3-(t-Butyldimethylsilyl)oxy]propyl-rapamycin

The same procedure as described in example 8, step a) using 3-(t-butyldimethylsilyl)oxyprop-1-yl triflate affords 40-O-[3-(t-butyldimethylsilyl)oxy]propyl-rapamycin: $^1\text{H NMR}$ (CDCl_3) δ 0.05 (6H, s), 0.72 (1H, dd), 0.90 (9H, s), 1.65 (3H, s), 1.74 (3H, s), 1.77 (2H, m), 3.03 (1H, m), 3.52-3.73 (7H, m); MS (FAB) m/z 1108 ($[\text{M}+\text{Na}]^+$), 1036 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$).

b) 40-O-(3-Hydroxy)propyl-rapamycin

10230X

23

- 23 -

Treatment of the compound obtained in step a) in the conditions described in example 8, step b) yields the title compound: ^1H NMR (CDCl_3) δ 0.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 1.80 (2H, m), 3.05 (1H, m), 3.55-3.91 (8H, m); MS (FAB) m/z 994 ($[\text{M}+\text{Na}]^+$), 940 ($[\text{M}-\text{OCH}_3]^+$), 922 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 904 ($[\text{M}-(\text{OCH}_3+2\text{H}_2\text{O})]^+$), 872 ($[\text{M}-(\text{OCH}_3+\text{CH}_3\text{OH}+2\text{H}_2\text{O})]^+$).

70240 X

MBA (rel. IC50)	1.6
IL-6 dep. prol. (rel. IC50)	2.7
MLR (rel. IC50)	11

Example 10: 40-O-(6-Hydroxy)hexyl-rapamycin

a) 40-O-[6-(t-Butyldimethylsilyl)oxy]hexyl-rapamycin

The same procedure as described in example 8, step a) using 6-(t-butyldimethylsilyl)oxyhex-1-yl triflate affords 40-O-[6-(t-Butyldimethylsilyl)oxy]hexyl-rapamycin: MS (FAB) m/z 1150 ($[\text{M}+\text{Na}]^+$).

b) 40-O-(6-Hydroxy)hexyl-rapamycin

Treatment of the compound obtained in step a) in the conditions described in example 8, step b) yields the title compound: ^1H NMR (CDCl_3) δ 0.72 (1H, dd), 1.38 (2H, m), 1.57 (4H, m), 1.65 (3H, s), 1.74 (3H, s), 3.02 (1H, m), 3.49-3.72 (8H, m); MS (FAB) m/z 1036 ($[\text{M}+\text{Na}]^+$), 982 ($[\text{M}-\text{OCH}_3]^+$), 964 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 946 ($[\text{M}-(\text{OCH}_3+2\text{H}_2\text{O})]^+$), 914 ($[\text{M}-(\text{OCH}_3+\text{CH}_3\text{OH}+2\text{H}_2\text{O})]^+$).

7024 1x

MBA (rel. IC50)	0.8
IL-6 dep. prol. (rel. IC50)	8.5
MLR (rel. IC50)	18

Example 11: 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin

a) 40-O-[2-(t-Butyldimethylsilyl)oxyethoxy]ethyl-rapamycin

The same procedure as described in example 8, step a) using 2-[2-(t-butyldimethylsilyl)oxyethoxy]ethyl triflate affords 40-O-[2-(t-butyldimethylsilyl)oxyethoxy]ethyl-rapamycin: ^1H NMR (CDCl_3) δ 0.06 (6H, s), 0.71 (1H, dd), 0.88 (9H, s), 1.65 (3H, s), 1.74 (3H, s), 3.07

24

- 24 -

(1H, m), 3.51-3.79 (11H, m); MS (FAB) m/z 1138 ([M+Na]⁺), 1115 (M⁺), 1097 ([M-H₂O]⁺), 1084 ([M-OCH₃]⁺), 1066 ([M-(OCH₃+H₂O)]⁺), 1048 ([M-(OCH₃+2H₂O)]⁺), 1034 ([M-(2CH₃OH+OH)]⁺), 1016 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

b) 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin

Treatment of the compound obtained in step a) in the conditions described in example 8, step b) yields the title compound: ¹H NMR (CDCl₃) δ 0.72 (1H, dd), 1.65 (3H, s), 1.74 (3H, s), 3.05 (1H, m), 3.51-3.77 (11H, m); MS (FAB) m/z 1024 ([M+Na]⁺), 1001 (M⁺), 983 ([M-H₂O]⁺), 970 ([M-OCH₃]⁺), 952 ([M-(OCH₃+H₂O)]⁺), 934 ([M-(OCH₃+2H₂O)]⁺), 920 ([M-(2CH₃OH+OH)]⁺), 902 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	1.2
IL-6 dep. prol. (rel. IC50)	3.2
MLR (rel. IC50)	2

Example 12: 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin

The same procedure as described in example 8, step a) using the triflate of glycerol acetonide affords the title compound: ¹H NMR (CDCl₃) δ 0.72 (1H, dd), 1.36 (3H, s), 1.42 (3H, s), 1.65 (3H, s), 1.75 (3H, s), 3.06 (1H, m), 3.55 (2H, m), 3.69 (3H, m), 4.06 (1H, dd), 4.26 (1H, m); MS (FAB) m/z 1050 ([M+Na]⁺), 996 ([M-OCH₃]⁺), 978 ([M-(OCH₃+H₂O)]⁺), 960 ([M-(OCH₃+2H₂O)]⁺).

MBA (rel. IC50)	0.9
IL-6 dep. prol. (rel. IC50)	8
MLR (rel. IC50)	290

Example 13: 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin

Treatment of the compound obtained in the previous example in the conditions described in example 3 yields the title compound: ¹H NMR (CDCl₃) δ 0.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 3.07 (1H, m), 3.68 (8H, m); MS (FAB) m/z 1010 ([M+Na]⁺), 956 ([M-OCH₃]⁺), 938 ([M-(OCH₃+H₂O)]⁺), 920 ([M-(OCH₃+2H₂O)]⁺), 888 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

25

- 25 -

TD260X

MBA (rel. IC50)	0.67
IL-6 dep. prol. (rel. IC50)	9
MLR (rel. IC50)	10

Example 14: 40-O-(2-Acetoxy)ethyl-rapamycin

To a stirred, cooled (0°C) solution of 53 mg (0.055 mmol) of 40-O-hydroxyethyl-rapamycin in 2 mL of methylene chloride is added 0.2 mL of pyridine followed by 0.02 mL (0.281 mmol) of acetyl chloride. The mixture is stirred for 3h and diluted with ethyl acetate, then washed with aq. sodium bicarbonate, cold 1N HCl and again with aq. sodium bicarbonate. The organic solution is dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (30:70 hexane-ethyl acetate) to afford the title compound as a white solid: ¹H NMR (CDCl₃) δ 0.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 2.08 (3H, s), 3.07 (1H, m), 3.78 (2H, dd), 4.20 (2H, dd); MS (FAB) m/z 1022 ([M+Na]⁺), 999 (M⁺), 982 ([M-OH]⁺), 968 ([M-OCH₃]⁺), 950 ([M-(OCH₃+H₂O)]⁺), 932 ([M-(OCH₃+2H₂O)]⁺), 918 ([M-(2CH₃OH+OH)]⁺), 900 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

TD261X

MBA (rel. IC50)	2
IL-6 dep. prol. (rel. IC50)	7.6
MLR (rel. IC50)	3.6

Example 15: 40-O-(2-Nicotinoyloxy)ethyl-rapamycin

The same procedure as described in the previous example using nicotinoyl chloride hydrochloride affords the title compound: ¹H NMR (CDCl₃) δ 0.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 3.07 (1H, m), 3.94 (2H, dd), 4.49 (2H, t), 7.39 (1H, dd), 8.31 (1H, ddd), 8.78 (1H, ddd), 9.24 (1H, dd); MS (FAB) m/z 1085 ([M+Na]⁺), 1063 ([M+H]⁺), 1045 ([M-OH]⁺), 1031 ([M-OCH₃]⁺), 1013 ([M-(OCH₃+H₂O)]⁺).

TD262X

MBA (rel. IC50)	1.1
IL-6 dep. prol. (rel. IC50)	6.9
MLR (rel. IC50)	5

26

- 26 -

Example 16: 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin

a) 40-O-(2-Bromoacetoxy)ethyl-rapamycin

The same procedure as described in example 14 using bromoacetyl chloride affords 40-O-(2-bromoacetoxy)ethyl-rapamycin: $^1\text{H NMR}$ (CDCl_3) δ 0.72 (1H, dd), 1.67 (3H, s), 1.76 (3H, s), 3.03 (1H, m), 3.82 (2H, m), 3.87 (2H, s), 4.31 (2H, m); MS (FAB) m/z 1100, 1102 ($[\text{M}+\text{Na}]^+$), 1077 (M^+), 1061 ($[\text{M}-\text{H}_2\text{O}]^+$), 1046, 1048 ($[\text{M}-\text{OCH}_3]^+$), 1028, 1030 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 1012 ($[\text{M}-(\text{OCH}_3+2\text{H}_2\text{O})]^+$), 996 ($[\text{M}-(2\text{CH}_3\text{OH}+\text{OH})]^+$), 980 ($[\text{M}-(\text{OCH}_3+\text{CH}_3\text{OH}+2\text{H}_2\text{O})]^+$).

b) 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin

To a stirred, cooled (-45°C) solution of 54 mg (0.05 mmol) of 40-O-(2-bromoacetoxy)ethyl-rapamycin in 0.5 mL of DMF is added a solution of 0.022 mL (0.25 mmol) of morpholine in 0.2 mL of DMF and the resulting mixture is stirred at that temperature for 1h, then treated with aq. sodium bicarbonate. This mixture is extracted three times with ethyl acetate. The organic solution is washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (95:5 ethyl acetate-methanol) yielding the title compound as an amorphous white solid: $^1\text{H NMR}$ (CDCl_3) δ 0.72 (1H, dd), 1.67 (3H, s), 1.76 (3H, s), 2.60 (3H, m), 3.07 (1H, m), 3.24 (2H, s), 3.78 (8H, m), 4.27 (2H, t); MS (FAB) m/z 1107 ($[\text{M}+\text{Na}]^+$), 1085 ($[\text{M}+\text{H}]^+$), 1067 ($[\text{M}-\text{OH}]^+$), 1053 ($[\text{M}-\text{OCH}_3]^+$), 1035 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$).

MBA (rel. IC50)	1.3
IL-6 dep. prol. (rel. IC50)	4
MLR (rel. IC50)	3.5

Example 17: 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin

The same procedure as described in example 16, step b) using imidazole affords the title compound: $^1\text{H NMR}$ (CDCl_3) δ 0.72 (1H, dd), 1.67 (3H, s), 1.78 (3H, s), 3.06 (1H, m), 3.80 (2H, m), 4.32 (2H, m), 4.73 (2H, s), 6.97 (1H, dd), 7.09 (1H, dd), 7.52 (1H, dd); MS (FAB) m/z 1066 ($[\text{M}+\text{H}]^+$), 1048 ($[\text{M}-\text{OH}]^+$), 1034 ($[\text{M}-\text{OCH}_3]^+$), 1016 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$).

MBA (rel. IC50)	1
-----------------	---

- 27 -

IL-6 dep. prol. (rel. IC50)	7.6
MLR (rel. IC50)	3.4

Example 18: 40-O-[2-(N-Methyl-N'-piperazinyl)acetoxylethyl-rapamycin

The same procedure as described in example 16, step b) using N-methylpiperazine affords the title compound: ¹H NMR (CDCl₃) δ 0.72 (1H, dd), 1.67 (3H, s), 1.77 (3H, s), 2.78 (4H, s and m), 3.02 (4H, bs), 3.08 (1H, m), 3.32 (2H, s), 3.80 (2H, dd), 4.27 (2H, t); MS (FAB) m/z 1098 ([M+H]⁺), 1066 ([M-OCH₃]⁺).

MBA (rel. IC50)	2.6
IL-6 dep. prol. (rel. IC50)	10.3
MLR (rel. IC50)	5

Example 19: 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin

To a stirred, cooled (-20°C) solution of 48 mg (0.05 mmol) of 40-O-hydroxyethyl-rapamycin and 0.023 mL (0.20 mmol) of 2,6-lutidine in 0.5 mL of methylene chloride is added 0.008 mL (0.05 mmol) of triflic anhydride. The mixture is stirred at this temperature for 2h, then allowed to warm to room temperature and stirred for one more hour. The reaction is quenched with aq. sodium bicarbonate and the resulting mixture is extracted with three portions of ethyl acetate. The organic solution is washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (30:70 hexane-ethyl acetate) to afford the title compound as a white solid: ¹H NMR (CDCl₃) δ 1.66 (3H, s), 1.75 (3H, s), 3.14 (3H, s), 3.35 (3H, s), 3.76 (4H, s); MS (FAB) m/z 948 ([M+Na]⁺), 925 (M⁺), 908 ([M-OH]⁺), 894 ([M-OCH₃]⁺), 876 ([M-(OCH₃+H₂O)]⁺), 858 ([M-(OCH₃+2H₂O)]⁺), 844 ([M-(2CH₃OH+OH)]⁺), 826 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	1.6
IL-6 dep. prol. (rel. IC50)	22.9
MLR (rel. IC50)	16

- 28 -

Example 20: (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin

a) (26R)-26-Dihydro-40-O-[2-(t-Butyldimethylsilyloxy)]ethyl-rapamycin

In 4.5 mL of 2:1 acetonitrile-acetic acid is dissolved 315 mg (1.2 mmol) of tetramethylammonium-triacetoxyborohydride. The resulting solution is stirred for 1h at room temperature and cooled to -35°C, then 161 mg (0.15 mmol) of 40-O-[2-(t-butyldimethylsilyl)oxy]ethyl-rapamycin is added. The resulting mixture is stirred at the same temperature overnight and is quenched by the addition of aq. sodium bicarbonate. The mixture is extracted with three portions of ethyl acetate. The organic solution is washed with aq. sodium bicarbonate, two portions of 30% aq. Rochelle's salt and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (40:60 hexane-ethyl acetate) to afford the title compound as a white solid: ¹H NMR (CDCl₃) δ 0.06 (6H, s), 0.73 (1H, dd), 0.90 (9H, s), 1.64 (3H, s), 1.67 (3H, s), 3.02 (1H, m), 3.15 (1H, m), 3.64 (3H, m), 3.71 (2H, dd), 3.91 (1H, s); MS (FAB) m/z 1096 ([M+Na]⁺), 1041 ([M-HOCH₃]⁺), 1024 ([M-(OCH₃+H₂O)]⁺), 1006 ([M-(OCH₃+2H₂O)]⁺), 974 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

b) (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin

Treatment of the compound obtained in step a) in the conditions described in example 8, step b) yields the title compound: ¹H NMR (CDCl₃) δ 0.75 (1H, dd), 1.66 (3H, s), 1.70 (3H, s), 3.18 (1H, m), 3.52-3.84 (7H, m); MS (FAB) m/z 982 ([M+Na]⁺), 928 ([M-OCH₃]⁺), 910 ([M-(OCH₃+H₂O)]⁺), 892 ([M-(OCH₃+2H₂O)]⁺).

MBA (rel. IC50)	3.9
IL-6 dep. prol. (rel. IC50)	53
MLR (rel. IC50)	18

Example 21: 28-O-Methyl-rapamycin

To a stirred solution of 103 mg (0.1 mmol) of 40-O-TBS-rapamycin (obtained by silylation of rapamycin with 1 eq. of TBS triflate in methylene chloride in the presence of 2 eq. of 2,6-lutidine at 0°C) in 0.5 mL of methylene chloride is added 85.8 mg (0.40 mmol) of proton sponge followed by 44 mg (0.30 mmol) of trimethyloxonium tetrafluoroborate. The

- 29 -

resulting brown heterogeneous mixture is stirred overnight, quenched with aq. sodium bicarbonate and extracted with ethyl acetate. The organic solution is washed with 1N HCl, aq. sodium bicarbonate and brine, then dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (60:40 hexane-ethyl acetate) to afford 40-O-t-butyldimethylsilyl-28-O-methyl-rapamycin. The latter compound is desilylated in the conditions described in example 10, step b) to afford, after PTLC (ethyl acetate), the title compound as a white solid: $^1\text{H NMR}$ (CDCl_3) δ 0.70 (1H, dd), 1.68 (6H, 2s), 2.95 (1H, m), 3.13 (3H, s), 3.14 (3H, s), 3.28 (3H, s), 3.41 (3H, s); MS (FAB) m/z 950 ($[\text{M}+\text{Na}]^+$), 927 (M^+), 909 ($[\text{M}-\text{H}_2\text{O}]^+$), 896 ($[\text{M}-\text{OCH}_3]^+$), 878 ($[\text{M}-(\text{OCH}_3+\text{H}_2\text{O})]^+$), 864 ($[\text{M}-(\text{OCH}_3+\text{CH}_3\text{OH})]^+$), 846 ($[\text{M}-(2\text{CH}_3\text{OH}+\text{OH})]^+$), 832 ($[\text{M}-(\text{OCH}_3+2\text{CH}_3\text{OH})]^+$), 814 ($[\text{M}-(3\text{CH}_3\text{OH}+\text{OH})]^+$).

MBA (rel. IC50)	1.58
IL-6 dep. prol. (rel. IC50)	1240
MLR (rel. IC50)	1300

Example 22: 40-O-(2-aminoethyl)-rapamycin

a) 40-O-(2-bromoethyl)-rapamycin

A solution of 914 mg rapamycin in 5 mL toluene containing 0.64 ml of 2,6-lutidine and 1.28 g of 2-bromoethyl triflate is heated at 65 C for 18 h. The reaction mixture is then cooled to room temperature, poured on 20 ml of a saturated bicarbonate solution and extracted with 3x 20 mL ethyl acetate. The organic phases are dried over sodium carbonate and the solvent removed at reduced pressure on the rotatory evaporator. The residue is chromatographed on 100 g silica gel, eluting with hexane/ethyl acetate 3/2 to afford 40-O-(2-bromoethyl)-rapamycin as an amorphous solid: MS (FAB) m/z 1044 and 1042 (100%; $\text{M}+\text{Na}$); 972 and 970 (55%, $\text{M}-(\text{MeOH}+\text{H}_2\text{O})$).

$^1\text{H-NMR}$ (CDCl_3) δ : 0.72 (1H, q, $J=12$ Hz); 3.13 (3H, s); 3.33 (3H, s); 3.45 (3H, s); 3.9 (4H, m); 4.78 (1H, s)

b) 40-O-(2-azidoethyl)-rapamycin

- 30 -

A solution of 2.4 g of 40-O-(2-bromoethyl)-rapamycin in 40 mL DMF is treated with 0.19 g sodium azide at room temperature. After 2h, the mixture is poured on 100 mL of saturated sodium bicarbonate and extracted with 3x 100 mL ethyl acetate. The organic phases are combined, dried over sodium sulfate and the solvent removed under reduced pressure. The crude product is purified by chromatography on silica gel eluting with hexane/ethyl acetate to afford 40-O-(2-azidoethyl)-rapamycin: MS (FAB): 1005 (100%, M+Na); 951 (24%, M-MeOH); 933 (57%, M-(MeOH+H₂O))

c) 40-O-(2-aminoethyl)-rapamycin

To a solution of 230 mg 40-O-(azidoethyl)-rapamycin in 3 mL of THF/water 5/1 at room temperature are added 307 mg of triphenylphosphine. The reaction mixture becomes yellow. After 7 h, the reaction mixture is loaded on x g silical gel and chromatographed with ethyl acetate/methanol/acetic acid 50/50/0.5 to afford the title product in the form of its acetate: MS (FAB) m/z 979 (45%, M+Na); 957 (100%, MH); 925 (63%, M-MeOH); 907 (25%, M-(MeOH+H₂O))

MBA (rel. IC₅₀): 0.7

IL-6 dep. prol. (rel. IC₅₀): 10

Example 23: 40-O-(2-acetaminoethyl)-rapamycin

To a solution of 101 mg of the acetate of 40-O-(2-aminoethyl)-rapamycin in 2 mL THF are added 0.02 mL pyridine and 0.07 mL acetyl chloride. The reaction mixture is kept at room temperature for 18h and then poured on 7 mL saturated sodium bicarbonate. The aqueous phase is extracted 3x with 5 mL ethyl acetate, the organic phases are combined and dried over sodium sulfate. The solvent is evaporated and the residue chromatographed on 10 g silica gel eluting first with ethyl acetate followed by ethyl acetate/methanol/acetic acid 50/50/0.5 to afford the title product: MS (FAB) m/z 1021 (20%, M+Na); 967 (28%, M-MeOH); 949 (100%, M-(MeOH+H₂O))

¹H-NMR (CDCl₃) δ: 0.71 (1H, q, J=12 Hz); 1.98 (3H, s); 3.13 (3H, s); 3.34 (3H, s); 3.44 (3H, s); 4.75 (1H, s)

MBA (rel. IC₅₀): 1.1

31

- 31 -

IL-6 dep. prol. (rel. IC50): 2.3

Example 24: 40-O-(2-nicotinamidoethyl)-rapamycin

101 mg of 40-(2-aminoethyl)-rapamycin acetate are dissolved in 5 ml ethyl acetate and extracted 2x with saturated sodium bicarbonate. The organic phase is dried over sodium sulfate and the solvent evaporated. The residue is dissolved in 2 mL THF and treated with 22 mg DCC and 15 mg nicotinic acid. After 15h at room temperature the reaction mixture is evaporated and the residue chromatographed on silica gel, eluting with ethyl acetate followed by ethyl acetate/methanol 9/1, to afford the title product: MS (FAB) m/z 1084 (80%, M+Na); 1062 (40%, MH); 1038 (100%, M-MeOH); 1012 (50%, M-(MeOH+H2O))
H-NMR (CDCl3) d: 0.72 (1H, q, J=12 Hz); 3.13 (3H, s); 3.33 (3H, s); 3.37 (3H, s); 7.39 (1H, dd; J=6 Hz, J=8 Hz), 8.19 (1H, d, J=8 Hz); 8.75 (1H, d, J=6 Hz); 9.04 (1H, broad s)
MBA (rel. IC50): 1.2

IL-6 dep. prol. (rel. IC50): 2.8

Example 25: 40-O-(2-(N-Methyl-imidazo-2'-ylcarbathoxamido)ethyl)-rapamycin

To a solution of 30 mg N-methyl-imidazol-2-carboxylic acid in 1 mL DMF are added 58 mg DCC and 58 mg HOBT. After 2h, 150 mg 40-O-(2-aminoethyl)-rapamycin are added and the reaction mixture is stirred for 18h at room temperature. The suspension is then filtered, the filtrate diluted with 5 mL ethyl acetate and washed with 2x 2 mL of a saturated aqueous bicarbonate solution. The organic phase is dried over sodium sulfate and the solvent evaporated under reduced pressure. The residue is chromatographed over 10 silica gel, eluting with hexane/ethyl acetate 1/4 and then ethyl acetate to afford the title product:

MS (FAB) m/z 1087 (36%, M+Na); 1065 (57%,MH); 1033 (100%, M-MeOH); 1015 (46%, M-(MeOH+H2O))

H-NMR (CDCl3) d: 0.72 (1H, q, J=12 Hz); 3.13 (3H, s); 3.33 (3H, s); 3.46 (3H, s); 4.03 (3H, s); 6.93 (1H, broad s); 6.98 (1H, broad s); 7.78 (1H, m)

MBA (rel. IC50): 1.1

- 32 -

IL-6 dep. prol. (rel. IC50): 7

Example 26: 40-O-(2-ethoxycarbonvlaminoethyl)-rapamycin

A solution of 200 mg 40-O-(2-azidoethyl)-rapamycin in 3 mL THF/water 5/1 is treated with 267 mg triphenylphosphine for 7h at room temperature. Then 0.4 mL pyridine are added followed by 194 µL ethyl chloroformiate. After 2 h, the reaction mixture is poured on 5 mL ethyl acetate and washed successively with 10 mL saturated sodium bicarbonate, 5 mL water and 5 ml 10% citric acid. The organic phase is dried over sodium sulfate and the solvent evaporated. The residue is chromatographed over 20 g silica gel, eluting with ethyl acetate followed by ethyl acetate/methanol 9/1, to afford the title product.: MS (FAB) m/z 1051 (35%, M+Na); 997 (30%, M-MeOH); 979 (100%, M-(MeOH+H2O))
H-NMR (CDCl3) d: 0.71 (1H, q, J=12 Hz); 1.24 (3H, t, J=8 Hz); 3.13 (3H, s); 3.34 (3H, s); 3.43 (3H, s); 4.10 (2H, q, J=8 Hz); 5.48 (1H, m)

MBA (rel. IC50): 1.1

IL-6 dep, prol. (rel. IC50): 1.7

Example 27: 40-O-(2-tolylsulfonamidoethyl)-rapamycin

A solution of 200 mg 40-O-(2-aminoethyl)-rapamycin in 3 mL THF is treated with 0.4 mL pyridine and 390 mg tosyl chloride and the reaction mixture is stirred for 12h at room temperature. The solution is then poured onto 5 ml of a saturated bicarbonate solution and the aqueous phase is extracted with 2x 5 mL ethyl acetate. The combined organic phases are washed with 5 mL of 10% citric acid and 5mL water. After drying on sodium sulfate the solvent is evaporated and the residue chromatographed on 20 g silica gel, eluting with hexane/ethyl acetate 1/1 to afford the title product as a white foam: MS (FAB) m/z 1133 (100%, M+Na); 1078 (25%, M-MeOH); 1061 (85%, M-(MeOH+H2O))
H-NMR (CDCl3) d: 0.68 (1H, q, J=12Hz); 2,43 (3H, s); 3,13 (3H, s); 3,35 (3H, s); 3,41 (3H, s); 4.76 (1H, s); 5.85 (1H, t, J=6Hz); 7.30 (2H, d, J=8 Hz); 7.75 (2H, d, J=8Hz).

MBA (rel. IC50): 15.9

IL-6 dep. prol. (rel. IC50): 14

- 33 -

Example 28: 40-O-[2-(4',5'-dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin

98 mg of 40-O-(2-azidoethyl)-rapamycin and 32 mg diethylacetylene dicarboxylate are suspended in 0.5 ml toluene and heated at 65 C for 5h. The reaction mixture is then cooled at room temperature, loaded on 10 g silica gel and eluted with hexane/ethyl acetate 1/1 to afford the title product: MS (FAB) m/z 1175 (20%, M+Na); 1121 (15%, M-MeOH); 1103 (60%, M-(MeOH+H₂O))

H-NMR (CDCl₃) δ: 0.62 (1H, q, J=12 Hz); 1.40 (3H, t, J=8 Hz); 1.42 (3H, t, J=8 Hz); 3.13 (3H, s); 3.25 (3H, s); 3.33 (3H, s)

MBA (rel. IC₅₀): 2.7

IL-6 dep. prol. (rel. IC₅₀): 12

The previous examples may also be made using as starting material instead of rapamycin, 9-deoxo-rapamycin, 26-dihydro rapamycin, or 9-deoxo-, 26-dihydro-rapamycin. Alternatively, and preferably, as described e.g., in example 20, the rapamycin compounds of the above examples may be hydrogenated or reduced, using suitable protecting groups where necessary. The following novel methods for reducing the keto at C9, or hydrogenating the keto at C26 are provided:

Example 29: Removal of keto at C9

A stream of hydrogen sulfide is passed at room temperature through a stirred solution of 3.2 g (3.5 mmol) of rapamycin in 50 ml pyridine and 2.5 ml DMF. The solution turns from colorless to yellow. After two hours, the introduction of hydrogen sulfide is stopped and stirring is continued for five days, during which time the solution turns gradually orange. TLC and HPLC analysis verifies complete consumption of the starting material and the presence of a single new compound. The solution is purged with nitrogen for one hour and concentrated under reduced pressure. The residue is taken up in ethyl acetate, washed with cold 1N HCl solution (3x), saturated sodium bicarbonate solution and saturated brine. The organic layer is dried over anhydrous sodium sulfate and filtered and concentrated under reduced pressure. The residue is taken up in ether and the precipitated

34

- 34 -

sulfur is filtered off. Concentration of the ethereal solution followed by column chromatography on silica gel (10:4:1 CH₂Cl₂/i-Pr₂O/MeOH) yields 9-deoxorapamycin as a colorless foam. The identity of the product is confirmed by nuclear magnetic resonance spectroscopy (NMR), mass spectrometry (MS), and/or infrared spectroscopy (IR). 9-deoxorapamycin is found to exhibit the following characteristic physical data: ¹H NMR (CDCl₃) δ 1.61 (3H,d,J = 1 Hz, C17-CH₃), 1.76 (3H,d,J = 1.2 Hz,C29-CH₃), 2.42 (1H,d,J = 14.5 Hz, H-9), 2.74 (1H,d,J = 14.5 Hz, H-9), 3.13 (3H,s,C16-OCH₃) 3.5 (3H,s,C27-OCH₃), 3.40 (3H,s,C39-OCH₃), 5.40 (1H,d,J = 10 Hz, H-30), 5.57 (1H,dd,J₁ = 8.6 Hz, J₂ = 15 Hz, H-22), 5.96 (1H,d,J = 9 Hz, H-18), 6.09 (1H,d,J = 1.7 Hz, 10-OH), 6.15 (1H,dd,J₁ = 10 Hz, J₂ = 15Hz, H-21), 6.37 (1H,dd,J₁ = 1.5 Hz, J₂ = 5 Hz, H-19), 6.38 (1H,J = 9.5 Hz, H-20). ¹³C NMR (CDCl₃) δ 38.5 (C-9), 98.0 (C-10), 170.7 (C-1), 173.0 (C-8), 208.8 (C-32), 216.9 (C-26).

MS(FAB) m/z 922 8[M+Na⁺], 899 (M⁺), 881 ([M-H₂O]⁺), 868 ([M-OCH₃]⁺), 850 ([M-(H₂O+OCH₃)]⁺).

IR (major peaks)(cm⁻¹) 987, 1086, 1193, 1453, 1616, 1717, 1739, 3443.

MBA (rel. IC₅₀): 1

MLR (rel. IC₅₀): 14

IL-6 dep. prol. (rel. IC₅₀): 9

Example 30: Dihydrogenation of keto at C26

To a stirred solution of 421 mg (1.6 mmol) of tetramethylammonium triacetoxymethylborohydride in 2 ml of acetonitrile is added 2 ml of acetic acid. The resulting mixture is stirred for 30 minutes at room temperature and cooled to -35°C. At this temperature a solution of 180 mg (0.2 mmol) of 9-deoxo-rapamycin in 1 ml of acetonitrile is added and the resulting mixture is allowed to stir for 24 hours. The mixture is quenched with a saturated sodium potassium tartrate solution and allowed to warm to room temperature. Stirring is continued until both layers are clear and ethyl acetate is added. The layers are separated and the aqueous layer is extracted twice with ethyl acetate. The resulting organic solution is washed once with a 10% sodium bicarbonate solution and twice with

36

- 35 -

saturated brine, then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (90:10 AcOEt-hexane). As the starting material in this case was 9-deoxorapamycin, the final compound is 9-deoxorapamycin, 26-dihydrorapamycin is produced as a colorless foam, having the following characteristic spectroscopic data: $^1\text{H NMR}$ (CDCl_3) (major isomer) δ .9 (3H,d,J = 6.9 Hz, CHCH_3), 0.93 (3H,d,J = 6.9 Hz, CHCH_3), 1.00 (3H,d,J = 6.9 Hz CHCH_3), 1.07 (3H,d,J = 6.9 Hz, CHCH_3), 1.17 (3H,d,J = 6.9 Hz, CHCH_3), 1.61 (3H,d,J = 1Hz, C17- CH_3), 1.73 (3H,d,J = 1.2 Hz, C29- CH_3), 2.43 (1H,dd,J = 4.1 and 16.0 Hz, H-33), 2.46 (1H,d,J = 13.8 Hz, H-9), 2.58 (1H,m,H-25), 2.77 (1H,d,J = 13.8 Hz, H-9), 2.82 (1H,dd,J = 8.3 and 16.0 Hz, H-33), 3.17 (1H,dd,J = 4.1 and 9.2 Hz, H-27), 3.61 (2H,m, H-14 and H28), 5.19 (1H,ddd,J = 4.1, 4.6 and 8.3 Hz, H-34), 5.49 (1H, broad d,J = 5.0 Hz, H-2), 5.56 (1H,d,J = 9.1 Hz, H-30), 5.75 (1H,dd,J = 6.9 and 14.7 Hz, H-22), 5.76 (1H,s,10-OH), 5.99 (1H,broad d,J = 9.2 Hz, H-18), 6.10 (1H,m,H-21), 6.36 (2H,m,H-19 and H-20); MS (FAB) m/z 924 ($[\text{M} + \text{Na}]$), 852 ($[\text{M}-(\text{H}_2\text{O} + \text{CH}_3\text{O})]^+$).
MBA (rel. IC_{50}): 47
MLR (rel. IC_{50}): 134
IL-6 dep. prol. (rel. IC_{50}): 78

26-dihydrorapamycin is prepared in the same manner, using rapamycin in place of 9-deoxorapamycin. This product has the following characteristic spectroscopic data: $^{13}\text{C-NMR}$ (CDCl_3) (major isomer) δ = 208.3 (C-32); 194.0 (C-9); 169.3 (C-1); 166.6 (C-8); 140.9 (C-22); 136.5 (C-29); 136.2 (C-17); 133.5 (C-20); 129.1 (C-21); 128.7 (C-18); 126.2 (C-30); 125.3 (C-19); 98.6 (C-10); 84.4 (C-39); 83.9 (C-16); 81.6 (C-27); 75.4 (C-34); 74.3 (C-28); 73.9 (C-40); 72.9 (C-26); 67.4 (C-14); 59.1 (27- OCH_3); 56.6 (39- OCH_3); 55.9 (16- OCH_3); 51.3 (C-2); 46.8 (C-31); 44.3 (C-6); 40.4 (C-33); 40.4 (C-25); 39.5 (C-24); 38.8 (C-15); 38.0 (C-36); 34.3 (C-23); 34.2 (C-38); 33.5 (C-11); 33.3 (C-37); 33.2 (C-35); 31.5 (C-42); 31.3 (C-41); 30.9 (C-13); 27.1 (C-12); 27.0 (C-3); 25.2 (C-5); 21.4 (23- CH_3); 20.7 (C-4); 17.3 (11- CH_3); 16.1 (31- CH_3); 15.9 (35- CH_3); 14.4 (25- CH_3); 14.2 (29- CH_3); 10.3 (17- CH_3).

36

- 36 -

MS (FAB) m/z : 884 (M-OCH₃, 35%); 866 (M-[OCH₃ + H₂O], 100%); 848 (M-[OCH₃ + 2 H₂O], 40%).

MBA (rel. IC₅₀): 1.7

MLR (rel. IC₅₀): 1

IL-6 dep. prol. (rel. IC₅₀): 7.5

37

MULTIPLE
FEE
(FOR

PENDING CLAIM
NOTIFICATION SHEET
(FORM PTO-875)

08/416623

APPLICANT

CLAIMS

	AS FILED		AFTER 1st AMENDMENT		AFTER 2nd AMENDMENT														
	IND.	DEP.	IND.	DEP.	IND.	DEP.							IND.	DEP.	IND.	DEP.			
1												51							
2												52							
3												53							
4												54							
5												55							
6												56							
7												57							
8												58							
9												59							
10												60							
11												61							
12												62							
13												63							
14												64							
15												65							
16												66							
17												67							
18												68							
19												69							
20												70							
21												71							
22												72							
23												73							
24												74							
25												75							
26												76							
27												77							
28												78							
29												79							
30												80							
31												81							
32												82							
33												83							
34												84							
35												85							
36												86							
37												87							
38												88							
39												89							
40												90							
41												91							
42												92							
43												93							
44												94							
45												95							
46												96							
47												97							
48												98							
49												99							
50												100							
TOTAL IND.												TOTAL IND.							
TOTAL DEP.												TOTAL DEP.							
TOTAL CLAIMS												TOTAL CLAIMS							

PTO-1360 (3-78)

*MAY BE USED FOR ADDITIONAL CLAIMS OR AMENDMENTS

U.S. DEPARTMENT of COMMERCE
Patent and Trademark Office

PATENT NUMBER				ORIGINAL CLASSIFICATION			
				CLASS		SUBCLASS	
				514		514	
APPLICATION SERIAL NUMBER				CROSS REFERENCE(S)			
08/416,673				CLASS		SUBCLASS (ONE SUBCLASS PER BLOCK)	
APPLICANT'S NAME (PLEASE PRINT)				340		456	
COTTENS ET AL							
IF REISSUE, ORIGINAL PATENT NUMBER							
INTERNATIONAL CLASSIFICATION							
A	G	K		31/395			
C	O	D		498/16			
GROUP ART UNIT			ASSISTANT EXAMINER (PLEASE STAMP OR PRINT FULL NAME)				
1202			Robert T. B...				
			PRIMARY EXAMINER (PLEASE STAMP OR PRINT FULL NAME)				

PTO 270

ISSUE CLASSIFICATION SLIP

U.S. DEPARTMENT OF COMMERCE

SEARCHED			
Class	Sub.	Date	Exmr.
540	456	18 APRIL	RJB
514	514	1996	
above to date		12 DEC	RJB
		1996	

SEARCH NOTES		
CAS-ON-LINE STN	Date	Exmr.
	18 APRIL	RJB
	1996	

INTERFERENCE SEARCHED			
Class	Sub.	Date	Exmr.
540	456	12 DEC	RJB
514	514	1996	

(RIGHT OUTSIDE)

514-514
 514 514
 Claims Success
 ISSUE CLASSIFICATION

FILED UNDER 35 U.S.C. 371

5665772

UTILITY SERIAL NUMBER 08/416673	PATENT DATE SEP 09 1997	PATENT NUMBER 5665772
------------------------------------	----------------------------	--------------------------

SERIAL NUMBER	FILING DATE	CLASS	SUBCLASS 514	GROUP ART UNIT 3	EXAMINER
---------------	-------------	-------	-----------------	---------------------	----------

APPLICANTS
 FROM THE PATENT DATA CENTER
 VERIFIED
 RJB

FOREIGN PRIORITY APPLICATIONS
 VERIFIED GREAT BRITAIN 92712201
 RJB

**CERTIFICATE
 JUN 30 1998
 OF CORRECTION**

Foreign priority claimed 35 USC 119 conditions met	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no	AS FILED	STATE OR COUNTRY	SHEETS DRWGS.	TOTAL CLAIMS	INDEP. CLAIMS	FILING FEE RECEIVED	ATTORNEY'S DOCKET NO.
Verified and Acknowledged	Examiner's Initials RJB		→						

ADDRESS
 ROBERT S HONOR
 SANDOZ CORPORATION
 59 ROUTE 10
 EAST HANOVER, NJ 07936-3050

TITLE
 D-ALKYLATED RAPAMYCIN DERIVATIVES AND PHARMACEUTICAL PREPARATIONS THEREOF

U.S. DEPT. OF COMM./PAT. & TM—PTO-436L (Rev.12-94)

PARTS OF APPLICATION FILED SEPARATELY		C. Steyer Applications Examiner 12/13	
NOTICE OF ALLOWANCE MAILED 12-16-96		CLAIMS ALLOWED	
ISSUE FEE 170		Total Claims 10	Print Claim 9
Amount Due 11390.00	Date Paid 3-17-97	DRAWING	
Label Area		Sheets Drwg. 0	Figs. Drwg. 0
Assistant Examiner Robert T. Bond PRIMARY EXAMINER ART UNIT 1202		Print Fig. 0	ISSUE BATCH NUMBER A50
Primary Examiner		PREPARED FOR ISSUE	
WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.			

Form PTO-436A (Rev. 8/92)

10
 ISSUE FEE IN FULL

(FACE)

Staple Issue Slip Here

5/4-5/4
5/4 5/4
Class Subclass
ISSUE CLASSIFICATION

UTILITY SERIAL NUMBER 08/4166

POSITION	ID NO.	DATE
CLASSIFIER	6	8-2-95
EXAMINER	600	8/21/95
TYPIST	88	1/13
VERIFIER	20	1/16
CORPS CORR.		
SPEC. HAND		
FILE MAINT.		
DRAFTING		

APPLICANTS

**CONTINUING DATE VERIFIED
RJB

**FOREIGN/PCT APPLICANTS VERIFIED
RJB

Foreign priority claimed
35 USC 119 conditions met

Verified and Acknowledged

ROBERT'S HONOR SANDOZ CORPORA
59 ROUTE 10
EAST HANOVER N

TITLE
O-ALKYLATED RA
1 MMLINDSUPPRESS

PARTS OF APPLICATION FILED SEPARATELY

NOTICE OF ALLOWANCE
12-16-96

ISSUE FEE

Amount Due \$1290.00
Date Paid 3-1

Label Area

Form PTO-436A (Rev. 8/92)

INDEX OF CLAIMS

Claim	Date
1	
2	
3	
4	12/96
5	4/96
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	

Claim	Date
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

SYMBOLS

- ✓ Rejected
- Allowed
- (Through numeral) Cancelled
- Restricted
- W Non-elected
- I Interference
- A Appeal
- O Objected

(LEFT INSIDE)

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only	
International Application No.	PCT/EP 93 / 0 2 6 0 4
International Filing Date	2 4 SEP 1993 (2 4. 09. 93)
EUROPEAN PATENT OFFICE PCT INTERNATIONAL APPLICATION Name of receiving Office and "PCT International Application"	
Applicant's or agent's file reference (if desired) (12 characters maximum)	100-7932

Box No. I	TITLE OF INVENTION RAPAMYCIN DERIVATIVES	
Box No. II	APPLICANT	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)</i>	<input type="checkbox"/> This person is also inventor.	
SANDOZ LTD. Lichtstrasse 35 CH-4002 Basle Switzerland	Telephone No. 061 324 44 53	
	Facsimile No. 061 322 75 32	
	Teleprinter No. 965 050 55	
State (i.e. country) of nationality: CH	State (i.e. country) of residence: CH	
This person is applicant for the purposes of:	<input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input checked="" type="checkbox"/> the States indicated in the Supplemental Box	
Box No. III	FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)</i>	This person is:	
SANDOZ-PATENT-GMBH Humboldtstrasse 3 D-79539 Lörrach Germany	<input checked="" type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)	
State (i.e. country) of nationality: DE	State (i.e. country) of residence: DE	
This person is applicant for the purposes of:	<input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input checked="" type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)</i>	This person is:	
SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. Brunner Strasse 59 A-1230 Vienna Austria	<input checked="" type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)	
State (i.e. country) of nationality: AT	State (i.e. country) of residence: AT	
This person is applicant for the purposes of:	<input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input checked="" type="checkbox"/> the States indicated in the Supplemental Box	
<input checked="" type="checkbox"/> Further applicants and/or (further) inventors are indicated on a continuation sheet.		

Continuation of Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS	
If none of the following sub-boxes is used, this sheet is not to be included in the request.	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) COTTENS, Sylvain In den Reben 12 CH-4108 Witterswil Switzerland	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)
State (i.e. country) of nationality: CH	State (i.e. country) of residence: CH
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) SEDRANI, Richard Herrenggrabenweg 15 CH-4054 Basle Switzerland	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)
State (i.e. country) of nationality: LU	State (i.e. country) of residence: CH
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)	This person is: <input type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)
State (i.e. country) of nationality:	State (i.e. country) of residence:
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)	This person is: <input type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)
State (i.e. country) of nationality:	State (i.e. country) of residence:
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<input type="checkbox"/> Further applicants and/or (further) inventors are indicated on another continuation sheet.	

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: agent common representative

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

SANDOZ LTD.
Patents & Trademarks Div.
Lichtstrasse 35
CH-4002 Basle
Switzerland

Telephone No.
061 324 44 53

Fascimile No.
061 322 75 32

Teleprinter No.
965 050 55

Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

- Regional Patent**
- EP European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, DE Germany, DK Denmark, ES Spain, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
 - OA OAPI Patent: Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Gabon, Guinea, Mali, Mauritania, Niger, Senegal, Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

- National Patent (if other kind of protection or treatment desired, specify on dotted line):**
- | | |
|---|---|
| <input type="checkbox"/> AT Austria | <input type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> AU Australia | <input type="checkbox"/> MW Malawi |
| <input type="checkbox"/> BB Barbados | <input type="checkbox"/> NL Netherlands |
| <input type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> NO Norway |
| <input type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> NZ New Zealand |
| <input type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> PL Poland |
| <input type="checkbox"/> CA Canada | <input type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> RU Russian Federation |
| <input type="checkbox"/> DE Germany | <input type="checkbox"/> SD Sudan |
| <input type="checkbox"/> DK Denmark | <input type="checkbox"/> SE Sweden |
| <input type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> FI Finland | <input type="checkbox"/> UA Ukraine |
| <input type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> HU Hungary | |
| <input checked="" type="checkbox"/> JP Japan | <input type="checkbox"/> VN Viet Nam |
| <input type="checkbox"/> KP Democratic People's Republic of Korea | |
| <input checked="" type="checkbox"/> KR Republic of Korea | |
| <input type="checkbox"/> KZ Kazakhstan | |
| <input type="checkbox"/> LK Sri Lanka | |
| <input type="checkbox"/> LU Luxembourg | |
| <input type="checkbox"/> MG Madagascar | |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

In addition to the designations made above, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except the designation(s) of _____.

The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

Supplemental Box *If the Supplemental Box is not used, this sheet need not be included in the request.*

Use this box in the following cases:

1. *If, in any of the Boxes, the space is insufficient to furnish all the information:*

in particular:

- (i) *if more than three persons are involved as applicants and/or inventors and no "continuation sheet" is available:*
- (ii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked:*
- (iii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America:*
- (iv) *if, in addition to the agent(s) indicated in Box No. IV, there are further agents:*
- (v) *if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," "certificate of addition," or "inventor's certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "Continuation" or "Continuation-in-part":*
- (vi) *if there are more than three earlier applications whose priority is claimed:*

in such case, write "Continuation of Box No. ..." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient;

in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III;

in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State or States (and/or, where applicable, European or OAPI patent) for the purposes of which the named person is applicant;

in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State or States (and/or, where applicable, European or OAPI patent) for the purposes of which the named person is inventor;

in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;

in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;

in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI.

2. *If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty:*

in such case, write "Statement Concerning Non-Prejudicial Disclosures or Exceptions to Lack of Novelty" and furnish that statement below.

Continuation of Box No. II

SANDOZ LTD. is applicant for all designated countries except DE (Germany), AT (Austria) and US.

Continuation of Box No. III

SANDOZ-PATENT-GMBH is applicant for DE (Germany) only

SANDOZ-ERFINDUNGEN

VERWALTUNGSGESELLSCHAFT M.B.H. is applicant for AT (Austria) only

Box No. VI PRIORITY CLAIM Further priority claims are indicated in the Supplemental Box

The priority of the following earlier application(s) is hereby claimed:

Country (in which, or for which, the application was filed)	Filing Date (day/month/year)	Application No.	Office of filing (only for regional or international application)
item (1) GB	9 October 1992 (09/10/92)	9221220.8	
item (2)			
item (3)			

Mark the following check-box if the certified copy of the earlier application is to be issued by the Office which for the purposes of the present international application is the receiving Office (a fee may be required):

The receiving Office is hereby requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s):

Box No. VII EARLIER SEARCH

Fill in where a search (international, international-type or other) by the International Searching Authority has already been carried out or requested and the Authority is now requested to base the international search, to the extent possible, on the results of that earlier search. Identify such search or request either by reference to the relevant application (or the translation thereof) or by reference to the search request:

Country (or regional Office): _____ Date (day/month/year): _____ Number: _____

Box No. VIII CHECK LIST

This international application contains the following number of sheets:

- 1. request : 5 sheets
- 2. description : 36 sheets
- 3. claims : 4 sheets
- 4. abstract : 1 sheet
- 5. drawings : - sheets
- Total : 46 sheets

This international application is accompanied by the item(s) marked below:

- 1. separate signed power of attorney
- 2. copy of general power of attorney
- 3. statement explaining lack of signature
- 4. priority document(s) identified in Box No. VI as item(s):
- 5. fee calculation sheet
- 6. separate indications concerning deposited microorganisms
- 7. nucleotide and/or amino acid sequence listing (diskette)
- 8. other (specify):

Figure No. _____ of the drawings (if any) should accompany the abstract when it is published.

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

<p>SANDOZ LTD. <i>J. Kramer</i> SANDOZ-PATENT-GMBH <i>Dr. B. Molac</i></p>	<p>SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H. <i>Haus</i> <i>Dieter</i> P. Räss</p>	<p><i>Sylvain Cottens</i> Sylvain Cottens <i>Richard Sedrani</i> Richard Sedrani</p>
--	--	--

For receiving Office use only

1. Date of actual receipt of the purported international application:	24 SEP 1993 (24.09.93)	2. Drawings: <input type="checkbox"/> received: <input checked="" type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		
4. Date of timely receipt of the required corrections under PCT Article 11(2):		
5. International Searching Authority specified by the applicant: ISA /	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid	

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 100-7932	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 93/02604	International filing date (day/month/year) 24/09/93	(Earliest) Priority Date (day/month/year) 09/10/92
Applicant SANDOZ LTD. et al.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Certain claims were found unsearchable (see Box I).
2. Unity of invention is lacking (see Box II).
3. The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing
 - filed with the international application.
 - furnished by the applicant separately from the international application,
 - but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
 - Transcribed by this Authority

4. With regard to the title,
 - the text is approved as submitted by the applicant.
 - the text has been established by this Authority to read as follows:

O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNO-SUPPRESSANTS

5. With regard to the abstract,
 - the text is approved as submitted by the applicant.
 - the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:
 - Figure No. _____ as suggested by the applicant. None of the figures.
 - because the applicant failed to suggest a figure.
 - because this figure better characterizes the invention.

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claim 9 refers to the description. Therefore (R.6.2(a),PCT) it has not been searched.
Claims searched completely: 1-8

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:


4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

Novel O-alkylated derivatives of rapamycin of formula (I), especially 40-O-alkylated derivatives, are found to have pharmaceutical utility, particularly as immunosuppressants.



(I)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 93/02604

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D498/18 C07F 18 A61K31/435 //C07D498/18,311:00,
273:00,221:00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07D C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 151 413 (C. E. CAUFIELD ET AL) 29 September 1992 see claims 1,13	1,7
X	US,A,5 120 842 (A. A. FAILLI ET AL) 9 June 1992 see claim 1	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

1

Date of the actual completion of the international search 14 December 1993	Date of mailing of the international search report 28. 12. 93
--	---

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+ 31-70) 340-3016	Authorized officer Voyiazoglou, D
--	---

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 93/02604

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5151413	29-09-92	NONE	
US-A-5120842	09-06-92	AU-A- 1389392	08-10-92
		EP-A- 0507556	07-10-92
		JP-A- 5078377	30-03-93

INTERNATIONAL SEARCH REPORT

International Application No

PC 93/02604

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 5 C07D498/18 C07F7/18 A61K31/435 //C07D498/18,311:00,
 273:00,221:00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 151 413 (C. E. CAUFIELD ET AL) 29 September 1992 see claims 1,13	1,7
X	US,A,5 120 842 (A. A. FAILLI ET AL) 9 June 1992 see claim 1	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

14 December 1993

Date of mailing of the international search report

28.12.93

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Voyiazoglou, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 93/02604

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5151413	29-09-92	NONE	
US-A-5120842	09-06-92	AU-A- 1389392	08-10-92
		EP-A- 0507556	07-10-92
		JP-A- 5078377	30-03-93

PATENT COOPERATION TREATY
PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 100-7932	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 93/02604	International filing date (day/month/year) 24/09/93	(Earliest) Priority Date (day/month/year) 09/10/92
Applicant SANDOZ LTD. et al.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Certain claims were found unsearchable (see Box I).
2. Unity of invention is lacking (see Box II).
3. The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing
 - filed with the international application.
 - furnished by the applicant separately from the international application,
 - but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
 - Transcribed by this Authority
4. With regard to the title,
 - the text is approved as submitted by the applicant.
 - the text has been established by this Authority to read as follows:
O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNO-SUPPRESSANTS
5. With regard to the abstract,
 - the text is approved as submitted by the applicant.
 - the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is:
 - Figure No. _____ as suggested by the applicant. None of the figures.
 - because the applicant failed to suggest a figure.
 - because this figure better characterizes the invention.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 93/02604

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claim 9 refers to the description. Therefore (R.6.2(a),PCT) it has not been searched.
Claims searched completely: 1-8

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:


4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

Novel O-alkylated derivatives of rapamycin of formula (I), especially 40-O-alkylated derivatives, are found to have pharmaceutical utility, particularly as immunosuppressants.



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 93/02604

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D498/18 C07F7/18 A61K31/435 //C07D498/18,311:00,
273:00,221:00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07D C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 151 413 (C. E. CAUFIELD ET AL) 29 September 1992 see claims 1,13	1,7
X	US,A,5 120 842 (A. A. FAILLI ET AL) 9 June 1992 see claim 1	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 December 1993

Date of mailing of the international search report

28.12.93

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Voyiazoglou, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 93/02604

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5151413	29-09-92	NONE	
US-A-5120842	09-06-92	AU-A- 1389392	08-10-92
		EP-A- 0507556	07-10-92
		JP-A- 5078377	30-03-93

Form PCT/ISA/210 (patent family annex) (July 1992)

DO/US WORKSHEET

U.S. Appl. No. 08/41677

International App. No. EP93/02604

Application filed by: 20 months .. 30 months

INTERNATIONAL APPLICATION PAPERS IN THE APPLICATION FILE:

- | | |
|--|---|
| <input checked="" type="checkbox"/> International application (RECORD COPY) | <input type="checkbox"/> Request form PCT/RO/101 |
| <input type="checkbox"/> Article 19 amendments | <input type="checkbox"/> PCT/IB/302 |
| <input checked="" type="checkbox"/> PCT/IB/331 | <input checked="" type="checkbox"/> PCT/ISA/210-Search Report |
| <input checked="" type="checkbox"/> PCT/IPEA/409 IPER (PCT/IPEA/416 on front) | <input checked="" type="checkbox"/> Search Report references |
| <input checked="" type="checkbox"/> Annexes to 409 | <input type="checkbox"/> Other _____ |
| <input checked="" type="checkbox"/> Priority document(s) No. <u>1</u> | |
| <input type="checkbox"/> INTERNATIONAL APPLICATION ON DOUBLE SIDED PAPER (COPIES MADE) | |

RECEIPTS FROM THE APPLICANT: (other than checked above)

- | | |
|---|---|
| <input checked="" type="checkbox"/> Basic National Fee (paid or authorized to charge) | <input type="checkbox"/> Preliminary amendment(s) filed |
| Translation of international application as filed: | |
| <input type="checkbox"/> Description | |
| <input checked="" type="checkbox"/> Claims | <input type="checkbox"/> Information Disclosure Statement |
| <input type="checkbox"/> Words in the drawing figure(s) | <input type="checkbox"/> Assignment document |
| <input type="checkbox"/> Article 19 amendments | <input checked="" type="checkbox"/> Power of attorney/Change of address |
| <input type="checkbox"/> Annexes to 409 | <input type="checkbox"/> Substitute specification |
| <input checked="" type="checkbox"/> Oath / Declaration | <input type="checkbox"/> Verified small status claim |
| <input type="checkbox"/> DNA diskette | <input type="checkbox"/> Other _____ |

Notes:

35 U.S.C. 371 - Receipt of Request (PTO-1390)	07 APR 1995
Date acceptable oath / declaration received	07 APR 1995
Date complete 35 U.S.C 371 requirements met	07 APR 1995
102(e) Date	
Date of completion of DO/EO 906 - Notification of Missing 102(e) Requirements	
Date of completion of DO/EO 907 - Notification of Acceptance for 102(e) date	
Date of completion of DO/EO 911 - Application accepted under 35 U.S.C. 1.11	
Date of completion of DO/EO 905 - Notification of Missing Requirements	09 APR 1995
Date of completion of DO/EO 916 - Notification of Defective Response	
Date of completion of DO/EO 903 - Notification of Acceptance	
Date of completion of DO/EO 909 - Notification of Abandonment	

WIPO Publication
 Publication No. W094/09010
 Publication Date 28 Apr 94
 Publication Language English
 Not Published
 U.S. only
 Designated
 EP request

Screening done by:

J. Smith

16

PATENT COOPERATION TREATY
PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 04 NOV 1994
REPORT PCT

Applicant's or agent's file reference 100-7932	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/EP 93/02604	International filing date (day/month/year) 24/09/1993
Priority date (day/month/year) 09/10/1992	
International Patent Classification (IPC) or national classification and IPC C07D498/18	
Applicant SANDOZ LTD. et al.	

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings amended during international preliminary examination and/or containing rectifications made before this Authority.

These annexes consists of a total of 4 sheets.

3. This report contains indications and corresponding pages relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV Lack of unity of invention
- V Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 08/03/1994	Date of completion of this report 02. 11. 94
Name and mailing address of the IPEA/  European Patent Office D-80298 Munich Tel. (+49-89) 2399-0, Tx: 523656 epmu d Fax: (+49-89) 2399-4465	Authorized officer  C. Ortega-Plaza

I. Basis of the report

1. This report has been drawn up on the basis of:

the international application as originally filed.

the description, pages 1-36 _____, as originally filed,
pages _____, filed with the demand,
pages _____, filed with the letter of _____,
pages _____, filed with the letter of _____.

the claims, No. _____, as originally filed,
No. _____, as amended under Article 19,
No. _____, filed with the demand,
No. 1-8 _____, filed with the letter of 18.10.94,
No. _____, filed with the letter of _____.

the drawings, sheets/fig _____, as originally filed,
sheets/fig _____, filed with the demand,
sheets/fig _____, filed with the letter of _____,
sheets/fig _____, filed with the letter of _____.

2. The amendments have resulted in the cancellation of: pages: _____
sheets of drawings/figures No.: _____.

3. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed:

The introduction of the proviso "provided that hydroxyalkoxyalkyl is other than hydroxyalkoxymethyl" does not meet the requirements of Art. 34, 2(b) PCT. This proviso does not exclude compounds which are disclosed in D1, since the acetals disclosed in D1 do not include acetals groups substituted by hydroxy. Moreover there is no basis to be found for the introduction of the said proviso in the description.

4. Additional observations, if necessary:

The introduction of the term "hydroxyalkoxyalkyl" in claim 1 relates to the correction of an obvious error. This term was forgotten in the original claim 1 by mistake but clearly appeared on page 4 of the description as one of the possible meanings for the radical R^1 . Since R^1 and R^2 have the same possible meanings the correction introduced in claim 1 is considered to be obvious.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims 1-8 _____	YES
	Claims _____	NO
Inventive Step (IS)	Claims _____	YES
	Claims 1-8 _____	NO
Industrial Applicability (IA)	Claims 1-8 _____	YES
	Claims _____	NO

2. CITATIONS AND EXPLANATIONS

1. The following documents have been considered for the establishment of this preliminary opinion:

D1 = US-A-5151413

D2 = US-A-5120842

2. The novelty of the subject-matter claimed has been established vis-à-vis the contents of D1 and D2 after restriction of the original claim 1 and introduction of a proviso.
3. The problem underlying the present application lies in the provision of further rapamycin derivatives useful as immunosuppressant agents.

Apart from the fact that the introduction of the proviso for excluding "hydroxyalkoxymethyl" cannot be found to be allowable the present claim still encompasses compounds which are the obvious equivalents to those disclosed in D1. D1 discloses acetals derivatives of

rapamycin and the present claim 1 encompasses i.a. the hemiacetal derivatives (cf. R^1 and/or R^2 being a hydroxymethylgroup). This fact also contradicts the argument brought by the Applicant that D1 and D2 should be considered as irrelevant for the analysis of inventive step since they relate to labile derivatives or protected forms of rapamycin and would act as prodrugs. A hemiacetal is more labile than an acetal derivative and the lability problem also applies to other claimed possibilities such as R^1 , R^2 being aminomethyl, dihydroxymethyl, etc., all of them derivatives according to the present claim 1. Therefore the fact that the Applicant displayed pharmacological data comparing some other present compounds with rapamycin can only be seen as illustrative as far as very close derivatives to those disclosed in D1 are still claimed. Moreover there are reasonable doubts on whether all the compounds encompassed by claim 1 solve the technical problem.


VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Some of the expressions employed in claim 1 have been used apparently in a very broad sense which cannot be interpreted without ambiguity. For instance "Aryl" is intended to encompass some substituted possibilities such as tolyl. Moreover these terms (aryl, acyl, etc.) which have been used in an open-ended way are not further clarified in the original description. Therefore claim 1 encompasses possibilities which cannot be considered to be supported by the description, nor relate to solutions of the technical problem.

(Amended) CLAIMS

1. A compound of Formula I



(I)

wherein

X is (H,H) or O;

Y is (H,OH) or O;

R¹ and R² are independently selected from

- H, alkyl, ~~monoalkyl~~, arylalkyl, hydroxyalkyl, dihydroxyalkyl,
- hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl,
- aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl,
- arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, and
- hydroxyalkoxyalkyl ~~and alkoxyalkyl, and (R³)₃Si where each R³ is~~
- ~~independently selected from H, methyl, ethyl, isopropyl, t-butyl, and phenyl;~~
- wherein "alk-" or "alkyl" refers to C₁₋₆ alkyl, branched or linear, preferably
- C_{1,3} alkyl, ~~in which the carbon chain may be optionally interrupted by an~~

ether (-O-) linkage; and

R⁴ is methyl or R⁴ and R¹ together form C₂₋₆ alkylene;

provided that R¹ and R² are not both H; and

provided that alkoxyalkyl or hydroxyalkoxyalkyl is other than alkoxymethyl or hydroxyalkoxymethyl

~~provided that where R³ is carbalkoxyalkyl or (R⁵)₃Si, X and Y are not both O.~~

2. Compounds according to claim 1 selected from the following:

1. 40-O-Benzyl-rapamycin
2. 40-O-(4'-Hydroxymethyl)benzyl-rapamycin
3. 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin
4. 40-O-Allyl-rapamycin
5. 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin
6. (2'E, 4'S)-40-O-(4',5'-Dihydroxypent-2'-en-1'-yl)-rapamycin
7. 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin
8. 40-O-(2-Hydroxy)ethyl-rapamycin
9. 40-O-(3-Hydroxy)propyl-rapamycin
10. 40-O-(6-Hydroxy)hexyl-rapamycin
11. 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin
12. 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin
13. 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin
14. 40-O-(2-Acetoxy)ethyl-rapamycin
15. 40-O-(2-Nicotinoyloxy)ethyl-rapamycin
16. 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin
17. 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin
18. 40-O-[2-(N-Methyl-N'-piperazinyl)acetoxy]ethyl-rapamycin
19. 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin
20. (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin
21. 28-O-Methyl-rapamycin
22. 40-O-(2-Aminoethyl)-rapamycin

AMENDED SHEET

23. 40-O-(2-Acetaminoethyl)-rapamycin
24. 40-O-(2-Nicotinamidoethyl)-rapamycin
25. 40-O-(2-(N-Methyl-imidazo-2'-ylcarbethoxamido)ethyl)-rapamycin
26. 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin
27. 40-O-(2-Tolylsulfonamidoethyl)-rapamycin
28. 40-O-[2-(4',5'-Dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin

Compounds according to claim 1 where X and Y are both O, R² is H, R⁴ is methyl, and R¹ is other than H.

The compound according to claim 1 which is 40-O-(2-Hydroxy)ethyl-rapamycin.

A process for making compounds according to any one of claims 1 through 4 comprising the steps of ~~obtained or obtainable by~~ (i) reacting a rapamycin, deoxorapamycin, or dihydrorapamycin (optionally in O-protected form) with an organic radical (R¹ or R² as defined in claim 1, optionally in protected form) attached to a leaving group (X) ~~under suitable acidic or neutral reaction conditions~~, such that

(a) X is CCl₃(NH)O- and the reaction takes place in the presence of an acid; or

(b) X is CF₃SO₂- and the reaction takes place in the presence of a base;

and (ii) optionally reducing and/or (where necessary) deprotecting the product.

A compound according to any one of claims 1-5 for use as a pharmaceutical.

A pharmaceutical composition comprising a compound according to any one of claims 1-5 together with a pharmaceutically acceptable diluent or carrier.

Use of a compound according to claims 1-5 in the manufacture of a medicament for treating or preventing any of the following conditions:

- (i) autoimmune disease,
- (ii) allograft rejection,

AMENDED SHEET

- (iii) graft vs. host disease,
- (iv) asthma,
- (v) multidrug resistance,
- (vi) tumors or hyperproliferative disorders, or
- (vii) fungal infections,
- (viii) inflammation,
- (ix) infection by pathogens having Mip or Mip-like factors, or
- (x) overdose of macrophilin-binding immunosuppressants.

~~9. Novel products, processes, and utilities substantially as described herein.~~

AMENDED CASE.

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION CONCERNING
DOCUMENT TRANSMITTED

To:

United States Patent and Trademark
Office
Washington, D.C.

in its capacity as elected Office

Date of mailing: 08 November 1994 (08.11.94)	
International application No.: PCT/EP93/02604	International filing date: 24 September 1993 (24.09.93)
Applicant: SANDOZ LTD. et al	

The International Bureau transmits herewith the following documents and number thereof:

_____ copy of the international preliminary examination report and annexes (Article 36(3)(a))

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorised officer: I. Britel Telephone No.: (41-22) 730.91.11
--	---

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 100-7932	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/HPEA:416)	
International application No. PCT/EP 93/ 02604	International filing date (day/month/year) 24/09/1993	Priority date (day/month/year) 09/10/1992
International Patent Classification (IPC) or national classification and IPC C07D498/18		
Applicant SANDOZ LTD. et al.		

1 This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2 This REPORT consists of a total of 6 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings amended during international preliminary examination and/or containing rectifications made before this Authority.

These annexes consists of a total of 4 sheets.

3 This report contains indications and corresponding pages relating to the following items:

- I Basis of the report
- II Priority
- III Statement of opinion with regard to novelty, inventive step and industrial applicability
- IV Lack of unity of invention
- V Reasoned statement with regard to novelty, inventive step or industrial applicability; reasons and explanations supporting such statement
- VI Citations of documents cited
- VII Changes subject to the international application
- VIII Other observations on the international application

Date of submission of the demand 08/03/1994	Date of completion of this report 02. 11. 94
Name and mailing address of the IPEA  European Patent Office D 50265 Munich Tel: (+49 89) 2199 0, Fax: 521656 epmu d Telex: (+49 89) 2199 3165	Authorized officer  C. Ortega-Plaza

Form PCT/HPEA:409 (cover sheet) (July 1992) P20476

(25/03/1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Intern. application No.
PCT/EP93/02604

I. Basis of the report

1. This report has been drawn up on the basis of:

the international application as originally filed.

the description, pages 1-36 _____, as originally filed,
pages _____, filed with the demand,
pages _____, filed with the letter of _____,
pages _____, filed with the letter of _____.

the claims, No. _____, as originally filed,
No. _____, as amended under Article 19,
No. _____, filed with the demand,
No. 1-8 _____, filed with the letter of 18.10.94,
No. _____, filed with the letter of _____.

the drawings, sheets/fig _____, as originally filed,
sheets/fig _____, filed with the demand,
sheets/fig _____, filed with the letter of _____,
sheets/fig _____, filed with the letter of _____.

2. The amendments have resulted in the cancellation of: pages: _____
sheets of drawings/figures No.: _____.

3. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed:

The introduction of the proviso "provided that hydroxyalkoxyalkyl is other than hydroxyalkoxymethyl" does not meet the requirements of Art. 34, 2(b) PCT. This proviso does not exclude compounds which are disclosed in D1, since the acetals disclosed in D1 do not include acetals groups substituted by hydroxy. Moreover there is no basis to be found for the introduction of the said proviso in the description.

4. Additional observations, if necessary:

The introduction of the term "hydroxyalkoxyalkyl" in claim 1 relates to the correction of an obvious error. This term was forgotten in the original claim 1 by mistake but clearly appeared on page 4 of the description as one of the possible meanings for the radical R^1 . Since R^1 and R^2 have the same possible meanings the correction introduced in claim 1 is considered to be obvious.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Intern. application No.
PCT/EP93/02604

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims 1-8 _____	YES
	Claims _____	NO
Inventive Step (IS)	Claims _____	YES
	Claims 1-8 _____	NO
Industrial Applicability (IA)	Claims 1-8 _____	YES
	Claims _____	NO

2. CITATIONS AND EXPLANATIONS

1. The following documents have been considered for the establishment of this preliminary opinion:

D1 = US-A-5151413
D2 = US-A-5120842

2. The novelty of the subject-matter claimed has been established vis-à-vis the contents of D1 and D2 after restriction of the original claim 1 and introduction of a proviso.
3. The problem underlying the present application lies in the provision of further rapamycin derivatives useful as immunosuppressant agents.

Apart from the fact that the introduction of the proviso for excluding "hydroxyalkoxymethyl" cannot be found to be allowable the present claim still encompasses compounds which are the obvious equivalents to those disclosed in D1. D1 discloses acetals derivatives of

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Intern. application No.
PCT/EP93/02604

rapamycin and the present claim 1 encompasses i.a. the hemiacetal derivatives (cf. R^1 and/or R^2 being a hydroxymethylgroup). This fact also contradicts the argument brought by the Applicant that D1 and D2 should be considered as irrelevant for the analysis of inventive step since they relate to labile derivatives or protected forms of rapamycin and would act as prodrugs. A hemiacetal is more labile than an acetal derivative and the lability problem also applies to other claimed possibilities such as R^1 , R^2 being aminomethyl, dihydroxymethyl, etc., all of them derivatives according to the present claim 1. Therefore the fact that the Applicant displayed pharmacological data comparing some other present compounds with rapamycin can only be seen as illustrative as far as very close derivatives to those disclosed in D1 are still claimed. Moreover there are reasonable doubts on whether all the compounds encompassed by claim 1 solve the technical problem.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Intern. application No.
PCT/EP93/02604


VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Some of the expressions employed in claim 1 have been used apparently in a very broad sense which cannot be interpreted without ambiguity. For instance "Aryl" is intended to encompass some substituted possibilities such as tolyl. Moreover these terms (aryl, acyl, etc.) which have been used in an open-ended way are not further clarified in the original description. Therefore claim 1 encompasses possibilities which cannot be considered to be supported by the description, nor relate to solutions of the technical problem.

(Amended) CLAIMS

1. A compound of Formula I



wherein

X is (H,H) or O:

Y is (H,OH) or O:

R¹ and R² are independently selected from

H, alkyl, ~~thioalkyl~~, arylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, and hydroxyalkoxyalkyl ~~caralkoxyalkyl~~, and (R³)₃Si where each R³ is independently selected from H, methyl, ethyl, isopropyl, ~~i~~ butyl, and phenyl; wherein "alk-" or "alkyl" refers to C₁₋₆ alkyl, branched or linear, preferably C₁₋₃ alkyl, ~~in which the carbon chain may be optionally interrupted by an~~

AMENDED SHEET

ether (-O-) linkage; and

R⁴ is methyl or R⁴ and R¹ together form C₂₋₆ alkylene;

provided that R¹ and R² are not both H; and

provided that alkoxyalkyl or hydroxyalkoxyalkyl is other than alkoxymethyl or hydroxyalkoxymethyl

~~provided that where R² is carbalkoxyalkyl or (R²)₃Si, X and Y are not both O.~~

2. Compounds according to claim 1 selected from the following:

1. 40-O-Benzyl-rapamycin
2. 40-O-(4'-Hydroxymethyl)benzyl-rapamycin
3. 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin
4. 40-O-Allyl-rapamycin
5. 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin
6. (2'E, 4'S)-40-O-(4',5'-Dihydroxypent-2'-en-1'-yl)-rapamycin
7. 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin
8. 40-O-(2-Hydroxy)ethyl-rapamycin
9. 40-O-(3-Hydroxy)propyl-rapamycin
10. 40-O-(6-Hydroxy)hexyl-rapamycin
11. 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin
12. 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin
13. 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin
14. 40-O-(2-Acetoxy)ethyl-rapamycin
15. 40-O-(2-Nicotinoyloxy)ethyl-rapamycin
16. 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin
17. 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin
18. 40-O-[2-(N-Methyl-N'-piperazinyl)acetoxy]ethyl-rapamycin
19. 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin
20. (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin
21. 28-O-Methyl-rapamycin
22. 40-O-(2-Aminoethyl)-rapamycin

AMENDED SHEET

23. 40-O-(2-Acetaminoethyl)-rapamycin
 24. 40-O-(2-Nicotinamidoethyl)-rapamycin
 25. 40-O-(2-(N-Methyl-imidazo-2'-ylcarbethoxamido)ethyl)-rapamycin
 26. 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin
 27. 40-O-(2-Tolylsulfonamidoethyl)-rapamycin
 28. 40-O-[2-(4',5'-Dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin
3. Compounds according to claim 1 where X and Y are both O, R² is H, R⁴ is methyl, and R¹ is other than H.
 4. The compound according to claim 1 which is 40-O-(2-Hydroxy)ethyl-rapamycin.
 5. A process for making compounds according to any one of claims 1 through 4 comprising the steps of ~~obtained or obtainable by~~ (i) reacting a rapamycin, deoxorapamycin, or dihydrorapamycin (optionally in O-protected form) with an organic radical (R¹ or R² as defined in claim 1, optionally in protected form) attached to a leaving group (X) ~~under suitable acidic or neutral reaction conditions~~, such that
 - (a) X is CCl₃(NH)O- and the reaction takes place in the presence of an acid; or
 - (b) X is CF₃SO₃- and the reaction takes place in the presence of a base;and (ii) optionally reducing and/or (where necessary) deprotecting the product.
 6. A compound according to any one of claims 1-5 for use as a pharmaceutical.
 7. A pharmaceutical composition comprising a compound according to any one of claims 1-5 together with a pharmaceutically acceptable diluent or carrier.
 8. Use of a compound according to claims 1-5 in the manufacture of a medicament for treating or preventing any of the following conditions:
 - (i) autoimmune disease,
 - (ii) allograft rejection,


AMENDED SHEET

- (iii) graft vs. host disease,
- (iv) asthma,
- (v) multidrug resistance,
- (vi) tumors or hyperproliferative disorders, or
- (vii) fungal infections,
- (viii) inflammation,
- (ix) infection by pathogens having Mip or Mip-like factors, or
- (x) overdose of macrophilin-binding immunosuppressants.

9. ~~Novel products, processes, and utilities substantially as described herein.~~

(Amended) CLAIMS

1. A compound of Formula I



(I)

wherein

X is (H,H) or O;

Y is (H,OH) or O;

R^1 and R^2 are independently selected from

H, alkyl, ~~thioalkyl~~, arylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxy-carbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, and hydroxyalkoxyalkyl ~~caralkoxyalkyl, and $(R^3)_3Si$ where each R^3 is~~ independently selected from H, methyl, ethyl, isopropyl, ~~t~~-butyl, and phenyl; wherein "alk-" or "alkyl" refers to C_{1-6} alkyl, branched or linear, preferably C_{1-3} alkyl, in which the carbon chain may be optionally interrupted by an

ether (-O-) linkage; and

R⁴ is methyl or R⁴ and R¹ together form C₂₋₆ alkylene;

provided that R¹ and R² are not both H; and

provided that alkoxyalkyl or hydroxyalkoxyalkyl is other than alkoxyethyl or hydroxyalkoxyethyl

provided that where R⁴ is carbalkoxyalkyl or (R²)₃Si, X and Y are not both O.

2. Compounds according to claim 1 selected from the following:

1. 40-O-Benzyl-rapamycin
2. 40-O-(4'-Hydroxymethyl)benzyl-rapamycin
3. 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin
4. 40-O-Allyl-rapamycin
5. 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin
6. (2'E, 4'S)-40-O-(4',5'-Dihydroxypent-2'-en-1'-yl)-rapamycin
7. 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin
8. 40-O-(2-Hydroxy)ethyl-rapamycin
9. 40-O-(3-Hydroxy)propyl-rapamycin
10. 40-O-(6-Hydroxy)hexyl-rapamycin
11. 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin
12. 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin
13. 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin
14. 40-O-(2-Acetoxy)ethyl-rapamycin
15. 40-O-(2-Nicotinoyloxy)ethyl-rapamycin
16. 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin
17. 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin
18. 40-O-[2-(N-Methyl-N'-piperazinyl)acetoxy]ethyl-rapamycin
19. 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin
20. (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin
21. 28-O-Methyl-rapamycin
22. 40-O-(2-Aminoethyl)-rapamycin

23. 40-O-(2-Acetaminoethyl)-rapamycin
 24. 40-O-(2-Nicotinamidoethyl)-rapamycin
 25. 40-O-(2-(N-Methyl-imidazo-2'-ylcarbethoxamido)ethyl)-rapamycin
 26. 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin
 27. 40-O-(2-Tolylsulfonamidoethyl)-rapamycin
 28. 40-O-[2-(4',5'-Dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin
3. Compounds according to claim 1 where X and Y are both O, R² is H, R⁴ is methyl, and R¹ is other than H.
 4. The compound according to claim 1 which is 40-O-(2-Hydroxy)ethyl-rapamycin.
 5. A process for making compounds according to any one of claims 1 through 4 comprising the steps of ~~obtained or obtainable by~~ (i) reacting a rapamycin, deoxorapamycin, or dihydrorapamycin (optionally in O-protected form) with an organic radical (R¹ or R² as defined in claim 1, optionally in protected form) attached to a leaving group (X) ~~under suitable acidic or neutral reaction conditions~~, such that
 - (a) X is CCl₃(NH)O- and the reaction takes place in the presence of an acid; or
 - (b) X is CF₃SO₃- and the reaction takes place in the presence of a base;and (ii) optionally reducing and/or (where necessary) deprotecting the product.
 6. A compound according to any one of claims 1-5 for use as a pharmaceutical.
 7. A pharmaceutical composition comprising a compound according to any one of claims 1-5 together with a pharmaceutically acceptable diluent or carrier.
 8. Use of a compound according to claims 1-5 in the manufacture of a medicament for treating or preventing any of the following conditions:
 - (i) autoimmune disease,
 - (ii) allograft rejection,

- (iii) graft vs. host disease,
- (iv) asthma,
- (v) multidrug resistance,
- (vi) tumors or hyperproliferative disorders, or
- (vii) fungal infections,
- (viii) inflammation,
- (ix) infection by pathogens having Mip or Mip-like factors, or
- (x) overdose of macrophilin-binding immunosuppressants.

~~9. Novel products, processes, and utilities substantially as described herein.~~

Add
A2

add
C1

PATENT COOPERATION TREATY


Nitin
SK
TH

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

To:
SANDOZ LTD.
Patents & Trademarks Division
Lichtstr. 35
4002 Basel
SUISSE



(PCT Rule 71.1)

Date of mailing (day/month/year) **02. 11. 94**

Applicant's or agent's file reference 100-7932		IMPORTANT NOTIFICATION	
International application No. PCT/EP 93/ 02604	International filing date (day/month/year) 24/09/1993	Priority date (day/month/year) 09/10/1992	
Applicant SANDOZ LTD. et al.			

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.


3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

1. **RE MINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA:  European Patent Office D-80298 Munich Tel. (+ 49-89) 2399-0, Tx: 523656 epmu d Fax (+ 49-89) 2399-4465	Authorized officer Jose Ramon Ambroa
--	--

PATENT COOPERATION TREATY

Handwritten initials and scribbles in the top right corner.

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

To:
SANDOZ LTD.
 Patents & Trademarks Division
 Lichtstr. 35
 4002 Basel
 SWITZERLAND

Date of mailing
 (day/month/year) **28. 12. 93**

Applicant's or agent's file reference
100-7932

FOR FURTHER ACTION See paragraphs 1 and 4 below

International application No.
PCT/EP 93/02604

International filing date
 (day/month/year) **24/09/93**


Applicant
SANDOZ LTD. et al.


1. The applicant is hereby notified that the international search report has been established and is transmitted herewith.
Filing of amendments and statement under Article 19:
 The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally **2 months** from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

Where? To the International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland
 Facsimile No.: (41-22) 740.14.35

 For more detailed instructions, see the notes on the accompanying sheet.
2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.
3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2; the applicant is notified that:
 - the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
 - no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.
4. Further action(s): The applicant is reminded of the following:
 Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.
 Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).
 Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority
 European Patent Office, P.B. 5818 Patentlaan 2
 NL-2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

M. PEIS

NOTES TO FORM PCT/ISA/220

These notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty and of the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

The claims only.

The description and the drawings may only be amended during international preliminary examination under Chapter II.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confounded with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

NOTES TO FORM PCT/ISA/220 (continued)

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; Claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 TO 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings which cannot be amended under Article 19(1).

The statement will be published with the international application and the amended claims.

The statement should be brief, it should not exceed 500 words if in English or if translated into English.

It should not be confounded with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It should not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

In what language?

The amendments must be made in the language in which the international application is published. The letter and any statement accompanying the amendments must be in the same language as the international application if that language is English or French; otherwise, it must be in English or French, at the choice of the applicant.

Consequence if a demand for international preliminary examination has already been filed?

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase?

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark
Office
Washington, D.C.

in its capacity as elected Office

Date of mailing: 28 April 1994 (28.04.94)	Applicant's or agent's file reference: 100-7932
International application No.: PCT/EP93/02604	Priority date: 09 October 1992 (09.10.92)
International filing date: 24 September 1993 (24.09.93)	
Applicant: SANDOZ LTD. et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International preliminary Examining Authority on:
08 March 1994 (08.03.94)

in a notice effecting later election filed with the International Bureau on:

2. The election was
 was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer:</p> <p>J. Zahra</p> <p>Telephone No.: (41-22) 730.91.11</p>
--	--

INSTRUCTIONS FOR FILING REQUEST-FOR PATENT FEE REFUND FORMS
[FORM NUMBER PTO-1577]

Fill out the form completely, and print or type all information.

1. **DATE OF REQUEST:** Enter the date you fill out the form.
2. **SERIAL/PATENT #:** Enter the Serial or Patent Number.
3. Enter a check mark or an X in the box preceding the type of fee to be refunded. If the fee you are refunding is not listed, place a check mark or an X in the box preceding "**Other** _____" and print or type the fee type on the following blank line.
4. **PAPER NUMBER:** Enter the **PAPER NUMBER** of the document for which a refund is requested. [**PAPER NUMBER** refers to the sequential number (on the outside of the official file wrapper) assigned to the document. If the document has no number assigned to it, you may leave this box blank.]
5. **DATE FILED:** Enter the Mailroom Date of the document for which a refund is requested.
6. **AMOUNT:** Enter the dollar amount of the refund.
7. **TOTAL AMOUNT OF REFUND:** Add the dollar amounts in the column labeled **AMOUNT** and enter the total in the box.
8. **TO BE REFUNDED BY:** Enter a check mark or an X in the box preceding **TREASURY CHECK OR CREDIT DEPOSIT A/C #** to indicate how the refund is to be made. Requests to credit a Deposit Account must be accompanied by formal authorization to credit the account. Formal authorization to credit a deposit account consists of a copy of the signed statement by the owner of the Deposit Account granting the Commissioner permission to credit their account, **stamped with the FEE ACCOUNTABILITY STAMP with the amount of the refund circled.**
9. **DEPOSIT ACCOUNT NUMBER:** If refund is by credit to a Deposit Account, enter the Deposit Account Number.
10. **REASON:** Enter a check mark or an X in the box preceding the reason the refund is being requested. If there is no fee due, enter the reason on the 3 blank lines provided.
11. **REFUND REQUESTED BY:** Only PTO personnel formally authorized to request refunds should enter their **NAME, TITLE, PHONE NUMBER, OFFICE** and **SIGNATURE** on these blanks. Supervisors shall provide the Office of Finance with an advance list of personnel authorized to sign this form.

COPIES: **WHITE:** *Attach to the official file.*
 YELLOW: *Attach to the official file.*
 PINK: *Retain for originating office.*

Mail or hand-carry the completed form with attachment(s) to:
Office of Finance
Refund Branch
Crystal Park One, Room 802B

UNITED STATES PATENT & TRADEMARK OFFICE
Washington, D.C. 20231

REQUEST FOR PATENT FEE REFUND			
1 Date of Request: _____		2 Serial/Patent # <u>08/416673</u>	
3 Please refund the following fee(s):	4 PAPER NUMBER	5 DATE FILED	6 AMOUNT
Filing	1	07/19/95	\$ 130
Amendment			\$
Extension of Time			\$
Notice of Appeal/Appeal			\$
Petition			\$
Issue			\$
Cert of Correction/Terminal Disc.			\$
Maintenance			\$
Assignment			\$
Other			\$
7 TOTAL AMOUNT OF REFUND			\$ 130
8 TO BE REFUNDED BY:			
Treasury Check			
Credit Deposit A/C #:			
9 [A--01B4]			
10 REASON:			
<input checked="" type="checkbox"/>	Overpayment		
<input type="checkbox"/>	Duplicate Payment		
<input type="checkbox"/>	No Fee Due (Explanation):		
11 REFUND REQUESTED BY: <u>P. Kidwell</u>			
TYPED/PRINTED NAME: <u>P. Kidwell</u>		TITLE: <u>Paralel Specialist</u>	
SIGNATURE: <u>P. Kidwell</u>		PHONE: <u>305-3656</u>	
OFFICE: <u>PCT</u>			
***** THIS SPACE RESERVED FOR FINANCE USE ONLY: *****			
APPROVED: <u>Bell Phillips</u>		DATE: <u>5-30-95</u>	

Instructions for completion of this form appear on the back. After completion, attach white and yellow copies to the official file and mail or hand-carry to:

**Office of Finance
Refund Branch
Crystal Park One, Room 802B**



UNITED STATES DEPARTMENT OF COMMERCE
 Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

#2

US APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
08/416.673	COTTENS	S 100-7932/PCT
		INTERNATIONAL APPLICATION NO.
		PCT/EP93/02604
		I.A. FILING DATE
		PRIORITY DATE
		09/24/93 10/09/93
		DATE MAILED: 05/11/95

5611
 ROBERT S. HONOR
 SANDOZ PATENT DEPT
 59 ROUTE 10
 E. HANOVER, N.J. 07930-1080

**NOTIFICATION OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C. 371
 AND 37 CFR 1.494 OR 1.495**

1. The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated Office (37 CFR 1.494), an Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is **ACCEPTED** for national patentability examination in the United States Patent and Trademark Office.

2. The United States Application Number assigned to the application is shown above and the relevant dates are:

<u>7 APR 1995</u>	<u>7 APR 1995</u>
35 U.S.C. 102(e) DATE	DATE OF RECEIPT OF 35 U.S.C. 371 REQUIREMENTS

3. A request for immediate examination under 35 U.S.C. 371(f) was received on _____ and the application will be examined in turn.

4. The following items have been received:

- U.S. Basic National Fee.
- Copy of the international application in:
 - a non-English language.
 - English.
- Translation of the international application into English.
- Oath or Declaration of inventors(s) for DO/EO/US.
- Copy of Article 19 amendments. Translation of Article 19 amendments into English.
 - The Article 19 amendments have have not been entered.
- The International Preliminary Examination Report in English and its Annexes, if any.
- Translation of Annexes to the International Preliminary Examination Report into English.
 - The Annexes have have not been entered.
- Preliminary amendment(s) filed 7 APR 1995 and _____
- Information Disclosure Statement(s) filed _____ and _____
- Assignment document.
- Power of Attorney and/or Change of Address.
- Substitute specification filed _____
- Verified Statement Claiming Small Entity Status.
- Priority Document.
- Copy of the Search Report and copies of the references cited therein.
- Other:

A Filing Receipt (PTO-103X) will be issued for the present application in due course. Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

Penelope K. ...
 Telephone: (703) 305-3650

Bond, R.
416673

=> fil reg; d que stat

FILE 'REGISTRY' ENTERED AT 11:43:38 ON 26 APR 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 American Chemical Society (ACS)


STRUCTURE FILE UPDATES: 19 APR 96 HIGHEST RN 175414-60-5
DICTIONARY FILE UPDATES: 25 APR 96 HIGHEST RN 175414-60-5

TSCA INFORMATION NOW CURRENT THROUGH DECEMBER 1995

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

L1

STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE
L2 687 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 3912 ITERATIONS
SEARCH TIME: 00.00.10

687 ANSWERS

=> fil ca,caplus
FILE 'CA' ENTERED AT 11:43:45 ON 26 APR 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 11:43:45 ON 26 APR 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2
L3 657 FILE CA
L4 667 FILE CAPLUS

TOTAL FOR ALL FILES
L5 1324 L2

=> s l5(1)((autoimmun? or auto immun?)(3a)(diseas? or disorder#) or
allograft? or graft? or transplant? or asthm? or (multidrug# or
drug#)(3a)resist? or tum? or carcin? or cancer? or neoplas? or fung? or
inflamm? or infect? or immunosupress? or immun? suppress?)
L6 132 FILE CA
L7 132 FILE CAPLUS

TOTAL FOR ALL FILES
L8 264 L5(L)((AUTOIMMUN? OR AUTO IMMUN?)(3A)(DISEAS? OR DISORDER#
) OR ALLOGRAFT? OR GRAFT? OR TRANSPLANT? OR ASTHM? OR (MUL
TIDRUG# OR DRUG#)(3A)RESIST? OR TUM? OR CARCIN? OR CANCER?
OR NEOPLAS? OR FUNG? OR INFLAMM? OR INFECT? OR IMMUNOSUPR
ESS? OR IMMUN? SUPPRESS?)

=> s l8 and (treat? or therap? or prevent? or inhibit?)
L9 105 FILE CA
L10 105 FILE CAPLUS

TOTAL FOR ALL FILES
L11 210 L8 AND (TREAT? OR THERAP? OR PREVENT? OR INHIBIT?)

=> s l8(1)(treat? or therap? or prevent? or inhibit?)
L12 51 FILE CA
L13 51 FILE CAPLUS


TOTAL FOR ALL FILES
L14 102 L8(L)(TREAT? OR THERAP? OR PREVENT? OR INHIBIT?)

=> dup rem l14; d 1-51 bib abs hitstr; fil caold

PROCESSING COMPLETED FOR L14
L15 51 DUP REM L14 (51 DUPLICATES REMOVED)

L15 ANSWER 1 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 1
AN 124:220512 CA
TI Use of leflunomide to control and reverse chronic allograft
rejection and to prevent or control xenograft rejection
IN Williams, James W.
PA USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
PI WO 9601111 A1 960118
DS W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG,
KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL,
RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR,
IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 95-US8246 950630
PRAI US 94-270908 940705
DT Patent
LA English
AB Methods are disclosed for controlling or reversing chronic rejection
of allografts in a transplantation patient by administering
leflunomide product alone, or in combination with one or more
immunosuppressive agents selected from the group consisting of
cyclosporine A, FK506, rapamycin and corticosteroids. Also
disclosed are methods of preventing or controlling acute and chronic
rejection of xenografts in a transplantation patient by
administering leflunomide product alone, or in combination with one
or more immunosuppressive agents selected from the group consisting
of cyclosporine A, FK506, rapamycin and corticosteroids. The effect
of e.g. leflunomide alone or with cyclosporine A on chronic
rejection of rat cardiac allografts and on rejection of concordant
hamster to rat cardiac xenografts is described.
IT 53123-88-9, Rapamycin
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(leflunomide or A771726, alone or in immunosuppressant
combination, to control and reverse chronic allograft
rejection and to prevent or control xenograft
rejection)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Me

L15 ANSWER 2 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 2
 AN 124:75919 CA
 TI Cytokine and alloantibody networks in long term cardiac allografts
 in rat recipients treated with rapamycin
 AU Wasowska, Barbara; Wieder, Kenneth J.; Hancock, Wayne W.; Zheng, Xin
 Xiao; Berse, Brygida; Binder, Jochen; Strom, Terry B.;
 Kupiec-Weglinski, Jerzy W.
 CS Harvard Medical School, Division of Immunology, Boston, MA, 02215,
 USA
 SO J. Immunol. (1996), 156(1), 395-404
 CODEN: JOIMA3; ISSN: 0022-1767
 DT Journal
 LA English
 AB Treatment with rapamycin (RPM) prevents accelerated rejection of
 (LEW.times.BN)F1 cardiac allografts in LEW rats presensitized with

BN skin grafts. This study analyzed the influence of RPM on cytokine (IL-2, IL-4, IL-10, and IL-12) and alloantibody networks in this model. Accelerated (24-h) rejection was associated with strong expression of intragraft IL-2 and IL-12 (p40) mRNAs, which reached maximal levels 3 to 6 h post-transplantation. IL-4 and IL-10 mRNAs were readily detectable throughout the observation period. RPM therapy abrogated rejection at 24 h and prolonged cardiac allograft survival to about 50 days. This effect was correlated with a profound initial depression of IL-2 mRNA; delayed expression of IL-2 mRNA was detected in well functioning grafts at >20 days. In RPM-treated hosts, expression of IL-12 (p40) mRNA was low at the early time points (6-24 h), but prominent in long term grafts. The expression of both IL-4 and IL-10 mRNAs was preserved in RPM-conditioned hosts. Immunohistol. anal. of long term allografts revealed an interstitial cellular infiltrate and areas of intimal proliferation within small arteries indicative of early transplant arteriosclerosis. Anal. of cytokine proteins showed dense labeling of mononuclear and some endothelial cells for IL-4 and IL-12 (p70), but not for IL-2 or IFN- γ . RPM treatment diminished the IgM alloantibody response in the serum and prevented the switch from IgM to IgG alloantibody in the early post-transplant period. However, an increase in circulating and intragraft IgM and, to a lesser extent, IgG, primarily of the IgG2b subclass, was evident in long term recipients. Thus, RPM treatment reduces, but does not completely inhibit, the expression of Th1-type and preserves the expression of Th2-type cytokines. The demonstration of IL-12 in long term allografts after RPM therapy may reflect late activation of macrophages that, coupled with the appearance of IGG2a and IgG2b, may contribute to the ultimate chronic rejection of cardiac allografts.

IT 53123-88-9, Rapamycin


RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 3 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 3
 AN 124:219447 CA
 TI The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
 AU Murgia, Maria G.; Jordan, Samantha; Kahan, Barry D.
 CS Medical School, University Texas, Houston, TX, USA
 SO Kidney Int. (1996), 49(1), 209-16
 CODEN: KDYIA5; ISSN: 0085-2538
 DT Journal
 LA English
 AB A 14-day ascending dose course of sirolimus (rapamycin, RAPA) was administered to quiescent renal transplant patients receiving a double-drug cyclosporine (CsA)/corticosteroid regimen in a double-blinded randomized study. Oral sirolimus or placebo was delivered twice daily in divided doses for 13 days and a final dose

was administered on the morning of study day 14. In addn., patients in the sirolimus- and placebo-treated groups were compared with a demog. matched, concurrently treated control cohort of 30 patients who received the same concn.-controlled CsA/corticosteroid regimen. The study cohort was partitioned into four sirolimus dose level groups: placebo (0 mg/m²/day, N = 10), low dose (1 to 3 mg/m²/day, N = 9), medium dose (5 to 6 mg/m²/day, N = 9), and high dose (7 to 13 mg/m²/day, N = 12). The primary side effect of sirolimus was a reversible decrease in platelet (PLT) and white blood cell (WBC) counts. Cholesterol values increased statistically significantly in the sirolimus-treated patients when compared with those of the placebo patients, but not when compared with those of the control group patients. There were no statistically significant differences in the steady-state av. concns. of CsA among sirolimus dose groups (including placebo). No differences were obsd. between the pre- and post-sirolimus treatment values of systolic and diastolic blood pressure values, glomerular filtration rates (GFR), serum creatinine values (SCr), and serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) or triglyceride levels. Because the principal side effects of sirolimus are distinct from the principal nephrotoxic properties of CsA, this drug combination may display potent immunosuppression without exacerbated toxicity.

IT 53123-88-9, Sirolimus

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(study in quiescent cyclosporine-prednisone-treated renal transplant humans and the side effect profile of sirolimus)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 4 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 4
 AN 123:102312 CA
 TI Studies in experimental models of chronic rejection: Use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analog) for the suppression of graft vascular disease and obliterative bronchiolitis
 AU Morris, R. E.; Huang, X.; Gregory, C. R.; Billingham, M. E.; Rowan, R.; Shorthouse, R.; Berry, G. J.
 CS School Medicine, Stanford University, Stanford, CA, USA
 SO Transplant. Proc. (1995), 27(3), 2068-9
 CODEN: TRPPA8; ISSN: 0041-1345
 DT Journal
 LA English
 AB Rapamycin and leflunomide suppression of graft vascular disease and obliterative bronchiolitis was studied.

IT 53123-88-9, Rapamycin


RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(rapamycin and leflunomide suppression of graft
vascular disease and obliterative bronchiolitis in
prevention of chronic rejection of transplanted
organs)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

L15 ANSWER 5 OF 51 CA COPYRIGHT 1996 ACS

DUPLICATE 5

AN 124:164642 CA

TI Effect of rapamycin on renal allograft survival in canine recipients

treated with antilymphocyte serum, donor bone marrow, and cyclosporine

AU Hartner, William C.; Van der Werf, Willem J.; Lodge, J. Peter A.; Gilchrist, Brian; De Fazio, Sally R.; Markees, Thomas G.; Yatko, Christopher; Monaco, Anthony P.; Gozzo, James J.

CS Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA

SO Transplantation (1995), 60(11), 1347-50
CODEN: TRPLAU; ISSN: 0041-1337

DT Journal

LA English

AB Rapamycin (Rapa) monotherapy can promote renal allograft survival in dogs, but it is very toxic. To attempt to augment the effectiveness of Rapa and reduce its toxicity in a tolerance induction protocol, canine renal allograft recipients were treated briefly with antilymphocyte serum (ALS), donor bone marrow cells (BMC), and a limited course of cyclosporine (CsA),. Rapa had little effect when CsA-treated recipients were given ALS on days -5 to -1 and BMC on day +1. When combined with CsA given days +13 to +39 significantly increased overall survival and was compatible with long-term survival after immunosuppression (6 grafts, 1 graft >212 days, 1 graft >470 days). Rapa appeared to prevent early rejections that can occur during treatment with these ALS/BMC/CsA protocols. Little toxicity of Rapa was obsd. with any treatment.

IT 53123-88-9, Rapamycin


RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (effect of rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 6 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 6
 AN 124:75874 CA
 TI Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts
 AU Schmid, Christof; Heemann, Uwe; Azuma, Haruhito; Tilney, Nicholas L.
 CS Surgical Research Laboratory, Harvard Medical School, Boston, MA, USA
 SO Transplantation (1995), 60(7), 729-33
 CODEN: TRPLAU; ISSN: 0041-1337
 DT Journal
 LA English
 AB The authors have examd. the effects of rapamycin (RPM) on transplant vasculopathy in long-surviving F344 rat heart allografts transplanted heterotopically into Lewis recipients. RPM was administered i.p. for the first 14 days in groups 1 and 2 (0.5 and 2

mg/kg/day), and daily throughout the follow-up period in groups 3 (0.5 mg/kg/day) and 4 (5 mg/kg for 14 days, followed by a maintenance dose of 2.5 mg/kg/day). Treatment with low dose cyclosporine (CsA; 1.5 mg/kg/day) in combination with RPM (0.5 mg/kg/day for 14 days) (group 5) and immunosuppression with CsA only (5 mg/kg for 14 days, followed by 1.5 mg/kg/day) (group 6) were also examd. F344 isograft recipients treated with RPM (0.5 mg/kg/day for 14 days) (group 7), those that were untreated (group 8), and hearts in naive F344 animals (group 9) served as controls. Grafts of group 1 were removed at 50, 75, 100, 150, and 200 days and infiltrating cell populations and surface mols. were compared with those of the other groups at 100 days. All allografts in treated hosts functioned >100 days; in contrast, grafts in untreated recipients were rejected acutely by 8 days (MST). The incidence of transplant vasculopathy in group 1 increased progressively (MST = 10%, 59%, 85%, and 80% at 50, 100, 150, and 200 days, resp.), as manifested by myointimal proliferation with dense mononuclear infiltration (predominantly ED1+ macrophages). Nos. of MHC class II + infiltrating cells were prominent, as was expression of adhesion mols. and cytokines. The incidence of graft disease and extent of cellular infiltration at 100 days was significantly lower in animals receiving increased maintenance doses of RPM (for groups 2, 3, and 4: 25%, 22%, and 10%, resp.). CsA treatment either in combination with RPM or alone (groups 5 and 6) failed to improve transplant vasculopathy, but reduced mononuclear cell infiltration. Isografts (groups 7 and 8) and naive hearts (group 9) developed no structural abnormalities throughout the follow-up period, regardless of RPM treatment. The authors conclude that the extent of transplant vasculopathy can be reduced markedly in this rat cardiac transplant model with maintenance RPM. Addn. of CsA modifies the morphol. picture but does not improve myointimal proliferation.

IT 53123-88-9, Rapamycin


RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapamycin inhibits transplant vasculopathy
in long-surviving rat heart allografts)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 7 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 7
 AN 124:164651 CA
 TI Potential applications of therapeutic drug monitoring of sirolimus
 immunosuppression in clinical renal transplantation
 AU Kahan, Barry D.; Murgia, Maria G.; Slaton, Joel; Napoli, Kim
 CS Medical School, University Texas, Houston, TX, 77030, USA
 SO Ther. Drug Monit. (1995), 17(6), 672-5
 CODEN: TDMODV; ISSN: 0163-4356
 DT Journal
 LA English
 AB Sirolimus is a potent immunosuppressive agent with a novel
 mechanisms of action. It inhibits the transduction of cytokine
 signals necessary for the proliferation and maturation of T cells.
 Because sirolimus blocks a broad spectrum of cytokine signals, it
 seems logical to use it as an adjunct to CsA-based

immunosuppression. The high degree of synergy between these two agents, as suggested by the rigorous median-effect anal., has been confirmed by a reduced rate of rejection episodes among human renal allograft recipients. However, Phase I studies document wide interindividual variation in the pharmacokinetic parameters of 26 stable renal transplant patients, thereby suggesting that optimal therapy may require monitoring of drug concns., which is a task that has been somewhat simplified by the good correlation of trough level to AUC. Development of a monoclonal antibody assay system may simplify the monitoring of drug concns. further. Addnl. studies of sirolimus will be required to det. the therapeutic concns. and ratios of sirolimus to CSA that provide optimal immunosuppression, and to assess the possibility of a steroid-free regimen.

IT 53123-88-9, Sirolimus

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (potential applications of therapeutic drug monitoring of sirolimus immunosuppression in human clin. renal transplantation)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



Me

L15 ANSWER 8 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 8
 AN 123:25354 CA
 TI Comparison of rapamycin, RS 61443, cyclosporine, and low-dose heparin as treatment for transplant vasculopathy in a rat model of chronic allograft rejection
 AU Schmid, C.; Heemann, U.; Azuma, H.; Tilney, N. L.
 CS Surgical Research Laboratory, Harvard Medical School, Boston, MA, USA
 SO Transplant. Proc. (1995), 27(1), 438-9
 CODEN: TRPPA8; ISSN: 0041-1345
 DT Journal
 LA English
 AB The therapeutic potential of the immunosuppressants rapamycin and RS 61443 (mycophenolate mofetil) and cyclosporine and low-dose heparin on a rat heart allograft model of chronic rejection were compared. Rapamycin treatment in appropriate doses continued over a long term almost completely prevented the development of transplant vasculopathy and assocd. cellular infiltration, whereas RS 61443, cyclosporine, and heparin treatment decreased the interstitial mononuclear infiltration, but did not affect chronic obliterative vasculitis.
 IT 53123-88-9, Rapamycin
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (comparison of rapamycin and RS 61443 and cyclosporine and low-dose heparin as treatment for transplant vasculopathy in a rat model of chronic heart allograft rejection)
 RN 53123-88-9 CA
 CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



Me

L15 ANSWER 9 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 9
 AN 123:473 CA
 TI Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis
 in vitro and suppresses narrowing in arterial allografts and in
 balloon-injured carotid arteries: Evidence that rapamycin
 antagonizes growth factor action on immune and nonimmune cells
 AU Morris, R. E.; Cao, W.; Huang, X.; Gregory, C. R.; Billingham, M.
 E.; Rowan, R.; Shorthouse, R. A.
 CS Departments Cardiothoracic Surgery and Pathology, Stanford
 University School Medicine, Stanford, CA, 94305-5247, USA
 SO Transplant. Proc. (1995), 27(1), 430-1
 CODEN: TRPPA8; ISSN: 0041-1345
 DT Journal
 LA English
 AB Rapamycin inhibits growth factor-stimulated vascular smooth muscle

cell DNA synthesis in vitro. This effect of rapamycin may be mediated through complexes of rapamycin with FKBP. The results indicate that rapamycin may have potential therapeutic benefit in controlling vascular manifestations of chronic rejection as well as arterial narrowing after balloon angioplasty.

IT 53123-88-9, Sirolimus

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (rapamycin antagonizes growth factor action on immune and nonimmune cells and therapeutic potential for artery allograft and balloon angioplasty)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

L15 ANSWER 10 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 10
AN 122:288826 CA
TI Cytokine and alloantibody networks in long-term cardiac allografts
in rapamycin-treated sensitized rat recipients
AU Wasowska, B.; Wieder, K. J.; Hancock, W. W.; Berse, B.; Binder, J.;
Strom, T. B.; Kupiec-Weglinski, J. W.
CS Harvard Medical School, Brigham and Women's Hospital, Boston, MA,
02115, USA
SO Transplant. Proc. (1995), 27(1), 423-6
CODEN: TRPPA8; ISSN: 0041-1345
DT Journal
LA English
AB The authors studied the influence of rapamycin therapy on cytokine
and alloantibody networks in long-term surviving cardiac allograft
recipients.
IT 53123-88-9, Rapamycin
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(cytokine and alloantibody networks in long-term cardiac
allografts in rapamycin-treated sensitized rat
recipients)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Me

L15 ANSWER 11 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 11
 AN 122:103948 CA
 TI Composition containing 16-hydroxytriptolide and immunosuppressant
 for treating transplantation rejection
 IN Jin, Renling; Wiedmann, Tien Wen
 PA Pharmagenesis, Inc., USA
 SO PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 PI WO 9426265 A1 941124
 DS W: AU, CA, CN, JP
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 AI WO 94-US4990 940505
 PRAI US 93-58321 930506
 US 94-222853 940405
 DT Patent

LA English

AB A compn. contg. 16-hydroxytriptolide and an immunosuppressant for use in immunosuppression therapy is disclosed. The immunosuppressant drug included in the compn. is selected from cyclosporin A, FK506, azathioprine, methotrexate, rapamycin, mycophenolic acid, and a glucocorticoid. The compn. is particularly useful for in treating transplantation rejection, graft vs. host disease, or autoimmune disease. In example, 16-hydroxytriptolide was purified from air-dried root xylem of *Tripterygium wilfordii* plants, characterized, and evaluated for it's activity in suppressing lymphocytes, inhibiting cytokine prodn. and action of interleukin 1 and 2 on thymocytes, and potential cytotoxicity.

IT 160625-92-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compn. contg. 16-hydroxytriptolide and immunosuppressant for treating transplantation rejection)

RN 160625-92-3 CA

CN Rapamycin, mixt. with (15S)-16-hydroxytriptolide (9CI) (CA INDEX NAME)


CM 1

CRN 139713-80-7

CMF C20 H24 O7

CDES 6:15S-TRIPTOLIDE

Absolute stereochemistry.



CM 2


CRN 53123-88-9

CMF C51 H79 N O13

CDES *

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 12 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 12
 AN 121:149047 CA
 TI An in vitro/in vivo method using tumor cells with a
 transformation-sensitive reporter unit for identifying
 anti-neoplastic drugs
 IN Leibowitz, Paul J.; Wadsworth, Samuel C.; Woon, Chee-Wai
 PA Exemplar Corp., USA
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 PI WO 9416080 A1 940721
 DS W: AU, CA, FI, JP, NO
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 AI WO 94-US237 940107
 PRAI US 93-2224 930108
 DT Patent

LA English

AB A method for testing the ability of a drug to interfere with development of neoplasia is described. A tumor cell having a transformation-sensitive reporter unit is introduced into a recipient organism under a condition which reduces the recipient organism's rejection of the tumor cell, a drug is administered to this organism, and a detn. is made as to whether the drug has affected the expression of a structural gene that is part of the transformation-sensitive reporter unit by assaying for the expressed product of the structural gene. Preferably, the method also includes prescreening the drug by administering the drug to a culture of the tumor cells that have the transformation-sensitive reporter unit. Tumor cells and organisms having a transplanted tumor cell are also provided.

IT 53123-88-9, Rapamycin

RL: ANST (Analytical study)

(in transplantation of tumor cells with transformation-sensitive reporter unit, for in vivo neoplasm inhibitor screening)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

PAGE 1-A



Me

L15 ANSWER 13 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 13
 AN 122:9774 CA
 TI O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
 IN Cotteñs, Sylvain; Sedrani, Richard
 PA Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H., Austria; Sandoz-Patent-GmbH; Sandoz Ltd.
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 PI WO 9409010 A1 940428
 DS W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RO, RU, SK, US
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 AI WO 93-EP2604 930924
 PRAI GB 92-21220 921009
 DT Patent
 LA English
 OS MARPAT 122:9774
 GI



AB Novel O-alkylated derivs. of rapamycin I [X = O, H₂; Y = O, H, OH; R₁, R₂ = H, (un)substituted alkyl, alkenyl, organosilyl; R₃ = Me; R₁R₃ = alkylene], esp. 40-O-alkylated derivs., have pharmaceutical utility, particularly as immunosuppressants. Rapamycin was treated with Me₃CSiMe₂OCH₂CH₂O₃SCF₃ and desilylated to give 40-O-(2-hydroxyethyl)rapamycin which had the following IC₅₀ relative to rapamycin 1: mixed lymphocyte reaction 2.2, IL-6-dependent proliferation 2.8, macrophilin binding 3.4.

IT 144006-35-9P 150481-78-0P 153786-35-7P
157582-80-4P 159351-60-7P 159351-63-0P
159351-64-1P 159351-65-2P 159351-67-4P
159351-69-6P 159351-72-1P 159351-74-3P
159351-77-6P 159351-78-7P 159351-79-8P
159351-80-1P 159351-82-3P 159351-83-4P
159351-84-5P 159351-85-6P 159351-87-8P
159351-88-9P 159351-90-3P 159351-91-4P
159351-92-5P 159351-93-6P 159351-94-7P
159351-95-8P 159351-98-1P 159351-99-2P
159407-14-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and immunosuppressant and neoplasm-
inhibiting activity of)

RN 144006-35-9 CA

CN Rapamycin, 33-deoxo-33-hydroxy-, (33R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A




PAGE 2-A

Me


RN 150481-78-0 CA
CN Rapamycin, 15-deoxo- (9CI) (CA INDEX NAME)




RN 153786-35-7 CA
 CN Rapamycin, 42-O-2-propenyl- (9CI) (CA INDEX NAME)



RN 157582-80-4 CA
 CN Rapamycin, 42-O-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)




RN 159351-60-7 CA
 CN Rapamycin, 42-O-[[4-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 159351-63-0 CA

CN Rapamycin, 42-O-[[4-(2,3-dihydroxyethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 159351-64-1 CA


CN Rapamycin, 42-O-[3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2-propenyl]-, [42[E(S)]]- (9CI) (CA INDEX NAME)



RN 159351-65-2 CA
 CN Rapamycin, 42-O-(4,5-dihydroxy-2-pentenyl)-, [42(2E,4S)]- (9CI) (CA INDEX NAME)




RN 159351-67-4 CA
 CN Rapamycin, 42-O-[2-(2-hydroxyethoxy)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 159351-69-6 CA
CN Rapamycin, 42-O-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 159351-72-1 CA
CN Rapamycin, 42-O-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



Me

RN 159351-74-3 CA
 CN Rapamycin, 42-O-(6-hydroxyhexyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me


RN 159351-77-6 CA
 CN Rapamycin, 42-O-[2-(2-hydroxyethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




Me

RN 159351-78-7 CA
 CN Rapamycin, 42-O-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-, [42(R)]-(9CI) (CA INDEX NAME)




RN 159351-79-8 CA
 CN Rapamycin, 42-O-[2-(acetyloxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




Me

RN 159351-80-1 CA
 CN Rapamycin, 42-O-[2-[(3-pyridinylcarbonyl)oxy]ethyl]- (9CI) (CA
 INDEX NAME)




RN 159351-82-3 CA
 CN Rapamycin, 42-O-[2-[(4-morpholinylacetyl)oxy]ethyl]- (9CI) (CA
 INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 159351-83-4 CA

CN Rapamycin, 42-O-[2-[(1H-imidazol-1-ylacetyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 159351-84-5 CA
CN Rapamycin, 42-O-[2-[[(4-methyl-1-piperidinyl)acetyl]oxy]ethyl]-
(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 159351-85-6 CA
CN Rapamycin, 41-O-demethyl-41,42-O-1,2-ethanediyl- (9CI) (CA INDEX
NAME)



RN 159351-87-8 CA
 CN Rapamycin, 33-deoxo-33-hydroxy-42-O-(2-hydroxyethyl)-, (33R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




Me

RN 159351-88-9 CA
 CN Rapamycin, 31-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A




PAGE 2-A

Me


RN 159351-90-3 CA
CN Rapamycin, 42-O-[2-[(3-pyridinylcarbonyl)amino]ethyl]- (9CI) (CA
INDEX NAME)



RN 159351-91-4 CA
 CN Rapamycin, 42-O-[2-[[1-methyl-1H-imidazol-1-yl)carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 159351-92-5 CA
 CN Rapamycin, 42-O-[2-[(ethoxycarbonyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 159351-93-6 CA
 CN Rapamycin, 42-O-[2-[[(4-methylphenyl) sulfonyl] amino]ethyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




Me

RN 159351-94-7 CA
 CN Rapamycin, 42-O-[2-[4,5-bis(ethoxycarbonyl)-1H-1,2,3-triazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 159351-95-8 CA
 CN Rapamycin, 42-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 159351-98-1 CA
 CN Rapamycin, 42-O-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 159351-99-2 CA
 CN Rapamycin, 42-O-[2-(acetylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 159407-14-4 CA
 CN Rapamycin, 15,33-dideoxy-33-hydroxy-, (33R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



Me

L15 ANSWER 14 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 14
 AN 120:315804 CA
 TI Use of rapamycin in the treatment of AIDS
 IN Vezina, Claude
 PA Biochem Pharma Inc., Can.
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 PI WO 9405300 A1 940317
 DS W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP,
 KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD,
 SE, SK, UA, US, VN
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR,
 IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
 AI WO 93-CA384 930902
 PRAI US 92-938774 920903

US 93-102822 930806

DT Patent

LA English

AB Rapamycin or an analog of rapamycin is used in the manuf. of a medicament for treating, arresting the development, or retarding the progression of AIDS or an HIV infection in an amt. sufficient to achieve a redn. of the level of serum p24 antigen. The EC50 was 0.0965 ng rapamycin/mL for treating CCRF-CEM cells acutely infected with HIV-1; the TC50 was 0.6494 ng/mL.

IT 53123-88-9, Rapamycin 53123-88-9D, Rapamycin, analogs and esters and prodrugs 136293-03-3
136583-67-0 140687-14-5 141342-62-3
141392-23-6 141937-17-9 141937-18-0
155312-05-3

RL: BIOL (Biological study)

(HIV infection and AIDS treatment with)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



Me

RN 53123-88-9 CA
 CN Rapamycin (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me


RN 136293-03-3 CA
 CN Rapamycin, 42-deoxy-42-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




Me


RN 136583-67-0 CA
CN Rapamycin, 27-oxime (9CI) (CA INDEX NAME)




RN 140687-14-5 CA
 CN Rapamycin, 27-hydrazone (9CI) (CA INDEX NAME)




RN 141342-62-3 CA
 CN Rapamycin, 7,32-di-O-demethyl- (9CI) (CA INDEX NAME)




RN 141392-23-6 CA
 CN Rapamycin, 32-O-demethyl- (9CI) (CA INDEX NAME)




RN 141937-17-9 CA
 CN Rapamycin, 15-deoxo-15-hydroxy- (9CI) (CA INDEX NAME)




RN 141937-18-0 CA
 CN Rapamycin, 15,27-deoxy-15,27-dihydroxy- (9CI) (CA INDEX NAME)



RN 155312-05-3 CA
 CN Rapamycin, 42-deoxy-42-(hydroxyimino)- (9CI) (CA INDEX NAME)



L15 ANSWER 15 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 15
 AN 121:133863 CA
 TI Preparation of rapamycin derivatives as antifungals,
 immunosuppressants, and neoplasm inhibitors.
 IN Luengo, Juan Ignacio
 PA Smithkline Beecham Corp., USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 PI WO 9402136 A1 940203
 DS W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN,
 MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR,
 IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
 AI WO 93-US6678 930716
 PRAI US 92-915146 920717
 DT Patent
 LA English
 OS MARPAT 121:133863
 GI




AB Title compds. [I; X, Y = H, OR10, SOnR10, NR10R11, alkyl, aryl; XY = O; n = 0-2; R1 = :O, (OR6,H), (H,H); R2 = :O, (H,H), (H,OH); R3, R6 = H, alkyl, COR7, CO2R7, CONHR7, CSOR7; R4 = :O, (H,OR6); R3R4 = bridging group; R5 = H, alkyl; R7 = alkyl, cycloalkyl, aryl, heterocyclyl; R10, R11 = H, alkyl, aryl; with provisos], were prepd. Thus, rapamycin was stirred with H2O and DDQ in CH2Cl2 to give 7-demethoxy-7-oxorapamycin. I inhibited *Saccharomyces cerevisiae* with IC12 < ng/mL. Generic dosage forms are given.

IT 151519-50-5P 157054-78-9P 157054-79-0P
 157054-80-3P 157054-81-4P 157054-82-5P
 157054-83-6P 157054-84-7P 157054-85-8P
 157054-86-9P 157054-87-0P 157054-88-1P
 157182-33-7P 157182-34-8P 157182-35-9P
 157182-36-0P 157182-37-1P 157182-38-2P
 157182-39-3P 157182-40-6P 157182-41-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as antifungal, immunosuppressant, and neoplasm inhibitor)

RN 151519-50-5 CA

CN Rapamycin, 7-O-demethyl- (9CI) (CA INDEX NAME)




RN 157054-78-9 CA

CN Rapamycin, 7-demethoxy-7-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157054-79-0 CA
CN Rapamycin, 7-demethoxy-7-(phenylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




Me

RN 157054-80-3 CA
 CN Rapamycin, 7-demethoxy-7-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157054-81-4 CA
CN Rapamycin, 7-demethoxy-7-(2-furanyl)-, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




Me

RN 157054-82-5 CA
 CN Rapamycin, 7-demethoxy-7-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157054-83-6 CA
CN Rapamycin, 7-demethoxy-7-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157054-84-7 CA
CN Rapamycin, 7-O-demethyl-7-O-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



Me

RN 157054-85-8 CA
 CN Rapamycin, 7-O-demethyl-7-O-[(3,4-dimethoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




Me

RN 157054-86-9 CA
 CN Rapamycin, 7-O-demethyl-7-O-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157054-87-0 CA
CN Rapamycin, 7-O-acetyl-7-O-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157054-88-1 CA
CN Rapamycin, 7-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157182-33-7 CA
CN Rapamycin, 7-demethoxy-7-(methylthio)-, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




Me

RN 157182-34-8 CA
 CN Rapamycin, 7-demethoxy-7-(phenylthio)-, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157182-35-9 CA
CN Rapamycin, 7-demethoxy-7-(2,4-dimethoxyphenyl)-, (7R)-(9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




Me

RN 157182-36-0 CA
 CN Rapamycin, 7-O-demethyl-, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157182-37-1 CA
CN Rapamycin, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




Me

RN 157182-38-2 CA
 CN Rapamycin, 7-O-demethyl-7-O-ethyl-, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

RN 157182-39-3 CA
CN Rapamycin, 7-O-demethyl-7-O-(2-hydroxyethyl)-, (7R)-(9CI) (CA
INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



Me

RN 157182-40-6 CA
 CN Rapamycin, 7-demethoxy-7-(2-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 157182-41-7 CA
 CN Rapamycin, 7-O-demethyl-7-O-[(3,4-dimethoxyphenyl)methyl]-, (7R)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



Me

IT 53123-88-9, Rapamycin

RL: RCT (Reactant)


(reaction of, in prepn. of antifungal, immunosuppressant, and
neoplasm inhibitor)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



Me

L15 ANSWER 16 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 16
 AN 121:73883 CA
 TI O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and
 O-alkynylheteroarylrapamycin derivatives for treatment of
 autoimmune, inflammatory, and other diseases
 IN Parsons, William H.; Sinclair, Peter J.; Wong, Frederick; Wyvratt,
 Matthew J.
 PA Merck and Co., Inc., USA
 SO U.S., 34 pp.
 CODEN: USXXAM
 PI US 5310901 A 940510
 AI US 93-26926 930305
 DT Patent
 LA English
 OS MARPAT 121:73883

GI




AB O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylrapamycin derivs. I (R1 = heteroaryl, substituted heteroaryl, heteroaryl-C1-10 alkyl, etc.; R2 = R1, H, Ph, substituted Ph, 1- or 2-naphthyl, etc.) have been prepd. from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compds. are useful in a mammalian host for the treatment of autoimmune diseases and diseases of inflammation, infectious diseases, the prevention of rejection of foreign organ transplants, and the treatment of solid tumors. Prepn. of selected I is included. 42-(1-Hydroxyethylindol-5-yl)oxyrapamycin inhibited proliferation of T-cells.

IT 156246-98-9 156246-99-0 156247-00-6
156247-01-7 156247-02-8 156247-03-9
156247-04-0 156247-05-1 156247-06-2
156247-07-3 156247-08-4 156247-09-5
156247-10-8 156247-11-9 156247-12-0
156247-13-1

RL: BIOL (Biological study)
(for autoimmune or inflammatory or other disease
treatment)

RN 156246-98-9 CA
CN Rapamycin, 42-O-(1-methyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



Me

RN 156246-99-0 CA
 CN Rapamycin, 42-O-(1-ethyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-00-6 CA
 CN Rapamycin, 31-O-(1-methyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-01-7 CA
 CN Rapamycin, 42-O-[1-(2-propenyl)-1H-indol-5-yl]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-02-8 CA
 CN Rapamycin, 42-O-(1-propyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-03-9 CA
 CN Rapamycin, 31-O-(1-ethyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-04-0 CA
 CN Rapamycin, 31-O-[1-(2-propenyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-05-1 CA
 CN Rapamycin, 31-O-(1-propyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




Me

RN 156247-06-2 CA
 CN Rapamycin, 42-O-[1-[(4-hydroxyphenyl)methyl]-1H-indol-5-yl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—OH


Me

PAGE 2-A


RN 156247-07-3 CA
CN Rapamycin, 31-O-[1-[(4-hydroxyphenyl)methyl]-1H-indol-5-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 156247-08-4 CA
CN Rapamycin, 42-O-1H-indol-5-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



Me

RN 156247-09-5 CA
 CN Rapamycin, 31-O-1H-indol-5-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-10-8 CA
 CN Rapamycin, 42-O-[1-(phenylmethyl)-1H-indol-5-yl]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-11-9 CA
 CN Rapamycin, 31-O-[1-(phenylmethyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-12-0 CA
 CN Rapamycin, 42-O-[1-(2-hydroxyethyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



Me

RN 156247-13-1 CA
 CN Rapamycin, 31-O-[1-(2-hydroxyethyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



Me

IT 53123-88-9, Rapamycin

RL: RCT (Reactant)


(reaction of, in rapamycin deriv. prepn. for autoimmune or
inflammatory or other disease treatment)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 17 OF 51 CA COPYRIGHT 1996 ACS . DUPLICATE 17
 AN 120:236175 CA
 TI Treatment of immunoinflammatory skin disease with rapamycin and
 cyclosporin A
 IN Caufield, Craig E.; Musser, John H.; Sehgal, Surendra N.
 PA American Home Products Corp., USA
 SO U.S., 4 pp. Cont.-in-part of U.S. Ser. No. 761,120, abandoned.
 CODEN: USXXAM
 PI US 5286730 A 940215
 AI US 92-931242 920817
 PRAI US 91-761120 910917
 DT Patent
 LA English
 AB Immunoinflammatory skin disease is treated in mammals by
 administering rapamycin, alone or in synergistic combination with

cyclosporin A, orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally. Rapamycin, alone or in combination with cyclosporin A, is useful in treating skin diseases such as psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrheic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitis, erythema, cutaneous eosinophilia, etc. Thus, topical application of 0.5 mg rapamycin prevented oxazolone-induced skin inflammation in mice.

IT 53123-88-9, Rapamycin 154325-43-6,
Rapamycin-cyclosporin A mixt.


RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(inflammation inhibition by, in skin)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

RN 154325-43-6 CA
CN Rapamycin, mixt. with cyclosporin A (9CI) (CA INDEX NAME)

CM 1


CRN 59865-13-3
CMF C62 H111 N11 O12
CDES *

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A

i-Pr

PAGE 1-B



PAGE 1-C




CM 2

CRN 53123-88-9
CMF C51 H79 N O13
CDES *

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

L15 ANSWER 18 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 18
AN 121:221396 CA
TI Rapamycin inhibits production of cytotoxic but not noncytotoxic
antibodies and preferentially activates T helper 2 cells that
mediate long-term survival of heart allografts in rats
AU Ferraresso, Marianno; Tian, Ling; Ghobrial, Rafik; Stepkowski,
Stanislaw M.; Kahan, Barry D.
CS Med. Sch., Univ. Texas, Houston, TX, 77030, USA
SO J. Immunol. (1994), 153(7), 3207-18
CODEN: JOIMA3; ISSN: 0022-1767
DT Journal
LA English

AB Rapamycin (RAPA) induces unresponsiveness toward heart allografts by at least two mechanisms: selective prodn. of noncytotoxic IgG2c-blocking Ab and preferential activation of Th2 cells. RAPA (0.8 mg/kg/day) delivered via a 14-day osmotic pump to Wistar Furth (WF; RT-1u) recipients prolongs Buffalo (BUF; RT-1b) heart allograft survival from a mean survival time (MST) of 6.5 days to 75.0 days, with 6 of 18 grafts beating for >100 days. Recipient sera or their IgG but not IgM fraction, obtained after postgrafting day 40, passively transfer the unresponsive state to sublethally irradiated secondary recipients in a dose-dependent and immunol.-specific fashion. Sera obtained after untreated WF hosts rejected BUF hearts contained IgG moieties of all subclasses that bound to class I MHC BUF epitopes. In contrast, the unresponsive sera contained predominantly non-C'-fixing IgG2c and only marginal amts. of activated (C') fixing IgG1, IgG2a, and IgG2b Ab. The transcription of IL-2, IL-4, and IL-10 mRNAs was assessed using a PCR method. There were similar increases in the levels of IL-2, IL-4, and IL-10 mRNA in heart allografts from both untreated and RAPA-treated recipients on day 5 postgrafting. In contrast, on days 60 and 300 postgrafting heart allografts from RAPA-treated unresponsive recipients showed increased levels of IL-10 and IL-4 but not of IL-2 mRNA, suggesting preferential activation of Th2 cells. Thus, RAPA treatment selectively inhibits the synthesis of C-binding of IgG subclasses, spares the non C-binding blocking IgG2c Ab, and preferentially activates Th2 cells.

IT 53123-88-9, Rapamycin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapamycin inhibits prodn. of cytotoxic antibodies and
activates T helper cells mediating long-term survival of heart
allografts)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 19 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 19
 AN 122:122704 CA
 TI Effect of single-dose, late treatment with rapamycin on skin
 allograft survival in ALS- and donor bone marrow cell-treated mice
 AU De Fazio, S.R.; Plowey, J.; Hartner, W.C.; Gozzo, J.J.
 CS Bouve College of Pharmacy and Health Sciences, Northeastern
 University, Boston, MA, 02115, USA
 SO Transplant. Proc. (1994), 26(6), 3102-3
 CODEN: TRPPA8; ISSN: 0041-1345
 DT Journal
 LA English
 AB This study investigated the effect of single doses of rapamycin
 (RAPA) administered 2 wk or more after grafting in mice grafted with
 class I disparate skin and given peritransplant ALS and
 post-transplant BMC. Thus, RAPA is a potent adjunct for the

induction of allograft unresponsiveness by ALS and BMC. Although it can be effectively administered soon after grafting, it may be particularly beneficial if given late, up to 4 wk, after grafting. This agent does not seem to interfere with suppressor cells that actively support continued graft survival. RAPA also has potential for treating graft rejection.

IT 53123-88-9, Rapamycin

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (effect of single-dose, late treatment with rapamycin on skin allograft survival in ALS- and donor bone marrow cell-treated mice)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

L15 ANSWER 20 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 20

AN 122:586 CA

TI Rapamycin inhibits corneal allograft rejection and neovascularization

AU Olsen, Timothy W.; Benegas, Nancy M.; Joplin, Andrea C.; Evangelista, Tony; Mindrup, Elizabeth A.; Holland, Edward J.

CS Department of Ophthalmology, University of Minnesota, Minneapolis, MN, USA

SO Arch. Ophthalmol. (Chicago) (1994), 112(11), 1471-5

CODEN: AROPAW; ISSN: 0003-9950

DT Journal

LA English

AB The immunosuppressive effect of rapamycin in prolonging allograft survival in the rat model of orthotopic allogeneic penetrating keratoplasty was studied. Thirty inbred Lewis rats received corneal allografts from Brown Norway donors. Animals were divided into two rapamycin treatment groups and one allogeneic control group. By the second week after surgery, all of the control animals had experienced allograft failure due to allograft rejection. However, allografts in seven of 10 animals in the low-dose treatment group and allografts in seven of nine animals in the high-dose treatment group remained clear. In addn., corneal neovascularization was markedly reduced in the treated animals. The systemic administration of rapamycin prolongs corneal allograft survival and significantly inhibits the neovascular component of rejection in the rat model of orthotopic allogeneic penetrating keratoplasty.

IT 53123-88-9, Rapamycin

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(rapamycin inhibition of corneal allograft rejection and neovascularization)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 21 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 21
 AN 120:124423 CA
 TI Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow
 AU Blazar, Bruce R.; Taylor, Patricia A.; Sehgal, Suren N.; Vallera, Daniel A.
 CS Dep. Pediatr., Univ. Minnesota Hosp., Minneapolis, MN, 55455, USA
 SO Blood (1994), 83(2), 600-9
 CODEN: BLOOAW; ISSN: 0006-4971
 DT Journal
 LA English
 AB The authors investigated the ability of the macrolide antifungal agent rapamycin (RAPA) to inhibit the rejection of T-cell-depleted (TCD) donor bone marrow (BM) transplanted into major

histocompatibility complex (MHC)-disparate irradiated recipients. RAPA (1.5 mg/kg) was administered for 14 days beginning on the day of transplant. In the present study, the authors have tested RAPA administration in two types of fully allogeneic BM transplantation (BMT) systems in which host T cells mediate the rejection of TCD BM grafts (DBA/1 transplanted into C57BL/6 and BALB/c transplanted into C57BL/6). In both instances, RAPA administration prevented the rejection of the donor graft, accelerated post-BMT hematopoietic recovery, and did not compromise recipient survival. Sequential post-BMT fluorescence-activated cell sorter anal. of the spleen showed that RAPA administration inhibited host CD4+ and CD8+ T-cell expansion that leads to graft rejection. To further investigate the effect of RAPA on T-cell subpopulations, the authors used two congenic donor mouse stains with isolated MHC class I (bm1) or class II (bm 12) mutations. In these studies, the authors showed that RAPA administration can inhibit MHC class I-restricted CD8+ or class II-restricted CD4+ T-cell-mediated graft rejection without compromising recipient survival. The RAPA-facilitated alloengraftment is multilineage and durable. The authors have also shown that RAPA speeds hematopoietic recovery post BMT. The authors conclude that RAPA represents a new therapeutic modality for promoting alloengraftment and accelerating hematopoietic recovery.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)


(bone marrow **graft rejection prevention** and hematopoietic recovery stimulation by, as immunosuppressant, CD4+ and CD8+ T-cell **inhibition** in mechanism of)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 22 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 22
 AN 119:247964 CA
 TI Method of inducing immunosuppression
 IN Sengal, Suren Nath; Armstrong, Jay Joseph; Eng, Chee Ping
 PA American Home Products Corp., USA
 SO Eur. Pat. Appl., 7 pp.
 CODEN: EPXXDW
 PI EP 562853 A1 930929
 DS R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
 AI EP 93-302288 930325
 PRAI US 92-858923 920327
 DT Patent
 LA English
 AB Administration of an anti-rejection effective amt. of

29-demethoxyrapamycin alone or in combination with .gtoreq.1 anti-rejection chemotherapeutic agents induces immunosuppression and is useful for preventing or treating organ or tissue transplant rejection. The chemotherapeutic agent is selected from azathioprine, corticosteroids, cyclophosphamide, rapamycin, cyclosporin A, FK 506, OKT 3, and ATG.

IT 53123-88-9, Rapamycin

RL: USES (Uses)

(immunosuppression from demethoxyrapamycin and, for **treating organ transplant rejection**)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

IT 83482-58-0


RL: USES (Uses)
(immunosuppression from, for treating organ
transplant rejection)

RN 83482-58-0 CA

CN Rapamycin, 32-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

L15 ANSWER 23 OF 51 CA COPYRIGHT 1996 ACS

DUPLICATE 23

AN 118:198242 CA

TI Use of rapamycin for the manufacture of a medicament for the
treatment of immunoinflammatory diseases

IN Caufield, Craig Eugene; Musser, John Henry; Sehgal, Surendra Nath


PA American Home Products Corp., USA

SO Eur. Pat. Appl., 6 pp.

CODEN: EPXXDW
 PI EP 533433 A1 930324
 DS R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
 AI EP 92-308384 920915
 PRAI US 91-761120 910917
 DT Patent
 LA English
 AB Pharmaceutical compn. contg. rapamycin (I) alone or in combination with cyclosporin A is used for the treatment of immunoinflammatory skin or bowel diseases. I applied to the ear of mice at 1.0 mg/ear significantly prevented an acute inflammation.
 IT 53123-88-9, Rapamycin
 RL: BIOL (Biological study)
 (pharmaceutical compn. contg., as inflammation inhibitor)
 RN 53123-88-9 CA
 CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A



Me

L15 ANSWER 24 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 24
AN 118:198240 CA
TI Rapamycin for the treatment of ocular inflammation
IN Kulkarni, Prasad S.
PA University of Louisville Research Foundation, Inc., USA
SO Can. Pat. Appl., 26 pp.
CODEN: CPXXEB
PI CA 2074641 AA 930126
AI CA 92-2074641 920724
PRAI US 91-735604 910725
DT Patent
LA English
AB An ocular inflammation such as uveitis, conjunctivitis,
episcleritis, scleritis, etc. is treated by oral, parenteral,
topical, transdermal, or rectal administration of rapamycin. Thus,
in rabbits with endotoxin-induced uveitis, rapamycin (10 mg/kg i.m.
twice a day) decreased the leukocyte count and protein, PGE1, and
LTB4 concns. in the aq. humor by 77, 22, 61, and 30%, resp.
IT 53123-88-9, Rapamycin
RL: BIOL (Biological study)
(ocular inflammation treatment with)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Me

L15 ANSWER 25 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 25
 AN 120:45468 CA
 TI Inhibition by rapamycin of leukocyte migration and bronchial hyperreactivity induced by injection of Sephadex beads to guinea pigs
 AU Nogueira de Francischi, Janetti; Conroy, Dolores M.; Maghni, Karim; Sirois, Pierre
 CS Fac. Med., Univ. Sherbrooke, Sherbrooke, PQ, J1H 5N4, Can.
 SO Br. J. Pharmacol. (1993), 110(4), 1381-6
 CODEN: BJPCBM; ISSN: 0007-1188
 DT Journal
 LA English
 AB The effect of rapamycin (0.001 to 5 mg kg⁻¹) on the increased leukocyte counts in bronchoalveolar lavage (BAL) fluid and hyperreactivity of isolated bronchial strips to histamine and

acetylcholine (ACh) was studied following the i.v. injection of Sephadex beads to guinea-pigs. The i.m. (i.m.) injection of rapamycin (0.012 to 5 mg kg⁻¹) dose-dependently inhibited the increase in leukocyte counts in BAL fluid. Rapamycin (5 mg kg⁻¹) reduced the nos. of eosinophils neutrophils, macrophages and lymphocytes in BAL fluid by 64, 55, 19 and 50% resp. In ann., rapamycin (0.012 to 5 mg kg⁻¹) significantly inhibited the Sephadex-induced hyperreactivity of bronchial tissue to both histamine and ACh. At a dose of 0.001 mg kg⁻¹, rapamycin did not significantly reduce leukocyte infiltration or bronchial hyperreactivity. Cyclosporin (5 mg kg⁻¹) significantly reduced both lymphocyte and eosinophil nos. in BAL fluid of Sephadex-injected guinea-pigs whereas dexamethasone (1 mg kg⁻¹) significantly reduced lymphocyte nos. Neither drug affected the bronchial hyperreactivity to histamine and ACh. It is concluded that the new immunosuppressive drug, rapamycin, is a potent inhibitor of leukocyte migration and bronchial hyperreactivity obsd. following the i.v. injection of Sephadex beads to guinea-pigs. Rapamycin also appears to be more effective than cyclosporin or dexamethasone in reducing leukocyte counts and bronchial hyperreactivity in this model. The authors' results suggest that inflammatory mechanisms which are inhibited by rapamycin may be important in the induction of Sephadex-induced hyperreactivity.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)


(leukocyte migration and bronchial hyperreactivity inhibition by, inflammatory mechanisms in relation to)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 26 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 26
 AN 120:45426 CA
 TI Rapamycin treatment depresses intragraft expression of KC/MIP-2,
 granzyme B, and IFN- γ . in rat recipients of cardiac allografts
 AU Wieder, Kenneth J.; Hancock, Wayne W.; Schmidbauer, Georg; Corpier,
 Cindy L.; Wieder, Irene; Kobzik, Lester; Strom, Terry B.;
 Kupiec-Weglinski, Jerzy W.
 CS Div. Immunol., Harvard Med. Sch., Boston, MA, 02215, USA
 SO J. Immunol. (1993), 151(2), 1158-66
 CODEN: JOIMA3; ISSN: 0022-1767
 DT Journal
 LA English
 AB Rapamycin (RPM) treatment prevents accelerated rejection of cardiac
 allografts in sensitized rats. The prominent feature of this brisk
 24-h rejection, which includes a panoply of both cellular and

humoral host immune responses, is a massive infiltration of rejecting grafts with neutrophils. In this study, the authors tested the hypothesis that RPM-mediated therapeutic effects on accelerated rejection may be linked to decreased expression of protein encoded by gro/melanoma-growth stimulatory activity gene (KC) and macrophage inflammatory protein-2 (MIP-2) genes, the operational rat homologues of the human intercrine-.alpha. cytokines with proinflammatory IL-8-like neutrophil activation/chemotactic properties. The induction of these genes was then correlated with mRNA profiles encoding for Th1-selective IFN-.gamma. and CTL-specific granzyme B proteins. Northern blot anal. of RNA from cardiac allografts of sensitized untreated recipients, revealed maximal levels of KC and MIP-2 mRNA at 3 to 6 h after transplantation. In contrast, IFN-.gamma. mRNA, which was at most very weakly expressed at 3 h, peaked between 6 to 12 h. As with IFN-.gamma., granzyme B transcripts were undetectable at 3 h, but peaked around the time of actual graft rejection at 24 h. RPM therapy abrogated accelerated rejection and prolonged cardiac allograft survival to ca. 46 days. This effect was assocd. with markedly reduce expression of KC and MIP-2 mRNA in the first 24 h as well as at 7 and 34 days after transplantation. Moreover, RPM completely blocked intragraft appearance of granzyme B and IFN-.gamma. mRNA in long term cardiac allografts. Immunohistol. anal. has revealed that accelerated rejection was assocd. with extensive neutrophil infiltration, which peaked at 18 to 24 h. At this time, leukocytes and endothelium were intensely stained for IL-8 and IFN-.gamma. antibodies. In contrast, the allografts from RPM-treated hosts showed essentially no neutrophil infiltration and minor, focal staining for IL-8 and IFN-.gamma.. This study demonstrates an assocn. between the early expression of genes for proinflammatory IL-8-dependent neutrophil chemotactic activity, and later expression of genes assocd. with activation/effector activity of CTL and NK cells. It also documents a novel effect of RPM in vivo, which results in the suppression of intragraft IL-8-like and CTL-dependent mRNA/protein prodn. and diminished neutrophil infiltration; these may contribute to the striking efficacy of RPM therapy in sensitized graft recipients.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)


(heart allograft rejection inhibition by,
gene expression and granzyme B and interferon-.gamma. response
in)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 27 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 27
 AN 120:208123 CA
 TI Reduction of Sephadex-induced lung inflammation and bronchial
 hyperreactivity by rapamycin
 AU Francischi, J. N.; Conroy, D. M.; Cloutier, S.; Sirois, P.
 CS Dep. Pharmacol., Fac. Med., Sherbrooke, PQ, J1H 5N4, Can.
 SO Braz. J. Med. Biol. Res. (1993), 26(10), 1105-10
 CODEN: BJMRDK; ISSN: 0100-879X
 DT Journal
 LA English
 AB The aim of the present work was to det. if rapamycin could affect an
 established inflammatory response. Guinea pigs were injected i.v.
 with Sephadex beads to induce lung inflammation and bronchial
 hyperreactivity. Bronchoalveolar lavage (BAL) fluid was collected
 2, 12 and 24 h after Sephadex administration and the cells were

counted. Bronchial tissue was used to construct dose-contraction response curves to histamine and acetylcholine 24 h after the Sephadex injection. Test animals were injected with rapamycin (5 mg/kg) i.m. 2 or 12 h after Sephadex injection, and BAL fluid was collected 24 h after Sephadex administration. Rapamycin administration 2 h after Sephadex reduced eosinophil and lymphocyte nos. in the BAL but did not affect the ex vivo bronchial hyperreactivity induced by Sephadex injection. However, rapamycin administration 12 h after Sephadex reduced BAL eosinophil and lymphocyte nos. and bronchial hyperreactivity. The increase in neutrophil nos. in BAL induced by Sephadex injection was not modified by rapamycin. Since lymphocyte nos. in BAL increased in Sephadex-treated animals at 12 h but not at 2 h after Sephadex injection, the results suggest that the inhibition of bronchial hyperreactivity by rapamycin may be dependent on the presence of lymphocytes elicited into the airways by Sephadex injection.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)

(bronchi hyperreactivity and lung inflammation inhibition by)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



Me

L15 ANSWER 28 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 28
 AN 118:231419 CA
 TI Chlamydia trachomatis Mip-like protein has peptidyl-prolyl cis/trans isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of chlamydial infection
 AU Lundemose, Anker G.; Kay, John E.; Pearce, John H.
 CS Sch. Biol. Sci., Univ. Birmingham, Birmingham, B15 2TT, UK
 SO Mol. Microbiol. (1993), 7(5), 777-83
 CODEN: MOMIEE; ISSN: 0950-382X
 DT Journal
 LA English
 AB The Mip-like protein of *C. trachomatis* has sequence similarity with both the Mip protein of *Legionella pneumophila*, a virulence factor necessary for optimal intracellular infection, and FK506-binding proteins (FKBPs) of both prokaryotic and eukaryotic origin. FKBPs contain a site for peptidyl-prolyl cis/trans isomerase activity, which is blocked upon binding of the drugs, FK506 or rapamycin. This paper reports that the recombinant chlamydial Mip-like protein exhibits a peptidyl-prolyl cis/trans isomerase activity which is inhibited by either rapamycin or FK506. In order to assess the role of the Mip-like protein in chlamydial infection, rapamycin or FK506 (25 μ M), were used in either treatment of chlamydial organisms prior to inoculation, or were present at different intervals through the infection. Pretreatment of organisms alone reduced infectivity for McCoy cells by 30%, with inhibition rising to 80% on more prolonged exposure from 0 to 8 h and 8 to 16 h post-inoculation and declining thereafter. When drug was present during the developmental cycle at intervals from 0 to 24 h post-inoculation abnormal chlamydia were induced in residual inclusions. Apparently, inhibition of the isomerase of the Mip-like protein interferes with .gtoreq.1 early events in the infective process that det. productive intracellular infection.
 IT 53123-88-9, Rapamycin
 RL: BIOL (Biological study)
 (treatment with, inhibition of Chlamydia trachomatis infection, chlamydial Mip-like protein peptidyl-prolyl cis/trans isomerase inhibition in relation to)
 RN 53123-88-9 CA
 CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




Me

L15 ANSWER 29 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 29
 AN 118:225155 CA
 TI Rapamycin effects on immunologic reconstitution
 AU Vogelsang, G. B.; Hess, A. D.
 CS Johns Hopkins Bone Marrow Transplant Unit, Baltimore, MD, USA
 SO Transplant. Proc. (1993), 25(1, Book 1), 727-8
 CODEN: TRPPA8; ISSN: 0041-1345
 DT Journal
 LA English
 AB The effects of rapamycin on the development of graft-vs.-host rejection disease were studied in rats subjected to gamma.-irradn. and bone marrow syngeneic grafting. Rapamycin at 2,4, or 6 mg/kg daily for 40 days did not induce the signs of disease, while control irradiated and grafted rats developed the disease after treatment with cyclosporin A.

IT 53123-88-9, Rapamycin
RL: BIOL (Biological study)
(bone marrow graft rejection response after
treatment with)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

L15 ANSWER 30 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 30
AN 118:247143 CA
TI Rapamycin reverses acute heart, kidney, and pancreases allograft
rejectin and prevents accelerated heart allograft rejection in the
rat


AU Chen, H.; Wu, J.; Xu, D.; Luo, H.; Daloze, P.
CS Notre-Dame Hosp., Univ. Montreal, Montreal, PQ, Can.
SO Transplant. Proc. (1993), 25(1, Book 1), 719-20
CODEN: TRPPA8; ISSN: 0041-1345

DT Journal
LA English

AB Rapamycin (RAPA), a lipophilic macrolide possessing striking structural similarity to FK 506, is an effective immunosuppressant for prevention of allograft rejection in rodents, pigs, and dogs. Rapamycin has been shown to act between the G1 and S phase of the T-cell activation cascade and to act with a mechanism different from either cyclosporine (CyA) or FK 506. Previous studies in our institution showed that RAPA acts directly on both T-cells and B cells and can strongly suppress in vitro Ig prodn. These observations have raised the potential for RAPA to reverse an established rejection and to prolong allograft survival in pre-sensitized recipients. These two aspects were investigated in this study, and their mechanisms were explored.

IT 53123-88-9, Rapamycin
RL: BIOL (Biological study)
(heart and kidney and pancreas allograft rejection prevention by)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Me


L15 ANSWER 31 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 31
 AN 118:247142 CA
 TI Effect of rapamycin on induction of unresponsiveness in ALS-treated,
 marrow-injected mice
 AU Bobbio, S. A.; Wood, M. L.; Monaco, A. P.
 CS Harvard Med. Sch., New England Deaconess Hosp., Boston, MA, USA
 SO Transplant. Proc. (1993), 25(1, Book 1), 717-18
 CODEN: TRPPA8; ISSN: 0041-1345
 DT Journal
 LA English
 AB The authors studied the effect of rapamycin (RPM) in potentiating
 graft survival with ALS and bone marrow (BM) in normal and adult
 thymectomized mice.
 IT 53123-88-9, Rapamycin
 RL: BIOL (Biological study)

(immunosuppression in ALS-treated bone marrow
transplant)

RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

L15 ANSWER 32 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 32
AN 118:247141 CA
TI Rapamycin treatment prevents and/or erases sensitization and
abrogates accelerated rejection of vascularized organ allografts
AU Schmidbauer, G.; Hancock, W. W.; Wasowska, B. A.; Sablinski, T.;
Kupiec-Weglinski, J. W.
CS Harvard Med. Sch., Brigham Women's Hosp., Boston, MA, USA
SO Transplant. Proc. (1993), 25(1, Book 1), 712-13

CODEN: TRPPA8; ISSN: 0041-1345

DT Journal

LA English

AB Rapamycin (RPM) exerts profound immunosuppressive effects and prevents acute rejection of vascularized organ allografts in rodents, dogs, pigs, and subhuman primates. This study evaluates therapeutic efficacy and analyzes the mode of action of RPM in a well-defined accelerated rejection model in presensitized rat recipients of cardiac allografts.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)

(prevention of rejection of vascularized heart allograft)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



Me


L15 ANSWER 33 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 33
 AN 120:124441 CA
 TI CsA, FK506, corticosteroids and rapamycin inhibit TNF.alpha.
 production by cultured PTEC
 AU Yard, Benito A.; Pancham, Roy R.; Paape, Marion E.; Daha, M. R.; van
 Es, Leendert A.; van der Woude, Fokko J.
 CS Dep. Nephrol., Univ. Hosp. Leiden, Leiden, Neth.
 SO Kidney Int. (1993), 44(2), 352-8
 CODEN: KDYIA5; ISSN: 0085-2538
 DT Journal
 LA English
 AB In this study the authors investigated the effect of
 immunosuppressive drugs on the interleukin-1 alpha (IL-1.alpha.)
 enhanced tumor necrosis factor alpha (TNF.alpha.) prodn. by proximal
 tubular epithelial cells (PTEC). Under basal conditions cultured
 PTEC produce between 0 to 390 pg/mL/105 cells of TNF.alpha.. Upon
 stimulation with IL-1.alpha. an enhancement of TNF.alpha. prodn. was
 seen in each cell line tested, ranging from 230 to 2424 pg/mL/105
 cells. The presence of cyclosporin A (CsA) during stimulation with
 IL-1.alpha. inhibited the enhanced TNF.alpha. prodn. in a dose
 dependent fashion, with a maximal inhibition of 90% at a concn. of
 250 ng/mL. Inhibition was at the level of mRNA as could be
 demonstrated by Northern blot anal. FK506, corticosteroids and
 rapamycin also inhibited TNF.alpha. prodn. in a dose dependent
 fashion, although not as effectively as CsA. Two corticosteroids
 were tested for their inhibitory effect on TNF.alpha. prodn. It was
 found that dexamethasone at a concn. of 10 ng/mL inhibited
 TNF.alpha. prodn. for almost 40%. A 100-fold higher concn. of
 hydrocortisone was necessary to yield similar inhibition. The
 effect of rapamycin on the IL-1.alpha. enhanced TNF.alpha. prodn.
 differed from the effect of CsA. While CsA induced a maximal
 inhibition of 90%, rapamycin only induced a maximal inhibition of
 37%, and even less inhibition at higher concns. of the drug. The
 presence of the various drugs was essential for their inhibitory
 effect, because removal of the drug from the PTEC by washing
 immediately resulted in loss of inhibition. Combinations of CsA and
 FK506 or rapamycin were not additive. However, combinations of
 rapamycin and FK506 were antagonistic when low concns. of rapamycin
 and FK506 were used. Low concns. of rapamycin with high concns. of
 FK506 were synergistic. Since TNF.alpha. is likely to be an
 important mediator in renal allograft rejection, these data suggest
 that the beneficial effect of immunosuppressive drugs after renal
 transplantation may partly be due to the effect on TNF.alpha. prodn.
 by renal parenchymal cells.
 IT 53123-88-9, Rapamycin
 RL: BIOL (Biological study)

(tumor necrosis factor-.alpha. formation by proximal tubular epithelial cells inhibition by)

RN 53123-88-9 CA
 CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

L15 ANSWER 34 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 34
 AN 119:195273 CA
 TI Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process
 AU Blazar, Bruce R.; Taylor, Patricia A.; Sehgal, Suren N.; Vallera, Daniel A.
 CS Dep. Pediatr., Univ. Minnesota Hosp. Clin., Minneapolis, MN, 55455,

USA
SO Ann. N. Y. Acad. Sci. (1993), 685(Immunomodulating Drugs), 73-85
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal
LA English
AB Rapamycin is a macrolide antifungal agent that mediates immunosuppression by blocking cytokine, mitogenic, and accessory signal responsiveness, but not cytokine prodn. The latter mechanism is responsible for the immunosuppressive effects of the structurally related analog, FK-506, which binds to the same high-affinity binding proteins, FKBP-12, FKBP-13, and FKBP-25. In ongoing studies, rapamycin (1.5 mg/kg/dose) administered i.p. once daily for 14 days beginning on the day of transplantation protected 50-90% of recipients from lethal GVHD (graft-vs.-host disease). Survivors completely engrafted and were tolerant of donor skin grafts, while rejecting third-party grafts. In this report, the authors present data that rapamycin is an effective form of ongoing acute GVHD therapy in mice.
IT 53123-88-9, Rapamycin
RL: BIOL (Biological study)
(graft-vs.-host disease treatment with)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Me


L15 ANSWER 35 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 35
 AN 119:195272 CA
 TI Prevention and treatment of allograft rejection in vivo by
 rapamycin: molecular and cellular mechanisms of action
 AU Morris, Randall Ellis
 CS Sch. Med., Stanford Univ., Stanford, CA, 94305-5247, USA
 SO Ann. N. Y. Acad. Sci. (1993), 685(Immunomodulating Drugs), 68-72
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English
 AB The purpose of this very brief descriptive article is to relate new
 information on the prevention and treatment of allograft rejection
 by rapamycin to its known effects in vitro at the mol. and cellular
 levels.
 IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)
(allograft rejection prevention and
treatment by, mol. and cellular mechanisms in)

RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

Me

L15 ANSWER 36 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 36
AN 117:63005 CA
TI Immunosuppressants for treatment of lung diseases
IN Kay, Anthony Barry; Barnes, Neil Christopher; Cole, Peter John
PA National Heart and Lung Institute, UK
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2

PI WO 9208474 A2 920529
DS W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP,
KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU, US
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR,
IT, LU, ML, MR, NL, SE, SN, TD, TG
AI WO 91-GB2049 911120
PRAI GB 90-25154 901120
GB 90-26620 901207
DT Patent
LA English
AB Specific pharmacol. targeting of T-lymphocytes provides a new approach to the treatment of chronic asthma (both in patients relatively sensitive and resistant to the effects of corticosteroids) and to the treatment of other lung diseases (e.g. bronchiectasis and cystic fibrosis), as well as sinusitis. Cyclosporin A (I) and other immunosuppressants (e.g. FK 506, rapamycin, humanized anti-CD4 antibodies) with the same or similar mode or site of action are provided for the treatment of diseases characterized by airflow obstruction and/or of chronic sinusitis. Also provided is an in vitro test for prediction of clin. response to corticosteroids and immunosuppressants. Corticosteroid resistance can be identified by the in vitro test, and corticosteroid-resistant patients thus identified can be treated with I or other suitable immunosuppressant. When patients with long-standing corticosteroid-dependent asthma were treated with I, there were significant increases above placebo in both morning and evening peak expiratory flow both pre- and post-bronchodilator. Patients on I suffered significantly fewer exacerbations requiring rescue prednisolone compared to placebo.
IT 53123-88-9, Rapamycin
RL: BIOL (Biological study)
(for **asthma** or other lung disease or chronic sinusitis **treatment**)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Me


L15 ANSWER 37 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 37
 AN 116:99319 CA
 TI Treatment of pulmonary inflammation with rapamycin
 IN Sturm, Robert J.; Adams, Laurel M.; Weichman, Barry M.
 PA American Home Products Corp., USA
 SO U.S., 3 pp.
 CODEN: USXXAM
 PI US 5080899 A 920114
 AI US 91-659782 910222
 DT Patent
 LA English
 AB Pulmonary inflammation is prevented or reversed in mammals by administering rapamycin orally, parenterally, intranasally, or intrabronchially for symptomatic relief of asthma, chronic obstructive pulmonary disease, emphysema, acute respiratory distress

syndrome, bronchitis, etc. Thus, in guinea pigs sensitized with ovalbumin by injection and then challenged with an ovalbumin aerosol, the no. of pulmonary inflammatory cells obsd. in bronchoalveolar lavage fluid was diminished by 88.1% compared to challenged controls by treatment with rapamycin (4.0 mg/kg orally 4 times).

IT 53123-88-9, Rapamycin
RL: BIOL (Biological study)
(lung inflammation prevention and treatment with)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

L15 ANSWER 38 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 38

AN 117:245187 CA

TI Efficacy and mechanism of action of rapamycin in presensitized recipients of experimental allografts

AU Chen, H.; Wu, J.; Luo, H.; Daloz, P.

CS Res. Cent., Notre-Dame Hosp., Montreal, PQ, H2L 4M1, Can.

SO Transplant. Proc. (1992), 24(5), 1669-70

CODEN: TRPPA8; ISSN: 0041-1345

DT Journal

LA English

AB This study shows that rapamycin (RAPA) is able to prevent accelerated rejection of allografts in the rat. This agent can strongly inhibit in vivo total Ig prodn., as well as donor-specific cytotoxic antibodies in accelerated rejection in presensitized animals. It suggests that RAPA could be used clin. to condition hyperimmunized potential recipients of allografts, currently condemned to a long wait for an unlikely compatible donor, or the probability of an early and irreversible rejection.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)


(allograft rejection inhibition by, mechanism of)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 39 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 39
 AN 118:15931 CA
 TI Immunosuppressants FK506 and rapamycin function as reversal agents
 of the multidrug resistance phenotype
 AU Arceci, Robert J.; Stieglitz, Kimberly; Bierer, Barbara E.
 CS Div. Pediatr. Oncol., Dana-Farber Cancer Inst., Boston, MA, 02115,
 USA
 SO Blood (1992), 80(6), 1528-36
 CODEN: BLOOAW; ISSN: 0006-4971
 DT Journal
 LA English
 AB The multidrug-resistant (MDR) phenotype is characterized in vitro by
 the resistance displayed by cell lines to a broad spectrum of
 natural product cytotoxic agents. This high level of
 cross-resistance is due to the increased expression of a membrane

glycoprotein termed P-glycoprotein. Encoded in humans by the *mdr1* gene, P-glycoprotein functions as an energy-dependent efflux pump of these cytotoxic agents. In this report, the authors demonstrate that the newly characterized immunosuppressant FK506 and its structural analog, rapamycin, are capable of functioning as MDR reversal agents. FK506 and rapamycin increase both intracellular, cytotoxic drug (daunomycin) accumulation, and the cytotoxicity of chemotherapeutic agents in multidrug-resistant cells. The increase of cytotoxic drug accumulation is obsd. at concns. of FK506 and rapamycin 1,000-fold greater than the concns. required for FK506 and rapamycin to inhibit T-lymphocyte activation and similar to those shown to be effective for other MDR reversal agents such as cyclosporine A (CsA) and verapamil. The effect of FK506 or rapamycin on both intracellular accumulation and cytotoxicity of daunomycin is additive. This is supported by the ability of FK506 and rapamycin to directly compete the binding of the photoaffinity analog ¹²⁵I-iodoaryl azidoprazosin to the P-glycoprotein. The data demonstrate that FK506 and rapamycin represent a new class of structurally distinct mols. that can function as MDR reversal agents and suggest a previously unidentified, potential clin. role for these compds.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)


(multidrug resistance reversal by, daunomycin uptake by P-glycoprotein inhibition in)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 40 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 40
 AN 118:73339 CA
 TI Anti-inflammatory effect of FK-506 on human skin mast cells
 AU De Paulis, Amato; Stellato, Cristiana; Cirillo, Raffaele;
 Ciccarelli, Anna; Oriente, Alfonso; Marone, Gianni
 CS Sch. Med., Univ. Naples Federico II, Naples, 80131, Italy
 SO J. Invest. Dermatol. (1992), 99(6), 723-8
 CODEN: JIDEAE; ISSN: 0022-202X
 DT Journal
 LA English
 AB FK-506 and the structurally related macrolide rapamycin are high-affinity ligands for a specific binding protein (FK-506 binding protein). The authors examd. the effects of FK-506 and rapamycin on the release of pre-formed (histamine) and de novo synthesized

inflammatory mediators (prostaglandin D2) from mast cells isolated from human skin tissue. FK-506 (0.1 to 100 nM) concn.-dependently inhibited (5 to 65%) histamine release from skin mast cells activated by anti-IgE. FK-506 was more potent in skin mast cells than in basophils (IC40 = 2.15 nM vs. 5.12 nM), whereas the max. inhibitory effect was higher in basophils than in skin mast cells (88.77% vs. 67.30%). FK-506 had little or no inhibitory effect on histamine release from skin mast cells challenged with compd. A23187 and substance P, resp., whereas it completely suppressed A23187-induced histamine release from basophils. FK-506 (0.1 to 100 nM) also inhibited (up to 65%) the de novo synthesis of prostaglandin D2 from skin mast cells challenged with anti-IgE. Despite its structural similarity to FK-506, rapamycin (10 to 300 nM) had little or no effect on the release of histamine from skin mast cells induced by anti-IgE, A23187, and substance P. However, rapamycin competitively antagonized the inhibitory effect of FK-506 on anti-IgE-induced histamine release from skin mast cells with a dissocn. const. of about 14 nM. These data indicate that FK-506, but not rapamycin, is a potent anti-inflammatory agent acting on skin mast cells presumably by binding to the FK-506 binding protein. It thus appears that binding to the FK-506 binding protein is necessary, but not sufficient to deliver an inhibitory signal to skin mast cells.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)


(histamine and prostaglandin D2 release by mast cells of humans response to, inflammation inhibition in relation to)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 41 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 41
 AN 118:52071 CA
 TI Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats
 AU Wang, Mou Er; Stepkowski, Stanislaw M.; Ferrareso, Mariano; Kahan, Barry D.
 CS Med. Sch., Univ. Texas, Houston, TX, 77030, USA
 SO Transplantation (1992), 54(4), 704-9
 CODEN: TRPLAU; ISSN: 0041-1337
 DT Journal
 LA English
 AB The capacity of delayed-onset rapamycin (RAPA) therapy to block destruction was examd. in rats undergoing heart allograft rejection. Untreated Wistar Furth (WFu; RT-1u) recipients rejected Buffalo

(BUF; RT-1b) heart allografts with a mean survival time of 6.5 days. A 14-day i.v. infusion of 0.8 mg RAPA/kg, begun on the day of transplantation, prolonged the survival to 74.1 days, 0.2 mg/kg to 32.3 days, and 0.08 mg/kg to 36.4 days. When RAPA therapy (0.8 mg/kg) was begun 3 or 4 days after transplantation, the grafts survived 85.2 and 70.2 days, resp. Therapy initiated on day 5 was much less effective; most transplants were rejected within 10 days; 1 graft survived 32 and 2 grafts 60 days. A 0.2 mg/kg RAPA dose started on day 3 or 4 prolonged graft survival, but not when started on day 5. The 0.08-mg/kg RAPA dose prolonged heart survival only when started on day 3. Wfu recipients treated with a subtherapeutic dose of cyclosporine (1 mg/kg) displayed prolonged heart allograft function when treated subsequently with RAPA (0.8 or 0.08) beginning on days 4, 5, or 6 postgrafting. These in vivo results were supported by in vitro expts. The frequency of BUF alloreactive elements among normal Wfu LN cells (fTc) was 337/106 T cells in limiting diln. assay. Addn. of RAPA (1 .mu.M) at the beginning of culture reduced the fTc to 17/106; addn. on days 4 or 6 gave values of 37.3/106 and 58.6/106, resp. Thus, both in vivo and in vitro data demonstrate that delayed RAPA therapy may interrupt alloimmune reactions.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)


(heart allograft rejection inhibition by
delayed therapy with)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 42 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 42
 AN 116:187663 CA
 TI Inhibition of host-versus-graft and graft-versus-host responses
 after small bowel transplantation in rats by rapamycin
 AU Stepkowski, Stanislaw M.; Chen, Hui Fang; Wang, Mou Er; Daloz,
 Pierre; Kahan, Barry D.
 CS Med. Sch., Univ. Texas, Houston, TX, 77030, USA
 SO Transplantation (1992), 53(2), 258-64
 CODEN: TRPLAU; ISSN: 0041-1337
 DT Journal
 LA English
 AB The effect of rapamycin (RAPA) on both host-vs.-graft (HVG) and
 graft-vs.-host (GVH) immune responses was examd. in small bowel
 transplant models using strongly histoincompatible donor-recipient
 combinations. Normal Wistar Furth (WFu; RT-1u) recipients rejected

Buffalo (BUF; RT-1b) small bowel allografts within a mean survival time (MST) of 10.5 days. Administration of RAPA (0.8 mg/kg) by continuous i.v. infusion for 14 days via an osmotic pump prolonged graft survival to 25.0 days. In a second strain combination, the 12.5 day survival of Brown Norway (BN; RT-1n) small bowel allografts in Lewis (RT-11) recipients was prolonged to 21.6 and 28.5 days by 14 days of i.v. RAPA at doses of 0.8 and 1.6 mg/kg, resp. In this model RAPA is five times more effective than cyclosporine, which at 4.0 mg/kg prolongs BN small bowel allografts in Lewis recipients to 21.6 \pm 6.3. T isolate HVG and GVH immune responses, (BN \times Lewis)F1 hybrid rats served as the graft donor or host, resp. In the HVG model, (BN \times Lewis)F1 small bowel allografts, which were rejected by normal Lewis recipients at 12.2 days, were prolonged to 40.8 \pm 5.8 days by RAPA (0.8 mg/kg \times 14 days). In the GVH model, the ability of Lewis small bowel allografts to produce severe GVH disease in untreated (BN \times Lewis)F1 recipients at 12.3 days was delayed to 21.3 days by 0.8 mg/kg RAPA. Thus, RAPA protects small bowel allografts more effectively against HVG than GVH immune responses.

IT 53123-88-9, Rapamycin

RL: BIOL (Biological study)


(host-vs.-graft and graft-vs.-host responses
after small bowel transplantation inhibition
by)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



Me

L15 ANSWER 43 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 43
 AN 116:143852 CA
 TI Treatment of organ transplantation rejection with immunosuppressants
 IN Ackerman, Neil Richard; Jaffee, Bruce Donald
 PA Du Pont Merck Pharmaceutical Co., USA
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 PI WO 9119498 A1 911226
 DS W: AU, CA, JP, KR
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
 AI WO 91-US3788 910605
 PRAI US 90-535672 900611
 DT Patent
 LA English
 OS MARPAT 116:143852

AB 2-Phenyl-4-quinolinecarboxylic acid derivs., such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinolinecarboxylic acid (I), in combination with other immunosuppressive agents are useful for the treatment and prevention of transplantation rejection, graft vs. host disease, autoimmune diseases, and chronic inflammatory diseases. The 2-phenyl-4-quinolinecarboxylic acid derivs. have a unique mechanism of action compared to other known immunosuppressive agents, and therefore have not been assocd. with the nephrotoxicity and hepatotoxicity seen with other immunosuppressants. In addn., the combination of drugs has a synergistic effect. I was tested in combination with cyclosporin A or azathioprine for the inhibition of the contact sensitivity response to 2,4-dinitrofluorobenzene in mice.

IT 53123-88-9D, Rapamycin, mixts. with quinolinecarboxylate

RL: BIOL (Biological study)

(organ transplantation rejection and chronic inflammation treatment with)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


PAGE 1-A



Me

L15 ANSWER 44 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 44
AN 115:105661 CA
TI Inhibition of skin graft rejection in mice by rapamycin: a novel
immunosuppressive macrolide
AU Eng, C. P.; Gullo-Brown, J.; Chang, J. Y.; Sehgal, S. N.
CS Wyeth-Ayerst Res., Princeton, NJ, 08543, USA
SO Transplant. Proc. (1991), 23(1, Bk. 1), 868-9
CODEN: TRPPA8; ISSN: 0041-1345
DT Journal
LA English
AB Rapamycin had marked potency over cyclosporin A and a combination of
the 2 drugs had a synergistic effect in prolonging graft survival
time in the mouse skin allograft model.
IT 53123-88-9, Rapamycin
RL: BIOL (Biological study)
(skin graft rejection inhibition by)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Me

L15 ANSWER 45 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 45
 AN 114:240620 CA
 TI Methods of inhibiting transplant rejection in mammals using
 rapamycin and derivatives and prodrugs thereof
 IN Calne, Roy
 PA UK
 SO Eur. Pat. Appl., 9 pp.
 CODEN: EPXXDW
 PI EP 401747 A2 901212
 DS R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
 AI EP 90-110612 900605
 PRAI US 89-362354 890606
 DT Patent
 LA English
 AB Organ and tissue transplant rejection in mammals is inhibited by

administration of rapamycin or rapamycin in combination with other chemotherapeutic agents for inhibiting transplant rejection, e.g. azathioprine, corticosteroids, cyclosporin, and FK506. Rapamycin was immunosuppressive and not toxic in rats down to 0.5 mg/kg. In pigs, the drug was tolerated at 1 mg/kg.

IT 134035-83-9, Azathioprine-rapamycin mixt.

134061-14-6, Cyclosporin-rapamycin mixt. 134127-87-0
, FK506-rapamycin mixt.

RL: BIOL (Biological study)

(animal transplant rejection inhibition with)

RN 134035-83-9 CA

CN Rapamycin, mixt. with 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine (9CI) (CA INDEX NAME)

CM 1

CRN 53123-88-9


CMF C51 H79 N O13

CDES *

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




Me

CM 2

CRN 446-86-6

CMF C9 H7 N7 O2 S



RN 134061-14-6 CA

CN Rapamycin, mixt. with cyclosporin (9CI) (CA INDEX NAME)

CM 1

CRN 79217-60-0

CMF Unspecified

CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 53123-88-9

CMF C51 H79 N O13

CDES *

Absolute stereochemistry.
Double bond geometry as shown.



Me


RN 134127-87-0 CA
 CN Rapamycin, mixt. with [3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone (9CI) (CA INDEX NAME)

CM 1

CRN 104987-11-3
 CMF C44 H69 N O12
 CDES *

Absolute stereochemistry.


Double bond geometry as shown.



CM 2

CRN 53123-88-9
CMF C51 H79 N 013
CDES *


Absolute stereochemistry.
Double bond geometry as shown.



Me

IT 53123-88-9, Rapamycin
 RL: BIOL (Biological study)
 (immunosuppressant, animal transplant rejection
 inhibition with)
 RN 53123-88-9 CA
 CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



Me

L15 ANSWER 46 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 46
 AN 101:222224 CA
 TI Activity of rapamycin (AY-22,989) against transplanted tumors
 AU Eng, C. P.; Sehgal, S. N.; Vezina, Claude
 CS Dep. Microbiol., Ayerst Res. Lab., Montreal, PQ, H3C 3J1, Can.
 SO J. Antibiot. (1984), 37(10), 1231-7
 CODEN: JANTAJ; ISSN: 0021-8820
 DT Journal
 LA English
 AB Rapamycin [53123-88-9] exhibits activity against several ascites and solid transplantable tumors; it is slightly active to inactive against leukemias. On a wt. basis, rapamycin was less active than 5-fluorouracil, cyclophosphamide and adriamycin, but rapamycin's maximal activity against Colon 38

tumor was similar to that of 5-fluorouracil [51-21-8] and cyclophosphamide [50-18-0]. Its activity was such that it significantly inhibited tumor growth at any stage of development. In the active dose range, rapamycin appeared less toxic than the other drugs. In the Colon 38 tumor model, rapamycin at a given dose exhibited the same activity when administered i.p., i.v., i.m. and s.c., upon oral administration, its activity was reduced but not abolished. Rapamycin was compatible with 5-fluorouracil and cyclophosphamide. The sequential treatment 5-fluorouracil-rapamycin-cyclophosphamide was superior to the sequence 5-fluorouracil-adriamycin [23214-92-8]-cyclophosphamide in protecting Colon 38 tumor-bearing mice. 29-Demethoxyrapamycin [83482-58-0] exerted only marginal activity against P388 lymphocytic leukemia; it was inactive against B16 melanocarcinoma and Colon 38 solid tumor.

IT 83482-58-0


RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (neoplasm-inhibiting activity of)

RN 83482-58-0 CA

CN Rapamycin, 32-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



Me

IT 53123-88-9


RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**neoplasm-inhibiting** activity of, drug
 combinations with)

RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



Me

L15 ANSWER 47 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 47
AN 101:203757 CA
TI Current NCI preclinical antitumor screening in vivo: results of
tumor panel screening, 1976-1982, and future directions
AU Venditti, John M.; Wesley, Robert A.; Plowman, Jacqueline
CS Div. Cancer Treat., Natl. Cancer Inst., Bethesda, MD, 20205, USA
SO Adv. Pharmacol. Chemother. (1984), 20, 1-20
CODEN: AVPCAQ; ISSN: 0065-3144
DT Journal
LA English
AB Experiences in preclin. antitumor agent screening by the Division of
Cancer Treatment of the NCI are summarized. Efficacies of various
tumor models in uncovering agents not selected by L1210 are
demonstrated.
IT 53123-88-9
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibition by)
RN 53123-88-9 CA
CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Me

L15 ANSWER 48 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 48
 AN 99:63770 CA
 TI Human brain tumor xenografts in nude mice as a chemotherapy model
 AU Houchens, David P.; Ovejera, Artemio A.; Riblet, Sylva M.; Slagel,
 Donald E.
 CS Battelle Mem. Inst., Columbus, OH, 43201, USA
 SO Eur. J. Cancer Clin. Oncol. (1983), 19(6), 799-805
 CODEN: EJCODS; ISSN: 0277-5379
 DT Journal
 LA English
 AB Two human brain tumors which were previously established
 in nude mice were used to det. antitumor efficacy of various
therapeutic agents. These tumors were a
 medulloblastoma (TE-671) and a glioma (U-251) with mass-doubling
 times of 3.5 and 5.5 days, resp., as s.c. implants in nude mice.

Intracranial **tumor** challenge was accomplished by inoculating tissue culture-grown cells of either **tumor** into the right cerebral hemisphere to a depth of 3 mm. Groups of mice which had been inoculated with **tumor** were **treated** with various doses and schedules of antineoplastic compds. by the i.p. route. A new drug (rapamycin [53123-88-9]) was very effective against the U-251 **tumor**. This model system should prove valuable in assessing the effects of various chemotherapeutic modalities against brain **tumors**.

L15 ANSWER 49 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 49
AN 98:22284 CA
TI Anticancer pharmaceuticals containing rapamycin and picibanil
PA Ayerst, McKenna and Harrison Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
PI JP 57159716 A2 821001 Showa
AI JP 82-35697 820305
PRAI US 81-241867 810309
DT Patent
LA Japanese
AB Pharmaceuticals contg. rapamycin (I) [53123-88-9] and picibanil (II) [39325-01-4] are **neoplasm inhibitors** for **treatment** of lymphocytic leukemia, colon **neoplasm**, mammary **cancer**, melanoma, etc. Thus, an injection was prepd. contg. I, II, butylated hydroxyanisole, anhyd. EtOH, Cremophor EL and H2O. Combinations of I and II were more effective than I or II alone in **inhibiting** the growth of lymphatic leukemia cells in mice.

L15 ANSWER 50 OF 51 CA COPYRIGHT 1996 ACS DUPLICATE 50
AN 93:88940 CA
TI Pharmaceutical compositions based on rapamycin for treatment of cancerous tumors
IN Sehgal, Surendra Nath; Vezina, Claude
PA Ayerst, McKenna and Harrison Ltd., Can.
SO Belg., 12 pp.
CODEN: BEXXAL
PI BE 877700 800114
PRAI US 78-957626 781103
DT Patent
LA French
AB Rapamycin (I) [53123-88-9] significantly prolonged the life span of lab. animals bearing **tumors** and decreased the size of the **tumors**. The ratio of the av. survival in days of mice bearing lymphatic leukemia P-388 and **treated** with I (9 daily i.p. 12.5-400 mg/kg injections) to that of nontreated leukemic mice was 1.28-1.46. In rats with mammary **tumors**, the ratio of the av. wt. of **tumors** at the beginning of **treatment** to that of **tumors** in nontreated animals was .10-.29. I may also be combined with presently used antineoplastic agents such as alkylating agents, antimetabolites,

estrogens, etc.

IT 53123-88-9

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibition by)


RN 53123-88-9 CA

CN Rapamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

Me

L15 ANSWER 51 OF 51 CA COPYRIGHT 1996 ACS

DUPLICATE 51

AN 90:351 CA

TI Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro
and in vivo evaluation

AU Baker, H.; Sidorowicz, A.; Sehgal, S. N.; Vezina, Claude

CS Dep. Microbiol., Ayerst Res. Lab., Montreal, Que., Can.
SO J. Antibiot. (1978), 31(6), 539-45
CODEN: JANTAJ; ISSN: 0021-8820
DT Journal
LA English
AB The activity of rapamycin (I) [53123-88-9], a new anti-Candida antibiotic, was not affected by pH values between 6 and 8; at pH 4, however activity was abolished. The min. inhibitory concn. of I did not vary drastically with the size of inoculum. Serum binding was extensive. Serum levels obtained in mice were higher after s.c. injection than after oral administration. I cured systemic candidosis in mice. I and amphotericin B, administered at 1, 4 and 24 h after infection, gave approx. the same percent survival after 30 days of observation. When the above treatment was extended by an addnl. daily treatment of 6 days, I by the s.c. route yielded a higher percentage of survival than either I or amphotericin B, administered orally, after a 30-day observation period. Vaginal candidosis in female rats was treated efficiently (91% cure) by I administered orally. No increase of resistance of C. albicans was obsd. during treatment.

FILE 'CAOLD' ENTERED AT 11:54:57 ON 26 APR 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1957-1966
FILE LAST UPDATED: 30 OCT 91 (910803/ED)

To help control your online searching costs, consider using the HCAOLD File when conducting SmartSELECT searches with large numbers of terms.

=> s 12
L16 0 L2


=> fil casreact
FILE 'CASREACT' ENTERED AT 11:57:34 ON 26 APR 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTENT:1985-1996 (VOL 102 ISS 1 - VOL 124 ISS 17)

>>> Several important enhancements to CASREACT functional group <<<
>>> searching were introduced. Enter HELP FGA or HELP FGC for more <<<
>>> information. <<<

=> d que stat
L17 STR

PRO



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L18 11 SEA FILE=CASREACT SSS FUL L17 (74 REACTIONS)

100.0% DONE 366 VERIFIED 74 HIT RXNS 11 DOCS
SEARCH TIME: 00.00.04

=> d 1-11 bib abs fhit

L18 ANSWER 1 OF 11 CASREACT COPYRIGHT 1996 ACS
AN 122:314360 CASREACT
TI C-22 ring stabilized rapamycin derivatives

IN Nelson, Frances C.
PA American Home Products Corp., USA
SO U.S., 22 pp.
CODEN: USXXAM
PI US 5387680 A 950207
AI US 93-105090 930810
DT Patent
LA English
OS MARPAT 122:314360
AB This invention provides C-22 substituted rapamycin derivs. and pharmaceutically acceptable salts thereof which are useful for inducing immunosuppression.


RX(1) OF 20 A + B ==> C...

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

A



B



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

C
YIELD 27%

RX(1) RCT A 155435-45-3

STAGE(1)


RGT D 4111-54-0 LiN(Pr-i)2
SOL 109-99-9 THF, 110-82-7 Cyclohexane

STAGE(2)

RCT B 333-27-7
PRO C 163389-48-8
NTE KEY STEP

L18 ANSWER 2 OF 11 CASREACT COPYRIGHT 1996 ACS
AN 122:105481 CASREACT
TI Synthetic modifications of ascomycin. I. Chemoselective removal of
the cyclohexyl residue of ascomycin
AU Zimmer, Reinhold; Grassberger, Maximilian A.; Baumann, Karl; Schulz,
Gerhard; Haidl, Ewald
CS Department Dermatology, Sandoz Forschungsinstitut, Vienna, A-1235,
Austria
SO Tetrahedron, (1994), 50(48), 13655-70
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
AB An efficient semisynthetic prepn. of des-28-(cyclohexyl)methylene-28-
oxo-ascomycin derivs. starting from 24,33-O-bis(tert-
butyldimethylsilyl)ascomycin is described. The strategy for prepg.
28-oxo-ascomycin derivs. involves the redn. of C-22 carbonyl group,
followed by 5-endo-cyclization of the resulting C-22 alc. with the
C-19/C-20 double bond using an oxymercuration reaction; ozonolysis
of the C-28/C-29 double bond and regeneration of the C-19/C-20
double bond. Further, the 20-mercury-substituted ascomycin derivs.
could be reduced in the corresponding metal free cyclic ethers using
n-Bu3SnH.


RX(12) OF 58 ...R + 2 AC ==> AB + AD...



R


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 1-B




AC


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *




AC

(12)
→






AB
YIELD 22%



AD
YIELD 42%

RX(12) RCT R 160466-87-5, AC 160549-89-3
 RGT Z 7647-01-0 HCl
 PRO AB 160466-90-0, AD 160466-93-3
 SOL 7732-18-5 Water, 75-05-8 MeCN

L18 ANSWER 3 OF 11 CASREACT COPYRIGHT 1996 ACS
 AN 122:80964 CASREACT
 TI A novel ring contraction of rapamycin
 AU Nelson, Frances C.; Stachel, Shawn J.; Mattes, James F.
 CS Chem. Sci., Wyeth-Ayerst Res., Princeton, NJ, 08543-8000, USA
 SO Tetrahedron Lett. (1994), 35(41), 7557-60
 CODEN: TELEAY; ISSN: 0040-4039
 DT Journal
 LA English
 GI




AB The first synthesis of a novel ring contracted analog of rapamycin, I, is reported. The synthesis employs a stereoselective and regioselective redn. of the C(27) ketone followed by a 1,3-acyl migration.

RX(1) OF 13 A + 2 B ==> C...

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Me

A



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Me

C
YIELD 84%

RX(1) RCT A 53123-88-9, B 994-30-9
RGT D 288-32-4 1H-Imidazole
PRO C 155435-45-3
SOL 68-12-2 DMF

L18 ANSWER 4 OF 11 CASREACT COPYRIGHT 1996 ACS
AN 122:80952 CASREACT
TI Manipulation of the Rapamycin Effector Domain. Selective
Nucleophilic Substitution of the C7 Methoxy Group
AU Luengo, Juan I.; Konialian-Beck, Arda; Rozamus, Leonard W.; Holt,
Dennis A.
CS Department of Medicinal Chemistry, SmithKline Beecham
Pharmaceuticals, King of Prussia, PA, 19406, USA
SO J. Org. Chem. (1994), 59(22), 6512-13
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CJACS-IMAGE; CJACS
AB The C7 methoxy group in rapamycin has been found to be labile toward
acidic reagents. Conditions have been developed to replace this
group with a no. of different nucleophiles, such as alcs., thiols,

and electron-rich arom. systems. This novel, efficient transformation allows the selective manipulation of the rapamycin effector domain.

RX(1) OF 16 A ==> B

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

A

(1)
→

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me


B

RX(1) RCT A 53123-88-9
 PRO B 157182-37-1
 CAT 104-15-4 TsOH
 SOL 67-56-1 MeOH
 NTE (2:1, REACTANT:PRODUCT)

L18 ANSWER 5 OF 11 CASREACT COPYRIGHT 1996 ACS
AN 121:255475 CASREACT
TI Acid catalyzed functionalization of rapamycin
AU Grinfeld, Alexander A.; Caufield, Craig E.; Schiksnis, Robert A.;
Mattes, James F.; Chan, Kelvin W.
CS Department Chemical Sciences, Wyeth-Ayerst Research, Inc.,
Princeton, NJ, 08543-8000, USA
SO Tetrahedron Lett. (1994), 35(37), 6835-8
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
AB Rapamycin rapidly undergoes demethoxylation at C-7 in the presence

of Lewis acids (BF₃.Et₂O, SnCl₄ etc.) to give a highly stabilized carbocation. This intermediate gives a tetraene or is trapped by nucleophiles to give functionalized trienes. Several examples of the substitution reaction and elaboration of the reaction scheme are reported.

RX(1) OF 8 2 A + 2 B ==> C + D



2 A

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

B

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

B


(1) \longrightarrow

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Me

C
YIELD 40%


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
PAGE 2-A



D
YIELD 40%

RX(1) RCT A 56-81-5, B 53123-88-9
RGT E 7646-78-8 SnCl4
PRO C 158615-16-8, D 158615-19-1
SOL 109-99-9 THF

L18 ANSWER 6 OF 11 CASREACT COPYRIGHT 1996 ACS
AN 121:35093 CASREACT
TI Lipase mediated hydrolysis of rapamycin 42-hemisuccinate benzyl and methyl esters
AU Adamczyk, Maciej; Gebler, John C.; Mattingly, Phillip G.
CS Abbott Diagn. Div., Abbott Lab., Abbott Park, IL, 60064, USA
SO Tetrahedron Lett. (1994), 35(7), 1019-22
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
GI



AB Benzyl and Me esters of rapamycin 42-hemisuccinate (I, R = CH₂Ph, Me) were hydrolyzed under very mild conditions to the rapamycin hemisuccinate I (R = H) using lipase from *Pseudomonas* sp. This selective deprotection was performed on a .gtoreq.100 mg scale for both esters resulting in 50% isolated yield from the Me ester and 29% from the benzyl ester of the desired acid.

RX(1) OF 2 2 A ==> B + C

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

A

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

A

(1) →

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

B
YIELD 68%

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


PAGE 2-A

Me

C
YIELD 32%

RX(1) RCT A 155589-15-4
RGT D 9001-62-1 Lipase
PRO B 155589-16-5, C 53123-88-9
SOL 7732-18-5 Water, 75-05-8 MeCN


L18 ANSWER 7 OF 11 CASREACT COPYRIGHT 1996 ACS
AN 119:249751 CASREACT
TI Total synthesis of rapamycin via a novel titanium-mediated aldol
macrocyclization reaction
AU Hayward, Cheryl M.; Yohannes, Daniel; Danishefsky, Samuel J.
CS Dep. Chem., Yale Univ., New Haven, CT, 06511-8118, USA.
SO J. Am. Chem. Soc. (1993), 115(20), 9345-6
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English
OS CJACS-IMAGE; CJACS
GI




AB A synthesis of rapamycin is described. The key step is the formation of the C-27-C-28 bond from the seco precursor I by an intramol. aldol condensation.

RX(1) OF 1 2 A ==> B + C


PAGE 1-A






2 A

(1) →



B
YIELD 11%



C

RX(1) RCT A 151058-36-5

STAGE(1)

RGT D 3981-83-7 Cl₃TiOPr-i


SOL 75-09-2 CH₂Cl₂

STAGE(2)

RGT E 121-44-8 Et₃N

PRO B 151122-98-4, C 151058-34-3

L18 ANSWER 8 OF 11 CASREACT COPYRIGHT 1996 ACS
AN 118:147403 CASREACT
TI Preparation of rapamycin pyrazoles as immunosuppressants
IN Failli, Amedeo A.; Steffan, Robert J.
PA American Home Products Corp., USA
SO U.S., 7 pp.
CODEN: USXXAM
PI US 5164399 A 921117
AI US 91-793765 911118
DT Patent
LA English
OS MARPAT 118:147403
GI



AB Title compds. [I; Z = Q¹, CO; R¹, R² = H, alkyl, (substituted) phenylalkyl; when R¹ is present, R² is absent, and vice versa; dotted lines = double bonds to complete pyrazole structure], were prepd. Thus, rapamycin was treated with Dess-Martin periodinane in CH₂Cl₂ for 2 h at room temp. to give 31-deoxy-31-oxorapamycin. This

was stirred 2 h with N2H4.H2O in MeOH at 60.degree. for 2 h to give I (Z = Q1, R1 or R2 = H) as a mixt. of tautomers. The latter showed IC50 = 205.3 nM in the comitogen-induced lymphocyte proliferation test.

RX(1) OF 3 2 A ==> B + C...

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

A


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A


Me

A

(1) →



B



C

RX(1) RCT A 53123-88-9

RGT D 87413-09-0 Martin's reagent
PRO B 146352-12-7, C 146352-14-9
SOL 75-09-2 CH2Cl2
NTE Room tem., 2 h

L18 ANSWER 9 OF 11 CASREACT COPYRIGHT 1996 ACS
AN 118:80729 CASREACT
TI (carbamoyl)rapamycin derivatives, a method for their preparation and their use as immunosuppressants
IN Kao, Wenling; Vogel, Robert Lewis; Musser, John Henry
PA American Home Products Corp., USA
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
PI EP 509795 A2 921021
DS R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE
AI EP 92-303401 920415
PRAI US 91-686728 910417
US 92-837048 920218
DT Patent
LA English
OS MARPAT 118:80729
AB Some rapamycin carbamate derivs. are claimed. Pharmaceuticals contg. said compds. are claimed. A mixt. of rapamycin, pyridine, and 4-fluorophenyl isocyanate was stirred at 0.degree. for 5 h to give rapamycin 42-[(4-fluorophenyl)carbamate] (I). The immunosuppressant activity of I was demonstrated in a thymocyte proliferation test, mixed lymphocyte reaction and in the survival of a pinch skin graft on mice.


RX(1) OF 6 A + B ==> C...

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A


Me

A



B






C

RX(1) RCT A 53123-88-9, B 18162-48-6
 RGT D 288-32-4 1H-Imidazole
 PRO C 143030-02-8
 SOL 68-12-2 DMF

L18 ANSWER 10 OF 11 CASREACT COPYRIGHT 1996 ACS
 AN 117:150807 CASREACT
 TI [(carbamoylalkyl)acyl]rapamycin derivatives, a method for their
 preparation and their use as immunosuppressants
 IN Caufield, Craig E.
 PA American Home Products Corp., USA
 SO U.S., 7 pp.
 CODEN: USXXAM
 PI US 5118677 A 920602
 AI US 91-703240 910520
 DT Patent
 LA English
 OS MARPAT 117:150807
 AB Certain rapamycin esters are claimed. Pharmaceuticals contg. said
 compds. as immunosuppressive agents are claimed. Acylrapamycin
 derivs. also have antifungal activity (no data). Acylation of
 rapamycin with N,N-dimethylsuccinamic acid gave 42-[4-
 (dimethylamino)-4-oxobutanoyl]rapamycin (I). I showed
 immunosuppressant activity in a mixed lymphocyte reaction and in a
 pinch skin graft survival test.

RX(1) OF 2 A + B ==> C



A


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 2-A

Me

B

(1) \longrightarrow



C
YIELD 10%

RX(1) RCT A 2564-95-6, B 53123-88-9
RGT D 1892-57-5 EtN:C:N(CH₂)₃NMe₂, E 1122-58-3 4-DMAP
PRO C 143029-88-3
SOL 75-09-2 CH₂Cl₂

L18 ANSWER 11 OF 11 CASREACT COPYRIGHT 1996 ACS

AN 117:111387 CASREACT

TI carbamoylrapamycin derivatives, a method for their preparation and their use as immunosuppressants

IN Kao, Wenling; Vogel, Robert L.; Musser, John H.

PA American Home Products Corp., USA

SO U.S., 7 pp.

CODEN: USXXAM

PI US 5118678 A 920602

AI US 91-686728 910417

DT Patent

LA English

OS MARPAT 117:111387

AB Certain derivs. of rapamycin, i.e., carbamoylrapamycin derivs., are claimed. Pharmaceuticals contg. said compds. as immunosuppressive agents are claimed. Rapamycin derivs. are also potential neoplasm inhibitors and antifungal agents. Treatment of rapamycin with 4-fluorophenyl isocyanate gave 42-[(4-fluorophenyl)carbamoyl]rapamycin (I) and 31,42-bis[(4-fluorophenyl)carbamoyl]rapamycin. I showed immunosuppressant activity in a mixed lymphocyte reaction and in a pinch skin graft survival test.


· RX(1) OF 4 A + B ==> C

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


PAGE 2-A

Me

A



B



C

RX(1) RCT A 53123-88-9, B 1195-45-5
RGT D 110-86-1 Pyridine
PRO C 143029-91-8

=> fil marpat; d que stat 119; fil marpatprev
FILE 'MARPAT' ENTERED AT 12:03:18 ON 26 APR 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 American Chemical Society (ACS)


FILE CONTENT: 1988-1996 (VOL 108 ISS 14 - VOL 124 ISS 17) (960419 ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	5492544	20 Feb 1996
DE	19525777	08 Feb 1996
EP	698933	28 Feb 1996
JP	08024363	30 Jan 1996
WO	9601624	25 Jan 1996

NOTICE: 1996 patents have started appearing in MARPAT.

L1 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
 ECLEVEL IS LIM ON ALL NODES
 ALL RING(S) ARE ISOLATED

L19 0 SEA FILE=MARPAT SSS FUL L1 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 190 ITERATIONS
 SEARCH TIME: 00.00.15

0 ANSWERS


FILE 'MARPATPREV' ENTERED AT 12:03:20 ON 26 APR 96
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 1996 American Chemical Society (ACS)

FILE COVERS CURRENT RECORDS AND IS UPDATED DAILY
FILE LAST UPDATED: 26 Apr 1996 (960426)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	5496810	05 Mar 1996
DE	4432888	21 Mar 1996
EP	702073	20 Mar 1996
JP	08050312	20 Feb 1996
WO	9602003	25 Jan 1996

=> d que stat; fil hom
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 27


STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L20 0 SEA FILE=MARPATPREV SSS FUL L1 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 4 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.03

FILE 'HOME' ENTERED AT 12:03:56 ON 26 APR 96





UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

SERIAL NUMBER FILING DATE PROMISED INVENTOR ATTORNEY

08/416,673 04/07/95 COTTENS

EXAMINER

12M2/0514

BOND, R. ART. US. PAT. NO. 1

ROBERT S HONOR
 SANDOZ CORPORATION
 59 ROUTE 10
 EAST HANOVER NJ 07936-1080

1202
 DATE MAILED

#3

This is a communication from the examiner in charge of your application
 COMMISSIONER OF PATENTS AND TRADEMARKS

05/14/96

This application has been examined Responsive to communication filed on _____ This action is made final

A shortened statutory period for response to this action is set to expire THREE (3) month(s), _____ days from the date of this letter.
 Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

1. Notice of References Cited by Examiner, PTO-892.
2. Notice of Draftsman's Patent Drawing Review, PTO-948.
3. Notice of Art Cited by Applicant, PTO-1449.
4. Notice of Informal Patent Application, PTO-152.
5. Information on How to Effect Drawing Changes, PTO-1474.
6. _____

Part II SUMMARY OF ACTION

1. Claims 1-5 are pending in the application.
 Of the above, claims _____ are withdrawn from consideration.
2. Claims _____ have been cancelled.
3. Claims _____ are allowed.
4. Claims 1-5 are rejected.
5. Claims _____ are objected to.
6. Claims _____ are subject to restriction or election requirement.
7. This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.
8. Formal drawings are required in response to this Office action.
9. The corrected or substitute drawings have been received on _____. Under 37 C.F.R. 1.84 these drawings are acceptable; not acceptable (see explanation or Notice of Draftsman's Patent Drawing Review, PTO-948).
10. The proposed additional or substitute sheet(s) of drawings, filed on _____, has (have) been approved by the examiner; disapproved by the examiner (see explanation).
11. The proposed drawing correction, filed _____, has been approved; disapproved (see explanation).
12. Acknowledgement is made of the claim for priority under 35 U.S.C. 119. The certified copy has been received not been received been filed in parent application, serial no. _____; filed on _____.
13. Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.
14. Other

EXAMINER'S ACTION

15. Claims 1-8 are now in the case.

16. Claims 1-8 are rejected under 35 U.S.C. § 112, first and second paragraphs, as the claimed invention is not described in such full, clear, concise and exact terms as to enable any person skilled in the art to make and use the same, and/or for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

17. The term "aryl" and terms derived from "aryl" encompass groups having any number of carbon atoms as well as groups having any number and type of un-named substituents. The term "acyl" and terms derived from "acyl" encompass groups derived from any organic acid not just from carboxylic acids.

18. A use is claimed in the United States as a method or process.

19. A composition claim such as 7 should not depend on a process claim such as 5.

20. The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

21. Claims 1-8 are rejected under 35 U.S.C. § 103 as being unpatentable over Goulet et al.

22. Goulet et al. discloses broadly either identical subject matter (in many cases) or subject matter which is very similar to the claimed subject matter. The various ether groups may be attached to the cyclohexyl group in the side chain of the rapamycins or in HO the large ring or in both positions. The reference discloses many of the same uses as those of applicants. The same methods of making the compounds as those employed by applicants are disclosed by the reference.

23. Since the Goulet reference claims much of the subject matter being claimed by applicants, the reference can only be removed by interference proceedings.

24. 3 MOS S.S.P.

25. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert T. Bond whose telephone number is (703) 308-4711.

Serial Number: 08/416,673
Art Unit: 1202

-4-

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

R.T. Bond:jab
May 11, 1996



ROBERT T. BOND
PRIMARY EXAMINER
ART UNIT 1202

TO SEPARATE, HOLD TOP AND BOTTOM EDGES, SNAP-APART AND DISCARD CARBON

FORM PTO-892 (REV. 3-78)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	SERIAL NO. 08/416,673	GROUPART UNIT 1202	ATTACHMENT TO PAPER NUMBER 3
NOTICE OF REFERENCES CITED		APPLICANT(S) COTTENS ET AL.		

U.S. PATENT DOCUMENTS													
*	DOCUMENT NO.							DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE	
*	A	3	1	2	0	8	4	2	9 JUN 1992	FAILLI ET AL.	540	542	1 APRIL 1991
*	B	5	1	5	1	4	1	3	29 SEPT 1992	CAUFIELD ET AL.	514	63	6 NOV 1991
	C	5	2	5	8	3	8	9	2 NOV 1993	GOULET ET AL.	514	291	9 NOV 1992
	D												
	E												
	F												
	G												
	H												
	I												
	J												
	K												

FOREIGN PATENT DOCUMENTS														
*	DOCUMENT NO.							DATE	COUNTRY	NAME	CLASS	SUB-CLASS	PERTINENT SHTS. DWG. PP. SPEC.	
	L													
	M													
	N													
	O													
	P													
	Q													

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	
R	
S	
T	
U	

EXAMINER <i>Robert J. Bonel</i>	DATE 30 APRIL 1996
------------------------------------	-----------------------

* A copy of this reference is not being furnished with this office action.
(See Manual of Patent Examining Procedure, section 707.05 (a).)

100-1232

The
Patent
Office

The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

I, the undersigned, being an officer duly authorised in accordance with Section 62(3) of the Patents and Designs Act 1907, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the Patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or the inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed 

Dated 23rd September 1993

COC1

For official use



13OCT 192400002476 PAT 1 77 UC 25.00

09 OCT 1992

Your reference

100-7932

9 221 220 . 8

Notes

Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-438 4700).

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

The
**Patent
Office**

**Request for grant of a
Patent
Form 1/77**

Patents Act 1977

1 Title of invention

1 Please give the title of the invention Organic Compounds.

2 Applicant's details

First or only applicant

2a If you are applying as a corporate body please give:

Corporate name SANDOZ LTD.

Country (and State of incorporation, if appropriate) Switzerland

2b If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2c **In all cases**, please give the following details:

Address 35 Lichtstrasse, CH-4002 Basle, Switzerland

UK postcode (if applicable)

Country Switzerland

ADP number (if known) 00703207001 ✓

2d, 2e and 2f: if there are further applicants please provide details on a separate sheet of paper.

Second applicant (if any)

2d If you are applying as a corporate body please give:
Corporate name

Country (and State
of incorporation, if
appropriate)

2e If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2f **In all cases**, please give the following details:

Address

UK postcode
(if applicable)

Country

ADP number
(if known)

Ⓜ An address for service in the United Kingdom must be supplied

Please mark correct box

Ⓜ **Address for service details**

3a Have you appointed an agent to deal with your application?

Yes No → go to 3b

↓
please give details below

Agent's name

B. A. YORKE & CO.

Agent's address

Coomb House
7, St. John's Road
Isleworth,

Postcode

Middlesex TW7 6NH ✓

Agent's ADP
number

1800001

3b: If you have appointed an agent, all correspondence concerning your application will be sent to the agent's United Kingdom address.

3b If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name

Address

Postcode

ADP number
(if known)

Daytime telephone
number (if available)

4 Reference number

4 Agent's or applicant's reference number (if applicable) **100-7932**

5 Claiming an earlier application date

5 Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Yes No → go to 6

↓
please give details below

number of earlier application or patent number

filing date (day month year)

and the Section of the Patents Act 1977 under which you are claiming:

15(4) (Divisional) 8(3) 12(6) 37(4)

Please mark correct box

Please mark correct box

6 If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number.

Please give the date in all number format, for example, 31/05/90 for 31 May 1990.

6 Declaration of priority

6 If you are declaring priority from previous application(s), please give:

Country of filing	Priority application number (if known)	Filing date (day, month, year)

- ⑦ The answer must be 'No' if...
- any applicant is not an inventor
- there is an inventor who is not an applicant, or
- any applicant is a corporate body.

⑧ Please supply duplicates of claim(s), abstract, description and drawing(s).

Please mark correct box(es)

⑨ You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here →

A completed fee sheet should preferably accompany the fee.

7 Inventorship

7 Are you (the applicant or applicants) the sole inventor or the joint inventors?
 Please mark correct box
 Yes No → **A Statement of Inventorship on Patents Form 7/77 will need to be filed (see Rule 15).**

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application.

Continuation sheets for this Patents Form 1/77	<input type="text" value="no"/>
Claim(s) <input type="text" value="3"/>	Description <input type="text" value="20"/>
Abstract <input type="text" value="1"/>	Drawing(s) <input type="text" value="no"/>

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)	<input type="text" value="no"/>
Translation(s) of Priority documents (please state how many)	<input type="text" value="no"/>
Patents Form 7/77 – Statement of Inventorship and Right to Grant (please state how many)	<input type="text" value="no"/>
Patents Form 9/77 – Preliminary Examination/Search	<input type="text" value="no"/>
Patents Form 10/77 – Request for Substantive Examination	<input type="text" value="no"/>

9 Request

I/We request the grant of a patent on the basis of this application.

Signed SANDOZ LTD. Date 06/10/1992
(Handwritten signature) (day month year)


Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to either:

- | | | |
|--|----|--|
| <input type="checkbox"/> The Comptroller
The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH | or | <input type="checkbox"/> The Comptroller
The Patent Office
25 Southampton Buildings
London
WC2A 1AY |
|--|----|--|

ORGANIC COMPOUNDS

This invention comprises novel derivatives of rapamycin having pharmaceutical utility, especially as immunosuppressants.

Rapamycin is a known macrolide antibiotic produced by Streptomyces hygroscopicus, having the structure depicted in Formula A:




(A)

See, e.g., McAlpine, J.B., et al., J. Antibiotics (1991) 44: 688;
Schreiber, S.L., et al., J. Am. Chem. Soc. (1991) 113: 7433; US

Patent No. 3 929 992. Rapamycin is an extremely potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable bioavailability as well as its high toxicity.

It has now surprisingly been discovered that certain novel derivatives of rapamycin (the Novel Compounds) have an improved pharmacologic profile over rapamycin and exhibit greater stability and bioavailability. The Novel Compounds are compounds having the structure of Formula I:



wherein

X is (H,H) or O;

Y is (H,H), (H,OH), or O; and

R¹ and R² are independently selected from
 H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl,
 dihydroxyalkyl, alkoxyalkyl, acyloxyalkyl, carbalkoxyalkyl,

aminoalkyl, alkylaminoalkyl, allyl and R^3_3Si where each R^3 is independently selected from H, methyl, ethyl, isopropyl, t-butyl, and phenyl; wherein "alk-" or "alkyl" refers to C_{1-6} alkyl, branched or linear, preferably C_{1-3} alkyl, in which the carbon chain may be optionally interrupted by an ether (-O-) linkage; and

provided that where X is O, then either Y is other than O, or R^1 or R^2 is other than H; and

provided that where R^1 or R^1 and R^2 are R^3_3Si , X and Y are not both O.

Among the preferred groups of Novel Compounds are

a) 9-deoxorapamycins where X is (H,H), Y is (H,H), (H,OH) or O, and R^1 and R^2 are independently selected from H, alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl;

b) 26-dihydro-rapamycins where X is O or (H,H), Y is (H,OH), and R^1 and R^2 are independently selected from H, alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl; and

c) 40-0-substituted and 28,40-0,0-disubstituted rapamycins where X is O or (H,H), Y is (H,H), (H,OH) or O, and R^1 and R^2 are independently selected from alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl.

The most preferred Novel Compounds are

1. 9-Deoxorapamycin (X=H,H; Y=O; $R^1=R^2=H$).
2. 26-Dihydro-rapamycin (X=O; Y=H,OH; $R^1=R^2=H$).
3. 9-Deoxo-26-dihydro-rapamycin (X=H,H; Y=H,OH; $R^1=R^2=H$).
4. 40-0-Carbethoxymethyl-rapamycin (X=Y=O; $R^1=CH_2COOCH_2CH_3$; $R^2=H$).

5. 40-O-Carboethoxymethyl-9-deoxorapamycin (X=H,H; Y=O, R¹=CH₂COOCH₂CH₃, R²=H).
6. 40-O-Benzyl-rapamycin (X=Y=O; R¹=CH₂C₆H₅; R₂=H).
7. 40-O-Allyl-rapamycin (X=Y=O; R¹=CH₂CHCH₂; R²=H).
8. 40-O-(2-Hydroxyethyl)-rapamycin (X=Y=O; R¹=CH₂CH₂OH, R₂=H).

The 9-deoxorapamycin compounds are produced by reducing a rapamycin using hydrogen sulfide, e.g. as described in Example 1, by reacting rapamycin with diphenyldiselenide and tributylphosphine or by other suitable reduction reaction.

The 26-dihydro-rapamycins are produced by reducing rapamycins or 9-deoxorapamycins from keto to hydroxy at C26 by a mild reduction reaction, such as a borohydride reduction reaction, e.g., as described in Example 2.

O-substitutions at C40 are accomplished by reacting the compound with a radical attached to a leaving group under acidic or neutral conditions, e.g., as described in Example 3. Further modifications are possible. For example, where the substituent at C40 is allyl, the isolated, monosubstituted double bond of the allyl moiety is highly amenable to further modification. O-substitutions at C28 are accomplished in the same manner, but with prior protection at C40.

The Novel Compounds are particularly useful for the following conditions:

a) Treatment and prevention of organ or tissue transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants. They are also indicated for the prevention of graft-versus-host disease, such as following bone marrow transplantation.

b) Treatment and prevention of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an aetiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases. Specific autoimmune diseases for which the compounds of the invention may be employed include, autoimmune haematological disorders (including e.g. haemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis and Crohn's disease) endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy) and juvenile dermatomyositis.

c) Treatment and prevention of asthma.

d) Treatment of multi-drug resistance (MDR). The Novel Compounds suppress P-glycoproteins (Pgp), which are the membrane transport molecules associated with MDR. MDR is particularly problematic in cancer patients and AIDS patients who will not respond to conventional chemotherapy because the medication is pumped out of the cells by Pgp. The Novel Compounds are therefore useful for enhancing the efficacy of other chemotherapeutic agents in the treatment and control of multidrug resistant conditions such as multidrug resistant cancer or multidrug resistant AIDS.

The Novel Compounds are also useful in treating proliferative disorders, e.g. tumors, hyperproliferative skin disorder and the like, and in treating fungal infections.

The pharmacological activity of the Novel Compounds are demonstrated in, e.g., the following tests:

1. Mixed lymphocyte reaction (MLR)

The Mixed Lymphocyte Reaction was originally developed in connection with allografts, to assess the tissue compatibility between potential organ donors and recipients, and is one of the best established models of immune reaction in vitro. A murine model MLR, e.g., as described by T. Meo in "Immunological Methods", L. Lefkovits and B. Peris, Eds., Academic Press, N.Y. pp. 227-239 (1979), is used to demonstrate the immunosuppressive effect of the Novel Compounds. Spleen cells (0.5×10^6) from Balb/c mice (female, 8-10 weeks) are co-incubated for 5 days with 0.5×10^6 irradiated (2000 rads) or mitomycin C treated spleen cells from CBA mice (female, 8-10 weeks). The irradiated allogeneic cells induce a proliferative response in the Balb/c spleen cells which can be measured by labeled precursor incorporation into the DNA. Since the stimulator cells are irradiated (or mitomycin C treated) they do not respond to the Balb/c cells with proliferation but do retain their antigenicity. The antiproliferative effect of the Novel Compounds on the Balb/c cells is measured at various dilutions and the concentration resulting in 50% inhibition of cell proliferation (IC_{50}) is calculated. The inhibitory capacity of the test sample may be compared to rapamycin and expressed as a relative IC_{50} (i.e. IC_{50} test sample/ IC_{50} rapamycin).

2. IL-6 mediated proliferation

The capacity of the Novel Compounds to interfere with growth factor associated signalling pathways is assessed using an interleukin-6 (IL-6)-dependent mouse hybridoma cell line. The assay is performed in 96-well microtiter plates. 5000 cells/well are cultivated in serum-free medium (as described by M. H. Schreier and R. Tees in Immunological Methods, I. Lefkovits and B. Pernis, eds., Academic Press 1981, Vol. II, pp. 263-275), supplemented with 1 ng recombinant IL-6/ml. Following a 66 hour incubation in the absence or presence of a test sample, cells are pulsed with 1 μ Ci (3-H)-thymidine/well for another 6 hours, harvested and counted by liquid scintillation. (3-H)-thymidine incorporation into DNA correlates with the increase in cell number and is thus a measure of cell proliferation. A dilution series of the test sample allows the calculation of the concentration resulting in 50% inhibition of cell proliferation (IC_{50}). The inhibitory capacity of the test sample may be compared to rapamycin and expressed as a relative IC_{50} (i.e. IC_{50} test sample/ IC_{50} rapamycin).

3. Macrophilin binding assay

Rapamycin and the structurally related immunosuppressant, FK-506, are both known to bind in vivo to macrophilin-12 (also known as FK-506 binding protein or FKBP-12), and this binding is thought to be related to the immunosuppressive activity of these compounds. The Novel Compounds also bind strongly to macrophilin-12, as is demonstrated in a competitive binding assay.

In this assay, FK-506 coupled to BSA is used to coat microtiter wells. Biotinylated recombinant human macrophilin-12 (biot-MAP) is allowed to bind in the presence or absence of a test sample to the immobilized FK-506. After washing (to remove non-specifically bound macrophilin), bound biot-MAP is assessed by incubation with a

streptavidin-alkaline phosphatase conjugate, followed by washing and subsequent addition of p-nitrophenyl phosphate as a substrate. The read-out is the OD at 405nm. Binding of a test sample to biot-MAP results in a decrease in the amount of biot-MAP bound to the FK-506 and thus in a decrease in the OD405. A dilution series of the test sample allows determination of the concentration resulting in 50% inhibition of the biot-MAP binding to the immobilized FK-506 (IC₅₀). The inhibitory capacity of a test sample is compared to the IC₅₀ of free FK-506 as a standard and expressed as a relative IC₅₀ (i.e., IC₅₀-test sample/ IC₅₀-free FK-506).

4. Localised Graft-Versus-Host (GvH) Reaction

In vivo efficacy of the Novel Compounds is proved in a suitable animal model, as described, e.g., in Ford et al, TRANSPLANTATION 10 (1970) 258. Spleen cells (1×10^7) from 6 week old female Wistar/Furth (WF) rats are injected subcutaneously on day 0 into the left hind-paw of female (F344 x WF)_{F1} rats weighing about 100g. Animals are treated for 4 consecutive days and the popliteal lymph nodes are removed and weighed on day 7. The difference in weight between the two lymph nodes is taken as the parameter for evaluating the reaction.

5. Kidney Allograft Reaction in Rat

One kidney from a female fisher 344 rat is transplanted onto the renal vessel of a unilaterally (left side) nephrectomised WF recipient rat using an end-to-end anastomosis. Ureteric anastomosis is also end-to-end. Treatment commences on the day of transplantation and is continued for 14 days. A contralateral nephrectomy is done seven days after transplantation, leaving the recipient relying on the performance of the donor kidney. Survival of the graft recipient is taken as the parameter for a functional graft.

6. Experimentally Induced Allergic Encephalomyelitis (EAE) in Rats

Efficacy of the Novel Compounds in EAE is measured, e.g., by the procedure described in Levine & Wenk, AMER J PATH 47 (1965) 61; McFarlin et al, J IMMUNOL 113 (1974) 712; Borel, TRANSPLANT. & CLIN. IMMUNOL 13 (1981) 3. EAE is a widely accepted model for multiple sclerosis. Male Wistar rats are injected in the hind paws with a mixture of bovine spinal cord and complete Freund's adjuvant. Symptoms of the disease (paralysis of the tail and both hind legs) usually develop within 16 days. The number of diseased animals as well as the time of onset of the disease are recorded.

7. Freund's Adjuvant Arthritis

Efficacy against experimentally induced arthritis is shown using the procedure described, e.g., in Winter & Nuss, ARTHRITIS & RHEUMATISM 9 (1966) 394; Billingham & Davies, HANDBOOK OF EXPERIMENTAL PHARMACOL (Vane & Ferreira Eds, Springer-Verlag, Berlin) 50/II (1979) 108-144. OFA and Wistar rats (male or female, 150g body weight) are injected i.c. at the base of the tail or in the hind paw with 0.1 ml of mineral oil containing 0.6 mg of lyophilised heat-killed Mycobacterium smegmatis. In the developing arthritis model, treatment is started immediately after the injection of the adjuvant (days 1 - 18); in the established arthritis model treatment is started on day 14, when the secondary inflammation is well developed (days 14-20). At the end of the experiment, the swelling of the joints is measured by means of a micro-caliper. ED₅₀ is the oral dose in mg/kg which reduces the swelling (primary or secondary) to half of that of the controls.

8. Antitumor and MDR activity

The antitumor activity of the Novel Compounds and their ability to enhance the performance of antitumor agents by alleviating multidrug resistance is demonstrated, e.g., by administration of an anticancer agent, e.g., colchicine or etoposide, to multidrug resistant cells and drug sensitive cells in vitro or to animals having multidrug resistant or drug sensitive tumors or infections, with and without co-administration of the Novel Compounds to be tested, and by administration of the Novel Compound alone.

Such in vitro testing is performed employing any appropriate drug resistant cell line and control (parental) cell line, generated, e.g. as described by Ling et al., J. Cell. Physiol. 83, 103-116 (1974) and Bech-Hansen et al. J. Cell. Physiol. 88, 23-32 (1976). Particular clones chosen are the multi-drug resistant (e.g. colchicine resistant) line CHR (subclone C5S3.2) and the parental, sensitive line AUX B1 (subclone AB1 S11).

In vivo anti-tumor and anti-MDR activity is shown, e.g., in mice injected with multidrug resistant and drug sensitive cancer cells. Ehrlich ascites carcinoma (EA) sub-lines resistant to drug substance DR, VC, AM, ET, TE or CC are developed by sequential transfer of EA cells to subsequent generations of BALB/c host mice in accordance with the methods described by Slater et al., J. Clin. Invest., 70, 1131 (1982).

Equivalent results may be obtained employing the Novel Compounds test models of comparable design, e.g. in vitro, or employing test animals infected with drug-resistant and drug sensitive viral strains, antibiotic (e.g. penicillin) resistant and sensitive bacterial strains, anti-mycotic resistant and sensitive fungal strains as well as drug resistant protozoal strains, e.g. Plasmodial strains, for example naturally occurring sub-strains of Plasmodium

falciparum exhibiting acquired chemotherapeutic, anti-malarial drug resistance.

9. Dosage forms

The Novel Compounds are utilized by administration of a pharmaceutically effective dose in pharmaceutically acceptable form to a subject in need of treatment. Appropriate dosages of the Novel Compounds will of course vary, e.g. depending on the condition to be treated (for example the disease type or the nature of resistance), the effect desired and the mode of administration.

In general however satisfactory results are obtained on administration orally at dosages on the order of from 0.05 to 5 or up to 10mg/kg/day, e.g. on the order of from 0.1 to 2 or up to 7.5 mg/kg/day administered once or, in divided doses 2 to 4x per day, or on administration parenterally, e.g. intravenously, for example by i.v. drip or infusion, at dosages on the order of from 0.01 to 2.5 up to 5 mg/kg/day, e.g. on the order of from 0.05 or 0.1 up to 1.0 mg/kg/day.

Suitable daily dosages for patients are thus on the order of 500 mg p.o., e.g. on the order of from 5 to 100 mg p.o., or on the order of from 0.5 to 125 up to 250 mg i.v., e.g. on the order of from 2.5 to 50 mg i.v..

Alternatively and even preferably, dosaging is arranged in patient specific manner to provide pre-determined trough blood levels, e.g. as determined by RIA technique. Thus patient dosaging may be adjusted so as to achieve regular on-going trough blood levels as measured by RIA on the order of from 50 or 150 up to 500 or 1000ng/ml, i.e. analogously to methods of dosaging currently employed for Ciclosporin immunosuppressive therapy.

The Novel Compounds are administered by any conventional route, in particular enterally, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectible solutions or suspensions. Suitable unit dosage forms for oral administration comprise, e.g. from 1 to 50 mg of a compound of the invention, usually 1 to 10 mg.

EXAMPLES:

In the following examples, characteristic spectroscopic data is given to facilitate identification. Peaks which do not differ significantly from rapamycin are not included. Biological data is expressed as a relative IC₅₀, compared to rapamycin in the case of the MLR and IL-6 mediated proliferation assays, and to FK-506 in the macrophilin binding assay. A higher IC₅₀ correlates with lower binding affinity.

EXAMPLE 1 - 9-deoxorapamycin

A stream of hydrogen sulfide is passed at room temperature through a stirred solution of 3.2 g (3.5 mmol) of rapamycin in 50 ml pyridine and 2.5 ml DMF. The solution turns from colorless to yellow. After two hours, the introduction of hydrogen sulfide is stopped and stirring is continued for five days, during which time the solution turns gradually orange. TLC and HPLC analysis verifies complete consumption of the starting material and the presence of a single new compound. The solution is purged with nitrogen for one hour and concentrated under reduced pressure. The residue is taken up in ethyl acetate, washed with cold 1N HCl solution (3x), saturated sodium bicarbonate solution and saturated brine. The organic layer is dried over anhydrous sodium sulfate and filtered and concentrated under reduced pressure. The residue is taken up in ether and the precipitated sulfur is filtered off. Concentration of the ethereal solution followed by column chromatography on silica gel (10:4:1 CH₂Cl₂/i-Pr₂O/MeOH) yields 9-deoxorapamycin as a colorless foam.

The identity of the product is confirmed by nuclear magnetic resonance spectroscopy (NMR), mass spectrometry (MS), and/or infrared spectroscopy (IR), and is found to exhibit the following characteristic physical data:

^1H NMR (CDCl_3) δ 1.61 (3H,d,J = 1 Hz, C17- CH_3), 1.76 (3H,d,J = 1.2 Hz,C29- CH_3), 2.42 (1H,d,J = 14.5 Hz, H-9), 2.74 (1H,d,J = 14.5 Hz, H-9), 3.13 (3H,s,C16- OCH_3) 3.5 (3H,s,C27- OCH_3), 3.40 (3H,s,C39- OCH_3), 5.40 (1H,d,J = 10 Hz, H-30), 5.57 (1H,dd, J_1 = 8.6 Hz, J_2 = 15 Hz, H-22), 5.96 (1H,d,J = 9 Hz, H-18), 6.09 (1H,d,J = 1.7 Hz, 10-OH), 6.15 (1H,dd, J_1 = 10 Hz, J_2 = 15Hz, H-21), 6.37 (1H,dd, J_1 = 1.5 Hz, J_2 = 5 Hz, H-19), 6.38 (1H,J = 9.5 Hz, H-20).

^{13}C NMR (CDCl_3) δ 38.5 (C-9), 98.0 (C-10), 170.7 (C-1), 173.0 (C-8), 208.8 (C-32), 216.9 (C-26).

MS(FAB) m/z 922 $8[\text{M}+\text{Na}^+]$, 899 (M^+), 881 ($[\text{M}-\text{H}_2\text{O}]^+$), 868 ($[\text{M}-\text{OCH}_3]^+$), 850 ($[\text{M}-(\text{H}_2\text{O}+\text{OCH}_3)]^+$).

IR (major peaks)(cm^{-1}) 987, 1086, 1193, 1453, 1616, 1717, 1739, 3443.

MLR - rel. IC_{50} = 14

IL-6 mediated proliferation - rel. IC_{50} = 9

Macrophilin binding - rel. IC_{50} = 1

EXAMPLE 2 - 9-Deoxo-26-dihydro-rapamycin

To a stirred solution of 421 mg (1.6 mmol) of tetramethylammonium triacetoxyborohydride in 2 ml of acetonitrile is added 2 ml of acetic acid. The resulting mixture is stirred for 30 minutes at room temperature and cooled to -35°C . At this temperature a solution of 180 mg (0.2 mmol) of 9-deoxo-rapamycin in 1 ml of acetonitrile is added and the resulting mixture is allowed to stir for 24 hours. The mixture is quenched with a saturated sodium potassium tartrate solution and allowed to warm to room temperature. Stirring is continued until both layers were clear and ethyl acetate is added. The layers are separated and the aqueous layer is extracted twice with ethyl acetate. The resulting organic

solution is washed once with a 10% sodium bicarbonate solution and twice with saturated brine, then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (90:10 AcOEt-hexane) to afford the title compound as colorless foam, having the following characteristic spectroscopic data:

$^1\text{H NMR}$ (CDCl_3) (major isomer) δ .9 (3H,d,J = 6.9 Hz, CHCH_3), 0.93 (3H,d,J = 6.9 Hz, CHCH_3), 1.00 (3H,d,J = 6.9 Hz CHCH_3), 1.07 (3H,d,J = 6.9 Hz, CHCH_3), 1.17 (3H,d,J = 6.9 Hz, CHCH_3), 1.61 (3H,d,J = 1Hz, C17- CH_3), 1.73 (3H,d,J = 1.2 Hz, C29- CH_3), 2.43 (1H,dd,J = 4.1 and 16.0 Hz, H-33), 2.46 (1H,d,J = 13.8 Hz, H-9), 2.58 (1H,m,H-25), 2.77 (1H,d,J = 13.8 Hz, H-9), 2.82 (1H,dd,J = 8.3 and 16.0 Hz, H-33), 3.17 (1H,dd,J = 4.1 and 9.2 Hz, H-27), 3.61 (2H,m, H-14 and H28), 5.19 (1H,ddd,J = 4.1, 4.6 and 8.3 Hz, H-34), 5.49 (1H, broad d,J = 5.0 Hz, H-2), 5.56 (1H,d,J = 9.1 Hz, H-30), 5.75 (1H,dd,J = 6.9 and 14.7 Hz, H-22), 5.76 (1H,s,10-OH), 5.99 (1H,broad d,J = 9.2 Hz, H-18), 6.10 (1H,m,H-21), 6.36 (2H,m,H-19 and H-20);

MS (FAB) m/z 924 ($[\text{M} + \text{Na}]$), 852 ($[\text{M}-(\text{H}_2\text{O} + \text{CH}_3\text{O})]^+$).

MLR - rel. IC_{50} = 134

IL-6 mediated proliferation - rel. IC_{50} = 78

Macrophilin binding - rel. IC_{50} = 47

EXAMPLE 3 - 26-dihydro-rapamycin

This is prepared as for Example 2, using rapamycin in place of 9-deoxorapamycin. The product has the following characteristic spectroscopic data:

13 C-NMR (CDCl₃) (major isomer) δ = 208.3 (C-32); 194.0 (C-9); 169.5 (C-1); 166.6 (C-8); 140.9 (C-22); 136.5 (C-29); 136.2 (C-17); 133.5 (C-20); 129.1 (C-21); 128.7 (C-18); 126.2 (C-30); 125.3 (C-19); 98.6 (C-10); 84.4 (C-39); 83.9 (C-16); 81.6 (C-27); 75.4 (C-34); 74.3 (C-28); 73.9 (C-40); 72.9 (C-26); 67.4 (C-14); 59.1 (27-OCH₃); 56.6 (39-OCH₃); 55.9 (16-OCH₃); 51.3 (C-2); 46.8 (C-31); 44.3 (C-6); 40.4 (C-33); 40.4 (C-25); 39.5 (C-24); 38.8 (C-15); 38.0 (C-36); 34.3 (C-23); 34.2 (C-38); 33.5 (C-11); 33.3 (C-37); 33.2 (C-35); 31.5 (C-42); 31.3 (C-41); 30.9 (C-13); 27.1 (C-12); 27.0 (C-3); 25.2 (C-5); 21.4 (23-CH₃); 20.7 (C-4); 17.3 (11-CH₃); 16.1 (31-CH₃); 15.9 (35-CH₃); 14.4 (25-CH₃); 14.2 (29-CH₃); 10.3 (17-CH₃).

MS (FAB) m/z : 884 (M-OCH₃, 35%); 866 (M-[OCH₃ + H₂O], 100%); 848 (M-[OCH₃ + 2 H₂O], 40%).

Macrophilin binding - rel. IC₅₀ = 1.7

MLR - rel. IC₅₀ = 1

IL-6 mediated proliferation - rel. IC₅₀ = 7.5

EXAMPLE 4 - 40-O-Carbethoxymethyl-rapamycin

To a stirred, cooled (0°C) solution of 183 mg (0.200 mmol) of rapamycin and 4 mg (8 μ mol 4 mol% of dirhodium tetraacetate dihydrate in 2 ml of CH₂Cl₂ is added over 15 min. a solution of 46 μ l (0.219 mmol 2.2 eq.) of ethyl diazoacetate in 0.5 ml of CH₂Cl₂. The resulting mixture is stirred for 1 hour at 0°C and for 30 more min. at room temperature, before being diluted with AcOEt and quenched with 1 N aqueous HCl. The layers are separated and the aqueous layer is extracted twice with AcoEt. The combined organic solution is washed with 10% aqueous NaHCO₃, dried over sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (40:60 hexane-AcOEt) to give 40-O-carbethoxymethyl-rapamycin as a colorless, amorphous solid, which exhibits the following characteristic spectroscopic data:

^1H NMR (CDCl_3) δ 1.28 (3H,t,J = 6.9 Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.15 (2H,m,H-39 and H-40), 4.19 (2H,q,J = 6.9 Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$), 4.29 (2H,s, $\text{OCH}_2\text{CO}_2\text{CH}_3$), 5.42 (1H,d,J = 9.7 Hz, H-30), 5.54 (1H,dd,J = 9.2 and 15.2 Hz, H-22), 5.97 (1H,d,J = 9.7 Hz, H-18), 6.13 (1H,dd,J = 10.0 and 15.2 Hz, H-21), 6.30 (1H,dd,J = 10.0 and 14.7 Hz, H-20), 6.38 (1H,dd,J = 9.7 and 14.7 Hz, H-19); MS (FAB) 1022 ($[\text{M} + \text{Na}]^+$), 968 ($[\text{M}-\text{OCH}_3]^+$), 950 ($[\text{M}-(\text{OCH}_3 + \text{H}_2\text{O})]^+$).

Macrophilin binding - rel. IC_{50} = 0.6

MLR - rel. IC_{50} = 23

IL-6 mediated proliferation - rel. IC_{50} = 10

EXAMPLE 5 - 40-0-Carbethoxymethyl-9-deoxo-rapamycin

Prepare as for Example 4, using 9-deoxorapamycin in place of rapamycin. The product is a colorless, amorphous solid having the following characteristic spectroscopic data:

^1H NMR (CDCl_3) δ 1.21 (3H,t,J = 6.9 Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$), 2.36 (1H,d,J = 13.8 Hz, H-9), 2.67 (1H,d,J = 13.8 Hz, H-9), 3.10 (2H,m,H-39 and H-40), 4.13 (2H,q,J = 6.9 Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$), 4.23 (2H,s, $\text{OCH}_2\text{CO}_2\text{CH}_2\text{CH}_3$), 5.33 (1H,d,J = 9.7 Hz, H-30), 5.53 (1H,dd,J = 8.6 and 15.1 Hz, H-22), 5.88 (1H,m,H-18), 6.08 (1H,m,H-21), 6.31 (2H,m,H-19 and H-20); MS (FAB) 1008 ($[\text{M} + \text{Na}]^+$), 936 ($[\text{M} - (\text{H}_2\text{O} + \text{OCH}_3)]^+$).

Macrophilin binding - rel. IC_{50} = 19

MLR - rel. IC_{50} = 155

IL-6 mediated proliferation - rel. IC_{50} = 412

EXAMPLE 6 - 40-O-Benzyl-rapamycin

A solution of 183 mg (0.200 mmol) of rapamycin in 0.7 ml of CH₂Cl₂ was diluted with 1.4 ml of cyclohexane. To this solution is added 75 μ l (0.402 mmol 2 eq.) of benzyl trichloroacetimidate, followed by 2.6 μ l (29 μ mol 15 mol%) of trifluoromethanesulfonic acid. A small amount of brown precipitate is formed, then gradually dissolved, the reaction mixture turning yellow. After 3 hours the mixture is diluted with AcOEt and quenched with 10% aqueous NaHCO₃. The layers are separated and the aqueous layer is extracted twice with AcOEt. The combined organic solution is washed with 10% aqueous NaHCO₃ and saturated brine, then dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (50:50 hexanes-AcOEt) to afford 40-O-benzyl-rapamycin as a colorless solid having the following characteristic spectroscopic data:

¹H NMR (CDCl₃) δ 3.24 (1H, mH-39), 4.65 and 4.71 (2H, AB, J = 11.5 Hz, PhCH₂), 7.22-7.38 (5H, M, aromatic protons); MS (FAB) 1026 (M + Na)⁺, 972 ([M - OCH₃]⁺), 954 ([M - OCH₃ + H₂O]⁺).

Macrophilin binding - rel. IC₅₀ = 1.8

IL-6 mediated proliferation - rel. IC₅₀ = 10

EXAMPLE 7 - 40-O-Allyl-rapamycin

To a stirred cooled (-78°C) solution of 0.33 ml (2.01 mmol) of triflic anhydride in 10 ml of CH₂Cl₂ is slowly added a solution of 0.14 ml (2.06 mmol) of allyl alcohol and 0.42 g (2.04 mmol) of 2,6-Di-t-butyl-4-methyl-pyridine in 5 ml of CH₂Cl₂. The resulting greenish solution is stirred for 1.5 hour and a solution of 915 mg (1.00 mmol) of rapamycin and 0.42 g (2.04 mmol) of 2,6-Di-t-butyl-4-methyl-pyridine in 5 ml of CH₂Cl₂ is added. Stirring is continued for 0.5 hour at -78°C and then the mixture is warmed to room temperature.

After one more hour of stirring the mixture is quenched with saturated sodium bicarbonate solution and the layers are separated. The aqueous layer is extracted twice with AcOEt. The combined organic solution is washed with saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated. The resulting green oil is purified by column chromatography on silica gel (hexanes-AcOEt 60:40) to afford 40-O-allyl-rapamycin as a colorless, amorphous solid having the following characteristic spectroscopic data.

$^1\text{H NMR}$ (CDCl_3) δ 3.05 (1H,m,H-39), 3.15 (1H,m,H-40), 4.13 (2H, broad d, $\text{OCH}_2\text{CH}=\text{CH}_2$), 5.14 (2H,m,H-34 and $\text{OCH}_2\text{CH}=\text{CH}_2$), 5.27 (2H,m,H-2 and $\text{OCH}_2\text{CH}=\text{CH}_2$), 5.92 (2H,m,H-18 and $\text{OCH}_2\text{CH}=\text{CH}_2$); MS (FAB) 976 ($[\text{M} + \text{NA}]^+$), 922 ($[\text{M}-\text{OCH}_3]^+$), 904 ($[\text{M}-(\text{OCH}_3 + \text{H}_2\text{O})]^+$).

Macrophilin binding - rel. $\text{IC}_{50} = 1$

IL-6 mediated proliferation - rel. $\text{IC}_{50} = 8$

EXAMPLE 8 - 40-O-(2-Hydroxyethyl)-rapamycin

To a stirred, cooled (0°C) solution of 1.05 g (6 mmol) of mono-TBS-ethyleneglycol and 2.46 g (12 mmol) of 2,6-di-*t*-Bu-4-Me-pyridine in 25 ml of CH_2Cl_2 is added 1.2 ml (6.6 mmol) of triflic anhydride. The resulting mixture is stirred for 1 hour at 0°C and quenched with 1N aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted twice with AcOEt. The combined organic solution is washed with aqueous sodium bicarbonate and sat. brine, dried over anhydrous sodium sulfate, filtered and concentrated. The green, oily residue is taken up in 50 ml of toluene and 3.08 g (15 mmol) of 2,6-di-*t*-butyl-4-methyl pyridine is added, followed by 2.3 g (2.5 mmol) of rapamycin. The resulting solution is heated to 70°C and stirred for 2 days at this temperature. The mixture is then cooled to room temperature and quenched with 1N aqueous sodium bicarbonate solution. The layers are separated and the aqueous layer is extracted three times with AcOEt.

The combined organic layers are washed with 1N aqueous sodium bicarbonate and saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The resulting green oil is purified by column chromatography on silica gel (60:40 hexane-AcOEt) to afford 40-O-(2-t-butyltrimethylsilyloxy)ethyl-rapamycin as a light brown, amorphous solid.

To a stirred, cooled (0°C) solution of 786 mg (0.73 mmol) of 40-O-(2-t-butyltrimethylsilyloxy)ethyl-rapamycin in 20 ml of acetonitrile is added 2 ml of HF-pyridine complex. This mixture is stirred at 0°C for 1 hour and quenched with 1N aqueous sodium bicarbonate. The aqueous solution is extracted three times with AcOEt. The resulting organic phase is washed with aqueous 1N sodium bicarbonate, cold 1N HCl and saturated brine, dried over sodium sulfate, filtered and concentrated. The brown residue is purified by column chromatography on silica gel (10:90 hexane-AcOEt) to afford 40-O-hydroxyethyl-rapamycin as a colorless, amorphous solid, having the following characteristic spectroscopic data:


¹H NMR (CDCl₃) δ 3.07 (1H, m, H-39), 3.12 (3H, s, C16-OCH₃), 3.16 (1H, m, H-16), 3.32 (4H, s, C27-OCH₃ and H-31), 3.43 (4H, s, C39-OCH₃ and H-6 ax), 3.56 (2H, m, 1H of OCH₂CH₂O and H-6 eq), 3.66 (3H, m, 2H of OCH₂CH₂O and H-40), 3.73 (2H, m, 1H of OCH₂CH₂O and H-27), 3.84 (1H, m, H-14); MS (FAB) m/z 980 ([M+Na]⁺), 926 ([M-OCH₃]⁺), 908 ([M-(H₂O+OCH₃)⁺]).

Macrophilin binding - rel. IC₅₀ = 0.9

IL-6 mediated proliferation - rel. IC₅₀ = 0.5

CLAIMS

1. A compound of Formula I



wherein

X is (H,H) or O;

Y is (H,H), (H,OH), or O; and

R¹ and R² are independently selected from

H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl, alkoxyalkyl, acyloxyalkyl, carbalkoxyalkyl, amino, alkylamino, aminoalkyl, alkylaminoalkyl, allyl and R³,Si where each R³ is independently selected from H, methyl, ethyl, isopropyl, t-butyl, and phenyl; wherein "alk-" or "alkyl" refers to C₁₋₆ branched or linear alkyl in which the carbon chain may be optionally interrupted by an ether (-O-) linkage;

provided that where X is O, then either Y is other than O, or R¹ or R² is other than H; and

provided that where R¹ or R² are R³₂Si, X and Y are not both O.

2. A compound according to claim 1 wherein
 - a) X is (H,H), Y is (H,H), (H,OH) or O, and R¹ and R² are independently selected from H, alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl; or
 - b) X is O or (H,H), Y is (H,OH), and R¹ and R² are independently selected from H, alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl; or
 - c) X is O or (H,H), Y is (H,H), (H,OH) or O, and R¹ and R² are independently selected from alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl.

3. A compound according to claim 2 selected from:

9-Deoxorapamycin,
26-Dihydro-rapamycin,
9-Deoxo-26-dihydro-rapamycin,
40-O-Carbethoxymethyl-rapamycin,
40-O-Carbethoxymethyl-9-deoxorapamycin,
40-O-Benzyl-rapamycin,
40-O-Allyl-rapamycin, and
40-O-(2-Hydroxyethyl)-rapamycin.

4. A compound according to any one of claims 1-3 for use as a pharmaceutical.

5. A pharmaceutical composition comprising a compound according to any one of claims 1-3 together with a pharmaceutically acceptable diluent or carrier.

6. Use of a compound according to claims 1-3 in the manufacture of a medicament for treating or preventing any of the following conditions:

- (i) autoimmune disease,
- (ii) allograft rejection,
- (iii) graft vs. host disease,
- (iv) asthma,
- (v) multidrug resistance,
- (vi) tumors or hyperproliferative disorders, or
- (vii) fungal infections.

7. Novel products, processes, and utilities substantially as described herein.

ABSTRACT

Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-O-substituted and 28,40-O,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as immunosuppressants.

6300/TH/RT 5818

06.Oct.1992 Tue 10:10

Case No. 100-7932/PCT
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
COTTENS, et al.
Serial No. 08/416,673 : Art Unit 1202
Filed: April 7, 1995 : Examiner: R. Bond
For: O-ALKYLATED RAPAMYCIN
DERIVATIVES...AS
IMMUNOSUPPRESSANTS

CLAIM OF PRIORITY

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Dear Sir:


In accordance with 35 USC 119 and the International Convention,
the priority and benefit of the filing date of each of the
following foreign patent applications mentioned in the
declaration of this application is hereby claimed:

GREAT BRITAIN APPLICATION NO. 9221220.8, filed October 9, 1992

A certified copy of each of the above-mentioned foreign patent
applications is appended.

A certified copy of each of the above-mentioned foreign patent
applications appears in the file of application Serial No.
, filed , now , having been filed therein
on

Respectfully submitted,



Thomas O. McGovern
Registration No. 25,741
Agent/Attorney for Applicants
(201) 503-8480

SANDOZ CORPORATION
59 Route 10
East Hanover, NJ 07936

Date: October 10, 1996
TOM:mjl

The
Patent
Office

08/416673
PCT/EP 93/02604

PRIORITY DOCUMENT

The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

REC'D	29 OCT 1993
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 62(3) of the Patents and Designs Act 1907, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the Patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or the inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed 

Dated 23rd September 1993

COO

An Executive Agency of the Department of Trade and Industry

④ Reference number

4 Agent's or applicant's reference number (if applicable) **100-7932**

Please mark correct box

⑤ Claiming an earlier application date

5 Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Yes No → go to 6

↓
please give details below

number of earlier application or patent number

filing date (day month year)

and the Section of the Patents Act 1977 under which you are claiming:

Please mark correct box

15(4) (Divisional) 8(3) 12(6) 37(4)

⑥ If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number.

Please give the date in all number format, for example, 31/05/90 for 31 May 1990.

⑥ Declaration of priority

6 If you are declaring priority from previous application(s), please give:

Country of filing	Priority application number (if known)	Filing date (day, month, year)

- 7 The answer must be 'No' if:
 - any applicant is not an inventor
 - there is an inventor who is not an applicant, or
 - any applicant is a corporate body.

7 Inventorship

7 Are you (the applicant or applicants) the sole inventor or the joint inventors?
 Please mark correct box
 Yes No **A Statement of Inventorship on Patents Form 7/77 will need to be filed (see Rule 15).**

8 Please supply duplicates of claim(s), abstract, description and drawing(s).

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application.

Continuation sheets for this Patents Form 1/77	<input type="text" value="no"/>
Claim(s)	<input type="text" value="3"/> Description <input type="text" value="20"/>
Abstract	<input type="text" value="1"/> Drawing(s) <input type="text" value="no"/>

Please mark correct box(es)

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)	<input type="text" value="no"/>
Translation(s) of Priority documents (please state how many)	<input type="text" value="no"/>
Patents Form 7/77 – Statement of Inventorship and Right to Grant (please state how many)	<input type="text" value="no"/>
Patents Form 9/77 – Preliminary Examination/Search	<input type="text" value="no"/>
Patents Form 10/77 – Request for Substantive Examination	<input type="text" value="no"/>

9 You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here →

9 Request


I/We request the grant of a patent on the basis of this application.

Signed SANDOZ LTD. Date 06/10/1992
(day month year)
[Signature]

A completed fee sheet should preferably accompany the fee.

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to either:

<input type="checkbox"/> The Comptroller The Patent Office Cardiff Road Newport Gwent NP9 1RH	or	<input type="checkbox"/> The Comptroller The Patent Office 25 Southampton Buildings London WC2A 1AY
--	----	--


For official use		13 OCT 1992 10:00 AM 09 OCT 1992
Your reference	100-7932	9 221 220 . 8

Notes
 Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-438 4700).

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

Warning
 After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

	<h2>Request for grant of a Patent</h2> <h3>Form 1/77</h3> <p>Patents Act 1977</p>
<p>1 Title of invention</p> <p>1 Please give the title of the invention Organic Compounds.</p>	
<p>2 Applicant's details</p> <p><input type="checkbox"/> First or only applicant</p> <p>2a If you are applying as a corporate body please give:</p> <p>Corporate name SANDOZ LTD.</p> <p>Country (and State of incorporation, if appropriate) Switzerland</p>	
<p>2b If you are applying as an individual or one of a partnership please give in full:</p> <p>Surname</p> <p>Forenames</p>	
<p>2c In all cases, please give the following details:</p> <p>Address 35 Lichtstrasse, CH-4002 Basle, Switzerland</p> <p>UK postcode (if applicable)</p> <p>Country Switzerland</p> <p>ADP number (if known) 00703207001 ✓</p>	

2d, 2e and 2f: if there are further applicants please provide details on a separate sheet of paper.

2d Secret applicant (if any)

2d If you are applying as a corporate body please give:

Corporate name

Country (and State
of incorporation, if
appropriate)

2e If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2f In all cases, please give the following details:

Address

UK postcode
(if applicable)

Country

ADP number
(if known)

Ⓢ An address for service in the United Kingdom must be supplied

Please mark correct box

Ⓢ Address for service details

3a Have you appointed an agent to deal with your application?

Yes No → go to 3b

↓
please give details below

Agent's name

B. A. YORKE & CO.

Agent's address

Coomb House
7, St. John's Road
Isleworth,

Postcode

Middlesex TW7 6NH ✓

Agent's ADP
number

180001

3b: If you have appointed an agent, all correspondence concerning your application will be sent to the agent's United Kingdom address.

3b If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name

Address

Postcode

Daytime telephone
number (if available)


ADP number
(if known)

ORGANIC COMPOUNDS

This invention comprises novel derivatives of rapamycin having pharmaceutical utility, especially as immunosuppressants.

Rapamycin is a known macrolide antibiotic produced by Streptomyces hygroscopicus, having the structure depicted in Formula

A:




(A)

See, e.g., McAlpine, J.B., et al., J. Antibiotics (1991) 44: 688;
Schreiber, S.L., et al., J. Am. Chem. Soc. (1991) 113: 7433; US

Patent No. 3 929 992. Rapamycin is an extremely potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable bioavailability as well as its high toxicity.

It has now surprisingly been discovered that certain novel derivatives of rapamycin (the Novel Compounds) have an improved pharmacologic profile over rapamycin and exhibit greater stability and bioavailability. The Novel Compounds are compounds having the structure of Formula I:



wherein

X is (H,H) or O;

Y is (H,H), (H,OH), or O; and

R¹ and R² are independently selected from
H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl,
dihydroxyalkyl, alkoxyalkyl, acyloxyalkyl, carbalkoxyalkyl,

aminoalkyl, alkylaminoalkyl, allyl and R^3_3Si where each R^3 is independently selected from H, methyl, ethyl, isopropyl, t-butyl, and phenyl; wherein "alk-" or "alkyl" refers to C_{1-6} alkyl, branched or linear, preferably C_{1-3} alkyl, in which the carbon chain may be optionally interrupted by an ether (-O-) linkage; and

provided that where X is O, then either Y is other than O, or R^1 or R^2 is other than H; and

provided that where R^1 or R^1 and R^2 are R^3_3Si , X and Y are not both O.

Among the preferred groups of Novel Compounds are

a) 9-deoxorapamycins where X is (H,H), Y is (H,H), (H,OH) or O, and R^1 and R^2 are independently selected from H, alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl;

b) 26-dihydro-rapamycins where X is O or (H,H), Y is (H,OH), and R^1 and R^2 are independently selected from H, alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl; and

c) 40-O-substituted and 28,40-O,0-disubstituted rapamycins where X is O or (H,H), Y is (H,H), (H,OH) or O, and R^1 and R^2 are independently selected from alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl.

The most preferred Novel Compounds are

1. 9-Deoxorapamycin (X=H,H; Y=O; $R^1=R^2=H$).
2. 26-Dihydro-rapamycin (X=O; Y=H,OH; $R^1=R^2=H$).
3. 9-Deoxo-26-dihydro-rapamycin (X=H,H; Y=H,OH; $R^1=R^2=H$).
4. 40-O-Carbethoxymethyl-rapamycin (X=Y=O; $R^1=CH_2COOCH_2CH_3$; $R^2=H$).

5. 40-O-Carboethoxymethyl-9-deoxorapamycin (X=H,H; Y=O, R¹=CH₂COOCH₂CH₃, R²=H).
6. 40-O-Benzyl-rapamycin (X=Y=O; R¹=CH₂C₆H₅; R₂=H).
7. 40-O-Allyl-rapamycin (X=Y=O; R¹=CH₂CHCH₂; R²=H).
8. 40-O-(2-Hydroxyethyl)-rapamycin (X=Y=O; R¹=CH₂CH₂OH, R₂=H).

The 9-deoxorapamycin compounds are produced by reducing a rapamycin using hydrogen sulfide, e.g. as described in Example 1, by reacting rapamycin with diphenyldiselenide and tributylphosphine or by other suitable reduction reaction.

The 26-dihydro-rapamycins are produced by reducing rapamycins or 9-deoxorapamycins from keto to hydroxy at C26 by a mild reduction reaction, such as a borohydride reduction reaction, e.g., as described in Example 2.

O-substitutions at C40 are accomplished by reacting the compound with a radical attached to a leaving group under acidic or neutral conditions, e.g., as described in Example 3. Further modifications are possible. For example, where the substituent at C40 is allyl, the isolated, monosubstituted double bond of the allyl moiety is highly amenable to further modification. O-substitutions at C28 are accomplished in the same manner, but with prior protection at C40.

The Novel Compounds are particularly useful for the following conditions:

a) Treatment and prevention of organ or tissue transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants. They are also indicated for the prevention of graft-versus-host disease, such as following bone marrow transplantation.

b) Treatment and prevention of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an aetiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases. Specific autoimmune diseases for which the compounds of the invention may be employed include, autoimmune haematological disorders (including e.g. haemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopaenia), systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis and Crohn's disease) endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy) and juvenile dermatomyositis.

c) Treatment and prevention of asthma.

d) Treatment of multi-drug resistance (MDR). The Novel Compounds suppress P-glycoproteins (Pgp), which are the membrane transport molecules associated with MDR. MDR is particularly problematic in cancer patients and AIDS patients who will not respond to conventional chemotherapy because the medication is pumped out of the cells by Pgp. The Novel Compounds are therefore useful for enhancing the efficacy of other chemotherapeutic agents in the treatment and control of multidrug resistant conditions such as multidrug resistant cancer or multidrug resistant AIDS.

The Novel Compounds are also useful in treating proliferative disorders, e.g. tumors, hyperproliferative skin disorder and the like, and in treating fungal infections.

The pharmacological activity of the Novel Compounds are demonstrated in, e.g., the following tests:

1. Mixed lymphocyte reaction (MLR)

The Mixed Lymphocyte Reaction was originally developed in connection with allografts, to assess the tissue compatibility between potential organ donors and recipients, and is one of the best established models of immune reaction in vitro. A murine model MLR, e.g., as described by T. Meo in "Immunological Methods", L. Lefkovits and B. Peris, Eds., Academic Press, N.Y. pp. 227-239 (1979), is used to demonstrate the immunosuppressive effect of the Novel Compounds. Spleen cells (0.5×10^6) from Balb/c mice (female, 8-10 weeks) are co-incubated for 5 days with 0.5×10^6 irradiated (2000 rads) or mitomycin C treated spleen cells from CBA mice (female, 8-10 weeks). The irradiated allogeneic cells induce a proliferative response in the Balb/c spleen cells which can be measured by labeled precursor incorporation into the DNA. Since the stimulator cells are irradiated (or mitomycin C treated) they do not respond to the Balb/c cells with proliferation but do retain their antigenicity. The antiproliferative effect of the Novel Compounds on the Balb/c cells is measured at various dilutions and the concentration resulting in 50% inhibition of cell proliferation (IC_{50}) is calculated. The inhibitory capacity of the test sample may be compared to rapamycin and expressed as a relative IC_{50} (i.e. IC_{50} test sample/ IC_{50} rapamycin).

2. IL-6 mediated proliferation

The capacity of the Novel Compounds to interfere with growth factor associated signalling pathways is assessed using an interleukin-6 (IL-6)-dependent mouse hybridoma cell line. The assay is performed in 96-well microtiter plates. 5000 cells/well are cultivated in serum-free medium (as described by M. H. Schreier and R. Tees in Immunological Methods, I. Lefkovits and B. Pernis, eds., Academic Press 1981, Vol. II, pp. 263-275), supplemented with 1 ng recombinant IL-6/ml. Following a 66 hour incubation in the absence or presence of a test sample, cells are pulsed with 1 μ Ci (3-H)-thymidine/well for another 6 hours, harvested and counted by liquid scintillation. (3-H)-thymidine incorporation into DNA correlates with the increase in cell number and is thus a measure of cell proliferation. A dilution series of the test sample allows the calculation of the concentration resulting in 50% inhibition of cell proliferation (IC_{50}). The inhibitory capacity of the test sample may be compared to rapamycin and expressed as a relative IC_{50} (i.e. IC_{50} test sample/ IC_{50} rapamycin).

3. Macrophilin binding assay

Rapamycin and the structurally related immunosuppressant, FK-506, are both known to bind in vivo to macrophilin-12 (also known as FK-506 binding protein or FKBP-12), and this binding is thought to be related to the immunosuppressive activity of these compounds. The Novel Compounds also bind strongly to macrophilin-12, as is demonstrated in a competitive binding assay.

In this assay, FK-506 coupled to BSA is used to coat microtiter wells. Biotinylated recombinant human macrophilin-12 (biot-MAP) is allowed to bind in the presence or absence of a test sample to the immobilized FK-506. After washing (to remove non-specifically bound macrophilin), bound biot-MAP is assessed by incubation with a

streptavidin-alkaline phosphatase conjugate, followed by washing and subsequent addition of p-nitrophenyl phosphate as a substrate. The read-out is the OD at 405nm. Binding of a test sample to biot-MAP results in a decrease in the amount of biot-MAP bound to the FK-506 and thus in a decrease in the OD405. A dilution series of the test sample allows determination of the concentration resulting in 50% inhibition of the biot-MAP binding to the immobilized FK-506 (IC₅₀). The inhibitory capacity of a test sample is compared to the IC₅₀ of free FK-506 as a standard and expressed as a relative IC₅₀ (i.e., IC₅₀-test sample/ IC₅₀-free FK-506).

4. Localised Graft-Versus-Host (GvH) Reaction

In vivo efficacy of the Novel Compounds is proved in a suitable animal model, as described, e.g., in Ford et al, TRANSPLANTATION 10 (1970) 258. Spleen cells (1 x 10⁷) from 6 week old female Wistar/Furth (WF) rats are injected subcutaneously on day 0 into the left hind-paw of female (F344 x WF)F₁ rats weighing about 100g. Animals are treated for 4 consecutive days and the popliteal lymph nodes are removed and weighed on day 7. The difference in weight between the two lymph nodes is taken as the parameter for evaluating the reaction.

5. Kidney Allograft Reaction in Rat

One kidney from a female fisher 344 rat is transplanted onto the renal vessel of a unilaterally (left side) nephrectomised WF recipient rat using an end-to-end anastomosis. Ureteric anastomosis is also end-to-end. Treatment commences on the day of transplantation and is continued for 14 days. A contralateral nephrectomy is done seven days after transplantation, leaving the recipient relying on the performance of the donor kidney. Survival of the graft recipient is taken as the parameter for a functional graft.

6. Experimentally Induced Allergic Encephalomyelitis (EAE) in Rats

Efficacy of the Novel Compounds in EAE is measured, e.g., by the procedure described in Levine & Wenk, AMER J PATH 47 (1965) 61; McFarlin et al, J IMMUNOL 113 (1974) 712; Borel, TRANSPLANT. & CLIN. IMMUNOL 13 (1981) 3. EAE is a widely accepted model for multiple sclerosis. Male Wistar rats are injected in the hind paws with a mixture of bovine spinal cord and complete Freund's adjuvant. Symptoms of the disease (paralysis of the tail and both hind legs) usually develop within 16 days. The number of diseased animals as well as the time of onset of the disease are recorded.

7. Freund's Adjuvant Arthritis

Efficacy against experimentally induced arthritis is shown using the procedure described, e.g., in Winter & Nuss, ARTHRITIS & RHEUMATISM 9 (1966) 394; Billingham & Davies, HANDBOOK OF EXPERIMENTAL PHARMACOL (Vane & Ferreira Eds, Springer-Verlag, Berlin) 50/II (1979) 108-144. OFA and Wistar rats (male or female, 150g body weight) are injected i.c. at the base of the tail or in the hind paw with 0.1 ml of mineral oil containing 0.6 mg of lyophilised heat-killed Mycobacterium smegmatis. In the developing arthritis model, treatment is started immediately after the injection of the adjuvant (days 1 - 18); in the established arthritis model treatment is started on day 14, when the secondary inflammation is well developed (days 14-20). At the end of the experiment, the swelling of the joints is measured by means of a micro-caliper. ED₅₀ is the oral dose in mg/kg which reduces the swelling (primary or secondary) to half of that of the controls.

8. Antitumor and MDR activity

The antitumor activity of the Novel Compounds and their ability to enhance the performance of antitumor agents by alleviating multidrug resistance is demonstrated, e.g., by administration of an anticancer agent, e.g., colchicine or etoposide, to multidrug resistant cells and drug sensitive cells in vitro or to animals having multidrug resistant or drug sensitive tumors or infections, with and without co-administration of the Novel Compounds to be tested, and by administration of the Novel Compound alone.

Such in vitro testing is performed employing any appropriate drug resistant cell line and control (parental) cell line, generated, e.g. as described by Ling et al., J. Cell. Physiol. 83, 103-116 (1974) and Bech-Hansen et al. J. Cell. Physiol. 88, 23-32 (1976). Particular clones chosen are the multi-drug resistant (e.g. colchicine resistant) line CHR (subclone C5S3.2) and the parental, sensitive line AUX B1 (subclone AB1 S11).

In vivo anti-tumor and anti-MDR activity is shown, e.g., in mice injected with multidrug resistant and drug sensitive cancer cells. Ehrlich ascites carcinoma (EA) sub-lines resistant to drug substance DR, VC, AM, ET, TE or CC are developed by sequential transfer of EA cells to subsequent generations of BALB/c host mice in accordance with the methods described by Slater et al., J. Clin. Invest, 70, 1131 (1982).

Equivalent results may be obtained employing the Novel Compounds test models of comparable design, e.g. in vitro, or employing test animals infected with drug-resistant and drug sensitive viral strains, antibiotic (e.g. penicillin) resistant and sensitive bacterial strains, anti-mycotic resistant and sensitive fungal strains as well as drug resistant protozoal strains, e.g. Plasmodial strains, for example naturally occurring sub-strains of Plasmodium

falciparum exhibiting acquired chemotherapeutic, anti-malarial drug resistance.

9. Dosage forms

The Novel Compounds are utilized by administration of a pharmaceutically effective dose in pharmaceutically acceptable form to a subject in need of treatment. Appropriate dosages of the Novel Compounds will of course vary, e.g. depending on the condition to be treated (for example the disease type or the nature of resistance), the effect desired and the mode of administration.

In general however satisfactory results are obtained on administration orally at dosages on the order of from 0.05 to 5 or up to 10mg/kg/day, e.g. on the order of from 0.1 to 2 or up to 7.5 mg/kg/day administered once or, in divided doses 2 to 4x per day, or on administration parenterally, e.g. intravenously, for example by i.v. drip or infusion, at dosages on the order of from 0.01 to 2.5 up to 5 mg/kg/day, e.g. on the order of from 0.05 or 0.1 up to 1.0 mg/kg/day.

Suitable daily dosages for patients are thus on the order of 500 mg p.o., e.g. on the order of from 5 to 100 mg p.o., or on the order of from 0.5 to 125 up to 250 mg i.v., e.g. on the order of from 2.5 to 50 mg i.v..

Alternatively and even preferably, dosaging is arranged in patient specific manner to provide pre-determined trough blood levels, e.g. as determined by RIA technique. Thus patient dosaging may be adjusted so as to achieve regular on-going trough blood levels as measured by RIA on the order of from 50 or 150 up to 500 or 1000ng/ml, i.e. analogously to methods of dosaging currently employed for Ciclosporin immunosuppressive therapy.

The Novel Compounds are administered by any conventional route, in particular enterally, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectible solutions or suspensions. Suitable unit dosage forms for oral administration comprise, e.g. from 1 to 50 mg of a compound of the invention, usually 1 to 10 mg.

EXAMPLES:

In the following examples, characteristic spectroscopic data is given to facilitate identification. Peaks which do not differ significantly from rapamycin are not included. Biological data is expressed as a relative IC_{50} , compared to rapamycin in the case of the MLR and IL-6 mediated proliferation assays, and to FK-506 in the macrophilin binding assay. A higher IC_{50} correlates with lower binding affinity.

EXAMPLE 1 - 9-deoxorapamycin

A stream of hydrogen sulfide is passed at room temperature through a stirred solution of 3.2 g (3.5 mmol) of rapamycin in 50 ml pyridine and 2.5 ml DMF. The solution turns from colorless to yellow. After two hours, the introduction of hydrogen sulfide is stopped and stirring is continued for five days, during which time the solution turns gradually orange. TLC and HPLC analysis verifies complete consumption of the starting material and the presence of a single new compound. The solution is purged with nitrogen for one hour and concentrated under reduced pressure. The residue is taken up in ethyl acetate, washed with cold 1N HCl solution (3x), saturated sodium bicarbonate solution and saturated brine. The organic layer is dried over anhydrous sodium sulfate and filtered and concentrated under reduced pressure. The residue is taken up in ether and the precipitated sulfur is filtered off. Concentration of the ethereal solution followed by column chromatography on silica gel (10:4:1 $CH_2Cl_2/i-Pr_2O/MeOH$) yields 9-deoxorapamycin as a colorless foam.

The identity of the product is confirmed by nuclear magnetic resonance spectroscopy (NMR), mass spectrometry (MS), and/or infrared spectroscopy (IR), and is found to exhibit the following characteristic physical data:

^1H NMR (CDCl_3) δ 1.61 (3H,d,J = 1 Hz, C17- CH_3), 1.76 (3H,d,J = 1.2 Hz,C29- CH_3), 2.42 (1H,d,J = 14.5 Hz, H-9), 2.74 (1H,d,J = 14.5 Hz, H-9), 3.13 (3H,s,C16- OCH_3) 3.5 (3H,s,C27- OCH_3), 3.40 (3H,s,C39- OCH_3), 5.40 (1H,d,J = 10 Hz, H-30), 5.57 (1H,dd, J_1 = 8.6 Hz, J_2 = 15 Hz, H-22), 5.96 (1H,d,J = 9 Hz, H-18), 6.09 (1H,d,J = 1.7 Hz, 10-OH), 6.15 (1H,dd, J_1 = 10 Hz, J_2 = 15Hz, H-21), 6.37 (1H,dd, J_1 = 1.5 Hz, J_2 = 5 Hz, H-19), 6.38 (1H,J = 9.5 Hz, H-20).

^{13}C NMR (CDCl_3) δ 38.5 (C-9), 98.0 (C-10), 170.7 (C-1), 173.0 (C-8), 208.8 (C-32), 216.9 (C-26).

MS(FAB) m/z 922 8[M+Na⁺], 899 (M⁺), 881 ([M-H₂O]⁺), 868 ([M-OCH₃]⁺), 850 ([M-(H₂O+OCH₃)]⁺).

IR (major peaks)(cm^{-1}) 987, 1086, 1193, 1453, 1616, 1717, 1739, 3443.

MLR - rel. IC₅₀ = 14

IL-6 mediated proliferation - rel. IC₅₀ = 9

Macrophilin binding - rel. IC₅₀ = 1

EXAMPLE 2 - 9-Deoxo-26-dihydro-rapamycin

To a stirred solution of 421 mg (1.6 mmol) of tetramethylammonium triacetoxymethylborohydride in 2 ml of acetonitrile is added 2 ml of acetic acid. The resulting mixture is stirred for 30 minutes at room temperature and cooled to -35°C. At this temperature a solution of 180 mg (0.2 mmol) of 9-deoxo-rapamycin in 1 ml of acetonitrile is added and the resulting mixture is allowed to stir for 24 hours. The mixture is quenched with a saturated sodium potassium tartrate solution and allowed to warm to room temperature. Stirring is continued until both layers were clear and ethyl acetate is added. The layers are separated and the aqueous layer is extracted twice with ethyl acetate. The resulting organic

solution is washed once with a 10% sodium bicarbonate solution and twice with saturated brine, then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (90:10 AcOEt-hexane) to afford the title compound as colorless foam, having the following characteristic spectroscopic data:

$^1\text{H NMR}$ (CDCl_3) (major isomer) δ .9 (3H,d,J = 6.9 Hz, CHCH_3), 0.93 (3H,d,J = 6.9 Hz, CHCH_3), 1.00 (3H,d,J = 6.9 Hz CHCH_3), 1.07 (3H,d,J = 6.9 Hz, CHCH_3), 1.17 (3H,d,J = 6.9 Hz, CHCH_3), 1.61 (3H,d,J = 1Hz, C17- CH_3), 1.73 (3H,d,J = 1.2 Hz, C29- CH_3), 2.43 (1H,dd,J = 4.1 and 16.0 Hz, H-33), 2.46 (1H,d,J = 13.8 Hz, H-9), 2.58 (1H,m,H-25), 2.77 (1H,d,J = 13.8 Hz, H-9), 2.82 (1H,dd,J = 8.3 and 16.0 Hz, H-33), 3.17 (1H,dd,J = 4.1 and 9.2 Hz, H-27), 3.61 (2H,m, H-14 and H28), 5.19 (1H,ddd,J = 4.1, 4.6 and 8.3 Hz, H-34), 5.49 (1H, broad d,J = 5.0 Hz, H-2), 5.56 (1H,d,J = 9.1 Hz, H-30), 5.75 (1H,dd,J = 6.9 and 14.7 Hz, H-22), 5.76 (1H,s,10-OH), 5.99 (1H,broad d,J = 9.2 Hz, H-18), 6.10 (1H,m,H-21), 6.36 (2H,m,H-19 and H-20);
MS (FAB) m/z 924 ($[\text{M} + \text{Na}]$), 852 ($[\text{M}-(\text{H}_2\text{O} + \text{CH}_3\text{O})]^+$).

MLR - rel. IC_{50} = 134

IL-6 mediated proliferation - rel. IC_{50} = 78

Macrophilin binding - rel. IC_{50} = 47

EXAMPLE 3 - 26-dihydro-rapamycin

This is prepared as for Example 2, using rapamycin in place of 9-deoxorapamycin. The product has the following characteristic spectroscopic data:

13 C-NMR (CDCl₃) (major isomer) δ = 208.3 (C-32); 194.0 (C-9); 169.3 (C-1); 166.6 (C-8); 140.9 (C-22); 136.5 (C-29); 136.2 (C-17); 133.5 (C-20); 129.1 (C-21); 128.7 (C-18); 126.2 (C-30); 125.3 (C-19); 98.6 (C-10); 84.4 (C-39); 83.9 (C-16); 81.6 (C-27); 75.4 (C-34); 74.3 (C-28); 73.9 (C-40); 72.9 (C-26); 67.4 (C-14); 59.1 (27-OCH₃); 56.6 (39-OCH₃); 55.9 (16-OCH₃); 51.3 (C-2); 46.8 (C-31); 44.3 (C-6); 40.4 (C-33); 40.4 (C-25); 39.5 (C-24); 38.8 (C-15); 38.0 (C-36); 34.3 (C-23); 34.2 (C-38); 33.5 (C-11); 33.3 (C-37); 33.2 (C-35); 31.5 (C-42); 31.3 (C-41); 30.9 (C-13); 27.1 (C-12); 27.0 (C-3); 25.2 (C-5); 21.4 (23-CH₃); 20.7 (C-4); 17.3 (11-CH₃); 16.1 (31-CH₃); 15.9 (35-CH₃); 14.4 (25-CH₃); 14.2 (29-CH₃); 10.3 (17-CH₃).

MS (FAB) m/z : 884 (M-OCH₃, 35%); 866 (M-[OCH₃ + H₂O], 100%); 848 (M-[OCH₃ + 2 H₂O], 40%).

Macrophilin binding - rel. IC₅₀ = 1.7

MLR - rel. IC₅₀ = 1

IL-6 mediated proliferation - rel. IC₅₀ = 7.5

EXAMPLE 4 - 40-O-Carbethoxymethyl-rapamycin

To a stirred, cooled (0°C) solution of 183 mg (0.200 mmol) of rapamycin and 4 mg (8 μ mol 4 mol% of dirhodium tetraacetate dihydrate in 2 ml of CH₂Cl₂ is added over 15 min. a solution of 46 μ l (0.219 mmol 2.2 eq.) of ethyl diazoacetate in 0.5 ml of CH₂Cl₂. The resulting mixture is stirred for 1 hour at 0°C and for 30 more min. at room temperature, before being diluted with AcOEt and quenched with 1 N aqueous HCl. The layers are separated and the aqueous layer is extracted twice with AcoEt. The combined organic solution is washed with 10% aqueous NaHCO₃, dried over sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (40:60 hexane-AcOEt) to give 40-O-carbethoxymethyl-rapamycin as a colorless, amorphous solid, which exhibits the following characteristic spectroscopic data:

^1H NMR (CDCl_3) δ 1.28 (3H,t,J = 6.9 Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.15 (2H,m,H-39 and H-40), 4.19 (2H,q,J = 6.9 Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$), 4.29 (2H,s, $\text{OCH}_2\text{CO}_2\text{CH}_3$), 5.42 (1H,d,J = 9.7 Hz, H-30), 5.54 (1H,dd,J = 9.2 and 15.2 Hz, H-22), 5.97 (1H,d,J = 9.7 Hz, H-18), 6.13 (1H,dd,J = 10.0 and 15.2 Hz, H-21), 6.30 (1H,dd,J = 10.0 and 14.7 Hz, H-20), 6.38 (1H,dd,J = 9.7 and 14.7 Hz, H-19); MS (FAB) 1022 ($[\text{M} + \text{Na}]^+$), 968 ($[\text{M}-\text{OCH}_3]^+$), 950 ($[\text{M}-(\text{OCH}_3 + \text{H}_2\text{O})]^+$).

Macrophilin binding - rel. IC_{50} = 0.6

MLR - rel. IC_{50} = 23

IL-6 mediated proliferation - rel. IC_{50} = 10

EXAMPLE 5 - 40-O-Carbethoxymethyl-9-deoxo-rapamycin

Prepare as for Example 4, using 9-deoxorapamycin in place of rapamycin. The product is a colorless, amorphous solid having the following characteristic spectroscopic data:

^1H NMR (CDCl_3) δ 1.21 (3H,t,J = 6.9 Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$), 2.36 (1H,d,J = 13.8 Hz, H-9), 2.67 (1H,d,J = 13.8 Hz, H-9), 3.10 (2H,m,H-39 and H-40), 4.13 (2H,q,J = 6.9 Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$), 4.23 (2H,s, $\text{OCH}_2\text{CO}_2\text{CH}_2\text{CH}_3$), 5.33 (1H,d,J = 9.7 Hz, H-30), 5.53 (1H,dd,J = 8.6 and 15.1 Hz, H-22), 5.88 (1H,m,H-18), 6.08 (1H,m,H-21), 6.31 (2H,m,H-19 and H-20); MS (FAB) 1008 ($[\text{M} + \text{Na}]^+$), 936 ($[\text{M} - (\text{H}_2\text{O} + \text{OCH}_3)]^+$).

Macrophilin binding - rel. IC_{50} = 19

MLR - rel. IC_{50} = 155

IL-6 mediated proliferation - rel. IC_{50} = 412

EXAMPLE 6 - 40-O-Benzyl-rapamycin

A solution of 183 mg (0.200 mmol) of rapamycin in 0.7 ml of CH_2Cl_2 was diluted with 1.4 ml of cyclohexane. To this solution is added 75 μl (0.402 mmol 2 eq.) of benzyl trichloroacetimidate, followed by 2.6 μl (29 μmol 15 mol%) of trifluoromethanesulfonic acid. A small amount of brown precipitate is formed, then gradually dissolved, the reaction mixture turning yellow. After 3 hours the mixture is diluted with AcOEt and quenched with 10% aqueous NaHCO_3 . The layers are separated and the aqueous layer is extracted twice with AcOEt. The combined organic solution is washed with 10% aqueous NaHCO_3 and saturated brine, then dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (50:50 hexanes-AcOEt) to afford 40-O-benzyl-rapamycin as a colorless solid having the following characteristic spectroscopic data:

^1H NMR (CDCl_3) δ 3.24 (1H, mH-39), 4.65 and 4.71 (2H, AB, J = 11.5 Hz, PhCH_2), 7.22-7.38 (5H, M, aromatic protons); MS (FAB) 1026 ($\text{M} + \text{Na}^+$), 972 ($[\text{M} - \text{OCH}_3]^+$), 954 ($[\text{M} - \text{OCH}_3 + \text{H}_2\text{O}]^+$).

Macrophilin binding - rel. IC_{50} = 1.8

IL-6 mediated proliferation - rel. IC_{50} = 10

EXAMPLE 7 - 40-O-Allyl-rapamycin

To a stirred cooled (-78°C) solution of 0.33 ml (2.01 mmol) of triflic anhydride in 10 ml of CH_2Cl_2 is slowly added a solution of 0.14 ml (2.06 mmol) of allyl alcohol and 0.42 g (2.04 mmol) of 2,6-Di-t-butyl-4-methyl-pyridine in 5 ml of CH_2Cl_2 . The resulting greenish solution is stirred for 1.5 hour and a solution of 915 mg (1.00 mmol) of rapamycin and 0.42 g (2.04 mmol) of 2,6-Di-t-butyl-4-methyl-pyridine in 5 ml of CH_2Cl_2 is added. Stirring is continued for 0.5 hour at -78°C and then the mixture is warmed to room temperature.

After one more hour of stirring the mixture is quenched with saturated sodium bicarbonate solution and the layers are separated. The aqueous layer is extracted twice with AcOEt. The combined organic solution is washed with saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated. The resulting green oil is purified by column chromatography on silica gel (hexanes-AcOEt 60:40) to afford 40-O-allyl-rapamycin as a colorless, amorphous solid having the following characteristic spectroscopic data.

$^1\text{H NMR}$ (CDCl_3) δ 3.05 (1H, m, H-39), 3.15 (1H, m, H-40), 4.13 (2H, broad d, $\text{OCH}_2\text{CH}=\text{CH}_2$), 5.14 (2H, m, H-34 and $\text{OCH}_2\text{CH}=\text{CH}_2$), 5.27 (2H, m, H-2 and $\text{OCH}_2\text{CH}=\text{CH}_2$), 5.92 (2H, m, H-18 and $\text{OCH}_2\text{CH}=\text{CH}_2$); MS (FAB) 976 ($[\text{M} + \text{NA}]^+$), 922 ($[\text{M}-\text{OCH}_3]^+$), 904 ($[\text{M}-(\text{OCH}_3 + \text{H}_2\text{O})]^+$).

Macrophilin binding - rel. $\text{IC}_{50} = 1$

IL-6 mediated proliferation - rel. $\text{IC}_{50} = 8$

EXAMPLE 8 - 40-O-(2-Hydroxyethyl)-rapamycin

To a stirred, cooled (0°C) solution of 1.05 g (6 mmol) of mono-TBS-ethyleneglycol and 2.46 g (12 mmol) of 2,6-di-t.-Bu-4-Me-pyridine in 25 ml of CH_2Cl_2 is added 1.2 ml (6.6 mmol) of triflic anhydride. The resulting mixture is stirred for 1 hour at 0°C and quenched with 1N aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted twice with AcOEt. The combined organic solution is washed with aqueous sodium bicarbonate and sat. brine, dried over anhydrous sodium sulfate, filtered and concentrated. The green, oily residue is taken up in 50 ml of toluene and 3.08 g (15 mmol) of 2,6-di-t-butyl-4-methyl pyridine is added, followed by 2.3 g (2.5 mmol) of rapamycin. The resulting solution is heated to 70°C and stirred for 2 days at this temperature. The mixture is then cooled to room temperature and quenched with 1N aqueous sodium bicarbonate solution. The layers are separated and the aqueous layer is extracted three times with AcOEt.

The combined organic layers are washed with 1N aqueous sodium bicarbonate and saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The resulting green oil is purified by column chromatography on silica gel (60:40 hexane-AcOEt) to afford 40-O-(2-t-butyltrimethylsilyloxy)ethyl-rapamycin as a light brown, amorphous solid.

To a stirred, cooled (0°C) solution of 786 mg (0.73 mmol) of 40-O-(2-t-butyltrimethylsilyloxy)ethyl-rapamycin in 20 ml of acetonitrile is added 2 ml of HF-pyridine complex. This mixture is stirred at 0°C for 1 hour and quenched with 1N aqueous sodium bicarbonate. The aqueous solution is extracted three times with AcOEt. The resulting organic phase is washed with aqueous 1N sodium bicarbonate, cold 1N HCl and saturated brine, dried over sodium sulfate, filtered and concentrated. The brown residue is purified by column chromatography on silica gel (10:90 hexane-AcOEt) to afford 40-O-hydroxyethyl-rapamycin as a colorless, amorphous solid, having the following characteristic spectroscopic data:


^1H NMR (CDCl_3) δ 3.07 (1H,m,H-39), 3.12 (3H,s,C16-OCH₃), 3.16 (1H,m,H-16), 3.32 (4H,s,C27-OCH₃ and H-31), 3.43 (4H,s,C39-OCH₃ and H-6 ax), 3.56 (2H,m,1H of OCH₂CH₂O and H-6 eq), 3.66 (3H,m,2H of OCH₂CH₂O and H-40), 3.73 (2H,m,1H of OCH₂CH₂O and H-27), 3.84 (1H,m,H-14); MS (FAB) m/z 980 ([M+Na]⁺), 926 ([M-OCH₃]⁺), 908 ([M-(H₂O+OCH₃)⁺]).

Macrophilin binding - rel. IC₅₀ = 0.9

IL-6 mediated proliferation - rel. IC₅₀ = 0.5

CLAIMS

1. A compound of Formula I



wherein

X is (H,H) or O;

Y is (H,H), (H,OH), or O; and

R¹ and R² are independently selected from H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl, alkoxyalkyl, acyloxyalkyl, carbalkoxyalkyl, amino, alkylamino, aminoalkyl, alkylaminoalkyl, allyl and R³₃Si where each R³ is independently selected from H, methyl, ethyl, isopropyl, *t*-butyl, and phenyl; wherein "alk-" or "alkyl" refers to C₁₋₆ branched or linear alkyl in which the carbon chain may be optionally interrupted by an ether (-O-) linkage;

provided that where X is O, then either Y is other than O, or R¹ or R² is other than H; and

provided that where R¹ or R¹ and R² are R³, Si, X and Y are not both O.

2. A compound according to claim 1 wherein
 - a) X is (H,H), Y is (H,H), (H,OH) or O, and R¹ and R² are independently selected from H, alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl; or
 - b) X is O or (H,H), Y is (H,OH), and R¹ and R² are independently selected from H, alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl; or
 - c) X is O or (H,H), Y is (H,H), (H,OH) or O, and R¹ and R² are independently selected from alkyl, allyl, arylalkyl, hydroxyalkyl and carbalkoxyalkyl.
3. A compound according to claim 2 selected from:
 - 9-Deoxorapamycin,
 - 26-Dihydro-rapamycin,
 - 9-Deoxo-26-dihydro-rapamycin,
 - 40-0-Carbethoxymethyl-rapamycin,
 - 40-0-Carbethoxymethyl-9-deoxorapamycin,
 - 40-0-Benzyl-rapamycin,
 - 40-0-Allyl-rapamycin, and
 - 40-0-(2-Hydroxyethyl)-rapamycin.
4. A compound according to any one of claims 1-3 for use as a pharmaceutical.

5. A pharmaceutical composition comprising a compound according to any one of claims 1-3 together with a pharmaceutically acceptable diluent or carrier.

6. Use of a compound according to claims 1-3 in the manufacture of a medicament for treating or preventing any of the following conditions:

- (i) autoimmune disease,
- (ii) allograft rejection,
- (iii) graft vs. host disease,
- (iv) asthma,
- (v) multidrug resistance,
- (vi) tumors or hyperproliferative disorders, or
- (vii) fungal infections.

7. Novel products, processes, and utilities substantially as described herein.

Figure to accompany abstract

- 24 -

Case 100-7932

ABSTRACT

Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-O-substituted and 28,40-O,O-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as immunosuppressants.

6300/TH/RT 5818

06.Oct.1992 Tue 10:10

Case No. 100-7932/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Express Mail Mailing Label Number TB723905600US

Date of Mailing April 7, 1995

I hereby certify that on the date indicated above the attached papers relating to International Application No.

PCT/EP93/02604

are being deposited with the United States Postal Service as Post Office to Addressee Express Mail addressed to the Commissioner of Patents and Trademarks, Box PCT, Washington, D.C. 20231 in accordance with 37 CFR 1.10.

Antoinette Lombardi
Signature of Person Mailing the Application

Antoinette Lombardi
Printed or Typed Name of Person Mailing the Application

APR 10 1995

0000



12C
5115196 Bond EP 1202

Case No. 100-7932/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
 Sylvain Cottens, et al. : Art Unit: 1202
 Serial No. 08/416,673 : Examiner: R. Bond
 Filed: April 7, 1995 :
 For: O-ALKYLATED RAPAMYCIN :
 DERIVATIVES AND THEIR :
 USE, PARTICULARLY AS :
 IMMUNOSUPPRESSANTS :

#4/A
150
11-4-96

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on October 11, 1996

(Date of Deposit)
Thomas O. McGovern
 Name of Person Signing
Thomas O. McGovern
 Signature
October 11, 1996
 Date of Signature

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action of May 14, 1996 on the above identified application, please amend the application as follows:

IN THE SPECIFICATION

Page 1, after the title, insert the expression -- This application is a 371 of PCT/EP93/02604, filed September 24, 1993. --

Al


IN THE CLAIMS

Please cancel claims 1 to 3 and 5 to 9, and add the following new claims 10 to 18:

230 DD 19-0134 11/01/96 08416673
23030 116 390.00CH

39

10. A compound of the formula



wherein R_1 is hydroxy(C_{1-6})alkyl or hydroxy(C_{1-6})alkoxy-
(C_{1-6})alkyl.

11. A compound according to claim 10 in which R'_1 is
hydroxy(C_{1-3})alkyl or hydroxy(C_{1-3})alkoxy(C_{1-3})alkyl.

12. A compound according to claim 10 in which R'_2 is
hydroxy(C_{1-3})alkyl.

13. A compound according to claim 10 in which R'_3 is
hydroxy(C_{1-3})alkoxy(C_{1-3})alkyl.

- 14. The compound according to claim 10^{18/1} which is 40-O-(3-hydroxypropyl)-rapamycin.
- 15. The compound according to claim 10^{18/1} which is 40-O-[2-(2-hydroxyethoxy)ethyl]-rapamycin.
- 16. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 10^{18/1} and a pharmaceutically acceptable carrier therefor.
- 17. A method of inducing an immunosuppressant effect in a subject in need of immunosuppression, which comprises administering to said subject an immunosuppressant effective amount of a compound according to claim 10^{18/1}.
- 18. A method of preventing allograft rejection in a subject in need of such treatment, which comprises administering to said subject a compound according to claim 10^{18/1} in an amount effective to prevent allograft rejection.

AD
CM 7/8

REMARKS

Claims 1 to 9 have been presented for examination and claims 4 and 10 to 18 are now in the application. No additional fee is required.

Claims 1 to 9 are rejected under the first and second paragraph of 35 USC 112. The Examiner indicates that the term "aryl" in claim 1 encompasses groups having any number of carbon atoms as well as any number and types of unnamed substituents, and the term "acyl" in the same claim embraces

4/1

groups derived from any organic acid. The Examiner also indicates that use claim 8 is improper and should be set out as a method or process claim and composition claim 7 should not depend on a process claim. Applicants have deleted claims 1, 7, and 8 from the application and have replaced them with new claims 10 and 16 to 18. The objected to aryl and acyl terminology appeared only in original claim 1 and does not appear in any of the claims now in the application. New pharmaceutical composition claim 16 is dependent on compound claim 10 in accordance with standard practice, and new method claims 17 and 18 have been drawn up using conventional method of treatment claim language. Applicants believe that the new claims meet all of the requirements of 35 USC 112; and, accordingly, no further comment regarding this rejection is believed necessary.

Claims 1 to 9 are rejected under 35 USC 103 over Goulet, et al. (of record). The Examiner indicates that Goulet broadly discloses either identical subject matter or subject matter which is very similar to the claimed subject matter. The Examiner notes that the reference also discloses many of the utilities of Applicants' compounds and the same method of making the compounds. The Examiner concludes that the claimed subject matter is unpatentable under 35 USC 103 over Goulet, unless the reference is removed in an interference proceedings. With regard to the claims now in the application, Applicants respectfully disagree and traverse the rejection.

It will be noted that the only compounds specifically disclosed in the Goulet patent are the 43-O-phenyl-rapamycin of Example 2 and claim 6, which would be 40-O-phenyl-rapamycin using the numbering system of the instant application, and the alkenyl and aryl substituted rapamycin derivatives of claims 4 and 5. Goulet does not disclose any compound which is even vaguely related structurally to the presently claimed rapamycin derivatives. Applicants' compounds, can be constructed by picking and choosing substituents from the broad generic language of the Goulet patent; but there is nothing in the patent which would suggest that the specific substituents required to obtain the instantly claimed compounds should be selected. In order to prepare Applicants' compound of claim 4 from the only Goulet compound exemplified, one would have to remove the phenyl group from the oxygen in the 40 position of Goulet's compound and replace it with a hydroxyethyl moiety selected from the immense number of substituents embraced by the "potentially infinite genus" disclosed in columns 3 to 6 of the Goulet patent. (Cf. *In re Jones*; 21 USPQ2d 1941). It is clear from the breadth of the reference that Applicant's modification of rapamycin could only be made with direction from the instant application. There is no way that one skilled in the art using the Goulet examples alone would be led to Applicants' compounds. Indeed, Goulet would appear to teach away from Applicants' substituents by focussing on the aryl and alkenyl substituents of the patent (Cf. *In re Baird*; 29 USPQ2d 1550). The Court of Customs and Patent Appeals indicated In re Taborsky (183 USPQ 50), that for obviousness, the prior

art must provide one with motivation to make the molecular modifications needed to arrive at the claimed compounds. In the present case, there is clearly nothing in the reference cited which would fairly suggest Applicants' compounds and motivate one to make the specific modifications required to obtain the instant invention.

In support of the patentability of the presently claimed compounds Applicants are enclosing a Declaration under Rule 132 (37 CFR 1.132), which compares the activity of Applicant's hydroxyalkyl and hydroxyalkoxyalkyl derivatives with the 40-O-phenyl-rapamycin exemplified in the Goulet patent. The results in the Declaration show that Applicants' three compounds are approximately 200 to 300 times more active than the Goulet compound in the well known and generally accepted Mixed Lymphocyte Reaction (MLR) test. These increases in activity are certainly totally unexpected, especially in light of the apparant aryl and alkenyl preferences in Goulet. Applicants submit, therefore, that the claimed compounds are clearly unobvious and patentable over the Goulet teachings; and accordingly, it is respectfully requested that the Examiner reconsider the instant rejection under 35 USC 103 and withdraw it.

The basis for new generic claim 10 and the preferred embodiments of claims 11 to 19 is found in the specification on page 3, lines 9 and 10 (number of carbon atoms); page 4, lines 21 to 26 (substituents) and compounds 9 and 11 on page 4. The new claims are fully supported by the present application, and it is respectfully requested that they be entered.

Applicants have also inserted on page 1 of the application the cross reference required by 37 CFR 1.78(a)(2) identifying the international PCT application from which priority is claimed and indicating the relationship between the applications.

The Failli, et al. and Caufield, et al. patents cited to show the state of the art have been noted by Applicants and no further comment regarding them is deemed necessary.

Enclosed is a formal Claim of Priority for the record on the instant application, which claims the priority dates under 35 USC 119 of the British priority document indicated. A certified copy of the British application is also enclosed.

It is respectfully requested that the period for filing a response to the Office Action of May 14, 1996 on the above identified application Serial No.08/416,673 originally set to expire August 14, 1996 be extended two months until October 14, 1996.

Please charge the extension fee of \$390.00 required by 37 CFR 1.97(b) to Deposit Account No. 19-0134 in the name of Sandoz Corporation.

In view of the above amendments and comment, it is believed that the claims now in the application are patentable over the prior art and in condition for allowance. Accordingly, it is respectfully requested that the Examiner withdraw the present rejection of the claims and pass the application to issue.

Respectfully submitted,

By Thomas O. McGovern
Thomas O. McGovern
Registration No. 25,741
(201) 503-8480

TOM:lmc

SANDOZ CORPORATION
59 Route 10
E. Hanover, N.J. 07936

October 11, 1996

Encl.: Page 7 of Amendment in triplicate;
Two Month Extension of Time;
Declaration;
Claim of Priority;
Certified British application;
COM Stamp;
Postcard



Case No. 100-7932

#5
KD
11-496

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:		
SYLVAIN COTTENS, et al.	:	Art Unit:	1202
Application No. 08/416673	:	Examiner:	Robert T. Bond
International filing date: Sept. 24, 1993	:		
For: O-Alkylated Derivatives of	:		
Rapamycin and Their Use,	:		
Particularly as Immunosuppressants	:		

DECLARATION OF DR. GERHARD ZENKE

I, GERHARD ZENKE, do hereby declare and say as follows:

1. I am an immunologist employed in the Immunology Department of Sandoz Pharma Ltd. in Basel, Switzerland. I have been employed by Sandoz since 1986. I hold a PhD degree from Max-Planck-Institute for Immunobiology, Freiburg, Germany. A copy of my curriculum vitae is attached hereto as Exhibit A.

2. My duties and responsibilities at Sandoz include, inter alia, directing and carrying out testing and screening of compounds to assess their potential as immunosuppressive drugs. One assay which is routinely used for this purpose is the Mixed Lymphocyte Reaction (MLR). The MLR was originally developed to assess the tissue compatibility between potential organ donors and recipients and has become one of the best established in vitro models for immune reaction. The murine MLR used in my laboratory is a standard, generally accepted assay for immunosuppression and is carried out essentially as described by T.Meo in "Immunological Methods", L. Lefkovits and B. Peris, Eds., Academic Press, N.Y. pp. 227-239 (1979). A detailed protocol of this MLR

used in my laboratory is attached hereto as Exhibit B. Over the years, I and those working in my laboratory under my supervision have carried out thousands of MLRs and have measured the immunosuppressive activity of many derivatives of rapamycin in this assay.

3. I have reviewed US Patent 5,258,389. The only compound specifically exemplified in this patent is the compound of example 2. (This compound is referred to in the patent as 42-O-phenyl rapamycin, but I will refer to it herein as 40-O-phenyl-rapamycin for consistency with the numbering system employed in the above-captioned application). The immunosuppressive activity of this compound in the MLR was assayed in my laboratory under my direction and compared to 40-O-hydroxyalkyl- and 40-O-hydroxyalkoxyalkyl-rapamycins exemplified in the above-captioned application. Rapamycin was used as a reference compound. Our results are as follows, expressed as the concentration required for 50% inhibition of proliferation relative to rapamycin (rIC_{50}):

<u>Compound</u>	<u>Mean $rIC_{50} \pm SD (n)$</u>
40-O-(2-Hydroxyethyl)-rapamycin	2.1 \pm 0.51 (4)
40-O-(3-Hydroxypropyl)-rapamycin	3.1 \pm 0.53 (4)
40-O-[2-(2-Hydroxyethoxy)ethyl]-rapamycin	2.1 \pm 0.22 (4)
40-O-Phenyl-rapamycin	650 \pm 70 (4)

SD: Standard deviation

n: Number of experiments

Based on the fact that the concentration of 40-O-phenyl-rapamycin required to obtain 50% inhibition of this MLR was on the order of 200x greater than the concentration required for the other three compounds, I can conclude that the 40-phenyl-rapamycin is markedly less immunosuppressive than the other three compounds. Given its relatively low intrinsic

immunosuppressive activity, it is extremely unlikely that 40-O-phenyl-rapamycin would have a pharmaceutically useful level of immunosuppressive activity in vivo, and it would certainly be expected to have a much lower level of activity than the other three compounds tested. That the 40-O-hydroxyalkyl and 40-O-hydroxyalkoxyalkyl derivatives of rapamycin would retain such a high level of immunosuppressive activity compared to the 40-O-phenyl derivative would not have been obvious and could not have been predicted from the disclosure in US 5,258,389.

I HEREBY DECLARE that all statements made in the foregoing declaration of my own knowledge are true, and all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


GERHARD ZENKE

Date: 30.9.96

Curriculum vitae

Name: Gerhard Zenke
Date of birth: June 9, 1956
Birthplace: Korbach, Germany
Nationality: German
Languages: German, English
Academic degree: Ph.D.
Family status: Married, three children
Private address: Adolf-Glattacker-Str. 8
D-79618 Rheinfelden

Education

1975-1977 Study of biology at the Philipps-University, Marburg, Germany
1977-1980 Study of biology at the Albert-Ludwigs-University, Freiburg, Germany
1980-1981 Diploma at the Institute for Genetics and Molecular Biology, University, Freiburg: "*In vitro* and *in vivo* transcripts of the rRNA operon from maize chloroplasts".
Graduation: Diploma of Biology
1982-1986 Thesis at the Max-Planck-Institute for Immunobiology, Freiburg: "Characterization of human antibodies with specificity against streptococcal group A carbohydrate by monoclonal anti-idiotopic antibodies".
Graduation: Ph.D.

Work experience

1986-1989 Department Biotechnology, Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland
Since 1990 Department Immunology, Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland

Exhibit A

PUBLICATIONS

1. Atanassov C.L., Naegeli, H.-U., Zenke, G., Schneider, C., Kramarova, L.I., Bronnikov, G.E. and van Regenmortel, M.H.V. (1995) Anti-lymphoproliferative activity of brown adipose tissue of hibernating squirrels is mainly caused by AMP. *Comp. Biochem. Physiol.* **112C**, 93-100.
2. Su Q., Weber L., Le Hir M., Zenke G. and Ryffel B. (1995) Nephrotoxicity of cyclosporin A and FK506: Inhibition of calcineurin phosphatase. *Renal Physiology and Biochemistry* **18**, 128-139.
3. Billich A., Hammerschmid F., Peichl F., Wenger R., Zenke G., Quesniaux V. and Rosenwirth B. (1995) Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type1: Interference with HIV protein-cyclophilin A interactions. *J. Virology* **69**, 2451-2461.
4. Rosenwirth B., Billich A., Datema R., Donatsch P., Hammerschmid F., Harrison R., Hiestand P., Jaksche H., Mayer P., Peichl P., Quesniaux V., Schatz F., Schuurman H. -J., Traber R., Wenger R., Wolff B., Zenke G. and Zurini M. (1994) Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. *Antimicrobial Agents and Chemotherapy* **38**, 1763-1772.
5. Stuetz A., Grassberger M. A., Baumann K., Edmunds A. J. F., Hiestand P., Meingassner J. G., Nussbaumer P., Schuler W. and Zenke G. (1994) Immunophilins as drug targets. In *Perspectives in Medicinal Chemistry* (Edited by Testa B., Kyburz E., Fuhrer W. and Giger R.), p. 427. Verlag Helvetica Chimica Acta, Basel.
6. Cottens S., Fehr T., Quesniaux V., Schuler W., Sedrani R. and Zenke G. (1994) The role of immunophilin binding in the immunosuppressive properties of CsA, FK506 and rapamycin derivatives. *Act. Chimie Therap. Ser.* **21**, 83.
7. Baumann K., Edmunds A. J. F., Grassberger M. A., Schulz G., Schuler W. and Zenke G. (1993) Modification of the immunosuppressant ascomycin (21-ethyl-FK506) at the C19-C20 double bond. *Tetrahedron Let.* **34**, 2295-2298.
8. Gram H., Strittmatter U., Lorenz M., Gluck D. and Zenke G. (1993) Phage display as a rapid gene expression system: production of bioactive cytokinephage and generation of neutralizing monoclonal antibodies. *J. Immunol. Methods* **161**, 169-176.
9. Schreier M. H., Baumann G. and Zenke G. (1993) Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties?. *Transplant. Proc.* **25**, 502-507.
10. Tschan T., Bohme K., Conscience Egli M., Zenke G., Winterhalter K. H. and Bruckner P. (1993) Autocrine or paracrine transforming growth factor-beta

modulates the phenotype of chick embryo sternal chondrocytes in serum-free agarose culture. *J. Biol. Chem.* **268**, 5156-5161.

11. Woerly G., Zenke G., Strittmatter U. and Ryffel B. (1993) Evidence for shared receptor proteins for human interleukin-3 and granulocyte-macrophage colony-stimulating factor in the human M-07 cell line. *J. Recept. Res.* **13**, 753-775.
12. Zenke G., Baumann G., Wenger R., Hiestand P., Quesniaux V., Andersen E. and Schreier M. H. (1993) Molecular mechanisms of immunosuppression by cyclosporins. *Ann. N. Y. Acad. Sci.* **685**, 330-335.
13. Baumann G., Zenke G., Wenger R., Hiestand P., Quesniaux V., Andersen E. and Schreier M. H. (1992) Molecular mechanisms of immunosuppression. *J. Autoimmun.* **5 Suppl A**, 67-72.
14. Gram H., Zenke G., Geisse S., Kleuser B. and Burki K. (1992) High-level expression of a human immunoglobulin gamma 1 transgene depends on switch region sequences. *Eur. J. Immunol.* **22**, 1185-1191.
15. Krause S. W., Kreutz M., Zenke G. and Andreesen R. (1992) Developmental regulation of granulocyte-macrophage colony-stimulating factor production during human monocyte-to-macrophage maturation. *Ann. Hematol.* **64**, 190-195.
16. Schreier M. H., Zenke G., Borel J. F. and Baumann G. (1992) The continuing search for new immunomodulators. *Transplant. Proc.* **24**, 19-21.
17. Zenke G., Zeder G., Strittmatter U., Andersen E., Kocher H. P., Quesniaux V. F., Schreier M. H. and Van Regenmortel M. H. (1992) Anti-cyclosporine monoclonal antibodies and their anti-idiotopic counterpart: structure and biological activity. *Mol. Immunol.* **29**, 343-351.
18. Lokker N. A., Zenke G., Strittmatter U., Fagg B. and Movva N. R. (1991) Structure-activity relationship study of human interleukin-3: role of the C-terminal region for biological activity. *EMBO J.* **10**, 2125-2131.
19. Lokker N. A., Movva N. R., Strittmatter U., Fagg B. and Zenke G. (1991) Structure-activity relationship study of human interleukin-3. Identification of residues required for biological activity by site-directed mutagenesis. *J. Biol. Chem.* **266**, 10624-10631.
20. Lokker N. A., Strittmatter U., Steiner C., Fagg B., Graff P., Kocher H. P. and Zenke G. (1991) Mapping the epitopes of neutralizing anti-human IL-3 monoclonal antibodies. Implications for structure-activity relationship. *J. Immunol.* **146**, 893-898.
21. Zenke G., Lokker N. A., Strittmatter U., Fagg B., Geisse S., Huber Wegmann G. and Kocher H. P. (1991) Purification and characterization of natural human interleukin-3. *Lymphokine Cytokine. Res.* **10**, 329-335.

22. Zenke G., Strittmatter U., Tees R., Andersen E., Fagg B., Kocher H. P. and Schreier M. H. (1991) A cocktail of three monoclonal antibodies significantly increases the sensitivity of an enzyme immunoassay for human granulocyte-macrophage colony-stimulating factor. *J. Immunoassay* **12**, 185-206.
23. Valent P., Schmidt G., Besemer J., Mayer P., Zenke G., Liehl E., Hinterberger W., Lechner K., Maurer D. and Bettelheim P. (1989) Interleukin-3 is a differentiation factor for human basophils. *Blood* **73**, 1763-1769.
24. Bloem A., Zenke G., Eichmann K. and Emmrich F. (1988) Human immune response to group A streptococcal carbohydrate (A-CHO). II. Antigen-independent stimulation of IgM anti-A-CHO production in purified B cells by a monoclonal anti-idiotopic antibody. *J. Immunol.* **140**, 277-282.
25. Emmrich F., Zenke G. and Eichmann K. (1986) Isotype restriction of idiotopes associated with human anti-streptococcal A carbohydrate antibodies. *Eur. J. Immunol.* **16**, 542-546.
26. Emmrich F., Bundle D., van der Zee J., Out T., Zenke G. and Eichmann K. (1985) Two human IgM myeloma proteins with unusual specificities for streptococcal carbohydrate-associated epitopes. *Scand. J. Immunol.* **21**, 119-126.
27. Zenke G., Eichmann K. and Emmrich F. (1985) Idiotope mapping on the variable region of an antibody clonotype produced by normal (nonmalignant) human B cells. *J. Immunol.* **135**, 4066-4072.
28. Emmrich F., Zenke G., Polke C. and Eichmann K. (1984) Characterization of minor and major idiotopes associated with human antibodies to N-acetyl-D-glucosamine. *Ann. Immunol.* **135C**, 95-106.
29. Zenke G., Eichmann K. and Emmrich F. (1984) Characterization of a major human antibody clonotype (1A) by monoclonal antibodies to combining site-associated idiotopes. *Eur. J. Immunol.* **14**, 164-170.
30. Kössel H., Edwards K., Koch W., Langridge P., Schiefermayr E., Schwarz Z., Strittmatter G. and Zenke G. (1982) Structural and functional analysis of an rRNA operon and its flanking tRNA genes from *Zea mays* chloroplasts. *Nucleic. Acids. Symp. Ser.* 117-120.
31. Zenke G., Edwards K., Langridge P. and Kossel H. (1982) The rRNA operon from maize chloroplasts: analysis of in vivo transcription products in relation to its structure. *Prog. Clin. Biol. Res.* **102 Pt B**, 309-319.

cv

Serum-free mouse mixed-lymphocyte reaction

Compounds

All compounds are dissolved in ethanol at 10^{-2} M and stored at -20°C . Samples to be tested were diluted on the day of the experiment in culture medium. The first dilution of the stocks was 1:100.

Experimental procedure

Mouse mixed-lymphocyte reaction (MLR)

Parameters affecting the magnitude of T cell proliferative responses like cell concentration, type of medium, mouse strain combinations, incubation conditions and culture time have been optimized according to Strong et al. (1973) and Meo (1979).

Cell preparation and counting:

Female, 8-10 weeks old CBA (H-2^k) and BALB/c mice (H-2^d) were obtained from BRL, Füllingsdorf, Switzerland. Single spleen cell suspensions are prepared by passage through 70 mm nylon cell strainer (Becton Dickinson, New Jersey, USA) in Hank's balanced salt solution (Gibco BRL AG, Basle, Switzerland) and twice repeated washing. The cells are finally resuspended in serum-free CG-medium (Bioreba, Basle, Switzerland). Viable cells are directly counted in the spleen cell preparation using the fluorescein diacetate method (Rotman and Papermaster, 1966). A solution of 5 mg/ml fluorescein diacetate in acetone is kept at -20°C . One part of a 1:100 dilution of the stock solution in phosphate buffered saline (Gibco) prepared fresh daily and kept on ice is mixed with nine parts of the cell suspension (prediluted in phosphate buffered saline). After 1-5 minutes at room temperature viable brightly fluorescing cells are counted in a Neubauer chamber under a fluorescent light microscope using appropriate excitation and barrier filters.

Assay performance:

Equal amounts of spleen cells from the two mouse strains are mixed. 2×10^5 cells per well (1×10^5 cells from each strain) are incubated with appropriate serial dilutions of samples in 200 μl serum-free CG-medium in flat bottom tissue culture microtiter plates (Costar, Cambridge, USA) for 4 days at 37°C in 5% CO_2 . Usually eight three-fold dilution steps in duplicates per sample are performed. One $\text{mCi } ^3\text{H}$ -thymidine (2Ci/mmol; Amersham, England) is added to each well. The plates are subsequently incubated for additional 16 hours. Cells are harvested (BetaplateTM 96-well harvester) on filter paper Filtermat A, which is finally washed, dried and counted after addition of scintillation liquid (Beta Plate Scint) in a BetaplateTM counter (entire equipment from Wallac Oy, Turku, Finland).

Data analysis

Background values (low control) of the MLR are the proliferation of BALB/c cells alone, which are subtracted from all values. Proliferation of mixed cells without any sample is taken as 100% proliferation (high control).

Percent inhibition by the samples is calculated according to the equation:

$$\text{Inhibition [\%]} = \frac{[(\text{high} - \text{low}) - (\text{sample} - \text{low})]}{(\text{high} - \text{low})} \times 100$$

The concentrations required for 50% inhibition (IC_{50} values) are determined using a four parameter logistic function.

Exhibit B

Calculation of relative activities

A number of independent experiments showed some minor variation in the absolute IC_{50} values of rapamycin. To compensate for this variability and to be able to determine relatively small differences in activity a titration of rapamycin as a reference is performed on each microtiter plate. Results obtained with derivatives of rapamycin are expressed as relative IC_{50} , e.g. the ratio of the IC_{50} of the derivative and the IC_{50} of rapamycin.

References

- Meo T. (1979) The MLR in the mouse. In *Immunological Methods* (Edited by Lefkovits L. and Pernis B.), p. 227. Academic Press, New York.
- Rotman B. and Papermaster B. W. (1966) Membrane properties of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters. *Proc. Natl. Acad. Sci. U. S. A.* **55**, 134
- Strong D. M., Ahmed A. A., Thurman G. B. and Sell K. W. (1973) In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester. *J. Immunol. Methods* **2**, 279-287.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: Box ISSUE FEE
ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

12M1/1216

ROBERT S HONOR
SANDOZ CORPORATION
59 ROUTE 10
EAST HANOVER NJ 07936-1080

APPLICATION NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
08/416,673	04/07/95	009	BOND, R	1202 12/16/96
First Named Applicant	COTTENS, SYLVAIN			

TITLE OF INVENTION O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
1	100-7932/PCT	514-514.000	H50 UTILITY	NO	\$1290.00	03/17/97

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.

HOW TO RESPOND TO THIS NOTICE:

- I. Review the SMALL ENTITY status shown above.
If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:
 - A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
 - B. If the status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO:

- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.

II. Part B of this notice should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "6b" of Part B should be completed.

III. All communications regarding this application must give application number and batch number. Please direct all communication prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

B

3. PATENT AND TRADEMARK OFFICE COPY



UNITED STATES DEPARTMENT OF COMMERCE
 Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

08/416,875 04/07/96 PATTENT

100 2000000

12M1/1216

1000000

ROBERT S. BONER
 SANDOZ CORPORATION
 58 ROUTE 10
 EAST HANOVER, NJ 07936-1000

1200

10/16/96
12/16/96
(1 Slip)

NOTICE OF ALLOWABILITY

PART I.

1. This communication is responsive to the communications received 13 OCT. 1996
2. All the claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice Of Allowance And Issue Fee Due or other appropriate communication will be sent in due course.
3. The allowed claims are 9-17 (renumbered as 1-9)
4. The drawings filed on _____ are acceptable.
5. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has been received. not been received. been filed in parent application Serial No. _____ filed on _____.
6. Note the attached Examiner's Amendment.
7. Note the attached Examiner Interview Summary Record, PTO-413.
8. Note the attached Examiner's Statement of Reasons for Allowance.
9. Note the attached NOTICE OF REFERENCES CITED, PTO-892.
10. Note the attached INFORMATION DISCLOSURE CITATION, PTO-1449.

PART II.

A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" indicated on this form. Failure to timely comply will result in the ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

1. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
2. APPLICANT MUST MAKE THE DRAWING CHANGES INDICATED BELOW IN THE MANNER SET FORTH ON THE REVERSE SIDE OF THIS PAPER.
 - a. Drawing informalities are indicated on the NOTICE RE PATENT DRAWINGS, PTO-948, attached hereto or to Paper No. _____, CORRECTION IS REQUIRED.
 - b. The proposed drawing correction filed on _____ has been approved by the examiner. CORRECTION IS REQUIRED.
 - c. Approved drawing corrections are described by the examiner in the attached EXAMINER'S AMENDMENT. CORRECTION IS REQUIRED.
 - d. Formal drawings are now REQUIRED.

Any response to this letter should include in the upper right hand corner, the following information from the NOTICE OF ALLOWANCE AND ISSUE FEE DUE: ISSUE BATCH NUMBER, DATE OF THE NOTICE OF ALLOWANCE, AND SERIAL NUMBER.

Attachments:

- Examiner's Amendment
- Examiner Interview Summary Record, PTO-413
- Reasons for Allowance
- Notice of References Cited, PTO-892
- Information Disclosure Citation, PTO-1449
- Notice of Informal Application, PTO-152
- Notice re Patent Drawings, PTO-948
- Listing of Bonded Draftsmen
- Other

Robert T. Bond

ROBERT T. BOND
 PRIMARY EXAMINER
 ART UNIT 1200
 A/c 203 308 7711

Serial Number: 08/416,673

-2-

Art Unit: 1202

EXAMINER'S AMENDMENT

1. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.
2. Before the specification, the following ABSTRACT has been added;

ABSTRACT

B1 Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert T. Bond whose telephone number is (703) 308-4711.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Bond:st
December 13, 1996

Robert T. Bond

ROBERT T. BOND
PRIMARY EXAMINER
ART UNIT 1202

42


PART B—ISSUE FEE TRANSMITTAL

MAILING INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE. Blocks 2 through 6 should be completed where appropriate. All further correspondence including the Issue Fee Receipt, the Patent, advance orders and notification of maintenance fees will be mailed to addressee entered in Block 1 unless you direct otherwise, by: (a) specifying a new correspondence address in Block 3 below; or (b) providing the PTO with a separate "FEE ADDRESS" for maintenance fee notifications with the payment of Issue Fee or thereafter. See reverse for Certificate of Mailing, below.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. #7

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Issue Fee, Assistant Commissioner for Patents, Washington D.C. 20231



2. INVENTOR(S) ADDRESS CHANGE (Complete only if there is a change)

INVENTOR'S NAME _____

Street Address _____

City, State and ZIP Code _____

CO-INVENTOR'S NAME _____

Street Address _____

City, State and ZIP Code _____

Check if additional changes are enclosed

1. CORRESPONDENCE ADDRESS

ROBERT S HONOR
SANDOZ CORPORATION
59 ROUTE 10
EAST HANOVER NJ 07936-1000

12M1/1216

DEC 19 1996

PAPER TO BE ENTERED

APPLICATION NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
08/416,673	04/07/95	009	BOND, R 1202	12/16/96

First Named Applicant: COTTENS, SYLVAIN

TITLE OF INVENTION: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
1	100-7932/PCT	514-514.000	H50	UTILITY	NO	\$1290.00 03/17/97

3. Correspondence address change (Complete only if there is a change)

4. For printing on the patent front page, list the names of not more than 3 registered patent attorneys or agents OR, alternatively, the name of a firm having as a member a registered attorney or agent. If no name is listed, no name will be printed.

1 Robert S. Honor

2 Melvyn M. Kassenoff

3 Thomas O. McGovern

5. ASSIGNMENT DATA TO BE PRINTED ON THE PATENT (print or type)

(1) NAME OF ASSIGNEE: SANDOZ LTD.

(2) ADDRESS: (CITY & STATE OR COUNTRY) Basle, Switzerland

6a. The following fees are enclosed:
 Issue Fee Advance Order - # of Copies _____

6b. The following fees should be charged to:
 DEPOSIT ACCOUNT NUMBER 19-0134
 (ENCLOSE A COPY OF THIS FORM)
 Issue Fee Advance Order - # of Copies 10
 Any Deficiencies in Enclosed Fees

The COMMISSIONER OF PATENTS AND TRADEMARKS is requested to apply the Issue Fee to the application identified above.

(Authorized Signature) *Thomas O McGovern* (Date) 3/14/97

NOTE: The Issue Fee will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the Patent and Trademark Office.

Certificate of Mailing

Note: If this certificate of mailing is used, it can only be used to transmit the Issue Fee. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Box ISSUE FEE
Assistant Commissioner for Patents
Washington, D.C. 20231

on: MARCH 14, 1997 (Date)

THOMAS O. MCGOVERN (Name of person making deposit)

Thomas O McGovern (Signature)

MARCH 14, 1997 (Date)

DA 1 190134 031797 142 1290.00

DA 1 190134 031797 561 30.00

1. TRANSMIT THIS FORM WITH FEE

#8/C
5/2/97
C-style
76

Case No. 100-7932/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Sylvain Cottens, et al. : Art Unit: 1202
Serial No. 08/416,673 : Examiner: R. Bond
Filed: April 7, 1995 : Batch No.: H50
For: O-ALKYLATED RAPAMYCIN :
DERIVATIVES AND THEIR :
USE, PARTICULARLY AS :
IMMUNOSUPPRESSANTS :

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on March 14, 1997

(Date of Deposit)

Thomas O. McGovern

Name of applicant, assignee, or Registered Representative

Thomas O. McGovern

Signature

March 14, 1997

Date of Signature

AMENDMENT UNDER 37 CFR 1.312

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Under the provision of 37 CFR 1.312, please amend the above identified application as follows:

IN THE CLAIMS

Please cancel claim 4, 9, and 10.

In line 1 of claims 11 to 15, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

In line 1 of claims 11, 12, and 13, after the word "which", delete the term "R₁", and insert in its place in each instance the term -- R¹ --.

RECEIVED
Pub. & Distribution
MAR 17 1997
04

SL10147 04/17/97 08416673

19-0134 100 142

1,290.00CH

SL10147 04/17/97 08416673

19-0134 100 561


3000CH

C

Claim 16, line 2; claim 17, line 4; and claim 18,
line 3, after the word "claim", delete the number "10", and
insert in its place in each instance the number -- 19 --.

Please add the following new claims ¹⁸ 19 and ¹⁹ 20.

~~178~~ 19. A compound of the formula



wherein R¹ is hydroxy(C₁₋₆)alkyl or
hydroxy(C₁₋₃)alkoxy(C₁₋₃)alkyl.

~~10~~
~~19~~ 20. The compound according to claim ~~19~~ which is
40-O-(3-hydroxyethyl)-rapamycin.

REMARKS

Claims 9 to 18 have been allowed and claims 11 to 20 are now in the application. No additional fee is required.

The instant application was allowed on December 16, 1996; and the issue fee is being submitted concurrently with this amendment.

It is respectfully requested that the above amendments of the claims be entered. The entering of these amendments will not require a new search nor will it require substantial additional work on the part of the Patent and Trademark Office. This Amendment is believed to be proper under the provisions of Rule 312, because it corrects minors errors in the structures and definitions of the claims. Claim 10 has been replaced with new claim 19 to remove the space in the double bond between carbons 17 and 18 in claim 10 and conform the bond to that of the generic compound of formula I on page 2 of the application. Substituent R¹ has been amended in claims 11 to 13 and in new claim 19 to properly identify it. The definition of substituent R¹ has also been amended to limit the alkylene groups of the hydroxyalkoxyalkyl moiety to the preferred C₁₋₃ alkylene set out on page 3, line 10 of the application. Applicant have added new claim 20 to the application to replace claim 4, which may have been inadvertently deleted from the application instead of claim 9, which was canceled by the Amendment of October 15, 1996.

The proposed amendment do not broaden the scope of the claims or introduce new matter. They were not presented earlier because it was only during a review of the allowed application that it was noted that the amendments were needed. It is therefore respectfully requested that the proposed amendment be entered under the provisions of 35 CFR 1.312.

Respectfully submitted,

By Thomas O. McGovern
Thomas O. McGovern
Registration No. 25,741
(201) 503-8480

TOM:lmc

NOVARTIS CORPORATION
59 Route 10
E. Hanover, N.J. 07936

March , 1997

Enclosures: COM Stamp; Postcard

9/09/97

PTO UTILITY GRANT

Paper Number 10

The Commissioner of Patents and Trademarks

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.

If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.

If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to an statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extension.

Bruce Lehman
Commissioner of Patents and Trademarks
Diana J. Mott
Attest

The United States of America



Form PTO-1584 (Rev. 097)

(RIGHT INSIDE)



Case No. 100-7932/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

Sylvain Cottens, et al. : Art Unit: 1202

Serial No. 08/416,673 : Examiner: R. Bond

Filed: April 7, 1995 : Batch No.: H50

For: O-ALKYLATED RAPAMYCIN :
 DERIVATIVES AND THEIR :
 USE, PARTICULARLY AS :
 IMMUNOSUPPRESSANTS :

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on March 14, 1997

(Date of Deposit)

Thomas O. McGovern

Name of applicant, assignee, or Registered Representative

Thomas O. McGovern

Signature

March 14, 1997

Date of Signature

AMENDMENT UNDER 37 CFR 1.312

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Under the provision of 37 CFR 1.312, please amend the above identified application as follows:

IN THE CLAIMS

Please cancel claim 4, 9, and 10.

In line 1 of claims 11 to 15, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

In line 1 of claims 11, 12, and 13, after the word "which", delete the term "R₁", and insert in its place in each instance the term -- R¹ --.



C d c

CASE 100-7932/PCT

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Phyllis Kelly
Type or print name

Phyllis Kelly
Signature

March 30, 1998
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.M.W.
11

IN RE APPLICATION OF
COTTENS ET AL.

U. S. Patent No. 5,665,772

Certificate of Correction Branch

APPLICATION NO: 08/416,673

FILED: APRIL 7, 1995

FOR: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE,
PARTICULARLY AS IMMUNOSUPPRESSANTS

APPROVED
May H. Green
JUN 03 1998

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE

APR 8 1998

FOR THE ASSISTANT COMMISSIONER FOR PAT. & T.M.

OF CORRECTION

REQUEST FOR CERTIFICATE OF CORRECTION

Sir:

An error has been noted in the above-identified United States Patent, and a Certificate of Correction is hereby requested.

In particular, the error resides in claim 10 of the issued patent. This claim was presented as new claim "20" of applicants' "Amendment Under 37 CFR 1.312" mailed March 14, 1997 (copy appended). At page 3 of said Amendment, applicants indicated that said claim 20 was intended to replace claim 4 of the application as filed, which applicants indicated may have been erroneously cancelled by the Office during prosecution.

However, through applicants' inadvertent error, said claim 20 was incorrectly drawn to the compound "40-0-(3-hydroxyethyl)-rapamycin," rather than reciting the compound of claim 4 of the application as filed.

05/20/1998
01 FC:145
LBERGER 00000024 190134 38637E
100.00

U. S. Patent No. 5,665,772
Atty Docket No. 100-7932/PCT
Request for Certificate of Correction

Accordingly, a Certificate of Correction is enclosed correcting the error in claim 10, lines 1-2 of the subject U.S. Patent No. 5,665,772 by deleting "40-0-(3-hydroxyethyl)-rapamycin" and replacing it with "40-O-(2-hydroxyethyl)-rapamycin". Applicants respectfully request issuance of said Certificate.

If the Office should deem the present request to be made pursuant to 37 CFR §1.323 ("Certificate of Correction of Applicant's Mistake"), and not 37 CFR §1.322(a) ("Certificate of Correction of Office Mistake"), then the Office is authorized to charge the fee of \$100 set forth in 37 CFR § 1.20(a) and any other fees necessitated by this paper, to Patentee's Deposit Account No. 19-0134. This page is enclosed in duplicate for fee purposes.

Respectfully submitted,



Diane E. Furman
Attorney for Applicants
Reg. No. 31,104

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6924

DEF:mjl
Date: March 30, 1998

Enclosures: "Amendment Under 37 CFR 1.312" (March 14, 1997)
Certificate of Correction (in duplicate)
This page in duplicate
Postcard

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 5,665,772
DATED : September 9, 1997
INVENTOR(S) : Sylvain Cottens and Richard Sedrani

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Claim 10, lines 1-2, delete "40-0-(3-hydroxyethyl)-rapamycin" and replace it with -- 40-0-(2-hydroxyethyl)-rapamycin --.



MAILING ADDRESS OF SENDER:
NOVARTIS CORPORATION
Patent and Trademark Department
564 Morris Avenue
Summit, NJ 07901-1027

PATENT NO. 5,665,772

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

REMARKS

Claims 9 to 18 have been allowed and claims 11 to 20 are now in the application. No additional fee is required.

The instant application was allowed on December 16, 1996; and the issue fee is being submitted concurrently with this amendment.

It is respectfully requested that the above amendments of the claims be entered. The entering of these amendments will not require a new search nor will it require substantial additional work on the part of the Patent and Trademark Office. This Amendment is believed to be proper under the provisions of Rule 312, because it corrects minors errors in the structures and definitions of the claims. Claim 10 has been replaced with new claim 19 to remove the space in the double bond between carbons 17 and 18 in claim 10 and conform the bond to that of the generic compound of formula I on page 2 of the application. Substituent R¹ has been amended in claims 11 to 13 and in new claim 19 to properly identify it. The definition of substituent R¹ has also been amended to limit the alkylene groups of the hydroxyalkoxyalkyl moiety to the preferred C₁₋₃ alkylene set out on page 3, line 10 of the application. Applicant have added new claim 20 to the application to replace claim 4, which may have been inadvertently deleted from the application instead of claim 9, which was canceled by the Amendment of October 15, 1996.

The proposed amendment do not broaden the scope of the claims or introduce new matter. They were not presented earlier because it was only during a review of the allowed application that it was noted that the amendments were needed. It is therefore respectfully requested that the proposed amendment be entered under the provisions of 35 CFR 1.312.

Respectfully submitted,

BY Thomas O. McGovern
Thomas O. McGovern
Registration No. 25,741
(201) 503-8480

TOM:lmc

NOVARTIS CORPORATION
59 Route 10
E. Hanover, N.J. 07936


March , 1997

Enclosures: COM Stamp; Postcard

Claim 16, line 2; claim 17, line 4; and claim 18, line 3, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

Please add the following new claims 19 and 20.

19. A compound of the formula



wherein R^1 is hydroxy(C_{1-6})alkyl or
hydroxy(C_{1-3})alkoxy(C_{1-3})alkyl.

20. The compound according to claim 19 which is
40-O-(3-hydroxyethyl)-rapamycin.

DATE : 5-15-98

EXPEDITE **EXPEDITE**

EXPEDITE

TO : Supervisor, Art Unit

1202

SUBJECT : Certificate of Correction Request in Patent No. 5665772

A response to the following question(s) is requested with respect to the accompanying request for a certificate of correction.

- 1. Would the change(s) requested under 37 CFR 1.323 constitute new matter or require reexamination of the application?
- 2. Would the change(s) requested under 37 CFR 1.323 materially affect the scope or meaning of the claims allowed by the examiner in the patent?
- 3. Applicant disagrees with change(s) initialed and dated by Examiner in lieu of an Examiner's Amendment. Should the change request be granted?
- 4. With respect to the change(s) requested, correcting Office errors, should the patent read as shown in the certificate of correction?
- 5. If the amendment filed _____ had been considered by the Examiner, would the amendment have been entered?

PLEASE RESPOND WITHIN 7 DAYS AND RETURN THE FILE TO
Room 918, PK-3

Michelle Williams
Patent Assistant

TO: CERTIFICATES OF CORRECTION BRANCH

DATE:

The decision regarding the change(s) requested in the certificate of correction is shown below.

- 1. YES NO Comments below
- 2. YES NO Comments below
- 3. YES NO Comments below
- 4. YES NO Comments below
- 5. YES NO Comments below

EXPEDITE

Comments _____

RUR
5-22-98

Muskund J. Shah
Supervisor

1811
Art Unit

A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	08/416673
	Filing Date	April 7, 1995
	First Named Inventor	Cotten, Sylvain
	Title	O-ALKYLATED RAPAMYCIN
	Art Unit	1202
	Examiner Name	Bond, Robert
	Attorney Docket Number	100-7932

I hereby revoke all previous powers of attorney given in the above-identified application.

A Power of Attorney is submitted herewith.

OR

I hereby appoint Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

01095

OR

I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

Practitioner(s) Name	Registration Number

Please recognize or change the correspondence address for the above-identified application to:

The address associated with the above-mentioned Customer Number.

OR

The address associated with Customer Number:

Firm or Individual Name

Address

City State Zip

Country

Telephone Email

I am the:

Applicant/Inventor.

OR

Assignee of record of the entire interest. See 37 CFR 3.71.
 Statement under 37 CFR 3.73(b) (Form PTO/SB/96) submitted herewith or filed on _____.

SIGNATURE of Applicant or Assignee of Record

Signature	<i>Gregory C. Houghton</i>	Date	4/21/09
Name	Gregory C. Houghton	Telephone	862 778-2614
Title and Company	Patent Attorney, Novartis		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Acknowledgement Receipt

EFS ID:	5189946
Application Number:	08416673
International Application Number:	
Confirmation Number:	9777
Title of Invention:	O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS
First Named Inventor/Applicant Name:	SYLVAIN COTTENS
Correspondence Address:	ROBERT S HONOR SANDOZ CORPORATION 59 ROUTE 10 - EAST HANOVER NJ 079361080 US - -
Filer:	Gregory Houghton./Cindy Klepacky
Filer Authorized By:	Gregory Houghton.
Attorney Docket Number:	100-7932/PCT
Receipt Date:	21-APR-2009
Filing Date:	07-APR-1995
Time Stamp:	14:23:25
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		PowerRevocation100-7932.pdf	295366 4710c0e86b82528ab5ebfad255d850ff16ba7795	yes	2
Multipart Description/PDF files in .zip description					
	Document Description		Start		End
	Power of Attorney		1		1
	Assignee showing of ownership per 37 CFR 3.73(b).		2		2
Warnings:					
Information:					
Total Files Size (in bytes):			295366		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Novartis AG

Application No./Patent No.: 08/416,673 / 5,665,772 Filed/Issue Date: April 7, 1995 / September 9, 1997

Titled: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

Novartis AG, a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- 1. the assignee of the entire right, title, and interest in;
- 2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is _____ %); or
- 3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

the patent application/patent identified above, by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 008422, Frame 0042, or for which a copy therefore is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet(s).

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Gregory C. Houghton
Signature

4/21/09
Date

Gregory C. Houghton

Patent Attorney

Printed or Typed Name

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA, 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
08/416,673	04/07/1995	SYLVAIN COTTENS	100-7932

CONFIRMATION NO. 9777

POA ACCEPTANCE LETTER

1095
NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER, NJ 07936-1080



Date Mailed: 04/29/2009

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 04/21/2009.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/deelliott/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
08/416,673	04/07/1995	SYLVAIN COTTENS	100-7932/PCT

CONFIRMATION NO. 9777

ROBERT S HONOR
SANDOZ CORPORATION
59 ROUTE 10
EAST HANOVER, NJ 079361080

POWER OF ATTORNEY NOTICE



Date Mailed: 04/29/2009

NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 04/21/2009.

- The Power of Attorney to you in this application has been revoked by the assignee who has intervned as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

/deElliott/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

05-19-09



CASE 100-7932/PCT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV 706065247 US	MAY 18, 2009
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE U.S. PATENT No. 5,665,772
 ISSUED: SEPTEMBER 9, 1997.
 INVENTORS: SYLVAIN COTTENS AND
 RICHARD SEDRANI
 FOR: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS
 IMMUNOSUPPRESSANTS

MS: Patent Ext.
 Director for Patents
 PO Box 1450
 Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR PATENT TERM EXTENSION APPLICATION


Sir:

Enclosed in triplicate is an application for the extension of U.S. Patent No. 5,665,772 under 35 U.S.C. §156.

The Director is hereby authorized to charge the Application Fee of \$1,120.00 prescribed by 37 C.F.R. §1.20(j)(1), as well as any additional fees which may be required in connection with the filing of this Application for Patent Term Extension, to Applicant's Deposit Account No. 19-0134 in the name of Novartis. Two additional copies of this transmittal letter are being submitted for charging purposes.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
 Patents Pharma
 One Health Plaza, Building 101
 East Hanover, NJ 07936-1080
 (862) 778-2614
 Date: 5/18/09


 Gregory C. Aughton
 Attorney for Applicants
 Reg. No. 47,666



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV70606524745
Express Mail Label Number

MAY 18 2009
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE U.S. PATENT NO. 5,665,772

ISSUED: September 9, 1997

INVENTORS: Sylvain Cottens and Richard Sedrani

FOR: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE,
PARTICULARLY AS IMMUNOSUPPRESSANTS

MS Patent Ext.
Director for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT TERM EXTENSION APPLICATION UNDER 35 U.S.C. §156

Sir:

Pursuant to 35 U.S.C. §156 and 37 C.F.R. §1.710 *et seq.*, Novartis AG ("Applicant"), a Corporation organized under the laws of Switzerland, hereby requests an extension of the patent term due to regulatory review of U.S. Patent No. 5,665,772, which was granted on September 9, 1997.


Applicant asserts that it is the owner of the entire right, title and interest in U.S. Patent No. 5,665,772 by virtue of an assignment from the inventors, Sylvain Cottens and Richard Sedrani, to Sandoz LTD, which later changed its name to Novartis AG. The assignment and name change to Novartis AG is recorded in the U.S. Patent and Trademark Office at Reel 008422, Frame 0042 on March 24, 1997. A copy of the assignment is attached hereto as Appendix A. A copy of the Power of Attorney evidencing that Novartis AG being the owner of the entire right, title and interest in and to U.S. Patent No. 5,665,772 appoints Gregory C. Houghton as its agent to act in its interest in this matter is attached hereto as Appendix B.

In accordance with 35 U.S.C. §156 and 37 C.F.R. §1.740, Applicant provides the following information in support of its request for a patent term extension. The following sections are numbered analogously to 37 C.F.R. §1.740.

05/19/2009 NNGUYEN1 00000000 190134 5665772
01 FC:1457 1120.00 DA

(1) Identification of the Approved Product

The approved product is Afinitor[®], which contains the active ingredient everolimus, having the chemical name 40-O-(2-hydroxyethyl)-rapamycin and having the chemical structure



2. Identification of the Federal Statute under which Regulatory Review Occurred

The approved product was subject to regulatory review under the Federal Food, Drug and Cosmetic Act, Section 505 (New Drugs).

3. The Date of Permission for Commercial Marketing

The approved product received permission for commercial marketing under Section 505 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. §355(c)) on March 30, 2009. A copy of the FDA approval letter is attached hereto as Appendix C.

4. Active Ingredient Statement

The sole active ingredient in Afinitor[®] is everolimus, which has not been previously approved for commercial marketing or use under Section 505 of the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, or the Virus-Serum Toxin Act prior to the approval of NDA 22-334 by the United States Food and Drug Administration on March 30, 2009.

A medical device known as The XIENCE[™] V Everolimus Eluting Coronary Stent System, which may also be distributed as the PROMUS[™] Everolimus Eluting Coronary Stent System, was approved by the Federal Food, Drug and Cosmetic Act under the authority of Section 515 on July 8, 2008. This medical device is indicated for improving coronary luminal diameter in patients with symptomatic heart disease. A copy of the of the FDA's premarket approval letter (PMA) is attached hereto as Appendix D.

5. Statement of Timely Filing

The last day on which this application could be submitted is May 29, 2009, which is 60 days after the approval of NDA 22-334 on March 30, 2009. This application is timely filed on or prior to May 29, 2009.

6. Identification of Patent for which Extension is Sought

This application seeks to extend the term of U.S. Patent No. 5,665,772, which issued September 9, 1997 to Sylvain Cottens and Richard Sedrani, the term of which would otherwise expire on September 9, 2014.

7. Patent Copy

A complete copy of U.S. Patent No. 5,665,772, identified in paragraph 6 above, is attached as Appendix E.

8. Post-Issuance Activity Statement

No Reexamination certificate, no terminal disclaimer, or Reissue has been issued or requested with respect to U.S. Patent No. 5,665,772. Two maintenance fees have become due since the patent has issued and both have been paid in a timely manner. Copies of the maintenance fee statements received by the United States Patent & Trademark Office indicating that the respective maintenance fees were timely paid, are attached hereto as Appendix F.

A Request for a Certificate of Correction for U.S. Patent No. 5,665,772 was mailed to the United States Patent and Trademark Office on March 30, 1998. A copy of the Request is attached hereto as Appendix G. The United States Patent and Trademark Office issued the Certificate of Correction for U.S. Patent No. 5,665,772 on June 30, 1998. A copy of the Certificate of Correction is attached hereto as Appendix H.

9. Statement Showing How the Claims of the Patent for which Extension is Sought Cover the Approved Product

Claims 1, 2, 3 and 10 of U.S. Patent No. 5,665,772 claim compounds which include the approved product, Afinitor®.

Claims 1-3 claim compounds, including everolimus, the active ingredient in the approved product. The active ingredient, everolimus, is the compound of claim 1 wherein R₁ is hydroxy(C₁₋₆)alkyl. Further, the active ingredient, everolimus, is the compound of claims 2 and 3, wherein R₁ is hydroxy(C₁₋₃)alkyl.

Claim 10, as corrected by the Certificate of Correction, claims everolimus by its chemical name, which is 40-O-(2-hydroxyethyl)-rapamycin. The Certificate of Correction is attached hereto as Appendix H.

Claim 7 claims pharmaceutical compositions containing a compound of claim 1, which as shown above, includes everolimus, the active ingredient of the approved product. Claim 7 claims a pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier therefor.

10. Statement of the Relevant Dates to Determine the Regulatory Review Period

The relevant dates and information pursuant to 35 U.S.C. §156(g) to enable the Secretary of Health and Human Services to determine the applicable regulatory review period are as follows:

(i) The patent for which extension of the term thereof is sought claims a human drug product. The human drug product is a composition containing everolimus.

(A) An Investigational New Drug Application for everolimus as an antiproliferative drug with an application as an anti-cancer agent was submitted on November 22, 2002. This was assigned IND 66,279. A request was made to cross-reference a previously filed Investigational New Drug Application for everolimus' use as an immunosuppressant. This cross-reference was to include safety data such as carcinogenicity data to support IND 66,279. The previously filed Investigational New Drug Application for everolimus as an antiproliferative drug with an application as an immunosuppressant was submitted on November 15, 1996, was received by the Department of Health and Human Services on November 19, 1996, was assigned IND No. 52,003, and became effective on December 19, 1996.

A copy of the IND letter, dated Dec. 18, 2002, to the FDA regarding IND 66,279 and a fax communication, dated Dec. 18, 2002, to the FDA regarding the cross-referencing of IND 52,003, and a fax communication, dated Dec. 19, 2002, from the FDA regarding IND 66,279 are attached as Appendix I. A copy of the IND application cover letter and table of contents, dated Nov. 15, 1996, concerning IND 52,003 and a copy of the acknowledgement letter, dated Nov. 26, 1996, from the FDA concerning IND 52,003 are attached as Appendix J. A copy of the IND application cover letter and table of contents, dated Nov. 22, 2002, concerning IND 66,279 and a copy of the acknowledgment/approval fax, dated Dec. 19, 2002 (copy also included in Appendix I), from the FDA concerning IND 66,279 are attached as Appendix K.

(B) A New Drug Application for Afinitor[®] was received by the Department of Health and Human Services on June 30, 2008 and granted NDA No. 22-334.

(C) NDA No. 22-334 was approved on March 30, 2009.

11. Brief Description of Activities Undertaken During the Regulatory Review Period

As a brief description of the activities undertaken during the applicable regulatory review period, attached hereto as Appendix L is a chronology of the major communications between the U.S. Food and Drug Administration and the Applicant in IND No. 66,279 and NDA No. 22-334 and in IND 52,003 (the cross-referenced IND).

12. Opinion of Eligibility for Extension

Applicant is of the opinion that U.S. Patent No. 5,665,772 is eligible for extension under 35 U.S.C. §156 and 37 C.F.R. §1.720 because it satisfies all of the requirements for such extension as follows:

(a) 35 U.S.C. §156(a) and 37 C.F.R. §1.720(a)

U.S. Patent No. 5,665,772 claims, everolimus, the active ingredient of a human drug product and pharmaceutical compositions containing the active ingredient. MPEP 2751 states:

"A patent is considered to claim the product at least in those situations where the patent claims the active ingredient per se, or claims a composition or formulation which contains the active ingredient(s) and reads on the composition or formulation approved for commercial marketing or use"

As pointed out in Section 9 of this Patent Term Extension Application, U.S. Patent No. 5,665,772 claims both the active ingredient per se (claims 1-3 and 10) and a composition containing the active ingredient (claim 7).

(b) 35 U.S.C. §156(a)(1) and 37 C.F.R. §1.720(g)

The term of U.S. Patent No. 5,665,772 (expiring September 9, 2014) has not expired before the submission of this application.

(c) 35 U.S.C. §156(a)(2) and 37 C.F.R. §1.720(b)

The term of U.S. Patent No. 5,665,772 has never been extended.

(d) 35 U.S.C. §156(a)(3) and 37 C.F.R. §1.720(c)

The application for extension of the term of U.S. Patent No. 5,665,772 is submitted by the authorized attorney of the owner of record thereof in accordance with the requirements of 35 U.S.C. §156(d) and 37 C.F.R. §1.740.

(e) 35 U.S.C. §156(a)(4) and 37 C.F.R. §1.720(d)

The approved product, Afinitor[®], has been subjected to a regulatory review period under 35 U.S.C. § 156(g)(1) before its commercial marketing or use.

(f) 37 C.F.R. §1.720(h)

No other patent has been extended for the same regulatory review period for the approved product, Afinitor[®].

(g) 35 U.S.C. §156(a)(5)(A) and 37 C.F.R. §1.720(e)(1)

The permission for the commercial marketing or use of the approved product, Afinitor[®] is the first received permission for commercial marketing or use of Afinitor[®] under Section 505, the provision of law under which the applicable regulatory review occurred.

As set forth in paragraph 4 above, a medical device known as The XIENCE[™] V Everolimus Eluting Coronary Stent System, which may also be distributed as the PROMUS[™] Everolimus Eluting Coronary Stent System, was approved by the Federal Food, Drug and Cosmetic Act under the authority of Section 515 on July 8, 2008. This medical device is indicated for improving coronary luminal diameter in patients with symptomatic heart disease.

13. Length of extension claimed under 37 C.F.R. §1.740(a)(12)

The length of extension of the patent term of U.S. Patent No. 5,665,772 requested by Applicant is 1,826 days (5 years), which length was calculated in accordance with 37 C.F.R. §1.775 as follows:

(a) The regulatory review period under 35 U.S.C. §156(g)(1)(B) began on December 19, 1996 (the effective date of the cross-referenced IND 52,003) and ended on March 30, 2009, amounting to a total of 4,484 days which is the sum of (i) and (ii) below:

(i) The period of review under 35 U.S.C. §156(g)(1)(B)(i), the "Testing Period," began on December 19, 1996 and ended on June 30, 2008 which is 4,211 days;

- (ii) The period for review under 35 U.S.C. §156(g)(1)(B)(ii), the "Application Period," began on June 30, 2008 and ended on March 30, 2009, which is 273 days;
- (b) The regulatory review period upon which the period for extension is calculated is the entire regulatory review period as determined in subparagraph (13)(a) above (4,484 days), less:
- (i) The number of days in the regulatory review period which were on or before the date on which the patent issued (Sept. 9, 1997), i.e., 264 days, and
- (ii) The number of days during which the Applicant did not act with due diligence, i.e., zero days, and
- (iii) One-half of the number of days remaining in the period in subparagraph (13)(a)(i) after subtracting the number of days in subparagraphs (13)(b)(i) and (13)(b)(ii), which is one-half of $(4211 - [264 + 0])$ or 1974 days;
- which results in a period of $4,484 - [264 + 0 + 1974 \text{ days}] = 2,246 \text{ days}$.
- (c) The number of days as determined in subparagraph (13)(b), when added to the original term (September 9, 2014), would result in the date of October 19, 2020.
- (d) Fourteen (14) years when added to the date of the NDA Approval Letter (March 30, 2009) would result in the date of March 30, 2023.
- (e) The earlier date as determined by subparagraphs (13)(c) and (13)(d) is October 19, 2020.
- (f) Since the original patent was issued after September 24, 1984, the extension otherwise obtainable is limited to not more than five (5) years. Five years, when added to the original expiration of U.S. Patent No. 5,665,772 (September 9, 2014), results in the date September 9, 2019.
- (g) The earlier date as determined in subparagraphs (13)(e) and (13)(f) is September 9, 2019.

14. Duty of Disclosure Acknowledgement Under 37 C.F.R. §1.740(a)(13)

Applicant acknowledges a duty to disclose to the Director of the United States Patent and Trademark Office and the Secretary of Health and Human Services any information which is material to the determination of entitlement to the extension sought.

15. Fee Charge

The prescribed fee for receiving and acting upon this application is to be charged to Applicant's Deposit Account No. 19-0134 as authorized in the attached transmittal letter, submitted in triplicate.

16. Correspondence Address Required by 37 C.F.R. §1.740(a)(15)

All correspondence relating to this application for patent term extension should be addressed to:


Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Bldg. 101
East Hanover, NJ 07936-1080

17. Certification Under 37 C.F.R. §1.740(b)

The undersigned hereby certifies that the instant application, including its attachments and supporting papers, is being submitted as one original and two copies thereof in accordance with 37 C.F.R. §1.740(b).


Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080



Gregory C. Houghton
Attorney for Applicant
Reg. No. 47,666
(862) 778-2614

Date: 5/18/09



REGISTRATION FORM COVER SHEET PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Appendix A

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
SYLVAIN COTTENS, RICHARD SEDRANI
Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies)
Name: NOVARTIS AG (formerly SANDOZ LTD)
Internal Address: CH-4002
Basle, Switzerland
Street Address: _____
City: _____ State: _____ ZIP: _____
Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other _____
Execution Date: MARCH 13, 1995

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____
A. Patent Application No.(s)
Case 100-7932/PCT
Serial No. 08/416,673
Filed 4/7/95
B. Patent No.(s)
Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Robert S. Honor
Internal Address: NOVARTIS CORP.
Patent and Trademark Dept.
Street Address: 59 Route 10
City: E. Hanover State: NJ ZIP: 07936

6. Total number of applications and patents involved:
7. Total fee (37 CFR 3.41).....\$ 40.00
 Enclosed
 Authorized to be charged to deposit account
8. Deposit account number:
19-0134
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.
Linda C. Rothwell Name of Person Signing
Linda C. Rothwell Signature
3/20/97 Date
Total number of pages including cover sheet, attachments, and document:

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

A S S I G N M E N T

I/We Sylvain Cottens and Richard Sedrani

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to SANDOZ LTD. (also known as SANDOZ AG), a Company organised under the laws of the Swiss Confederation, of 4002 Basle, Switzerland, its successors and assigns, all my/our right, title and interest, in and for the United States of America, in and to the O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

invented by me/us and described in the specification for United States Letters Patent therefor, executed on even date herewith, and all United States Letters Patent which may be granted therefor, and all divisions, reissues, continuations and extensions thereof, the said interest being the entire ownership of the said Letters Patent when granted, to be held and enjoyed by the said SANDOZ LTD., its successors, assigns or other legal representatives, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this assignment and sale had not been made;

And I/we hereby authorize and request the Commissioner of Patents to issue said Letters Patent to the said SANDOZ LTD.

Signed this day of *March 13* 19*55* *Sylvain Cottens*
Sylvain Cottens

Signed this day of *March 13* 19*55* *Richard Sedrani*
Richard Sedrani

Signed this day of _____ 19_____

Signed this day of _____ 19_____

Appendix B

Case No. 100-7932/PCT

**DECLARATION AND POWER OF ATTORNEY
FOR UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and

I believe that I am the original, first and sole inventor (if only one name is listed below)
or an original, first and joint inventor (if more than one name is listed below) of the subject
matter which is claimed and for which a United States patent is sought on the invention
entitled

O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY
AS IMMUNOSUPPRESSANTS

the specification of which

is attached hereto.

was filed on _____ 19 ____ as application Serial No. 0/

and, if these brackets contain an X , was amended on _____ 19 ____

was filed as Patent Cooperation Treaty international application No. PCT/EP93/02604

on September 24 _____, 19 93 _____, if these brackets contain an X , was

amended under Patent Cooperation Treaty Article 19 on _____, 19 ____

and, if these brackets contain an X , was amended on _____, 19 ____

entered the national stage in the United States and was accorded Serial No.

on _____, 19 ____ , and if these brackets contain an X

was amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified
specification including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose all information which is known by me to be material
to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim the benefit under Title 35, United States Code, §119 of any foreign
application(s) for patent or inventor's certificate indicated below and of any Patent
Cooperation Treaty international application(s) designating at least one country other than the
United States indicated below and have also identified any foreign application(s) for

patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

<u>Country:</u>	<u>Number:</u>	<u>Filing Date:</u>	<u>Priority Claimed:</u>
<u>Great Britain</u>	<u>9221220.8</u>	<u>October 9, 1992</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and of any Patent Cooperation Treaty international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

<u>Application</u>	<u>Status (Pending,</u>
<u>Serial No.</u>	<u>Abandoned, Patented)</u>
<u>Filed</u>	
<u>none</u>	_____
_____	_____
_____	_____
_____	_____

I hereby appoint the following:

ROBERT S. HONOR	Reg. No. 22,801
THOMAS O. MCGOVERN	Reg. No. 25,741
MELVYN M. KASSENOFF	Reg. No. 26,389
JOSEPH J. BOROVIAN	Reg. No. 26,631
DIANE E. FURMAN	Reg. No. 31,104
CARL W. BATTLE	Reg. No. 30,731
ANDREW N. PARFOMAK	Reg. No. 32,431
JOHN L. CHIATALAS	Reg. No. 31,818
CAROL A. LOESCHORN	Reg. No. 35,590
MICHAEL P. MORRIS	Reg. No. 34,513
THOMAS C. DOYLE	Reg. No. 22,340

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademarks Office connected therewith. Please address all communications to ROBERT S. HONOR, SANDOZ CORPORATION, 59 Route 10, East Hanover, New Jersey 07936-1080, whose telephone number is 201-503-8485.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statement may jeopardize the validity of the application or any patent issuing thereon.

Sole inventor or first joint inventor:

Full name : Sylvain Cottens
Signature : *Sylvain Cottens*
Date : March 13, 1995
Citizenship : Switzerland
Residence : In den Reben 12, CH-4108 Wittenswil,
Switzerland
P.O. Address: same as above

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declarations) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.



Second joint inventor,
if any:

Full name : Richard Sedrani
Signature : Richard Sedrani
Date : Nov 13 1935
Citizenship : Luxembourg
Residence : Herrenggrabenweg 15, CH-4054 Basle,
Switzerland
P.O. Address : same as above

Third joint inventor,
if any:

Full name : _____
Signature : _____
Date : _____
Citizenship : _____
Residence : _____
P.O. Address: _____

Fourth joint inventor,
if any:

Full name : _____
Signature : _____
Date : _____
Citizenship : _____
Residence : _____
P.O. Address: _____

Fifth joint inventor
if any:

Full name : _____
Signature : _____
Date : _____
Citizenship : _____
Residence : _____
P.O. Address: _____

POWER OF ATTORNEY OR REVOCAION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	08/416673
	Filing Date	April 7, 1995
	First Named Inventor	Cotten, Sylvain
	Title	O-ALKYLATED RAPAMYCIN
	Art Unit	1202
	Examiner Name	Bond, Robert
	Attorney Docket Number	100-7932

I hereby revoke all previous powers of attorney given in the above-identified application.

A Power of Attorney is submitted herewith.

OR

I hereby appoint Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

01095

OR

I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

Practitioner(s) Name	Registration Number

Please recognize or change the correspondence address for the above-identified application to:

The address associated with the above-mentioned Customer Number.

OR

The address associated with Customer Number:

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Email		

I am the:

Applicant/Inventor.

OR

Assignee of record of the entire interest. See 37 CFR 3.71.
 Statement under 37 CFR 3.73(b) (Form PTO/SB/96) submitted herewith or filed on _____.

SIGNATURE of Applicant or Assignee of Record

Signature	<i>Gregory C. Houghton</i>	Date	4/2/09
Name	Gregory C. Houghton	Telephone	862 778-2614
Title and Company	Patent Attorney, Novartis		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Novartis AG
Application No./Patent No.: 08/416,673 / 5,665,772 Filed/Issue Date: April 7, 1995 / September 9, 1997
Titled: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

Novartis AG, a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest in;
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is _____ %); or
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made) the patent application/patent identified above, by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 008422, Frame 0042, or for which a copy therefore is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet(s).

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Gregory C. Houghton
Signature

4/21/09
Date

Gregory C. Houghton
Printed or Typed Name

Patent Attorney
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Appendix C



DEPARTMENT OF HEALTH & HUMAN SERVICES


Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 22-334

NDA APPROVAL

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080



Attention: Sibylle R. Jennings, Ph.D.
Senior Associate Director, Drug Regulatory Affairs

Dear Dr. Jennings:

Please refer to your new drug application (NDA) dated June 27, 2008, received June 30, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Afinitor[®] (everolimus) tablets 5 mg and 10 mg.

We acknowledge receipt of your submissions dated July 29, August 4, 20, 21 (2), 26, 29, September 5 (2), 9, 11, 25 (2), 29 (2), 30 (2), October 14, 17, 20, 21, 24, 28, 31, November 11, 19, 26, December 5, 10, 22, 2008, January 12, 20, 30, February 5, 10, 17, 18, 20, 23 (2), 25, 26, 27, March 3, 10, 11, 12, 20, 25, and 27, 2009.

This new drug application provides for the use of Afinitor[®] (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

An expiration dating period of 24 months is granted when stored as recommended in the approved product labeling. You may extend the expiration dating based on accrual of real-time stability data and report this in an annual report for this NDA.

This application was not taken to a meeting of the Oncologic Drugs Advisory Committee (ODAC) because the application is based on a trial demonstrating a clinically and statistically significant improvement in progression-free survival with an acceptable benefit/risk ratio. Progression-free survival has previously been used as the basis for approval of drugs for the treatment of advanced renal cell carcinoma and the safety profile is similar to that of other drugs approved for this indication.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the

product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable since this disease does not occur in the pediatric population.

POSTMARKETING REQUIREMENTS UNDER 505 (o)

Title IX, Subtitle A, Section 901 of the Food and Drug Administration Amendments Act of 2007 (FDAAA) amends the FDCA to authorize FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute (section 505(o)(3)(A), 21 U.S.C. 355(o)(3)(A)). This provision took effect on March 25, 2008.

Trial A2303 evaluated everolimus in patients with moderate hepatic impairment (Child Pugh Class B) and due to increases in everolimus exposure, a dose reduction is needed in these patients. No exposure data are available for patients with severe hepatic impairment and current labeling recommends that Afinitor[®] (everolimus) should not be used in these patients.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify an unexpected serious risk of increased drug exposure when Afinitor[®] (everolimus) is administered to patients with severe hepatic impairment.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA has not yet been established and is not sufficient to assess these serious risks.

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess the unexpected serious risk of increased drug exposure when Afinitor[®] (everolimus) is administered to patients with severe hepatic impairment.

Therefore, based on appropriate scientific data, FDA has determined that you are required, pursuant to section 505(o)(3) of the FDCA, to complete the following postmarketing clinical trial:

1. Conduct a trial in patients with severe hepatic impairment (Child Pugh Class C). This trial need not be conducted in patients with cancer and a single dose evaluation will be appropriate. The protocol should be submitted prior to initiation for review and concurrence.

The timetable you submitted on March 3, 2009 states that you will conduct this trial according to the following timetable:

Final Protocol Submission:	May 14, 2009
Trial Start Date:	October 14, 2009
Final Report Submission:	April 14, 2011

Submit protocols to your IND 66,279, with a cross-reference letter to this NDA 22-334. Submit all final report(s) to your NDA. Use the following designators to prominently label all submissions, including supplements, relating to this postmarketing requirement as appropriate:

- **Required Postmarketing Protocol under 505(o)**
- **Required Postmarketing Final Report under 505(o)**
- **Required Postmarketing Correspondence under 505(o)**

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

POSTMARKETING COMMITMENTS

We remind you of your postmarketing commitments in your submission dated March 27, 2009. These commitments are listed below.

2. Submit the final, per-protocol overall survival analysis of protocol C2240 which was to be conducted 2 years after randomization of the last patient.

Protocol Submission: July 27, 2006
Trial Start Date: December 6, 2006
Final Report Submission: June 2010

3. Develop a 2.5 mg dosage form (tablet) to allow for proper dose reductions when Afinitor[®] (everolimus) is co-administered with moderate CYP3A4 inhibitors. The 2.5 mg dosage form should be sufficiently distinguishable from the 5 mg and 10 mg tablets. Full chemistry, manufacturing and controls (CMC) information for the 2.5 mg dosage form including batch and stability data, updated labeling, and an updated environmental assessment should be submitted as a prior approval supplement.

Protocol Submission Date: May 14, 2009
Final Report Submission: January 14, 2010

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical trials number of patients entered into each trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled "Postmarketing Commitment Protocol", "Postmarketing Commitment Final Report", or "Postmarketing Commitment Correspondence."

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert and patient package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 22-334."

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "Final Printed Carton and Container Labels for approved NDA 22-334." Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

NDA 22-334

Page 5

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

METHODS VALIDATION

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.

If you have any questions, call Christy Cottrell, Regulatory Project Manager, at (301) 796-4256.

Sincerely,

(See appended electronic signature page)

Richard Pazdur, M.D.
Director
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use AFINITOR safely and effectively. See full prescribing information for AFINITOR.

AFINITOR (everolimus) tablets for oral administration
Initial U.S. Approval: 2009

INDICATIONS AND USAGE

AFINITOR is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib. (1)

DOSAGE AND ADMINISTRATION

- 10 mg once daily with or without food. (2.1)
- Treatment interruption and/or dose reduction to 5 mg once daily may be needed to manage adverse drug reactions. (2.2)
- For patients with Child-Pugh class B hepatic impairment, reduce dose to 5 mg once daily. (2.2)
- If strong inducers of CYP3A4 are required, increase AFINITOR dose in 5 mg increments to a maximum of 20 mg once daily. (2.2)

DOSAGE FORMS AND STRENGTHS

5 mg and 10 mg tablets with no score. (3)

CONTRAINDICATIONS

Hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients. (4)

WARNINGS AND PRECAUTIONS

- Non-infectious pneumonitis: Monitor for clinical symptoms or radiological changes; fatal cases have occurred. Manage by dose reduction or discontinuation until symptoms resolve, and consider use of corticosteroids. (5.1)
- Infections: Increased risk of infections, some fatal. Monitor for signs and symptoms, and treat promptly. (5.2)

- Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common. Management includes mouthwashes (without alcohol or peroxide) and topical treatments. (5.3)
- Laboratory test alterations: Elevations of serum creatinine, blood glucose, and lipids may occur. Decreases in hemoglobin, neutrophils, and platelets may also occur. Monitor renal function, blood glucose, lipids, and hematologic parameters prior to treatment and periodically thereafter. (5.4)
- Vaccinations: Avoid live vaccines and close contact with those who have received live vaccines. (5.7)
- Use in pregnancy: Fetal harm can occur when administered to a pregnant woman. Apprise women of potential harm to the fetus. (5.8, 8.1)

ADVERSE REACTIONS

Most common adverse reactions (incidence $\geq 30\%$) are stomatitis, infections, asthenia, fatigue, cough, and diarrhea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS

- Strong and moderate CYP3A4 or P-gP inhibitors: Avoid concomitant use. (5.5, 7.1)
- Strong CYP3A4 inducers: Avoid concomitant use. If combination cannot be avoided, increase dose of AFINITOR. (2.2, 7.2)

USE IN SPECIFIC POPULATIONS

- Nursing mothers: Discontinue drug or nursing, taking into consideration the importance of drug to the mother. (8.3)
- Hepatic impairment: AFINITOR should not be used in patients with Child-Pugh class C hepatic impairment. For patients with Child-Pugh class B hepatic impairment, reduce dose to 5 mg daily. (2.2, 5.6, 8.7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling

Revised: 03/2009

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Recommended Dose
- 2.2 Dose Modifications

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Non-infectious Pneumonitis
- 5.2 Infections
- 5.3 Oral Ulceration
- 5.4 Laboratory Tests and Monitoring
- 5.5 Drug-drug Interactions
- 5.6 Hepatic Impairment
- 5.7 Vaccinations
- 5.8 Use in Pregnancy

6 ADVERSE REACTIONS

- 6.1 Clinical Studies Experience

7 DRUG INTERACTIONS

- 7.1 Agents that may Increase Everolimus Blood Concentrations
- 7.2 Agents that may Decrease Everolimus Blood Concentrations
- 7.3 Agents whose Plasma Concentrations may be altered by Everolimus

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

- 17.1 Non-infectious Pneumonitis
- 17.2 Infections
- 17.3 Oral Ulceration
- 17.4 Laboratory Tests and Monitoring
- 17.5 Drug-drug Interactions
- 17.6 Hepatic Impairment
- 17.7 Vaccinations
- 17.8 Pregnancy
- 17.9 FDA-approved Patient Labeling

* Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

AFINITOR® is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

The recommended dose of AFINITOR for treatment of advanced renal cell carcinoma is 10 mg, to be taken once daily at the same time every day, either with or without food [see *Clinical Pharmacology (12.3)*]. AFINITOR tablets should be swallowed whole with a glass of water. The tablets should not be chewed or crushed.

Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.

2.2 Dose Modifications

Management of severe and/or intolerable adverse reactions may require temporary dose reduction and/or interruption of AFINITOR therapy. If dose reduction is required, the suggested dose is 5 mg daily [see *Warnings and Precautions (5.1)*].

Hepatic impairment: For patients with moderate hepatic impairment (Child-Pugh class B), reduce the dose to 5 mg daily. AFINITOR has not been evaluated in patients with severe hepatic impairment (Child-Pugh class C) and should not be used in this patient population [see *Warnings and Precautions (5.6)* and *Use in Specific Populations (8.7)*].

Strong CYP3A4 inducers: Avoid the use of concomitant strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, phenobarbital). If patients require co-administration of a strong CYP3A4 inducer, consider increasing the AFINITOR dose from 10 mg daily up to 20 mg daily (based on pharmacokinetic data), using 5 mg increments. This dose of AFINITOR is predicted to adjust the AUC to the range observed without inducers. However, there are no clinical data with this dose adjustment in patients receiving strong CYP3A4 inducers. If the strong inducer is discontinued, the AFINITOR dose should be returned to the dose used prior to initiation of the strong CYP3A4 inducer [see *Drug Interactions (7.2)*].

3 DOSAGE FORMS AND STRENGTHS

5 mg tablet

White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with "5" on one side and "NVR" on the other.

10 mg tablet

White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with "UHE" on one side and "NVR" on the other.

4 CONTRAINDICATIONS

Hypersensitivity to the active substance, to other rapamycin derivatives, or to any of the excipients. Hypersensitivity reactions manifested by symptoms including, but not limited to, anaphylaxis, dyspnea, flushing, chest pain, or angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment) have been observed with everolimus and other rapamycin derivatives.

5 WARNINGS AND PRECAUTIONS

5.1 Non-infectious Pneumonitis

Non-infectious pneumonitis is a class effect of rapamycin derivatives, including AFINITOR. In the randomized study, non-infectious pneumonitis was reported in 14% of patients treated with AFINITOR. The incidence of Common Toxicity Criteria (CTC) grade 3 and 4 non-infectious pneumonitis was 4% and 0%, respectively [see *Adverse Reactions (6.1)*]. Fatal outcomes have been observed.

Consider a diagnosis of non-infectious pneumonitis in patients presenting with non-specific respiratory signs and symptoms such as hypoxia, pleural effusion, cough, or dyspnea, and in whom infectious, neoplastic, and other causes have been excluded by means of appropriate investigations. Advise patients to report promptly any new or worsening respiratory symptoms.

Patients who develop radiological changes suggestive of non-infectious pneumonitis and have few or no symptoms may continue AFINITOR therapy without dose alteration. If symptoms are moderate, consider interrupting therapy until symptoms improve. The use of corticosteroids may be indicated. AFINITOR may be reintroduced at 5 mg daily.

For cases where symptoms of non-infectious pneumonitis are severe, discontinue AFINITOR therapy and the use of corticosteroids may be indicated until clinical symptoms resolve. Therapy with AFINITOR may be re-initiated at a reduced dose of 5 mg daily depending on the individual clinical circumstances.

5.2 Infections

AFINITOR has immunosuppressive properties and may predispose patients to infections, especially infections with opportunistic pathogens [see *Adverse Reactions (6.1)*]. Localized and systemic infections, including pneumonia, other bacterial infections and invasive fungal infections, such as aspergillosis or candidiasis, have occurred in patients taking AFINITOR. Some of these infections have been severe (e.g., leading to respiratory failure) or fatal. Physicians and patients should be aware of the increased risk of infection with AFINITOR, be vigilant for signs and symptoms of infection and institute appropriate treatment promptly. Complete treatment of pre-existing invasive fungal infections prior to starting treatment with AFINITOR. If a diagnosis of invasive systemic fungal infection is made, discontinue AFINITOR and treat with appropriate antifungal therapy.

5.3 Oral Ulceration

Mouth ulcers, stomatitis, and oral mucositis have occurred in patients treated with AFINITOR. In the randomized study, approximately 44% of AFINITOR-treated patients developed mouth ulcers, stomatitis, or oral mucositis, which were mostly CTC grade 1 and 2 [see *Adverse Reactions (6.1)*]. In such cases, topical treatments are recommended, but alcohol- or peroxide-containing mouthwashes should be avoided as they may exacerbate the condition. Antifungal agents should not be used unless fungal infection has been diagnosed [see *Drug Interactions (7.1)*].

5.4 Laboratory Tests and Monitoring

Renal Function

Elevations of serum creatinine, usually mild, have been reported in clinical trials [see *Adverse Reactions (6.1)*]. Monitoring of renal function, including measurement of blood urea nitrogen (BUN) or serum creatinine, is recommended prior to the start of AFINITOR therapy and periodically thereafter.

Blood Glucose and Lipids

Hyperglycemia, hyperlipidemia, and hypertriglyceridemia have been reported in clinical trials [see *Adverse Reactions (6.1)*]. Monitoring of fasting serum glucose and lipid profile is recommended prior to the start of AFINITOR therapy and periodically thereafter. When possible, optimal glucose and lipid control should be achieved before starting a patient on AFINITOR.

Hematological Parameters

Decreased hemoglobin, lymphocytes, neutrophils, and platelets have been reported in clinical trials [see *Adverse Reactions (6.1)*]. Monitoring of complete blood count is recommended prior to the start of AFINITOR therapy and periodically thereafter.

5.5 Drug-drug Interactions

Due to significant increases in exposure of everolimus, co-administration with strong or moderate inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, amprenavir, indinavir, nelfinavir, delavirdine, fosamprenavir, voriconazole, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil or diltiazem) or P-glycoprotein (PgP) should be avoided [see *Drug Interactions (7.1)*].

An increase in the AFINITOR dose is recommended when co-administered with a strong CYP3A4 inducer (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, phenobarbital) [see *Dosage and Administration (2.2)* and *Drug Interactions (7.2)*].

5.6 Hepatic Impairment

The safety and pharmacokinetics of AFINITOR were evaluated in a study in eight patients with moderate hepatic impairment (Child-Pugh class B) and eight subjects with normal hepatic function. Exposure was increased in patients with moderate hepatic impairment, therefore a dose reduction is recommended.

AFINITOR has not been studied in patients with severe hepatic impairment (Child-Pugh class C) and should not be used in this population [see *Dosage and Administration (2.2)* and *Use in Specific Populations (8.7)*].

5.7 Vaccinations

The use of live vaccines and close contact with those who have received live vaccines should be avoided during treatment with AFINITOR. Examples of live vaccines are: intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines.

5.8 Use in Pregnancy

Pregnancy Category D

There are no adequate and well-controlled studies of AFINITOR in pregnant women. However, based on mechanism of action, AFINITOR may cause fetal harm when administered to a pregnant woman. Everolimus caused embryo-fetal toxicities in animals at maternal exposures that were lower than human exposures at the recommended dose of 10 mg daily. If this drug is used during pregnancy or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to use an effective method of contraception while using AFINITOR and for up to 8 weeks after ending treatment [see *Use in Specific Populations (8.1)*].

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in another section of the label:

- Non-infectious pneumonitis [see *Warnings and Precautions (5.1)*].
- Infections [see *Warnings and Precautions (5.2)*].

6.1 Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.

The data described below reflect exposure to AFINITOR (n=274) and placebo (n=137) in a randomized, controlled trial in patients with metastatic renal cell carcinoma who received prior treatment with sunitinib and/or sorafenib. The median age of patients was 61 years (range 27-85), 88% were Caucasian, and 78% were male. The median duration of blinded study treatment was 141 days (range 19-451) for patients receiving AFINITOR and 60 days (range 21-295) for those receiving placebo.

The most common adverse reactions (incidence $\geq 30\%$) were stomatitis, infections, asthenia, fatigue, cough, and diarrhea. The most common grade 3/4 adverse reactions (incidence $\geq 3\%$) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia. The most common laboratory abnormalities (incidence $\geq 50\%$) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine. The most common grade 3/4 laboratory abnormalities (incidence $\geq 3\%$) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia. Deaths due to acute respiratory failure (0.7%), infection (0.7%) and acute renal failure (0.4%) were observed on the AFINITOR arm but none on the placebo arm. The rates of treatment-emergent adverse events (irrespective of causality) resulting in permanent discontinuation were 14% and 3% for the AFINITOR and placebo treatment groups, respectively. The most common adverse reactions (irrespective of causality) leading to treatment discontinuation were pneumonitis and dyspnea. Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction. The most common medical interventions required during AFINITOR treatment were for infections, anemia, and stomatitis.

Table 1 compares the incidence of treatment-emergent adverse reactions reported with an incidence of $\geq 10\%$ for patients receiving AFINITOR 10 mg daily versus placebo. Within each MedDRA system organ class, the adverse reactions are presented in order of decreasing frequency.

	AFINITOR 10 mg/day N=274			Placebo N=137		
	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4
	%	%	%	%	%	%
Any Adverse Reaction	97	52	13	93	23	5

	AFINITOR 10 mg/day N=274			Placebo N=137		
	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4
	%	%	%	%	%	%
Gastrointestinal Disorders						
Stomatitis ^a	44	4	<1	8	0	0
Diarrhea	30	1	0	7	0	0
Nausea	26	1	0	19	0	0
Vomiting	20	2	0	12	0	0
Infections and Infestations^b	37	7	3	18	1	0
General Disorders and Administration Site Conditions						
Asthenia	33	3	<1	23	4	0
Fatigue	31	5	0	27	3	<1
Edema peripheral	25	<1	0	8	<1	0
Pyrexia	20	<1	0	9	0	0
Mucosal inflammation	19	1	0	1	0	0
Respiratory, Thoracic and Mediastinal Disorders						
Cough	30	<1	0	16	0	0
Dyspnea	24	6	1	15	3	0
Epistaxis	18	0	0	0	0	0
Pneumonitis ^c	14	4	0	0	0	0
Skin and Subcutaneous Tissue Disorders						
Rash	29	1	0	7	0	0
Pruritus	14	<1	0	7	0	0
Dry skin	13	<1	0	5	0	0
Metabolism and Nutrition Disorders						
Anorexia	25	1	0	14	<1	0
Nervous System Disorders						
Headache	19	<1	<1	9	<1	0
Dysgeusia	10	0	0	2	0	0
Musculoskeletal and Connective Tissue Disorders						
Pain in extremity	10	1	0	7	0	0
Median Duration of Treatment (d)		141			60	

CTCAE Version 3.0

^a Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.

^b Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (6%), pneumonia (6%), urinary tract infection (5%), bronchitis (4%), and sinusitis (3%), and also including aspergillosis (<1%), candidiasis (<1%), and sepsis (<1%).

^c Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.

Other notable adverse reactions occurring more frequently with AFINITOR than with placebo, but with an incidence of <10% include:

Gastrointestinal disorders: Abdominal pain (9%), dry mouth (8%), hemorrhoids (5%), dysphagia (4%)

General disorders and administration site conditions: Weight decreased (9%), chest pain (5%), chills (4%)

Respiratory, thoracic and mediastinal disorders: Pleural effusion (7%), pharyngolaryngeal pain (4%), rhinorrhea (3%)

Skin and subcutaneous tissue disorders: Hand-foot syndrome (reported as palmar-plantar erythrodysesthesia syndrome) (5%), nail disorder (5%), erythema (4%), onychoclasia (4%), skin lesion (4%), acneiform dermatitis (3%)

Metabolism and nutrition disorders: Exacerbation of pre-existing diabetes mellitus (2%), new onset of diabetes mellitus (<1%)

Nervous system disorders: Insomnia (9%), dizziness (7%), paresthesia (5%)

Eye disorders: Eyelid edema (4%), conjunctivitis (2%)

Vascular disorders: Hypertension (4%)

Renal and urinary disorders: Renal failure (3%)

Cardiac disorders: Tachycardia (3%), congestive cardiac failure (1%)

Musculoskeletal and connective tissue disorders: Jaw pain (3%)

Hematologic disorders: Hemorrhage (3%)

Key treatment-emergent laboratory abnormalities are presented in Table 2.

Table 2 Key Laboratory Abnormalities Reported at a Higher rate in the AFINITOR Arm than the Placebo Arm

Laboratory Parameter	AFINITOR 10 mg/day N=274			Placebo N=137		
	All grades %	Grade 3 %	Grade 4 %	All grades %	Grade 3 %	Grade 4 %
Hematology^a						
Hemoglobin decreased	92	12	1	79	5	<1
Lymphocytes decreased	51	16	2	28	5	0
Platelets decreased	23	1	0	2	0	<1
Neutrophils decreased	14	0	<1	4	0	0
Clinical Chemistry						
Cholesterol increased	77	4	0	35	0	0
Triglycerides increased	73	<1	0	34	0	0
Glucose increased	57	15	<1	25	1	0
Creatinine increased	50	1	0	34	0	0
Phosphate decreased	37	6	0	8	0	0
Aspartate transaminase (AST) increased	25	<1	<1	7	0	0
Alanine transaminase (ALT) increased	21	1	0	4	0	0
Bilirubin increased	3	<1	<1	2	0	0

CTCAE Version 3.0

^a Includes reports of anemia, leukopenia, lymphopenia, neutropenia, pancytopenia, thrombocytopenia.

7 DRUG INTERACTIONS

Everolimus is a substrate of CYP3A4, and also a substrate and moderate inhibitor of the multidrug efflux pump Pgp. *In vitro*, everolimus is a competitive inhibitor of CYP3A4 and a mixed inhibitor of CYP2D6.

7.1 Agents that may Increase Everolimus Blood Concentrations

CYP3A4 Inhibitors and Pgp Inhibitors: In healthy subjects, compared to AFINITOR treatment alone there were significant increases in everolimus exposure when AFINITOR was coadministered with:

- ketoconazole (a strong CYP3A4 inhibitor and a Pgp inhibitor) - C_{max} and AUC increased by 3.9- and 15.0-fold, respectively.
- erythromycin (a moderate CYP3A4 inhibitor and a Pgp inhibitor) - C_{max} and AUC increased by 2.0- and 4.4-fold, respectively.
- verapamil (a moderate CYP3A4 inhibitor and a Pgp inhibitor) - C_{max} and AUC increased by 2.3- and 3.5-fold, respectively.

Concomitant strong or moderate inhibitors of CYP3A4 and Pgp inhibitors should not be used [see *Warnings and Precautions (5.5)*].

7.2 Agents that may Decrease Everolimus Blood Concentrations

CYP3A4 Inducers: In healthy subjects, co-administration of AFINITOR with rifampin, a strong inducer of CYP3A4, decreased everolimus AUC and C_{max} by 64% and 58% respectively, compared to everolimus treatment alone. Consider a dose increase of AFINITOR when co-administered with strong inducers of CYP3A4 or Pgp if alternative treatment cannot be administered [see *Dosage and Administration (2.2)* and *Warnings and Precautions (5.5)*].

7.3 Agents whose Plasma Concentrations may be Altered by Everolimus

Studies in healthy subjects indicate that there are no clinically significant pharmacokinetic interactions between AFINITOR and the HMG-CoA reductase inhibitors atorvastatin (a CYP3A4 substrate) and pravastatin (a non-CYP3A4 substrate) and population pharmacokinetic analyses also detected no influence of simvastatin (a CYP3A4 substrate) on the clearance of AFINITOR.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category D [see *Warnings and Precautions (5.8)*].

There are no adequate and well-controlled studies of AFINITOR in pregnant women. However, based on mechanism of action, AFINITOR may cause fetal harm when administered to a pregnant woman. Everolimus caused embryo-fetal toxicities in animals at maternal exposures that were lower than human exposures at the recommended dose of 10 mg daily. If this drug is used during pregnancy or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to use an effective method of contraception while receiving AFINITOR and for up to 8 weeks after ending treatment.

In animal reproductive studies, oral administration of everolimus to female rats before mating and through organogenesis induced embryo-fetal toxicities, including increased resorption, pre-implantation and post-implantation loss, decreased numbers of live fetuses, malformation (e.g., sternal cleft) and retarded skeletal development. These effects occurred in the absence of maternal toxicities. Embryo-fetal toxicities occurred at approximately 4% the exposure (AUC_{0-24h}) in patients receiving the recommended dose of 10 mg daily. In rabbits, embryotoxicity evident as an increase in resorptions occurred at an oral dose approximately 1.6 times the recommended human dose on a body surface area basis. The effect in rabbits occurred in the presence of maternal toxicities.

In a pre- and post-natal development study in rats, animals were dosed from implantation through lactation. At approximately 10% of the recommended human dose based on body surface area, there were no adverse effects on delivery and lactation and there were no signs of maternal toxicity. However, there was reduced

body weight (up to 9% reduction from the control) and slight reduction in survival in offspring (~5% died or missing). There were no drug-related effects on the developmental parameters (morphological development, motor activity, learning, or fertility assessment) in the offspring.

Doses that resulted in embryo-fetal toxicities in rats and rabbits were ≥ 0.1 mg/kg (0.6 mg/m²) and 0.8 mg/kg (9.6 mg/m²), respectively. The dose in the pre- and post-natal development study in rats that caused reduction in body weights and survival of offspring was 0.1 mg/kg (0.6 mg/m²).

8.3 Nursing Mothers

It is not known whether everolimus is excreted in human milk. Everolimus and/or its metabolites passed into the milk of lactating rats at a concentration 3.5 times higher than in maternal serum. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from everolimus, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

The safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

In the randomized study, 41% of AFINITOR-treated patients were ≥ 65 years in age, while 7% percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see *Clinical Pharmacology* (12.3)].

No dosage adjustment is required in elderly patients [see *Clinical Pharmacology* (12.3)].

8.6 Renal Impairment

No clinical studies were conducted with AFINITOR in patients with decreased renal function. Renal impairment is not expected to influence drug exposure and no dosage adjustment of everolimus is recommended in patients with renal impairment [see *Clinical Pharmacology* (12.3)].

8.7 Hepatic Impairment

For patients with moderate hepatic impairment (Child-Pugh class B), the dose should be reduced to 5 mg daily [see *Dosage and Administration* (2.2), *Warnings and Precautions* (5.6) and *Clinical Pharmacology* (12.3)].

The impact of severe hepatic impairment (Child-Pugh class C) has not been assessed and use in this patient population is not recommended [see *Warnings and Precautions* (5.6)].

10 OVERDOSAGE

In animal studies, everolimus showed a low acute toxic potential. No lethality or severe toxicity were observed in either mice or rats given single oral doses of 2000 mg/kg (limit test).


Reported experience with overdose in humans is very limited. Single doses of up to 70 mg have been administered. The acute toxicity profile observed with the 70 mg dose was consistent with that for the 10 mg dose.

11 DESCRIPTION

AFINITOR (everolimus), an inhibitor of mTOR, is an antineoplastic agent.

The chemical name of everolimus is (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxo-4-aza-tricyclo[30.3.1.0^{12,23}]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone.

The molecular formula is C₅₁H₈₃NO₁₄ and the molecular weight is 958.2. The structural formula is



AFINITOR is supplied as tablets for oral administration containing 5 mg and 10 mg of everolimus together with butylated hydroxytoluene, magnesium stearate, lactose monohydrate, hypromellose, croscopovidone and lactose anhydrous as inactive ingredients.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Everolimus is an inhibitor of mTOR (mammalian target of rapamycin), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation and inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in *in vitro* and/or *in vivo* studies.

12.2 Pharmacodynamics

QT/QTc Prolongation Potential

In a randomized, placebo-controlled, crossover study, 59 healthy subjects were administered a single oral dose of AFINITOR (20 mg and 50 mg) and placebo. There is no indication of a QT/QTc prolonging effect of AFINITOR in single doses up to 50 mg.

Exposure Response Relationships

Markers of protein synthesis show that inhibition of mTOR is complete after a 10 mg daily dose.

12.3 Pharmacokinetics

Absorption

In patients with advanced solid tumors, peak everolimus concentrations are reached 1 to 2 hours after administration of oral doses ranging from 5 mg to 70 mg. Following single doses, C_{max} is dose-proportional between 5 mg and 10 mg. At doses of 20 mg and higher, the increase in C_{max} is less than dose-proportional, however AUC shows dose-proportionality over the 5 mg to 70 mg dose range. Steady-state was achieved within two weeks following once-daily dosing.

Food effect: Based on data in healthy subjects taking 1 mg everolimus tablets, a high-fat meal reduced C_{max} and AUC by 60% and 16%, respectively. No data are available with AFINITOR 5 mg and 10 mg tablets.

Distribution

The blood-to-plasma ratio of everolimus, which is concentration-dependent over the range of 5 to 5000 ng/mL, is 17% to 73%. The amount of everolimus confined to the plasma is approximately 20% at blood concentrations observed in cancer patients given AFINITOR 10 mg/day. Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.

Metabolism

Everolimus is a substrate of CYP3A4 and P-gP. Following oral administration, everolimus is the main circulating component in human blood. Six main metabolites of everolimus have been detected in human blood, including three monohydroxylated metabolites, two hydrolytic ring-opened products, and a phosphatidylcholine conjugate of everolimus. These metabolites were also identified in animal species used in toxicity studies, and showed approximately 100-times less activity than everolimus itself.

In vitro, everolimus competitively inhibited the metabolism of CYP3A4 and was a mixed inhibitor of the CYP2D6 substrate dextromethorphan. The mean steady-state C_{max} following an oral dose of 10 mg daily is more than 12-fold below the K_i -values of the *in vitro* inhibition. Therefore, an effect of everolimus on the metabolism of CYP3A4 and CYP2D6 substrates is unlikely.

Excretion

No specific excretion studies have been undertaken in cancer patients. Following the administration of a 3 mg single dose of radiolabelled everolimus in patients who were receiving cyclosporine, 80% of the radioactivity was recovered from the feces, while 5% was excreted in the urine. The parent substance was not detected in urine or feces. The mean elimination half-life of everolimus is approximately 30 hours.

Patients with Renal Impairment

Approximately 5% of total radioactivity was excreted in the urine following a 3 mg dose of [14 C]-labeled everolimus. In a population pharmacokinetic analysis which included 170 patients with advanced cancer, no significant influence of creatinine clearance (25 – 178 mL/min) was detected on oral clearance (CL/F) of everolimus [see *Use in Specific Populations* (8.6)].

Patients with Hepatic Impairment

The average AUC of everolimus in eight subjects with moderate hepatic impairment (Child-Pugh class B) was twice that found in eight subjects with normal hepatic function. AUC was positively correlated with serum bilirubin concentration and with prolongation of prothrombin time and negatively correlated with serum albumin concentration. A dose reduction for patients with Child-Pugh class B hepatic impairment is recommended. AFINITOR should not be used in patients with severe (Child-Pugh class C) hepatic impairment as the impact of severe hepatic impairment on everolimus exposure has not been assessed [see *Dosage and Administration* (2.2), *Warnings and Precautions* (3.6) and *Use in Specific Populations* (8.7)].

Effects of Age and Gender

In a population pharmacokinetic evaluation in cancer patients, no relationship was apparent between oral clearance and patient age or gender.

Ethnicity

Based on a cross-study comparison, Japanese patients (n = 6) had on average exposures that were higher than non-Japanese patients receiving the same dose.

Based on analysis of population pharmacokinetics, oral clearance (CL/F) is on average 20% higher in Black patients than in Caucasians.

The significance of these differences on the safety and efficacy of everolimus in Japanese or Black patients has not been established.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Administration of everolimus for up to 2 years did not indicate oncogenic potential in mice and rats up to the highest doses tested (0.9 mg/kg) corresponding respectively to 4.3 and 0.2 times the estimated clinical exposure (AUC_{0-24h}) at the recommended human dose of 10 mg daily.

Everolimus was not genotoxic in a battery of *in vitro* assays (Ames mutation test in *Salmonella*, mutation test in L5178Y mouse lymphoma cells, and chromosome aberration assay in V79 Chinese hamster cells). Everolimus was not genotoxic in an *in vivo* mouse bone marrow micronucleus test at doses up to 500 mg/kg/day (1500 mg/m²/day, approximately 255-fold the recommended human dose, based on the body surface area), administered as two doses, 24 hours apart.

Based on non-clinical findings, male fertility may be compromised by treatment with AFINITOR. In a 13-week male fertility study in rats, testicular morphology was affected at 0.5 mg/kg and above, and sperm motility, sperm count, and plasma testosterone levels were diminished at 5 mg/kg, which resulted in infertility at 5 mg/kg. Effects on male fertility occurred at the AUC_{0-24h} values below that of therapeutic exposure (approximately 10%-81% of the AUC_{0-24h} in patients receiving the recommended dose of 10 mg daily). After a 10-13 week non-treatment period, the fertility index increased from zero (infertility) to 60% (12/20 mated females were pregnant).

Oral doses of everolimus in female rats at ≥ 0.1 mg/kg (approximately 4% the AUC_{0-24h} in patients receiving the recommended dose of 10 mg daily) resulted in increases in pre-implantation loss, suggesting that the drug may reduce female fertility. Everolimus crossed the placenta and was toxic to the conceptus (see Use in Specific Populations (8.1)).

14 CLINICAL STUDIES

An international, multicenter, randomized, double-blind trial comparing AFINITOR 10 mg daily and placebo, both in conjunction with best supportive care, was conducted in patients with metastatic renal cell carcinoma whose disease had progressed despite prior treatment with sunitinib, sorafenib, or both sequentially. Prior therapy with bevacizumab, interleukin 2, or interferon-α was also permitted. Randomization was stratified according to prognostic score^a and prior anticancer therapy.

Progression-free survival (PFS), documented using RECIST (Response Evaluation Criteria in Solid Tumors) was assessed via a blinded, independent, central radiologic review. After documented radiological progression, patients could be unblinded by the investigator: those randomized to placebo were then able to receive open-label AFINITOR 10 mg daily.

In total, 416 patients were randomized 2:1 to receive AFINITOR (n=277) or placebo (n=139). Demographics were well balanced between the two arms (median age 61 years; 77% male, 88% Caucasian, 74% received prior sunitinib or sorafenib, and 26% received both sequentially).

AFINITOR was superior to placebo for progression-free survival (see Table 3 and Figure 1). The treatment effect was similar across prognostic scores and prior sorafenib and/or sunitinib. The overall survival (OS) results were not mature and 32% of patients had died by the time of cut-off.


Table 3 Efficacy Results by Central Radiologic Review

	AFINITOR N=277	Placebo N=139	Hazard Ratio (95%CI)	p-value ^a
Median Progression-free Survival (95% CI)	4.9 months (4.0 to 5.5)	1.9 months (1.8 to 1.9)	0.33 (0.25 to 0.43)	<0.0001
Objective Response Rate	2%	0%	n/a ^b	n/a ^b

^a Log-rank test stratified by prognostic score.

^b Not applicable.

Figure 1 Kaplan-Meier Progression-free Survival Curves



15 REFERENCES

1. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell cancer. *J Clin Oncol* (2004) 22:454-63.
2. NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.
3. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
4. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. *Am J Health-Syst Pharm.* (2006) 63:1172-1193.
5. Polovich, M., White, J. M., & Kelleher, L.O. (eds.) 2005. *Chemotherapy and biotherapy guidelines and recommendations for practice* (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.

16 HOW SUPPLIED/STORAGE AND HANDLING

5 mg tablets

White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with "S" on one side and "NVR" on the other; available in:

Blisters of 28 tablets.....NDC 0078-0566-51

Each carton contains 4 blister cards of 7 tablets each

10 mg tablets

White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with "UHE" on one side and "NVR" on the other; available in:

Blisters of 28 tablets.....NDC 0078-0567-51

Each carton contains 4 blister cards of 7 tablets each

Store AFINITOR (everolimus) tablets at 25° C (77°F); excursions permitted between 15°–30°C (59°–86°F). [See USP Controlled Room Temperature.] Store in the original container, protect from light and moisture. Keep this and all drugs out of the reach of children.

Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.^{3,5} AFINITOR tablets should not be crushed. Direct contact of crushed tablets with the skin or mucous membranes should be avoided. If such contact occurs, wash thoroughly as outlined in the references. Personnel should avoid exposure to crushed tablets.

17 PATIENT COUNSELING INFORMATION

See FDA-approved Patient Labeling (17.9)

17.1 Non-Infectious Pneumonitis

Warn patients of the possibility of developing non-infectious pneumonitis. In clinical studies, some non-infectious pneumonitis cases have been severe and occasionally fatal. Advise patients to report promptly any new or worsening respiratory symptoms [see Warnings and Precautions (5.1)].

17.2 Infections

Inform patients that they may be more susceptible to infections while being treated with AFINITOR. In clinical studies, some of these infections have been severe (e.g., leading to respiratory failure) and occasionally fatal. Patients should be aware of the signs and symptoms of infection and should report any such signs or symptoms promptly to their physician [see Warnings and Precautions (5.2)].

17.3 Oral Ulceration

Inform patients of the possibility of developing mouth ulcers, stomatitis and oral mucositis. In such cases, mouthwashes and/or topical treatments are recommended, but these should not contain alcohol or peroxide [see Warnings and Precautions (5.3)].

17.4 Laboratory Tests and Monitoring

Inform patients of the need to monitor blood chemistry and hematology prior to the start of AFINITOR therapy and periodically thereafter [see Warnings and Precautions (5.4)].

17.5 Drug-drug Interactions

Avoid concurrent treatment with strong or moderate CYP3A4 and P-gP inhibitors and strong CYP3A4 and P-gP inducers. If AFINITOR must be co-administered with strong CYP3A4 inducers, consider a dose increase and carefully monitor the patient for clinical response. Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [see Warnings and Precautions (5.5)].

17.6 Hepatic Impairment

Advise patients that AFINITOR is not recommended in patients with severe hepatic impairment (Child-Pugh class C). Prescribe a reduced dose of 5 mg AFINITOR per day for patients with moderate hepatic impairment (Child Pugh class B) [see Dosage and Administration (2), Warnings and Precautions (5.6) and Clinical Pharmacology (12)].

17.7 Vaccinations

Advise patients to avoid the use of live vaccines and close contact with those who have received live vaccines [see Warnings and Precautions (5.7)].

17.8 Pregnancy

Advise female patients of childbearing potential that AFINITOR may cause fetal harm and that an effective method of contraception should be used during therapy with AFINITOR and for 8 weeks after ending treatment.

17.9 FDA-approved Patient Labeling

PATIENT INFORMATION

AFINITOR®

(a-fin-it-or)
(everolimus)
Tablets

Read this patient information leaflet before you start taking AFINITOR and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

What is the most important information I should know about AFINITOR?

- **AFINITOR can cause you to have lung or breathing problems.** Tell your healthcare provider right away if you have new or worsening cough, shortness of breath, difficulty breathing, or wheezing. In some patients lung or breathing problems have been severe, and can even lead to death. You may need to stop AFINITOR for awhile or use a lower dose.
- **AFINITOR can make you more likely to have an infection** such as pneumonia or a bacterial or fungal infection. In some patients infections have been severe, and can even lead to death. You may need to be treated as soon as possible. Tell your healthcare provider right away if you have a temperature of 100.5° F or above, chills, or do not feel well.

What is AFINITOR?

AFINITOR is a prescription medicine used to treat people with advanced kidney cancer (renal cell carcinoma or RCC).

AFINITOR stops cancer cells from making new cancer cells and also cuts off the blood supply to the cancer. This may slow the growth and spread of kidney cancer.

AFINITOR has not been studied in children.

Who should not take AFINITOR?

Do not take AFINITOR if you are allergic to AFINITOR or to any of its ingredients. See the end of this leaflet for a complete list of ingredients in AFINITOR. Talk to your healthcare provider before taking this medicine if you are allergic to:

- sirolimus (Rapamune®, rapamycin)
- temsirolimus (Torisel®).

Ask your healthcare provider if you do not know.

What should I tell my healthcare provider before taking AFINITOR?

Before taking AFINITOR, tell your healthcare provider about all your medical conditions including if you:

- Have or have had liver problems.
- Have diabetes or high blood sugar.
- Have high cholesterol levels.
- Are scheduled for any immunization of a live vaccine or may be around people who have recently received an immunization with a live vaccine. If you are not sure about the type of immunization or vaccine, ask your healthcare provider.
- Are pregnant, or could become pregnant. AFINITOR may harm your pregnancy or fetus. You should use effective birth control while using AFINITOR and for 8 weeks after stopping treatment.
- Are breast-feeding or plan to breast-feed. It is not known if AFINITOR passes into your breast milk. You and your healthcare provider should decide if you will take AFINITOR or breast-feed. You should not do both.

How does AFINITOR impact your childbearing potential?

- AFINITOR may decrease male and female fertility.

Tell your healthcare provider about all of the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

AFINITOR can affect the way other medicines work, and other medicines can affect how AFINITOR works. Using AFINITOR with other medicines can cause serious side effects.

Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. Especially tell your healthcare provider if you take:

- St. John's Wort (also known as *Hypericum perforatum*)
- Medicine for:
 - Fungal infections
 - Bacterial infections
 - Tuberculosis
 - Seizures
 - HIV-AIDS

- Heart conditions or high blood pressure
- Immunosuppression

Ask your healthcare provider or pharmacist if you are not sure if your medicine is one of those taken for the conditions listed above. If you are taking any medicines for the conditions listed above, your healthcare provider might need to prescribe a different medicine. You should also tell your healthcare provider before you start taking any new medicine.

How should I take AFINITOR?

AFINITOR comes in 5 mg and 10 mg tablets.

- Take AFINITOR exactly as your healthcare provider tells you.
- Swallow AFINITOR tablets whole with a glass of water. Do not crush or chew the tablets. If you cannot swallow AFINITOR tablets whole, tell your healthcare provider.
- Take AFINITOR each day, at about the same time, with or without food.
- If you take too much AFINITOR contact your healthcare provider or go to the nearest hospital emergency department right away. Take the pack of AFINITOR with you.
- If you miss a dose of AFINITOR, you may still take it up to 6 hours after the time you normally take it. If it is more than 6 hours after you normally take your AFINITOR, skip the dose for that day. The next day, take AFINITOR at your usual time. Do not take 2 doses to make up for the one that you missed. If you are not sure about what to do, call your healthcare provider.
- You will have regular blood tests before you start and during your treatment with AFINITOR. These tests will show the number of blood cells in your body to see if AFINITOR is having an unwanted effect on these cells. Also, blood tests will monitor how your kidneys and liver are working and your blood sugar levels.

What should I avoid while taking AFINITOR?

- Do not drink grapefruit juice or eat grapefruit during your treatment with AFINITOR. It may make the amount of AFINITOR in your blood increase to a harmful level.

What are the possible side effects of AFINITOR?

AFINITOR can cause serious side effects. See the, "What is the most important information I should know about AFINITOR?" section at the beginning of this leaflet.

Common side effects:

- **Mouth ulcers.** AFINITOR can cause mouth ulcers and sores. Tell your healthcare provider if you have pain, discomfort, or open sores in your mouth. You might need treatment with a special mouthwash or mouth gel. Ask your healthcare provider what type of mouthwash or mouth gel to use.
- **Infections**
- **Feeling weak or tired**
- **Cough, shortness of breath, and lung or breathing problems**
- **Diarrhea**
- **Rash, dry skin, and itching**
- **Nausea and vomiting**
- **Fever**
- **Loss of appetite**
- **Swelling of arms, hands, feet, ankles, face or other parts of the body**
- **Abnormal taste**
- **Inflammation of lining of the digestive system**
- **Headache**
- **Nose bleeds**
- **Pain in arms and legs**

Tell your healthcare provider if you have any side effect that bothers you or does not go away.

These are not all the possible side effects of AFINITOR. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How do I store AFINITOR?

- Keep AFINITOR at room temperature, between 59° to 86° F (15° to 30°C).
- Keep AFINITOR in the original package.
- Open blister package just before taking AFINITOR; use scissors to open blister.
- Keep the package and tablets dry.
- Keep AFINITOR out of light.
- Safely throw away AFINITOR that is out of date or no longer needed.

Keep this and all medicines out of the reach and sight of children.

General information about AFINITOR

Medicines are sometimes prescribed for conditions that are not mentioned in this patient information leaflet. Do not use AFINITOR for a condition for which it was not prescribed.

Do not give AFINITOR to other people, even if they have the same problem you have. It may harm them.

This leaflet summarizes the most important information about AFINITOR. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information written for healthcare professionals.

For more information call 1-888-423-4648.

What are the ingredients in AFINITOR?

Active ingredient: everolimus.

Inactive ingredients: butylated hydroxytoluene, magnesium stearate, lactose monohydrate, hypromellose, crospovidone, lactose anhydrous.

The brands listed are the trademarks or register marks of their respective owners and are not trademarks or register marks of Novartis.

Manufactured by:

Novartis Pharma Stein AG
Stein, Switzerland


Distributed by:

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936


MARCH 2009

PRINTED IN THE U.S.A.


T2009-14 / T2009-15



Description: AFINITOR 5 mg Trade Carton		
Material Group No: • 12578774	Component No.: • 9700333	Supersedes: • N/A
Dimensions:		
Number of Colors: 3		
Black	PMS 1817	PMS 122
Do Not Print Dotted Lines -----		
Signature Area		
		LD&C
		PE
NOVARTIS		




Description: AFINITOR 10 mg Trade Carton		
Material Group No: • 157 E3724	Component No.: • 8050 or • •	Superalloyes: • MLW • •
Dimensions:		
Number of Colors: 3		
Color 1: ■	Color 2: ■ PMS 1617	Color 3: ■ PMS 1258
Do Not Print Dashed Lines -----		
Signature Area		LDEC
		PE
NOVARTIS		



Description: Afinitor 10 mg Sample Carton		
Material Group No: • UCF 01724 •	Component No: • 809X101 •	Supersedes: • N/A •
Dimensions:		
Number of Colors: 3		
Each	PMS 18-17	PMS 1-235
Do Not Print Dotted Lines		
Signature Area		
		LD&C
		PE
NOVARTIS		

12 mil DataBar (RSS) Limited


ZNV-NPD-887



Description: Afinitor 5 mg Trade Foil Blister strip of 7's		
Material Group No.:	Component No.:	Supersedes Component No.:
• ZNV	• 5001594	• NEW
• NPD-887	•	•
•	•	•
Dimensions:		
Number of Colors: 2 Black		PMS 1817
RSS Bar Code: 00300780566612		
Do Not Print Dotted Lines -----		
Signature Area		
		LD&C
		PE

12 mil DataBar (RSS) Limited


ZNV-NPD-888



Description: Afinitor 10 mg Trade Foil Blister strip of 7's		
Material Group No.:	Component No.:	Supersedes Component No.:
• ZNV	• 5001595	• NEW
• NPD-888	•	•
•	•	•
Dimensions:		
Number of Colors: 1 Black		
RSS Bar Code: 00300780567619		
Do Not Print Dotted Lines		
Signature Area		
		LD&C
		PE

12 mil DataBar (RSS) Limited

ZNV-NPD-888



Description: Afinitor 10 mg Sample Foil Blister strip of 7's		
Material Group No.: • ZNV • NPD-888 •	Component No.: • 5001740 • •	Supersedes Component No.: • NEW • •
Dimensions:		
Number of Colors: 1 Black		
RSS Bar Code: 00300789567610		
Do Not Print Dotted Lines -----		
Signature Area		
		LD&C
		PE

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Richard Pazdur
3/30/2009 01:00:32 PM

Appendix D



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUL 2 2008

Ms. Kendra Basler
Regulatory Affairs Associate
Abbott Vascular
Cardiac Therapies
3200 Lakeside Drive
Santa Clara, CA 95054-2807

Re: P070015
XIENCE™ V Everolimus Eluting Coronary Stent System
PROMUST™ Everolimus Eluting Coronary Stent System
Filed: June 1, 2007
Amended: July 5, September 4, November 8, and December 13, 2007; February 20,
April 2, May 12, May 13, June 9, June 23, and June 26, 2008
Procode: NIQ

Dear Ms. Basler:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) for the XIENCE™ V Everolimus Eluting Coronary Stent System, which will also be distributed as the PROMUST™ Everolimus Eluting Coronary Stent System. This device is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to *de novo* native coronary artery lesions (length \leq 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. We are pleased to inform you that the PMA is approved. You may begin commercial distribution of the device in accordance with the conditions described below and in the "Conditions of Approval" (enclosed).

The sale, distribution, and use of this device are restricted to prescription use in accordance with 21 CFR 801.109 within the meaning of section 520(e) of the Federal Food, Drug, and Cosmetic Act (the act) under the authority of section 515(d)(1)(B)(ii) of the act. FDA has also determined that, to ensure the safe and effective use of the device, the device is further restricted within the meaning of section 520(e) under the authority of section 515(d)(1)(B)(ii), (1) insofar as the labeling specify the requirements that apply to the training of practitioners who may use the device as approved in this order and (2) insofar as the sale, distribution, and use must not violate sections 502(q) and (r) of the act.

In addition to the periodic report (often referred to as annual report) requirements outlined in the enclosure, you have agreed to provide the following data in a separate postapproval study report:

1. You should collect and report to the Agency on an annual basis clinical outcomes through 5 years post-procedure on at least 80% of patients enrolled (excluding those discontinued due to death) from SPIRIT FIRST, SPIRIT II, SPIRIT III, and SPIRIT IV. When appropriate or as requested by FDA, you should submit PMA supplements requesting approval to update your Instructions for Use (IFU) to include these data.
2. You should collect clinical data on the implantation of the PMA-approved, commercially-distributed XIENCE V product in the U.S. The trial should be statistically powered to evaluate the annual rates of stent thrombosis, and the rate of cardiac death plus myocardial infarction (MI) through five years in patients treated with the XIENCE V stent according to its labeled indications. These data are needed to evaluate whether the rate of stent thrombosis plateaus or increases over time, and to evaluate the impact of stent thrombosis on rates of cardiac death and MI. These data are also needed to evaluate the potential for rare adverse events related to the drug substance and/or drug carrier that could not be detected in your initial clinical trials. You should also collect additional data on clinical outcomes (including target lesion revascularization rates at 12 months post-implantation) associated with use of the XIENCE V 4.0 mm diameter stent to confirm the outcomes observed in the 4.0 mm Arm of the SPIRIT III trial.

You have proposed collecting these data from at least 5000 patients enrolled in the XIENCE V USA Postmarket Registry. FDA agrees that the registry protocol submitted in Supplement 97 of your Investigational Device Exemption (IDE), G050050, with the planned modifications to the statistical analysis plan, is acceptable. Please provide progress reports at 6, 12, 18, and 24 months and annually thereafter through 5 years with data from your U.S. registry. When appropriate or as requested by FDA, you should submit PMA supplements requesting approval to update your IFU to include these data. Please note that if subsequent data analyses identify areas of significant off-label use, you should submit an IDE to conduct an appropriate study to evaluate the off-label use.

3. You should conduct or participate in a study that will develop clinical data to identify the optimal duration of dual antiplatelet therapy following percutaneous intervention with the XIENCE V drug-eluting stent.

The issue of the optimal duration of dual antiplatelet therapy following PCI with drug-eluting stents (DES) remains a key question that has not been addressed by any clinical trials conducted to date on the Cordis Cypher DES, the Boston Scientific Taxus Express² DES, the Endeavor DES, or the XIENCE V DES. At the December 7 – 8, 2006 meeting of FDA's Circulatory System Devices Advisory Panel meeting on DES thrombosis, the Panel recommended that the labeling for all marketed DES include the then-current ACC/AHA/SCAI guidelines for dual anti-platelet therapy, which specified that patients should receive aspirin indefinitely and clopidogrel for a minimum of 3 or 6 months for the Cypher or Taxus stents, respectively, after implantation, with this duration extended to 12 months in patients who are at low risk for bleeding complications.

However, it is important to recognize that the current recommendation for an extended duration of clopidogrel use reflects a consensus opinion among experts within cardiovascular professional societies based on limited data, rather than on rigorous randomized clinical trials. Further, it is not clear that 12 months is the optimal maximum duration of a dual anti-platelet therapy. In fact, the ACC/AHA/SCAI guidelines were recently revised to specify that patients with low bleeding risks should receive clopidogrel for at least 12 months post-procedure. While extending the duration of clopidogrel use may decrease the risk of very late stent thrombosis events, this strategy may also result in an increased risk for major bleeding complications and involves lifestyle modifications, such as deferral of surgical and dental procedures that may affect a patient's health and overall quality of life. Finally, it is known that stent thrombosis can occur in some individuals despite the continued use of dual antiplatelet therapy. With these considerations in mind, it is imperative that the risks and benefits of continued clopidogrel use be evaluated to determine with greater precision the optimal duration of dual anti-platelet therapy to ensure that these patients receive the best care possible.

Based on the important public health impact of this information, as stated above, you should collect clinical data to identify the optimal duration of dual anti-platelet therapy following PCI with the XIENCE V stent. Such an evaluation should encompass a consecutively enrolled patient population or utilize an approach to enroll patients representative of the actual use of your commercialized product. You may wish to limit your investigation to the XIENCE V stent, or your study may involve pooling with other approved drug-eluting stents. You may also choose to collect these data in a manner that would satisfy, wholly or in part, condition #2 above. When appropriate or as requested by FDA, you should submit PMA supplements requesting approval to update your IFU to include these data. You should submit your proposed plan to address this issue within six months of the date of this letter.

As FDA views the investigation of the optimal duration of dual anti-platelet therapy as a DES class effect, we are requesting that manufacturers of other approved DES collect the same information.

4. You should comply with the commitments made in Amendment 11 related to the implementation of updated final product testing methodologies.

Expiration dating for this device has been established and approved at 12 months.

CDRH does not evaluate information related to contract liability warranties, however you should be aware that any such warranty statements must be truthful, accurate, and not misleading, and must be consistent with applicable Federal and State laws.

CDRH will notify the public of its decision to approve your PMA by making available a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CDRH Internet HomePage located at <http://www.fda.gov/cdrh/pmapage.html>. Written requests for this information can also be made

Page 4 – Ms. Kendra Basler

to the Dockets Management Branch. (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by requesting an opportunity for administrative review, either through a hearing or review by an independent advisory committee, under section 515(g) of the Federal Food, Drug, and Cosmetic Act (the act).

Failure to comply with any postapproval requirement constitutes a ground for withdrawal of approval of a PMA. Commercial distribution of a device that is not in compliance with these conditions is a violation of the act.

You are reminded that, as soon as possible and before commercial distribution of your device, you must submit an amendment to this PMA submission with copies of all approved labeling in final printed form. The labeling will not routinely be reviewed by FDA staff when PMA applicants include with their submission of the final printed labeling a cover letter stating that the final printed labeling is identical to the labeling approved in draft form. If the final printed labeling is not identical, any changes from the final draft labeling should be highlighted and explained in the amendment.

All required documents should be submitted in triplicate, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing.

PMA Document Mail Center (HFZ-401)
Center for Devices and Radiological Health
Food and Drug Administration
9200 Corporate Blvd.
Rockville, Maryland 20850

If you have any questions concerning this approval order, please contact Dr. Heather Agler at 240-276-4229.

Sincerely yours,



Donna-Bea Tillman, Ph.D., M.P.A.
Director
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

4

Last Modified: 10-18-06

CONDITIONS OF APPROVAL

PREMARKET APPROVAL APPLICATION (PMA) SUPPLEMENT. Before making any change affecting the safety or effectiveness of the device, submit a PMA supplement for review and approval by FDA unless the change is of a type for which a "Special PMA Supplement-Changes Being Effected" is permitted under 21 CFR 814.39(d) or an alternate submission is permitted in accordance with 21 CFR 814.39(e) or (f). A PMA supplement or alternate submission shall comply with applicable requirements under 21 CFR 814.39 of the final rule for Premarket Approval of Medical Devices.

All situations that require a PMA supplement cannot be briefly summarized; therefore, please consult the PMA regulation for further guidance. The guidance provided below is only for several key instances.

A PMA supplement must be submitted when unanticipated adverse effects, increases in the incidence of anticipated adverse effects, or device failures necessitate a labeling, manufacturing, or device modification.

A PMA supplement must be submitted if the device is to be modified and the modified device should be subjected to animal or laboratory or clinical testing designed to determine if the modified device remains safe and effective.

A "Special PMA Supplement - Changes Being Effected" is limited to the labeling, quality control and manufacturing process changes specified under 21 CFR 814.39(d)(2). It allows for the addition of, but not the replacement of previously approved, quality control specifications and test methods. These changes may be implemented before FDA approval upon acknowledgment by FDA that the submission is being processed as a "Special PMA Supplement - Changes Being Effected." This procedure is not applicable to changes in device design, composition, specifications, circuitry, software or energy source.

Alternate submissions permitted under 21 CFR 814.39(e) apply to changes that otherwise require approval of a PMA supplement before implementation of the change and include the use of a 30-day PMA supplement or annual postapproval report (see below). FDA must have previously indicated in an advisory opinion to the affected industry or in correspondence with the applicant that the alternate submission is permitted for the change. Before such can occur, FDA and the PMA applicant(s) involved must agree upon any needed testing protocol, test results, reporting format, information to be reported, and the alternate submission to be used.

Alternate submissions permitted under 21 CFR 814.39(f) for manufacturing process changes include the use of a 30-day Notice. The manufacturer may distribute the device 30 days after the date on which the FDA receives the 30-day Notice, unless the FDA notifies the applicant within 30 days from receipt of the notice that the notice is not adequate.

POSTAPPROVAL REPORTS. Continued approval of this PMA is contingent upon the submission of postapproval reports required under 21 CFR 814.84 at intervals of 1 year from the date of approval of the original PMA. Postapproval reports for supplements approved under the original PMA, if applicable, are to be included in the next and subsequent annual reports for the original PMA unless specified otherwise in the approval order for the PMA supplement. Two copies identified as "Annual Report" and bearing the applicable PMA reference number are to be submitted to the PMA Document Mail Center (HFZ-401), Center for Devices and Radiological Health, Food and Drug Administration, 9200 Corporate Blvd., Rockville, Maryland 20850. The postapproval report shall indicate the beginning and ending date of the period covered by the report and shall include the following information required by 21 CFR 814.84:

1. Identification of changes described in 21 CFR 814.39(a) and changes required to be reported to FDA under 21 CFR 814.39(b).
2. Bibliography and summary of the following information not previously submitted as part of the PMA and that is known to or reasonably should be known to the applicant:
 - a. unpublished reports of data from any clinical investigations or nonclinical laboratory studies involving the device or related devices ("related" devices include devices which are the same or substantially similar to the applicant's device); and
 - b. reports in the scientific literature concerning the device.

If, after reviewing the bibliography and summary, FDA concludes that agency review of one or more of the above reports is required, the applicant shall submit two copies of each identified report when so notified by FDA.

ADVERSE REACTION AND DEVICE DEFECT REPORTING. As provided by 21 CFR 814.82(a)(9), FDA has determined that in order to provide continued reasonable assurance of the safety and effectiveness of the device, the applicant shall submit 3 copies of a written report identified, as applicable, as an "Adverse Reaction Report" or "Device Defect Report" to the PMA Document Mail Center (HFZ-401), Center for Devices and Radiological Health, Food and Drug Administration, 9200 Corporate Blvd., Rockville, Maryland 20850 within 10 days after the applicant receives or has knowledge of information concerning:

1. A mix-up of the device or its labeling with another article.
2. Any adverse reaction, side effect, injury, toxicity, or sensitivity reaction that is attributable to the device and:
 - a. has not been addressed by the device's labeling; or
 - b. has been addressed by the device's labeling but is occurring with unexpected severity or frequency.

3. Any significant chemical, physical or other change or deterioration in the device, or any failure of the device to meet the specifications established in the approved PMA that could not cause or contribute to death or serious injury but are not correctable by adjustments or other maintenance procedures described in the approved labeling. The report shall include a discussion of the applicant's assessment of the change, deterioration or failure and any proposed or implemented corrective action by the applicant. When such events are correctable by adjustments or other maintenance procedures described in the approved labeling, all such events known to the applicant shall be included in the Annual Report described under "Postapproval Reports" above unless specified otherwise in the conditions of approval to this PMA. This postapproval report shall appropriately categorize these events and include the number of reported and otherwise known instances of each category during the reporting period. Additional information regarding the events discussed above shall be submitted by the applicant when determined by FDA to be necessary to provide continued reasonable assurance of the safety and effectiveness of the device for its intended use.

REPORTING UNDER THE MEDICAL DEVICE REPORTING (MDR) REGULATION.

The Medical Device Reporting (MDR) Regulation became effective on December 13, 1984. This regulation was replaced by the reporting requirements of the Safe Medical Devices Act of 1990 which became effective July 31, 1996 and requires that all manufacturers and importers of medical devices, including in vitro diagnostic devices, report to the FDA whenever they receive or otherwise become aware of information, from any source, that reasonably suggests that a device marketed by the manufacturer or importer:

1. May have caused or contributed to a death or serious injury; or
2. Has malfunctioned and such device or similar device marketed by the manufacturer or importer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

The same events subject to reporting under the MDR Regulation may also be subject to the above "Adverse Reaction and Device Defect Reporting" requirements in the "Conditions of Approval" for this PMA. FDA has determined that such duplicative reporting is unnecessary. Whenever an event involving a device is subject to reporting under both the MDR Regulation and the "Conditions of Approval" for a PMA, the manufacturer shall submit the appropriate reports required by the MDR Regulation within the time frames as identified in 21 CFR 803.10(c) using FDA Form 3500A, i.e., 30 days after becoming aware of a reportable death, serious injury, or malfunction as described in 21 CFR 803.50 and 21 CFR 803.52 and 5 days after becoming aware that a reportable MDR event requires remedial action to prevent an unreasonable risk of substantial harm to the public health. The manufacturer is responsible for submitting a baseline report on FDA Form 3417 for a device when the device model is first reported under 21 CFR 803.50. This baseline report is to include the PMA reference number. Any written report and its envelope is to be specifically identified, e.g., "Manufacturer Report," "5-Day Report," "Baseline Report," etc.

Any written report is to be submitted to:

Food and Drug Administration
Center for Devices and Radiological Health
Medical Device Reporting
PO Box 3002
Rockville, Maryland 20847-3002

Additional information on MDR is available at <http://www.fda.gov/cdrh/devadvice/351.html>



US005665772A

United States Patent [19]

Cottens et al.

[11] Patent Number: **5,665,772**[45] Date of Patent: **Sep. 9, 1997**

[54] **O-ALKYLATED RAPAMYCIN DERIVATIVES
AND THEIR USE, PARTICULARLY AS
IMMUNOSUPPRESSANTS**

[75] Inventors: **Sylvain Cottens, Witterswil; Richard
Sedrani, Basel, both of Switzerland**

[73] Assignee: **Sandoz Ltd., Basel, Switzerland**

[21] Appl. No.: **416,673**

[22] PCT Filed: **Sep. 24, 1993**

[86] PCT No.: **PCT/EP93/02604**

§ 371 Date: **Apr. 7, 1995**

§ 102(e) Date: **Apr. 7, 1995**

[87] PCT Pub. No.: **WO94/09610**

PCT Pub. Date: **Apr. 28, 1994**

[30] **Foreign Application Priority Data**

Oct. 9, 1992 [GB] United Kingdom 9221220

[51] Int. Cl.⁶ **A61K 31/395; C07D 498/16**

[52] U.S. Cl. **514/514; 540/456**

[58] Field of Search **540/456; 514/514**

[56] **References Cited**

U.S. PATENT DOCUMENTS

5,120,842 6/1992 Failli et al. 540/542
5,151,413 9/1992 Caufield et al. 514/63
5,258,389 11/1993 Goulet et al. 514/291

Primary Examiner—Robert T. Bond

Attorney, Agent, or Firm—Robert S. Honor; Melvyn M.
Kassenoff; Thomas O. McGovern

[57] **ABSTRACT**

Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.

10 Claims, No Drawings


1

O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

This application is a 371 of PCT/EP93/02604, filed Sep. 24, 1993.


This invention comprises novel alkylated derivatives of rapamycin having pharmaceutical utility, especially as immunosuppressants.

Rapamycin is a known macrolide antibiotic produced by *Streptomyces hygroscopicus*, having the structure depicted in Formula A:



See, e.g., McAlpine, J. B., et al., *J. Antibiotics* (1991) 44: 688; Schreiber, S. L., et al., *J. Am. Chem. Soc.* (1991) 113: 7433; U.S. Pat. No. 3,929,992. Rapamycin is an extremely potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable bioavailability as well as its high toxicity. Moreover, rapamycin is highly insoluble, making it difficult to formulate stable galenic compositions.

It has now surprisingly been discovered that certain novel derivatives of rapamycin (the Novel Compounds) have an improved pharmacologic profile over rapamycin, exhibit greater stability and bioavailability, and allow for greater ease in producing galenic formulations. The Novel Compounds are alkylated derivatives of rapamycin having the structure of Formula I:



wherein

2

X is (H,H) or O;

Y is (H,OH) or O;

R^1 and R^2 are independently selected from H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxy-carbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, carbalkoxyalkyl, and $(R^3)_3Si$ where each R^3 is independently selected from H, methyl, ethyl, isopropyl, t-butyl, and phenyl; wherein "alk-" or "alkyl" refers to C_{1-6} alkyl, branched or linear preferably C_{1-3} alkyl, in which the carbon chain may be optionally interrupted by an ether ($-O-$) linkage; and

R^4 is methyl, or R^4 and R^1 together form C_{2-5} alkylene; provided that R^1 and R^2 are not both H; and provided that where R^1 is $(R^3)_3Si$ or carbalkoxyalkyl, X and Y are not both O.

Preferred Novel Compounds include the following:

1. 40-O-Benzyl-rapamycin
 2. 40-O-(4'-Hydroxymethyl)benzyl-rapamycin
 3. 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin
 4. 40-O-Allyl-rapamycin
 5. 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin
 6. (2'E,4'S)-40-O-(4',5'-Dihydroxypent-2'-en-1'-yl)-rapamycin
 7. 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin
 8. 40-O-(2-Hydroxy)ethyl-rapamycin
 9. 40-O-(3-Hydroxy)propyl-rapamycin
 10. 40-O-(6-Hydroxy)hexyl-rapamycin
 11. 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin
 12. 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin
 13. 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin
 14. 40-O-(2-Acetoxy)ethyl-rapamycin
 15. 40-O-(2-Nicotinoyloxy)ethyl-rapamycin
 16. 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin
 17. 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin
 18. 40-O-[2-(N-Methyl-N'-piperaziny)acetoxy]ethyl-rapamycin
 19. 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin
 20. (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin
 21. 28-O-Methyl-rapamycin
 22. 40-O-(2-Aminoethyl)-rapamycin
 23. 40-O-(2-Acetaminoethyl)-rapamycin
 24. 40-O-(2-Nicotinamidoethyl)-rapamycin
 25. 40-O-(2-(N-Methyl-imidazo-2'-yl)carbethoxamido)ethyl-rapamycin
 26. 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin
 27. 40-O-(2-Tolylsulfonamidoethyl)-rapamycin
 28. 40-O-[2-(4',5'-Dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin
- The Novel Compounds for immunosuppressive use are preferably the 40-O-substituted rapamycins where X and Y are both O, R^2 is H, R^4 is methyl, and R^1 is other than H; most preferably where R^1 is selected from hydroxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl, and aminoalkyl; especially 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-(2-acetaminoethyl)-rapamycin.
- Preferably O-substitution at C40 or O,O-disubstitution at C28 and C40 is performed according to the following general process: Rapamycin (or dihydro or deoxorapamycin) is reacted with an organic radical attached to a leaving group (e.g., RX where R is the organic radical,

e.g., an alkyl, allyl, or benzyl moiety, which is desired as the O-substituent, and X is the leaving group, e.g., $\text{CCl}_3\text{C}(\text{NH})\text{O}$ or CF_3SO_2 under suitable reaction conditions, preferably acidic or neutral conditions, e.g., in the presence of an acid like trifluoromethanesulfonic acid, camphorsulfonic acid, p-toluenesulfonic acid or their respective pyridinium or substituted pyridinium salts when X is $\text{CCl}_3(\text{NH})\text{O}$ or in the presence of a base like pyridine, a substituted pyridine, diisopropylethylamine or pentamethylpiperidine when X is CF_3SO_2 . O-substituents at C28 only are accomplished in the same manner, but with prior protection at C40. Further modifications are possible. For example, where the substituent is allyl, the isolated, monosubstituted double bond of the allyl moiety is highly amenable to further modification.

The 9-deoxorapamycin compounds are preferably produced by reducing a rapamycin using hydrogen sulfide, by reacting rapamycin with diphenyldiselenide and tributylphosphine or by other suitable reduction reaction.

The 26-dihydro-rapamycins are preferably produced by reducing rapamycins or 9-deoxorapamycins from keto to hydroxy at C26 by a mild reduction reaction, such as a borohydride reduction reaction.

The Novel Compounds are particularly useful for the following conditions:

- a) Treatment and prevention of organ or tissue transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants. They are also indicated for the prevention of graft-versus-host disease, such as following bone marrow transplantation.
- b) Treatment and prevention of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an etiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases. Specific autoimmune diseases for which the compounds of the invention may be employed include, autoimmune hematological disorders (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis and Crohn's disease) endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy) and juvenile dermatomyositis.
- c) Treatment and prevention of asthma.
- d) Treatment of multi-drug resistance (MDR). The Novel Compounds suppress P-glycoproteins (Pgp), which are the membrane transport molecules associated with MDR. MDR is particularly problematic in cancer patients and AIDS patients who will not respond to conventional chemotherapy because the medication is pumped out of the cells by Pgp. The Novel Compounds are therefore useful for enhancing the efficacy of other chemotherapeutic agents in the treatment and control of multidrug resistant conditions such as multidrug resistant cancer or multidrug resistant AIDS.
- e) Treatment of proliferative disorders, e.g. tumors, hyperproliferative skin disorder and the like.
- f) Treatment of fungal infections.
- g) Treatment and prevention of inflammation, especially in potentiating the action of steroids.
- h) Treatment and prevention of infection, especially infection by pathogens having Mip or Mip-like factors.
- i) Treatment of overdoses of FK-506, rapamycin, immunosuppressive Novel Compounds, and other macrophilin binding immunosuppressants.

The invention thus provides the Novel Compounds described herein, for use as novel intermediates or as pharmaceuticals, methods of treating or preventing the above-described disorders by administering an effective amount of Novel Compound to a patient in need thereof, use of a Novel Compound in the manufacture of a medicament for treatment or prevention of the above-described disorders, and pharmaceutical compositions comprising a Novel Compound in combination or association with a pharmaceutically acceptable diluent or carrier.

Most of the Novel Compounds described herein are highly immunosuppressive, especially those Novel Compounds which are O-substituted at C40, and these Novel Compounds are particularly useful in indications a and b, but not in indication i. Those of the Novel Compounds which are less immunosuppressive, especially those which are O-substituted at C28 only, are particularly useful in indications h and i, but are less preferred in indications a or b.

The Novel Compounds are utilized by administration of a pharmaceutically effective dose in pharmaceutically acceptable form to a subject in need of treatment. Appropriate dosages of the Novel Compounds will of course vary, e.g. depending on the condition to be treated (for example the disease type or the nature of resistance), the effect desired and the mode of administration.

In general however satisfactory results are obtained on administration orally at dosages on the order of from 0.05 to 5 or up to 10 mg/kg/day, e.g. on the order of from 0.1 to 2 or up to 7.5 mg/kg/day administered once or, in divided doses 2 to 4x per day, or on administration parenterally, e.g. intravenously, for example by i.v. drip or infusion, at dosages on the order of from 0.01 to 2.5 up to 5 mg/kg/day, e.g. on the order of from 0.05 or 0.1 up to 1.0 mg/kg/day. Suitable daily dosages for patients are thus on the order of 500 mg p.o., e.g. on the order of from 5 to 100 mg p.o., or on the order of from 0.5 to 125 up to 250 mg i.v., e.g. on the order of from 2.5 to 50 mg i.v.

Alternatively and even preferably, dosaging is arranged in patient specific manner to provide pre-determined trough blood levels, e.g. as determined by RIA technique. Thus patient dosaging may be adjusted so as to achieve regular on-going trough blood levels as measured by RIA on the order of from 50 or 150 up to 500 or 1000 ng/ml, i.e. analogously to methods of dosaging currently employed for Cyclosporin immunosuppressive therapy.

The Novel Compounds may be administered as the sole active ingredient or together with other drugs. For example, in immunosuppressive applications such as prevention and treatment of graft vs. host disease, transplant rejection, or autoimmune disease, the Novel Compounds may be used in combination with Cyclosporin, FK-506, or their immunosuppressive derivatives; corticosteroids; azathioprene; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to CD3, CD4, CD25, CD28, or CD45; and 7 or other immunomodulatory compounds. For anti-inflammatory applications, the Novel Compounds can be used together with anti-inflammatory agents, e.g., corticos-

teroids. For anti-infective applications, the Novel Compounds can be used in combination with other anti-infective agents, e.g., anti-viral drugs or antibiotics.

The Novel Compounds are administered by any conventional route, in particular enterally, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectable solutions or suspensions. Suitable unit dosage forms for oral administration comprise, e.g. from 1 to 50 mg of a compound of the invention, usually 1 to 10 mg. Pharmaceutical compositions comprising the novel compounds may be prepared analogously to pharmaceutical compositions comprising rapamycin, e.g., as described in EPA 0 041 795, which would be evident to one skilled in the art.

The pharmacological activity of the Novel Compounds is demonstrated in, e.g., the following tests:

1. Mixed lymphocyte reaction (MLR)

The Mixed Lymphocyte Reaction was originally developed in connection with allografts, to assess the tissue compatibility between potential organ donors and recipients, and is one of the best established models of immune reaction in vitro. A murine model MLR, e.g., as described by T. Meo in "Immunological Methods", L. Lefkowitz and B. Pernis, Eds., Academic Press, N.Y. pp. 227-239 (1979), is used to demonstrate the immunosuppressive effect of the Novel Compounds. Spleen cells (0.5×10^6) from Balb/c mice (female, 8-10 weeks) are co-incubated for 5 days with 0.5×10^6 irradiated (2000 rads) or mitomycin C treated spleen cells from CBA mice (female, 8-10 weeks). The irradiated allogeneic cells induce a proliferative response in the Balb/c spleen cells which can be measured by labeled precursor incorporation into the DNA. Since the stimulator cells are irradiated (or mitomycin C treated) they do not respond to the Balb/c cells with proliferation but do retain their antigenicity. The antiproliferative effect of the Novel Compounds on the Balb/c cells is measured at various dilutions and the concentration resulting in 50% inhibition of cell proliferation (IC_{50}) is calculated. The inhibitory capacity of the test sample may be compared to rapamycin and expressed as a relative IC_{50} (i.e. IC_{50} test sample/ IC_{50} rapamycin).

2. IL-6 mediated proliferation

The capacity of the Novel Compounds to interfere with growth factor associated signalling pathways is assessed using an interleukin-6 (IL-6)-dependent mouse hybridoma cell line. The assay is performed in 96-well microtiter plates. 5000 cells/well are cultivated in serum-free medium (as described by M. H. Schreier and R. Tees in Immunological Methods, L. Lefkowitz and B. Pernis, eds., Academic Press 1981, Vol. II, pp. 263-275), supplemented with 1 ng recombinant IL-6/ml. Following a 66 hour incubation in the absence or presence of a test sample, cells are pulsed with 1 μ Ci (3-H)-thymidine/well for another 6 hours, harvested and counted by liquid scintillation. (3-H)-thymidine incorporation into DNA correlates with the increase in cell number and is thus a measure of cell proliferation. A dilution series of the test sample allows the calculation of the concentration resulting in 50% inhibition of cell proliferation (IC_{50}). The inhibitory capacity of the test sample may be compared to rapamycin and expressed as a relative IC_{50} (i.e. IC_{50} test sample/ IC_{50} rapamycin).

3. Macrophilin binding assay

Rapamycin and the structurally related immunosuppressant, FK-506, are both known to bind in vivo to macrophilin-12 (also known as FK-506 binding protein or FKBP-12), and this binding is thought to be related to the immunosuppressive activity of these com-

pounds. The Novel Compounds also bind strongly to macrophilin-12, as is demonstrated in a competitive binding assay.

In this assay, FK-506 coupled to BSA is used to coat microtiter wells. Biotinylated recombinant human macrophilin-12 (biot-MAP) is allowed to bind in the presence or absence of a test sample to the immobilized FK-506. After washing (to remove non-specifically bound macrophilin), bound biot-MAP is assessed by incubation with a streptavidin-alkaline phosphatase conjugate, followed by washing and subsequent addition of p-nitrophenyl phosphate as a substrate. The read-out is the OD at 405 nm. Binding of a test sample to biot-MAP results in a decrease in the amount of biot-MAP bound to the FK-506 and thus in a decrease in the OD₄₀₅. A dilution series of the test sample allows determination of the concentration resulting in 50% inhibition of the biot-MAP binding to the immobilized FK-506 (IC_{50}). The inhibitory capacity of a test sample is compared to the IC_{50} of free FK-506 as a standard and expressed as a relative IC_{50} (i.e., IC_{50} -test sample/ IC_{50} -free FK-506).

4. Localized Graft-Versus-Host (GvH) Reaction

In vivo efficacy of the Novel Compounds is proved in a suitable animal model, as described, e.g., in Ford et al, TRANSPLANTATION 10 (1970) 258. Spleen cells (1×10^7) from 6 week old female Wistar/Furth (WF) rats are injected subcutaneously on day 0 into the left hind-paw of female (F344 \times WF)_{F1} rats weighing about 100 g. Animals are treated for 4 consecutive days and the popliteal lymph nodes are removed and weighed on day 7. The difference in weight between the two lymph nodes is taken as the parameter for evaluating the reaction.

5. Kidney Allograft Reaction in Rat

One kidney from a female fisher 344 rat is transplanted onto the renal vessel of a unilaterally (left side) nephrectomized WF recipient rat using an end-to-end anastomosis. Ureteric anastomosis is also end-to-end. Treatment commences on the day of transplantation and is continued for 14 days. A contralateral nephrectomy is done seven days after transplantation, leaving the recipient relying on the performance of the donor kidney. Survival of the graft recipient is taken as the parameter for a functional graft.

6. Experimentally Induced Allergic Encephalomyelitis (EAE) in Rats

Efficacy of the Novel Compounds in EAE is measured, e.g., by the procedure described in Levine & Weak, AMER J PATH 47 (1965) 61; McFarlin et al, J IMMUNOL 113 (1974) 712; Borel, TRANSPLANT. & CLIN. IMMUNOL 13 (1981) 3. EAE is a widely accepted model for multiple sclerosis. Male Wistar rats are injected in the hind paws with a mixture of bovine spinal cord and complete Freund's adjuvant. Symptoms of the disease (paralysis of the tail and both hind legs) usually develop within 16 days. The number of diseased animals as well as the time of onset of the disease are recorded.

7. Freund's Adjuvant Arthritis

Efficacy against experimentally induced arthritis is shown using the procedure described, e.g., in Winter & Nuss, ARTHRITIS & RHEUMATISM 9 (1966) 394; Billingham & Davies, HANDBOOK OF EXPERIMENTAL PHARMACOLOGY (Vane & Ferreira Eds, Springer-Verlag, Berlin) 50/II (1979) 108-144. OFA and Wistar rats (male or female, 150 g body weight) are injected i.e. at the base of the tail or in the hind paw with 0.1 ml of mineral oil containing 0.6 mg of lyophilized heat-killed Mycobacterium smegmatis. In the developing arthritis model, treatment is started immediately after the injection of the adjuvant (days 1-18); in the

established arthritis model treatment is started on day 14, when the secondary inflammation is well developed (days 14-20). At the end of the experiment, the swelling of the joints is measured by means of a micro-caliper. ED₅₀ is the oral dose in mg/kg which reduces the swelling (primary or secondary) to half of that of the controls.

8. Antitumor and MDR activity

The antitumor activity of the Novel Compounds and their ability to enhance the performance of antitumor agents by alleviating multidrug resistance is demonstrated, e.g., by administration of an anticancer agent, e.g., colchicine or etoposide, to multidrug resistant cells and drug sensitive cells in vitro or to animals having multidrug resistant or drug sensitive tumors or infections, with and without co-administration of the Novel Compounds to be tested, and by administration of the Novel Compound alone.

Such in vitro testing is performed employing any appropriate drug resistant cell line and control (parental) cell line, generated, e.g. as described by Ling et al., *J. Cell. Physiol.* 83, 103-116 (1974) and Bech-Hansen et al. *J. Cell. Physiol.* 88, 23-32 (1976). Particular clones chosen are the multidrug resistant (e.g. colchicine resistant) line CHR (subclone CSS3.2) and the parental, sensitive line AUX B1 (subclone AB1 S11).

In vivo anti-tumor and anti-MDR activity is shown, e.g., in mice injected with multidrug resistant and drug sensitive cancer cells. Ehrlich ascites carcinoma (EA) sub-lines resistant to drug substance DR, VC, AM, ET, TE or CC are developed by sequential transfer of EA cells to subsequent generations of BALB/c host mice in accordance with the methods described by Slater et al., *J. Clin. Invest.* 70, 1131 (1982).

Equivalent results may be obtained employing the Novel Compounds test models of comparable design, e.g. in vitro, or employing test animals infected with drug-resistant and drug sensitive viral strains, antibiotic (e.g. penicillin) resistant and sensitive bacterial strains, anti-mycotic resistant and sensitive fungal strains as well as drug resistant protozoal strains, e.g. Plasmodial strains, for example naturally occurring sub-strains of *Plasmodium falciparum* exhibiting acquired chemotherapeutic, anti-malarial drug resistance.

9. FKBP binding

Certain of the Novel Compounds are not immunosuppressive, particularly those which are O-substituted at C28 only, such as 28-O-methyl-rapamycin. This can be shown in standard in vitro assays in comparison to FK506 and rapamycin. FK506, for example, is known to be a potent inhibitor of IL-2 transcription, as can be shown in an IL-2 reporter gene assay. Rapamycin, although not active in the IL-2 reporter gene assay, strongly inhibits IL-6 dependent T-cell proliferation. Both compounds are very potent inhibitors of the mixed lymphocyte reaction. Nonimmunosuppressivity can also be shown in the in vivo models 1-7 above. Even those Novel Compounds which are not immunosuppressive, however, bind to macrophilin, which confers certain utilities in which nonimmunosuppressivity is an advantage.

Those of the Novel Compounds which bind strongly to macrophilin and are not themselves immunosuppressive can be used in the treatment of overdoses of macrophilin-binding immunosuppressants, such as FK506, rapamycin, and the immunosuppressive Novel Compounds.

10. Steroid potentiation

The macrophilin binding activity of the Novel Compounds also makes them useful in enhancing or potentiating the action of corticosteroids. Combined treatment with the compounds of the invention and a corticosteroid, such as

dexamethasone, results in greatly enhanced steroidal activity. This can be shown, e.g., in the murine mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter gene assay, e.g., as described in Ning, et al., *J. Biol. Chem.* (1993) 268: 6073. This synergistic effect allows reduced doses of corticosteroids, thereby reducing the risk of side effects in some cases.

11. Mip and Mip-like factor inhibition

Additionally, the Novel Compounds bind to and block a variety of Mip (macrophage infectivity potentiator) and Mip-like factors, which are structurally similar to macrophilin. Mip and Mip-like factors are virulence factors produced by a wide variety of pathogens, including those of the genera *Chlamidia*, e.g., *Chlamidia trachomatis*; *Neisseria*, e.g., *Neisseria meningitidis*; and *Legionella*, e.g., *Legionella pneumophila*; and also by the obligately parasitic members of the order Rickettsiales. These factors play a critical role in the establishment of intracellular infection. The efficacy of the Novel Compounds in reducing the infectivity of pathogens which produce Mip or Mip-like factors can be shown by comparing infectivity of the pathogens in cells culture in the presence and absence of the macrolides, e.g., using the methods described in Lundemose, et al., *Mol. Microbiol.* (1993) 7: 777. The nonimmunosuppressive compounds of the invention are preferred for use in this indication for the reason that they are not immunosuppressive, thus they do not compromise the body's natural immune defenses against the pathogens.

The Novel Compounds are also useful in assays to detect the presence or amount of macrophilin-binding compounds, e.g., in competitive assays for diagnostic or screening purposes. Thus, in another embodiment, the invention provides for use of the Novel Compounds as a screening tool to determine the presence of macrophilin-binding compounds in a test solution, e.g., blood, blood serum, or test broth to be screened. Preferably, a Novel Compound is immobilized in microtiter wells and then allowed to bind in the presence and absence of a test solution to labelled macrophilin-12 (FKBP-12). Alternatively, the FKBP-12 immobilized in microtiter wells and allowed to bind in the presence and absence of a test solution to a Novel Compound which has been labelled, e.g., fluoro-, enzymatically- or radio-labelled, e.g., a Novel Compound which has been O-substituted at C40 and/or C28 with a labelling group. The plates are washed and the amount of bound labelled compound is measured. The amount of macrophilin-binding substance in the test solution is roughly inversely proportional to the amount of bound labelled compound. For quantitative analysis, a standard binding curve is made using known concentrations of macrophilin bind compound.

EXAMPLES:

In the following examples, characteristic spectroscopic data is given to facilitate identification. Peaks which do not differ significantly from rapamycin are not included. Biological data is expressed as a relative IC₅₀, compared to rapamycin in the case of the mixed lymphocyte reaction (MLR) and IL-6 dependent proliferation (IL-6 dep. prol.) assays, and to FK-506 in the macrophilin binding assay (MBA). A higher IC₅₀ correlates with lower binding affinity. Example 1: 40-O-Benzyl-rapamycin

To a stirred solution of 183 mg (0.200 mmol) of rapamycin in 2.1 mL of 2:1 cyclo-hexane-methylene chloride is added 75 μ L (0.402 mmol) of benzyl-trichloroacetimidate, followed by 2.6 μ L (29 μ mol 15 mol %) of trifluoromethanesulfonic acid whereupon the mixture turned immediately yellow. After 3 h the mixture is diluted with ethyl acetate and

quenched with 10% aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted twice with ethyl acetate. The combined organic solution is washed with 10% aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (50:50 hexane-ethyl acetate) to afford 40-O-benzyl-rapamycin as a white amorphous solid: $^1\text{H NMR}$ (CDCl_3) δ 0.73 (1H, dd), 1.65 (3H, s), 1.73 (3H, s), 3.12 (4H, s and m), 3.33 (3H, s), 3.49 (3H, s), 4.15 (1H, bd), 4.65 (1H, d), 4.71 (1H, d), 7.22-7.38 (5H, m); MS (FAB) m/z 1026 ($[\text{M}+\text{Na}]^+$), 972 ($[\text{M}-\text{OCH}_3]^+$), 954 ($[\text{M}-\text{OCH}_3+\text{H}_2\text{O}]^+$).

MBA (rel. IC50)	1.8
IL-6 dep. prol. (rel. IC50)	10
MLR (rel. IC50)	110

Example 2: 40-O-(4'-Hydroxymethyl)benzyl-rapamycin

a) 40-O-[4'-(t-Butyldimethylsilyloxy)methyl]benzyl-rapamycin

To a stirred, cooled (-78°C .) solution of 345 μL (2.0 mmol) of triflic anhydride in 5 mL of methylene chloride is added a solution of 504 mg (2.0 mmol) of 4-(t-butyldimethylsilyloxy)methyl-benzyl alcohol and 820 mg (4.0 mmol) of 2,6-di-t-butyl-4-methyl-pyridine in 5 mL of methylene chloride. The resulting mixture is warmed to -20°C . and stirring is continued at this temperature for 0.5 h. The mixture is then cooled back to -78°C . and a solution of 914 mg (1.0 mmol) of rapamycin in 5 mL of methylene chloride is added. This mixture is allowed to warm to room temperature overnight and is then quenched with 10% aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted with ethyl acetate. The combined organic solution is washed with saturated brine, dried over sodium sulfate, filtered under reduced pressure and concentrated. The residue is purified by column chromatography on silica gel (50:50 hexane-ethyl acetate) to afford 40-O-[4'-(t-butyldimethylsilyloxy)methyl]benzyl-rapamycin a white foam: MS (FAB) m/z 1170 ($[\text{M}+\text{Na}]^+$), 1098 ($[\text{M}-\text{OCH}_3+\text{H}_2\text{O}]^+$).

b) 40-O-(4'-Hydroxymethyl)benzyl-rapamycin

To a stirred, cooled (0°C .) solution of 98 mg (0.093 mmol) of the compound obtained in example 2 in 2 mL of acetonitrile is added 0.2 mL of HF-pyridine. The resulting mixture is stirred for 2 h and quenched with aqueous sodium bicarbonate, then extracted with ethyl acetate. The organic solution is washed with brine, dried over sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (20:80 hexane-ethyl acetate) to afford the title compound as a white foam: $^1\text{H NMR}$ (CDCl_3) δ 0.73 (1H, dd), 1.65 (3H, s), 1.74 (3H, s), 3.22 (1H, m), 4.67 (4H, m), 7.35 (4H, m); MS (FAB) m/z 1056 ($[\text{M}+\text{Na}]^+$), 1002 ($[\text{M}-\text{OCH}_3]^+$), 984 ($[\text{M}-\text{OCH}_3+\text{H}_2\text{O}]^+$), 966 ($[\text{M}-\text{OCH}_3+2\text{H}_2\text{O}]^+$), 934 ($[\text{M}-\text{OCH}_3+\text{CH}_3\text{OH}+2\text{H}_2\text{O}]^+$).

MBA (rel. IC50)	2.7
IL-6 dep. prol. (rel. IC50)	3.9
MLR (rel. IC50)	3

Example 3: 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin

a) 40-O-[4'-(2,2-Dimethyl-1,3-dioxolan-4-yl)]benzyl-rapamycin

In 10 mL of 1:1 cyclohexane-methylene chloride is dissolved 452 mg (1.24 mmol) of 4-(2,2-dimethyl-1,3-dioxolan-

4-yl)benzyl trichloroacetimidate, followed by 0.14 mL (0.64 mmol) of 2,6-di-t-butylpyridine 56 μL (0.64 mmol) of trifluoromethanesulfonic acid. To this mixture is added a solution of 587 mg (0.64 mmol) of rapamycin in 2 mL of methylene chloride. The reaction is stirred overnight at room temperature and quenched with aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted twice with ethyl acetate. The combined organic solution is washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (50:50 hexane-ethyl acetate) to give 40-O-[4'-(2,2-Dimethyl-1,3-dioxolan-4-yl)]benzyl-rapamycin as a white, amorphous solid: $^1\text{H NMR}$ (CDCl_3) δ 0.73 (1H, dd), 1.48 (3H, s), 1.55 (3H, s), 1.65 (3H, s), 1.74 (3H, s), 3.67 (3H, m), 4.28 (1H, dd), 4.62 (1H, d), 4.69 (1H, d), 5.06 (1H, dd), 7.33 (4H, m), MS (FAB) m/z 1126 ($[\text{M}+\text{Na}]^+$), 1072 ($[\text{M}-\text{OCH}_3]^+$), 1054 ($[\text{M}-\text{OCH}_3+\text{H}_2\text{O}]^+$), 1014 ($[\text{M}-\text{OCH}_3+\text{CH}_3\text{COCH}_3]^+$), 996 ($[\text{M}-\text{OCH}_3+\text{H}_2\text{O}+\text{CH}_3\text{COCH}_3]^+$), 978 ($[\text{M}-\text{OCH}_3+2\text{H}_2\text{O}+\text{CH}_3\text{COCH}_3]^+$).

b) 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin

To a solution of 90.7 mg (0.08 mmol) of 40-O-[4'-(2,2-Dimethyl-1,3-dioxolan-4-yl)]benzyl-rapamycin in 4 mL of methanol is added 1 mL of 1N aqueous HCl. After 2 h the mixture is quenched with aqueous sodium bicarbonate and extracted twice with ethyl acetate. The organic solution is washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue is purified by column chromatography on silica gel (ethyl acetate) and the title compound is obtained as a white foam: $^1\text{H NMR}$ (CDCl_3) δ 0.73 (1H, dd), 1.65 (3H, s), 1.74 (3H, s), 3.70 (4H, m), 4.63 (1H, d), 4.69 (1H, d), 4.80 (1H, dd), 7.33 (4H, m); MS (FAB) m/z 1086 ($[\text{M}+\text{Na}]^+$), 1032 ($[\text{M}-\text{OCH}_3]^+$), 1014 ($[\text{M}-\text{OCH}_3+\text{H}_2\text{O}]^+$), 996 ($[\text{M}-\text{OCH}_3+2\text{H}_2\text{O}]^+$).

MBA (rel. IC50)	0.92
IL-6 dep. prol. (rel. IC50)	10.5
MLR (rel. IC50)	22

Example 4: 40-O-Allyl-rapamycin

To a stirred, cooled (-78°C .) solution of 0.33 mL (2.01 mmol) of triflic anhydride in 10 mL of methylene chloride is slowly added a solution of 0.14 mL (2.06 mmol) of allyl alcohol and 0.42 g (2.04 mmol) of 2,6-di-t-butyl-4-methyl-pyridine in 5 mL of methylene chloride. The resulting greenish solution is stirred for 1.5 h and a solution of 915 mg (1.00 mmol) of rapamycin and 0.42 g (2.04 mmol) of 2,6-di-t-butyl-4-methyl-pyridine in 5 mL of methylene chloride is added. Stirring is continued for 0.5 h at -78°C . and then the mixture is warmed to room temperature. After one more hour the mixture is quenched with aqueous sodium bicarbonate and the layers are separated. The aqueous layer is extracted twice with ethyl acetate. The combined organic solution is washed with aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The resulting green oil is purified by column chromatography on silica gel (60:40 hexane-ethyl acetate) to afford the title compound as a colorless, amorphous solid: $^1\text{H NMR}$ (CDCl_3) δ 0.72 (1H, dd), 1.65 (3H, s), 1.74 (3H, s), 3.05 (1H, m), 4.13 (2H, bd), 5.14 (2H, m), 5.27 (2H, m), 5.92 (2H, m), MS (FAB) m/z 976 ($[\text{M}+\text{Na}]^+$), 922 ($[\text{M}-\text{OCH}_3]^+$), 904 ($[\text{M}-\text{OCH}_3+\text{H}_2\text{O}]^+$), 886 ($[\text{M}-\text{OCH}_3+2\text{H}_2\text{O}]^+$), 872 ($[\text{M}-\text{OCH}_3+\text{OH}]^+$), 854 ($[\text{M}-\text{OCH}_3\text{OH}+2\text{H}_2\text{O}]^+$).

MBA (rel. IC50)	1
IL-6 dep. prol. (rel. IC50)	8
MLR (rel. IC50)	260

Example 5: 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin

To a stirred, cooled (-78° C.) solution of 0.64 g (4.00 mmol) of E-(4S)-4,5-O-isopropylidene-pent-2-en-1,4,5-triol and 1.26 g (6.00 mmol) of 2,6-di-t-butyl-4-methylpyridine in 20 mL of methylene chloride is added 0.82 mL (5.00 mmol) of triflic anhydride. The resulting mixture is stirred at this temperature for 2 h and a solution of 1.82 g (2.00 mmol) of rapamycin and 1.26 g (6.00 mmol) of 2,6-di-t-butyl-4-methylpyridine in 5 mL of methylene chloride is added. The mixture is allowed to gradually warm to room temperature overnight and is then quenched with aqueous sodium bicarbonate. The layers are separated and the aqueous layer is extracted three times with ethyl acetate. The organic solution is washed with aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (40:60 hexane-ethyl acetate) to afford the title compound as a white solid: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.38 (3H, s), 1.42 (3H, s), 1.65 (3H, s), 1.73 (3H, s), 3.06 (1H, m), 3.58 (2H, m), 4.08 (1H, dd), 4.15 (2H, m), 4.52 (1H, bdd), 5.72 (1H, m), 5.88 (1H, m); MS (FAB) m/z 1076 ([M+Na]⁺), 1022 ([M-OCH₃]⁺), 1004 ([M-OCH₃+H₂O]⁺), 964 ([M-(OCH₃+CH₃COCH₃)]⁺), 946 ([M-(OCH₃+H₂O+CH₃COCH₃)]⁺), 946 ([M-(OCH₃+2H₂O+CH₃COCH₃)]⁺).

MBA (rel. IC50)	0.64
IL-6 dep. prol. (rel. IC50)	11
MLR (rel. IC50)	8

Example 6: (2'E, 4'S)-40-O-(4,5'-Dihydroxypent-2'-en-1'-yl)-rapamycin

The conditions described in example 3, step b) applied to the compound obtained in the previous example, followed by purification through column chromatography on silica gel (95:5 ethyl acetate-methanol) afford the title compound as a white foam: ¹H NMR (CDCl₃) 80.68 (1H, dd), 3.04 (1H, m), 4.18 (5H, m), 5.75 (1H, dd), 5.88 (1H, m), MS (FAB) m/z 1036 ([M+Na]⁺), 1013 (M⁺), 995 ([M-H₂O]⁺), 982 ([M-OCH₃]⁺), 964 ([M-(OCH₃+H₂O)]⁺), 946 ([M-(OCH₃+2H₂O)]⁺), 832 ([M-(2CH₃OH+OH)]⁺), 914 ([M-(OCH₃CH₂OH+2H₂O)]⁺).

MBA (rel. IC50)	1.7
IL-6 dep. prol. (rel. IC50)	12
MLR (rel. IC50)	3.5

Example 7: 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin

a) 40-O-[2-(t-Butyldimethylsilyloxy)ethoxycarbonylmethyl-rapamycin

To a stirred solution of 2.74 g (3.00 mmol) of rapamycin and 30 mg (0.06 mmol) of dirhodium tetraacetate dihydrate in 30 mL of methylene chloride is added a solution of 0.38 mL (3.60 mmol) of 2-(t-butylidimethylsilyloxy)ethyl diazoacetate in 10 mL of methylene chloride over 5 h. After the addition is complete stirring is continued for one more hour, then the reaction is quenched with 1N aq. HCl. The layers are separated and the aqueous layer is extracted with ethyl

acetate. The combined organic solution is washed with aq. sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (40:60 hexane-ethyl acetate) yielding 40-O-[2-(t-butylidimethylsilyloxy)ethoxycarbonylmethyl-rapamycin: ¹H NMR (CDCl₃) 80.06 (6H, s), 0.68 (1H, dd), 0.88 (9H, s), 1.64 (3H, s), 1.73 (3H, s), 3.12 (5H, s and m), 3.81 (2H, dd), 4.19 (2H, dd), 4.32 (2H, s); MS (FAB) m/z 1152 ([M+Na]⁺), 1080 ([M-(OCH₃+H₂O)]⁺).

b) 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin

To a stirred, cooled (0° C.) solution of 81 g (0.07 mmol) of 40-O-[2-(t-butylidimethylsilyloxy)ethoxycarbonylmethyl-rapamycin in 1.5 mL of acetonitrile is added 0.15 mL of HF-pyridine. After 2 h the reaction is quenched with aq. sodium bicarbonate. The mixture is extracted with ethyl acetate. The organic solution is washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by PTLC (ethyl acetate) to afford the title compound as a white solid: ¹H NMR (CDCl₃) 80.70 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 3.13 (5H, s and m), 3.85 (3H, m), 4.25 (5H, m); MS (FAB) m/z 1038 ([M+Na]⁺), 984 ([M-(OCH₃)]⁺), 966 ([M-(OCH₃+H₂O)]⁺), 948 ([M-(OCH₃+2H₂O)]⁺).

MBA (rel. IC50)	4
IL-6 dep. prol. (rel. IC50)	9.7
MLR (rel. IC50)	2.1

Example 8: 40-O-(2-Hydroxy)ethyl-rapamycin

a) 40-O-[2-(t-Butyldimethylsilyloxy)ethyl-rapamycin

A solution of 9.14 g (10 mmol) of rapamycin and 4.70 mL (40 mmol) of 2,6-lutidine in 30 mL of toluene is warmed to 60° C. and a solution of 6.17 g (20 mmol) of 2-(t-butylidimethylsilyloxy)ethyl triflate and 2.35 mL (20 mmol) of 2,6-lutidine in 20 mL of toluene is added. This mixture is stirred for 1.5 h. Then two batches of a solution of 3.08 g (10 mmol) of triflate and 1.2 mL (10 mmol) of 2,6-lutidine in 10 mL of toluene are added in a 1.5 h interval. After addition of the last batch, stirring is continued at 60° C. for 2 h and the resulting brown suspension is filtered. The filtrate is diluted with ethyl acetate and washed with aq. sodium bicarbonate and brine. The organic solution is dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (40:60 hexane-ethyl acetate) to afford 40-O-[2-(t-butylidimethylsilyloxy)ethyl-rapamycin as a white solid: ¹H NMR (CDCl₃) 80.06 (6H, s), 0.72 (1H, dd), 0.90 (9H, s), 1.65 (3H, s), 1.75 (3H, s), 3.02 (1H, m), 3.63 (3H, m), 3.72 (3H, m); MS (FAB) m/z 1094 ([M+Na]⁺), 1022 ([M-(OCH₃+H₂O)]⁺).

b) 40-O-(2-Hydroxy)ethyl-rapamycin

To a stirred, cooled (0° C.) solution of 4.5 g (4.2 mmol) of 40-O-[2-(t-butylidimethylsilyloxy)ethyl-rapamycin in 20 mL of methanol is added 2 mL of 1N HCl. This solution is stirred for 2 h and neutralized with aq. sodium bicarbonate. The mixture is extracted with three portions of ethyl acetate. The organic solution is washed with aq. sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica gel (ethyl acetate) gave the title compound as a white solid: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 3.13 (5H, s and m), 3.52-3.91 (8H, m); MS (FAB) m/z 980 ([M+Na]⁺), 926 ([M-(OCH₃)]⁺), 908 ([M-(OCH₃+H₂O)]⁺), 890 ([M-(OCH₃+2H₂O)]⁺), 876 ([M-(2CH₃OH+OH)]⁺), 858 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	2.2
IL-6 dep. prol. (rel. IC50)	2.8
MLR (rel. IC50)	3.4

Example 9: 40-O-(3-Hydroxy)propyl-rapamycin**a) 40-O-[3-(t-Butyldimethylsilyloxy)propyl-rapamycin**

The same procedure as described in example 8, step a) using 3-(t-butyldimethylsilyloxy)prop-1-yl triflate affords 40-O-[3-(t-butyldimethylsilyloxy)propyl-rapamycin: ¹H NMR (CDCl₃) 80.05 (6H, s), 0.72 (1H, dd), 0.90 (9H, s), 1.65 (3H, s), 1.74 (3H, s), 1.77 (2H, m), 3.03 (1H, m), 3.52-3.73 (7H, m); MS (FAB) m/z 1108 ([M+Na]⁺), 1036 ([M-(OCH₃+H₂O)]⁺).

b) 40-O-(3-Hydroxy)propyl-rapamycin

Treatment of the compound obtained in step a) in the conditions described in example 8, step b) yields the title compound: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 1.80 (2H, m), 3.05 (1H, m), 3.55-3.91 (8H, m); MS (FAB) m/z 994 ([M+Na]⁺), 940 ([M-(OCH₃)⁺], 922 ([M-(OCH₃+H₂O)]⁺), 904 ([M-(OCH₃+2H₂O)]⁺), 872 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	1.6
IL-6 dep. prol. (rel. IC50)	2.7
MLR (rel. IC50)	11

Example 10: 40-O-(6-Hydroxy)hexyl-rapamycin**a) 40-O-[6-(t-Butyldimethylsilyloxy)hexyl-rapamycin**

The same procedure as described in example 8, step a) using 6-(t-butyldimethylsilyloxy)hex-1-yl triflate affords 40-O-[6-(t-butyldimethylsilyloxy)hexyl-rapamycin: MS (FAB) m/z 1150 ([M+Na]⁺).

b) 40-O-(6-Hydroxy)hexyl-rapamycin

Treatment of the compound obtained in step a) in the conditions described in example 8, step b) yields the title compound: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.38 (2H, m), 1.57 (4H, m), 1.65 (3H, s), 1.74 (3H, s), 3.02 (1H, m), 3.49-3.72 (8H, m); MS (FAB) m/z 1036 ([M+Na]⁺), 982 ([M-(OCH₃)⁺], 964 ([M-(OCH₃+H₂O)]⁺), 946 ([M-(OCH₃+2H₂O)]⁺), 914 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	0.8
IL-6 dep. prol. (rel. IC50)	8.5
MLR (rel. IC50)	18

Example 11: 40-O-[2-(2-Hydroxyethoxy)ethyl-rapamycin**a) 40-O-[2-(t-Butyldimethylsilyloxy)ethoxy]ethyl-rapamycin**

The same procedure as described in example 8, step a) using 2-[2-(t-butyldimethylsilyloxy)ethoxy]ethyl triflate affords 40-O-[2-(t-butyldimethylsilyloxy)ethoxy]ethyl-rapamycin: ¹H NMR (CDCl₃) 80.06 (6H, s), 0.71 (1H, dd), 0.88 (9H, s), 1.65 (3H, s), 1.74 (3H, s), 3.07 (1H, m), 3.51-3.79 (11H, m); MS (FAB) m/z 1138 ([M+Na]⁺), 1115 (M⁺), 1097 ([M-H₂O]⁺), 1084 ([M-(OCH₃)⁺], 1066 ([M-(OCH₃+H₂O)]⁺), 1048 ([M-(OCH₃+2H₂O)]⁺), 1034 ([M-(2CH₃OH+OH)]⁺), 1016 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

b) 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin

Treatment of the compound obtained in step a) in the conditions described in example 8, step b) yields the title compound: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.65 (3H, s), 1.74 (3H, s), 3.05 (1H, m), 3.51-3.77 (11H, m); MS (FAB) m/z 1024 ([M+Na]⁺), 1001 (M⁺), 983 ([M-H₂O]⁺), 970

([M-(OCH₃)⁺], 952 ([M-(OCH₃+H₂O)]⁺), 934 ([M-(OCH₃+2H₂O)]⁺), 920 ([M-(2CH₃OH+OH)]⁺), 902 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	1.2
IL-6 dep. prol. (rel. IC50)	3.2
MLR (rel. IC50)	2

Example 12: 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin

The same procedure as described in example 8, step a) using the triflate of glycerol acetonide affords the title compound: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.36 (3H, s), 1.42 (3H, s), 1.65 (3H, s), 1.75 (3H, s), 3.06 (1H, m), 3.55 (2H, m), 3.69 (3H, m), 4.06 (1H, dd), 4.26 (1H, m); MS (FAB) m/z 1050 ([M+Na]⁺), 996 ([M-(OCH₃)⁺], 978 ([M-(OCH₃+H₂O)]⁺), 960 ([M-(OCH₃+2H₂O)]⁺).

MBA (rel. IC50)	0.9
IL-6 dep. prol. (rel. IC50)	8
MLR (rel. IC50)	290

Example 13: 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin

Treatment of the compound obtained in the previous example in the conditions described in example 3 yields the title compound: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 3.07 (1H, m), 3.68 (8H, m); MS (FAB) m/z 1010 ([M+Na]⁺), 956 ([M-(OCH₃)⁺], 938 ([M-(OCH₃+H₂O)]⁺), 920 ([M-(OCH₃+2H₂O)]⁺), 888 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	0.67
IL-6 dep. prol. (rel. IC50)	9
MLR (rel. IC50)	10

Example 14: 40-O-(2-Acetoxy)ethyl-rapamycin

To a stirred, cooled (0° C.) solution of 53 mg (0.055 mmol) of 40-O-hydroxyethyl-rapamycin in 2 mL of methylene chloride is added 0.2 mL of pyridine followed by 0.02 mL (0.281 mmol) of acetyl chloride. The mixture is stirred for 3 h and diluted with ethyl acetate, then washed with aq. sodium bicarbonate, cold 1N HCl and again with aq. sodium bicarbonate. The organic solution is dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (30:70 hexane-ethyl acetate) to afford the title compound as a white solid: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 2.08 (3H, s), 3.07 (1H, m), 3.78 (2H, dd), 4.20 (2H, dd); MS (FAB) m/z 1022 ([M+Na]⁺), 999 (M⁺), 982 ([M-(OH)]⁺), 968 ([M-(OCH₃)⁺], 950 ([M-(OCH₃+H₂+H₂O)]⁺), 932 ([M-(OCH₃+2H₂O)]⁺), 918 ([M-(2CH₃OH+OH)]⁺), 900 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	2
IL-6 dep. prol. (rel. IC50)	7.6
MLR (rel. IC50)	3.6

Example 15: 40-O-(2-Nicotinoyloxy)ethyl-rapamycin

The same procedure as described in the previous example using nicotinoyl chloride hydrochloride affords the title compound: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.65 (3H, s), 1.75 (3H, s), 3.07 (1H, m), 3.94 (2H, dd), 4.49 (2H, t), 7.39 (1H, dd), 8.31 (1H, ddd), 8.78 (1H, ddd), 9.24 (1H, dd); MS (FAB) m/z 1085 ([M+Na]⁺), 1063 ([M+H]⁺), 1045

([M-OH]⁺), 1031 ([M-(OCH₃)⁺], 1013 ([M-(OCH₃+H₂O)]⁺).

MBA (rel. IC50)	1.1
IL-6 dep. prol. (rel. IC50)	6.9
MLR (rel. IC50)	5

Example 16: 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin

a) 40-O-(2-Bromoacetoxy)ethyl-rapamycin

The same procedure as described in example 14 using bromoacetyl chloride affords 40-O-(2-bromoacetoxy)ethyl-rapamycin: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.67 (3H, s), 1.76 (3H, s), 3.03 (1H, m), 3.82 (2H, m), 3.87 (2H, s), 4.31 (2H, m); MS (FAB) m/z 1100, 1102 ([M+Na]⁺), 1077 (M⁺), 1061 ([M-H₂O]⁺), 1046, 1048 ([M-(OCH₃)⁺], 1028, 1030 ([M-(OCH₃+H₂O)]⁺), 1012 ([M-(OCH₃+2H₂O)]⁺), 996 ([M-(2CH₃OH+OH)]⁺), 980 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

b) 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin

To a stirred, cooled (-45° C.) solution of 54 mg (0.05 mmol) of 40-O-(2-bromoacetoxy)ethyl-rapamycin in 0.5 mL of DMF is added a solution of 0.022 mL (0.25 mmol) of morpholine in 0.2 mL of DMF and the resulting mixture is stirred at that temperature for 1 h, then treated with aq. sodium bicarbonate. This mixture is extracted three times with ethyl acetate. The organic solution is washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (95:5 ethyl acetate-methanol) yielding the title compound as an amorphous white solid: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.67 (3H, s), 1.76 (3H, s), 2.60 (3H, m), 3.07 (1H, m), 3.24 (2H, s), 3.78 (8H, m), 4.27 (2H, t); MS (FAB) m/z 1107 ([M+Na]⁺), 1085 ([M+H]⁺), 1067 ([M-OH]⁺), 1053 ([M-(OCH₃)⁺], 1035 ([M-(OCH₃+H₂O)]⁺).

MBA (rel. IC50)	1.3
IL-6 dep. prol. (rel. IC50)	4
MLR (rel. IC50)	3.5

Example 17: 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin

The same procedure as described in example 16, step b) using imidazole affords the title compound: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.67 (3H, s), 1.78 (3H, s), 3.06 (3H, m), 3.80 (2H, m), 4.32 (2H, m), 4.73 (2H, s), 6.97 (1H, dd), 7.09 (1H, dd), 7.52 (1H, dd); MS (FAB) m/z 1066 ([M+Na]⁺), 1048 ([M+OH]⁺), 1034 ([M-(OCH₃)⁺], 1016 ([M-(OCH₃+H₂O)]⁺).

MBA (rel. IC50)	1
IL-6 dep. prol. (rel. IC50)	7.6
MLR (rel. IC50)	3.4

Example 18: 40-O-[2-(N-Methyl-N'-piperazinyl)acetoxy]ethyl-rapamycin

The same procedure as described in example 16, step b) using N-methylpiperazine affords the title compound: ¹H NMR (CDCl₃) 80.72 (1H, dd), 1.67 (3H, s), 1.77 (3H, s), 2.78 (4H, s and m), 3.02 (4H, bs), 3.08 (1H, m), 3.32 (2H, s), 3.80 (2H, dd), 4.27 (2H, t); MS (FAB) m/z 1098 ([M+Na]⁺), 1066 ([M-(OCH₃)⁺].

MBA (rel. IC50)	2.6
IL-6 dep. prol. (rel. IC50)	10.3
MLR (rel. IC50)	5

Example 19: 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin

To a stirred, cooled (-20° C.) solution of 48 mg (0.05 mmol) of 40-O-hydroxyethyl-rapamycin and 0.023 mL (0.20 mmol) of 2,6-lutidine in 0.5 mL of methylene chloride is added 0.008 mL (0.05 mmol) of triflic anhydride. The mixture is stirred at this temperature for 2 h, then allowed to warm to room temperature and stirred for one more hour. The reaction is quenched with aq. sodium bicarbonate and the resulting mixture is extracted with three portions of ethyl acetate. The organic solution is washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (30:70 hexane-ethyl acetate) to afford the title compound as a white solid: ¹H NMR (CDCl₃) 81.66 (3H, s), 1.75 (3H, s), 3.14 (3H, s), 3.35 (3H, s), 3.76 (4H, s); MS (FAB) m/z 948 ([M+Na]⁺), 925 (M⁺), 908 ([M-OH]⁺), 894 ([M-(OCH₃)⁺], 876 ([M-(OCH₃+H₂O)]⁺), 858 ([M-(OCH₃+2H₂O)]⁺), 844 ([M-(2CH₃OH+OH)]⁺), 826 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	1.6
IL-6 dep. prol. (rel. IC50)	22.9
MLR (rel. IC50)	16

Example 20: (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin

a) (26R)-26-Dihydro-40-O-[2-(t-Butyldimethylsilyloxy)]ethyl-rapamycin

In 4.5 mL of 2:1 acetonitrile-acetic acid is dissolved 315 mg (1.2 mmol) of tetramethylammonium-triacetoxyborohydride. The resulting solution is stirred for 1 h at room temperature and cooled to -35° C., then 161 mg (0.15 mmol) of 40-O-[2-(t-butyldimethylsilyloxy)]ethyl-rapamycin is added. The resulting mixture is stirred at the same temperature overnight and is quenched by the addition of aq. sodium bicarbonate. The mixture is extracted with three portions of ethyl acetate. The organic solution is washed with aq. sodium bicarbonate, two portions of 30% aq. Rochelle's salt and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (40:60 hexane-ethyl acetate) to afford the title compound as a white solid: ¹H NMR (CDCl₃) 80.06 (6H, s), 0.73 (1H, dd), 0.90 (9H, s), 1.64 (3H, s), 1.67 (3H, s), 3.02 (1H, m), 3.15 (1H, m), 3.64 (3H, m), 3.71 (2H, dd), 3.91 (1H, s); MS (FAB) m/z 1096 ([M+Na]⁺), 1041 ([M-HOCH₃]⁺), 1024 ([M-(OCH₃+H₂O)]⁺), 1006 ([M-(OCH₃+2H₂O)]⁺), 974 ([M-(OCH₃+CH₃OH+2H₂O)]⁺).

MBA (rel. IC50)	3.9
IL-6 dep. prol. (rel. IC50)	53
MLR (rel. IC50)	18

Example 21: 28-O-Methyl-rapamycin

To a stirred solution of 103 mg (0.1 mmol) of 40-O-TBS-rapamycin (obtained by silylation of rapamycin with 1 eq. of TBS triflate in methylene chloride in the presence of 2 eq. of 2,6-lutidine at 0° C.) in 0.5 mL of methylene chloride is added 85.8 mg (0.40 mmol) of proton sponge followed by 44

mg (0.30 mmol) of trimethyloxonium tetrafluoroborate. The resulting brown heterogeneous mixture is stirred overnight, quenched with aq. sodium bicarbonate and extracted with ethyl acetate. The organic solution is washed with 1N HCl, aq. sodium bicarbonate and brine, then dried over anhydrous sodium sulfate, filtered and concentrated. The residue is purified by column chromatography on silica gel (60:40 hexane-ethyl acetate) to afford 40-O-t-butyldimethylsilyl-28-O-methyl-rapamycin. The latter compound is desilylated in the conditions described in example 10, step b) to afford, after PTLC (ethyl acetate), the title compound as a white solid: ¹H-NMR (CDCl₃) δ: 0.71 (1H, dd), 1.68 (6H, 2s), 2.95 (1H, m), 3.13 (3H, s), 3.14 (3H, s), 3.28 (3H, s), 3.41 (3H, s); MS (FAB) m/z 950 ([M+Na]⁺), 927 (M⁺), 909 ([M-H₂O]⁺), 896 ([M-OCH₃]⁺), 878 ([M-(OCH₃+H₂O)]⁺), 864 ([M-(OCH₃+CH₃OH)]⁺), 846 ([M-(2CH₃OH+OH)]⁺), 832 ([M-(OCH₃+2CH₃OH)]⁺), 814 ([M-(3CH₃OH+OH)]⁺).

MBA (rel. IC50)	1.58
IL-6 dep. prol. (rel. IC50)	1240
MLR (rel. IC50)	1300

Example 22: 40-O-(2-aminoethyl)-rapamycin

a) 40-O-(2-bromoethyl)-rapamycin

A solution of 914 mg rapamycin in 5 mL toluene containing 0.64 ml of 2,6-lutidine and 1.28 g of 2-bromoethyl triflate is heated at 65° C. for 18 h. The reaction mixture is then cooled to room temperature, poured on 20 ml of a saturated bicarbonate solution and extracted with 3x20 mL ethyl acetate. The organic phases are dried over sodium carbonate and the solvent removed at reduced pressure on the rotary evaporator. The residue is chromatographed on 100 g silica gel, eluting with hexane/ethyl acetate 3/2 to afford 40-O-(2-bromoethyl)-rapamycin as an amorphous solid: MS (FAB) m/z 1044 and 1042 (100%; M+Na); 972 and 970 (55%, M-(MeOH+H₂O)). H-NMR (CDCl₃) δ: 0.72 (1H, q, J=12 Hz); 3.13 (3H, s); 3.33 (3H, s); 3.45 (3H, s); 3.9 (4H, m); 4.78 (1H, s)

b) 40-O-(2-azidoethyl)-rapamycin

A solution of 2.4 g of 40-O-(2-bromoethyl)-rapamycin in 40 mL DMF is treated with 0.19 g sodium azide at room temperature. After 2 h, the mixture is poured on 100 mL of saturated sodium bicarbonate and extracted with 3x100 mL ethyl acetate. The organic phases are combined, dried over sodium sulfate and the solvent removed under reduced pressure. The crude product is purified by chromatography on silica gel eluting with hexane/ethyl to afford 40-O-(2-azidoethyl)-rapamycin: MS (FAB): 1005 (100%, M+Na); 951 (24%, M-MeOH); 933 (57%, M-(MeOH+H₂O))

c) 40-O-(2-aminoethyl)-rapamycin

To a solution of 230 mg 40-O-(azidoethyl)-rapamycin in 3 mL of THF/water 5/1 at room temperature are added 307 mg of triphenylphosphine. The reaction mixture becomes yellow. After 7 h, the reaction mixture is loaded on x g silica gel and chromatographed with ethyl acetate/methanol/acetic acid 50/50/0.5 to afford the title product in the form of its acetate: MS (FAB) m/z 979 (45%, M+Na); 957 (100% MH); 925 (63%, M-MeOH); 907 (25%, M-(MeOH+H₂O)) MBA (rel. IC50): 0.7

IL-6 dep. prol. (rel. IC50): 10

Example 23: 40-O-(2-acetaminoethyl)-rapamycin

To a solution of 101 mg of the acetate of 40-O-(2-aminoethyl)-rapamycin in 2 mL THF are added 0.02 mL pyridine and 0.07 mL acetyl chloride. The reaction mixture is kept at room temperature for 18 h and then poured on 7 mL saturated sodium bicarbonate. The aqueous phase is

extracted 3x with 5 mL ethyl acetate, the organic phases are combined and dried over sodium sulfate. The solvent is evaporated and the residue chromatographed on 10 g silica gel eluting first with ethyl acetate followed by ethyl acetate/methanol/acetic acid 50/50/0.5 to afford the title product: MS (FAB) m/z 1021 (20%, M+Na); 967 (28%, M-MeOH); 949 (100%, M-(MeOH+H₂O)) H-NMR (CDCl₃) δ: 0.71 (1H, q, J=12 Hz); 1.98 (3H, s); 3.13 (3H, s); 3.34 (3H, s); 3.44 (3H, s); 4.75 (1H, s)

MBA (rel. IC50): 1.1

IL-6 dep. prol. (rel. IC50): 2.3

Example 24: 40-O-(2-nicotinamidoethyl)-rapamycin

101 mg of 40-O-(2-aminoethyl)-rapamycin acetate are dissolved in 5 mL ethyl acetate and extracted 2x with saturated sodium bicarbonate. The organic phase is dried over sodium sulfate and the solvent evaporated. The residue is dissolved in 2 mL THF and treated with 22 mg DCC and 15 mg nicotinic acid. After 15 h at room temperature the reaction mixture is evaporated and the residue chromatographed on silica gel, eluting with ethyl acetate followed by ethyl acetate/methanol 9/1, to afford the title product: MS (FAB) m/z 1084 (80%, M+Na); 1062 (40%, MH); 1038 (100%, M-MeOH); 1012 (50%, M-(MeOH+H₂O)) H-NMR (CDCl₃) δ: 0.72 (1H, q, J=12 Hz); 3.13 (3H, s); 3.33 (3H, s); 3.37 (3H, s); 7.39 (1H, dd); J=6 Hz, J=8 Hz), 8.19 (1H, d, J=8 Hz); 8.75 (1H, d, J=6 Hz); 9.04 (1H, broad s)

MBA (rel. IC50): 1.2

IL-6 dep. prol. (rel. IC50): 2.8

Example 25: 40-O-(2-(N-Methyl-imidazo-2'-ylcarboxamido)ethyl)-rapamycin

To a solution of 30 mg N-methyl-imidazol-2-carboxylic acid in 1 mL DMF are added 58 mg DCC and 58 mg HOBT. After 2 h, 150 mg 40-O-(2-aminoethyl)-rapamycin are added and the reaction mixture is stirred for 18 h at room temperature. The suspension is then filtered, the filtrate diluted with 5 mL ethyl acetate and washed with 2x2 mL of a saturated aqueous bicarbonate solution. The organic phase is dried over sodium sulfate and the solvent evaporated under reduced pressure. The residue is chromatographed over 10 silica gel, eluting with hexane/ethyl acetate ¼ and then ethyl acetate to afford the title product: MS (FAB) m/z 1087 (36%, M+Na); 1065 (57%, MH); 1033 (100%, M-MeOH); 1015 (46%, M-(MeOH+H₂O)) H-NMR (CDCl₃) δ: 0.72 (1H, q, J=12 Hz); 3.13 (3H, s); 3.33 (3H, s); 3.46 (3H, s); 4.03 (3H, s); 6.93 (1H, broad s); 6.98 (1H, broad s); 7.78 (1H, m);

MBA (rel. IC50): 1.1

IL-6 dep. prol. (rel. IC50): 7

Example 26: 40-O-(2-ethoxycarbonylaminoethyl)-rapamycin

A solution of 200 mg 40-O-(2-azidoethyl)-rapamycin in 3 mL THF/water 5/1 is treated with 267 mg triphenylphosphine for 7 h at room temperature. Then 0.4 mL pyridine are added followed by 194 µL ethyl chloroformate. After 2 h, the reaction mixture is poured on 5 mL ethyl acetate and washed successively with 10 mL saturated sodium bicarbonate, 5 mL water and 5 mL 10% citric acid. The organic phase is dried over sodium sulfate and the solvent evaporated. The residue is chromatographed over 20 g silica gel, eluting with ethyl acetate followed by ethyl acetate/methanol 9/1, to afford the title product: MS (FAB) m/z 1051 (35%, M+Na); 997 (30%, M-MeOH); 979 (100%, M-(MeOH+H₂O))

H-NMR (CDCl₃) δ: 0.71 (1H, q, J=12 Hz); 1.24 (3H, t, J=8 Hz); 3.13 (3H, s); 3.34 (3H, s); 3.43 (3H, s); 4.10 (2H, q, J=8 Hz); (1H, m)

MBA (rel. IC₅₀): 1.1

IL-6 dep. prol. (rel. IC₅₀): 1.7

Example 27: 40-O-(2-tolylsulfonamidoethyl)-rapamycin

A solution of 200 mg 40-O-(2-aminoethyl)-rapamycin in 3 mL THF is treated with 0.4 mL pyridine and 390 mg tosyl chloride and the reaction mixture is stirred for 12 h at room temperature. The solution is then poured onto 5 ml of a saturated bicarbonate solution and the aqueous phase is extracted with 2x5 mL ethyl acetate. The combined organic phases are washed with 5 mL of 10% citric acid and 5 mL water. After drying on sodium sulfate the solvent is evaporated and the residue chromatographed on 20 g silica gel, eluting with hexane/ethyl acetate 1/1 to afford the title product as a white foam: MS (FAB) m/z 1133 (100%, M+Na); 1078 (25%, M-MeOH); 1061 (85%, M-(MeOH+H₂O))

H-NMR (CDCl₃) d: 0.68 (1H, q, J=12 Hz); 2.43 (3H, s); 3.13 (3H, s); 3.35 (3H, s); 3.41 (3H, s); 4.76 (1H, s); 5.85 (1H, t, J=6 Hz); 7.30 (2H, d, J=8 Hz); 7.75 (2H, d, J=8 Hz).

MBA (rel. IC₅₀): 15.9

IL-6 dep. prol. (rel. IC₅₀): 14

Example 28: 40-O-[2-(4',5'-dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin

98 mg of 40-O-(2-azidoethyl)-rapamycin and 32 mg diethylacetylene dicarboxylate are suspended in 0.5 ml toluene and heated at 65° C. for 5 h. The reaction mixture is then cooled at room temperature, loaded on 10 g silica gel and eluted with hexane/ethyl acetate 1/1 to afford the title product: MS (FAB) m/z 1175 (20%, M+Na); 1121 (15%, M-MeOH); 1103 (60%, M-(MeOH+H₂O))

H-NMR (CDCl₃) d: 0.62 (1H, q, J=12 Hz); 1.40 (3H, t, J=8 Hz); 1.42 (3H, t, J=8 Hz); 3.13 (3H, s); 3.25 (3H, s); 3.33 (3H, s)

MBA (rel. IC₅₀): 2.7

IL-6 dep. prol. (rel. IC₅₀): 12

The previous examples may also be made using as starting material instead of rapamycin, 9-deoxo-rapamycin, 26-dihydro rapamycin, or 9-deoxo-, 26-dihydro-rapamycin. Alternatively, and preferably, as described e.g., in example 20, the rapamycin compounds of the above examples may be hydrogenated or reduced, using suitable protecting groups where necessary. The following novel methods for reducing the keto at C9, or hydrogenating the keto at C26 are provided:

Example 29: Removal of keto at C9

A stream of hydrogen sulfide is passed at room temperature through a stirred solution of 3.2 g (3.5 mmol) of rapamycin in 50 ml pyridine and 2.5 ml DMF. The solution turns from colorless to yellow. After two hours, the introduction of hydrogen sulfide is stopped and stirring is continued for five days, during which time the solution turns gradually orange. TLC and HPLC analysis verifies complete consumption of the starting material and the presence of a single new compound. The solution is purged with nitrogen for one hour and concentrated under reduced pressure. The residue is taken up in ethyl acetate, washed with cold 1N HCl solution (3x), saturated sodium bicarbonate solution and saturated brine. The organic layer is dried over anhydrous sodium sulfate and filtered and concentrated under reduced pressure. The residue is taken up in ether and precipitated sulfur is filtered off. Concentration of the ethereal solution followed by column chromatography on silica gel (10:4:1 CH₂Cl₂/i-Pr₂O/MeOH) yields 9-deoxorapamycin as a colorless foam. The identity of the product is confirmed by nuclear magnetic resonance spectroscopy (NMR), mass spectrometry (MS), and/or infrared spectroscopy (IR). 9-deoxorapamycin is found to exhibit the

following characteristic physical data: ¹H NMR (CDCl₃) δ1.61 (3H,d,J=1 Hz, C17-CH₃), 1.76 (3H,d,J=1.2 Hz, C29-CH₃), 2.42 (1H,d,J=14.5 Hz, H-9), 2.74 (1H,d,J=14.5 Hz, H-9), 3.13 (3H,s,C16-OCH₃), 3.5 (3H,s,C27-OCH₃), 3.40 (3H,s,C39-OCH₃), 5.40 (1H,d,J=10 Hz, H-30), 5.57 (1H, dd,J=8.6 Hz, J₂=15 Hz, H-22), 5.96 (1H,d,J=9 Hz, H-18), 6.09 (1H,d,J=1.7 Hz, 10-OH), 6.15 (1H,dd,J₁=10 Hz, J₂=15 Hz, H-21), 6.37 (1H,dd,J₁=1.5 Hz, J₂=5 Hz, H-19), 6.38 (1H,J=9.5 Hz, H-20). ¹³C NMR (CDCl₃) 838.5 (C-9), 98.0 (C-10), 170.7 (C-1), 173.0 (C-8), 208.8 (C-32), 216.9 (C-26).

MS(FAB) m/z 922 8[M+Na⁺], 899 (M⁺), 881 ([M-H₂O]⁺), 868 ([M-OCH₃]⁺), 850 ([M-(H₂O+OCH₃)]⁺).

IR (major peaks)(cm⁻¹) 987, 1086, 1193, 1453, 1616, 1717, 1739, 3443.

MBA (rel. IC₅₀): 1

MLR (rel. IC₅₀): 14

IL-6 dep. prol. (rel. IC₅₀): 9

Example 30: Dihydrogenation of keto at C26

To a stirred solution of 421 mg (1.6 mmol) of tetramethylammonium triacetoxyborohydride in 2 ml of acetonitrile is added 2 ml of acetic acid. The resulting mixture is stirred for 30 minutes at room temperature and cooled to -35° C. At this temperature a solution of 180 mg (0.2 mmol) of 9-deoxo-rapamycin in 1 ml of acetonitrile is added and the resulting mixture is allowed to stir for 24 hours. The mixture is quenched with a saturated solution potassium tartrate solution and allowed to warm to room temperature. Stirring is continued until both layers are clear and ethyl acetate is added. The layers are separated and the aqueous layer is extracted twice with ethyl acetate. The resulting organic solution is washed once with a 10% sodium bicarbonate solution and twice with saturated brine, then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue is purified by column chromatography on silica gel (90:10 AcOEt-hexane). As the starting material in this case was 9-deoxorapamycin, the final compound is 9-deoxorapamycin, 26-dihydro-rapamycin is produced as a colorless foam, having the following characteristic spectroscopic data: ¹H NMR (CDCl₃) (major isomer) E0.9 (3H,d,J=6.9 Hz, CHCH₃), 0.93 (3H,d,J=6.9 Hz, CHCH₃), 1.00 (3H,d,J=6.9 Hz, CHCH₃), 1.07 (3H,d,J=6.9 Hz, CHCH₃), 1.17 (3H,d,J=6.9 Hz, CHCH₃), 1.61 (3H,d,J=1 Hz, C17-CH₃), 1.73 (3H,d,J=1.2 Hz, C29-CH₃), 2.43 (1H,dd,J=4.1 and 16.0 Hz, H-33), 2.46 (1H,dd,J=13.8 Hz, H-9), 2.58 (1H,m,H-25), 2.77 (1H,dd,J=13.8 Hz, H-9), 2.82 (1H,dd,J=8.3 and 16.0 Hz, H-33), 3.17 (1H,dd,J=4.1 and 9.2 Hz, H-27), 3.61 (2H,m, H-14 and H28), 5.19 (1H,ddd,J=4.1, 4.6 and 8.3 Hz, H-34), 5.49 (1H, broad d,J=5.0 Hz, H-2), 5.56 (1H,d,J=9.1 Hz, H-30), 5.75 (1H,dd, J=6.9 and 14.7 Hz, H-22), 5.76 (1H,s,10-OH), 5.99 (1H, broad d,J=9.2 Hz, H-18), 6.10 (1H,m,H-21), 6.36 (2H,m,H-19 and H-20);

MS (FAB) m/z 924 (M+Na), 852 ([M-(H₂O+CH₃O)]⁺).

MBA (rel. IC₅₀): 47

MLR (rel. IC₅₀): 134

IL-6 dep. prol. (rel. IC₅₀): 78

26-dihydro-rapamycin is prepared in the same manner, using rapamycin in place of 9-deoxorapamycin. This product has the following characteristic spectroscopic data: ¹³C-NMR (CDCl₃) (major isomer) δ=208.3 (C-32); 194.0 (C-9); 169.3 (C-1); 166.6 (C-8); 140.9 (C-22); 136.5 (C-29); 136.2 (C-17); 133.5 (C-20); 129.1 (C-21); 128.7 (C-18); 126.2 (C-30); 125.3 (C-19); 98.6 (C-10); 84.4 (C-39); 83.9 (C-16); 81.6 (C-27); 75.4 (C-34); 74.3 (C-28); 73.9 (C-40); 72.9 (C-26); 67.4 (C-14); 59.1 (27-OCH₃); 56.6 (39-OCH₃); 55.9 (16-OCH₃); 51.3 (C-2); 46.8 (C-31); 44.3 (C-6); 40.4

21

(C-33); 40.4 (C-25); 39.5 (C-24); 38.8 (C-15); 38.0 (C-36);
34.3 (C-23); 34.2 (C-38); 33.5 (C-11); 33.3 (C-37); 33.2
(C-35); 31.5 (C-42); 31.3 (C-41); 30.9 (C-13); 27.1 (C-12);
27.0 (C-3); 25.2 (C-5); 21.4 (23-CH₃); 20.7 (C-4); 17.3 (11-
CH₃); 16.1 (31-CH₃); 15.9 (35-CH₃); 14.4 (25-CH₃); 14.2
(29-CH₃); 10.3 (17-CH₃).

MS (FAB) m/z: 884 (M-OCH₃, 35%); 866 (M-[OCH₃+
H₂O], 100%); 848 (M-[OCH₃+2 H₂O], 40%).


MBA (rel. IC₅₀): 1.7

MLR (rel. IC₅₀): 1

IL-6 dep. prol. (rel. IC₅₀): 7.5

We claim:

1. A compound of the formula



22

wherein R¹ is hydroxy(C₁₋₆)alkyl or
hydroxy(C₁₋₃)alkoxy(C₁₋₃)alkyl.

2. A compound according to claim 1 in which R¹ is
hydroxy(C₁₋₃)alkyl or hydroxy(C₁₋₃)alkoxy(C₁₋₃)alkyl.

3. A compound according to claim 1 in which R¹ is
hydroxy(C₁₋₃)alkyl.

4. A compound according to claim 1 in which R¹ is
hydroxy(C₁₋₃)alkoxy(C₁₋₃)alkyl.

5. The compound according to claim 1 which is 40-O-
(3-hydroxypropyl)-rapamycin.

6. The compound according to claim 1 which is 40-O-
[2-(2-hydroxyethoxy)ethyl]-rapamycin.

7. A pharmaceutical composition comprising a therapeu-
tically effective amount of a compound according to claim
1 and a pharmaceutically acceptable carrier therefor.

8. A method of inducing an immunosuppressant effect in
a subject in need of immunosuppression, which comprises
administering to said subject an immunosuppressant effective
amount of a compound according to claim 1.

9. A method of preventing allograft rejection in a subject
in need of such treatment, which comprises administering to
said subject a compound according to claim 1 in an amount
effective to prevent allograft rejection.

10. The compound according to claim 1 which is 40-O-
(3-hydroxyethyl)-rapamycin.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,665,772
DATED : September 9, 1997
INVENTOR(S) : Sylvain Cottens and Richard Sedrani

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 10, lines 1-2, delete "40-0-(3-hydroxyethyl)-rapamycin" and replace it with — 40-0-(2-hydroxyethyl)-rapamycin —.

Signed and Sealed this
Thirtieth Day of June, 1998

Attest:



Attesting Officer

BRUCE LEHMAN

Commissioner of Patents and Trademarks




UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

000000

M123K

ROBERT S HONOR
SANDOZ CORPORATION
59 ROUTE 10
EAST HANOVER NJ 07936-1080



MAINTENANCE FEE STATEMENT

The data shown below is from the records of the Patent and Trademark Office. If the maintenance fees and any necessary surcharges have been timely paid for the patents listed below, the notation "PAID" will appear in column 11, "STAT" below.

If a maintenance fee payment is defective, the reason is indicated by code in column 11, "STAT" below. **TIMELY CORRECTION IS REQUIRED IN ORDER TO AVOID EXPIRATION OF THE PATENT. NOTE 37 CFR 1.377. THE PAYMENT(S) WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION. IF PAYMENT OR CORRECTION IS SUBMITTED DURING THE GRACE PERIOD, A SURCHARGE IS ALSO REQUIRED. NOTE 37 CFR 1.20(h).**

If the statement of small entity status is defective the reason is indicated below in column 10 for the related patent number. **THE STATEMENT OF SMALL ENTITY STATUS WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION.**

ITEM NBR	PATENT NUMBER	FEE CDE	FEE AMT	SUR CHARGE	SERIAL NUMBER	PATENT DATE	FILE DATE	PAY YR	SML ENT	STAT
1	5,665,772	183	850	----	08/416,673	09/09/97	04/07/95	04	NO	PAID

4/100-7932/PCT

DEF

ITM NBR	ATTY DKT NUMBER
1	100-7932/PCT

**DIRECT THE RESPONSE TOGETHER WITH ANY QUESTIONS ABOUT THIS NOTICE TO:
COMMISSIONER OF PATENTS AND TRADEMARKS, BOX M. FEE, WASHINGTON, D.C. 20231**



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D. C. 20231

Customer Num: 1095

NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER NJ 07936-1080

MAINTENANCE FEE STATEMENT

The data shown below is from the records of the Patent and Trademark Office. If the maintenance fees and any necessary surcharges have been timely paid for the patents listed below, the notation "PAID" will appear in column 10, "STAT", below.

If a maintenance fee payment is defective, the reason is indicated by code in column 10, "STAT" below. **TIMELY CORRECTION IS REQUIRED IN ORDER TO AVOID EXPIRATION OF THE PATENT. NOTE 37 CFR 1.377. THE PAYMENT(S) WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION. IF PAYMENT OR CORRECTION IS SUBMITTED DURING THE GRACE PERIOD, A SURCHARGE IS ALSO REQUIRED. NOTE 37 CFR 1.20(k) and (l).**

If the statement of small entity status is defective the reason is indicated below in column 10 for the related patent number. **THE STATEMENT OF SMALL ENTITY STATUS WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION.**

PATENT NUMBER	FEE CODE	FEE AMT	SUR CHARGE	APPLICATION NUMBER	PATENT DATE	FILE DATE	PAY YR	SML ENT	STAT	ATTY DKT NUM
5,665,772	1552	\$2,300.00	\$0.00	08/416,673	09/09/97	04/07/95	08	NO	PAID	100-7932/PCT


**DIRECT YOUR RESPONSE TOGETHER WITH ANY QUESTIONS ABOUT THIS NOTICE TO:
Mail Stop: M. Correspondence, Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450**

Appendix G

Case No. 100-7932/PCT
Application/Serial No. 02/416,673
Mailing Date: March 30, 1998
Due Date: _____

The Patent & Trademark Office acknowledges, and has stamped hereon the date of receipt of the items checked below:

- Amendment - Fee \$ _____ *Amendment Under 37 CFR 1.312 (3-14-98)*
- Appeal Brief - Fee \$ _____
- Application Filing Papers - Fee \$ _____
 - PCT national stage
 - Provisional Application
- Assignment Recordation - Fee \$ _____
- Associate Power of Attorney
- Claim of Priority
 - Certified Copy(ies)
- Declaration and Power of Attorney
- Declaration Rule 131 Rule _____
- Foreign Filing license request
- Formal Drawings
- Information Disclosure Statement - Fee \$ _____
- Issue Fee Transmittal - Fee \$ _____
- Letter/Response
- Notice of Appeal - Fee \$ 1998
- Petition for _____ - Fee \$ _____
- Petition for extension of time - Fee \$ _____
- Reply Brief
- Request for Oral Hearing - Fee \$ _____
- Request for Certification of Correction - Fee \$ 100.00
-



DEF 83049/97

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Phyllis Kelly
Type or print name

Phyllis Kelly
Signature

March 30, 1998
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

COTTENS ET AL.

U. S. Patent No. 5,665,772

Certificate of Correction Branch

APPLICATION NO: 08/416,673

FILED: APRIL 7, 1995

FOR: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE,
PARTICULARLY AS IMMUNOSUPPRESSANTS

Assistant Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR CERTIFICATE OF CORRECTION

Sir:

An error has been noted in the above-identified United States Patent, and a Certificate of Correction is hereby requested.

In particular, the error resides in claim 10 of the issued patent. This claim was presented as new claim "20" of applicants' "Amendment Under 37 CFR 1.312" mailed March 14, 1997 (copy appended). At page 3 of said Amendment, applicants indicated that said claim 20 was intended to replace claim 4 of the application as filed, which applicants indicated may have been erroneously cancelled by the Office during prosecution.

However, through applicants' inadvertent error, said claim 20 was incorrectly drawn to the compound "40-0-(3-hydroxyethyl)-rapamycin," rather than reciting the compound of claim 4 of the application as filed.


U. S. Patent No. 5,665,772
Atty Docket No. 100-7932/PCT
Request for Certificate of Correction

Accordingly, a Certificate of Correction is enclosed correcting the error in claim 10, lines 1-2 of the subject U.S. Patent No. 5,665,772 by deleting "40-O-(3-hydroxyethyl)-rapamycin" and replacing it with "40-O-(2-hydroxyethyl)-rapamycin". Applicants respectfully request issuance of said Certificate.

If the Office should deem the present request to be made pursuant to 37 CFR §1.323 ("Certificate of Correction of Applicant's Mistake"), and not 37 CFR §1.322(a) ("Certificate of Correction of Office Mistake"), then the Office is authorized to charge the fee of \$100 set forth in 37 CFR § 1.20(a) and any other fees necessitated by this paper, to Patentee's Deposit Account No. 19-0134. This page is enclosed in duplicate for fee purposes.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6924



Diane E. Furman
Attorney for Applicants
Reg. No. 31,104

DEF:mjl
Date: March 30, 1998

Enclosures: "Amendment Under 37 CFR 1.312" (March 14, 1997)
Certificate of Correction (in duplicate)
This page in duplicate
Postcard

Case No. 100-7932/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Sylvain Cottens, et al. : Art Unit: 1202
Serial No. 08/416,673 : Examiner: R. Bond
Filed: April 7, 1995 : Batch No.: H50
For: O-ALKYLATED RAPAMYCIN :
DERIVATIVES AND THEIR :
USE, PARTICULARLY AS :
IMMUNOSUPPRESSANTS :

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, on March 14, 1997

(Date of Deposit)

Thomas O. McGovern

Name of applicant, agent, or
Registered representative

Thomas O. McGovern

Signature

March 14, 1997

Date of Signature

AMENDMENT UNDER 37 CFR 1.312

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Under the provision of 37 CFR 1.312, please amend the above identified application as follows:

IN THE CLAIMS

Please cancel claim 4, 9, and 10.


In line 1 of claims 11 to 15, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

In line 1 of claims 11, 12, and 13, after the word "which", delete the term "R₁", and insert in its place in each instance the term -- R¹ --.

Claim 16, line 2; claim 17, line 4; and claim 18, line 3, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

Please add the following new claims 19 and 20.

19. A compound of the formula



wherein R^1 is hydroxy(C_{1-6})alkyl or hydroxy(C_{1-3})alkoxy(C_{1-3})alkyl.

20. The compound according to claim 19 which is 40-O-(3-hydroxyethyl)-rapamycin.

REMARKS

Claims 9 to 18 have been allowed and claims 11 to 20 are now in the application. No additional fee is required.

The instant application was allowed on December 16, 1996; and the issue fee is being submitted concurrently with this amendment.

It is respectfully requested that the above amendments of the claims be entered. The entering of these amendments will not require a new search nor will it require substantial additional work on the part of the Patent and Trademark Office. This Amendment is believed to be proper under the provisions of Rule 312, because it corrects minors errors in the structures and definitions of the claims. Claim 10 has been replaced with new claim 19 to remove the space in the double bond between carbons 17 and 18 in claim 10 and conform the bond to that of the generic compound of formula I on page 2 of the application. Substituent R¹ has been amended in claims 11 to 13 and in new claim 19 to properly identify it. The definition of substituent R¹ has also been amended to limit the alkylene groups of the hydroxyalkoxyalkyl moiety to the preferred C₁₋₃ alkylene set out on page 3, line 10 of the application. Applicant have added new claim 20 to the application to replace claim 4, which may have been inadvertently deleted from the application instead of claim 9, which was canceled by the Amendment of October 15, 1996.

The proposed amendment do not broaden the scope of the claims or introduce new matter. They were not presented earlier because it was only during a review of the allowed application that it was noted that the amendments were needed. It is therefore respectfully requested that the proposed amendment be entered under the provisions of 35 CFR 1.312.

Respectfully submitted,

By Thomas O. McGovern
Thomas O. McGovern
Registration No. 25,741
(201) 503-8480

TOM:lmc

NOVARTIS CORPORATION
59 Route 10
E. Hanover, N.J. 07936

March , 1997

Enclosures: COM Stamp; Postcard

Case No. 100-7932/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Sylvain Cottens, et al. : Art Unit: 1202
Serial No. 08/416,673 : Examiner: R. Bond
Filed: April 7, 1995 : Batch No.: H50
For: O-ALKYLATED RAPAMYCIN :
DERIVATIVES AND THEIR :
USE, PARTICULARLY AS :
IMMUNOSUPPRESSANTS :

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, on March 14, 1997

(Date of Deposit)

Thomas Q. McGovern

Name of applicant, attorney, or
Registered representative

Thomas Q. McGovern

Signature

March 14, 1997

Date of Signature

AMENDMENT UNDER 37 CFR 1.312

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Under the provision of 37 CFR 1.312, please amend the above identified application as follows:

IN THE CLAIMS

Please cancel claim 4, 9, and 10.


In line 1 of claims 11 to 15, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

In line 1 of claims 11, 12, and 13, after the word "which", delete the term "R₁", and insert in its place in each instance the term -- R¹ --.

Claim 16, line 2; claim 17, line 4; and claim 18, line 3, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

Please add the following new claims 19 and 20.

19. A compound of the formula



wherein R^1 is hydroxy(C_{1-6})alkyl or hydroxy(C_{1-3})alkoxy(C_{1-3})alkyl.

20. The compound according to claim 19 which is 40-O-(3-hydroxyethyl)-rapamycin.

REMARKS

Claims 9 to 18 have been allowed and claims 11 to 20 are now in the application. No additional fee is required.

The instant application was allowed on December 16, 1996; and the issue fee is being submitted concurrently with this amendment.

It is respectfully requested that the above amendments of the claims be entered. The entering of these amendments will not require a new search nor will it require substantial additional work on the part of the Patent and Trademark Office. This Amendment is believed to be proper under the provisions of Rule 312, because it corrects minors errors in the structures and definitions of the claims. Claim 10 has been replaced with new claim 19 to remove the space in the double bond between carbons 17 and 18 in claim 10 and conform the bond to that of the generic compound of formula I on page 2 of the application. Substituent R¹ has been amended in claims 11 to 13 and in new claim 19 to properly identify it. The definition of substituent R¹ has also been amended to limit the alkylene groups of the hydroxyalkoxyalkyl moiety to the preferred C₁₋₃ alkylene set out on page 3, line 10 of the application. Applicant have added new claim 20 to the application to replace claim 4, which may have been inadvertently deleted from the application instead of claim 9, which was canceled by the Amendment of October 15, 1996.

The proposed amendment do not broaden the scope of the claims or introduce new matter. They were not presented earlier because it was only during a review of the allowed application that it was noted that the amendments were needed. It is therefore respectfully requested that the proposed amendment be entered under the provisions of 35 CFR 1.312.

Respectfully submitted,

By Thomas O. McGovern
Thomas O. McGovern
Registration No. 25,741
(201) 503-8480

TOM:lmc

NOVARTIS CORPORATION
59 Route 10
E. Hanover, N.J. 07936

March , 1997

Enclosures: COM Stamp; Postcard

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,665,772

DATED : September 9, 1997

INVENTOR(S) : Sylvain Cottens and Richard Sedrani

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 10, lines 1-2, delete "40-0-(3-hydroxyethyl)-rapamycin" and replace it with — 40-0-(2-hydroxyethyl)-rapamycin —.

Signed and Sealed this
Thirtieth Day of June, 1998

Attest:



BRUCE LEHMAN

Commissioner of Patents and Trademarks

Attesting Officer

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07836-1080

Tel 973 781 8300



December 18, 2002

Richard Pazdur, MD
Director
Division of Oncology Drug Products/HFD-150
Food and Drug Administration
Woodmont FDA Oncology Drug Group
Attn: Division Document Control Room #3067
1451 Rockville Pike
Rockville, Maryland 20852-1448

IND No. 66,279

RAD001 (Oncology)

- Response to FDA Request for Information

Serial No. 002

Dear Dr. Pazdur:

Reference is made to our Investigational New Drug Application (IND) for RAD001 (also RAD001C, SDZ RAD, SDZ RAD 666, SDZ 222-666, evirolimus) submitted to the division on November 22, 2002 and to a telephone call from Dr. Haripada Sarker on December 18, 2002. Dr. Sarker requested that Novartis provide the following statement of clarification to allow cross referencing of IND 52,003 for this compound originally filed by Sandoz Pharmaceuticals Corporation (now Novartis Pharmaceuticals Corporation) within the FDA Division of Special Pathogens and Immunologic Drug Products (HFD-590):

As of January 1, 1997, the former Ciba Pharmaceuticals Division and Sandoz Pharmaceuticals Corporation became Novartis Pharmaceutical Corporation.

If you have any questions or comments regarding this submission, please contact me at (862) 778-8165.

Sincerely,


A handwritten signature in black ink, appearing to read 'Kevin M. Carl'.

Kevin M. Carl, Pharm.D.
Drug Regulatory Affairs

KMC/da
Submitted in triplicate

Desk copies: Ann Staten and Haripada Sarker (HFD-150) via fax at 301/594-0498

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION INVESTIGATIONAL NEW DRUG APPLICATION (IND) (TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312)		Form Approved: OMB No. 0910-0014. Expiration Date: September 30, 2002 See OMB Statement on Reverse.												
1. NAME OF SPONSOR NOVARTIS PHARMACEUTICALS CORPORATION		2. DATE OF SUBMISSION December 18, 2002												
3. ADDRESS (Number, Street, City, State and Zip Code) One Health Plaza East Hanover, New Jersey 07936-1080		4. TELEPHONE NUMBER (Include Area Code) (862) 778-8185 Kevin M. Carl, PharmD, Post-Doctoral Fellow												
5. NAME(S) OF DRUG (Include all available names: Trade, Generic, Chemical, Code) RAD001		6. IND NUMBER (If previously assigned) 66,279												
7. INDICATION(S) (Covered by this submission) Solid Tumor Cancers														
8. PHASE(S) OF CLINICAL INVESTIGATION TO BE CONDUCTED: <input checked="" type="checkbox"/> PHASE 1 <input type="checkbox"/> PHASE 2 <input type="checkbox"/> PHASE 3 <input type="checkbox"/> OTHER (Specify)														
9. LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS (21 CFR Part 312), NEW DRUG OR ANTIBIOTIC APPLICATIONS (21 CFR Part 314), DRUG MASTER FILES (21 CFR Part 314.420), AND PRODUCT LICENSE APPLICATIONS (21 CFR Part 601) REFERRED TO IN THIS APPLICATION. IND 52,003 DIVISION OF SPECIAL PATHOGENS AND IMMUNOLOGIC DRUG PRODUCTS (HFD 590)														
10. IND submission should be consecutively numbered. The initial IND should be numbered "Serial number: 000." The next submission (e.g., amendment, report, or correspondence) should be numbered "Serial Number: 001." Subsequent submissions should be numbered consecutively in the order in which they are submitted.		SERIAL NUMBER 002												
11. THIS SUBMISSION CONTAINS THE FOLLOWING: (Check all that apply) <table style="width: 100%; border: none;"> <tr> <td colspan="2"><input type="checkbox"/> INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND)</td> <td><input type="checkbox"/> RESPONSE TO CLINICAL HOLD</td> </tr> <tr> <td> PROTOCOL AMENDMENT(S): <input type="checkbox"/> NEW PROTOCOL <input type="checkbox"/> CHANGE IN PROTOCOL <input type="checkbox"/> NEW INVESTIGATOR </td> <td> INFORMATION AMENDMENT(S): <input type="checkbox"/> CHEMISTRY/MICROBIOLOGY <input type="checkbox"/> PHARMACOLOGY/TOXICOLOGY <input type="checkbox"/> CLINICAL </td> <td> IND SAFETY REPORT(S): <input type="checkbox"/> INITIAL WRITTEN REPORT <input type="checkbox"/> FOLLOW-UP TO A WRITTEN REPORT </td> </tr> <tr> <td colspan="2"><input checked="" type="checkbox"/> RESPONSE TO FDA REQUEST FOR INFORMATION</td> <td><input type="checkbox"/> ANNUAL REPORT <input type="checkbox"/> GENERAL CORRESPONDENCE</td> </tr> <tr> <td colspan="2"><input type="checkbox"/> REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN, INACTIVED, TERMINATED OR DISCONTINUED</td> <td><input type="checkbox"/> OTHER _____ (Specify)</td> </tr> </table>			<input type="checkbox"/> INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND)		<input type="checkbox"/> RESPONSE TO CLINICAL HOLD	PROTOCOL AMENDMENT(S): <input type="checkbox"/> NEW PROTOCOL <input type="checkbox"/> CHANGE IN PROTOCOL <input type="checkbox"/> NEW INVESTIGATOR	INFORMATION AMENDMENT(S): <input type="checkbox"/> CHEMISTRY/MICROBIOLOGY <input type="checkbox"/> PHARMACOLOGY/TOXICOLOGY <input type="checkbox"/> CLINICAL	IND SAFETY REPORT(S): <input type="checkbox"/> INITIAL WRITTEN REPORT <input type="checkbox"/> FOLLOW-UP TO A WRITTEN REPORT	<input checked="" type="checkbox"/> RESPONSE TO FDA REQUEST FOR INFORMATION		<input type="checkbox"/> ANNUAL REPORT <input type="checkbox"/> GENERAL CORRESPONDENCE	<input type="checkbox"/> REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN, INACTIVED, TERMINATED OR DISCONTINUED		<input type="checkbox"/> OTHER _____ (Specify)
<input type="checkbox"/> INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND)		<input type="checkbox"/> RESPONSE TO CLINICAL HOLD												
PROTOCOL AMENDMENT(S): <input type="checkbox"/> NEW PROTOCOL <input type="checkbox"/> CHANGE IN PROTOCOL <input type="checkbox"/> NEW INVESTIGATOR	INFORMATION AMENDMENT(S): <input type="checkbox"/> CHEMISTRY/MICROBIOLOGY <input type="checkbox"/> PHARMACOLOGY/TOXICOLOGY <input type="checkbox"/> CLINICAL	IND SAFETY REPORT(S): <input type="checkbox"/> INITIAL WRITTEN REPORT <input type="checkbox"/> FOLLOW-UP TO A WRITTEN REPORT												
<input checked="" type="checkbox"/> RESPONSE TO FDA REQUEST FOR INFORMATION		<input type="checkbox"/> ANNUAL REPORT <input type="checkbox"/> GENERAL CORRESPONDENCE												
<input type="checkbox"/> REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN, INACTIVED, TERMINATED OR DISCONTINUED		<input type="checkbox"/> OTHER _____ (Specify)												
CHECK ONLY IF APPLICABLE														
JUSTIFICATION STATEMENT MUST BE SUBMITTED WITH APPLICATION FOR ANY CHECKED CATEGORY. REFER TO THE ONLINE SECTION FOR FURTHER INFORMATION.														
<input checked="" type="checkbox"/> TREATMENT IND (21 CFR 312.50) <input type="checkbox"/> TREATMENT PROTOCOL (21 CFR 312.51) <input type="checkbox"/> CHANGE OF REQUEST NOTIFICATION (21 CFR 312.52)														
FOR FDA USE ONLY														
CDR/DBIND/DGD RECEIPT STAMP	DDR RECEIPT STAMP	IND NUMBER ASSIGNED:												
		DIVISION ASSIGNMENT:												

12. CONTENTS OF APPLICATION This application contains the following items: <i>(Check all that apply)</i>		
<input type="checkbox"/> 1. Form FDA 1571 [21 CFR 312.23(a)(1)] <input type="checkbox"/> 2. Table of Contents [21 CFR 312.23(a)(2)] <input type="checkbox"/> 3. Introductory statement [21 CFR 312.23(a)(3)] <input type="checkbox"/> 4. General Investigational plan [21 CFR 312.23(a)(3)] <input type="checkbox"/> 5. Investigator's brochure [21 CFR 312.23(a)(5)] <input type="checkbox"/> 6. Protocol(s) [21 CFR 312.23(a)(6)] <ul style="list-style-type: none"> <input type="checkbox"/> a. Study protocol(s) [21 CFR 312.23(a)(6)] <input type="checkbox"/> b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572 <input type="checkbox"/> c. Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572 <input type="checkbox"/> d. Institutional Review Board data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572 <input type="checkbox"/> 7. Chemistry, manufacturing, and control data [21 CFR 312.23(a)(7)] <ul style="list-style-type: none"> <input type="checkbox"/> Environmental assessment or claim for exclusion [21 CFR 312.23(a)(7)(iv)(e)] <input type="checkbox"/> 8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)] <input type="checkbox"/> 9. Previous human experience [21 CFR 312.23(a)(9)] <input type="checkbox"/> 10. Additional information [21 CFR 312.23(a)(10)]		
13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO IF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION? <input type="checkbox"/> YES <input type="checkbox"/> NO IF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED.		
14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS Nicholas Shand, MD Senior Clinical Research Physician Clinical Research		
15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRUG Dionigi Maladorno, MD Medical Safety Expert Clinical Safety and Epidemiology		
<p>I agree not to begin clinical investigations until 30 days after FDA's receipt of the IND unless I receive earlier notification by FDA that the studies may begin. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set fourth in 21 CFR Part 56 will be responsible for initial and continuing review and approval of each of the studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.</p>		
16. NAME OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE Kevin M. Carl, PharmD, Post-Doctoral Fellow Drug Regulatory Affairs	17. SIGNATURE OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE 	
18. ADDRESS (Number, Street, City, State and Zip Code) One Health Plaza East Hanover, New Jersey 07936-1080	19. TELEPHONE NUMBER (Include Area Code) (862) 778-8165	20. DATE 12/18/2002
(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)		
Public reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:		
Food and Drug Administration CBER (HFM-99) 1401 Rockville Pike Rockville, MD 20852-1448	Food and Drug Administration CDER (HFD-94) 5516 Nicholson Lane Kensington, MD 20895	"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number"
Please DO NOT RETURN this application to this address.		

***** -COMM. JOURNAL- ***** DATE DEC-18-2002 ***** TIME 14:33 *****

MODE = MEMORY TRANSMISSION

START=DEC-18 14:31

END=DEC-18 14:33

FILE NO. =488

STN NO.	COMM.	ABBR NO.	STATION NAME/TEL NO.	PAGES	DURATION
001	OK		913015940498	002/002	00:01:05

-DRA ONCOLOGY BU -

***** -

- ***** -

973 781 5217- *****

Kevin Carl, PharmD
Drug Regulatory Affairs

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936

Tel (973) 781 8165
Fax (973) 781 5217

 **NOVARTIS**

Fax

Attention	Ann Staten Project Manager Division of Oncology Drug Products (HFD-150) Food and Drug Administration
Fax Number	(301) 594-0498
Number of pages	2 (Including coversheet)
Date	December 18, 2002
Concerning	URGENT: RAD001 IND No. 66,279 - FDA Request for Information

Dear Ann,

Dr. Sarker requested that Novartis provide the accompanying statement of clarification to allow cross referencing of IND 52,003 for this compound originally filed by Sandoz Pharmaceuticals Corporation (now Novartis Pharmaceuticals Corporation) within the FDA Division of Special Pathogens and Immunologic Drug Products (HFD-590).

Sincerely,
Kevin

RAD001 IND # 66,279 Dec 19, 2002

Archives
cc: Chron

Fax



DIVISION OF ONCOLOGY DRUG PRODUCTS
Center for Drug Evaluation and Research, HFD-150
Parklawn Building
5600 Fishers Lane, Rockville, MD 20857

To: Kevin Carl, Novartis	From: Ann Staten, Project Manager
Fax: 973-781-5217	Fax: 301-827-4590
Phone: 973-781-8165	Phone: 301-594-0490
Pages: 1	Date: December 19, 2002
Re: IND 66,279 RAD001	

Urgent For Review Please Comment Please Reply Please Recycle

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination or other action based on the content of the communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us at the above address by mail. Thank you.

Dear Mr. Carl,

Please refer to your Investigational New Drug Application (IND) submitted November 22, 2002 pursuant to section 505(l) of the Federal Food, Drug, and Cosmetic Act for RAD001.

We have completed the review of your IND and conclude it is reasonably safe to proceed with your proposed study based upon your December 19, 2002 agreement to correct the deficiency, which was forwarded to you by e-mail transmission on December 18, 2002.

Please let me know if you have any questions.

Sincerely,

Ann

APPENDIX J

SANDOZ PHARMACEUTICALS CORPORATION
59 ROUTE 10, EAST HANOVER, NEW JERSEY 07936-1080



DRUG REGISTRATION & REGULATORY AFFAIRS

TEL 201 503 7500
FAX 201 503 6325

November 15, 1996

Food and Drug Administration
Center for Drug Evaluation
and Research
Central Document Room
12229 Wilkins Avenue
Rockville Maryland 20857

INVESTIGATIONAL
NEW DRUG APPLICATION

Serial No. 000

Gentleman:

In accordance with 21 CFR §312.23, Sandoz Pharmaceuticals Corporation is submitting an Investigational New Drug Application (FDA Form 1571) and supporting documents for the following investigational compound:

SDZ RAD Capsules

Indication: Prophylaxis of organ rejection

Please note that we have included in IND Section X, Additional Information, a Point-By-Point Response to the FDA communication of October 11, 1996 which provided general comments and recommendations for product development. The Pre-IND Briefing Book for SDZ RAD was submitted to the FDA Division of Anti-Viral Drug Products/HFD-530 on August 26, 1996.

This IND and all subsequent amendments are confidential and their contents are not to be disclosed without the express written consent of Sandoz Pharmaceuticals Corporation.

If there are comments or question, please call me at (201) 503-7646.

Sincerely,

Ronald G. Van Valen
Associate Director
Drug Registration and Regulatory Affairs

Attachments: Volumes 1-14
submitted in quadruplicate
cc: S. Cobb/HFD-530 (letter only)

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION INVESTIGATIONAL NEW DRUG APPLICATION (IND) (TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312)		Form Approved: OMB No. 0910-0014. Expiration Date: November 30, 1995. See OMB Statement on Reverse.
		NOTE: No drug may be shipped or clinical investigation begun until an IND for that investigation is in effect (21 CFR 312.40).
1. NAME OF SPONSOR Sandoz Pharmaceuticals Corporation		2. DATE OF SUBMISSION November 15, 1996
3. ADDRESS (Number, Street, City, State and Zip Code) 59 Route 10 East Hanover, New Jersey 07936-1080		4. TELEPHONE NUMBER (Include Area Code) (201) 503-7646 Ronald G. Van Valen
5. NAME(S) OF DRUG (Include all available names: Trade, Generic, Chemical, Code) SDZ RAD		6. IND NUMBER (If previously assigned)
7. INDICATION(S) (Covered by this submission) Adjunct Immunosuppressant Organ Transplantation		
8. PHASE(S) OF CLINICAL INVESTIGATION TO BE CONDUCTED: <input type="checkbox"/> PHASE 1 <input checked="" type="checkbox"/> PHASE 2 <input type="checkbox"/> PHASE 3 <input type="checkbox"/> OTHER _____ (Specify)		
9. LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS (21 CFR Part 312), NEW DRUG OR ANTIBIOTIC APPLICATIONS (21 CFR Part 312), DRUG MASTER FILES (21 CFR Part 314.420), AND PRODUCT LICENSE APPLICATIONS (21 CFR Part 601) REFERRED TO IN THIS APPLICATION. <p style="text-align: center;">Type I DMF 5846 - Sandoz Pharma Ltd.</p>		
10. IND submission should be consecutively numbered. The initial IND should be numbered "Serial number: 000." The next submission (e.g., amendment, report, or correspondence) should be numbered "Serial Number: 001." Subsequent submissions should be numbered consecutively in the order in which they are submitted.		SERIAL NUMBER <p style="text-align: center;"><u>000</u></p>
11. THIS SUBMISSION CONTAINS THE FOLLOWING: (Check all that apply)		
<input checked="" type="checkbox"/> INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND) <input type="checkbox"/> RESPONSE TO CLINICAL HOLD		
PROTOCOL AMENDMENT(S): <input type="checkbox"/> NEW PROTOCOL <input type="checkbox"/> CHANGE IN PROTOCOL <input type="checkbox"/> NEW INVESTIGATOR	INFORMATION AMENDMENT(S): <input type="checkbox"/> CHEMISTRY/MICROBIOLOGY <input type="checkbox"/> PHARMACOLOGY/TOXICOLOGY <input type="checkbox"/> CLINICAL	IND SAFETY REPORT(S): <input type="checkbox"/> INITIAL WRITTEN REPORT <input type="checkbox"/> FOLLOW-UP TO A WRITTEN REPORT
<input type="checkbox"/> RESPONSE TO FDA REQUEST FOR INFORMATION <input type="checkbox"/> ANNUAL REPORT <input type="checkbox"/> GENERAL CORRESPONDENCE		
<input type="checkbox"/> REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN, INACTIVATED, TERMINATED OR DISCONTINUED <input type="checkbox"/> OTHER _____ (Specify)		
CHECK ONLY IF APPLICABLE		
JUSTIFICATION STATEMENT MUST BE SUBMITTED WITH APPLICATION FOR ANY CHECKED BELOW. REFER TO THE CITED CFR SECTION FOR FURTHER INFORMATION.		
<input type="checkbox"/> TREATMENT IND 21 CFR §12.35(b) <input type="checkbox"/> TREATMENT PROTOCOL 21 CFR §12.35(a) <input type="checkbox"/> CHARGE REQUEST/NOTIFICATION 21 CFR §12.7(d)		
FOR FDA USE ONLY		
CDR/DBIND/OGD RECEIPT STAMP	DDR RECEIPT STAMP	IND NUMBER ASSIGNED:
		DIVISION ASSIGNMENT:

STATEMENT OF CONFIDENTIALITY

SANDOZ PHARMACEUTICALS CORPORATION has expended substantial sums of money in developing the information and data contained in this original Investigational New Drug Application for SDZ RAD and considers such information and data to be its valuable commercial property.

Further, SANDOZ PHARMACEUTICALS CORPORATION considers the information contained in the following pages to be trade secrets, therefore, protected by 21 U.S.C. 331 (j).

SECTION II TABLE OF CONTENTS SDZ RAD		
	VOL	PAGE NO.
SECTION I - 1571 FORM		
A. DESCRIPTION OF CRO, IF ANY, TO WHOM OBLIGATIONS HAVE BEEN TRANSFERRED	N/A	N/A
SECTION II - TABLE OF CONTENTS		
	1	2-1
SECTION III - INTRODUCTORY STATEMENT		
Sectional Table of Contents	1	3-1
A. NAME OF DRUG, ACTIVE INGREDIENTS	1	3-2
B. PHARMACOLOGIC CLASS	1	3-3
C. STRUCTURAL FORMULA	1	3-4
D. FORMULATION OF DOSAGE FORMS	1	3-5
E. ROUTE OF ADMINISTRATION	1	3-6
F. BROAD CLINICAL OBJECTIVES AND DURATION OF CLINICAL INVESTIGATION	1	3-6
G. SUMMARY OF PREVIOUS HUMAN EXPERIENCE WITH THE DRUG	1	3-6
*H. WITHDRAWAL FROM INVESTIGATIONAL OR MARKETING USE IN ANY COUNTRY	N/A	N/A
SECTION IV - GENERAL INVESTIGATIONAL PLAN		
Sectional Table of Contents	1	4-1
A. RATIONALE FOR STUDIES	1	4-2
B. INDICATION(S) TO BE STUDIED	1	4-3
C. GENERAL APPROACH TO INVESTIGATION	1	4-3
D. KINDS OF TRIALS DURING FIRST YEAR (June 1996 - May 1997)	1	4-4
E. ESTIMATED NUMBER OF PATIENTS IN THE FIRST YEAR STUDIES	1	4-5
F. RISKS ANTICIPATED ON THE BASIS OF TOXICOLOGICAL DATA OR PRIOR USE IN HUMANS	1	4-5
SECTION V - INVESTIGATOR'S BROCHURE		
	1	5-1

*N/A = not applicable

**SECTION II
TABLE OF CONTENTS
SDZ RAD**

	VOL.	PAGE NO.
SECTION VI - PROTOCOL		
Sectional Table of Contents	1	6-1
A. Protocol for Study No. RADB 154	1	6-2
1. Case Report Forms	1	6-78
2. Investigator's Forms		
a. Barry D. Kahan, MD, PhD		
1. FDA Form 1572	1	6-132
2. Curricula Vitae	1	6-134
B. PROTOCOL FOR STUDY No. RADB 202	2	6-197
1. Case Report Forms	2	6-263
2. Investigators' Forms		
a. David Grant, MD		
1. FDA Form 1572	2	6-308
2. Curricula Vitae	2	6-310
b. Gary Levy, MD		
1. FDA Form 1572	2	6-324
2. Curricula Vitae	2	6-326
C. PROTOCOL FOR STUDY No. RADB 151	2	6-373
1. Case Report Forms	2	6-459
2. Investigators' Forms		
a. Harold Palevsky, MD		
1. FDA Form 1572	2	6-508
2. Curricula Vitae	2	6-510
b. Randall E. Morris, MD		
1. FDA Form 1572	2	6-531
2. Curricula Vitae	2	6-533

**SECTION II
TABLE OF CONTENTS
SDZ RAD**

	VOL	PAGE NO.
SECTION VII - CHEMISTRY, MANUFACTURING AND CONTROLS DATA		
Sectional Table of Contents	3	7-1
A. DRUG SUBSTANCE	3	7-2
1. Description of Drug Substance	3	7-4
2. Name and Address of Manufacturer	3	7-48
3. General Method of Preparation	3	7-49
4. Acceptable Limits and Analytical Methods	3	7-67
5. Stability Information	3	7-102
B. DRUG PRODUCT	3	7-106
1. Introduction	3	7-107
2. List of Components	3	7-109
3. Quantitative Composition	3	7-110
4. Name and Address of Manufacturer	3	7-114
5. Description of the Manufacturing and Packaging Processes	3	7-115
6. Acceptable Limits and Analytical Methods	3	7-133
7. Stability Information	3	7-215
C. PLACEBO	3	7-243
1. Quantitative Composition	3	7-244
2. Description of Manufacturing Process	3	7-248
3. Control	3	7-255
D. LABELS AND LABELING TO BE FORWARDED TO EACH INVESTIGATOR	3	7-260
1. Sample Labels for Study No. RADB 154	3	7-261
2. Sample Labels for Study No. RADB 202	3	7-266
3. Sample Labels for Study No. RADB 151	3	7-269
E. ENVIRONMENTAL IMPACT ANALYSIS STATEMENT	3	7-270

**SECTION II
TABLE OF CONTENTS
SDZ RAD**

	VOL	PAGE NO.
SECTION VIII - PHARMACOLOGY AND TOXICOLOGY DATA		
Sectional Table of Contents	4	8-1
A. REGULATORY OVERVIEW	4	8-5
B. DESCRIPTION OF DRUG SUBSTANCE AND FORMULATION	4	8-10
C. PRECLINICAL SUMMARY	4	8-12
1. PHARMACOLOGICAL EXPOSE	4	8-12
2. TOXICOLOGY SUMMARY	4	8-71
3. PHARMACOKINETICS AND BIOLOGICAL DISPOSITION SUMMARY	4	8-117
D. INDIVIDUAL STUDY REPORTS	4	8-133
1. Toxicology Reports	4	8-133
Acute Toxicity Studies	4	8-133
• <u>Doc No. 203-023</u> Acute Oral Toxicity Study in Mice	4	8-133
• <u>Doc No. 203-051</u> Acute Intravenous Toxicity Study in Mice	4	8-173
• <u>Doc No. 203-052</u> Amendment No.1 Acute Intravenous Toxicity Study in Mice	4	8-239
• <u>Doc No. 203-024</u> Acute Oral Toxicity Study in Rats	4	8-249
• <u>Doc No. 203-047</u> Acute Intravenous Toxicity Study in Rats	4	8-290
• <u>Doc No. 203-048</u> Amendment No.1 Acute Intravenous Toxicity Study in Rats	4	8-350
Multidose Toxicity Studies		
• <u>Doc No. 203-060</u> Dose Range Finding Study (Intravenous Infusion Administration) in Rats	5	8-361
• <u>Doc No. 203-038</u> A 2-Week Oral (Gavage) Dose-Range-Finder Study in Rats	6	8-596

**SECTION II
TABLE OF CONTENTS
SDZ RAD**

	VOL	PAGE NO.
SECTION VIII (cont'd)		
• <u>Doc No. 203-053</u> Comparative Intravenous Infusion Study in Rats	6	8-878
• <u>Doc No. 203-042</u> Toxicity Study by Oral Gavage Administration to HanIbm Wistar Rats for 4 Weeks followed by a 2 Week Reversible Period	7	8-981
• <u>Doc No. 203-050</u> A Repeat Toxicity Study by Oral Gavage Administration to HanIbm Wistar Rats for 4 Weeks followed by a 2 Week Reversibility Period	9	8-1607
• <u>Doc No. 203-055</u> Dose Escalating Study (Oral Administration) in Cynomolgus Monkeys	10	8-2117
• <u>Doc No. 203-059</u> 14-Day Dose Range Finding Study (Oral Route) in Cynomolgus Monkeys	10	8-2168
• <u>Doc No. 203-012</u> Dose Finding Study in Cynomolgus Monkeys by Intravenous Infusion for 2 Weeks	10	8-2285
• <u>Doc No. 203-021</u> 14-Day Dose Range Finding Study (Intravenous Infusion Administration) In Cynomolgus Monkeys	10	8-2319
• <u>Doc No. 203-054</u> Toxicity Study by Oral (Gavage) Administration to Cynomolgus Monkeys for 4 Weeks followed by a 2 Week Reversibility Period	10	8-2340
Reproduction Studies		
• <u>Doc No. 203-058</u> An Oral Fertility Dose-Range-Finding Study in Male Rats	11	8-2704
• <u>Doc No. 203-057</u> An Oral Reproduction Toxicity Dose-Range-Finding Study in Female Rats with Toxicokinetics and Placental Transfer	11	8-2933
• <u>Doc No. 203-056</u> An Oral Embryo-Fetal Development Dose-Range-Finding Study in Rabbits with Toxicokinetics and Placental Transfer	12	8-3090
Mutagenicity Studies		
• <u>Doc No. 203-016</u> Mutagenicity Test Using Salmonella Typhimurium	12	8-3226
• <u>Doc No. 203-040</u> Mutagenicity Test Using Salmonella Typhimurium (Batch Control)	12	8-3328

**SECTION II
TABLE OF CONTENTS
SDZ RAD**

	VOL.	PAGE NO.
SECTION VIII (cont'd)		
• <u>Doc No. 203-046</u> Mutation at the Thymidine Kinase (<i>tk</i>) Locus of Mouse Lymphoma L5178Y Cells using the Microtitre® Fluctuation Technique	12	8-3370
• <u>Doc No. 203-025</u> Chromosomal Aberration Test with V79 Chinese Hamster Cells	12	8-3446
• <u>Doc No. 203-041</u> Mouse Bone Marrow Micronucleus Test by the Oral Route	12	8-3497
Tolerance Study		
• <u>Doc No. 203-031</u> A Local Intravenous Tolerability Study in Rabbits	12	8-3538
2. Pharmacokinetic Reports		
• <u>Doc No. 303-013</u> Absorption, Distribution, Metabolism and Excretion in Rats after Single Intravenous (1mg/kg, 10mg/kg) and Oral (1.5mg/kg, 15mg/kg) Administration of [³ H]SDZ RAD 666	13	8-3581
• <u>Doc No. 303-049</u> Absorption, Disposition and Excretion in Cynomolgus Monkeys after Single Intravenous (1mg/kg.) and Oral (5mg/kg) Administration of [³ H]SDZ RAD 666	13	8-3619
• <u>Doc No. 303-039</u> Addendum Toxicokinetic Report: A Repeat Toxicity Study By Oral Gavage Administration To Hanlbm Wistar Rats For 4 Weeks Followed By A 2 Week Reversibility Period	13	8-3688
• <u>Doc No. 303-044</u> Blood Distribution and Plasma Protein Binding	13	8-3720
• <u>Doc No. 303-014</u> Dose-Dependent Brain Penetration in Rats: A Comparative Study with Rapamycin	13	8-3733
• <u>Doc No. 303-015</u> Liquid Chromatography-Reverse Isotope Dilution Method (LC-RID) for the Determination of [³ H]SDZ RAD 666 in Biological Media	13	8-3751
• <u>Doc No. 303-017</u> Development and Validation of an ELISA	13	8-3760
• <u>Doc No. 303-035</u> Addendum Toxicokinetic Report: A Comparative 2 Week Oral (Gavage) Toxicity Study in the Rat with a Micro-Emulsion and a Solid Dispersion	13	8-3784

SECTION II TABLE OF CONTENTS SDZ RAD		
	VOL.	PAGE NO.
SECTION IX - PREVIOUS HUMAN EXPERIENCE WITH INVESTIGATIONAL DRUG		
Sectional Table of Contents	14	9-1
A. PREVIOUS MARKETING OR INVESTIGATIONAL INFORMATION	14	9-2
1. Information relevant to safety of the proposed investigation	14	9-2
B. CLINICAL INFORMATION ON ACTIVE COMPONENTS OF A COMBINATION DRUG	14	9-3
C. HISTORY OF MARKETING AND WITHDRAWAL FROM ANY MARKET	14	9-3
D. SUMMARY OF CLINICAL STUDIES USING RAPAMYCIN	14	9-3
E. PHARMACOKINETICS OF RAPAMYCIN	14	9-3
F. LITERATURE	14	9-15
G. SYNOPSES AND PROTOCOL		
1. Synopsis for Study No. RADW 101	14	9-107
2. Synopsis for Study No. RADW 102	14	9-114
3. Protocol for Study No. RADW 101-E-00 with Amendments No. 1-3 and Sample Case Report Forms	14	9-120
H. PRELIMINARY SUPPLEMENT NO. 1 TO CLINICAL STUDY REPORT RADW 101-E-00	14	9-272
SECTION X - ADDITIONAL INFORMATION		
Sectional Table of Contents	14	10-1
A. DRUG DEPENDENCE AND ABUSE POTENTIAL	14	10-2
B. RESPONSE TO FDA	14	10-2



DEPARTMENT OF HEALTH & HUMAN SERVICES


Public Health Service

Food and Drug Administration
Rockville MD 20857

IND 52,003

Date NOV 25 1996

Sandoz Pharmaceuticals Corporation
59 Route 10
East Hanover, New Jersey 07936-1080
ATTN: Michael S. Perry, DVM, Ph.D.



Dear Sir or Madam:

We acknowledge receipt of your Investigational New Drug Application (IND) submitted pursuant to Section 505(i) of the Federal Food, Drug, and Cosmetic Act. Please note the following identifying data:

IND Number Assigned: 52,003

Sponsor: Sandoz Pharmaceuticals Corporation

Name of Drug: SDZ RAD

Date of Submission: November 15, 1996

Date of Receipt: November 19, 1996

Studies in humans may not be initiated until 30 days after the date of receipt shown above. If, within the 30-day waiting period, we identify deficiencies in the IND that require correction before human studies begin or that require restriction of human studies until correction, we will notify you immediately that the study may not be initiated ("clinical hold") or that certain restrictions must be placed on it. In the event of such notification, you must continue to withhold, or to restrict, such studies until you have submitted material to correct the deficiencies, and we have notified you that the material you submitted is satisfactory.

It has not been our policy to object to a sponsor, upon receipt of this acknowledgement letter, either obtaining supplies of the investigational drug or shipping it to investigators listed in the IND. However, if drug is shipped to investigators, they should be reminded that studies may not begin under the IND until 30 days after the IND receipt date or later if the IND is placed on clinical hold.

IND 52,003

Page 2


You are responsible for compliance with the Federal Food, Drug, and Cosmetic Act and the regulations implementing that Act (Title 21 of the Code of Federal Regulations). Those responsibilities include reporting any adverse experience associated with use of the drug that is both serious and unexpected to the FDA as soon as possible and in no event later than 10 working days after initial receipt of the information and reporting any unexpected fatal or life-threatening experience to the FDA by telephone no later than 3 working days after receipt of the information (21 CFR 312.32), and submission of annual progress reports (21 CFR 312.33).

Please forward all future communications concerning this IND in triplicate, identified by the above IND number, and addressed as follows:

Food and Drug Administration
Center for Drug Evaluation and Research (HFD-530)
Attention: Document Control Room
5600 Fishers Lane
Rockville, Maryland 20857

Should you have any questions concerning this IND, please contact: **CAROLE BROGDNEX**
@(301) 827-2335

Sincerely yours,



Chief, Project Management Staff
Division of Anti-Viral Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

cc: Original IND - pink
HFD-530 - yellow
HFD-530/CSO - green

IND ACKNOWLEDGEMENT

FORM FDA 3228a (11/95)

APPENDIX K

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080
Tel 973 781 8300



November 22, 2002

Center for Drug Evaluation and Research
Food and Drug Administration
Document and Records Section
12229 Wilkins Avenue
Rockville, MD 20852

**INVESTIGATIONAL NEW DRUG
APPLICATION**

Serial No. 000

Dear Sir or Madam:

In accordance with 21 CFR § 312.23, Novartis Pharmaceuticals Corporation is submitting an Investigational New Drug Application (IND) and supporting documents for the following investigational compound:

RAD001

RAD001 (also RAD001C, SDZ RAD, SDZ RAD 666, SDZ 222-666, evirolimus) has an extensive prior regulatory history within the FDA Division of Special Pathogens and Immunologic Drug Products (HFD-590) under IND 52,003. Consequently, portions of this IND cross-reference contents of IND 52,003 within HFD-590. Additionally, NDA filing for RAD001 within HFD-590 is planned for December 2002 under NDA number 21-560 and the trade name Certican™.

RAD001 is a macrolide, a new derivative of rapamycin, hydroxyethylated to increase polarity and facilitate its formulation for oral administration. RAD001 is being developed as an antiproliferative drug with applications as an immunosuppressant and anticancer agent. In the transplantation setting, numerous studies have been conducted with RAD001 with over a thousand patients having received the drug for over a year as part of a multidrug immunosuppressant regimen. RAD001 acts by selectively inhibiting mTOR (mammalian target of rapamycin), an intracellular protein kinase implicated in the control of cellular proliferation by it of activated T-lymphocytes or neoplastic cells.

Reference is made to a telephone conversation with Ms. Ann Staten, Project Manager (HFD-150), on September 6, 2002 discussing our intent to file this IND within the Division of Oncology Drug Products. During this conversation, we discussed the possibility of submission of IND safety reports for all oncology related events only to the Oncology Division and Ms. Staten asked that we revisit this proposal formally within the IND cover letter at the time of filing in order to obtain FDA guidance. Is this proposal acceptable?

Novartis Pharmaceuticals Corporation considers the information contained within this IND and all subsequent amendments to confidential, and their contents are not to be disclosed without

express written consent.

If you have any questions or comments regarding this submission, please contact me at (862) 778-8165.

Sincerely,



Kevin M. Carl, PharmD
Drug Regulatory Affairs

/da
Submitted in triplicate

Attachments: Form FDA 1571
Volumes 1-26

Coverletter: Ann Staten (HFD-150) via fax at 301/827-4590




Novartis Pharmaceuticals Corporation
East Hanover, New Jersey

STATEMENT OF CONFIDENTIALITY

NOVARTIS PHARMACEUTICALS CORPORATION has expended substantial sums of money in developing the information and data contained in this Investigational New Drug application for RAD and considers such information and data to be its valuable commercial property

Further, NOVARTIS PHARMACEUTICALS CORPORATION considers the information contained in the following pages to be trade secrets, therefore, protected by 21 U.S.C. 331 (j).

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION INVESTIGATIONAL NEW DRUG APPLICATION (IND) (TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312)		Form Approved: OMB No. 0910-0014. Expiration Date: September 30, 2002 See OMB Statement on Reverse.
1. NAME OF SPONSOR NOVARTIS PHARMACEUTICALS CORPORATION		2. DATE OF SUBMISSION November 22, 2002
3. ADDRESS (Number, Street, City, State and Zip Code) One Health Plaza East Hanover, New Jersey 07936-1080		4. TELEPHONE NUMBER (Include Area Code) (862) 778-8165 Kevin M. Carl, PharmD, Post-Doctoral Fellow
5. NAME(S) OF DRUG (Include all available names: Trade, Generic, Chemical, Code) RAD001		6. IND NUMBER (if previously assigned)
7. INDICATION(S) (Covered by this submission) Solid Tumor Cancers		
8. PHASE(S) OF CLINICAL INVESTIGATION TO BE CONDUCTED: <input checked="" type="checkbox"/> PHASE 1 <input type="checkbox"/> PHASE 2 <input type="checkbox"/> PHASE 3 <input type="checkbox"/> OTHER _____ (Specify)		
9. LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS (21 CFR Part 312), NEW DRUG OR ANTIBIOTIC APPLICATIONS (21 CFR Part 314), DRUG MASTER FILES (21 CFR Part 314.420), AND PRODUCT LICENSE APPLICATIONS (21 CFR Part 601) REFERRED TO IN THIS APPLICATION. IND 52.003 DIVISION OF SPECIAL PATHOGENS AND IMMUNOLOGIC DRUG PRODUCTS (HFD 590)		
10. IND submission should be consecutively numbered. The initial IND should be numbered "Serial number: 000." The next submission (e.g., amendment, report, or correspondence) should be numbered "Serial Number: 001." Subsequent submissions should be numbered consecutively in the order in which they are submitted.		SERIAL NUMBER 000
11. THIS SUBMISSION CONTAINS THE FOLLOWING: (Check all that apply) <input checked="" type="checkbox"/> INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND) <input type="checkbox"/> RESPONSE TO CLINICAL HOLD PROTOCOL AMENDMENT(S): INFORMATION AMENDMENT(S): IND SAFETY REPORT(S): <input type="checkbox"/> NEW PROTOCOL <input type="checkbox"/> CHEMISTRY/MICROBIOLOGY <input type="checkbox"/> INITIAL WRITTEN REPORT <input type="checkbox"/> CHANGE IN PROTOCOL <input type="checkbox"/> PHARMACOLOGY/TOXICOLOGY <input type="checkbox"/> FOLLOW-UP TO A WRITTEN REPORT <input type="checkbox"/> NEW INVESTIGATOR <input type="checkbox"/> CLINICAL <input type="checkbox"/> RESPONSE TO FDA REQUEST FOR INFORMATION <input type="checkbox"/> ANNUAL REPORT <input type="checkbox"/> GENERAL CORRESPONDENCE <input type="checkbox"/> REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN, INACTIVED, TERMINATED OR DISCONTINUED <input type="checkbox"/> OTHER _____ (Specify)		
CHECK ONLY IF APPLICABLE		
JUSTIFICATION STATEMENT MUST BE SUBMITTED WITH APPLICATION FOR ANY CHECKED BELOW. REFER TO THE CITED CFR SECTION FOR FURTHER INFORMATION. <input type="checkbox"/> TREATMENT IND 21 CFR 312.35(b) <input type="checkbox"/> TREATMENT PROTOCOL 21 CFR 312.35(a) <input type="checkbox"/> CHARGE REQUEST/NOTIFICATION 21 CFR 312.7(d)		
FOR FDA USE ONLY		
CDR/DBIND/DGD RECEIPT STAMP	DDR RECEIPT STAMP	IND NUMBER ASSIGNED:
		DIVISION ASSIGNMENT:

12. CONTENTS OF APPLICATION		
This application contains the following items: <i>(Check all that apply)</i>		
<input checked="" type="checkbox"/> 1. Form FDA 1571 [21 CFR 312.23(a)(1)] <input checked="" type="checkbox"/> 2. Table of Contents [21 CFR 312.23(a)(2)] <input checked="" type="checkbox"/> 3. Introductory statement [21 CFR 312.23(a)(3)] <input checked="" type="checkbox"/> 4. General Investigational plan [21 CFR 312.23(a)(3)] <input checked="" type="checkbox"/> 5. Investigator's brochure [21 CFR 312.23(a)(5)] <input checked="" type="checkbox"/> 6. Protocol(s) [21 CFR 312.23(a)(6)] <ul style="list-style-type: none"> <input checked="" type="checkbox"/> a. Study protocol(s) [21 CFR 312.23(a)(6)] <input checked="" type="checkbox"/> b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572 <input checked="" type="checkbox"/> c. Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572 <input checked="" type="checkbox"/> d. Institutional Review Board data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572 <input checked="" type="checkbox"/> 7. Chemistry, manufacturing, and control data [21 CFR 312.23(a)(7)] <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Environmental assessment or claim for exclusion [21 CFR 312.23(a)(7)(iv)(e)] <input checked="" type="checkbox"/> 8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)] <input checked="" type="checkbox"/> 9. Previous human experience [21 CFR 312.23(a)(9)] <input type="checkbox"/> 10. Additional information [21 CFR 312.23(a)(10)]		
13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO IF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION? <input type="checkbox"/> YES <input type="checkbox"/> NO IF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED.		
14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS Nicholas Shand, MD Senior Clinical Research Physician Clinical Research		
15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRUG Dionigi Maladorno, MD Medical Safety Expert Clinical Safety and Epidemiology		
I agree not to begin clinical investigations until 30 days after FDA's receipt of the IND unless I receive earlier notification by FDA that the studies may begin. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set forth in 21 CFR Part 56 will be responsible for initial and continuing review and approval of each of the studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.		
16. NAME OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE Kevin M. Cari, PharmD, Post-Doctoral Fellow Drug Regulatory Affairs	17. SIGNATURE OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE 	
18. ADDRESS (Number, Street, City, State and Zip Code) One Health Plaza East Hanover, New Jersey 07936-1080	19. TELEPHONE NUMBER (Include Area Code) (862) 778-8165	20. DATE 11/22/02
(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)		
Public reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:		
Food and Drug Administration CBER (HFM-99) 1401 Rockville Pike Rockville, MD 20852-1448	Food and Drug Administration CDER (HFD-94) 5516 Nicholson Lane Kensington, MD 20895	"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number"
Please DO NOT RETURN this application to this address.		

RAD 001

Investigational New Drug Application

Author(s): Judith Fast
Document type: IND Table of Contents
Document status: Final
Submission date: 22-November-2002
Number of pages: 19

Property of Novartis Pharmaceuticals Corporation
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis Pharmaceuticals Corporation

	Vol	Page No.
1. 1571 Form	1	1-1
2. Table of Contents	1	2-1
3. Introductory statement		
Sectional Table of Contents	1	3-1
• Name of Drug, Active Ingredient	1	3-4
• Pharmacological Class	1	3-4
• Structural Formula	1	3-5
• Formulation of Dosage Form	1	3-5
• Route of Administration	1	3-5
• Broad Clinical Objectives	1	3-5
• Summary of Previous Human Experience	1	3-6
• Withdrawal of Investigational or Marketing Use in any Country	1	3-8
4. General Investigational Plan		
Sectional Table of Contents	1	4-1
• Rationale for Study	1	4-4
• Indication to be Studied	1	4-7
• General Approach to Investigation	1	4-7
• Kinds of Trials During the First Year	1	4-9
• Estimated Number of Subjects in the Study	1	4-9
• Risks Anticipated on the Basis of Toxicology Data	1	4-10
5. Investigator's Brochure	1	5-1
6. Protocol		
Sectional Table of Contents	1	6-1

	Vol	Page No.
• Protocol Study No. RAD001C2206	1	6-2
A phase I-II, open-label study of RAD001 in combination with Glivec® (imatinib) in patients with Glivec-refractory/resistant gastrointestinal stromal tumors		
• Investigator Forms		
• George Demetri, MD	1	6-99
• Form FDA 1572	1	6-99
• Curriculum Vitae	1	6-105
7. Chemistry, manufacturing and controls		
Sectional Table of Contents	1	7-1
• Introduction	1	7-2
• Drug Substance	1	7-6
		x-reference IND# 52,003 11/15/96
• Drug product		
• Composition	1	7-8
• Sites of manufacture, packaging and control	1	7-10
• Batch formula and method of preparation	1	7-12
• Excipient controls	1	7-17
• Specifications and control procedures	1	7-19
• Method Validation	N/A	N/A
• Batch analysis	1	7-23
• Brief description of container/closure system	1	7-26
• Stability tests	1	7-28
• Placebo and/or comparator	N/A	N/A
• Clinical label	1	7-36
• Environmental assessment	1	7-38
8. Pharmacology and Toxicology Data		
Sectional Table of Contents	2	8-1
• Introduction	2	8-19

	Vol	Page No.
• Preclinical Summaries		
• Pharmacology Summary	2	8-22
• Toxicology Summary/DMPK Summary	2	8-84
• Preclinical References		
• Cited Pharmacology Reports/Literature		
[1] Dennis PB, Fumagalli S, Thomas G. Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. <i>Curr Opin Genet Dev</i> 1999;9:49-54.	2	8-125
[2] Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. <i>Curr Opin Invest Drugs</i> 2002;3(2):295-304.	2	8-131
[3] Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. <i>J Biol Chem</i> 1998;273:14424-14429.	2	8-141
[4] Mahajan PB. Modulation of transcription of rRNA genes by rapamycin. <i>Int J Immunopharmacol</i> 1994;16:711-721	2	8-147
[5] Leicht M, Simm A, Bertsch G, Hoppe J. Okadaic acid induces cellular hypertrophy in AKR-2B fibroblasts: involvement of the p70S6 kinase in the onset of protein and rRNA synthesis. <i>Cell Growth Differ</i> 1996;7:1199-1209.	2	8-157
[6] Ziegler WH, Parekh DB, Le-Good JA, Whelan RD, Kelly JJ, Frech M, Hemmings BA, Parker PJ. Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an atypical PKC complex. <i>Curr Biol</i> 1999;9:522-529.	2	8-168
[7] Le-Bihan S, Marsaud V, Mercier-Bodard C, Baulieu EE, Mader S, White JH, Renoir JM. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progesterin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells. <i>Mol Endocrinol</i> 1998;12: 986-1001.	2	8-176
[8] Bonatti S, Simili M, Galli A, Bagnato P, Pigullo S, Schiestl RH, Abbondandolo A. Inhibition of the Mr 70,000 S6 kinase pathway by rapamycin results in chromosome malsegregation in yeast and mammalian cells. <i>Chromosoma</i> 1998;107:498-506.	2	8-192
[9] Francesc V, Chambard JC, Pouysségur J. p70 S6 Kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. <i>J Biol Chem</i> 1999;274:26776-26782.	2	8-201
[10] Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. <i>J Cell Physiol</i> 1999;178:235-246.	2	8-208

	Vol	Page No.
[11] Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Fiegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. <i>Nat Med</i> 2002;8:128-135.	2	8-220
[12] Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. <i>Nature Cancer</i> 2002;2:489-501.	2	8-228
[13] Inoki K, Li Y, Zhu T, Wu J, Guan K-L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. <i>Nat Cell Biol</i> 2002; published online: 12 August 2002; DOI: 10.1038/ncb839.	2	8-241
[14] Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. <i>Biochem J</i> 1999;344:427-431.	2	8-251
[15] Neshat MS, Mellinshoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. <i>Proc Natl Acad Sci</i> 2001;98:10314-10319.	2	8-256
[16] Podsypanina K, Lee RT, Polltis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Giaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten ^{+/-} mice. <i>Proc Natl Acad Sci</i> 2001;98:10320-10325	2	8-262
[17] Meyer T, Becker M, Centeleghe M, Köppler J, Liebetanz J, Manfrina D, Martin N, Muller L, Fabbro D, Lane H, O'Reilly T. Enzymatic profile of RAD001: In vitro inhibition of protein kinases. <i>Novartis Release Ready Report</i> 2001;RD-2001-01088	2	8-268
[18] Hattenberger M, Muller M, Vaxelaire J, Sedrani R, Lane H, O'Reilly T. RAD001 potentiates the activity of conventional anticancer cytotoxics in vitro. <i>Novartis Release Ready Report</i> 2000;RD-2000-02546.	2	8-282
[19] Hattenberger M, Boulay A, Lane HA, Maira M, O'Reilly T. In vitro antiproliferative activity of RAD001 against a broad panel of tumor cell lines. <i>Novartis Release Ready Study Report</i> 2002;RD-2002-03223.	2	8-295
[20] Beuvink I, Zilbermann F, Zumstein-Mecker S, Sedrani R, Thomas G, O'Reilly T, Lane H. Downregulation of mTOR targets in tumor cell lines in vitro (comparison with CCI-779). <i>Novartis Release Ready Report</i> 2000;RD-2000-02544.	2	8-313
[21] Hungerford V, Thomas G, Schuler W. RAD inhibits the growth factor-stimulated activation of p70 S6 kinase. <i>Novartis Release Ready Report</i> 2000;RD-2000-02151.	2	8-331

	Vol	Page No.
[22] Boulay A, Zumstein-Mecker S, Stephan C, Solf R, Ruetz S, O'Reilly T, Lane HA. RAD001 potentiates the loss of A549 cell viability induced by gemcitabine treatment in vitro. Novartis Release Ready Study Report 2002;RD-2002-03250.	2	8-341
[23] Boulay A, Hattenberger M, Zumstein-Mecker S, Solf R, Ruetz S, O'Reilly T, Lane H. Effect of scheduling on the in vitro antiproliferative activity of RAD001/gemcitabine combinations in A549 cells. Novartis Release Ready Report 2001;RD-2001-01087.	26	8-9732
[24] Wood JM, Theuer A. RAD001: effects on endothelial and fibroblast cell proliferation. Novartis Release Ready Report 2001;RD-2001-00852.	2	8-357
[25] Boulay A, Hattenberger M, O'Reilly T, Maira M, Lane HA. Comparison of the antiproliferative activity of RAD001 with activation of the PTEN/PI3 kinase/Akt/mTOR pathway in tumor cell lines. Novartis Release Ready Study Report 2002;RD-2002-03252.	2	8-369
[26] Muller M, Vaxelaire J, Hattenberger M, Sedrani R, Lane H, O'Reilly T. RAD001 is an effective antitumor agent in experimental KB-31 xenograft tumor models of epidermoid cancer. Novartis Release Ready Report 2000;RD-2000-02549.	2	8-388
[27] Zumstein-Mecker S, Beuvink I, Zilbermann F, Muller M, Vaxelaire, Sedrani R, Thomas G, O'Reilly T, Lane H. Downregulation of mTOR targets in tumors and skin derived from KB-31 human epidermoid carcinoma xenograft studies. Novartis Release Ready Report 2000;RD-2000-02541.	2	8-404
[28] Marti A, Stolz B, Haller R, Tobler S, O'Reilly T, Lane H. Effect of the rapamycin derivative RAD001 in the syngeneic CA20948 rat pancreatic tumor model. Novartis Release Ready Report 2002;RD-2002-03707	26	8-9744
[29] Zumstein-Mecker S, Beuvink I, Zilbermann F, Stephan C, Haller R, Tobler S, Thomas G, Stolz B, O'Reilly T, Lane H. Prolonged inactivation of p70 ^{S6k} in tumors and skin derived from CA20948 pancreatic tumor-bearing rats. Novartis Release Ready Report 2001;RD-2001-00450.	2	8-422
[30] Zumstein-Mecker S, Beuvink I, Zilbermann F, Sedrani R, Hattenberger M, Thomas G, O'Reilly T, Lane H. Inhibition of the mTOR target p70s6k in rat peripheral lymphocytes. Novartis Release Ready Report 2000;RD-2000-02545.	2	8-437
[31] Zumstein-Mecker S, Boulay A, Beuvink I, Zilbermann F, Haller R, Tobler S, Thomas G, Stolz B, O'Reilly T, Lane H. Prolonged inactivation of p70 ^{S6k} in peripheral blood mononucleocytes derived from CA20948 pancreatic tumor-bearing rats and non-tumor-bearing rats. Novartis Release Ready Report 2002;RD-2002-03817.	3	8-451
[32] Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-826.	3	8-471

	Vol	Page No.
[33] Zumstein-Mecker S, Stephan C, Boulay A, Lane HA. Detection of p70S6 activity in human peripheral mononucleocytes (PBMCs) using the 40S ribosomal protein kinase assay. Novartis Release Ready Study Report 2002;RD-2002-02974.	3	8-491
[34] Vaxelaire J, Muller M, Hattenberger, Lane H, O'Reilly T. RAD001 is an effective antitumor agent in experimental A549 xenograft tumor model of lung cancer. Novartis Release Ready Report 2001;RD-2001-00848.	3	8-507
[35] Wenger F, O'Reilly T, Martinuzzi-Duboc L, Tinetto W, Lane H, Brandt R, Cozens R. RAD001 is an effective antitumor agent in experimental NCI H-596 lung xenograft tumor model of lung cancer. Novartis Release Ready Report; 2001;RD-2001-00860.	3	8-523
[36] Hattenberger M, Weckbecker G, Muller M, Vaxelaire J, Sedrani R, Lane H, O'Reilly T. Evaluation of the antitumor activity of RAD001 in experimental xenograft tumor models of pancreatic cancer. Novartis Release Ready Report 2000;RD-2000-02548.	3	8-538
[37] Vaxelaire J, Muller M, Hattenberger M, Sedrani R, Lane H, O'Reilly T. RAD001 is active in vivo against xenograft tumors of HCT116 human colon carcinoma, a cell line resistant to RAD001 in vitro. Novartis Release Ready Report 2000;RD-2000-02550.	3	8-565
[38] Muller M, Vaxelaire J, Hattenberger M, Maira SM, Lane H, O'Reilly T. RAD001 is an effective antitumor agent in the experimental NCI H-520 xenograft tumor model of lung cancer. Novartis Release Ready Study Report 2002;RD-2002-00002.	3	8-594
[39] Fiebig HH, Dengler WA, Roth T. Human tumor xenografts: predictivity, characterization and discovery of new anticancer agents. In: Fiebig HH, Burger AM, editors. Relevance of tumor models for anticancer drug development. Contrib Oncol Basel: Karger, 1999;54:29-50.	3	8-612
[40] Fiebig HH, Cozens R, O'Reilly T. Activity of RAD001 against low passage human tumor xenografts. Novartis Release Ready Report 2000;RD-2000-02552.	3	8-634
[41] Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992;80:1528-1536.	3	8-654
[42] Muller M, Vaxelaire J, Hattenberger M, Lane H, O'Reilly T. RAD001 is an effective antitumor agent against experimental epidermoid multi-drug resistant KB-8511 tumors. Novartis Release Ready Study Report 2002;RD-2002-03237.	3	8-663
[43] Akiyam S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Molec Genetics 1985;11:117-126.	3	8-682

	Vol	Page No.
[44] Fojo A, Akiyama S, Gottesman MM, Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. <i>Cancer Res</i> 1997;45:3002-3007.	3	8-692
[45] Wenger F, O'Reilly T, Martinuzzi-Duboc L, Tinetto W, Lane H, Brandt R, Cozens R. Evaluation of RAD001 in combination with conventional anticancer agents against experimental NCI H-596 lung xenograft tumor models of cancer. <i>Novartis Release Ready Report</i> 2001;RD-2001-00861.	3	8-698
[46] Muller M, Hattenberger M, Vaxelaire J, Lane H, O'Reilly T. Evaluation of RAD001 in combination with conventional anticancer agents against experimental KB-31 epidermoid xenograft tumors. <i>Novartis Release Ready Report</i> 2001;RD-2001-00849.	3	8-727
[47] Vaxelaire J, Hattenberger M, Muller M, Lane HA, O'Reilly T. Effect of administration schedule on the antitumor activity of RAD001 in combination with Taxol®. <i>Novartis Release Ready Study Report</i> 2002;RD-2002-03251.		To be submitted in 12/2002
[48] Muller M, Vaxelaire J, Hattenberger M, Lane HA, O'Reilly T. Administration schedule has little effect on the antitumor activity of RAD001 in combination with cisplatin. <i>Novartis Release Ready Study Report</i> 2002;RD-2002-03253.		To be submitted in 12/2002
[49] Hattenberger M, Muller M, Vaxelaire J, Lane HA, O'Reilly T. Administration schedule has little effect on the antitumor activity of RAD001 in combination with low dose gemcitabine against NCI H-596 lung tumor xenografts. <i>Novartis Release Ready Study Report</i> 2002;RD-2002-02354.		To be submitted in 12/2002
[50] Wood JM, Schnell CR. RAD001: effects on angiogenesis-induced by growth factor-impregnated, subcutaneous implants in mice. <i>Novartis Release Ready Report</i> 2001; RD-2001-00853.	3	8-768
[51] Wood JM, Schnell CR. RAD001: effects in orthotopic B16/BL6 melanoma model in C57BL/6 mice. <i>Novartis Release Ready Report</i> 2001; RD-2001-00854.	3	8-783
[52] Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: A review of the evidence. <i>Kidney Int.</i> 2000; 59:3-16.	3	8-809
[53] Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH. A new rapamycin derivative: pharmacological properties in vitro and in vivo. <i>Transplantation</i> 1997;64: 36-42.	3	8-823
[54] Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. <i>Transplantation</i> 2000;73:920-925.	3	8-830

	Vol	Page No.
[55] O'Reilly T, Schmutz P, Hattenberger M, Vaxelaire J, Muller M, Lane H, Huesser C. Reduction of the immunosuppressive properties of RAD001 by intermittent administration. Novartis Release Ready Study Report 2002; RD-2002-01534.	26	8-9759
[56] Vaxelaire J, Muller M, Hattenberger M, O'Reilly, T. Studies on the tolerability of athymic BALB/c <i>nu/nu</i> (nude) mice to RAD001. Novartis Release Ready Report 2000;RD-2000-02547.	3	8-836
[57] Muller M, Hattenberger M, Vaxelaire J, O'Reilly, T. Tolerability of athymic BALB/c <i>nu/nu</i> (nude) mice to RAD001 in combination with conventional cytotoxic anti-cancer agents. Novartis Release Ready Report 2001;RD-2001-00401.	3	8-845
[58] Vaxelaire J, Muller M, Hattenberger M, Lane H, O'Reilly, T. Tolerability of athymic BALB/c <i>nu/nu</i> (nude) mice to RAD001 in combination with carboplatin. Novartis Release Ready Report 2001;RD-2001-00844.	3	8-864
[59] Muller M, Hattenberger M, Vaxelaire J, Lane H, O'Reilly, T. Effect of schedule on the tolerability of athymic BALB/c <i>nu/nu</i> (nude) mice to RAD001 in combination with gemcitabine. Novartis Release Ready Report 2001;RD-2001-00850.	3	8-879
[60] Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. <i>Nat Rev Drug Discov.</i> 2002;1:493-502	3	8-893
[61] Muller M, O'Reilly T, Vaxelaire J, Hattenberger M, Maira SM. Tolerability of concomitant STI571 (Glivec®) and RAD001 in athymic Harlan mice. Novartis Release Ready Study Report 2002;RD-2002-03186.	26	8-9777
• Cited DMPK & Toxicology Reports and Literature		
[1] Kretz O. Pharmacokinetics and excretion after single intravenous and peroral administration (0.9 mg/kg) of 3H-labeled RAD001 to mice. Novartis Pharma AG, 28-Aug-2000. Document DMPK(CH)R98-707	4	8-903
[2] Figueiredo J, Kretz O. RAD001: Pharmacokinetics in mice after intravenous bolus administration (0.9 mg/kg) with RAD001. Novartis Pharma AG, 16-Mar-2000. Document DMPK(CH)R00-874	4	8-920
[3] Lemaire M, Dannecker R. SDZ RAD: Absorption, distribution, metabolism and excretion in rats after single intravenous (1 mg/kg, 10 mg/kg) and oral (1.5 mg/kg, 15 mg/kg) administration of [³ H]SDZ RAD. Sandoz Pharma Ltd., 25-Jan-1996. Document 303-013 (159604.010)		**x- reference to IND 52,003 11/15/96
[4] Schuetz H. SDZ RAD: Distribution and excretion of total radioactivity in rats after peroral administration of 1.5 mg/kg ¹⁴ C-labelled SDZ RAD. Novartis Pharma AG, 10-Mar-1998. Document 303-092 (DMPK(CH)1997/515)	4	8-936

	Vol	Page No.
[5] Schweitzer A. RAD001: Whole-body autoradioluminography in albino and pigmented rats after po and iv doses of [³ H]RAD001. Novartis Pharma AG, 19-Nov-1998. Document 303-097 (DMPK(CH)R98-194)	4	8-954
[6] Schweitzer A. RAD001: Embryofetal transfer in pregnant rats on day 13 and day 17 of gestation after po administration of [³ H]RAD001. Novartis Pharma AG, 20-Nov-1998. Document 303-098 (DMPK(CH)R98-732)	4	8-969
[7] Lemaire M. RAD001: Dose-dependent brain penetration in rat. Novartis Pharma AG, 4-Oct-2000. Document DMPK(CH)R00-2214	4	8-983
[8] Lemaire M. SDZ RAD (SDZ 222-666): Absorption, disposition and excretion in Cynomolgus monkeys after single intravenous (1 mg/kg) and oral (5 mg/kg) administration of [³ H]SDZ RAD. Sandoz Pharma Ltd., 23-Sep-1996. Document 303-049 (162258.01)		**x- reference to IND 52,003 11/15/96
[9] Kaufmann H, Kawai R. RAD001: In vitro blood distribution, plasma protein binding and stability of RAD001 in mouse plasma. Novartis Pharma AG, 28-Aug-2000. Document DMPK(CH)R00-1253	4	8-996
[10] Duerr L, Lemaire M. SDZ RAD: Blood distribution and plasma protein binding. Sandoz Pharma Ltd., 18-Jul-1996. Document 303-044		**
[11] Zimmermann H. RAD001: Protein binding of RAD001 in serum from healthy volunteers and from patients with moderate hepatic insufficiency. Novartis Pharma AG, 22-Feb-2001. Document DMPK(CH)R00-2228	4	8-1008
[12] Crowe A, Bruelisauer A, Delaborde S, Dannecker R, Lemaire M. SDZ RAD: Intestinal absorption and presystemic metabolism of SDZ RAD. Novartis Pharma AG, 17-Dec-1997. Document 303-086 (DMPK(CH)1997/417)	4	8-1022
[13] Bruelisauer A. SDZ RAD: Liquid chromatography-reverse isotope dilution method (LC-RID) for the determination of [³ H]SDZ RAD in biological media. Sandoz Pharma Ltd., 21-Sep-1995. Document 303-015 (159606)		**
[14] Feltin M, Hensel S. SDZ RAD: Determination of SDZ RAD in whole blood by HPLC with uv detection. Method description and validation. Sandoz Pharma Ltd., 21-Aug-1996. Document 303-045	4	8-1048
[15] Legay F. SDZ RAD: Development and validation of an ELISA. Sandoz Pharma Ltd., 21-Sep-1995. Document 303-017 (160139)		**
[16] Jean C, Laplanche R. SDZ RAD: Method of determination of SDZ RAD in blood by liquid chromatography/atmospheric pressure chemical ionization/mass spectrometry (HPLC/APCI/MS). Method description and validation. Sandoz Pharma Ltd., 26-Nov-1996. Document 303-066	4	8-1083

	Vol	Page No.
[17] Jean C, Stefani M. SDZ RAD: Quantitative determination of rapamycin and SDZ RAD in blood samples after single and multiple administration in human and monkey. Novartis Pharma AG, 9-Dec-1997. Document 303-085 (DMPK(CH)1997/287)	4	8-1190
[18] Vickers A, Dannecker R. SDZ RAD 666: In vitro biotransformation. Sandoz Pharma Ltd., 28-Mar-1996. Document 303-037	4	8-1206
[19] Dannecker R, Hauck C. SDZ RAD: Human in vitro biotransformation. LC-MS investigation of metabolites. Novartis Pharma AG, 18-Dec-1997. Document DMPK(CH)1997/467	4	8-1228
[20] Fischer V, Tynes R. RAD: Metabolism in human liver: potential for drug-drug interactions. Novartis Pharm. Corp., 28-Jan-1998. Document 303-090 (DMPK(US)1998/005)	4	8-1241
[21] Zimmerlin A, Kraus G, Heitz F. RAD001: Inhibition of RAD001 in vitro metabolism by ketoconazole, itraconazole and fluconazole. Novartis Pharma AG, 31-May-2000. Document DMPK(CH)R99-2448	5	8-1279
[22] Wiegand H, Meno-Tetang G. In vitro blood distribution and plasma protein binding of RAD001 in rat plasma. Addendum 2 to report: In vitro blood distribution, plasma protein binding and stability of RAD001 in mouse plasma. Novartis Pharma AG. 08-Oct-2001. Document DMPK(CH) R00-1253-2.	5	8-1291
[23] Dannecker R, Kretz O. Galactogenic transfer, kinetics and metabolism in milk and blood after single peroral administration (0.9 mg/kg) of ³ H-labeled RAD001 to lactating rats. Novartis Pharma AG. 18-June-2001. Document DMPK(CH) R98-708.	5	8-1303
[24] Fraser S. Effect of RAD N BHT on action potential parameters in sheep isolated cardiac Purkinje fibers. Quintiles Scotland Limited, Edinburgh, UK. Report No. ITU00201 (Sponsor's reference No. 982042), 09-Dec-1998.	5	8-1329
[25] Kameda H. General pharmacology of SDZ-RAD. Preclinical Safety, Toxicology/ Pathology, Novartis Pharma K.K., Tsukuba-shi, Japan. Report No. RAD 02-c, 29-Aug-1997.	5	8-1363
[26] McAllister KH. RAD001: Primary observation test of RAD001. Novartis Pharma AG, Basel, Switzerland, PKF-93-02177, 24-Oct-2000.	5	8-1381
[27] Yamada Y. Antigenicity study of SDZ RAD. Nihon Bioresearch Inc., Hashima Laboratory, Hashima, Japan. Report No. 802416, 18-Aug-1997.	5	8-1392
[28] Buescher H, Buchheit K, PKF222-666 (RAD): Effect of RAD on lung function in the guinea pig.(Safety Pharmacology) Preclinical Safety, Novartis Pharma AG, Basel, Switzerland, RD-2000-01492, 11-Aug-2000.	5	8-1446

	Vol	Page No.
[29] Kimura M, Mitani H. RAD: Cardiovascular effect of RAD in anesthetized pigs. Novartis Pharma KK, Tsukuba-shi, Japan, RD-2000-1460, 25-Jul-2000.	5	8-1452
[30] Pfister T. SDZ RAD 666: Acute oral toxicity study in mice. Research & Consulting Company Ltd., Itingen, Switzerland. RCC Project No. 393131 (203-023), 16-Jan-1996.		**x- reference to IND 52,003 11/15/96
[31] Pfister T. SDZ RAD 666: Acute oral toxicity study in rats. Research & Consulting Company Ltd., Itingen, Switzerland. RCC Project No. 393118 (203-024), 12-Jan-1996.		**
[32] Pfister T. SDZ RAD 666: Acute intravenous toxicity study in mice. Research & Consulting Company Ltd., Itingen, Switzerland. RCC Project No. 393142 (203-051), 12-Jan-1996.		**
[33] Pfister T. SDZ RAD 666: Acute intravenous toxicity study in rats. Research & Consulting Company Ltd., Itingen, Switzerland. RCC Project No. 393120 (203-047), 16-Jan-1996.		**
[34] Noakes JP. SDZ RAD: Range finding toxicity study by oral gavage administration to CD-1 mice for 13 weeks. Huntingdon Life Sciences Ltd, Eye, England. Report No. 96/SPM107/1177 (203-082), 06-Nov-1997.		**
[35] Mahl A. SDZ RAD 666: A 2-week oral (gavage) dose-range-finding study in rats. Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Report No. 196DFR (203-038), 28-Mar-1996.		**
[36] Schmid H, Allard G, Keller B, Weber K, Amstrom J. SDZ RAD: A comparative 2-week oral (gavage) toxicity study in the rat with a microemulsion and a solid dispersion. Research & Consulting Company Ltd., Itingen, Switzerland. RCC Project No. 617951 (203-078). 14-Aug-1997.		x-reference to IND 52,003 01/26/98
[37] Chase KR. SDZ RAD: Toxicity study by oral gavage administration to Han/IBM Wistar rats for 4 weeks followed by a 2 week reversibility period. Huntingdon Life Sciences Ltd, Eye, England. Report No. 95/SPM**/0888 (203-042), 14-Jun-1996. Chase KR. Additional pathology investigations to a toxicity study by oral gavage administration to Han/IBM Wistar rats for 4 weeks followed by a 2 week reversibility period. Huntingdon Life Sciences Ltd, Alconbury, England. Report No. NVR052/002947 (BS-101), 02-Aug-2000.		**
[38] Chase KR. SDZ RAD: A repeat toxicity study by oral gavage administration to Han/IBM Wistar rats for 4 weeks followed by a 2 week reversibility period. Huntingdon Life Sciences Ltd, Eye, England. Report No. 96/SPM090/0404 (203-050), 08-Aug-1996. Chase KR. Electron microscopy report. Huntingdon Life Sciences Ltd, Huntingdon, England. Report No. SPM 090/960876, 21-Aug-1996.		**

	Vol	Page No.
[39] Nicholls IM. SDZ RAD: Toxicity study by oral gavage administration to Hanlbm Wistar rats for 26 weeks followed by a 4-week reversibility period. Huntingdon Life Sciences Ltd, Eye, England. Report No. 96/SPM083/1130 (203-069), 11-Apr-1997		x-reference to IND 52,003 01/26/98
[40] Makin A. SDZ RAD: Dose range finding study (intravenous infusion administration) in rats. Huntingdon Life Sciences Ltd., Huntingdon, England. Report No. SAZ 500/951169 (203-060), 05-Sep-1996.		**x-reference to IND 52,003 11/15/96
[41] Makin A. SDZ RAD: Comparative intravenous infusion study in rats. Huntingdon Life Sciences Ltd, Huntingdon, England. Report No. SAZ 522/960021 (203-053), 20-Aug-1996.		**
[42] Cooper S. SDZ RAD: Toxicity study by intravenous (bolus) administration to Hanlbm Wistar rats for 2 weeks. Huntingdon Life Sciences Ltd, Eye, England. Study SPM115/970022 (203-071), 04-Aug-1997.		x-reference to IND 52,003 01/26/98
[43] Spähni M. RAD001: A 2-week oral (gavage) dose-range finding study in minipigs. Novartis Pharma AG, Basel, Switzerland. Report No. 212DFP (BS-610), 15-May-2000.	5	8-1463
[44] Mahl A. SDZ RAD: 4-week oral (gavage) toxicity study in minipigs. Novartis Pharma AG, Basel, Switzerland. Report No. 971033 (BS-659), 10-Aug-2000.	6	8-1565
[45] Brinck P. SDZ RAD: Two-week intravenous infusion toxicity study in minipigs. Scantox, Lille Skensved, Denmark. Report No.19404 (203-075), 13-Aug-1997.		x-reference to IND 52,003 01/26/98
[46] Makin A. SDZ RAD: Dose escalating study (oral administration) in cynomolgus monkeys. Huntingdon Life Science Ltd., Huntingdon, England. Report No. SAZ 471/943030 (203-055), 13-Aug-1996.		**
[47] Makin A. SDZ RAD: 14-day dose range finding study (oral route) in cynomolgus monkeys. Huntingdon Life Sciences Ltd., Huntingdon, England. Report No. SAZ 494/951127 (203-059), 03-Sep-1996. Makin A. Supplementary report: ECG analysis. Huntingdon Life Sciences Ltd., Huntingdon, England. Report No. NVR 036/984906a (BS-032), 23-Dec-1998.		**
[48] Noakes JP. SDZ RAD: Toxicity study by oral gavage administration to cynomolgus monkeys for 4 weeks followed by a 2-week reversibility period. Huntingdon Life Sciences Ltd., Eye, England. Report No. 95/SPM049/1008 (203-054), 19-Aug-1996		**
[49] Zühke U. SDZ RAD: 28-day oral gavage toxicity study in juvenile cynomolgus monkeys with a 2-week reversibility period. Covance Laboratories GmbH, Münster, Germany. Report No. 1463-019 (203-070), 03-Jul-1997.		x-reference to IND 52,003 01/26/98

	Vol	Page No.
[50] Noakes JP. SDZ RAD: Toxicity study by oral gavage administration to cynomolgus monkeys for 26 weeks. Huntingdon Life Sciences Ltd, Eye, England. Report No. 96/SPM078/1067 (203-072), 05-Aug-1997. Noakes JP. Addendum to final report: Virology. Addendum No. SPM078/980023 (BS-033), 25-Feb-1998.		x-reference to IND 52,003 01/26/98
[51] Zühlke U. SDZ RAD: 52-week oral (gavage) toxicity study in the cynomolgus monkey. Covance Laboratories GmbH, Münster, Germany. Report No. 1463-045, Sponsor's Ref. No. 972001 (BS-375), 02-Nov-1999.	7-8	8-1863
[52] Makin A. SDZ RAD 666: Dose finding study in Cynomolgus monkeys by intravenous infusion for 2 weeks. Huntingdon Research Centre, Huntingdon, England. Report No. SAZ 484/950394 (203-012), 21-Aug-1995.		**x-reference to IND 52,003 11/15/96
[53] Makin A. SDZ RAD: 4-week toxicity study in Cynomolgus monkeys by intravenous infusion followed by a 2-week reversibility period. Huntingdon Life Sciences Ltd, Huntingdon, England. Study SAZ 523/960379 (203-079), 26-Sep-1997.	9	8-2443
[54] Makin A. SDZ RAD: 4-week toxicity study in Cynomolgus monkeys by intravenous infusion followed by a 2-week reversibility period. Huntingdon Life Sciences Ltd, Huntingdon, England. Report No. SAZ 539/962684 (203-083), 13-Oct-1997.	10	8-2802
[55] Längle U. RAD001 (SDZ RAD-666): An oral dose-escalating study in dogs. Novartis Pharma AG, Basel, Switzerland. Report No. 41DED (BS-674), 30-Aug-2000.	10	8-3106
[56] Noakes JP. SDZ RAD: Comparative toxicity study in Hanlbm Wistar rats with batches differing in by-product content. Huntingdon Life Sciences Ltd, Eye, England. Report No. 96/SPM091/0532 (203-076), 12-Aug-1997.		x-reference to IND 52,003 01/26/98
[57] Mahl A. RAD001: 4-week oral toxicity study in rats (batch comparison). Novartis Pharma AG, Basel, Switzerland. Report No. 991094 (BS-697), 20-Sep-2000.	11	8-3124
[58] Schmid H, Allard G, Keller B, Weber K, Chevalier HJ. SDZ RAD Solid dispersion: A comparative 2-week oral (gavage) toxicity study in the rat with two different batches. RCC Itingen, Switzerland. RCC Project 634678 (203-077), 25-Aug-1997.		x-reference to IND 52,003 01/26/98
[59] Webley LJ. SDZ RAD: Oncogenicity study by oral gavage administration to Hanlbm Wistar rats for 104 weeks. Huntingdon Life Sciences Ltd, Eye, England. Report No. SPM113/973228 (BS-468), 26-Oct-1999. Webley LJ. Additional pathology investigations to an oncogenicity study by oral gavage administration to Hanlbm Wistar rats for 104 weeks (Study number SPM/113). Huntingdon Life Sciences Ltd, Huntingdon, England. Report No. NVR053/00 3100 (BS-103), 02-Aug-2000.	12-16	8-3502

	Vol	Page No.
[60] Thomas H. SDZ RAD (SDZ 222-666): An oral 13-week investigative fertility study in male rats with 13 weeks recovery. Novartis Pharma AG, Basel, Switzerland. Report No. 7073R (203-094), 05-Oct-1998.	17	8-6011
[61] Chase KR. SDZ RAD: Oncogenicity study by oral gavage administration to CD-1 mice for 104 weeks. Huntingdon Life Sciences Ltd, Eye, England. Report No. SPM118/973229 (BS-418), 08-Oct-1999.	18-24	8-6586
[62] Bartmann K. SDZ RAD (SDZ 222-666): An oral fertility dose-range-finding study in male rats. Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Report No. 7061R (203-058), 18-Sep-1996.		**x- reference to IND 52,003 11/15/96
[63] Bartmann K. SDZ RAD 666 (SDZ 222-666): An oral reproductive toxicity dose-range-finding study in female rats with toxicokinetics and placental transfer. Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Report No. 1060R (203-057), 18-Sep-1996.		**
[64] Thomas H. SDZ RAD (SDZ 222-666): An oral fertility and embryo-fetal development study in female rats. Novartis Pharma Ltd, Basel, Switzerland. Novartis Report No. 3074R (203-073), 25-Aug-1997.		x-reference to IND 52,003 01/26/98
[65] Bartmann K. SDZ RAD 666 (SDZ 222-666): An oral embryo-fetal development dose-range-finding study in rabbits with toxicokinetics and placental transfer. Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Study 2059K (203-056), 18-Sep-1996.		**
[66] Thomas H. SDZ RAD (SDZ 222-666): An oral embryo-fetal development study in rabbits. Novartis Pharma AG, Basel, Switzerland. Novartis Report No. 4070K (203-074), 02-Sep-1997.		x-reference to IND 52,003 01/26/98
[67] Yourenneff M. RAD001: An oral pre- and postnatal development study in rats. Novartis Pharmaceuticals Corp., East Hanover, NY, USA. Report No. 987105 (US-75392), 06-Dec-1999.	25	8-9120
[68] Suter W. SDZ RAD 666: Mutagenicity test using Salmonella typhimurium. Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Report No. Mut.Bakt.27/95 (203-016), 19-Sep-1995.		**x- reference to IND 52,003 11/15/96
[69] Suter W. SDZ RAD 666 (SDZ 222-666): Mutagenicity test using Salmonella typhimurium (batch control). Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Report No. Mut.Bakt.10/96 (203-040), 30-May-1996.		**
[70] Suter W. SDZ RAD 666 (SDZ 222-666): Mutagenicity test using Salmonella typhimurium (batch control). Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Report No. Mut.Bakt.52/96 (203-062), 08-Oct-1996.		x-reference to IND 52,003 01/26/98

	Vol	Page No.
[71] Suter W. SDZ RAD (Solid dispersion): Mutagenicity test using Salmonella typhimurium. Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Report No. Mut.Bakt. 66/96 (203-063), 23-Oct-1996.		x-reference to IND 52,003 01/26/98
[72] Martus HJ. RAD001: Mutagenicity test using Salmonella typhimurium (batch control). Novartis Pharma AG, Basel, Switzerland. Report No. 001801 (BS-482), 02-Mar-2000.	26	8-9486
[73] Fellows M. SDZ RAD: Mutation at the thymidine kinase (tk) locus of mouse lymphoma L5178Y cells using the microtitre fluctuation technique. Corning Hazelton (Europe), Harrogate, England. Report No. 1463/4-1052 (203-046), 23-Jul-1996.		**x- reference to IND 52,003 11/15/96
[74] Locher F. SDZ RAD 666: Chromosomal aberration test with V79 Chinese hamster cells. Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Report No. Z59 (203-025), 17-Jan-1996.		**
[75] Locher F. SDZ RAD (Solid dispersion): Chromosomal aberration test with V79 Chinese hamster cells. Novartis Pharma AG, Basel, Switzerland. Report No. Z63 (203-067), 13-Mar-1997.		x-reference to IND 52,003 01/26/98
[76] Pötter F. RAD001: Chromosome aberration test with V79 Chinese hamster cells. Novartis Pharma AG, Basel, Switzerland. Study 001831 (BS-725), 05-Jun-2000.	26	8-9513
[77] Suter W. SDZ RAD 666 (SDZ 222-666): Mouse bone marrow micronucleus test by the oral route. Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Report No. MK 36 (203-041), 28-May-1996.		**
[78] Jackson AM. SDZ RAD: Comparative study of ophthalmic toxicity by oral gavage administration to CD rats and HanIbm rats for 4 weeks. Huntingdon Life Sciences Ltd, Eye, England. Report No. 96/SPM098/0796 (203-068), 14-Apr-1997.		x-reference to IND 52,003 01/26/98
[79] Längle UW. SDZ RAD 666: A local intravenous tolerability study in rabbits. Sandoz Pharma Ltd, Basel, Switzerland. Sandoz Study 80LTRB (203-031), 26-Jan-1996.		**
[80] Van Huygevoort AHBM. Primary skin irritation/corrosion study with RAD001 in the rabbit (4-hour semi-occlusive application). NOTOX B.V. 's-Hertogenbosch, The Netherlands. NOTOX Project 246781 (BS-811), 11-Jan-1999.	26	8-9568
[81] Van Huygevoort AHBM. Assessment of contact hypersensitivity to RAD001 in the albino guinea pig (Maximization test). NOTOX B.V. 's-Hertogenbosch, The Netherlands. NOTOX Project 246792 (BS-812), 11-Jan-1999.	26	8-9577

	Vol	Page No.
[82] Figueiredo J, Brügger J, Müller M, Vaxelaire J, Hattenberger M, Lane H, O'Reilly T. Pharmacokinetics of RAD001 in BALB/c nu/nu mice bearing subcutaneous KB-31 human epidermoid tumors. Novartis Release Ready Report 2000;RD-2000-02553	26	8-9593
[83] O'Reilly T, Marti A, McMahon L, Lane HA. Pharmacokinetics of RAD001 in pancreatic tumor-bearing Lewis rats. Novartis Release Ready Study Report 2002;RD-2002-02884.	26	8-9607
[84] Hattenberger M, Boulay A, Lane HA, Maira M, O'Reilly T. In vitro antiproliferative activity of RAD001 against a broad panel of tumor cell lines. Novartis Release Ready Study Report 2002;RD-2002-03223.	2	8-295
[85] Vaxelaire J, Müller M, Hattenberger, Lane H, O'Reilly T. RAD001 is an effective antitumor agent in experimental A549 xenograft tumor model of lung cancer. Novartis Release Ready Report 2001;RD-2001-00848.	3	8-507
[86] Müller M, Vaxelaire J, Hattenberger M, Sedrani R, Lane H, O'Reilly T. RAD001 is an effective antitumor agent in experimental KB-31 xenograft tumor models of epidermoid cancer. Novartis Release Ready Report 2000;RD-2000-02549.	2	8-388
[87] Vaxelaire J, Müller M, Hattenberger M, Sedrani R, Lane H, O'Reilly T. RAD001 is active in vivo against xenograft tumors of HCT116 human colon carcinoma, a cell line resistant to RAD001 in vitro. Novartis Release Ready Report 2000;RD-2000-02550.	3	8-565
[88] Theuer A, Wood JM. RAD001: effects on endothelial and fibroblast cell proliferation. Novartis Release Ready Report 2001;RD-2001-00852.	2	8-357
[89] Wood JM, Schnell CR. RAD001: effects on angiogenesis-induced by growth factor-impregnated, subcutaneous implants in mice. Novartis Release Ready Report 2001; RD-2001-00853.	3	8-768
[90] Wood JM, Schnell CR. RAD001: effects in orthotopic B16/BL16 melanoma model in C57/BL/6 mice. Novartis Release Ready Report 2001; RD-2001-00854.	3	8-783
[91] Brügger J, McMahon L, Lane HA, O'Reilly T. Pharmacokinetics of RAD001 in non-tumor bearing athymic BALB/c nu/nu mice. Novartis Release Ready Study Report 2002;RD-2002-02880.	26	8-9625
[92] Boulay A, Hattenberger M, O'Reilly T, Maira M, Lane HA. Comparison of the antiproliferative activity of RAD001 with activation of the PTEN/PI3 kinase/Akt/mTOR pathway in tumor cell lines. Novartis Release Ready Study Report 2002;RD-2002-03252	2	8-369
[93] RAD001: Phase 1 study in patients with advanced solid tumors, 2101/2, Novartis Pharma AG, Basel, Switzerland		Study in Progress (Europe)

	Vol	Page No.
External Reports		
L1 Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 1998; 15: 1666-1672.	26	8-9651
L2 Calne RY, Collier DSJ, Lim S, Pollard SG, Samaan A, White DJG, Thiru S. Rapamycin for immunosuppression in organ allografting. The Lancet 1989; July 22:227.	26	8-9658
L3 Collier DSJ, Calne R, Thiru S, Lim S, Pollard SG, Barron P, Da Costa M, White DJG. Rapamycin in experimental renal allografts in dogs and pigs. Transplantation Proceedings 1990; 22(4):1674-1675.	26	8-9659
L4 Gunji Y, Ochiai T, Sakamoto K, Suzuki T, Nagata M, Nakajima K, Komori A, Asano T, Isono K, Hamaguchi K. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin or RS-61443. Transplantation Proceedings 1993; 25(1):752-753	26	8-9661
L5 Yanchar NL, Fedorak RN, Kneteman NM, Sigalet DL. Nutritional and intestinal effects of the novel immunosuppressive agents: deoxyspergualin, rapamycin, and mycophenolate mofetil. Clinical Biochemistry 1996; 9(4):363-369.	26	8-9663
L6 DiJoseph JF, Sehgal SN. Sirolimus: Side effect profile in animal studies. Principals in drug development in transplantation and autoimmunity, ed. by Liebermann R and Mukherjee A. 1996; R.G. Landes Company, Chapter 12.3, 289-94.	26	8-9670
L7 Chan CC, Martin DF, Xu D, Roberge FG. Side effects of rapamycin in the rat. Journal of Ocular Pharmacology and Therapeutics 1995; 11(2):177-181.	26	8-9676
L8 Vu MD, Qi S, Xu D, Wu J, Fitzsimmons WE, Sehgal SN, Dumont L, Busque S, Daloz P, Chen H. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64(12):1853-1856.	26	8-9681
L9 Prakasam G, Yeh JK, Chen MM, Castro-Magana M, Liang CT, Aloia JF. Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchietomized rats. Bone 1999; 24(5):491-497.	26	8-9685
L10 Chen MM, Yeh JK, Aloia JF. Histologic evidence: growth hormone completely prevents reduction in cortical bone gain and partially prevents cancellous osteopenia in the tibia of hypophysectomized rats. The Anatomical Record 1997; 249(2):163-172.	26	8-9692

	Vol	Page No.
L11 Graeves P. Histopathology of preclinical toxicity studies: interpretation and relevance in drug safety evaluation. Elsevier, Amsterdam, 1990; 210-214.	26	8-9702
L12 Francesc V, Chambard JC, Pouysségur J. p70 S6 Kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem 1999;274:26776-26782.	26	8-9710
L13 Yu Y, Sato JD: MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999;178:235-246.	2	8-208
L14 Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Fiegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135.	2	8-220
L15 Lesniak MS, Langer R, Brem H. Drug delivery to tumors of the central nervous system. Curr Neurol Neurosci Rep 2001; 1:210-216.	26	8-9717
L16 Papadopoulos MC, Saadoun S, Davies DC, Bell BA. Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 2001; 15:101-108.	26	8-9724
9. Previous Human Experience with Investigational Drug		
Sectional Table of Contents	26	9-1
• Summary of Human Findings	26	9-3
• Human Pharmacokinetics and Metabolism	26	9-5
• Safety and efficacy in Humans	26	9-10
Relevant published information and bibliography	N/A	N/A

RAD001 IND # 66,279 Dec 19, 2002

Archives
cc: Chron

Fax



DIVISION OF ONCOLOGY DRUG PRODUCTS
Center for Drug Evaluation and Research, HFD-150
Parklawn Building
5600 Fishers Lane, Rockville, MD 20857

To: Kevin Carl, Novartis	From: Ann Staten, Project Manager
Fax: 973-781-5217	Fax: 301-827-4590
Phone: 973-781-8165	Phone: 301-594-0490
Pages: 1	Date: December 19, 2002
Re: IND 66,279 RAD001	

Urgent For Review Please Comment Please Reply Please Recycle

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination or other action based on the content of the communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us at the above address by mail. Thank you.

Dear Mr. Carl,

Please refer to your Investigational New Drug Application (IND) submitted November 22, 2002 pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act for RAD001.

We have completed the review of your IND and conclude it is reasonably safe to proceed with your proposed study based upon your December 19, 2002 agreement to correct the deficiency, which was forwarded to you by e-mail transmission on December 18, 2002.

Please let me know if you have any questions.

Sincerely,

Ann

APPENDIX L

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	04/08/2009	Amendment updates reference standards and retest period and storage temperature in support of upcoming clinical studies (PS).	813		CMC Amendment	
66,279	RAD 001C	04/03/2009	Updated CMC for 0.25mg, 0.5mg, 0.75 mg and 1 mg tablets in support of upcoming clinical studies. (PS)	811		CMC Amendment	
66,279	RAD 001C	03/19/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Irene Ghobrial, Dana Farber Cancer Institute, Boston, MA (PS).	801		Other	
66,279	RAD 001C	03/17/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Joseph Sinning, Harold Lleeve Regional Cancer Center, Waterbury, CT (PS).	800		Other	
66,279	RAD 001C	03/13/2009	Email Response to FDA Request including executive summary of final key results of Protocol CRAD001C2121 Regarding Bioavailability of everolimus.			Other	
66,279	RAD 001C	03/12/2009	Provided executive summary of final key results of Protocol CRAD001C2121 Regarding Bioavailability of everolimus (PS).	798		Clinical Information Amendr	
66,279	RAD 001C	03/12/2009	New Protocol CRAD001M2301 entitled "A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC)" (PS).	799		New Protocol	
66,279	RAD 001C	03/10/2009	Acknowledge Withdrawal of SN598 Special Protocol Assessment requested on May 1, 2008. Withdrawal requested on October 15, 2008.			Other	
66,279	RAD 001C	03/10/2009	Acknowledge Withdrawal of SN579 Special Protocol Assessment requested on April 7, 2008. Withdrawal requested on November 13, 2008.			Other	
66,279	RAD 001C	03/06/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Jennifer Chan, Dana-Farber Cancer Institute, Boston, MA (PS).	796		Other	
66,279	RAD 001C	03/06/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Anne Beaven, Duke University Medical Center, Durham, NC (PS).	795		Other	
66,279	RAD 001C	02/27/2009	Study CRAD001N2301 new protocol. (PS)	790		New Protocol	
66,279	RAD 001C	02/24/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Denise Yardley, SCRI Oncology Research Consortium, Nashville, TN (PS).	786		Other	
66,279	RAD 001C	02/20/2009	Annual Report covering the period of November 24, 2007 to November 24, 2008 (PS).	785		Annual Report	
66,279	RAD 001C	02/19/2009	Amendment No. 3 to Protocol CRAD001L2201 (PS).	783		Change In Protocol	
66,279	RAD 001C	02/18/2009	Request for Type B EOP2 meeting to discuss development plan of RAD001 for the treatment of patients with locally advanced or metastatic breast cancer. (PS)	781		Request for FDA Meeting	
66,279	RAD 001C	02/11/2009	PHHO2008US15235; follow-up (PS)	780		Safety Report	
66,279	RAD 001C	02/10/2009	PHHY2008DE25330; follow-up (PS)	779		Safety Report	
66,279	RAD 001C	02/10/2009	PHHO2009IT00723; follow-up (PS)	778		Safety Report	
66,279	RAD 001C	02/09/2009	PHHO2008US14020; follow-up (PS)	777		Safety Report	
66,279	RAD 001C	02/09/2009	PHHO2009IT00723; follow-up (PS)	776		Safety Report	

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 02/06/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Fury, Memorial Sloan-Kettering Cancer Center, NY. (PS)	774		Other
66,279	RAD 001C 02/06/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Wen W. Ma, Roswell Park Cancer Institute, Buffalo, NY. (PS)	775		Other
66,279	RAD 001C 02/05/2009	Studies CRAD001L2401,CRAD001N2201,CRAD001L2201,CRAD00 new investigator (PS).	773		New Investigator
66,279	RAD 001C 02/03/2009	Submission of Clinical Information Amendment providing for changes to the Investigator Brochure, Edition 7 Release Date: 21-Jan-2009 (PS)	772		Clinical Information Amendr
66,279	RAD 001C 01/29/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Sarah Ketchum, Mercy Oncology/Hematology Center Portland, ME (PS).	769		Other
66,279	RAD 001C 01/29/2009	PHHO2009IT00723; follow-up (PS)	771		Safety Report
66,279	RAD 001C 01/29/2009	PHHO2008FR13655; follow-up (PS)	770		Safety Report
66,279	RAD 001C 01/27/2009	PHHO2008FR13655 (PS)	768		Safety Report
66,279	RAD 001C 01/26/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Herbert Hurwitz, Duke University Medical Center Durham, NC (PS).	766		Other
66,279	RAD 001C 01/26/2009	PHHO2008US15235; follow-up (PS)	767		Safety Report
66,279	RAD 001C 01/21/2009	PHHO2008US14734 (PS)	765		Safety Report
66,279	RAD 001C 01/21/2009	PHHO2009IT00723 (PS)	764		Safety Report
66,279	RAD 001C 01/15/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Talpaz, Ann Arbor, MI. (PS)	763		Other
66,279	RAD 001C 01/15/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Jochem H. Lorch, Dana Farber Cancer Institute, Boston, MA (PS)	762		Other
66,279	RAD 001C 01/14/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Mark W. Kieran, Dana Farber Cancer Institute, Boston, MA (PS).	761		Other
66,279	RAD 001C 01/14/2009	PHHO2008US15235; follow-up (PS)	760		Safety Report
66,279	RAD 001C 01/13/2009	PHHO2008TR15236; follow-up (PS)	759		Safety Report
66,279	RAD 001C 01/09/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Herbert Hurwitz, Duke University Medical Center, Durham, NC (PS)	758		Other
66,279	RAD 001C 01/09/2009	PHHO2008TR15236; follow-up (PS)	757		Safety Report
66,279	RAD 001C 01/08/2009	Letter authorizing FDA to refer to IND 66,279 in support of IND filed by Dr. Zev A. Wainberg, David Geffen School of Medicine at UCLA, Los Angeles, CA (PS).	756		Other
66,279	RAD 001C 01/07/2009	PHHO2008US14020; follow-up (PS)	755		Safety Report
66,279	RAD 001C 01/07/2009	PHHO2008US15235 (PS)	754		Safety Report
66,279	RAD 001C 01/07/2009	PHHO2008DE11094; follow-up (PS)	753		Safety Report
66,279	RAD 001C 01/05/2009	PHHO2008TR15236 (PS)	752		Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 01/02/2009	PHHO2008DE11982; follow-up (PS)	751		Safety Report
66,279	RAD 001C 12/29/2008	PHHO2008US13880; follow-up (PS)	750		Safety Report
66,279	RAD 001C 12/26/2008	PHHO2008CH13360; follow-up (PS)	749		Safety Report
66,279	RAD 001C 12/26/2008	PHHO2008CH13379; follow-up (PS)	748		Safety Report
66,279	RAD 001C 12/18/2008	Letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. Zev A. Wainberg, David Geffen School of Medicine at UCLA, Los Angeles, CA (PS).	746		General Correspondence
66,279	RAD 001C 12/17/2008	Letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. Mark H. Kirschbaum, City of Hope National Cancer Center, Duarte, CA. (PS)	745		General Correspondence
66,279	RAD 001C 12/16/2008	Studies CRAD001L2401,CRAD001N2201,CRAD001L2201,CRAD00 new investigator. (PS)	744		New Investigator
66,279	RAD 001C 12/15/2008	PHHO2007US20875; follow-up (PS)	743		Safety Report
66,279	RAD 001C 12/12/2008	PHHO2008BE12855; follow-up (PS)	742		Safety Report
66,279	RAD 001C 12/10/2008	Revision to letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. Bergsland, UCSF Comprehensive Cancer Center, San Francisco, CA (PS)	738		Other
66,279	RAD 001C 12/10/2008	Letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. Gilad Amiel, Baylor College of Medicine, Houston, TX (PS)	739		General Correspondence
66,279	RAD 001C 12/10/2008	Letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA (PS)	740		General Correspondence
66,279	RAD 001C 12/10/2008	PHHO2008DE11094; follow-up (PS)	741		Safety Report
66,279	RAD 001C 12/09/2008	PHHO2008US14020; follow-up (PS)	736		Safety Report
66,279	RAD 001C 12/09/2008	PHHO2008DE11982 (PS)	737		Safety Report
66,279	RAD 001C 12/08/2008	PHHO2008IT09241; follow-up (PS)	735		Safety Report
66,279	RAD 001C 12/05/2008	PHHO2008US14020 (PS)	734		Safety Report
66,279	RAD 001C 12/04/2008	PHHO2008US13880 (PS)	733		Safety Report
66,279	RAD 001C 12/03/2008	The final internal meeting minutes from the DLBCL FDA end of phase II meeting to discuss a study in diffuse large B-cell lymphoma. (PS)			Other
66,279	RAD 001C 12/03/2008	PHHO2008DE11491; follow-up (PS)	732		Safety Report
66,279	RAD 001C 12/03/2008	Amendment No. 2 to Protocol CRAD001L2201(PS).	731		Change In Protocol
66,279	RAD 001C 12/02/2008	PHHO2008IT09241; follow-up (PS)	727		Safety Report
66,279	RAD 001C 12/02/2008	PHHO2008CH13360; follow-up (PS)	728		Safety Report
66,279	RAD 001C 12/02/2008	PHHO2008CH13379; follow-up (PS)	729		Safety Report
66,279	RAD 001C 12/02/2008	PHHO2008US14108 (PS)	730		Safety Report
66,279	RAD 001C 11/26/2008	PHHO2008CH13360; follow-up (PS)	725		Safety Report
66,279	RAD 001C 11/26/2008	PHHO2008CH13379; follow-up (PS)	726		Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 11/25/2008	PHHO2007AU11574; follow-up (PS)	722		Safety Report
66,279	RAD 001C 11/25/2008	PHHO2008IT01481; follow-up (PS)	723		Safety Report
66,279	RAD 001C 11/25/2008	PHHO2008IT09241 (PS)	724		Safety Report
66,279	RAD 001C 11/21/2008	PHHO2008TW11206; follow-up (PS)	720		Safety Report
66,279	RAD 001C 11/21/2008	PHHO2008DE11094; follow-up (PS)	721		Safety Report
66,279	RAD 001C 11/19/2008	PHHO2008CH13379 (PS)	718		Safety Report
66,279	RAD 001C 11/19/2008	PHHO2008CH13360 (PS)	719		Safety Report
66,279	RAD 001C 11/18/2008	PHHO2008TW11206; follow-up (PS)	717		Safety Report
66,279	RAD 001C 11/17/2008	PHHO2008BE12855 (PS)	716		Safety Report
66,279	RAD 001C 11/14/2008	PHHO2008DE11491; follow-up (PS)	715		Safety Report
66,279	RAD 001C 11/13/2008	Withdrawal request for special protocol assessment submitted on April 7, 2008 (SN579) for protocol CRAD001M2301. (PS)	714		General Correspondence
66,279	RAD 001C 11/13/2008	Email Withdrawal of SPA Submitted 20080417			Other
66,279	RAD 001C 11/13/2008	PHHO2008US12593; follow-up (PS)	713		Safety Report
66,279	RAD 001C 11/12/2008	Study CRAD001L2401 change in protocol, amendment 2. (PS)	711		Change In Protocol
66,279	RAD 001C 11/12/2008	Amendment No. 3 to Protocol CRAD001C2116 (PS).	712		Change In Protocol
66,279	RAD 001C 11/11/2008	Email with FDA letter regarding pediatric studies attached.			Other
66,279	RAD 001C 11/11/2008	PHHO2008IT11948; follow-up (PS)	710		Safety Report
66,279	RAD 001C 11/10/2008	PHHY2008DE25330; follow-up (PS)	709		Safety Report
66,279	RAD 001C 11/10/2008	New Protocol CRAD001C2121 entitled "A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects" (PS).	708		New Protocol
66,279	RAD 001C 11/06/2008	Letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. Lipton, Milton S. Hershey Medial Center, Hershey, PA. (PS)	706		Other
66,279	RAD 001C 11/06/2008	PHHO2008CA11400; follow-up (PS)	707		Safety Report
66,279	RAD 001C 11/05/2008	Letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. Glenn Kroog, Memorial Sloan-Kettering Cancer Center, NY. (PS)	705		General Correspondence
66,279	RAD 001C 11/04/2008	Study CRAD001L2401 new investigator. (PS)	704		New Investigator
66,279	RAD 001C 10/29/2008	PHHY2008SG20428 follow-up (PS)	703		Safety Report
66,279	RAD 001C 10/28/2008	Letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. Gariand, Arizona Cancer Center, Tuscon, AZ. (PS)	700		General Correspondence
66,279	RAD 001C 10/28/2008	Letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. Bergsland, UCSF Comprehensive Cancer Center, San Francisco, CA. (PS)	701		General Correspondence

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C	10/28/2008	Letter authorizing FDA to refer to IND 66,279 in support of an IND filed by Dr. George, Dana-Farber Cancer Institute, Boston, MA. (PS)	702		General Correspondence
66,279	RAD 001C	10/28/2008	PHHO2008DE11094 follow-up (PS)	698		Safety Report
66,279	RAD 001C	10/28/2008	PHHO2008DE12119 follow-up (PS)	699		Safety Report
66,279	RAD 001C	10/27/2008	PHHY2008DE25330 (PS)	697		Safety Report
66,279	RAD 001C	10/27/2008	PHHO2007US20875; follow-up (PS)	695		Safety Report
66,279	RAD 001C	10/27/2008	PHHO2008US12593 (PS)	696		Safety Report
66,279	RAD 001C	10/24/2008	PHHO2008DE11094 (PS)	694		Safety Report
66,279	RAD 001C	10/21/2008	PHHO2008DE12119 (PS)	693		Safety Report
66,279	RAD 001C	10/17/2008	E-mail from FDA. Conformation of Type A meeting (TC) on September 18, 2008 and follow-up questions. (PS)			Other
66,279	RAD 001C	10/16/2008	PHHO2008IT11948 (PS)	692		Safety Report
66,279	RAD 001C	10/16/2008	E-mail to FDA regarding withdrawal of SPA for protocol CRAD001M2302. (PS)			Other
66,279	RAD 001C	10/15/2008	This correspondence to the FDA is to withdraw the request for special protocol assessment for study CRAD001M2302. (PS)	691		General Correspondence
66,279	RAD 001C	10/15/2008	New investigator to study CRAD001L2401 and new investigator to study CRAD001C2111. (PS)	690		New Investigator
66,279	RAD 001C	10/14/2008	Email to/from the FDA regarding the pending letter for the PPSR.			Other
66,279	RAD 001C	10/14/2008	Email from/to the FDA regarding the meeting minutes of the September 18, 2008 Type A meeting.			Other
66,279	RAD 001C	10/14/2008	PHHO2008DE11491 (PS)	688		Safety Report
66,279	RAD 001C	10/14/2008	PHHO2007US00556; follow-up (PS)	689		Safety Report
66,279	RAD 001C	10/10/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Dr. Matthew Fury, MD. (PS)	687		Other
66,279	RAD 001C	10/08/2008	PHHO2008CA04926; follow-up (PS)	686		Safety Report
66,279	RAD 001C	10/07/2008	Email from/to the FDA containing the word document of the EoP2 questions.			Other
66,279	RAD 001C	10/03/2008	EOP2 briefing book for the meeting scheduled for November 13, 2008. (PS)	681		Briefing Book
66,279	RAD 001C	10/03/2008	PHHO2008AR00668; follow-up (PS)	685		Safety Report
66,279	RAD 001C	10/02/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66279 for RAD001(everolimus) in support of an Investigational New Drug Application (IND) that will be filed by Kristin Zorn, M.D. (PS)	684		Other

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 10/02/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66279 for RAD001(everolimus) in support of an Investigational New Drug Application (IND) that will be filed by John D. Hainsworth, MD. (PS)	683		Other
66,279	RAD 001C 10/01/2008	Reference is made to the Letter of Authorization submitted on September 10, 2008 (SN 667) to authorize the FDA to refer to IND 66,279 for RAD001 (everolimus) in support of an Investigational New Drug Application (IND) that will be filed by Dr. David R. Gandara. With this submission Novartis would like to correct, that the principal investigator for the above mentioned study is Dr. Randeep Sangha, MD. (PS)	682		Other
66,279	RAD 001C 09/30/2008	PHHO2008TW11206 (PS)	679		Safety Report
66,279	RAD 001C 09/30/2008	PHHO2008CA11400 (PS)	680		Safety Report
66,279	RAD 001C 09/23/2008	PHHO2008US10695;Follow-Up (PS)	678		Safety Report
66,279	RAD 001C 09/23/2008	PHHO2008DE10143;Follow-Up (PS)	677		Safety Report
66,279	RAD 001C 09/19/2008	Email to/from the FDA regarding the Type A meeting scheduled for September 18, 2008.			Other
66,279	RAD 001C 09/19/2008	PHHO2008NO01190;Follow-Up (PS)	675		Safety Report
66,279	RAD 001C 09/18/2008	PHHY2008JP20446;Follow-Up (PS)	674		Safety Report
66,279	RAD 001C 09/18/2008	PHHY2008SG20428 (PS)	673		Safety Report
66,279	RAD 001C 09/17/2008	Email to/from the FDA regarding the pending PPSR.			Other
66,279	RAD 001C 09/16/2008	PHHO2008US10695 (PS)	672		Safety Report
66,279	RAD 001C 09/12/2008	PHHO1997FR03054 (PS)	671		Safety Report
66,279	RAD 001C 09/12/2008	Email from/to the FDA regarding the Type A meeting scheduled for September 18, 2008.			Other
66,279	RAD 001C 09/11/2008	PHHO1997NO02602 (PS)	670		Safety Report
66,279	RAD 001C 09/11/2008	Email from/to the FDA confirming the Type A meeting scheduled for September 18, 2008 and containing Novartis' follow-up questions.			Other
66,279	RAD 001C 09/10/2008	PHHO2008CA00612; follow-up (PS)	669		Safety Report
66,279	RAD 001C 09/10/2008	PHHO2007US21124; follow-up (PS)	668		Safety Report
66,279	RAD 001C 09/10/2008	Email from/to the FDA confirming the EoP2 meeting scheduled for November 13, 2008.			Other
66,279	RAD 001C 09/10/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66279 for RAD001(everolimus) in support of an Investigational New Drug Application (IND) that will be filed by David R. Gandara, MD. (PS)			Other
66,279	RAD 001C 09/09/2008	Email from the FDA containing the FDA's preliminary responses to Novartis' questions submitted in the meeting request submitted dated July 14, 2008.			Other

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	09/05/2008	New protocol RAD001O2101 entitled: "A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma". (PS)	666			New Protocol
66,279	RAD 001C	09/05/2008	Amendment No. 1 to protocol CRAD001L2201. (PS)	665			Change In Protocol
66,279	RAD 001C	09/04/2008	PHHO2007FR07389; follow-up (PS)	664			Safety Report
66,279	RAD 001C	09/03/2008	PHHO2008DE10143 (PS)	663			Safety Report
66,279	RAD 001C	09/02/2008	PHHO2007US21124;Follow-Up (PS)	660			Safety Report
66,279	RAD 001C	09/02/2008	PHHO2008FR08863;Follow-Up (PS)	661			Safety Report
66,279	RAD 001C	09/02/2008	PHHO2008CY09722;Follow-Up (PS)	662			Safety Report
66,279	RAD 001C	09/02/2008	Email to FDA following up on the pending SPAs for protocol M2301 (SEGA, submitted April 7, 2008), and protocol M2302 (Angyomyolipoma, submitted May 1, 2008).				Other
66,279	RAD 001C	08/29/2008	Request for Type B meeting to seek the agency's advice on the proposed development plan for RAD001 in patients with Diffuse Large B-Cell Lymphoma (DLBCL) and the acceptability of the design of the Phase III registration trial (Study CRAD001N2301), which will form the primary basis to support registration and approval of this indication. (PS)	659			Request for FDA Meeting
66,279	RAD 001C	08/28/2008	PHHO2008CA04926;Follow-Up (PS)	657			Safety Report
66,279	RAD 001C	08/28/2008	PHHO2008FR08863;Follow-Up (PS)	656			Safety Report
66,279	RAD 001C	08/28/2008	PHHO2008US05802; follow-up (PS)	658			Safety Report
66,279	RAD 001C	08/27/2008	New investigator to study CRAD001L2201 and CRAD001L2401. (PS)	655			New Investigator
66,279	RAD 001C	08/22/2008	At this time, Novartis is submitting an IND Amendment to provide updated Chemistry, Manufacturing and Controls information for the drug product. An updated packaging site list is provided in this amendment. (PS)	653			CMC Amendment
66,279	RAD 001C	08/22/2008	PHHO2008AU08078;Follow-Up (PS)	654			Safety Report
66,279	RAD 001C	08/19/2008	PHHO2008CY09722;Follow-Up (PS)	652			Safety Report
66,279	RAD 001C	08/14/2008	New Investigator to Study CRAD001L2201 (PS)	651			New Investigator
66,279	RAD 001C	08/13/2008	Email to FDA informing them that the desk copies of the briefing documentation for the the Type A Meeting have been submitted.				Other
66,279	RAD 001C	07/31/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Michael K. Gibson, MD. (PS)	650			Other
66,279	RAD 001C	07/31/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Allan Lipton, MD. (PS)	649			Other
66,279	RAD 001C	07/31/2008	PHHO2008US05802;Follow-Up (PS)	648			Safety Report

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	07/28/2008	Fax FDA LETTER Informing Novartis that their meeting request dated July 14, 2008 has been granted.				Other
66,279	RAD 001C	07/25/2008	PHHO2008FR08382;Follow-Up (PS)	646			Safety Report
66,279	RAD 001C	07/22/2008	PHHO2008FR08382;Follow-Up (PS)	645			Safety Report
66,279	RAD 001C	07/21/2008	PHHO2008AU07680;Follow-Up (PS)	644			Safety Report
66,279	RAD 001C	07/16/2008	PHHO2008FR08382;Follow-Up (PS)	642			Safety Report
66,279	RAD 001C	07/16/2008	PHHO2008US07823; Follow-Up (PS)	643			Safety Report
66,279	RAD 001C	07/16/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RADOOL (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Daniel Cho, MD. (PS)	641			Other
66,279	RAD 001C	07/16/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RADOOL (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Charles A. Coltman, Jr. M.D. (PS)	640			Other
66,279	RAD 001C	07/14/2008	Request for Type A meeting to discuss the FDA's stance on whether the requested protocol change to include children under the age of 3 years is acceptable and to gain clarification on procedural aspects of a potential protocol change at this point in the SPA process. (PS)	639			Request for FDA Meeting
66,279	RAD 001C	07/10/2008	PHHO2007FR09520;Follow-Up (PS)	638			Safety Report
66,279	RAD 001C	07/09/2008	PHHO2008AU08078;Follow-Up (PS)	637			Safety Report
66,279	RAD 001C	07/03/2008	PHHO2007PL06777; Follow-Up (PS)	636			Safety Report
66,279	RAD 001C	07/03/2008	Email to FDA requesting advice on SPA submission on April 7, 2008, serial number 579.				Other
66,279	RAD 001C	07/03/2008	New Protocol to Study CRAD001L2201 entitled A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney. (PS)	635			New Protocol
66,279	RAD 001C	07/02/2008	PHHO2008DE05923;Follow-Up (PS)	632			Safety Report
66,279	RAD 001C	07/02/2008	PHHO2008US07899;Follow-Up (PS)	631			Safety Report
66,279	RAD 001C	07/02/2008	PHHO2007ES08365;Follow-Up (PS)	633			Safety Report
66,279	RAD 001C	07/02/2008	New Investigator to Study CRAD001C2324 (PS)	634			New Investigator
66,279	RAD 001C	07/01/2008	PHHO2008US07823;Follow-Up (PS)	630			Safety Report
66,279	RAD 001C	06/30/2008	PHHO2008US06493;Follow-Up (PS)	629			Safety Report
66,279	RAD 001C	06/27/2008	PHHO2008AU07680;Follow-Up (PS)	628			Safety Report
66,279	RAD 001C	06/26/2008	Amendment No. 1 to protocol CRAD001C2114. (PS)	626			Change In Protocol
66,279	RAD 001C	06/26/2008	PHHO2008CA00612;Follow-Up (PS)	627			Safety Report
66,279	RAD 001C	06/24/2008	PHHO2008CA00612;Follow-Up (PS)	625			Safety Report
66,279	RAD 001C	06/20/2008	PHHO2007FR03202;Follow-Up (PS)	624			Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 06/19/2008	PHHO2008DE05923; Follow-Up (PS)	623		Safety Report
66,279	RAD 001C 06/17/2008	New Investigator to Study CRAD001C2410 (PS)	622		New Investigator
66,279	RAD 001C 06/16/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Dr. Maysa M. Abu-Khalaf, M.D. (PS)	621		Other
66,279	RAD 001C 06/13/2008	PHHO2007US21124; Follow-Up (PS)	620		Safety Report
66,279	RAD 001C 06/12/2008	PHHO2008DE05923; Follow-Up (PS)	619		Safety Report
66,279	RAD 001C 06/12/2008	PHHO2008US04833; Follow-Up (PS)	618		Safety Report
66,279	RAD 001C 06/10/2008	PHHO2008DE05923; Follow-Up (PS)	616		Safety Report
66,279	RAD 001C 06/10/2008	Amendment No. 1 to protocol CRAD001L2401. (PS)	617		Change In Protocol
66,279	RAD 001C 06/06/2008	This correspondence to the FDA contains a copy of the original PPSR for RAD 001 submitted on February 19, 2007 (SN 294), a copy of the revised PPSR submitted on August 13, 2007 (SN 379), a copy of the publication 'Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors' (Fouladi M et al. (2007) J Clin Oncology;25:4806-4812) and a copy of the Novartis draft of a Written Request following the new template (provided via e-mail on June 02, 2008). (PS)	613		General Correspondence
66,279	RAD 001C 06/06/2008	PHHO2008US06493; Follow-Up (PS)	615		Safety Report
66,279	RAD 001C 06/06/2008	PHHO2008US01900; Follow-Up (PS)	614		Safety Report
66,279	RAD 001C 06/06/2008	FDA LETTER Responding to Novartis' request for special protocol assessment submitted on May 1, 2008.			Other
66,279	RAD 001C 06/05/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Richard M. Stone, M.D. (PS)	612		Other
66,279	RAD 001C 06/03/2008	PHHO2007DE20351; Follow-Up (PS)	611		Safety Report
66,279	RAD 001C 06/02/2008	PHHO2007FR14620; Follow-Up (PS)	610		Safety Report
66,279	RAD 001C 06/02/2008	Email to FDA containing the new templated of the revised written request.			Other
66,279	RAD 001C 05/30/2008	PHHO2008AR00668; Follow-Up (PS)	609		Safety Report
66,279	RAD 001C 05/29/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Dr. Roberto Pili, M.D. (PS)	608		Other
66,279	RAD 001C 05/22/2008	This submission is in response to the FDA request received on April 17, 2008, requesting a list of all manufacturing and testing sites, their CFN/FEI numbers and contact person's information, involved in the production of the clinical trial material for the treatment protocol CRAD001L2401. (PS)	605		Response to FDA Request

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 05/22/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Susan M. Chang, MD. (PS)	606		Other
66,279	RAD 001C 05/22/2008	New investigator to study CRAD001C2116, CRAD001C2241, CRAD001C2410. (PS)	607		New Investigator
66,279	RAD 001C 05/09/2008	FDA LETTER Informing Novartis that they may proceed with the treatment protocol for use in patients with metastatic carcinoma of the kidney who have progressed despite vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.			Other
66,279	RAD 001C 05/09/2008	PHHO2007FR14620;Follow-Up (PS)	604		Safety Report
66,279	RAD 001C 05/09/2008	New investigators to study CRAD001C2324. (PS)	603		New Investigator
66,279	RAD 001C 05/07/2008	Email to FDA responding to their fax dated May 6, 2008.			Response to FDA Request
66,279	RAD 001C 05/07/2008	New investigators to study RAD001C2324. (PS)	601		New Investigator
66,279	RAD 001C 05/07/2008	This correspondence to the FDA contains Novartis' response to the FDA comments dated May 6, 2008 regarding the informed consent. (PS)	602		General Correspondence
66,279	RAD 001C 05/06/2008	Fax FDA LETTER Requesting information regarding the Informed Consent submitted with the treatment protocol.			Other
66,279	RAD 001C 05/06/2008	This correspondence to the FDA is to re-submit the trade name Afinitor for trademark review in light of the upcoming NDA submission in the treatment of patients with advanced renal cell carcinoma. (PS)	600		General Correspondence
66,279	RAD 001C 05/06/2008	Email to FDA regarding the submission of the updated tradename review.			Other
66,279	RAD 001C 05/05/2008	Email to FDA informing them of Novartis' response to their comments on treatment protocol CRA001L2401 (FDA Faxes dated 23 and 29 April 2008). Also includes a copy of the draft protocol amendment.			Other
66,279	RAD 001C 05/01/2008	PHHO2008DE03857; follow-up (PS)	597		Safety Report
66,279	RAD 001C 05/01/2008	Email to FDA informing them that Novartis has submitted the request for SPA for study CRAD001M2302. Also providing the FDA with the names of three treating physicians of angliomyolipoma patients.			Other
66,279	RAD 001C 05/01/2008	Request for special protocol assessment for study CRAD001M2302. (PS)	598		Other
66,279	RAD 001C 04/30/2008	PHEH2000US08591;Follow-Up (PS)	595		Safety Report
66,279	RAD 001C 04/30/2008	PHHO2008US04833; follow-up (PS)	596		Safety Report
66,279	RAD 001C 04/29/2008	New protocol CRAD001N2201 entitled: 'An open-label, single-arm phase II study of RAD001 in patients with refractory mantle cell lymphoma'. (PS)	592		New Protocol
66,279	RAD 001C 04/29/2008	PHHO2008CA04926;Follow-Up (PS)	593		Safety Report
66,279	RAD 001C 04/29/2008	PHHO2008JP04055;Follow-Up (PS)	594		Safety Report
66,279	RAD 001C 04/29/2008	Fax FDA LETTER Requesting additional information on the treatment protocol submitted on March 26, 2008.			Other

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 04/28/2008	PHHO2008US04833; Follow-Up (PS)	591		Safety Report
66,279	RAD 001C 04/25/2008	PHHO2007IT19720; Follow-Up (PS)	590		Safety Report
66,279	RAD 001C 04/24/2008	Fax FDA LETTER Requesting additional clinical information on the treatment protocol submitted March 26, 2008.			Other
66,279	RAD 001C 04/23/2008	PHHO2008US01900; follow-up (PS)	589		Safety Report
66,279	RAD 001C 04/23/2008	Fax to FDA responding to their April 17, 2008 request for additional CMC information.			Response to FDA Request
66,279	RAD 001C 04/22/2008	PHHO2008US04833 (PS)	587		Safety Report
66,279	RAD 001C 04/22/2008	PHHO2008US04735 (PS)	586		Safety Report
66,279	RAD 001C 04/22/2008	Amendment No. 3 to protocol CRAD001J2101. (PS)	588		Change In Protocol
66,279	RAD 001C 04/22/2008	Email to FDA containing the new draft WR template for the PPSR submitted on August 13, 2007, serial number 379.			Other
66,279	RAD 001C 04/21/2008	PHHO2008IT01481; follow-up (PS)	585		Safety Report
66,279	RAD 001C 04/18/2008	PHHO2008DE03857; follow-up (PS)	584		Safety Report
66,279	RAD 001C 04/17/2008	Fax FDA LETTER Requesting additional CMC information on the treatment protocol submitted March 26, 2008.			Other
66,279	RAD 001C 04/15/2008	PHHO2008JP04055 (PS)	583		Safety Report
66,279	RAD 001C 04/15/2008	HA meeting minutes of the April 3, 2008 Pre-NDA meeting between Novartis and the FDA to discuss the planned NDA for RAD011 for metastatic renal cell carcinoma (mRCC) and advanced pancreatic neuroendocrine tumors (pNET).			FDA/Novartis Meeting Minu
66,279	RAD 001C 04/14/2008	Email to FDA containing the e-mail trail on the topic Special Protocol Assessment (SPA) for clinical study protocol CRAD001M2301 entitled 'A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC), and for clinical study protocol CRAD001M2302 'A randomized, double-blind, placebo-controlled study of RAD0001 in the treatment of Angiomyolipomata in patients with either			Other
66,279	RAD 001C 04/14/2008	At this time Novartis is providing a CMC information amendment to provide updated information, manufacturing sites, stability programs and other CMC changes to the drug product. (PS)	582		CMC Amendment
66,279	RAD 001C 04/11/2008	PHHO2007FR18497; follow-up (PS)	581		Safety Report
66,279	RAD 001C 04/08/2008	PHHO2008IT01481; follow-up (PS)	580		Safety Report
66,279	RAD 001C 04/07/2008	FDA and Novartis email correspondence. Novartis has submitted request for SPA on April 7, 2008; relevant to protocol CRAD001M2301. Cover letter of this submission is appended (PS)			Other
66,279	RAD 001C 04/07/2008	Protocol CRAD001M2301 request for SPA. (PS)	579		Other
66,279	RAD 001C 04/04/2008	Email correspondence to FDA regarding Pre-NDA meeting for RAD001 and providing electronic copies of the handouts which we brought to the meeting: the background slides to Novartis' follow- up questions, and the draft Table of Contents of the RAD001 eCTD (PS)			Other
66,279	RAD 001C 04/04/2008	PHHO2008DE03857; follow-up (PS)	578		Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 04/02/2008	FDA email with appended responses and comments, in preparation for Pre-NDA meeting of April, 3 2008 (PS)			Other
66,279	RAD 001C 04/02/2008	Email between FDA and Novartis related to outstanding CMC and Clinical questions and comments pertaining to discussion set for Pre-NDA meeting on April 3, 2008 (PS)			Other
66,279	RAD 001C 04/02/2008	FDA email providing a list of attendees for Pre-NDA meeting (PS)			Other
66,279	RAD 001C 03/31/2008	Email to FDA containing an updated list of Novartis participants for the Pre-NDA meeting scheduled on April 3, 2008.			Other
66,279	RAD 001C 03/31/2008	Email from FDA regarding the revised FDA template letter and containing an updated PPSR template.			Other
66,279	RAD 001C 03/28/2008	Email to FDA containing the revised FDA template letter, with regard to the PPSR.			Other
66,279	RAD 001C 03/28/2008	PHHO2008DE03857 (PS)	577		Safety Report
66,279	RAD 001C 03/27/2008	PHHO2008US01990; follow-up (PS)	576		Safety Report
66,279	RAD 001C 03/26/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Eileen O'Reilly, M.D. (PS)	571		Other
66,279	RAD 001C 03/26/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Chong-Xian Pan, MD, PhD. (PS)	572		Other
66,279	RAD 001C 03/26/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Matthew I. Milowsky, MD. (PS)	573		Other
66,279	RAD 001C 03/26/2008	New protocol CRAD001L2401 entitled: "An open-label, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who have progressed despite vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy". (PS)	574		New Protocol
66,279	RAD 001C 03/26/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Jochen H. Lorch, M.D., M.S. (PS)	575		Other
66,279	RAD 001C 03/25/2008	PHHO2007NO19319 follow-up (PS)	570		Safety Report
66,279	RAD 001C 03/25/2008	PHHO2007US21124 follow-up (PS)	569		Safety Report
66,279	RAD 001C 03/25/2008	Email to FDA responding to their request for an electronic copy of the request for trade name review, which was submitted on September 24, 2007.			Response to FDA Request
66,279	RAD 001C 03/21/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) for treatment use in a single patient that will be filed by Dr. Shawn Glisson. (PS)	568		Other

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 03/20/2008	PHHO2007US20563; follow-up (PS)	566		Safety Report
66,279	RAD 001C 03/20/2008	New investigator to study CRAD001C2242 and CRAD001C2325. New investigators to study CRAD001C2324. (PS)	567		New Investigator
66,279	RAD 001C 03/20/2008	Email to FDA regarding the submission of a treatment protocol intended to allow for expanded access to RAD001 for the treatment of patients with metastatic renal cell carcinoma (mRCC) who have progressed despite VEGFr TKI therapy.			Other
66,279	RAD 001C 03/19/2008	Email to/from the FDA regarding the establishment of the secure e-mail.			Other
66,279	RAD 001C 03/18/2008	Email to FDA containing the cover letter for the Pre-NDA briefing book and the the briefing book amendment.			Other
66,279	RAD 001C 03/17/2008	PHHO2007US21124; Follow-Up (PS)	565		Safety Report
66,279	RAD 001C 03/13/2008	Email to the FDA containing an electronic copy of the amendment to the Pre-NDA Briefing book that was submitted on March 13, 2008.			Briefing Book
66,279	RAD 001C 03/13/2008	Email to the FDA containing questions regarding the pending PPSR and pending pre-market evaluation of trademark.			Other
66,279	RAD 001C 03/13/2008	This correspondence to the FDA contains an amendment to the Pre-NDA briefing book for the April 3, 2008 Pre-NDA meeting. (PS)	564		General Correspondence
66,279	RAD 001C 03/12/2008	PHHO2008AU01363 (PS)	563		Safety Report
66,279	RAD 001C 03/12/2008	Email to the FDA containing the Pre-NDA questions and cover letter, as well as the list of Novartis attendees for the meeting scheduled April 3, 2008.			Other
66,279	RAD 001C 03/12/2008	Email to FDA regarding the planned SPAs for SEGa and AML studies.			Other
66,279	RAD 001C 03/10/2008	Email to/from the FDA regarding the planned SPA for SEGA and AML studies and the delay until in submission.			Other
66,279	RAD 001C 03/07/2008	PHHO2007US21124; follow-up (PS)	561		Safety Report
66,279	RAD 001C 03/07/2008	PHHO2007NO19319; follow-up (PS)	562		Safety Report
66,279	RAD 001C 03/05/2008	Briefing book for Pre-NDA meeting scheduled for April 3, 2008. (PS)	560		Briefing Book
66,279	RAD 001C 03/05/2008	Email to FDA informing them that the Pre-NDA briefing book was submitted on March 3, 2008.			Other
66,279	RAD 001C 03/04/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Jennifer Chan, MD. (PS)	559		Other
66,279	RAD 001C 03/03/2008	PHHO2008AR00668 (PS)	558		Safety Report
66,279	RAD 001C 02/28/2008	PHHO2008US02416 (PS)	556		Safety Report
66,279	RAD 001C 02/28/2008	PHHO2008IT01481; follow-up (PS)	557		Safety Report
66,279	RAD 001C 02/27/2008	PHHO2007IT19720; follow-up (PS)	554		Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 02/26/2008	Amendment No. 2 and 3 to protocol CRAD001C2111. (PS)	553		Change In Protocol
66,279	RAD 001C 02/25/2008	PHHO2007FR13915; follow-up (PS)	552		Safety Report
66,279	RAD 001C 02/20/2008	PHHO2007NO19319; follow-up (PS)	548		Safety Report
66,279	RAD 001C 02/20/2008	PHHO2007IT19720; follow-up (PS)	549		Safety Report
66,279	RAD 001C 02/20/2008	PHHO2007FR14001; follow-up (PS)	550		Safety Report
66,279	RAD 001C 02/19/2008	PHHO2008FR02098 (PS)	545		Safety Report
66,279	RAD 001C 02/19/2008	PHHO2007FR14620; follow-up (PS)	546		Safety Report
66,279	RAD 001C 02/15/2008	Novartis is herewith providing the Statistical Analysis Plan for protocol CRAD001C2239 prior to data base lock. (PS)	544		Other
66,279	RAD 001C 02/14/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Sunil Sharma, MD. (PS)	542		Other
66,279	RAD 001C 02/14/2008	PHHO2008US01900 (PS)	543		Safety Report
66,279	RAD 001C 02/13/2008	Amendment No. 1 and 2 to protocol CRad001J2101. (PS)	540		Change In Protocol
66,279	RAD 001C 02/13/2008	Amendment No. 1 and 2 to protocol CRAD001C2116. (PS)	541		Change In Protocol
66,279	RAD 001C 02/12/2008	PHHO2008IT01481 (PS)	538		Safety Report
66,279	RAD 001C 02/12/2008	New investigators to study CRAD001C2324. (PS)	539		New Investigator
66,279	RAD 001C 02/08/2008	PHHO2007FR17369; follow-up (PS)	536		Safety Report
66,279	RAD 001C 02/08/2008	PHHO2007JP19109; follow-up (PS)	537		Safety Report
66,279	RAD 001C 02/08/2008	Email to FDA informing them of Novartis' intent to submit SPAs for SEGA and AML studies.			General Correspondence
66,279	RAD 001C 02/07/2008	PHHO2007FR14001; follow-up (PS)	534		Safety Report
66,279	RAD 001C 02/07/2008	PHHO2007FR13915 (PS)	535		Safety Report
66,279	RAD 001C 02/06/2008	PHHO2007IT19720; follow-up (PS)	533		Safety Report
66,279	RAD 001C 02/06/2008	Email from/to the FDA regarding the Pre-NDA meeting request submitted on January 30, 2008.			Other
66,279	RAD 001C 02/05/2008	PHBS2007BE07399; follow-up (PS)	532		Safety Report
66,279	RAD 001C 01/31/2008	PHHO2007FR18943; Follow-Up (PS)	529		Safety Report
66,279	RAD 001C 01/31/2008	PHHO2007NO19319; Follow-Up (PS)	528		Safety Report
66,279	RAD 001C 01/28/2008	PHHO2007FR18943; follow-up (PS)	524		Safety Report
66,279	RAD 001C 01/28/2008	PHHO2007FR20512; follow-up (PS)	525		Safety Report
66,279	RAD 001C 01/28/2008	PHHO2007FR18940; follow-up (PS)	526		Safety Report
66,279	RAD 001C 01/25/2008	PHHO2007NO19319; follow-up (PS)	523		Safety Report
66,279	RAD 001C 01/23/2008	PHHO2007DE20351; Follow-Up (PS)	520		Safety Report
66,279	RAD 001C 01/23/2008	PHHO2007IT19720 (PS)	521		Safety Report

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	01/22/2008	PHHO2007FR11090; follow-up (PS)	518			Safety Report
66,279	RAD 001C	01/22/2008	PHHO2007FR12501; follow-up (PS)	519			Safety Report
66,279	RAD 001C	01/21/2008	PHHO2007US17617; Follow-Up (PS)	517			Safety Report
66,279	RAD 001C	01/16/2008	PHHO2007US20875; Follow-Up (PS)	516			Safety Report
66,279	RAD 001C	01/15/2008	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Svetomir Markovic, MD, Ph.D. (PS)	515			Other
66,279	RAD 001C	01/09/2008	New investigator to study CRAD001C2324 and new investigator to study CRAD001C2325. (PS)	514			New Investigator
66,279	RAD 001C	01/04/2008	PHHO2007JP17929; Follow-Up (PS)	513			Safety Report
66,279	RAD 001C	01/04/2008	PHHO2007US21124; Follow-Up (PS)	512			Safety Report
66,279	RAD 001C	01/02/2008	PHHO2007FR18943; Follow-Up (PS)	510			Safety Report
66,279	RAD 001C	01/02/2008	PHHO2007JP19109; Follow-Up (PS)	508			Safety Report
66,279	RAD 001C	01/02/2008	PHHO2007FR11090; Follow-Up (PS)	511			Safety Report
66,279	RAD 001C	12/27/2007	PHHO2007US20563; Follow-Up (PS)	507			Safety Report
66,279	RAD 001C	12/27/2007	PHHO2007FR19560; Follow-Up (PS)	506			Safety Report
66,279	RAD 001C	12/24/2007	PHHO2007DE20351; Follow-Up (PS)	504			Safety Report
66,279	RAD 001C	12/24/2007	PHHO2007FR20512; Follow-Up (PS)	503			Safety Report
66,279	RAD 001C	12/24/2007	PHHO2007US13764; Follow-Up (PS)	505			Safety Report
66,279	RAD 001C	12/20/2007	This clinical information amendment contains updated Investigator's Brochure, Edition 6, which replaces Edition 5. (PS)	502			Clinical Information Amendr
66,279	RAD 001C	12/20/2007	PHHO2007FR19560; Follow-up (PS)	500			Safety Report
66,279	RAD 001C	12/20/2007	PHHO2007DE20052; Follow-Up (PS)	501			Safety Report
66,279	RAD 001C	12/18/2007	PHHO2007FR18943; follow-up (PS)	496			Safety Report
66,279	RAD 001C	12/18/2007	PHHO2007CA19062 (PS)	497			Safety Report
66,279	RAD 001C	12/18/2007	PHHO2007DE20052 (PS)	499			Safety Report
66,279	RAD 001C	12/18/2007	New investigator to study CRAD001C2324, CRAD001C2325, CRAD001C2410. (PS)	498			New Investigator
66,279	RAD 001C	12/17/2007	PHHO2007US06570 (PS)	495			Safety Report
66,279	RAD 001C	12/13/2007	PHHO2007US17944; follow-up (PS)	493			Safety Report
66,279	RAD 001C	12/13/2007	PHHO2007JP19109; follow-up (PS)	494			Safety Report
66,279	RAD 001C	12/12/2007	PHBS2007TR02235; Follow-Up (PS)	492			Safety Report
66,279	RAD 001C	12/11/2007	PHHO2007FR19043; Follow-Up (PS)	490			Safety Report
66,279	RAD 001C	12/11/2007	PHHO2007JP17929; Follow-Up (PS)	491			Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 12/10/2007	PHHO2007FR19560 (PS)	488		Safety Report
66,279	RAD 001C 12/10/2007	PHHO2007FR18940 (PS)	487		Safety Report
66,279	RAD 001C 12/10/2007	Amendment No. 1 to protocol CRAD001C2241. (PS)	489		Change In Protocol
66,279	RAD 001C 12/07/2007	PHHO2007FR17914; follow-up (PS)	485		Safety Report
66,279	RAD 001C 12/07/2007	This correspondence to the FDA is to inform them that Dr. Myra Herrie has changed her responsibilities and that, effective immediately, Sibylle Jennings will be the Regulatory Affairs contact for this IND, specifically for the request for orphan drug designation for RAD001 (everolimus) for the treatment of renal carcinoma submitted October 8, 2007, Reference No. 07-2511, and for the request of orphan designation for RAD001 (everolimus) for treatment of patients with gastroenteropancreatic	486		General Correspondence
66,279	RAD 001C 12/06/2007	PHHO2007FR18497; follow-up (PS)	480		Safety Report
66,279	RAD 001C 12/06/2007	PHHO2007NO19319 (PS)	481		Safety Report
66,279	RAD 001C 12/06/2007	PHHO2007JP17929; follow-up (PS)	482		Safety Report
66,279	RAD 001C 12/06/2007	PHHO2007FR11090; follow-up (PS)	483		Safety Report
66,279	RAD 001C 12/06/2007	New investigators to study CRAD001C2242, CRAD001C2324 and CRAD001C2325. (PS)	484		New Investigator
66,279	RAD 001C 12/05/2007	PHHO2007CA19062; follow-up (PS)	477		Response to FDA Request
66,279	RAD 001C 12/05/2007	PHHO2000NO08769 (PS)	478		Safety Report
66,279	RAD 001C 12/05/2007	PHHO2007FR18943 (PS)	479		Safety Report
66,279	RAD 001C 12/04/2007	PHHO2007JP19109 (PS)	475		Safety Report
66,279	RAD 001C 12/04/2007	This correspondence to the FDA is to inform them that Dr. Myra Herrie has transferred responsibilities for this IND to Sibylle Jennings effective immediately. (PS)	476		General Correspondence
66,279	RAD 001C 11/30/2007	New investigators to Study CRAD001C2242 and new investigator to Study CRAD001C2325. (PS)	473		New Investigator
66,279	RAD 001C 11/30/2007	PHHO2007TW16075 (PS)	472		Safety Report
66,279	RAD 001C 11/30/2007	PHHO2007CA19062 (PS)	471		
66,279	RAD 001C 11/30/2007	New investigator to study CRAD001C2101 and new investigators to study CRAD001C2242. (PS)	474		New Investigator
66,279	RAD 001C 11/29/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by John W. Sweetenham, MD. (PS)	469		Other
66,279	RAD 001C 11/29/2007	PHHO2006US22078; follow-up (PS)	470		Safety Report
66,279	RAD 001C 11/28/2007	PHHO2007FR17369; follow-up (PS)	466		Safety Report
66,279	RAD 001C 11/28/2007	PHHO2007US17617; follow-up (PS)	467		Safety Report
66,279	RAD 001C 11/28/2007	PHHO2007FR19043 (PS)	468		Safety Report
66,279	RAD 001C 11/27/2007	PHHO2007CA19062 (PS)	465		Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C	11/21/2007	PHHO2007FR17914; follow-up (PS)	461	Safety Report
66,279	RAD 001C	11/21/2007	PHHO2007FR18497 (PS)	462	Safety Report
66,279	RAD 001C	11/21/2007	PHHO2007FR11090 (PS)	463	Safety Report
66,279	RAD 001C	11/21/2007	Please note that this serial number is a request for Orphan drug designation and was issued Orphan number 072541 by the FDA and therefore can be located in REDI under this number not IND 66,279 as originally submitted.	464	Other
66,279	RAD 001C	11/20/2007	PHHO2007FR03202; follow-up (PS)	460	Safety Report
66,279	RAD 001C	11/15/2007	PHHO2007ES08365; follow-up (PS)	459	Safety Report
66,279	RAD 001C	11/12/2007	PHHO2007JP17793; follow-up (PS)	458	Safety Report
66,279	RAD 001C	11/09/2007	PHHO2007FR17914 (PS)	454	Safety Report
66,279	RAD 001C	11/09/2007	PHHO2007JP17929 (PS)	455	Safety Report
66,279	RAD 001C	11/09/2007	New investigator to study CRAD001J2101. (PS)	457	New Investigator
66,279	RAD 001C	11/09/2007	New investigators to Study CRAD001C2242. (PS)	456	New Investigator
66,279	RAD 001C	11/08/2007	PHHO2007AU14332; follow-up (PS)	452	Safety Report
66,279	RAD 001C	11/08/2007	PHHO2007US17944 (PS)	453	Safety Report
66,279	RAD 001C	11/07/2007	PHHO2007CA15784; follow-up (PS)	451	Safety Report
66,279	RAD 001C	11/05/2007	PHHO2007US17617 (PS)	449	Safety Report
66,279	RAD 001C	11/05/2007	PHHO2007ES08365; follow-up (PS)	450	Safety Report
66,279	RAD 001C	11/02/2007	PHHO2007US12809; follow-up (PS)	448	Safety Report
66,279	RAD 001C	11/01/2007	PHHO2007SE15401; follow-up (PS)	447	Safety Report
66,279	RAD 001C	10/30/2007	PHHO2007FR17369 (PS)	445	Safety Report
66,279	RAD 001C	10/30/2007	PHHO2007JP17793 (PS)	446	Safety Report
66,279	RAD 001C	10/24/2007	PHHO2007FR03202 FOLLOW-UP (PS)	442	Safety Report
66,279	RAD 001C	10/24/2007	PHHO2007CA17142 (PS)	443	Safety Report
66,279	RAD 001C	10/18/2007	PHHO2007FR03202 folow-up (PS)	440	Safety Report
66,279	RAD 001C	10/18/2007	New investigators to Study CRAD001C2325. (PS)	441	New Investigator
66,279	RAD 001C	10/18/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by John D. Hainsworth. (PS)	439	Other
66,279	RAD 001C	10/17/2007	PHHO2007US13977;Follow-Up (PS)	438	Safety Report
66,279	RAD 001C	10/16/2007	PHHO2007US12809; Follow-Up (PS)	437	Safety Report
66,279	RAD 001C	10/15/2007	PHHO2007CA15784; follow-up (PS)	436	Safety Report
66,279	RAD 001C	10/12/2007	PHHO2007US16146 (PS)	434	Safety Report
66,279	RAD 001C	10/12/2007	PHHO2007FR0302; follow-up (PS)	435	Safety Report

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	10/10/2007	PHHO2007FR03202; follow-up (PS)	433		Safety Report	
66,279	RAD 001C	10/09/2007	PHHO2007DE15860 (PS)	432		Safety Report	
66,279	RAD 001C	10/08/2007	PHHO2007US13977 (PS)	431		Safety Report	
66,279	RAD 001C	10/08/2007	PHHO2007US15872; follow-up (PS)	430		Safety Report	
66,279	RAD 001C	10/05/2007	PHHO2007US13764; Follow-Up (PS)	429		Safety Report	
66,279	RAD 001C	10/04/2007	PHHO2007CA15784; Follow-Up (PS)	428		Safety Report	
66,279	RAD 001C	10/04/2007	PHHO2007US15872; Follow-Up (PS)	427		Safety Report	
66,279	RAD 001C	10/03/2007	PHHO2007US12809 (PS)	426		Safety Report	
66,279	RAD 001C	10/02/2007	Email to FDA containing the draft slides for the EoP2 meeting to discuss development in TSC (SEGA + AML).			Other	
66,279	RAD 001C	10/02/2007	Novartis meeting minutes on October 2, 2007. Type EOP2 meeting, to discuss proposed trials for TSC and sponsor's questions. (PS)			FDA/Novartis Meeting Minu	
66,279	RAD 001C	09/28/2007	PHHO2004BE07879; follow-up (PS)	423		Safety Report	
66,279	RAD 001C	09/28/2007	Amendment No. 4 to protocol CRAD001C2111 (PS)			Change In Protocol	
66,279	RAD 001C	09/28/2007	This correspondence to the FDA is to correct the IND number listed on box 6 of the 1571. (PS)	425		General Correspondence	
66,279	RAD 001C	09/27/2007	PHHO2007FR03202; follow-up (PS)	422		Safety Report	
66,279	RAD 001C	09/26/2007	Email to FDA containing a word document of questions posed in the briefing book.			Other	
66,279	RAD 001C	09/26/2007	Email to FDA containing the revised FDA template letter.			Other	
66,279	RAD 001C	09/25/2007	Email to FDA containing the documentation sent to the FDA requesting Tradename Review for RAD001.			Other	
66,279	RAD 001C	09/25/2007	PHHO2007AU14332; follow-up (PS)	419		Safety Report	
66,279	RAD 001C	09/25/2007	PHHO2007SE15401 (PS)	420		Safety Report	
66,279	RAD 001C	09/25/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Mary-Ellen Taplin, MD (PS)	421		Other	
66,279	RAD 001C	09/24/2007	At this time, Novartis is submitting documentation to the Oncology Division in support of the current strategy of two brand names for the active ingredient everolimus for the transplant and oncology indications. Novartis is hereby requesting pre-market evaluation of the trademark AFINITOR. (PS)	418		General Correspondence	
66,279	RAD 001C	09/21/2007	PHHO2007AU14332 (PS)	417		Safety Report	
66,279	RAD 001C	09/20/2007	PHHO2007US07788; follow-up (PS)	415		Safety Report	
66,279	RAD 001C	09/20/2007	PHHO2007AU11574; follow-up (PS)	416		Safety Report	
66,279	RAD 001C	09/19/2007	PHHO2007ES08365; follow-up (PS)	414		Safety Report	
66,279	RAD 001C	09/18/2007	PHHO2007FR14001; follow-up (PS)	412		Safety Report	

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 09/18/2007	PHHO2007FR14620 (PS)	413		Safety Report
66,279	RAD 001C 09/17/2007	Email from FDA containing the FDA letter informing Novartis of the FDA's formal written request.			Other
66,279	RAD 001C 09/14/2007	New investigators to Study CRAD001C2242, CRAD001C2325 and new investigator to Study CRAD001C2324. (PS)	411		New Investigator
66,279	RAD 001C 09/13/2007	PHHO2004BE07879; follow-up (PS)	410		Safety Report
66,279	RAD 001C 09/12/2007	Email to/from the FDA regarding the due date for the PPSR.			Other
66,279	RAD 001C 09/11/2007	PHHO2007FR14001; follow-up (PS)	409		Safety Report
66,279	RAD 001C 09/10/2007	PHHO2004US12965; follow-up (PS)	408		Safety Report
66,279	RAD 001C 09/10/2007	FDA LETTER responding to serial number 368, SPA submitted on July 26, 2007.			Other
66,279	RAD 001C 09/07/2007	PHHO2004BE07879; follow-up (PS)	407		Safety Report
66,279	RAD 001C 09/06/2007	PHHO2007BE13048; follow-up (PS)	401		Safety Report
66,279	RAD 001C 09/06/2007	PHHO2007BE12170; follow-up (PS)	402		Safety Report
66,279	RAD 001C 09/06/2007	Novartis Pharmaceuticals Corporation, hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Vassiliki Papadimitrakopoulou. (PS)	406		Other
66,279	RAD 001C 09/06/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Suleiman Alfred Massarweh (PS)	403		Other
66,279	RAD 001C 09/06/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Shanthi Marur, MD. (PS)	404		Other
66,279	RAD 001C 09/06/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Bo Lu, MD, Ph.D. (PS)	405		Safety Report
66,279	RAD 001C 09/05/2007	PHHO2007FR14001 (PS)	400		
66,279	RAD 001C 08/31/2007	PHHO2007US11543; Follow-Up (PS)	399		Safety Report
66,279	RAD 001C 08/30/2007	PHHO2004BE07879; Follow-Up (PS)	398		Safety Report
66,279	RAD 001C 08/28/2007	PHHO2007FR10519; Follow-Up (PS)	397		Safety Report
66,279	RAD 001C 08/27/2007	PHHO2007US11397; Follow-Up (PS)	396		Safety Report
66,279	RAD 001C 08/23/2007	PHHO2007BE13048; Follow-Up (PS)	394		Safety Report
66,279	RAD 001C 08/23/2007	PHHO2007FR10519; Follow-Up (PS)	393		Safety Report
66,279	RAD 001C 08/21/2007	PHHO2007FR09520; Follow-Up (PS)	391		Safety Report

REF	PRODC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	08/21/2007	This correspondence to the FDA is to submit the December 22, 2006 letter and amendment 1 of the protocol CRAD001C2325. (PS)	392		General Correspondence	
66,279	RAD 001C	08/20/2007	Email from FDA approving the compassionate use request.			Other	
66,279	RAD 001C	08/20/2007	PHHO2007BE12170;Follow-Up (PS)	388		Safety Report	
66,279	RAD 001C	08/17/2007	PHHO2007BE13048;Follow-Up (PS)	386		Safety Report	
66,279	RAD 001C	08/17/2007	PHHO2007AU11574;Follow-Up (PS)	387		Safety Report	
66,279	RAD 001C	08/16/2007	PHHO2007FR12501;Follow-Up (PS)	384		Safety Report	
66,279	RAD 001C	08/15/2007	PHHO2007US09880;Follow-Up(PS)	383		Safety Report	
66,279	RAD 001C	08/15/2007	PHHO2007IT12077;Follow-Up (PS)	381		Safety Report	
66,279	RAD 001C	08/15/2007	PHHO2007FR10519;Follow-Up (PS)	382		Safety Report	
66,279	RAD 001C	08/14/2007	Attached please find a copy of documentation sent via email 380 to Ms. Dottie Pease on August 13, 2007 in support of a request for Compassionate Use of RAD001 (in combination with bevacizumab) for a single patient diagnosed with advanced carcinoid cancer in November 2006. The patient in question, is being treated by Seth Cohen, MD at Monmouth Medical Center in Long Branch, NJ. (PS)			General Correspondence	
66,279	RAD 001C	08/13/2007	Proposed Pediatric Study Request submitted for the treatment of patients with refractory brain and musculoskeletal cancers (PS)	379		Other	
66,279	RAD 001C	08/10/2007	PHHO2007FR12501;Follow-Up (PS)	377		Safety Report	
66,279	RAD 001C	08/10/2007	PHHO2004BE07879;Follow-Up (PS)	378		Safety Report	
66,279	RAD 001C	08/07/2007	PHHO2007BE12170;Follow-Up (PS)	376		Safety Report	
66,279	RAD 001C	08/06/2007	New investigators to Study CRAD001C2241 and CRAD001C2325 and new investigator to Study CRAD001C2242 and CRAD001C2116 (PS)	375		New Investigator	
66,279	RAD 001C	08/03/2007	PHHO2007FR09520;Follow-Up (PS)	374		Safety Report	
66,279	RAD 001C	08/02/2007	Email to the FDA responding to their request for a word document detailing the original questions asked of FDA with CRAD001C2325 SPA.			Other	
66,279	RAD 001C	08/02/2007	PHHO2007US11543;Follow-Up (PS)	373		Safety Report	
66,279	RAD 001C	08/01/2007	PHHO2007FR03202;Follow-Up (PS)	372		Safety Report	
66,279	RAD 001C	08/01/2007	Email from/to the FDA regarding the electronic version of the IRC.			Other	
66,279	RAD 001C	07/31/2007	PHHO2007PL06777; follow-up (PS)	370		Safety Report	
66,279	RAD 001C	07/31/2007	PHHO2007IT12077 (PS)	371		Safety Report	
66,279	RAD 001C	07/31/2007	PHHO2007US04089; follow-up (PS)	369		Safety Report	
66,279	RAD 001C	07/30/2007	Email to/from the FDA regarding the FDA request for additional information on the PPSR.			Response to FDA Request	
66,279	RAD 001C	07/27/2007	Email to/from the FDA regarding serial number 368, SPA submitted on July 26, 2007.			Other	

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 07/26/2007	PHHO2007US07788; follow-up (PS)	366		Safety Report
66,279	RAD 001C 07/26/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Sandy Srinivas, MD (PS)	367		Other
66,279	RAD 001C 07/26/2007	Amendment No. 2 to SPA, Protocol CRAD001C2325 (PS)	368		Change In Protocol
66,279	RAD 001C 07/25/2007	FDA LETTER Informing Novartis that the FDA is unable to issue a written request based on the February 19, 2007, Pediatric study request			Other
66,279	RAD 001C 07/24/2007	PHHO2007US07788 (PS)	365		Safety Report
66,279	RAD 001C 07/24/2007	PHHO2007US11543 (PS)	364		Safety Report
66,279	RAD 001C 07/23/2007	This correspondence to the FDA is regarding the written request and as to whether or not the FDA has any information as to the status of the PPSR. (PS)	363		General Correspondence
66,279	RAD 001C 07/20/2007	PHHO2007US11397; follow-up (PS)	362		Safety Report
66,279	RAD 001C 07/17/2007	Email to FDA regarding the meeting package for the August 14, 2007 meeting.			Other
66,279	RAD 001C 07/17/2007	Resubmission of protocol CRAD001C2324 for Special Protocol Assessment (PS)	361		Other
66,279	RAD 001C 07/17/2007	PHHO2007US11397 (PS)	360		Safety Report
66,279	RAD 001C 07/16/2007	Briefing book for Type B meeting which is scheduled for August 14, 2007 to discuss the plan for development and registration (sNDA) of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) and angiomyolipoma (AML) associated with either tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM). (PS)	359		Briefing Book
66,279	RAD 001C 07/11/2007	Email to/from the FDA regarding the May 31, 2007 meeting request.			Request for FDA Meeting
66,279	RAD 001C 07/11/2007	PHRM2007FR01778 (PS)	358		Safety Report
66,279	RAD 001C 07/09/2007	PHHO2007ES08365;Follow-Up (PS)	356		Safety Report
66,279	RAD 001C 07/09/2007	PHHO2007PL06777;Follow-Up (PS)	357		Safety Report
66,279	RAD 001C 07/03/2007	New protocol CRAD001C2118 entitled: "A blinded, randomized, placebo and active controlled, single-dose crossover study to investigate the effect of RAD001 on cardiac intervals in healthy volunteers" (PS)	353		New Protocol
66,279	RAD 001C 07/03/2007	New investigator to Study CRAD001C211, CRAD001C2241, CRAD001C2325 and CRAD001J2101 (PS)	354		New Investigator
66,279	RAD 001C 07/03/2007	PHHO2005US14500. (PS)	355		Safety Report
66,279	RAD 001C 06/25/2007	PHHO2007US09880;Follow-Up (PS)	352		Safety Report
66,279	RAD 001C 06/21/2007	PHHO2007PL06777;Follow-Up (PS)	351		Safety Report
66,279	RAD 001C 06/21/2007	PHHO2007FR07389;Follow-Up (PS)	350		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C	06/20/2007	Email from/to FDA containing Novartis' draft questions and concept protocol to help facilitate the FDA's review of Novartis' meeting request.			Other
66,279	RAD 001C	06/19/2007	PHBS2007BE07399; Follow-Up (PS)	348		Safety Report
66,279	RAD 001C	06/13/2007	TELECON with FDA to discuss the email received on June 12, 2007 from Dottie Pease.			Memo of Record (telephone report)
66,279	RAD 001C	06/13/2007	PHHO2007FR07389; Follow-Up (PS)	347		Safety Report
66,279	RAD 001C	06/12/2007	Email from FDA regarding the meeting request submitted on May 31, 2007.			Other
66,279	RAD 001C	06/08/2007	FDA LETTER Responses to serial number 320, for a special clinical protocol assessment submitted on April 30, 2007.			Other
66,279	RAD 001C	06/07/2007	PHHO2006US22078; Follow-Up (PS)	346		Safety Report
66,279	RAD 001C	06/06/2007	PHHO2007PL06777; Follow-Up (PS)	345		Safety Report
66,279	RAD 001C	06/06/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Scott K. Kuwada, MD (PS)	343		Other
66,279	RAD 001C	06/06/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by James C. Yao, MD (PS)	344		Other
66,279	RAD 001C	06/05/2007	PHHO2006US22078; Follow-Up (PS)	341		Safety Report
66,279	RAD 001C	06/05/2007	PHBS2007BE07399; Follow-Up (PS)	342		Safety Report
66,279	RAD 001C	06/04/2007	New investigator to Study CRAD001C2240 and new investigators to Study CRAD001C2325 (PS)	340		New Investigator
66,279	RAD 001C	05/31/2007	Novartis hereby is formally requesting a Type B meeting with the Division of Oncology Drug Products to discuss the development plan and registration strategy for RAD001 (everolimus) in Tuberous Sclerosis Complex (TSC) and sporadic lymphangiomyomatosis (LAM). (PS)	339		Request for FDA Meeting
66,279	RAD 001C	05/30/2007	Email from FDA containing the FDA responses to Novartis' questions for the SPA meeting scheduled for June 7, 2007			Other
66,279	RAD 001C	05/30/2007	Email to FDA confirming that Novartis would still like to have the scheduled meeting on June 7, 2007			Other
66,279	RAD 001C	05/30/2007	PHHO2007ES08365; Follow-up (PS)	338		Safety Report
66,279	RAD 001C	05/25/2007	PHHO2007PL06777; Follow-up (PS)	337		Safety Report
66,279	RAD 001C	05/24/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Ravi D Rao, M.B.B.S (PS)	335		Other
66,279	RAD 001C	05/24/2007	New investigator to Study CRAD001C2114 and CRAD001C2116 and new investigators to Study CRAD001C2242 and CRAD001C2325 (PS)	336		New Investigator

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	05/23/2007	Email to FDA responding to their request for a completed template summarizing information from PPSR submitted to FDA on Feb 15, 2007.				Response to FDA Request
66,279	RAD 001C	05/23/2007	PHBS2007BE07399; Follow-up (PS)	334			Safety Report
66,279	RAD 001C	05/22/2007	PHHO2007PL06777; follow-up (PS)	333			Safety Report
66,279	RAD 001C	05/21/2007	Novartis Pharmaceuticals Corporation hereby authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Jann N. Sarkaria, M.D. (PS)	332			Other
66,279	RAD 001C	05/18/2007	PHHO2007FR07389; Follow-up (PS)	331			Safety Report
66,279	RAD 001C	05/18/2007	PHRM2007FR01407; Follow-up (PS)	330			Safety Report
66,279	RAD 001C	05/18/2007	PHBS2007BE07399; Follow-up (PS)	329			Safety Report
66,279	RAD 001C	05/16/2007	PHHO2006US11747; follow-up (PS)	328			Safety Report
66,279	RAD 001C	05/15/2007	PHBS2007BE07399 (PS)	327			Safety Report
66,279	RAD 001C	05/15/2007	New investigators to Study CRAD001C2116, CRAD001J2101, CRAD001C2240 and CRAD001C2325 (PS)	326			New Investigator
66,279	RAD 001C	05/09/2007	PHHO2007FR07389 (PS)	325			Safety Report
66,279	RAD 001C	05/08/2007	Email to FDA containing the questions for the June 7, 2007 meeting.				Other
66,279	RAD 001C	05/08/2007	Email to FDA regarding the EOP2 meeting request and briefing book (ES)				Request for FDA Meeting
66,279	RAD 001C	05/08/2007	PHHO2007DE07018 (PS)	323			Safety Report
66,279	RAD 001C	05/08/2007	Briefing book for Type A meeting which is scheduled for June 7, 2007 (PS)	324			Briefing Book
66,279	RAD 001C	05/03/2007	PHHO2007PL06777 (PS)	322			Safety Report
66,279	RAD 001C	05/02/2007	New investigator to Study CRAD001C2325 (PS)	321			New Investigator
66,279	RAD 001C	04/27/2007	Request for Special Protocol Assessment for study CRAD001C2324 (PS)	320			Other
66,279	RAD 001C	04/23/2007	PHHO2007DE03665; follow-up (PS)	319			Safety Report
66,279	RAD 001C	04/20/2007	Email from FDA with a tentative meeting date for April 16, 2007 meeting request.				Other
66,279	RAD 001C	04/20/2007	New investigator to Study CRAD001C2239 and CRAD001C2325. New investigators to Study CRAD001C2240 and CRAD001C2241 (PS)	318			New Investigator
66,279	RAD 001C	04/18/2007	Email from FDA informing Novartis that the submission does not qualify for an SPA since the study has already started.				Other
66,279	RAD 001C	04/16/2007	Email to the FDA regarding the dates of the FDA letters received containing their feedback on the SPA for CRAD001C2240.				Other
66,279	RAD 001C	04/16/2007	Request for Type A meeting to discuss the Special Protocol Assessment Clinical Protocol CRAD001C2239 (PS)	317			Request for FDA Meeting

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 04/13/2007	New protocol CRAD001C2410 entitled: "A Pilot Multicenter Phase I/II Trial of RAD001 in patients with Recurrent Glioblastoma Multiforme" (PS)	316		New Protocol
66,279	RAD 001C 04/11/2007	PHHO2007US00556; follow-up (PS)	315		Safety Report
66,279	RAD 001C 04/09/2007	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Walter Stadler, MD (PS)	314		General Correspondence
66,279	RAD 001C 04/09/2007	General correspondence to the FDA to provide clarity around recent communications that have a significant impact on Novartis' development planning while continuing to work within the regulatory framework of 21 CFR 312 (PS)			General Correspondence
66,279	RAD 001C 04/03/2007	PHHO2007US4089; follow-up (PS)	313		Safety Report
66,279	RAD 001C 03/30/2007	Email response to FDA's request for an electronic copy of the final signed version of the Independent Radiological Review Charter for Protocol CRAD001C2240 which incorporates the FDA's feedback received via fax on December 7, 2006.			Response to FDA Request
66,279	RAD 001C 03/30/2007	Email to FDA regarding the final signed IRC for CRAD001C2240.			Response to FDA Request
66,279	RAD 001C 03/30/2007	PHHO2007US05182 (PS)	312		Safety Report
66,279	RAD 001C 03/27/2007	PHHO2006US20476; Follow-up (PS)	311		Safety Report
66,279	RAD 001C 03/26/2007	Study CRAD001C2239, CRAD001C2240 new investigators and Study CRAD001C2241 New Investigator (PS)	310		New Investigator
66,279	RAD 001C 03/19/2007	New investigators to Study CRAD001C2240 and new investigator to Study CRAD001C2325 (PS)	309		New Investigator
66,279	RAD 001C 03/15/2007	PHHO2007US04089; follow-up (PS)	307		Safety Report
66,279	RAD 001C 03/15/2007	PHHO2007CA02219; follow-up (PS)	308		Safety Report
66,279	RAD 001C 03/14/2007	PHHO2007US04215 (PS)	306		Safety Report
66,279	RAD 001C 03/13/2007	PHHO2007US04089 (PS)	305		Safety Report
66,279	RAD 001C 03/12/2007	FDA LETTER Comments on the December 20, 2006, serial number 267 SPA and January 25, 2007, serial number 280 amendment.			Other
66,279	RAD 001C 03/08/2007	Amendment No. 1 to SPA Protocol CRAD001C2240 (PS)	304		Change In Protocol
66,279	RAD 001C 03/08/2007	New investigator to Study CRAD001C2239 and CRAD001C2240. New investigators to Study CRAD001C2325 (PS)	303		New Investigator
66,279	RAD 001C 03/07/2007	PHHO2007DE03665 (PS)	302		Safety Report
66,279	RAD 001C 02/28/2007	PHHO2008FR02098; follow-up (PS)	555		Safety Report
66,279	RAD 001C 02/26/2007	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Dr. Ana Maria Gonzalez-Angulo, M.D. (PS)	298		Other

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	02/26/2007	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Bert O'Neil, M.D. (PS)	299			Other
66,279	RAD 001C	02/26/2007	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Srdan Verstovsek, M.D., Ph.D. (PS)	300			Other
66,279	RAD 001C	02/26/2007	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Johanna Bendell, M.D. (PS)	301			Other
66,279	RAD 001C	02/22/2007	FDA LETTER Responses to the November 6, 2006, serial number 252, request for SPA.				Other
66,279	RAD 001C	02/22/2007	PHHO2007CA02219; follow-up (PS)	296			Safety Report
66,279	RAD 001C	02/22/2007	This Annual report covers the period December 25, 2005 through December 24, 2006 (PS)	297			Annual Report
66,279	RAD 001C	02/20/2007	Email from FDA responding to Novartis' question regarding the PPSR being submitted.				Other
66,279	RAD 001C	02/19/2007	Proposed Pediatric Study Request submitted for the treatment of refractory cancers in a pediatric population (ages 3-16) (Protocol No. CRAD001C2244) (PS)	294			Other
66,279	RAD 001C	02/19/2007	New investigators to Study CRAD001C2114, CRAD001C2240 and CRAD001C2241 (PS)	295			New Investigator
66,279	RAD 001C	02/19/2007	This annual report covers the period November 27, 2006 through November 26, 2007. (PS)	547			Annual Report
66,279	RAD 001C	02/15/2007	PHBS2006AT07989; follow-up (PS)	293			Safety Report
66,279	RAD 001C	02/13/2007	At this time, Novartis is submitting an IND amendment to provide updated information on the manufacturing sites, stability programs, and other CMC changes. The summary of changes and the updated IND sections are included in this submission (PS)	292			CMC Amendment
66,279	RAD 001C	02/09/2007	PHHO2007CA02219; follow-up (PS)	290			Safety Report
66,279	RAD 001C	02/09/2007	New Protocol RAD001C2242 entitled: "An open-label, multicenter Phase 1 study investigating the combination of RAD001, cetuximab and irinotecan as second-line therapy after FOLFOX (or XELOX) plus bevacicunab (if given as part of local standard practice) in patients with metastatic colorectal adenocarcinoma" (PS)	291			New Protocol
66,279	RAD 001C	02/08/2007	Novartis Pharmaceuticals Corporation authorizes FDA to refer to IND 66279 for RAD001 (everolimus) in support of an Investigational New Drug Application (IND) that will be filed by Dr. Mark Stein (PS)	289			Other
66,279	RAD 001C	02/08/2007	PHHO2007CA02219; follow-up (PS)	288			Safety Report
66,279	RAD 001C	02/07/2007	PHHO2007CA02219 (PS)	287			Safety Report
66,279	RAD 001C	02/06/2007	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Daniel George, MD (PS)	285			Other

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	02/06/2007	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Jorae A. Ciarcia, MD (PS)	286			Other
66,279	RAD 001C	02/05/2007	New investigators to Study CRAD001C2239 and CRAD001C2240 (PS)	284			New Investigator
66,279	RAD 001C	02/01/2007	PHHO2004BE07879; follow-up (PS)	283			Safety Report
66,279	RAD 001C	01/29/2007	This submissions contains copies of the materials sent on January 25, 2007, serial number 280 (PS)	282			General Correspondence
66,279	RAD 001C	01/26/2007	Email to FDA informing them that the materials sent via email have been sent directly to them instead of the central document room.				Response to FDA Request
66,279	RAD 001C	01/26/2007	PHHO2006US22076; follow-up (PS)	281			Safety Report
66,279	RAD 001C	01/25/2007	PHHO2007US00556; follow-up (PS)	279			Safety Report
66,279	RAD 001C	01/19/2007	PHHO2006US22076 (PS)	278			Safety Report
66,279	RAD 001C	01/18/2007	New investigator/Sub investigator to Study CRAD001C2111 (PS)	276			New Investigator
66,279	RAD 001C	01/18/2007	PHHO2007US00556 (PS)	277			Safety Report
66,279	RAD 001C	01/17/2007	Email to FDA informing them of the upcoming Novartis FDA CRADA meeting.				Other
66,279	RAD 001C	01/16/2007	Email from FDA replying to the meeting cancellation of the January 18, 2007 Type A meeting.				Other
66,279	RAD 001C	01/16/2007	New investigator to Study CRAD001C2239 and CRAD001C2325. New investigators to Study CRAD001C2240 (PS)	275			New Investigator
66,279	RAD 001C	01/09/2007	This correspondence is to provide the FDA with Novartis' questions for the Type A meeting which is scheduled for January 18, 2007 (ES)				General Correspondence
66,279	RAD 001C	01/03/2007	Email to FDA containing serial number 274, an addendum to the briefing book (ES)				General Correspondence
66,279	RAD 001C	01/03/2007	The addendum the the briefing book contains simulation data which is highly relevant to the planned discussions and the conclusions are supportive of the Novartis position as stated in the protocol. Please note that this submission in REDI only contains the cover letter and 1571, as this is all we received for archiving). (PS)	274			Other
66,279	RAD 001C	01/01/2007	Email from FDA responding to Novartis' questions regarding the FDA information request for the simulation methods.				Other
66,279	RAD 001C	12/28/2006	PHHO2006FR20729; Follow-up	273			Safety Report
66,279	RAD 001C	12/22/2006	Email from FDA with responses to Novartis' questions regarding protocol CRAD001C2325				Other
66,279	RAD 001C	12/22/2006	PHHO2005DE16006; Follow-Up	272			Safety Report
66,279	RAD 001C	12/21/2006	New investigator to Study CRAD001C2239 and CRAD001C2241, new investigators to Study CRAD001C2240 (PS)	271			New Investigator
66,279	RAD 001C	12/21/2006	PHHO2006FR20729; Follow-up	270			Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 12/21/2006	PHBS2006ES19190; Follow-Up	269		Safety Report
66,279	RAD 001C 12/21/2006	PHBS2006ES19166; Follow-Up	268		Safety Report
66,279	RAD 001C 12/20/2006	Amendment No. 2 to Protocol CRAD001C2239 (PS)	267		Change In Protocol
66,279	RAD 001C 12/18/2006	PHHO2006FR20566; Follow-Up	266		Safety Report
66,279	RAD 001C 12/18/2006	PHHO2006IT15311; Follow-Up	265		Safety Report
66,279	RAD 001C 12/13/2006	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Gabriela Chiorean, MD (PS)	264		Other
66,279	RAD 001C 12/12/2006	In response to FDA request the email contains the questions q posed in BB submitted with SPA for CRAD001C2325 (RAD001 in Carcinoid IND66,279) on Nov 6, 2006 (Serial 252) (ES)			Response to FDA Request
66,279	RAD 001C 12/12/2006	PHHO2006US17466; follow-up (PS)	263		Safety Report
66,279	RAD 001C 12/12/2006	New investigator to Study CRAD001C2111, CRAD001C2239, and new investigators to CRAD001C2241 (PS)	262		New Investigator
66,279	RAD 001C 12/08/2006	PHHO2006IT15311; follow-up (PS)	260		Safety Report
66,279	RAD 001C 12/08/2006	This correspondence is to inform the FDA of the transfer of specific obligations to a contract research organization for clinical drug supply management of selected sites in protocol CRAD001C2240 (PS)	261		General Correspondence
66,279	RAD 001C 12/07/2006	New investigators to Study CRAD001C2239 (PS)	259		New Investigator
66,279	RAD 001C 12/07/2006	Fax from FDA containing the Medical imaging responses to serial number 249.			Other
66,279	RAD 001C 12/06/2006	PHHO2006US11747; follow-up (PS)	258		Safety Report
66,279	RAD 001C 11/21/2006	Email from FDA confirming the postponement of the November 27, 2006teleconference to January 18, 2007.			Other
66,279	RAD 001C 11/16/2006	Email response to the FDA request for a copy of the draft IRC charter for CRAD001C2239 protocol.			Response to FDA Request
66,279	RAD 001C 11/15/2006	Amendment No. 1 to Protocol RAD001C2235 (PS)	257		Change In Protocol
66,279	RAD 001C 11/09/2006	PHHO2004US12965; follow-up (PS)	256		Safety Report
66,279	RAD 001C 11/07/2006	This submission contains RAD001C Investigator's Brochure Edition 5 (PS)	253		Clinical Information Amendr
66,279	RAD 001C 11/07/2006	New investigator to Study CRAD001C2206 (PS)	254		New Investigator
66,279	RAD 001C 11/07/2006	PHHO2006US17466; Follow-Up (PS)	255		Safety Report
66,279	RAD 001C 11/06/2006	Request for special protocol assessment for Study CRAD001C2325 (PS)	252		Other
66,279	RAD 001C 10/31/2006	PHHO2006US17466 (PS)	251		Safety Report
66,279	RAD 001C 10/24/2006	Briefing Book is being submitted in preparation for the Type A meeting to gain clarification on FDA's responses , provide clarification on Novartis position and ensure agreement on any additional modifications which may be required to allow for a positive agency determination regarding protocol CRAD001C2240 and allow the study to proceed (PS)	249		Briefing Book

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	10/24/2006	PHBS2006ES15520; follow-up (PS)	250		Safety Report	
66,279	RAD 001C	10/23/2006	Email responding to FDA that Novartis acknowledges receipt of the e-mail and the proposed date of the meeting for November 27th 2PM.			Other	
66,279	RAD 001C	10/23/2006	Email to FDA regarding the number of copies needed of the briefing book and the meeting date of November 10, 2006 for the Type A meeting.			Other	
66,279	RAD 001C	10/23/2006	PHHO2006US11747; follow-up (PS)	248		Safety Report	
66,279	RAD 001C	10/23/2006	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Andrew X. Zhu, MD, PhD (PS)	247		Other	
66,279	RAD 001C	10/20/2006	Email response to the FDA request for an electronic copy of the Type A meeting request.			Request for FDA Meeting	
66,279	RAD 001C	10/17/2006	PHBS2006S15520; Follow-up (PS)	246		Safety Report	
66,279	RAD 001C	10/13/2006	Novartis Pharmaceuticals Corporation authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Barbara Burtress, MD (PS)	245		Other	
66,279	RAD 001C	10/09/2006	Type A meeting request to gain further clarification on the responses received by the FDA, particularly for questions 3, 7 and 11. More specifically Novartis wishes to identify any additional modifications to the proposed pivotal study, analysis plan and independent radiological review charter necessary to adequately meet the requirements for a regulatory submission of phase III protocol CRAD001C2240 data in support of approval of RAD001 for the treatment of patients with metastatic renal cell carcinomas who have	244		Request for FDA Meeting	
66,279	RAD 001C	10/06/2006	PHHO2006IT15311 (PS)	243		Safety Report	
66,279	RAD 001C	10/03/2006	New investigator to Study No. RAD001C2239 (PS)	241		New Investigator	
66,279	RAD 001C	10/03/2006	PHHO2006IT15311 (PS)	242		Safety Report	
66,279	RAD 001C	09/29/2006	PHHO2006IT09039; Follow Up (PS)	240		Safety Report	
66,279	RAD 001C	09/27/2006	Addressing issues raised per September 26, 2006 phone call noting discrepancies between information Novartis submitted and the FDA website so that Entry 506-0814195-3 can be released. (PS)			Other	
66,279	RAD 001C	09/25/2006	New investigator to Study No. RAD001C2206 and new investigators to Study No. RAD001C2239 (PS)	239		New Investigator	
66,279	RAD 001C	09/19/2006	New Protocol RAD001J2101 entitled: "A phase Ib study investigating the combination of AD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer" (PS)	238		New Protocol	
66,279	RAD 001C	09/15/2006	FDA LETTER response to SPA for CRAD001C2240 (PS)			Other	
66,279	RAD 001C	09/13/2006	New Protocol RAD001C2114 entitled, "A two-step phase 1 study investigating the combination of RAD001 with carboplatin, paclitaxel and bevacizumab in non-small-cell lung cancer (NSCLC) patients not treated previously with systemic therapy (PS)	236		New Protocol	

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 09/13/2006	New Protocol RAD001C2116 entitled: " A phase Ib study investigating the combination of RAD001 with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer not previously treated with chemotherapy" (PS)	237		New Protocol
66,279	RAD 001C 09/07/2006	TELECON with FDA on September 7, 2006 to discuss the request for an e-copy of the CRAD001C2240 SPA and the timelines for FDA review/response of Oncology PPSR (PS)			Memo of Record (telephone report)
66,279	RAD 001C 09/07/2006	Email regarding the request from FDA for an electronic copy fo the SPA for protocol CRAD001C2240 (PS)			Response to FDA Request
66,279	RAD 001C 08/31/2006	PHHO2006US02640; follow-up (PS)	234		Safety Report
66,279	RAD 001C 08/31/2006	Novartis Pharmaceuticals Corporation hereby authorizes the FDA to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by John D. Hainsworth, M.D. (PS)	235		Other
66,279	RAD 001C 08/29/2006	New investigator to Study No. CRAD001C2206 (PS)	233		New Investigator
66,279	RAD 001C 08/23/2006	Email response to FDA request for TOC and and electronic copy of the 11 protocol specific questions listed in section 5 of the briefing book submitted on July 28, 2006 (PS)			Response to FDA Request
66,279	RAD 001C 08/22/2006	New Protocol, RAD001C2241 entitled, "A single arm, multicenter phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti- EGFR antibody (if appropriate), bevacizumab, fluoropyrimidine, oxaliplatin, and irinotecan- based regimens (PS)	231		New Protocol
66,279	RAD 001C 08/18/2006	PHHO2006BE00473; follow-up (PS)	228		Safety Report
66,279	RAD 001C 08/18/2006	PHHO2006DE09301; follow-up (PS)	229		Safety Report
66,279	RAD 001C 08/18/2006	PHHO2006US11747; follow-up (PS)	230		Safety Report
66,279	RAD 001C 08/17/2006	PHHO2006US11747; follow-up (PS)	227		Safety Report
66,279	RAD 001C 08/16/2006	PHHO2006BE00473 (PS)	226		Safety Report
66,279	RAD 001C 08/15/2006	PHHO2006US11747 (PS)	225		Safety Report
66,279	RAD 001C 08/04/2006	New investigator to Study CRAD001C2239 (PS)	224		New Investigator
66,279	RAD 001C 07/28/2006	Request for special protocol assessment for Study CRAD001C2240 (PS)	223		Other
66,279	RAD 001C 07/28/2006	PHHO2006DE09652; follow-up (PS)	222		Safety Report
66,279	RAD 001C 07/27/2006	Amendment No. 2 to Protocol CRAD001JC2222 (PS)	221		Change In Protocol
66,279	RAD 001C 07/26/2006	PHHO2006CA03486; follow-up (PS)	220		Safety Report
66,279	RAD 001C 07/25/2006	PHHO2006DE09859; follow-up (PS)	219		Safety Report
66,279	RAD 001C 07/21/2006	Documentation FDA position: Pediatric Exclusivity requirements NDA submission for active moiety.			Other
66,279	RAD 001C 07/21/2006	PHHO2006DE09652; follow-up (PS)	218		Safety Report
66,279	RAD 001C 07/20/2006	PHHO2006DE09652; follow-up (PS)	215		Safety Report
66,279	RAD 001C 07/20/2006	PHHO2006IT09039; follow-up (PS)	216		Safety Report

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	07/20/2006	PHHO2006DE09301; Follow Up (PS)	217			Safety Report
66,279	RAD 001C	07/19/2006	PHHO2006DE09652; follow-up (PS)	214			Safety Report
66,279	RAD 001C	07/17/2006	PHHO2006IT09039; follow-up (PS)	213			Safety Report
66,279	RAD 001C	07/11/2006	At the request of the principal investigator for the study, Novartis Pharmaceuticals Corporation is hereby amending this letter to reflect a change in principal investigator for the study. Novartis authorizes the Food and Drug Administration to refer to IND 66,279 RAD001 (everolimus) Tablets in support of an Investigational New Drug Application (IND) that will be filed by Alice Elizabeth Guardino, M.D., Ph.D. (PS)	212			Other
66,279	RAD 001C	07/07/2006	FDA LETTER (email) FDA Response to questions on briefing book for Type A Meeting scheduled for July 11,2006 (CRAD001C2239 SPA follow-up).	203			Other
66,279	RAD 001C	07/07/2006	PHHO2006DE09652 Follow Up	210			Safety Report
66,279	RAD 001C	07/07/2006	Referencing General Correspondence letter of Authorization SN156. Novartis is amending this letter to reflect a change in address and study title.				Safety Report
66,279	RAD 001C	07/05/2006	PHBS2006AT07989 Follow Up	209			Safety Report
66,279	RAD 001C	06/27/2006	PHBS2006AT07989 Follow up	206			Safety Report
66,279	RAD 001C	06/27/2006	PHHO2006DE09859 Follow Up	207			Safety Report
66,279	RAD 001C	06/27/2006	PHNU2006DE02164 (PS)	208			Safety Report
66,279	RAD 001C	06/22/2006	Referencing General Correspondence Letter of Authorization SN 157. Novartis Pharmaceutical Corporation is hereby amending this letter.				General Correspondence
66,279	RAD 001C	06/21/2006	PHHO2006DE09301 Follow Up	204			Safety Report
66,279	RAD 001C	06/20/2006	Type A meeting briefing book to support the discussion for a special protocol assessment for CRAD001C2239 submitted on April 3, 2006 (Serial No. 183). (PS)	203			Briefing Book
66,279	RAD 001C	06/19/2006	Referencing an authorization to the FDA by Novartis to refer to IND 66,279 RAD001.				General Correspondence
66,279	RAD 001C	06/19/2006	Referencing an authorization to the FDA by Novartis to refer to IND 66,279 RAD001.				General Correspondence
66,279	RAD 001C	06/16/2006	PHHO2006IT09039 Follow Up	200			Safety Report
66,279	RAD 001C	06/16/2006	Email responding to the FDA request for the questions which will be presented in the briefing document for the FDA Type A meeting scheduled for July 11, 2006.				Other
66,279	RAD 001C	06/14/2006	PHHO2006IT07069 Follow Up	198			Safety Report
66,279	RAD 001C	06/13/2006	7 Day Safety Report PHHO2006IT09039 (PS)				Safety Report
66,279	RAD 001C	06/05/2006	Request for Type A Meeting to gain clarification on responses and modifications to the analysis regarding treatment with RAD001 alone or in combination with Sandostatin for patients with NET, who failed treatment with cytotoxic chemotherapy				Request for FDA Meeting

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 06/02/2006	Reference is made to IND 66,279 Annual Report for RAD001 dated February 24, 2006 regarding the clinical review reported to the FDA for a Phase II Study of RAD001C			Response to FDA Request
66,279	RAD 001C 05/30/2006	Protocol C2111 Amendment 1 and Protocol C2206 Amendment 5. (PS)	195		Change In Protocol
66,279	RAD 001C 05/23/2006	PHBS2006ES06880 Follow Up	194		Safety Report
66,279	RAD 001C 05/19/2006	PHHO2006IT07069 Follow Up	193		Safety Report
66,279	RAD 001C 05/19/2006	FDA LETTER responding to the April 3, 2006, serial number 182, request for SPA.			Other
66,279	RAD 001C 05/18/2006	Referencing General Correspondence Letter of Authorization SN 158. Novartis is amending the letter for the purpose of reflecting changes in the protocol title.			General Correspondence
66,279	RAD 001C 05/18/2006	Email to FDA following receipt of their responses, accepting the option of canceling the scheduled face-to-face meeting.			Request for FDA Meeting
66,279	RAD 001C 05/17/2006	Email from FDA with their responses to Novartis' questions for the EOP 1-2 meeting.			Other
66,279	RAD 001C 05/11/2006	PHHO2006IT07069 Follow Up	191		Safety Report
66,279	RAD 001C 05/01/2006	Amendment No. 1 to Protocol 2222.	190		Change In Protocol
66,279	RAD 001C 04/21/2006	Email response to FDA request for a summary document , outlining the requested information for the pivotal and supportive trials to be submitted for approval of RAD001.			Response to FDA Request
66,279	RAD 001C 04/13/2006	Amendment to Letter of Authorization, dated November 22, 2005 (SN153) in support of an IND that will be filed by Gerber Wulf, MD, PhD.	188		General Correspondence
66,279	RAD 001C 04/13/2006	Study 2235 update to new investigator address	189		New Investigator
66,279	RAD 001C 04/12/2006	Submitted 14 desk copies of the briefing book and appendices in anticipation of a possible meeting on May 20 or June 12, 2006 to discuss the development plan and registration strategy for RAD001 (everolimus) in advanced metastatic renal cancer.	187		Request for FDA Meeting
66,279	RAD 001C 04/10/2006	PHHO2005FR20026	186		Safety Report
66,279	RAD 001C 04/07/2006	Request for Type B meeting to discuss the development plan and registration strategy for RAD001 in advanced metastatic renal cancer.	185		Request for FDA Meeting
66,279	RAD 001C 04/07/2006	Email to FDA responding to request for a word document with the list of questions submitted in the briefing book for the SPA for protocol CRAD001C2239.			Other
66,279	RAD 001C 04/05/2006	PHHO2005US06739	184		Safety Report
66,279	RAD 001C 04/04/2006	Email to FDA responding to their request for desk copies of the SPA as well as the indication.			Response to FDA Request
66,279	RAD 001C 04/03/2006	Request for Special Protocol Assessment for CRAD001C2239.	183	2239	Other
66,279	RAD 001C 03/15/2006	PHNR2006AU00570	182		Safety Report
66,279	RAD 001C 03/15/2006	PHNR2006AU00570 Follow Up			Safety Report
66,279	RAD 001C 03/14/2006	PHHO2005US19658	181		Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 03/14/2006	PHHO2005US19658 Follow Up			Safety Report
66,279	RAD 001C 03/08/2006	PHHO2006CA03486	180		Safety Report
66,279	RAD 001C 03/08/2006	PHHO2006CA03486 Follow Up			Safety Report
66,279	RAD 001C 02/27/2006	This submission addresses FDA concerns regarding a number of adverse events associated with a clinical study of RAD001C in patients with renal cancer, which were submitted by Dr. Amato under private IND 71,586.	179		General Correspondence
66,279	RAD 001C 02/24/2006	This Annual Report covers the period December 25, 2004 through November 25, 2005. Includes clinical study information, abstract of published papers on RAD001 (Oncology) and Appendix 1.	178		Annual Report
66,279	RAD 001C 02/23/2006	Dr. George Demetri: Malignant neoplasm progression, ascites, cholelithiasis, pleural effusion, dyspnoea; Follow-up#1.	177	2206	Safety Report
66,279	RAD 001C 02/06/2006	[FRANCE] Dr. Jean-Charles Soria: Mental disorder, back pain, delusional disorder, persecutory type, myalgia; Follow-up#2.	176	2235	Safety Report
66,279	RAD 001C 02/01/2006	[FRANCE] Dr. Jacques Dantal: Respiratory tract infection, lung disorder, fluid overload; Follow-up#1.	175	2420	Safety Report
66,279	RAD 001C 01/24/2006	[FRANCE] Dr. Jacques Dantal: Lung disorder.	174	2420	Safety Report
66,279	RAD 001C 01/18/2006	The current submission provides response to questions raised by FDA and includes detailed data from protocol 2206, which were identified as critical to resolve the clinical hold deficiencies for Dr. Ryan's IND 73,986.	173	2206	Response to Clinical Hold
66,279	RAD 001C 01/18/2006	[FRANCE] Dr. Jean-Charles Soria: Back pain, mental disorder, delusional disorder, persecutory type, myalgia; Follow-up#1.	172	2235	Safety Report
66,279	RAD 001C 01/18/2006	This submission provides response to questions raised by FDA and includes detailed data from protocol 2206, which were identified as critical to resolve the clinical hold deficiencies for Dr. Ryan's IND 73,986.	173		Response to Clinical Hold
66,279	RAD 001C 01/11/2006	Dr. Howard Sher: Muscular weakness, myopathy steroid, hydrocephalus, cognitive deterioration, general physical health deterioration, mood altered, depression, cardiovascular disorder, fall; Follow-up#2.	171	2408	Safety Report
66,279	RAD 001C 01/10/2006	E-MAIL from FDA containing response to NVS questions for discussion during January 12, 2006 meeting.			Other
66,279	RAD 001C 01/03/2006	[BELGIUM] Dr. Van Oosterom: Gastritis haemorrhagic, right ventricular failure, pulmonary hypertension, anaemia, haematochezia, general physical health deterioration; Follow-up#1.	170	2206	Safety Report
66,279	RAD 001C 12/30/2005	[FRANCE] Dr. Jean-Charles Soria: Back pain, mental disorder, delusional disorder, persecutory type, myalgia.	169	C2235	Safety Report
66,279	RAD 001C 12/23/2005	Michelle Roos: Hyponatraemia, vomiting, diarrhoea, viral infection, dehydration.	168	AUS15	Safety Report
66,279	RAD 001C 12/22/2005	Dr. Howard Sher: Muscular weakness, myopathy steroid, hydrocephalus, fall; Follow-up#1.	167	2408	Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	12/21/2005	NVS acknowledges receipt of FDA response dated July 7, 2005 to Special Protocol Assessment requested for CRAD001C2223, which was submitted to FDA on May 11, 2005, and hereby requests additional information on statistical procedures outlined in the protocol.	166			General Correspondence
66,279	RAD 001C	12/20/2005	Dr. Alex Adjei: Pulmonary embolism, malignant neoplasm progression, chest pain, dyspnoea, respiratory failure, productive cough; Follow-up#2.	165	US15		Safety Report
66,279	RAD 001C	12/19/2005	Dr. Howard Sher: Muscular weakness, fall.	163	2408		Safety Report
66,279	RAD 001C	12/19/2005	This submission provides the Edition 4 of the Investigators' Brochure, which replaces Edition 3, dated 30-Aug-2004. Also included is the summary of changes, outlining the updates incorporated in Edition 4.	164			Clinical Information Amendr
66,279	RAD 001C	12/16/2005	Novartis is amending the Letter of Authorization submitted to the Agency on November 22, 2005, SN 151, in support of an IND that will be filed by Charles A. Coltman, Jr., MD.	162			General Correspondence
66,279	RAD 001C	12/06/2005	This submission provides the briefing book and appendices, 161 including cited references, for the January 12, 2006 meeting to discuss the development plan and registration strategy for RAD001 in carcinoid tumors and pancreatic neuroendocrine tumors. Three copies were forward to the Division of Oncology, as well as fourteen desk copies.	161			General Correspondence Response to FDA Request
66,279	RAD 001C	12/06/2005	E-MAIL detailing questions presented in briefing document for the FDA meeting scheduled for January 12, 2006.				Other
66,279	RAD 001C	12/02/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Tiffany Svahn, MD.	160			General Correspondence
66,279	RAD 001C	12/02/2005	This letter authorizes FDA to refer to this IND in support of IND that will be filed by Robert. J. Motzer, MD.	159			General Correspondence
66,279	RAD 001C	12/02/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Jonathan Rosenberg, MD.	158			General Correspondence
66,279	RAD 001C	12/02/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Chandra Belani, MD.	157			General Correspondence
66,279	RAD 001C	12/02/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Robert Figlin, MD.	156			General Correspondence
66,279	RAD 001C	12/02/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by John. D. Hainsworth, MD.	155			General Correspondence
66,279	RAD 001C	11/22/2005	Richard Stone: Pneumonitis, nausea, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis, fatigue, productive cough, respiratory distress; Follow-up#4.	154	2207		Safety Report
66,279	RAD 001C	11/22/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Lyndsay N. Harris, MD.	153			General Correspondence
66,279	RAD 001C	11/22/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Shirish. M. Gadgeel, MD.	151			General Correspondence
66,279	RAD 001C	11/22/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Philip. J. Gold. MD.	150			General Correspondence
66,279	RAD 001C	11/22/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by John R. Murren. MD.	149			General Correspondence
66,279	RAD 001C	11/22/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Milind Javle. MD.	148			General Correspondence

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C	11/22/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Mitchell Gross, MD.	152		General Correspondence
66,279	RAD 001C	11/17/2005	[GERMANY] Prof. Struber: Renal impairment, immunosuppressant drug level increased, blood creatinine increased, drug interaction; Follow-up#1.	146	DE06	Safety Report
66,279	RAD 001C	11/14/2005	Dr. Judith Wolf: Hyponatraemia, condition aggravated, anorexia, nausea, asthenia, muscle spasms, hypotension.	145	2409	Safety Report
66,279	RAD 001C	11/11/2005	Dr. Lauren Abrey: International normalised ratio increased, haematuria, drug interaction; Follow-up#1.	143	C2408	Safety Report
66,279	RAD 001C	11/11/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Christopher Ryan, MD.	144		General Correspondence
66,279	RAD 001C	11/01/2005	New Investigator to Study No. 2222: Dr. Stephen M. Schultz, MD.	142	2222	New Investigator
66,279	RAD 001C	11/01/2005	Dr. Lauren Abrey: International normalised ratio increased, haematuria.	141	C2408	Safety Report
66,279	RAD 001C	10/31/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Francisco J. Esteva, MD.	140		General Correspondence
66,279	RAD 001C	10/31/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Lawrence S. Blaszkowsky, MD.	139		Safety Report
66,279	RAD 001C	10/31/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Dr. Deborah Toppmeyer.	138		General Correspondence
66,279	RAD 001C	10/31/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Amanda Psyri, MD.	137		General Correspondence
66,279	RAD 001C	10/31/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Nooper Raje, MD.	136		General Correspondence
66,279	RAD 001C	10/31/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Leonard B. Saltz, MD.	135		General Correspondence
66,279	RAD 001C	10/31/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Manuel Hidalgo, MD., Ph.D.	134		General Correspondence
66,279	RAD 001C	10/26/2005	E-MAILS to/from FDA requesting a meeting date. FDA scheduled a meeting for January 12, 2006 and requested the background package by December 8, 2005.			Request for FDA Meeting
66,279	RAD 001C	10/17/2005	This correspondence is a request for a Type B meeting with the Division of Oncology Drug Products to discuss the development plan and registration strategy for RAD001 in carcinoid tumors and pancreatic neuroendocrine tumors.	133		Request for FDA Meeting
66,279	RAD 001C	10/14/2005	[GERMANY] Prof. Struber: Renal impairment, drug interaction, immunosuppressant drug level increased, blood creatinine increased.	132	ADE06	Safety Report
66,279	RAD 001C	10/04/2005	Dr. Alex Adjei: Pulmonary embolism, chest pain, dyspnoea, respiratory failure, productive cough; Follow-up#1.	131	AUS15	Safety Report
66,279	RAD 001C	09/28/2005	New Investigator to Study No. 2222: Dr. Hope S. Rugo.	130	2222	New Investigator
66,279	RAD 001C	09/28/2005	Dr. Alex Adjei: Pulmonary embolism, chest pain, dyspnoea, respiratory failure, productive cough.	129	AUS15	Safety Report
66,279	RAD 001C	09/27/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Mario Sznol, MD.	128		General Correspondence
66,279	RAD 001C	09/27/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Christopher W. Ryan, MD.	127		General Correspondence

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 09/27/2005	New Investigator to Study No. 2222: Dr. Victor Vogel, MD.	126	2222	New Investigator
66,279	RAD 001C 09/26/2005	Richard Stone, MD: Pneumonitis, nausea, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis, fatigue, productive cough, respiratory distress; Follow-up#3.	125	2207	Safety Report
66,279	RAD 001C 09/23/2005	Richard Stone, MD: Pneumonia bacterial, diarrhoea, supraventricular tachycardia, hypokalaemia, pleural effusion, hypoxia, dyspnoea, crackles lung, troponin increased; Follow-up#2.	124	2207	Safety Report
66,279	RAD 001C 09/01/2005	TELECON from FDA regarding an authorization letter for an Investigator's IND for Dr. Khuri. NVS had submitted the information to FDA on August 31, 2005 (SNs 121 and 122), however, the letters were not received at this time, therefore, NVS faxed the information to the Division, as per their request.			General Correspondence
66,279	RAD 001C 08/31/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Fadio Khuri, MD.	122		General Correspondence
66,279	RAD 001C 08/31/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Fadio Khuri, MD.	121		General Correspondence
66,279	RAD 001C 08/31/2005	This Annual Report covers the period December 25, 2003 to December 24, 2004. The addendum provides clarification on the 15-day safety reports submitted (section 1.1.6) during the relevant period.			Annual Report
66,279	RAD 001C 08/31/2005	E-MAIL from FDA responding to NVS telephone request regarding dual reporting of safety reports, in which FDA stated that all SAEs for oncology, as well as transplantation, be reported to both Divisions.			Other
66,279	RAD 001C 08/25/2005	Richard Stone MD: Pneumonitis, nausea, drug interaction potentiation, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis; Follow-up#2.	119	2207	Safety Report
66,279	RAD 001C 08/19/2005	Amendment No. 4 to Study No. 2206.	117	2206	Change In Protocol
66,279	RAD 001C 08/18/2005	New Investigator to Study No. 2235: Drs. S. Sharma, V. Papadimitrakopoulou.	116	2235	New Investigator
66,279	RAD 001C 08/10/2005	Amendment No. 5 to Study No. 2101.	115	2101	Change In Protocol
66,279	RAD 001C 08/09/2005	Dr. Francis Giles: Leukocytoclastic vasculitis, hyperglycaemia, oedema peripheral, calcinosis, pain, erythema, rash, eschar; Follow-up#1	114	2406	Safety Report
66,279	RAD 001C 08/05/2005	[GREAT BRITAIN] Dr. Ian Judson: Gastrointestinal haemorrhage, bone marrow depression, cardiac arrest, malignant neoplasm progression, melaena, vomiting, haemoglobin decreased, platelet count decreased, dyspnoea, abdominal pain, loss of consciousness; Follow-up#5	113	2101	Safety Report
66,279	RAD 001C 08/05/2005	[AUSTRALIA] Dr. Dan Chambers: Vasculitis gastrointestinal, leukocytoclastic vasculitis, dermatitis allergic, neutropenia, white blood cell count decreased, diarrhoea, vomiting, intestinal ischaemia, biopsy intestine abnormal, biopsy colon abnormal, petechiae, biopsy skin abnormal; Follow-up#1	112		Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 08/03/2005	[AUSTRALIA] Dr. Dan Chambers: Vasculitis gastrointestinal, leukocytoclastic vasculitis, dermatitis allergic, neutropenia, white blood cell count decreased, diarrhoea, vomiting, intestinal ischaemia, biopsy intestine abnormal, biopsy colon abnormal, petechiae, biopsy skin abnormal.	110		Safety Report
66,279	RAD 001C 08/03/2005	Correspondence responding to FDA feedback dated July 7,2005, regarding the May 11, 2005 Special Protocol Assessment request.	111		General Correspondence
66,279	RAD 001C 08/02/2005	This correspondence informs the FDA that the regulatory responsibilities for this product have been transferred to a new manager.	109		General Correspondence
66,279	RAD 001C 07/26/2005	New Investigator to Study No. 2222: Dr. Rachel A. Borso.	108	2222	New Investigator
66,279	RAD 001C 07/14/2005	Howard Burris. MD: Mental status changes, anaemia; Follow-up#2.	107	2101	Safety Report
66,279	RAD 001C 07/07/2005	FDA LETTER containing responses to questions contained in the May 11, 2005, request for a special protocol assessment.			
66,279	RAD 001C 07/06/2005	Dr. Judith Wolf: Hyperglycaemia.	106	2409	Safety Report
66,279	RAD 001C 07/01/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated idioventricular rhythm: Follow-up#5	105	2403	Safety Report
66,279	RAD 001C 06/30/2005	[GREAT BRITAIN] Prof. Ian Judson: Cryptogenic organizing pneumonia, lung infiltration, dyspnoea, dyspnoea exertional; Follow-up#2	104	2101	Safety Report
66,279	RAD 001C 06/29/2005	New Investigator to Study No. 2111: Dr. Vali Papadimitrakopoulou.	103	2111	New Investigator
66,279	RAD 001C 06/29/2005	E-mail to FDA regarding SPA status.			
66,279	RAD 001C 06/21/2005	[AUSTRALIA] Dr. Josette Eris: Drug exposure during pregnancy, premature rupture of membranes, normal delivery, hypertension; Follow-up#1.	102	A2307	Safety Report
66,279	RAD 001C 06/17/2005	This amendment contains supportive documentation for two new tablet strengths, 1.25 mg (6001322.001) and 2.5 mg (3747250.004).	100		CMC Amendment
66,279	RAD 001C 06/09/2005	This Letter authorizes FDA to refer to this IND in support of an IND that will be filed by Anjali S. Advani, MD.	099		General Correspondence
66,279	RAD 001C 06/09/2005	Submission of Investigator's Brochure, Edition 3, replacing Edition 2 dated 11-nov-2002.	098		Clinical Information Amendr
66,279	RAD 001C 06/08/2005	Howard Burris, MD: Mental status changes, anaemia; Follow-up#1.	097	C2101	Safety Report
66,279	RAD 001C 06/02/2005	Dr. L. Miller: Cardiac tamponade, Anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated idioventricular rhythm; Follow-up#4.	096	A2403	Safety Report
66,279	RAD 001C 06/02/2005	[GREAT BRITAIN] Dr. Ian Judson: Gastrointestinal haemorrhage, bone marrow depression, circulatory collapse, cardiac arrest, malignant neoplasm progression, melaena, vomiting, haemoglobin decreased, platelet count decreased, dyspnoea, abdominal pain, loss of consciousness; Follow-up#4.	095	2101	Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 06/01/2005	[AUSTRALIA] Dr. Steve Chadban: Drug exposure during pregnancy, cerebral ventricle dilatation, renal disorder, umbilical cord vascular disorder.	094	A2307E1	Safety Report
66,279	RAD 001C 06/01/2005	[AUSTRALIA] Dr. Josette Eris: Drug exposure during pregnancy, premature rupture of membranes, normal delivery, hypertension.	093	A2307	Safety Report
66,279	RAD 001C 05/31/2005	[GREAT BRITAIN] Dr. Ian Judson: Gastrointestinal haemorrhage, bone marrow depression, circulatory collapse, cardiac arrest, malignant neoplasm progression, melaena, vomiting, haemoglobin decreased, platelet count decreased, dyspnoea, abdominal pain, loss of consciousness; Follow-up#3.	092	2101	Safety Report
66,279	RAD 001C 05/31/2005	E-mails to/from FDA regarding SPA questions.			
66,279	RAD 001C 05/26/2005	[SWITZERLAND] Dr. D. Uehlinger: Eye haemorrhage, Retinal detachment, eye operation; Follow-up#1.	091	A2307E1	Safety Report
66,279	RAD 001C 05/16/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated idioventricular rhythm; follow-up#3	090	2403	Safety Report
66,279	RAD 001C 05/12/2005	Submission of a revised page of the Briefing Book submitted May 11, 2005.	089		General Correspondence
66,279	RAD 001C 05/12/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Dr. Douglas Yee, MD.	088		General Correspondence
66,279	RAD 001C 05/12/2005	Richard Stone, MD: Interstitial lung disease, pneumonitis, nausea, drug interaction potentiation, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis; Follow-up#1	087	2207	Safety Report
66,279	RAD 001C 05/11/2005	In reference to the End-of-Phase 2 meeting held October 25, 2004, this submissions contains a request for special protocol assessment for Phase 3 study No. C2223.	086		
66,279	RAD 001C 05/11/2005	Richard Stone, MD: Pneumonia, diarrhoea, dyspnoea, hypoxia, pleural effusion, crackles lung; Follow-up#1.	085	2207	Safety Report
66,279	RAD 001C 05/06/2005	[SWITZERLAND] Dr. D. Uehlinger: Eye haemorrhage, retinal detachment, eye operation.	084	A2307	Safety Report
66,279	RAD 001C 05/06/2005	Richard Stone, MD: Pneumonia, hypoxia, diarrhoea, pleural effusion, dyspnoea, crackles lung.	083	2207	Safety Report
66,279	RAD 001C 05/05/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated idioventricular rhythm; Follow-up#2.	082	2403	Safety Report
66,279	RAD 001C 05/04/2005	Richard Stone, MD: Interstitial disease, pneumonitis, nausea, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis.	081	2207	Safety Report
66,279	RAD 001C 05/03/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated idioventricular rhythm; Follow-up#1	080	A2403	Safety Report
66,279	RAD 001C 04/28/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall.	079	A2403	Safety Report
66,279	RAD 001C 04/27/2005	[GREAT BRITAIN] Prof. Ian Judson: Cryptogenic organizing pneumonia, lung infiltration, dyspnoea, dyspnoea exertional; Follow-up#1	078	2101	Safety Report

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 04/26/2005	Dr. Ian Judson: Cardiac arrest, malignant neoplasm progression, circulatory collapse, bone marrow depression, gastrointestinal haemorrhage, haemoglobin decreased, platelet count decreased, dyspnoea, abdominal pain, loss of consciousness, vomiting, melaena; Follow-up#2.	077	2101	Safety Report
66,279	RAD 001C 04/25/2005	[GERMANY] Peter Reichardt: Neoplasm progression, tumour haemorrhage, haemoglobin decreased, blood lactate dehydrogenase increased, blood potassium increased, blood uric acid increased, hyperbilirubinaemia, blood creatinine increased; Follow-up#1.	076	2206	Safety Report
66,279	RAD 001C 04/20/2005	E-mail to FDA regarding SPA and list of investigators participating in study 2223.			
66,279	RAD 001C 04/18/2005	[GERMANY] Peter Reichardt: Tumor lysis syndrome, tumour haemorrhage, haemoglobin decreased, blood lactate dehydrogenase increased, blood potassium increased, blood uric acid increased, hyperbilirubinaemia, blood creatinine increased.	075	2206	Safety Report
66,279	RAD 001C 04/11/2005	New Protocol to Study No. 2111 entitled, "A combined phase 1 and 2 study investigating the combination of RAD001 and erlotinib in patients with advanced NSCLC previously treated only with chemotherapy. This trial combines erlotinib (Tarceva), an approved agent for locally advanced or metastatic NSCL after failure of at least one prior chemotherapy regimen, with the investigational drug RAD001. The erlotinib tablets used in the studies are supplied by OSI Pharmaceuticals. OSI submitted a letter of	074	2111 2235	New Protocol
66,279	RAD 001C 04/08/2005	[GERMANY] Dr. Kaltenhaeuser: Septic shock, peripheral occlusive disease, vasculitis, drug level decreased, skin ulcer, haemoglobin decreased, C-reactive protein increased.	073		Safety Report
66,279	RAD 001C 04/08/2005	James Yao: Hypoglycaemia, feeling abnormal, confusional state.	072	BUS52	Safety Report
66,279	RAD 001C 04/06/2005	Howard A. Burris, III, MD: Epistaxis, platelet count decreased, bleeding time prolonged.	071	2101	Safety Report
66,279	RAD 001C 04/06/2005	[SPAIN] Dr. Tabemero: Malignant neoplasm progression, stomatitis, drug ineffective, enterocolitis, abdominal pain, anorexia, vomiting, constipation, skin lesion, metastases to peritoneum, performance status decreased, respiratory disorder, hypoalbuminaemia, generalised oedema.	070	2107	Safety Report
66,279	RAD 001C 04/06/2005	[BELGIUM] Dr. Van Oosterom: Gastritis haemorrhagic, thrombocytopenia, anaemia, nausea, vomiting, melaena.	069	2206	Safety Report
66,279	RAD 001C 04/06/2005	Dr. Meir Wetzler, MD: Cardiac failure congestive, asthma, dyspnoea, oedema peripheral, eyelid oedema, weight increased, dilatation atrial, ventricular hypertrophy.	068	2207	Safety Report
66,279	RAD 001C 04/06/2005	[BELGIUM] Dr. Van Oosterom: Gastritis haemorrhagic, right ventricular failure, pulmonary hypertension, anaemia, haematochezia, general physical health deterioration.	067	2206	Safety Report
66,279	RAD 001C 04/06/2005	E-mails to/from FDA regarding a sample CRF requirement for an SPA.			
66,279	RAD 001C 04/04/2005	TELECON with FDA regarding CIOMS VI safety reporting requirements and investigator notifications.			Memo of Record (telephone report)
66,279	RAD 001C 04/01/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Ingrid Mayer, MD.	066		General Correspondence

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	04/01/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Mary-Ellen Taplin, MD.	065			General Correspondence
66,279	RAD 001C	04/01/2005	E-mail to FDA regarding submission date for SPA for Study 2223.				
66,279	RAD 001C	03/28/2005	This amendment provides for the following dosage forms and or pharmaceutical intermediate: RAD001 5 mg Tablets and RAD001 9.09% Solid Dispersion.	064			CMC Amendment
66,279	RAD 001C	03/21/2005	[GREAT BRITAIN] Dr. Ian Judson: Cardiac arrest, malignant neoplasm progression, circulatory collapse, bone marrow depression, gastrointestinal haemorrhage, haemoglobin decreased, platelet count decreased, dyspnoea, abdominal pain, loss of consciousness, vomiting, melaena: Follow-up#1.	063	2101		Safety Report
66,279	RAD 001C	03/15/2005	[GREAT BRITAIN] Dr. Ian Judson: Cardiac arrest, malignant neoplasm progression, circulatory collapse, bone marrow depression, gastrointestinal haemorrhage, haemoglobin decreased, platelet count decreased, dyspnoea, abdominal pain, loss of consciousness, vomiting, melaena.	062	2101		Safety Report
66,279	RAD 001C	03/08/2005	Dr. George Demetri: Malignant neoplasm progression, ascites, drug interaction, cholelithiasis, pleural effusion, dyspnoea.	061	C2206		Safety Report
66,279	RAD 001C	02/23/2005	This Annual Report covers the period December 25, 2003 through December 23, 24, 2004. Includes clinical study information, general investigation plan for the coming year and a investigator brochure.	060			Annual Report
66,279	RAD 001C	02/01/2005	[GREAT BRITAIN] Prof. Ian Judson: Criptogenic organizing pneumonia, lung infiltration, dyspnoea, dyspnoea exertional.	059	2101		Safety Report
66,279	RAD 001C	01/28/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Robert J. Amato, MD.	058			General Correspondence
66,279	RAD 001C	01/28/2005	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by Gini Fleming, MD.	057			General Correspondence
66,279	RAD 001C	01/24/2005	New Investigator to Study No. 2106: Dr. David A. Reardon, MD.	056	2106		New Investigator
66,279	RAD 001C	01/24/2005	This letter authorizes FDA to refer to the IND that will be filed by Daniel George, MD.	055			General Correspondence
66,279	RAD 001C	01/14/2005	E-mail to FDA regarding the action items from the October 25, meeting.				
66,279	RAD 001C	12/21/2004	New Investigator to Study No. 2207: Drs. S. Petersdorf, R. M. Stone, S. Goldberg.	054	2207		New Investigator
66,279	RAD 001C	12/17/2004	E-mails to/from FDA regarding delay of SPA request.				
66,279	RAD 001C	12/08/2004	Howard Burris. MD: Mental status changes, anaemia.	053			Safety Report
66,279	RAD 001C	12/07/2004	Dr. Francis Giles: Leukocytoclastic vasculitis, hyperglycaemia, oedema peripheral, calcinosis, pain, erythema, rash eschar.	052	2406		Safety Report
66,279	RAD 001C	12/01/2004	New Investigator to Study No. 2207: Dr. Charles A. Schiffer, MD.	051	2207		New Investigator

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	11/23/2004	In reference to the End-of-Phase 2 meeting held on October 25, 2004, this correspondence notifies the Agency of Novartis' intent to request a Special Protocol Assessment for a pivotal Phase 3 study, CRAD001C2223.	050			General Correspondence
66,279	RAD 001C	11/19/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed T. Witzig, MD.	048			General Correspondence
66,279	RAD 001C	11/16/2004	E-mails to/from FDA concerning the clinical pharmacology review of submission dated July 30, 2004.				
66,279	RAD 001C	11/15/2004	Dr. Vincent Miller: Multi-organ failure, chest pain, back pain, asthenia, diarrhoea, hypotension.	047	C2406		Safety Report
66,279	RAD 001C	11/15/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed D. A. Reardon and H. S. Friedman.	046			General Correspondence
66,279	RAD 001C	11/15/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed T. Witzig, MD.	045			General Correspondence
66,279	RAD 001C	11/11/2004	New protocol to Study No. 2222 entitled, "A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole (Femara) as preoperative therapy of primary breast cancer in postmenopausal women.	044	2222		New Protocol
66,279	RAD 001C	11/09/2004	E-mail from FDA stating that there are no comments from the clinical pharmacology review of the July 30, 2004 submission for Study 2106.				
66,279	RAD 001C	10/29/2004	E-mails to/from FDA regarding October 25 meeting minutes.				
66,279	RAD 001C	10/25/2004	FDA minutes of the EOP2 meeting held on October 25, 2004.				FDA/Novartis Meeting Minu
66,279	RAD 001C	10/19/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by P. O'Dwyer, MD.	043			General Correspondence
66,279	RAD 001C	10/19/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by E. Rivera, MD.	042			General Correspondence
66,279	RAD 001C	10/07/2004	New Investigator to Study No. 2207. Dr. Brian J. Druker, MD.	041	2207		New Investigator
66,279	RAD 001C	09/23/2004	New Investigator to Study No. 2101: Dr. V. A. Papadimitrakopoulou; Study No. 2207: Dr. R. A. Larson.	040	2101 2207		New Investigator
66,279	RAD 001C	09/22/2004	E-mails to/from FDA regarding End-of-Phase 2 meeting.				
66,279	RAD 001C	09/20/2004	This Briefing Book is being submitted in preparation for a Type B (End-of-Phase 2) meeting scheduled for October 21, 2004.	039			Briefing Book
66,279	RAD 001C	09/20/2004	E-mail to FDA containing electronic version of documents requested from End-of-Phase 2 Briefing Book.				
66,279	RAD 001C	08/31/2004	FAX from FDA contained information on the EOP2 meeting requested (Serial No. 037).				
66,279	RAD 001C	08/25/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by S. N. Markovic, MD.	038			General Correspondence
66,279	RAD 001C	08/18/2004	This correspondence requests a Type B meeting with the Division to discuss a development plan and registration strategy for RAD001 in combination therapy for advanced breast cancer.	037			Request for FDA Meeting

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 08/11/2004	This correspondence re-submits a letter of authorization dated August 31, 2004, Serial No. 031 with the correct name of the investigator: T. Cloughesy, MD.	036		General Correspondence
66,279	RAD 001C 08/03/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by M. Prados, MD.	035		General Correspondence
66,279	RAD 001C 08/03/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by A. Yung, MD.	034		General Correspondence
66,279	RAD 001C 08/03/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by P. Wen, MD.	033		General Correspondence
66,279	RAD 001C 08/03/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by H. S. Friedman, MD.	032		General Correspondence
66,279	RAD 001C 08/03/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by C. L. Sawyers, MD.	031		General Correspondence
66,279	RAD 001C 07/30/2004	New Protocol to Study No. 2106 entitled, "A phase IB/II, multicenter, two-arm, dose escalation study of oral AEE788 administered in combination with oral RAD001 on a continuous once daily dosing schedule in adult patients with first or second recurrent or relapsing glioblastoma multiforme."	030	2106	New Protocol
66,279	RAD 001C 07/29/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by J. C. Yao, MD	029		General Correspondence
66,279	RAD 001C 07/27/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by A. Adjei, MD.	028		General Correspondence
66,279	RAD 001C 07/23/2004	New Investigator to Study No. 2207: Dr. Meir Wetzler, MD.	027	2207	New Investigator
66,279	RAD 001C 07/22/2004	This correspondence informs the Division that the regulatory responsibilities have been transferred to a new regulatory manager, C. Vanderlinden.	026		General Correspondence
66,279	RAD 001C 06/17/2004	New Protocol: Study No. 2207 entitled, "A phase I-II study of RAD001 in combination with imatinib (Glivec/Gleevec) in patients with chronic myelogenous leukemia (CML) in chronic phase who are not in complete cytogenetic response to imatinib-alone at Study entry.	025	2207	New Protocol
66,279	RAD 001C 06/07/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by M. Fouladi, MD.	023		General Correspondence
66,279	RAD 001C 05/24/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by H. Hurwitz, MD.	022		General Correspondence
66,279	RAD 001C 05/18/2004	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by D. Franz, MD.	021		General Correspondence
66,279	RAD 001C 05/11/2004	E-mails to/from FDA regarding the response to FDA comments for Study 2107			
66,279	RAD 001C 04/27/2004	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by D. George, MD.	020		General Correspondence
66,279	RAD 001C 04/06/2004	Amendment No. 1 to Study No. 2107.	019	2107	Change in Protocol
66,279	RAD 001C 03/25/2004	This letter authorizes FDA to refer this IND in support of an IND to be sponsored by J. Wolf.	018		General Correspondence
66,279	RAD 001C 02/10/2004	New Investigator to Study No. 2107: Dr. Howard A. Burris.	016	2107	New Investigator
66,279	RAD 001C 01/29/2004	This letter authorizes FDA to refer to this IND in support of two INDs that will be filed by Memorial Sloan-Kettering Cancer Center.	015		General Correspondence

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
66,279	RAD 001C	01/15/2004	This correspondence authorizes the FDA to refer to this IND in support of an IND that will be filed by F. Giles, MD.	014			General Correspondence
66,279	RAD 001C	01/09/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by H. Scher, MD.	013			General Correspondence
66,279	RAD 001C	01/09/2004	This letter authorizes the FDA to refer to this IND in support of an IND that will be filed by V. A. Miller, MD.	012			General Correspondence
66,279	RAD 001C	01/07/2004	New protocol: Study No. 2107 entitled, "A" phase 1b study investigating safety, tolerability and molecular pharmacodynamic effects of RAD001 monotherapy in patients with solid cancers.	011	2107		New Protocol
66,279	RAD 001C	12/15/2003	New Investigator to Study No. 2101: Dr. Howard. A. Burris, III, MD.	010	2101		New Investigator
66,279	RAD 001C	12/01/2003	FAX from FDA containing comments from the clinical pharmacology review on Serial No. 006 dated March 7, 2003.				
66,279	RAD 001C	10/07/2003	New protocol and Amendment No. 1, No. 2, and No. 3, to Study No. 2101: entitled, "A phase 1b study of RAD001 in combination with gemcitabine, investigating safety, tolerability pharmacokinetics and pharmacodynamics in patients with advanced solid tumors.	009	2101		New Protocol
66,279	RAD 001C	05/02/2003	Amendments No. 1 and 2 to Study No. 2206.	007	2206		Change In Protocol
66,279	RAD 001C	03/07/2003	Response to comments from the Pharmacology Reviewer on Serial No. 005 received February 25, 2002.	006			Response to FDA Request
66,279	RAD 001C	03/05/2003	FDA LETTER stating that the proposed clinical study may proceed and also contains recommendations and/or requests for information in reference to the original IND.				
66,279	RAD 001C	02/25/2003	FAX from FDA containing comments from the clinical pharmacology review on Serial No. 005.				
66,279	RAD 001C	01/17/2003	This correspondence responds to comments received from the Pharmacology Reviewer regarding Study RAD001.	005			Response to FDA Request
66,279	RAD 001C	12/31/2002	FAX from FDA containing comments from the Medical Reviewer on Serial No. 003, dated December 19, 2002.				
66,279	RAD 001C	12/30/2002	FAX from FDA containing comments from the Chemistry review.				
66,279	RAD 001C	12/19/2002	FAX from FDA which states that the review of the IND is completed and that the proposed clinical study may begin based on the December 19, 2002 agreement to correct the deficiency.				
66,279	RAD 001C	12/19/2002	E-mail to FDA in response to the deficiency and comments received December 18, 2002.				
66,279	RAD 001C	12/19/2002	FAX from FDA containing comments from the Medical review.				
66,279	RAD 001C	12/19/2002	Response to comments received from the Medical Reviewer regarding Study No. 2206.	003			Response to FDA Request
66,279	RAD 001C	12/18/2002	E-mail from FDA containing a deficiency and comments on the original IND.				
66,279	RAD 001C	12/18/2002	Response to FDA for a statement of clarification to allow cross referencing of IND 52,003 (Division of Special Pathogens and Immunologic Drug Products).	002			Response to FDA Request

REF	PRODUC DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
66,279	RAD 001C 12/06/2002	This submission responds to an FDA request for desk copies of relevant sections of the original IND.	001		Response to FDA Request
66,279	RAD 001C 11/22/2002	This original IND for RAD001 is being developed as an antiproliferative drug with applications as an immunosuppressant and anticancer agent. Protocol: Study No. RAD001C2206 entitled, "A phase I-II, open-label study of RAD001 in combination with Glivec (imatinib) in patients with Glivec-refractory/resistant gastrointestinal stromal tumors". Investigator: G. Demetri, MD.	000	C2206	Original IND

REF	PROD DATE	DESCRIPTION	SUP TYPE
22-334	Afinitor 04/07/2009	Final printed labeling as requested in the approval letter dated March 30, 2009 for S000 in Structured product labeling format. Also includes the final printed carton and container labels (eCTD-seq0046).	000 Labeling
22-334	Afinitor 03/30/2009	FDA LETTER approving the new drug application submitted June 27, 2008. This new drug application provides for the use of Afinitor (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.	
22-334	Afinitor 03/27/2009	Final proposed labeling of US PI as received from FDA on March 25, 2009. Also includes agreement to Post-Marketing Commitments received on March 26, 2009 (eCTD-seq0045).	Labeling
22-334	Afinitor 03/20/2009	Response to FDA Request received March 18, 2009 regarding adverse event table (eCTD-seq0043).	Clinical
22-334	Afinitor 03/12/2009	Response to FDA request for time-to-treatment-failure analysis combining the PFS events per investigator with events based on treatment discontinuation. Also providing a by-patient listing explaining differences between the dates for PFS events and the main reasons for treatment discontinuation (eCTD-seq0042)	Clinical
22-334	Afinitor 03/11/2009	Response to CMC information request received on March 9 and 10, 2009 (eCTD-seq0041).	CMC
22-334	Afinitor 03/10/2009	Response to request for clinical and statistical information received via email on March 6, 2009 (eCTD-seq0040).	Clinical
22-334	Afinitor 03/03/2009	Response to request for proposed PMR timelines and clinical information request received via email on March 2, 2009. (eCTD-seq0039).	Clinical
22-334	Afinitor 02/27/2009	Response to FDA Request Updated Proposed Label Requested on February 23, 2009 (eCTD-seq0038).	Labeling
22-334	Afinitor 02/25/2009	Response to FDA request for Statistical information dated February 24, 2009 (eCTD-seq0037).	Other
22-334	Afinitor 02/23/2009	Response to FDA CMC information email request dated February 19, 2009. Response to FDA Clinical information email request dated February 19, 2009 and February 20, 2009 (eCTD-seq0036).	Clinical CMC
22-334	Afinitor 02/20/2009	Corrected cover letter for seq. 0034 regarding incorrect "Document Status" (sent Feb. 17, 2009). Cover sheet was marked "draft", but information was final (eCTD-seq-0035).	General Corresponden
22-334	Afinitor 02/18/2009	Response to FDA regarding Clinical Information request (eCTD-seq0034).	Other
22-334	Afinitor 02/17/2009	Investigators Prof. Stephanie Oudard and Prof. Camillo Pota response to FDA inspectional observations. Inspections were held Dec. 8-12, 2009 and Dec. 15-19, 2009 respectively (eCTD-seq0033).	General Corresponden
22-334	Afinitor 02/10/2009	Response to clinical information request of February 9, 2009 (eCTD-seq0032)	Clinical
22-334	Afinitor 02/06/2009	Email Response to Statistical Request Regarding Sequence 31	Other
22-334	Afinitor 01/20/2009	Response to FD-483 observations from FDA Inspection November 17-21, 2008, CFN 9611204 Novartis Pharma AG, Site Basel (eCTD-seq0029).	CMC
22-334	Afinitor 12/22/2008	Response to DRISK Comments on PPI (eCTD-seq0027)	Labeling
22-334	Afinitor 12/10/2008	Response to Clinical Pharmacology Information Request received by e-mail on December 7, 2008. Novartis is providing all requested bio-analytical reports (eCTD-seq0026)	Clinical

REF	PROD DATE	DESCRIPTION	SUP TYPE
22-334	Afinitor 12/05/2008	Response to clinical pharmacology information request received via email on November 4, 2008, discussed at a telecon on November 5, 2008 and November 26, 2008. Submission also includes a revised Financial Disclosure Certification. (eCTD-seq0025).	Clinical
22-334	Afinitor 11/26/2008	This submission is in response to information requests received October 10 and November 13, 2008. Novartis providing the RECIST CRFs for 93 patients and the eCRF screenshots for 210 patients as agreed. (eCTD-0024)	Clinical
22-334	Afinitor 11/11/2008	Response to FDA question about number of patients with post study treatment in raw and derived datasets. (eCTD-0022)	General Corresponden
22-334	Afinitor 10/31/2008	Novartis is providing the written response to the information Request referenced herein. (eCTD-0021).	CMC
22-334	Afinitor 10/28/2008	With this submission Novartis is providing the third and last part of the response to the Information Requests received via email on September 22, and September 23, 2008, which addresses the request to quantify missing tumor assessments both for site (local) evaluations and evaluations carried out by independent review (central) and compare the missing patterns between the two sources. (eCTD-seq0019)	Clinical
22-334	Afinitor 10/24/2008	This amendment is in response to the FDA request received via email on October 9, 2008 and includes the combined datasets for the C2101-02 PK data analysis including concentration data that was missing in the datasets for this study submitted in the original NDA. Novartis is also re-submitting the updated PK datasets with nominal time for clinical oncology studies C1101, C2104, C2108, C2207, and C2222. Also With this submission Novartis is submitting a revised version of the population PK study report which we submitted with the 90-Day Safety Update [September 30, 2008, sequeene 0011, CTD	Clinical
22-334	Afinitor 10/21/2008	This amendment contains the response to the FDA request received by email on September 22, 2008 for the by-patient listing of all discrepancies between the central and local reviews, with the incorporation of a comments column to document potential explanations. (eCTD-seq0017)	Clinical
22-334	Afinitor 10/21/2008	This correspondence to the FDA is to inform them of the minor discrepancies discovered for protocol deviations codes as"E 08-Patient has a severe and/or uncontrolled medical condition" for 3 patients at Dr. Robert Motzer's site (number 513) at Memorial Sloan-Kettering Cancer Center (York, US) which are incorrect. (eCTD-seq0018)	General Corresponden
22-334	Afinitor 10/17/2008	This amendment contains the additional datasets for study C2107 requested by email on October 8, 2008, as well as the request by email on October 9, 2008 for the resubmission of the dataset for study C2119. (eCTD-seq0016)	Clinical
22-334	Afinitor 10/14/2008	This amendment contains the response to the information request received by email on October 2, 2008 for the datasets for studies C2107 and C2239. (eCTD-seq0015)	Clinical
22-334	Afinitor 09/29/2008	Response to FDA request received via email on September 22 and 23, 2008. (eCTD-seq0013)	Clinical
22-334	Afinitor 09/29/2008	Response to FDA request received via email on August 29, 2008. At this time Novartis is submitting the responses to the unanswered questions in the CMC information request. (eCTD-seq0012)	CMC
22-334	Afinitor 09/18/2008	Response to Division of Scientific Investigation request regarding information for Everolimus. The response includes information from Study 2240 Centers 0513 and 0606 and 0756. (ES)	Other
22-334	Afinitor 09/11/2008	This correspondence to the FDA is to follow-up on the question about reader concordance raised at the applicant orientation meeting. (eCTD-seq0009)	General Corresponden

REF	PROD DATE	DESCRIPTION	SUP TYPE
22-334	Afinitor 09/09/2008	This amendment is in response to the information request made via email on August 28, 2008 for the list of drug substance batches (pre-clinical and clinical) used to support NDA 22-334 and the batch data for one drug substance batch that has not been submitted. (eCTD-seq0010)	CMC
22-334	Afinitor 09/07/2008	Novartis is submitting an Amending to the Pending NDA for providing registration stability update and a shelf life extension for the 5mg and 10mg Afinitor® (everolimus) Tablets. Also included in this submission is a correction of the name and address of a quality control and stability testing site for the 5mg and 10mg Afinitor® (everolimus) Tablets. The updated address was also provided in the Establishment Information included in the Amendment Sequence 0006, submission date of 29-Aug-2008. (eCTD-seq0007)	CMC
22-334	Afinitor 09/05/2008	This amendment is in response to the CMC information request received via email on August 29, 2008. (eCTD-seq0008)	CMC
22-334	Afinitor 08/29/2008	At this time, Novartis is submitting an amendment in response to the information request received dated 22-Jul-2008, to provide complete updated drug substance information to NDA No. 22-334. This amendment is submitted in accordance to the agreements reached in the teleconference held between Novartis associates and FDA representatives from the Division of Special Pathogens and Transplant Products, and the Oncology Drug Products Division to discuss the requirements for transfer of responsibility for NDA review of the everolimus drug substance information in support of the Afinitor	CMC
22-334	Afinitor 08/26/2008	This amendment contains a 60 day efficacy update of the pivotal Phase III study CRAD001C2240, which is provided as an amendment to 2.7.3 Summary of Clinical Efficacy. (eCTD-seq0005)	Clinical
22-334	Afinitor 08/21/2008	This amendment to the pending NDA is in response to the emails received on July 31 and August 12, 2008 for the datasets of the thorough QT study C2118. (eCTD-seq0004)	Clinical
22-334	Afinitor 08/20/2008	Novartis meeting minutes submitted to the FDA of the August 13, 2008 meeting between Novartis and the FDA to discuss and agree on the requirements for transfer of responsibility for NDA review of the everolimus drug substance information in support of the Afinitor NDA CMC review. (eCTD-seq0003)	FDA/Novartis Meeting Minutes
22-334	Afinitor 08/04/2008	This amendment to the pending NDA is in response to the FDA requested received via email on July 24, 2008 and July 25, 2008. (eCTD-seq0002)	Clinical
22-334	Afinitor 07/29/2008	This amendment to the pending NDA is in response to the FDA request received July 17, 2008 for the annotated label with each line numbered. (eCTD-seq0001)	Labeling
22-334	Afinitor 06/27/2008	Original NDA for the treatment of advanced renal cell carcinoma (RCC). (eCTD-seq0000)	Original NDA

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	04/08/2009	Amendment updates reference standards and retest period and storage temperature in support of upcoming clinical studies (PS).	885		CMC Amendment
52,003	Certican®	04/03/2009	Updated CMC for 0.25mg, 0.5mg, 0.75 mg and 1 mg tablets in support of upcoming clinical studies. (PS)	884		CMC Amendment
52,003	Certican®	03/27/2009	Response to FDA request to submit final study reports CRAD001A B158, B158E1 and B158E2. (PS)	880		Response to FDA Request
52,003	Certican®	03/25/2009	Request for teleconference to help guide Novartis and clarify FDA recommendations from February 19, 2009 communication for exposure-response analyses. (PS)	0879		Request for FDA Meeting
52,003	Certican®	03/04/2009	7-day safety report PHHO2009US02442			Safety Report
52,003	Certican®	03/04/2009	Clinical information amendment - Revised Statistical Plan CRAD001A2309. (PS)	872		Clinical Information Amendr
52,003	Certican®	02/19/2009	7-day safety report PHHO2009US01705 (PS)			Safety Report
52,003	Certican®	02/11/2009	PHHO2008US15235; follow-up (PS)	865		Safety Report
52,003	Certican®	02/10/2009	PHHY2008DE25330; follow-up (PS)	864		Safety Report
52,003	Certican®	02/10/2009	PHHO2009IT00723; follow-up (PS)	863		Safety Report
52,003	Certican®	02/09/2009	PHHO2009IT00723; follow-up (PS)	862		Safety Report
52,003	Certican®	02/09/2009	PHHO2008US14020; follow-up (PS)	861		Safety Report
52,003	Certican®	02/04/2009	CRAD001H2304,CRAD001A2309,CRAD001A2310,CRAD001A2309 new investigator (PS)	860		New Investigator
52,003	Certican®	01/30/2009	Submission to gain preliminary advice from FDA on future development program for Certican in combination with reduced exposure tacrolimus in renal transplantation. Note cover letter incorrectly states date as 1/30/2008.(PS)	859		Clinical Information Amendr
52,003	Certican®	01/29/2009	PHHO2008FR13655; follow-up (PS)	858		Safety Report
52,003	Certican®	01/29/2009	PHHO2009IT00723; follow-up (PS)	857		Safety Report
52,003	Certican®	01/27/2009	7-day safety report PHHO2008FR13655 (PS)			Safety Report
52,003	Certican®	01/27/2009	PHHO2008FR13655 (PS)	856		Safety Report
52,003	Certican®	01/26/2009	PHHO2008US15235; follow-up (PS)	855		Safety Report
52,003	Certican®	01/21/2009	7-day safety report PHHO2008US14734. (PS)			Safety Report
52,003	Certican®	01/21/2009	PHHO2008US14734 (PS)	854		Safety Report
52,003	Certican®	01/21/2009	PHHO2009IT00723 (PS)	853		Safety Report
52,003	Certican®	01/14/2009	PHHO2008US15235; follow-up (PS)	852		Safety Report
52,003	Certican®	01/13/2009	PHHO2008TR15263; follow-up (PS)	851		Safety Report
52,003	Certican®	01/12/2009	Annual Report covering the period November 15, 2007 to November 14, 2008. (PS)	850		Annual Report
52,003	Certican®	01/09/2009	PHHO2008TR15236; follow-up (PS)	849		Safety Report
52,003	Certican®	01/07/2009	PHHO2008US14020; follow-up (PS)	848		Safety Report
52,003	Certican®	01/07/2009	PHHO2008DE11094; follow-up (PS)	847		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	01/07/2009	PHHO2008US15235 (PS)	846		Safety Report
52,003	Certican®	01/06/2009	Clinical information amendment - updated statistical analysis plan for study CRAD001A2309. (PS)	845		Clinical Information Amendr
52,003	Certican®	01/05/2009	PHHO2008TR15236 (PS)	844		Safety Report
52,003	Certican®	01/02/2009	PHHO2008DE11982; follow-up (PS)	843		Safety Report
52,003	Certican®	12/29/2008	PHHO2008US13880; follow-up (PS)	842		Safety Report
52,003	Certican®	12/26/2008	PHHO2008CH13360; follow-up (PS)	841		Safety Report
52,003	Certican®	12/26/2008	PHHO2008CH13379; follow-up (PS)	840		Safety Report
52,003	Certican®	12/18/2008	Clinical information amendment - proposals for PK/PD statistical methods/table shells. (PS)	839		Clinical Information Amendr
52,003	Certican®	12/15/2008	PHHO2007US20875; follow-up (PS)	838		Safety Report
52,003	Certican®	12/12/2008	PHHO2008BE12855; follow-up (PS)	837		Safety Report
52,003	Certican®	12/10/2008	PHHO2008DE11094; follow-up (PS)	836		Safety Report
52,003	Certican®	12/09/2008	PHHO2008US14020; follow-up (PS)	834		Safety Report
52,003	Certican®	12/09/2008	PHHO2008DE11982 (PS)	835		Safety Report
52,003	Certican®	12/08/2008	PHHO2008IT09241; follow up (PS)	833		Safety Report
52,003	Certican®	12/05/2008	PHHO2008US14020 (PS)	832		Safety Report
52,003	Certican®	12/04/2008	PHHO2008US13880 (PS)	831		Safety Report
52,003	Certican®	12/03/2008	PHHO2008DE11491; follow-up (PS)	830		Safety Report
52,003	Certican®	12/02/2008	PHHO2008IT09241; follow-up (PS)	826		Safety Report
52,003	Certican®	12/02/2008	PHHO2008CH13360; follow-up (PS)	827		Safety Report
52,003	Certican®	12/02/2008	PHHO2008CH13379; follow-up (PS)	828		Safety Report
52,003	Certican®	12/02/2008	PHHO2008US14108 (PS)	829		Safety Report
52,003	Certican®	11/26/2008	PHHO2008CH13379; follow-up (PS)	824		Safety Report
52,003	Certican®	11/26/2008	PHHO2008CH13360; follow-up (PS)	825		Safety Report
52,003	Certican®	11/25/2008	PHHO2008IT01481; follow-up (PS)	821		Safety Report
52,003	Certican®	11/25/2008	PHHO2008IT09241 (PS)	822		Safety Report
52,003	Certican®	11/25/2008	PHHO2007AU11574; follow-up (PS)	823		Safety Report
52,003	Certican®	11/21/2008	PHHO2008DE11094; follow-up (PS)	819		Safety Report
52,003	Certican®	11/21/2008	PHHO2008TW11206; follow-up (PS)	820		Safety Report
52,003	Certican®	11/19/2008	PHHO2008CH13379 (PS)	817		Safety Report
52,003	Certican®	11/19/2008	PHHO2008CH13360 (PS)	818		Safety Report
52,003	Certican®	11/18/2008	PHHO2008TW11206; follow-up (PS)	816		Safety Update
52,003	Certican®	11/17/2008	PHHO2008BE12855 (PS)	815		Safety Report

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	11/14/2008	PHHO2008DE11491; follow-up (PS)	814		Safety Report
52,003	Certican®	11/13/2008	PHHO2008US12593; follow-up (PS)	813		Safety Report
52,003	Certican®	11/11/2008	PHHO2008IT11948; follow-up (PS)	812		Safety Report
52,003	Certican®	11/10/2008	PHHY2008DE25330; follow-up (PS)	811		Safety Report
52,003	Certican®	11/06/2008	Study CRAD001H2304 new investigator. (PS)	809		New Investigator
52,003	Certican®	11/06/2008	PHHO2008CA11400; follow-up (PS)	810		Safety Report
52,003	Certican®	10/29/2008	PHHY2008SG20428 follow-up (PS)	808		Safety Report
52,003	Certican®	10/28/2008	PHHO2008DE11094 follow-up (PS)	806		Safety Report
52,003	Certican®	10/28/2008	PHHO2008DE12119 follow-up (PS)	807		Safety Report
52,003	Certican®	10/27/2008	PHHY2008DE25330 follow-up (PS)	805		Safety Report
52,003	Certican®	10/27/2008	PHHO2007US20875; follow-up (PS)	803		Safety Report
52,003	Certican®	10/27/2008	PHHO2008US12593 (PS)	804		Safety Report
52,003	Certican®	10/24/2008	PHHO2008DE11094; follow-up (PS)	802		Safety Report
52,003	Certican®	10/21/2008	PHHO2008DE12119 (PS)	801		Safety Report
52,003	Certican®	10/20/2008	7-day safety report PHHO2008DE11094 (PS)			Safety Report
52,003	Certican®	10/16/2008	7-Day safety report PHHO2008DE12119. (PS)			Safety Report
52,003	Certican®	10/16/2008	PHHO2008IT11948 (PS)	800		Safety Report
52,003	Certican®	10/14/2008	PHHO2008DE11491 (PS)	798		Safety Report
52,003	Certican®	10/14/2008	PHHO2007US00556; follow-up (PS)	799		Safety Report
52,003	Certican®	10/08/2008	PHHO2008CA04926; follow-up (PS)	796		Safety Report
52,003	Certican®	10/03/2008	PHHO2008AR00668; follow-up (PS)	795		Safety Report
52,003	Certican®	09/30/2008	PHHO2008TW11206 (PS)	793		Safety Report
52,003	Certican®	09/30/2008	PHHO2008CA11400 (PS)	794		Safety Report
52,003	Certican®	09/23/2008	PHHO2008US10695 follow-up (PS)	791		Safety Report
52,003	Certican®	09/23/2008	PHHO2008DE10143 follow-up (PS)	792		Safety Report
52,003	Certican®	09/19/2008	PHHO2008NO01190 (PS)	790		Safety Report
52,003	Certican®	09/18/2008	PHHY2008SG20428 (PS)	788		Safety Report
52,003	Certican®	09/18/2008	PHHY2008JP20446 (PS)	789		Safety Report
52,003	Certican®	09/16/2008	PHHO2008US10695 (PS)	787		Safety Report
52,003	Certican®	09/15/2008	7-Day Safety report PHHY2008SG20428 (PS)			Safety Report
52,003	Certican®	09/15/2008	7-day safety report PHHO2008US12593 (PS)			Safety Report
52,003	Certican®	09/12/2008	PHHO1997FR03054 (PS)	786		Safety Report
52,003	Certican®	09/11/2008	PHHO1997NO02606 follow-up (PS)	785		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	09/10/2008	PHHO2007US21124 follow-up (PS)	783			Safety Report
52,003	Certican®	09/10/2008	PHHO2008CA00612 follow-up (PS)	784			Safety Report
52,003	Certican®	09/08/2008	Study CRAD001A2310 change in protocol, amendment 7. (PS)	782			Change In Protocol
52,003	Certican®	09/04/2008	PHHO2007FR07389 follow-up (PS)	781			Safety Report
52,003	Certican®	09/03/2008	PHHO2008DE10143 (PS)	780			Safety Report
52,003	Certican®	09/02/2008	PHHO2008CY09722 follow-up (PS)	777			Safety Report
52,003	Certican®	09/02/2008	PHHO2008FR08863 follow-up (PS)	778			Safety Report
52,003	Certican®	09/02/2008	PHHO2007US21124 follow-up (PS)	779			Safety Report
52,003	Certican®	08/29/2008	Study CRAD001H2304, CRAD001A2309, CRAD001A2401 new investigator (PS)	776			New Investigator
52,003	Certican®	08/28/2008	PHHO2008FR08863 (PS)	773			Safety Report
52,003	Certican®	08/28/2008	PHHO2008CA04926 follow-up (PS)	774			Safety Report
52,003	Certican®	08/28/2008	PHHO2008US05802 follow-up (PS)	775			Safety Report
52,003	Certican®	08/22/2008	PHHO2008AU08078 follow-up (PS)	772			Safety Report
52,003	Certican®	08/20/2008	7-Day IND Safety Notification PHHO2008FR08863 (PS)				Safety Report
52,003	Certican®	08/19/2008	PHHO2008CY09722 (PS)	771			Safety Report
52,003	Certican®	07/31/2008	PHHO2008FR08382 follow-up (PS)	769			Safety Report
52,003	Certican®	07/31/2008	PHHO2008US05802 (PS)	770			Safety Report
52,003	Certican®	07/29/2008	7-Day IND Safety Notification PHHO2008US05802 (PS)				Safety Report
52,003	Certican®	07/25/2008	PHHO2008FR08382 follow-up (PS)	768			Safety Report
52,003	Certican®	07/22/2008	PHHO2008FR08382 follow-up (PS)	767			Safety Report
52,003	Certican®	07/21/2008	PHHO2008AU07680 follow-up (PS)	766			Safety Report
52,003	Certican®	07/16/2008	PHHO2008FR08382 (PS)	764			Safety Report
52,003	Certican®	07/16/2008	PHHO2008US07823 follow-up (PS)	765			Safety Report
52,003	Certican®	07/10/2008	PHHO2007FR09520 follow-up (PS)	763			Safety Report
52,003	Certican®	07/09/2008	PHHO2008AU08078 (PS)	762			Safety Report
52,003	Certican®	07/03/2008	Study CRAD001H2304 new investigator. (PS)	760			New Investigator
52,003	Certican®	07/03/2008	PHHO2007PL06777 follow-up (PS)	761			Safety Report
52,003	Certican®	07/02/2008	PHHO2008DE05923 follow-up (PS)	757			Safety Report
52,003	Certican®	07/02/2008	PHHO2007ES08365 follow-up (PS)	758			Safety Report
52,003	Certican®	07/02/2008	PHHO2008US07899 (PS)	759			Safety Report
52,003	Certican®	06/30/2008	PHHO2008US06493 follow-up (PS)	755			Safety Report
52,003	Certican®	06/27/2008	PHHO2008AU07680 (PS)	754			Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	06/26/2008	PHHO2008CA00612 follow-up (PS)	753		Safety Report	
52,003	Certican®	06/20/2008	PHHO2007FR03202 follow-up (PS)	751		Safety Report	
52,003	Certican®	06/19/2008	PHHO2008DE05923 follow-up (PS)	750		Safety Report	
52,003	Certican®	06/13/2008	PHHO2007US21124 follow-up (PS)	749		Safety Report	
52,003	Certican®	06/12/2008	PHHO2008US04833 follow-up (PS)	747		Safety Report	
52,003	Certican®	06/12/2008	PHHO2008DE05923 follow-up (PS)	748		Safety Report	
52,003	Certican®	06/10/2008	PHHO2008DE05923 (PS)	746		Safety Report	
52,003	Certican®	06/09/2008	Study CRAD001H2304 new investigator. (PS)	745		New Investigator	
52,003	Certican®	06/06/2008	Response to address FDA statistical comments, a copy of the DMC charter and additional comments in response to FDA letter dated November 29, 2007. (PS)	742		Clinical Information Amendr Response to FDA Request	
52,003	Certican®	06/06/2008	PHHO2008US01900 follow-up (PS)	744		Safety Report	
52,003	Certican®	06/03/2008	PHHO2007DE20351 follow-up (PS)	741		Safety Report	
52,003	Certican®	06/02/2008	PHHO2007FR14620 follow-up (PS)	740		Safety Report	
52,003	Certican®	05/30/2008	PHHO2008AR00668 follow-up (PS)	739		Safety Report	
52,003	Certican®	05/09/2008	PHHO2007FR14620 follow-up (PS)	738		Safety Report	
52,003	Certican®	05/01/2008	PHHO2008DE03857 follow-up (PS)	737		Safety Report	
52,003	Certican®	04/30/2008	PHEH2000US08591 follow-up (PS)	735		Safety Report	
52,003	Certican®	04/30/2008	PHHO2008US04833 follow-up (PS)	736		Safety Report	
52,003	Certican®	04/29/2008	PHHO2008CA04926 (PS)	733		Safety Report	
52,003	Certican®	04/29/2008	PHHO2008JP04055 follow-up (PS)	734		Safety Report	
52,003	Certican®	04/28/2008	PHHO2008US04833 follow-up (PS)	732		Safety Report	
52,003	Certican®	04/25/2008	PHHO2007IT19720 follow-up (PS)	731		Safety Report	
52,003	Certican®	04/23/2008	PHHO2008US01900 follow-up (PS)	730		Safety Report	
52,003	Certican®	04/22/2008	PHHO2008US04735 (PS)	728		Safety Report	
52,003	Certican®	04/22/2008	PHHO2008US04833 (PS)	729		Safety Report	
52,003	Certican®	04/21/2008	PHHO2008IT01481 follow-up (PS)	727		Safety Report	
52,003	Certican®	04/18/2008	PHHO2008DE03857 follow-up (PS)	726		Safety Report	
52,003	Certican®	04/15/2008	PHHO2008JP04055 (PS)	725		Safety Report	
52,003	Certican®	04/15/2008	Per FDA request, submission of statistical analysis plan prior to database lock for study CRAD001A2309. (PS)	724		Clinical Information Amendr Response to FDA Request	
52,003	Certican®	04/11/2008	PHHO2007FR18497 follow-up (PS)	723		Safety Report	
52,003	Certican®	04/08/2008	PHHO2008IT01481 follow-up (PS)	722		Safety Report	
52,003	Certican®	04/04/2008	PHHO2008DE03857 follow-up (PS)	721		Safety Report	
52,003	Certican®	04/03/2008	Study CRAD001A2401 new investigator. (PS)	720		New Investigator	

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	04/01/2008	Submission to FDA of notification from the study Data Monitoring Committee and a copy of the communication sent to study investigators. (PS)	719		Clinical Information Amendr
52,003	Certican®	03/28/2008	PHHO2008DE03857 (PS)	718		Safety Report
52,003	Certican®	03/27/2008	PHHO2008US01900 follow-up (PS)	717		Safety Report
52,003	Certican®	03/25/2008	PHHO2007US2114 follow-up (PS)	715		Safety Report
52,003	Certican®	03/25/2008	PHHO2007NO19319 follow-up (PS)	716		Safety Report
52,003	Certican®	03/21/2008	Study CRAD001A2401 new investigator (PS)	714		New Investigator
52,003	Certican®	03/20/2008	PHHO2007US20563 follow-up (PS)	713		Safety Report
52,003	Certican®	03/17/2008	PHHO2007US21124 follow-up (PS)	712		Safety Report
52,003	Certican®	03/12/2008	PHHO2008AU01363 (PS)	711		Safety Report
52,003	Certican®	03/07/2008	PHHO2007US21124 follow-up (PS)	709		Safety Report
52,003	Certican®	03/07/2008	PHHO2007NO19319 follow-up (PS)	710		Safety Report
52,003	Certican®	03/03/2008	PHHO2008AR00668 (PS)	708		Safety Report
52,003	Certican®	02/28/2008	PHHO2008FR02098 FOLLOW-UP (PS)	705		Safety Report
52,003	Certican®	02/28/2008	PHHO2008US02416 (PS)	706		Safety Report
52,003	Certican®	02/28/2008	PHHO2008IT01481 FOLLOW-UP (PS)	707		Safety Report
52,003	Certican®	02/27/2008	PHHO2007IT19720 FOLLOW-UP (PS)	704		Safety Report
52,003	Certican®	02/25/2008	PHHO2007FR13915 follow-up (PS)	703		Safety Report
52,003	Certican®	02/21/2008	PHHO2008US01900 follow-up (PS)	701		Safety Report
52,003	Certican®	02/21/2008	Study CRAD001A2401 new investigator. (PS)	702		New Investigator
52,003	Certican®	02/20/2008	PHHO2007FR14001 FOLLOW-UP (PS)	698		Safety Report
52,003	Certican®	02/20/2008	PHHO2007IT19720 FOLLOW-UP (PS)	699		Safety Report
52,003	Certican®	02/20/2008	PHHO2007NO19319 (FOLLOW-UP) (PS)	700		Safety Report
52,003	Certican®	02/19/2008	PHHO2008FR02098 (PS)	696		Safety Report
52,003	Certican®	02/19/2008	PHHO2007FR14620 FOLLOW-UP (PS)	697		Safety Report
52,003	Certican®	02/14/2008	PHHO2008US01900 (PS)	695		Safety Report
52,003	Certican®	02/13/2008	Letter of cross reference granting permission to FDA/HFD-590 to allow representatives from the CDRH Interventional Cardiology Devices Branch to review and discuss those parts of our documents relevant for Abbott Vascular's XIENCE V application. (PS)	694		Other
52,003	Certican®	02/12/2008	PHHO2008IT01481 (PS)	693		Safety Report
52,003	Certican®	02/08/2008	PHHO2007JP19109 FOLLOW-UP (PS)	692		Safety Report
52,003	Certican®	02/08/2008	PHHO2007FR17369 FOLLOW-UP (PS)	691		Safety Report
52,003	Certican®	02/07/2008	PHHO2007FR14001 FOLLOW-UP (PS)	689		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	02/07/2008	PHHO2007FR13915 (PS)	690		Safety Report
52,003	Certican®	02/06/2008	PHHO2007IT19720 FOLLOW-UP (PS)	688		Safety Report
52,003	Certican®	01/31/2008	PHHO2007NO19319 FOLLOW-UP (PS)	685		Safety Report
52,003	Certican®	01/31/2008	PHHO2007FR18943 FOLLOW-UP (PS)	686		Safety Report
52,003	Certican®	01/28/2008	PHHO2007FR18943 FOLLOW-UP (PS)	682		Safety Report
52,003	Certican®	01/28/2008	PHHO2007FR20512 FOLLOW-UP (PS)	683		Safety Report
52,003	Certican®	01/28/2008	PHHO2007FR18940 FOLLOW-UP (PS)	684		Safety Report
52,003	Certican®	01/25/2008	Studies CRAD001A2309 and CRAD001A2310 change in protocol, amendment 3. (PS)	680		Change In Protocol
52,003	Certican®	01/25/2008	PHHO2007NO19319 FOLLOW-UP (PS)	681		Safety Report
52,003	Certican®	01/23/2008	PHHO2007DE20351 FOLLOW-UP (PS)	677		Safety Report
52,003	Certican®	01/23/2008	PHHO2007IT9720 (PS)	678		Safety Report
52,003	Certican®	01/23/2008	PHHO2007JP19109 FOLLOW-UP (PS)	679		Safety Report
52,003	Certican®	01/22/2008	PHHO2007FR12501 FOLLOW-UP (PS)	675		Safety Report
52,003	Certican®	01/22/2008	PHHO2007FR11090 FOLLOW-UP (PS)	676		Safety Report
52,003	Certican®	01/21/2008	PHHO2007US17617 FOLLOW-UP (PS)	674		Safety Report
52,003	Certican®	01/16/2008	PHHO2007US20875 (PS)	673		Safety Report
52,003	Certican®	01/09/2008	Annual Report covering the period November 15, 2006 to November 14, 2007. (PS)	672		Annual Report
52,003	Certican®	01/04/2008	PHHO2007US21124 (PS)	670		Safety Update
52,003	Certican®	01/04/2008	PHHO2007JP17929 FOLLOW-UP (PS)	671		Safety Report
52,003	Certican®	01/02/2008	PHHO2007JP19109 FOLLOW-UP (PS)	666		Safety Report
52,003	Certican®	01/02/2008	PHHO2007DE20351 FOLLOW-UP (PS)	667		Safety Report
52,003	Certican®	01/02/2008	PHHO2007FR18943 FOLLOW-UP (PS)	668		Safety Report
52,003	Certican®	01/02/2008	PHHO2007FR11090 FOLLOW-UP (PS)	669		Safety Report
52,003	Certican®	12/27/2007	PHHO2007FR19560 Follow-up. (PS)	665		Safety Report
52,003	Certican®	12/27/2007	PHHO2007US20563. (PS)	664		Safety Report
52,003	Certican®	12/24/2007	PHHO2007US13764 Follow-up. (PS)	662		Safety Report
52,003	Certican®	12/24/2007	PHHO2007FR20512. (PS)	663		Safety Report
52,003	Certican®	12/24/2007	PHHO2007DE20351. (PS)	661		Safety Report
52,003	Certican®	12/20/2007	PHHO2007FR19560 Follow-up. (PS)	660		Safety Report
52,003	Certican®	12/20/2007	PHHO2007DE20052 Follow-up. (PS)	659		Safety Report
52,003	Certican®	12/19/2007	Novartis is submitting a IND Amendment to provide update CMC information for the drug substance RAD001-stabilized with BHT (everolimus) and drug product. (PS)	658		CMC Amendment

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	12/18/2007	PHHO2007FR18943 Follow-up. (PS)	656		Safety Report
52,003	Certican®	12/18/2007	PHHO2007DE20052. (PS)	657		Safety Report
52,003	Certican®	12/18/2007	PHHO2007CA19062 Follow-up. (PS)	655		Safety Report
52,003	Certican®	12/17/2007	PHHO2007US06570. (PS)	654		Safety Report
52,003	Certican®	12/13/2007	PHHO2007JP19109 Follow-up. (PS)	653		Safety Report
52,003	Certican®	12/13/2007	PHHO2007US17944 Follow-up. (PS)	652		Safety Report
52,003	Certican®	12/12/2007	PHBS2007TR02235. (PS)	651		Safety Report
52,003	Certican®	12/11/2007	PHHO2007FR19043 Follow-up. (PS)	650		Safety Report
52,003	Certican®	12/11/2007	PHHO2007JP17929 Follow-up. (PS)	649		Safety Report
52,003	Certican®	12/10/2007	PHHO2007FR19560. (PS)	648		Safety Report
52,003	Certican®	12/10/2007	PHHO2007FR18940. (PS)	647		Safety Report
52,003	Certican®	12/07/2007	PHHO2007FR17914 Follow-up. (PS)	646		Safety Report
52,003	Certican®	12/06/2007	PHHO2007JP17929 Follow-up. (PS)	644		Safety Report
52,003	Certican®	12/06/2007	PHHO2007NO19319. (PS)	643		Safety Report
52,003	Certican®	12/06/2007	PHHO2007FR18497 Follow-up. (PS)	642		Safety Report
52,003	Certican®	12/06/2007	PHHO2007FR11090 Follow-up. (PS)	645		Safety Report
52,003	Certican®	12/05/2007	PHHO2007CA19062 Follow-up. (PS)	639		Safety Report
52,003	Certican®	12/05/2007	PHHO200NO08769 Follow-up. (PS)	640		Safety Report
52,003	Certican®	12/05/2007	PHHO2007FR18943. (PS)	641		Safety Report
52,003	Certican®	12/04/2007	PHHO2007JP19109. (PS)	638		Safety Report
52,003	Certican®	11/30/2007	PHHO2007TW16075. (PS)	637		Safety Report
52,003	Certican®	11/30/2007	PHHO2007CA19062 Follow-up. (PS)	636		Safety Report
52,003	Certican®	11/29/2007	PHHO2006US22078 FOLLOW-UP (PS)	635		Safety Report
52,003	Certican®	11/28/2007	PHHO2007FR17369 FOLLOW-UP (PS)	632		Safety Report
52,003	Certican®	11/28/2007	PHHO2007US17617 FOLLOW-UP (PS)	633		Safety Report
52,003	Certican®	11/28/2007	PHHO2007FR19043 (PS)	634		Safety Report
52,003	Certican®	11/27/2007	PHHO2007CA19062 (PS)	631		Safety Report
52,003	Certican®	11/21/2007	PHHO2007FR11090. (PS)	630		Safety Report
52,003	Certican®	11/21/2007	PHHO2007FR18497. (PS)	629		Safety Report
52,003	Certican®	11/21/2007	PHHO2007FR17914 Follow-up. (PS)	628		Safety Report
52,003	Certican®	11/20/2007	PHHO2007FR03202 Follow-up. (PS)	627		Safety Report
52,003	Certican®	11/15/2007	PHHO2007ES08365 Follow-up. (PS)	626		Safety Report
52,003	Certican®	11/12/2007	PHHO2007JP17793 Follow-up. (PS)	625		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	11/09/2007	PHHO2007JP17929. (PS)	624		Safety Report
52,003	Certican®	11/09/2007	PHHO2007FR17914 Follow-up. (PS)	623		Safety Report
52,003	Certican®	11/08/2007	PHHO2007US17944. (PS)	622		Safety Report
52,003	Certican®	11/08/2007	PHHO2007AU14332. Follow-up (PS)	621		Safety Report
52,003	Certican®	11/07/2007	PHHO2007CA15784 Follow-up. (PS)	620		Safety Report
52,003	Certican®	11/05/2007	PHHO2007US17617 (PS)	619		Safety Report
52,003	Certican®	11/05/2007	PHHO2007ES08365 Follow-up (PS)	618		Safety Report
52,003	Certican®	11/02/2007	PHHO2007US12809 Follow-up (PS)	617		Safety Report
52,003	Certican®	11/01/2007	PHHO2007SE15401. Follow-up (PS)	616		Safety Report
52,003	Certican®	10/30/2007	PHHO2007FR17369 (PS)	615		Safety Report
52,003	Certican®	10/30/2007	PHHO2007JP17793 (PS)	614		Safety Report
52,003	Certican®	10/29/2007	PHHO2007US12809 follow-up (PS)	613		Safety Report
52,003	Certican®	10/24/2007	PHHO2007CA17142. (PS)	612		Safety Report
52,003	Certican®	10/24/2007	PHHO2007FR03202 Follow-up (PS)	611		Safety Report
52,003	Certican®	10/18/2007	PHHO2007FR03202 Follow-up. (PS)	610		Safety Report
52,003	Certican®	10/17/2007	PHHO2007US13977 Follow-up. (PS)	609		Safety Report
52,003	Certican®	10/16/2007	PHHO2007US12809 Follow-up. (PS)	607		Safety Report
52,003	Certican®	10/16/2007	The regulatory purpose of this study is to support additional Phase 3 development and approval for use of Certican (everolimus) in liver transplantation. (PS)	608		Clinical Information Amendr
52,003	Certican®	10/15/2007	PHHO2007CA15784 Follow-up. (PS)	606		Safety Report
52,003	Certican®	10/12/2007	PHHO2007FRO3202 Follow-up. (PS)	605		Safety Report
52,003	Certican®	10/12/2007	PHHO2007US16146. (PS)	604		Safety Report
52,003	Certican®	10/10/2007	PHHO2007FR03202 Follow-up. (PS)	603		Safety Report
52,003	Certican®	10/09/2007	PHHO2007DE15860. (PS)	602		Safety Report
52,003	Certican®	10/08/2007	PHHO2007US15872 Follow-up. (PS)	600		Safety Report
52,003	Certican®	10/08/2007	PHHO2007US13977. (PS)	601		Safety Report
52,003	Certican®	10/05/2007	PHHO2007US13764. (PS)	599		Safety Report
52,003	Certican®	10/04/2007	PHHO2007CA15784. (PS)	598		Safety Report
52,003	Certican®	10/04/2007	PHHO2007US15872. (PS)	597		Safety Report
52,003	Certican®	10/03/2007	PHHO2007US12809. (PS)	596		Safety Report
52,003	Certican®	09/28/2007	PHHO2004BE07879 Follow-up. (PS)	595		Safety Report
52,003	Certican®	09/27/2007	TC with Diana Daly/HGS DRA re FDA comments. (PS)			Memo of Record (telephone report)
52,003	Certican®	09/27/2007	PHHO2007FR03202. Follow-up (PS)	594		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	09/25/2007	PHHO2007SE15401. (PS)	592		Safety	Report
52,003	Certican®	09/25/2007	PHHO2007AU14332 Follow-up. (PS)	593		Safety	Report
52,003	Certican®	09/24/2007	New Investigator to Study No. CRAD001A2309 and Study No. CRAD001A2401. (PS)	581		New Investigator	
52,003	Certican®	09/21/2007	PHHO2007AU11574 Follow-up. (PS)	591		Safety	Update
52,003	Certican®	09/20/2007	PHHO2007US07788 Follow-up. (PS)	589		Safety	Report
52,003	Certican®	09/20/2007	PHHO2007AU11574 Follow-up. (PS)	590		Safety	Report
52,003	Certican®	09/19/2007	PHHO2007ES08365 Follow-up. (PS)	588		Safety	Report
52,003	Certican®	09/18/2007	PHHO2007FR14001 Follow-up. (PS)	586		Safety	Report
52,003	Certican®	09/18/2007	PHHO2007FR14620. (PS)	587		Safety	Report
52,003	Certican®	09/13/2007	PHHO2004BE07879 Follow-up. (PS)	585		Safety	Report
52,003	Certican®	09/12/2007	CRAD001D2201 report. This report is provided for use in regulatory submissions and Investigator Brochure. (PS)				Other
52,003	Certican®	09/11/2007	PHHO2007FR14001 Follow-up. (PS)	584		Safety	Report
52,003	Certican®	09/10/2007	PHHO2004US12965 Follow-up. (PS)	583		Safety	Report
52,003	Certican®	09/07/2007	PHHO2004BE07879 Follow-up. (PS)	582		Safety	Report
52,003	Certican®	09/06/2007	PHHO2007BE13048 Follow-up. (PS)	579		Safety	Report
52,003	Certican®	09/06/2007	PHHO2007BE12170 Follow-up. (PS)	580		Safety	Report
52,003	Certican®	09/05/2007	PHHO2007FR14001. (PS)	578		Safety	Report
52,003	Certican®	08/31/2007	PHHO2007US11543 Follow-up. (PS)	577		Safety	Report
52,003	Certican®	08/30/2007	PHHO2004BE07879 Follow-up. (PS)	576		Safety	Report
52,003	Certican®	08/28/2007	PHHO2007FR10519 Follow-up. (PS)	575		Safety	Report
52,003	Certican®	08/27/2007	PHHO2007US11397. Follow-up (PS)	574		Safety	Report
52,003	Certican®	08/23/2007	PHHO2007BE13048. Follow-up (PS)	573		Safety	Report
52,003	Certican®	08/23/2007	PHHO2007FR10519. Follow-up (PS)	572		Safety	Report
52,003	Certican®	08/21/2007	PHHO2007FR09520 Follow-up. (PS)	571		Safety	Report
52,003	Certican®	08/20/2007	PHHO2007BE12170 Follow-up. (PS)	570		Safety	Report
52,003	Certican®	08/17/2007	PHHO2007AU11574; Follow-Up (PS)	569		Safety	Report
52,003	Certican®	08/17/2007	PHHO2007FR09520; Follow-Up (PS)	568		Safety	Report
52,003	Certican®	08/17/2007	PHHO2007BE13048; Follow-Up (PS)	567		Safety	Report
52,003	Certican®	08/16/2007	PHHO2007FR12501; Follow-Up (PS)	566		Safety	Report
52,003	Certican®	08/15/2007	Fax to FDA 7-Day IND Safety Report. (PS)			Safety	Report
52,003	Certican®	08/15/2007	PHHO2007IT12077 Follow-up (PS)	565		Safety	Report
52,003	Certican®	08/15/2007	PHHO2007US09880 Follow-up. (PS)	564		Safety	Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	08/15/2007	PHHO2007FR10519. (PS)	563		Safety Report
52,003	Certican®	08/14/2007	Fax to FDA 7-Day IND Safety Report. (PS)			Safety Report
52,003	Certican®	08/10/2007	PHHO2004BE07879. Follow-up (PS)	562		Safety Report
52,003	Certican®	08/10/2007	PHHO2007FR12501. (PS)	561		Safety Report
52,003	Certican®	08/08/2007	The purpose of this submission is to provide response with supporting documentation to address the FDA statistical comments requesting additional justification for the 10% non-inferiority margin for the composite efficacy endpoint (graft lost, death or lost to follow-up) at 12 months post transplant. (PS)	560		Clinical Information Amendr
52,003	Certican®	08/07/2007	PHHO2007BE12170;Follow-Up (PS)	559		Safety Report
52,003	Certican®	08/03/2007	PHHO2007FR09520;Follow-Up (PS)	558		Safety Report
52,003	Certican®	08/02/2007	PHHO2007US11543;Follow-Up (PS)	557		Safety Report
52,003	Certican®	08/01/2007	PHHO2007FR03202; Follow- Up (PS)	556		Safety Report
52,003	Certican®	07/31/2007	PHHO2007PL06777;Follow- Up (PS)	553		Safety Report
52,003	Certican®	07/31/2007	PHHO2007US04089;Follow-Up (PS)	555		Safety Report
52,003	Certican®	07/31/2007	PHHO2007IT12077;Follow-Up (PS)	554		Safety Report
52,003	Certican®	07/31/2007	Fax to FDA 7-Day Safety Report. (PS)			Other
52,003	Certican®	07/26/2007	New Investigator to Study No. CRAD001A2310. (PS)	551		New Investigator
52,003	Certican®	07/26/2007	PHHO2007US07788;Follow-Up (PS)	552		Safety Report
52,003	Certican®	07/24/2007	PHHO2007US11543;Follow-Up (PS)	549		Safety Report
52,003	Certican®	07/24/2007	PHHO2007US07788;Follow-Up (PS)	550		Safety Report
52,003	Certican®	07/20/2007	PHHO2007US11397; Follow-Up (PS)	548		Safety Report
52,003	Certican®	07/18/2007	Fax to FDA 7-Day IND Safety Report (PH02007US11397) (PS)			Safety Report
52,003	Certican®	07/17/2007	PHHO2007US11397;Follow-Up (PS)	547		Safety Report
52,003	Certican®	07/13/2007	The purpose of this submission is to support additional discussions with the Division on the regulatory value of Study A2411 in support of the Certican cardiac transplant NDA (No. 21-628) review. (PS)	546		Clinical Information Amendr
52,003	Certican®	07/11/2007	Clarification regarding Liver Protocol Comments. (PS)			Other
52,003	Certican®	07/11/2007	PHRM2007FR01778;Follow-Up (PS)	545		Safety Report
52,003	Certican®	07/09/2007	PHHO2007ES08365 Follow-up (PS)	544		Safety Report
52,003	Certican®	07/09/2007	PHHO2007PL06777 Follow-up (PS)	543		Safety Report
52,003	Certican®	07/03/2007	PHHO2005US14500. (PS)	542		Safety Report
52,003	Certican®	06/26/2007	Fax from FDA regarding Liver Protocol Comments. (PS)			Other
52,003	Certican®	06/25/2007	PHHO2007US09880 (PS)	541		Safety Report
52,003	Certican®	06/21/2007	PHHO2007PL06777 Follow-up (PS)	540		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	06/21/2007	PHHO2007FR07389 Follow-up (PS)	539		Safety Report
52,003	Certican®	06/19/2007	New Investigator to Study No. CRAD001A2309. (PS)	538		New Investigator
52,003	Certican®	06/19/2007	PHBS2007BE07399 Follow-up (PS)	537		Safety Report
52,003	Certican®	06/13/2007	PHHO2007FR07389 Follow-up (PS)	536		Safety Report
52,003	Certican®	06/07/2007	PHHO2006US22078;Follow-Up (PS)	535		Safety Report
52,003	Certican®	06/06/2007	PHHO2007PL06777;Follow-Up (PS)	534		Safety Report
52,003	Certican®	06/05/2007	PHHO2006US22078;Follow-Up (PS)	533		Safety Report
52,003	Certican®	06/05/2007	PHBS2007BE07399;Follow-Up (PS)	532		Safety Report
52,003	Certican®	05/31/2007	Fax from FDA Liver transplantation comments. (PS)			Other
52,003	Certican®	05/30/2007	PHHO2007ES08365 (PS)	531		Safety Report
52,003	Certican®	05/25/2007	PHHO2007PL06777; Follow-Up (PS)	530		Safety Report
52,003	Certican®	05/23/2007	This submission provides description of the Data Monitoring Committee (DMC) Charter for the studies of Certican (everolimus). (PS)	529		Clinical Information Amendr
52,003	Certican®	05/23/2007	PHBS2007BE07399. Follow-up (PS)	528		Safety Report
52,003	Certican®	05/23/2007	Certican Liver tx protocol/FDA comments ongoing review/written comments expected 1-2 weeks. (PS)			Other
52,003	Certican®	05/22/2007	PHHO2007PL06777. Follow-up (PS)	527		Safety Report
52,003	Certican®	05/18/2007	PHBS2007BE07399. Follow-up (PS)	524		Safety Report
52,003	Certican®	05/18/2007	PHRM2007FR01407 (PS)	525		Safety Report
52,003	Certican®	05/18/2007	PHHO2007FR07389. Follow-up (PS)	526		Safety Report
52,003	Certican®	05/16/2007	PHHO2006US11747. Follow-up (PS)	523		Safety Report
52,003	Certican®	05/15/2007	PHBS2007BE07399 (PS)	522		Safety Report
52,003	Certican®	05/09/2007	PHHO2007FR07389 (PS)	521		Safety Report
52,003	Certican®	05/09/2007	Fax to FDA. (7-Day Safety Report). (PS)			Safety Report
52,003	Certican®	05/08/2007	PHHO2007DE07018. (PS)	520		Safety Report
52,003	Certican®	05/03/2007	PHHO2007PL06777. (PS)	519		Safety Report
52,003	Certican®	04/30/2007	This Annual Report covers the period November 15, 2005 through November 14, 2006. (PS)	518		Annual Report
52,003	Certican®	04/23/2007	PHHO2007DE03665 Follow-up. (PS)	517		Safety Report
52,003	Certican®	04/11/2007	PHHO2007US00556. Follow-up (PS)	516		Safety Report
52,003	Certican®	04/03/2007	PHHO2007US04089. Follow-up (PS)	515		Safety Report
52,003	Certican®	03/30/2007	PHHO2007US05182 (PS)	513		Safety Report
52,003	Certican®	03/15/2007	PHHO2007US04089. Follow-up (PS)	510		Safety Report
52,003	Certican®	03/15/2007	PHHO2007CA002219. Follow-up	511		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	03/14/2007	PHHO2007US04215 (PS)	509			Safety Report
52,003	Certican®	03/13/2007	PHHO2007US04089 (PS)	508			Safety Report
52,003	Certican®	03/08/2007	The purpose of the communication is to provide a letter of cross reference granting permission to the FDA Division of Special Pathogen and Transplant Products/HFD-590 to allow representatives from the CDRH Interventional Cardiology Devices Branch (ICDB) to review and discuss those parts of our documents relevant for Abbott Vascular's and Novartis.	506			Other
52,003	Certican®	03/08/2007	New Investigator to Study No. CRAD001A2309 and Study No. CRAD001A2310. (PS)	507			New Investigator
52,003	Certican®	03/07/2007	PHHO2007DE03665. (PS)	505			Safety Report
52,003	Certican®	02/23/2007	The purpose of this communication is to submit a request for teleconference to discuss the draft study protocol with statistical justifications for a pivotal study in liver transplantation. We also providing a response to the FDA request for information made during teleconference on November 15, 2006. (PS)	504			Response to FDA Request
52,003	Certican®	02/22/2007	PHHO2007CA02219 Follow-up	503			Safety Report
52,003	Certican®	02/15/2007	PHBS2006AT07989 Follow-up. (PS)	502			Safety Report
52,003	Certican®	02/09/2007	PHHO2007CA02219 Follow-up. (PS)	501			Safety Report
52,003	Certican®	02/08/2007	PHHO2007CA02219 Follow-up. (PS)	500			Safety Report
52,003	Certican®	02/07/2007	Novartis is submitting IND amendment to provide updated information on the manufacturing sites and stability programs. The summary of changes and the updated IND sections are included in submission. (ES)	498			CMC Amendment
52,003	Certican®	02/07/2007	PHHO2007CA02219 (PS)	499			Safety Report
52,003	Certican®	02/05/2007	PHBS2007BE07399 FOLLOW-UP (PS)	687			Safety Report
52,003	Certican®	02/01/2007	PHHO2005BE07879 (PS)	497			Safety Report
52,003	Certican®	01/29/2007	Fax from FDA. November 15, 2006 Meeting Minutes. (ES)				Other
52,003	Certican®	01/26/2007	PHHO2006US22076 Follow-up. (PS)	496			Safety Report
52,003	Certican®	01/25/2007	PHHO2007US00556. (PS)	495			Safety Report
52,003	Certican®	01/19/2007	PHHO2006US22076. (PS)	494			Safety Report
52,003	Certican®	01/18/2007	PHHO2007US00556. (PS)	493			Safety Report
52,003	Certican®	12/28/2006	PHHO2006FR20729 Follow-up.	492			Safety Report
52,003	Certican®	12/22/2006	PHHO2005DE16006 Follow-up#2. (PS)	491			Safety Report
52,003	Certican®	12/22/2006	New Investigator to Study No. CRAD001A2309. (ES)	490	2309		New Investigator
52,003	Certican®	12/21/2006	PHHO2006FR20729. (PS)	489			Safety Report
52,003	Certican®	12/21/2006	PHBS2006ES19166. (PS)	488			Safety Report
52,003	Certican®	12/21/2006	PHBS2006ES19190. (PS)	487			Safety Report
52,003	Certican®	12/18/2006	PHHO2006IT15311 Follow-up.	486			Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	12/18/2006	PHHO2006FR20566. (PS)	485		Safety Report
52,003	Certican®	12/12/2006	PHHO2006US17466. Follow-up	484		Safety Report
52,003	Certican®	12/08/2006	PHHO2006IT15311. Follow-up	483		Safety Report
52,003	Certican®	12/06/2006	PHHO2006US11747 Follow-up. (PS)	482		Safety Report
52,003	Certican®	11/14/2006	Liver Transplantation Questions and Comments. (ES)			Other
52,003	Certican®	11/09/2006	PHHO2004US12965 Follow-up. (PS)	481		Safety Report
52,003	Certican®	11/07/2006	PHHO2006US17466 Follow-up. (PS)	480		Safety Report
52,003	Certican®	10/31/2006	PHHO2006US17466. (PS)	479		Safety Report
52,003	Certican®	10/24/2006	PHBS2006ES15520. Follow-up (PS)	478		Safety Report
52,003	Certican®	10/23/2006	PHHO2006US11747. Follow-up (PS)	477		Safety Report
52,003	Certican®	10/18/2006	New Investigator to Study No. CRAD001A2310. (ES)	469	2310	New Investigator
52,003	Certican®	10/18/2006	FDA has postponed the TC discussion for liver transplant on 23 Oct (2-3pm). (PS)			Other
52,003	Certican®	10/17/2006	PHBS2006ES15520. (PS)	476		Safety Report
52,003	Certican®	10/13/2006	The purpose of this submission is to provide additional information to support the discussions. (PS)	475		Response to FDA Request
52,003	Certican®	10/10/2006	This amendment describes the procedure to discontinue the study and allows for minimal data collection for the final visit to be conducted at Month 12 or on the date of last contact with the patient. (PS)	474	B253	Change In Protocol
52,003	Certican®	10/06/2006	The purpose of this submission is to provide a point response to the Division's comments. (PS)	472		Response to FDA Request
52,003	Certican®	10/06/2006	PHHO2006IT15311 Follow-up. (PS)	473		Safety Report
52,003	Certican®	10/03/2006	PHHO2006IT15311. (PS)	471		Safety Report
52,003	Certican®	09/29/2006	PHHO2006IT09039 Follow-up. (PS)	468		Safety Report
52,003	Certican®	09/26/2006	Fax to FDA. (7-Day Safety Report).			Safety Report
52,003	Certican®	09/14/2006	New Investigator to Study No. CRAD001A2309. Study No. CRAD001A2310 and Study No. CRAD001A2401. (PS)	461	2309 2310 2401	New Investigator
52,003	Certican®	08/31/2006	Fax from FDA. 10/23/06 Teleconference Grant Letter. (ES)			Other
52,003	Certican®	08/31/2006	FDA Letter. Type B meeting is scheduled October 23, 2006 to discuss general clinical design issues and regulatory requirements to support the approval of Certican in liver transplantation. (PS)			General Correspondence
52,003	Certican®	08/31/2006	PHHO2006US02640 (PS)	467		Safety Report
52,003	Certican®	08/28/2006	PHHO2006US02640. (PS)	466		Safety Report
52,003	Certican®	08/21/2006	The purpose of this submission is to request a teleconference to discuss general clinical study design issues and requirements to support the approval of Certican in liver transplantation. (ES)	465		Other
52,003	Certican®	08/18/2006	PHHO2006US11747 Follow-up. (PS)	464		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	08/18/2006	PHHO2006BE00473 Follow-up. (PS)	463		Safety Report
52,003	Certican®	08/18/2006	PHHO2006DE09301 Follow-up. (PS)	462		Safety Report
52,003	Certican®	08/17/2006	PHHO2006US11747 Follow-up. (PS)	460		Safety Report
52,003	Certican®	08/16/2006	PHHO2006BE00473. (PS)	459		Safety Report
52,003	Certican®	08/15/2006	PHHO2006US11747. (PS)	458		Safety Report
52,003	Certican®	07/28/2006	PHHO2006DE09652 Follow-up. (PS)	457		Safety Report
52,003	Certican®	07/26/2006	PHHO2006CA03486 Follow-up. (PS)	456		Safety Report
52,003	Certican®	07/25/2006	PHHO2006DE09859 Follow-up. (PS)	455		Safety Report
52,003	Certican®	07/21/2006	PHHO2006DE09652 Follow-up.	454		Safety Report
52,003	Certican®	07/20/2006	PHHO2006DE09652 Follow-up. (PS)	451		Safety Report
52,003	Certican®	07/20/2006	PHHO2006IT09039 Follow-up. (PS)	452		Safety Report
52,003	Certican®	07/20/2006	PHHO2006DE09301 Follow-up. (PS)	453		Safety Report
52,003	Certican®	07/19/2006	PHHO2006DE09652 Follow-Up.	450		Safety Report
52,003	Certican®	07/19/2006	New Investigator to Study No. CRAD001A2309, Study No. CRAD001A2310, Study No. CRAD001A2401. (PS)	449		New Investigator
52,003	Certican®	07/17/2006	PHHO2006IT09039 Follow-Up.	448		Safety Report
52,003	Certican®	07/07/2006	PHHO2006DE09652.	447		Safety Report
52,003	Certican®	07/05/2006	PHBS2006AT07989 Follow-Up.	446		Safety Report
52,003	Certican®	06/27/2006	Comments pertaining to the statistical analysis plan for study 2411 provided in submission number 434.			
52,003	Certican®	06/27/2006	PHHO2006DE09859.	443		Safety Report
52,003	Certican®	06/27/2006	PHBS2006AT07989.	442		Safety Report
52,003	Certican®	06/27/2006	PHNU2006DE02164.	444		Safety Report
52,003	Certican®	06/27/2006	PHHO2006FR09362 Follow-Up.	325		Safety Report
52,003	Certican®	06/27/2006	PHHO2006FR05415 Follow-Up.	324		Safety Report
52,003	Certican®	06/24/2006	PHHO2008CA00612 (PS)	752		Safety Report
52,003	Certican®	06/21/2006	PHHO2006DE09301 Follow-Up.	441		Safety Report
52,003	Certican®	06/16/2006	PHHO2006IT09039.	440		Safety Report
52,003	Certican®	06/15/2006	PHHO2006DE09301.	439		Safety Report
52,003	Certican®	06/14/2006	PHHO2006IT07069 Follow-Up.	438		Safety Report
52,003	Certican®	06/14/2006	Fax to FDA. 7-Day IND Safety Report - (PHHO2006DE09301). (PS)			Safety Report
52,003	Certican®	06/13/2006	Fax to FDA. 7-Day IND Safety Report.			Safety Report
52,003	Certican®	06/06/2006	PHHO2008US06493 (PS)	743		Safety Report
52,003	Certican®	05/23/2006	PHBS2006ES06880. (PS)	437		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	05/19/2006	PHHO2006IT07069 Follow-up.	436			Safety Report
52,003	Certican®	05/11/2006	FDA request on January 31, 2006 Submitted a copy of the statistical analysis plan for the ongoing European heart study A2411.	434	A2411		Response to FDA Request
52,003	Certican®	05/11/2006	PHHO2006IT07069.	435			Safety Report
52,003	Certican®	05/02/2006	Working protocol for RAD001A2309 including Amendment 1 and Amendment 2.	433	A2309		Response to FDA Request
52,003	Certican®	05/01/2006	Amendment 1 to Study No. CRAD001A2310.	432			Change In Protocol
52,003	Certican®	04/17/2006	New Investigator to Study No. CRAD001A2309. New Investigator to Study No. CRAD001A2310. New Investigator to Study No. CRAD001A2401.	431			New Investigator
52,003	Certican®	04/11/2006	E-mail. Re: FDA TC on May 3, 2006 to discuss the everolimus transplant data proposal and requirements for pediatric data exclusivity (2nd Written Request). PS				Other
52,003	Certican®	03/17/2006	To discuss the eligibility requirements for Certican (enerolimus) to obtain pediatric data exclusivity.	428			General Correspondence
52,003	Certican®	03/15/2006	PHNR2006AU00570	427			Safety Report
52,003	Certican®	03/14/2006	PHHO2005US19658	426			Safety Report
52,003	Certican®	03/14/2006	New Investigator to Study No. CRAD001A2309.	425	2309		New Investigator
52,003	Certican®	03/13/2006	Amendment No. 2 to Protocol CRAD001A2309.	424			Change In Protocol
52,003	Certican®	03/08/2006	PHHO2006CA03486	423			Safety Report
52,003	Certican®	02/24/2006	Extension E-02 top Study No. CRAD001 B351.	422	B351		Change In Protocol
52,003	Certican®	02/23/2006	Amendment No. 1 to Study No. CRAD001A2309.	421	2309		Change In Protocol
52,003	Certican®	02/23/2006	Dr. George Demetri: Malignant neoplasm progression, ascites, cholelithiasis, pleural effusion, dyspnoea; Follow-up#3.	420	2206		Safety Report
52,003	Certican®	02/06/2006	[FRANCE] Dr. Jean-Charles Soria: Mental disorder, back pain, delusional disorder, persecutory type, myalgia; Follow-up#2.	419	2235		Safety Report
52,003	Certican®	02/01/2006	[FRANCE] Dr. Jacques Dantal: Respiratory tract infection, lung disorder, fluid overload: Follow-up#1	418	2420		Safety Report
52,003	Certican®	01/27/2006	This Annual Report covers the period November 15, 2004 through November 14, 2005. Includes clinical study information, preclinical study information and Foreign marketing developments.	417			Annual Report
52,003	Certican®	01/24/2006	[FRANCE] Dr. Jacques Dantal: Lung disorder.	416	2420		Safety Report
52,003	Certican®	01/19/2006	New Investigator to Study No. 2310: Drs. G. Ewald, S. D. Lick, N. Pereira, J. Boehmer, D. F. Pauly. Study No. 2309: Dr. S. Mulgaonkar. Study No. 2401: M. A. Hardy.	415	2310 2309 2401		New Investigator
52,003	Certican®	01/18/2006	[FRANCE] Dr. Jean-Charles Soria: Back pain, mental disorder, delusional disorder, persecutory type, myalgia; Follow-up#1.	413	2235		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	01/18/2006	This clinical information amendment contains Study CRAD001A2403 to support the discussions of January 31, 2006 between NVS and FDA regarding the next steps for Certican for the prophylaxis of organ rejection in heart transplant recipients.	414		Clinical Information Amendr
52,003	Certican®	01/11/2006	Dr. Howard Sher: Muscular weakness, myopathy steroid, hydrocephalus, cognitive deterioration, general physical health deterioration, mood altered, depression, cardiovascular disorder, fall; Follow-up#2.	412	2408	Safety Report
52,003	Certican®	01/04/2006	This submission contains documentation (Study No. CRAD001A2411) to support the discussions with the Agency for the January 31, 2006 meeting regarding next steps for Certican for the prophylaxis of organ rejection in heart transplant recipients.	411		Clinical Information Amendr Response to FDA Request
52,003	Certican®	01/03/2006	[BELGIUM] Dr. Van Oosterom: Gastritis haemorrhagic, right ventricular failure, pulmonary hypertension, anaemia, haematochezia, general physical health deterioration; Follow-up#3.	410	2206	Safety Report
52,003	Certican®	12/30/2005	[FRANCE] Dr. Jean-Charles Soria: Back pain, mental disorder, delusional disorder, persecutory type, myalgia.	409	C2235	Safety Report
52,003	Certican®	12/23/2005	Michelle Roos: Hyponatraemia, vomiting, diarrhoea, viral infection, dehydration.	408	AUS15	Safety Report
52,003	Certican®	12/22/2005	Dr. Howard Sher: Muscular weakness, myopathy steroid, hydrocephalus, fall; Fallow-up#1.	407	C2408	Safety Report
52,003	Certican®	12/20/2005	Dr. Alex Adjei: Pulmonary embolism, malignant neoplasm progression, chest pain, dyspnoea, respiratory failure, productive cough; Follow-up#2.	405	AUS15	Safety Report
52,003	Certican®	12/20/2005	New Investigator to Study No. A2310: Dr. Dale. G. Renlund, MD.	406	A2310	New Investigator
52,003	Certican®	12/19/2005	Dr. Howard Sher: Muscular weakness, fall.	404	2408	Safety Report
52,003	Certican®	12/19/2005	New Investigator to Study No. A2309: Dr. Adrian Cotterell, MD.	403	A2309	New Investigator
52,003	Certican®	12/13/2005	New Investigator to Study No. A2309: Drs. J. Leone, S. R. Abul-Ezz, M. L. Aaronson, B. Mistry. Study No. A2401: Dr. J. D. Scandling.	402	A2309 A2401	New Investigator
52,003	Certican®	12/07/2005	New Investigator to Study No. A2309: Drs. C. Franklin, H. Shidban, D. Y. Kim, T. D. Johnston. Study No. A2401: Dr. A. J. Tector.	401	A2309 A2401	New Investigator
52,003	Certican®	12/05/2005	New Investigator to Study No. A2309: Drs. B. Kahan, T. O'Connor, F. Shihab, T. Pruett. Study No. A2401: Drs. S. Bunnapradist, R. Ettenger. Study No. A2403: Dr. L. Czer.	400	A2309 A2401 A2403	New Investigator
52,003	Certican®	11/22/2005	Richard Stone. MD: Pneumonitis, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis, fatigue, productive cough, respiratory distress; Follow-up#4.	399	2207	Safety Report
52,003	Certican®	11/17/2005	[GERMANY] Prof. Struber: Renal impairment, immunosuppressant drug level increased, blood creatinine increased, drug interaction; Follow-up#1.	398	DE06	Safety Report
52,003	Certican®	11/14/2005	Dr. Judith Wolf: hyponatraemia, condition aggravated, anorexia, nausea, asthenia, muscle spasms, hypotension.	397	2409	Safety Report
52,003	Certican®	11/11/2005	Dr. Lauren Abrey: International normalised ratio increased, haematuria, drug interaction; Follow-up#1.	396	C2408	Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	11/01/2005	Dr. Lauren Abrey: International normalised ratio increased, haematuria.	395	C2408	Safety Report
52,003	Certican®	10/21/2005	The purpose of this submission is to provide a point-by-point response to the Division's comments for study CRAD001A2310.	394		Clinical Information Amendr Response to FDA Request
52,003	Certican®	10/14/2005	[GERMANY] Prof. Struber: Renal impairment, drug interaction, immunosuppressant drug level increased, blood creatinine increased.	393	ADE06	Safety Report
52,003	Certican®	10/04/2005	Dr. Alex Adjei: Pulmonary embolism, chest pain, dyspnoea, respiratory failure, productive cough; Follow-up#1.	392	AUS15	Safety Report
52,003	Certican®	09/30/2005	FDA FAX containing statistical team comments pertaining to Study A2310, submitted 8/29/2005. FDA requested a copy of the final Statistical Analysis Plan and DSMB for Study A2310 prior to the primary data analysis.		A2310	Other
52,003	Certican®	09/28/2005	Dr. Alex Adjei: pulmonary embolism, chest pain, dyspnoea, respiratory failure, productive cough.	391	AUS15	Safety Report
52,003	Certican®	09/26/2005	Richard Stone, MD: Pneumonitis, nausea, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis, fatigue, productive cough, respiratory distress; Follow-up#3.	390	2207	Safety Report
52,003	Certican®	09/23/2005	Richard Stone: Pneumonia bacterial, diarrhoea, supraventricular tachycardia, hypokalaemia, pleural effusion, hypoxia, dyspnoea, crackles lung, troponin increased; Follow-up#2.	389	2207	Safety Report
52,003	Certican®	09/23/2005	E-MAILS to/from FDA regarding draft protocol A2310 submitted to the Division on September 6, 2005 (SN 387). In addition, NVS responded to FDA request for the location of IVUS Data Analysis Results for Heart B253 for NDA 21-628 update #2.		A2310	Response to FDA Request
52,003	Certican®	09/22/2005	Fax to FDA (7-Day Safety Report).			Safety Report
52,003	Certican®	09/16/2005	Amendment No. 1 to Study No. RAD001 B253 E3.	388	B253	Change In Protocol
52,003	Certican®	09/06/2005	New Protocol to Study No. A2310 entitled, "A 24-month, multicenter, randomized, open-label noninferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced neoral versus 3.0 g MMF with standard dose Neoral in de novo heart transplant recipients.	387	A2310	New Protocol
52,003	Certican®	08/25/2005	Richard Stone MD: Pneumonitis, nausea, drug interaction potentiation, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis; Follow-up#2.	386	2207	Safety Report
52,003	Certican®	08/23/2005	Dr. Diane Cibrik: Nephropathy toxic, drug interaction, renal tubular necrosis, blood creatinine increased.	385	US09	Safety Report
52,003	Certican®	08/19/2005	New Investigator to Study No. CRAD001A2401: Drs. S. Greenstein, J. D. Mahan, J. R. Thistlethwaite, M. Cooper, D. Laskow, P. Morrissey, L. Chan, C. A. Shadur, O. Pankewycz. Study No. CRAD001A2403: Drs. M. W. Weston, M. J. Zucker, D. Mancini.	384	2401 2403	New Investigator
52,003	Certican®	08/09/2005	Dr. Francis Giles: Leukocytoclastic vasculitis, hyperglycaemia, oedema peripheral, calcinosis, pain, erythema, rash, eschar; Follow-up#1.	383	2406	Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	08/09/2005	TELECON confirming meeting scheduled with FDA for August 22, 2005, to discuss protocol A2310 with modeling simulations.				Memo of Record (telephone report)
52,003	Certican®	08/05/2005	[GREAT BRITAIN] Dr. Ian Judson: Gastrointestinal haemorrhage, bone marrow depression, cardiac arrest, malignant neoplasm progression, melaena, vomiting, haemoglobin decreased, platelet count decreased, dyspnoea, abdominal pain, loss of consciousness; Follow-up#3	382	2101		Safety Report
52,003	Certican®	08/05/2005	[AUSTRALIA] Dr. Dan Chambers: Vasculitis gastrointestinal, leukocytoclastic vasculitis, dermatitis allergic, neutropenia, white blood cell count decreased, diarrhoea, vomiting, intestinal ischaemia, biopsy colon abnormal, petechiae, biopsy skin abnormal: Follow-up#1	381			Safety Report
52,003	Certican®	08/03/2005	[AUSTRALIA] Dr. Dan Chambers: Vasculitis gastrointestinal, leukocytoclastic vasculitis, dermatitis allergic, neutropenia, white blood cell count decreased, diarrhoea, vomiting, intestinal ischaemia, biopsy intestine abnormal, biopsy colon abnormal, petechiae, biopsy skin abnormal.	380			Safety Report
52,003	Certican®	08/02/2005	FDA FAX containing minutes from telecon of July 21, 2005. FDA also addressed NVS request for a follow-up teleconference to discuss the heart protocol (A2310).				FDA/Novartis Meeting Minu
52,003	Certican®	07/06/2005	Dr. Judith Wolf: Hyperglycaemia; Follow-up#1.	378	C2409		Safety Report
52,003	Certican®	07/01/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated idioventricular rhythm; Follow-up#5	377	A2403		Safety Report
52,003	Certican®	06/30/2005	[GREAT BRITAIN] Prof. Ian Judson: Cryptogenic organizing pneumonia, lung infiltration, dyspnoea, dyspnoea exertional; Follow-up#1	376	2101		Safety Report
52,003	Certican®	06/27/2005	This submission provides a point-by-point response to the Division's comments for study CRAD001A2310 submitted February 4, 2005.	375			Clinical Information Amendr
52,003	Certican®	06/22/2005	New Protocol to Study No. CRAD001 A2309 entitled, "A 24-Month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral versus 1.44 g Myfortic with standard dose of Neoral in de novo renal transplant patients.	374	A2309		New Protocol
52,003	Certican®	06/21/2005	[AUSTRALIA] Dr. Josette Eris: Drug exposure during pregnancy, premature rupture of membranes, normal delivery, hypertension; Follow-up#1.	373	A2307		Safety Report
52,003	Certican®	06/08/2005	Howard Burris, MD: Mental status changes, anaemia.	372	2101		Safety Report
52,003	Certican®	06/03/2005	TELECON with FDA in order to schedule a telecon on 21-Jul-2005 to discuss protocol A2310 (heart) statistical model and simulations for exposures. The Division will also respond to NVS proposals on A2309 (kidney) at the same time.				Memo of Record (telephone report)
52,003	Certican®	06/02/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated idioventricular rhythm; Follow-up#4.	371	A2403		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	06/02/2005	[GREAT BRITAIN] Dr. Ian Judson: Gastrointestinal haemorrhage, bone marrow depression, circulatory collapse, cardiac arrest, malignant neoplasm progression, melaena, vomiting, haemoglobin decreased, platelet count decreased, dyspnoea, abdominal pain, loss of consciousness; Follow-up#2.	370	2101	Safety Report
52,003	Certican®	06/01/2005	[AUSTRALIA] Dr. Steve Chadban: Drug exposure during pregnancy, cerebral ventricle dilatation, renal disorder, umbilical cord vascular disorder.	369	2307E1	Safety Report
52,003	Certican®	06/01/2005	[AUSTRALIA] Dr. Josette Eris: Drug exposure during pregnancy, premature rupture of membranes, normal delivery, hypertension.	368	A2307	Safety Report
52,003	Certican®	05/31/2005	[GREAT BRITAIN] Dr. Ian Judson: Gastrointestinal haemorrhage, bone marrow depression, circulatory collapse, cardiac arrest, malignant neoplasm progression, melaena, vomiting, haemoglobin decreased, platelet count decreased, dyspnoea, abdominal pain, loss of consciousness; Follow-up#1.	367	2101	Safety Report
52,003	Certican®	05/26/2005	[SWITZERLAND] Dr. D. Uehlinger: Eye haemorrhage, Retinal detachment, eye operation; Follow-up#1.	366	A2307	Safety Report
52,003	Certican®	05/20/2005	Response to request to provide questions for discussion on study CRAD001A2301.	365		Response to FDA Request
52,003	Certican®	05/19/2005	This Annual Report covers the period November 15, 2003 through November 14, 2004. Includes clinical study information, preclinical study information, Foreign marketing developments and outstanding regulatory business.	364		Annual Report
52,003	Certican®	05/16/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated Idioventricular rhythm; Follow-up#3.	363	2403	Safety Report
52,003	Certican®	05/13/2005	Point-by-point response to the Division's comments for Study CRAD001A2309.	362		Response to FDA Request
52,003	Certican®	05/12/2005	Richard Stone. MD: Interstitial lung disease, pneumonitis, nausea, drug interaction potentiation, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis; Follow-up#1.	361	2207	Safety Report
52,003	Certican®	05/12/2005	Amendment No. 4 to Study No. CRAD001AUS09.	360	US09	Change In Protocol
52,003	Certican®	05/11/2005	Richard Stone. MD: Pneumonia, diarrhoea, dyspnoea, hypoxia, pleural effusion, crackles lung; Follow-up#1	359	2207	Safety Report
52,003	Certican®	05/06/2005	[SWITZERLAND] Dr. D. Uehlinger: Eye haemorrhage, retinal detachment, eye operation.	358	2307E1	Safety Report
52,003	Certican®	05/06/2005	Richard Stone: Pneumonia, hypoxia, diarrhoea, pleural effusion, dyspnoea, crackles lung.	357	2207	Safety Report
52,003	Certican®	05/05/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated Idioventricular rhythm; Follow-up#2.	356	A2403	Safety Report
52,003	Certican®	05/05/2005	TELECON with FDA regarding Advisory Committee meeting date and the teleconference to be scheduled for the new heart study A2310 regarding modeling and simulations.			Memo of Record (telephone report)
52,003	Certican®	05/04/2005	Richard Stone, MD: Interstitial lung disease, pneumonitis, nausea, dyspnoea, hypoxia, pleural effusion, performance status decreased, cough, pulmonary fibrosis.	355	2207	Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	05/03/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall, cardiac arrest, accelerated idioventricular rhythm; Follow-up#1	354	2403	Safety Report
52,003	Certican®	04/28/2005	Dr. L. Miller: Cardiac tamponade, anastomotic leak, unresponsive to verbal stimuli, fall.	353	2403	Safety Report
52,003	Certican®	04/27/2005	[GREAT BRITAIN] Prof. Ian Judson: Cryptogenic organizing pneumonia, lung infiltration, dyspnoea, dyspnoea exertional.	352	2101	Safety Report
52,003	Certican®	04/24/2005	[GERMANY] Peter Reichardt: Neoplasm progression, tumour haemorrhage, haemoglobin decreased, blood lactate dehydrogenase increased, blood potassium increased, blood uric acid increased, hyperbilirubinaemia, blood creatinine increased; Follow-up#1.	350	2206	Safety Report
52,003	Certican®	04/19/2005	New Investigator to Study No. CRAD001A2401: Drs. M. Koerner, E. Hartmann, H. Shidban, J. D. Whelchel, J. Leone, G. Basadonna. Study No. CRAD001A2403: Drs. D. Mancini, L. R. Goldberg.	349	A2401 A2403	New Investigator
52,003	Certican®	04/18/2005	[GERMANY] Peter Reichardt: Tumour lysis syndrome, tumour haemorrhage, haemoglobin decreased, blood lactate dehydrogenase increased, blood potassium increased, blood uric acid increased, hyperbilirubinaemia, blood creatinine increased.	348	2206	Safety Report
52,003	Certican®	04/08/2005	James Yao: Hypoglycaemia, feeling abnormal, confusional state.	347	BUS52	Safety Report
52,003	Certican®	04/06/2005	[GERMANY] Dr. Kaltenhaeuser: Septic shock, peripheral occlusive disease, vasculitis, drug level decreased, skin ulcer, haemoglobin decreased, C-reactive protein increased.	346		Safety Report
52,003	Certican®	04/04/2005	TELECON with FDA regarding CIOMS VI recommendations and investigator notifications from transplant and oncology indications.			Memo of Record (telephone report)
52,003	Certican®	03/28/2005	FAX from FDA containing questions on Serial Number 339, 341 and 342.			
52,003	Certican®	03/15/2005	[SWITZERLAND] Malabsorption, acne, drug interaction, drug level decreased.	345		Safety Report
52,003	Certican®	03/09/2005	New Investigator to Study No. CRAD001A2401: Drs. L. Goldberg, A. H. Wilkinson, R. Peddi, C. A. Shadur.	344	A2401	New Investigator
52,003	Certican®	03/02/2005	[CANADA] DR. Cole: Diffuse alveolar damage, cryptogenic organizing pneumonia, obliterative bronchiolitis, lung transplant rejection, cardiac arrest, pneumonia, viral infection, respiratory tract infection, pulmonary oedema, pulmonary fibrosis, respiratory disorder, haemodynamic instability, dyspnoea, hypoxia, myalgia, pyrexia, productive cough, respiratory failure, circulatory collapse.	343	A2401	Safety Report
52,003	Certican®	02/16/2005	Submission of replacement pages for the draft clinical protocol (Study CRAD001A2310) submitted February 4, 2005 (Serial No. 339).	342		Clinical Information Amendr
52,003	Certican®	02/07/2005	New Investigator to Study No. CRAD001A2405: Drs. Randall C. Starling, John M. Herre.	340	2405	New Investigator
52,003	Certican®	02/04/2005	This submission provides a point-by-point response to the Division's comments dated December 3, 2004, and contains the revised complete protocols for review and comment.			Clinical Information Amendr Response to FDA Request

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	01/25/2005	Letter of cross reference granting permission to the Division of Special Pathogen and Immunologic Drug Products to allow representatives from other branches of the FDA to discuss those parts of our documents relevant for Guidant's Drug Eluting Stent Investigational Device Exemptions.	338			General Correspondence
52,003	Certican®	01/14/2005	This letter authorizes the FDA to refer to this IND (and NDA 21-560 and 21-628) in support of an IND that will be filed by W. H. Tang, MD.	337			General Correspondence
52,003	Certican®	12/22/2004	New Investigator to Study No. CRAD001A2403: Dr. Leslie Miller, MD.	336	A2403		New Investigator
52,003	Certican®	12/14/2004	New Investigator to Study No. CRAD001AUS09: Dr. Oleh Pankewycz, MD. Study No. CRAD001A2401: Dr. Randall Starling.	335	US09 A2401		New Investigator
52,003	Certican®	12/09/2004	[CANADA] Dr. Cole: Diffuse alveolar damage, cryptogenic organizing pneumonia, obliterative bronchiolitis, lung transplant rejection, cardiac arrest, pneumonia, viral infection, respiratory tract infection, pulmonary oedema, pulmonary fibrosis, respiratory disorder, haemodynamic instability, dyspnoea, hypoxia, myalgia, pyrexia, productive cough; Follow-up#2.	334	2401		Safety Report
52,003	Certican®	12/03/2004	New Investigator to Study No. CRAD001A2401: Drs. P. J. Hauptman, A. Guasch, R. M. Ferguson. Study No. CRAD001A2403: Dr. G. M. Felker. Study No. CRAD001A2405: Dr. J. Kobashigawa.	333	2401 2403 2405		New Investigator
52,003	Certican®	11/05/2004	New Investigator to Study No. CRAD001US09: Drs. D. Cibrik, M. Hardy; Study No. CRAD001A2401: Drs. J. Butler, F. Wright, G. Klintmalm, K. Butt, J. A. Hill; Study No. CRAD001 A2403: Drs. B. Rayburn, F. W. Smart; Study No. CRAD001 A2405: Dr. L. Miller.	332	US09 A2401 A2403 A2405		Annual Report
52,003	Certican®	11/02/2004	Dr. Meir Wetzler, MD: Cardiac failure congestive, asthma, dyspnoea, oedema peripheral, eyelid oedema, weight increased, dilatation atrial, ventricular hypertrophy; Follow-up#1	331	2207		Safety Report
52,003	Certican®	10/29/2004	[CANADA] Dr. Cole: Lung transplant rejection, cardiac arrest, pneumonia, viral infection, respiratory tract infection, respiratory disorder, haemodynamic instability, dyspnoea, hypoxia, myalgia, productive cough; Follow-up#1	330	2401		Safety Report
52,003	Certican®	10/26/2004	New Investigator to Study No. CRAD001A2401: Drs. D. Hricik, V. G. Valentine, H. J. Eisen, T. Pruett, R. Benza, J. Curtis, P. R. Rajagopalan. Study No. CRAD001A2403: Dr. A. J. Tector.	329	A2401 A2403		New Investigator
52,003	Certican®	10/19/2004	[SPAIN] Dr. Tabernero: Malignant neoplasm progression, stomatitis, drug ineffective, enterocolitis, abdominal pain, anorexia, vomiting, constipation, skin lesion, metastases to peritoneum, performance status decreased, respiratory disorder, hypoalbuminaemia, generalised oedema; Follow-up#1.	328	C2107		Safety Report
52,003	Certican®	10/15/2004	[CANADA] Dr. Cole: Lung transplant rejection, cardiac arrest, pneumonia, respiratory tract infection, viral infection, respiratory disorder, haemodynamic instability, dyspnoea, hypoxia, myalgia, pyrexia, productive cough.	327	2401		Safety Report
52,003	Certican®	10/12/2004	Dr. Meir Wetzler, MD: Cardiac failure congestive, dyspnoea, oedema peripheral, eyelid oedema, weight increased, dilatation atrial, ventricular hypertrophy.	326	2207		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	10/01/2004	New Investigator to Study No. CRAD001A2401: Drs. B. Kahan, J. E. Loyd, A. Frost, D. J. Conti, J. M. Hare. Study No. CRAD001US09: Drs. M. T. Sellers, M. Cooper, S. Bunnapradist, V. R. Peddi, E. Hartmann, D. Norman.	325	A2401 US09	New Investigator	
52,003	Certican®	09/27/2004	Dr. Francis Giles: Leucocytoclastic vasculitis, hyperglycaemia, oedema peripheral, calcinosis; deep vein thrombosis, pain, erythema, rash, eschar.	324	2406	Safety Report	
52,003	Certican®	09/24/2004	New Investigator to Study No. US09; Drs. S. Mulgonkar, M. I. Lorber, E. Elkhammas, R. B. Love, D. G. Wombolt; Study No.2403; Dr. H.J. Eisen; Study No. 2405; Dr. S. F. Davis.	323	US09 2403 2405	New Investigator	
52,003	Certican®	09/23/2004	[SPAIN] Dr. Tabernero: Enterocolitis, stomatitis, abdominal pain, anorexia, vomiting, constipation.	322	C2107	Safety Report	
52,003	Certican®	09/20/2004	New Investigator to Study No. CRAD001A2401: Drs. S. Mulgonkar, M. I. Lorber, E. Elkhammas, R. B. Love, D. G. Wombolt; Study No. CRAD001US09: Drs. J. Ortiz, S. Greenstein, M. I. Abecassis, G. Francos, R. Stephan.	321	A2401 US09	New Investigator	
52,003	Certican®	09/08/2004	Dr. Judith Wolf: Hyperglycaemia.	320	2409	Safety Report	
52,003	Certican®	09/03/2004	New protocol to Study No. CRAD001 A2403 entitled, "A six-Month, multicenter, randomized, Open-label Study of the Safety, Tolerability and Efficacy of two Neoral doses in addition to Certican and Steroids in de novo Heart Transplant Recipients". Investigator: Howard Eisen, MD.	319	A2403	New Protocol	
52,003	Certican®	08/27/2004	Vincent Valentine. MD: Renal failure acute, renal insufficiency, thrombocytopenia, lung transplant rejection, hyperglycaemia, blood creatinine increased, blood urea increased, fatigue, malaise, graft loss: Follow-up#1	318	B152	Safety Report	
52,003	Certican®	08/20/2004	New protocol to Study No. CRAD001 A2405 entitled, "A Six-Month, Multicenter, Open-Label, single arm, pilot study of the renal safety of Everolimus in addition to Neoral in cardiac transplant recipients with established Allograft Vasculopathy". Also, Amendment 1 to Protocol CRAD001 A2405. New Investigator: Howard Eisen, MD. And Information Amendment: New Concept design for De Novo Heart Study.	317	A2405	New Protocol	
52,003	Certican®	08/18/2004	Vincent Valentine. MD; Lung transplant rejection, renal failure acute, renal insufficiency, thrombocytopenia, hyperglycaemia, fatigue, malaise, graft loss, blood creatinine increased, blood urea increased.	316	B152E1	Safety Report	
52,003	Certican®	08/12/2004	[SWITZERLAND] Prof. W. Kiowski: Pyrexia, C-reactive protein increased, red blood cell sedimentation rate increased; Follow-up#2	315	B253	Safety Report	
52,003	Certican®	07/08/2004	Dr. George Demetri: Ascites, disease progression, drug interaction, dyspnoea; Follow-up#2	314	2206	Safety Report	
52,003	Certican®	07/02/2004	Dr. George Demetri: Ascites, disease progression, dyspnoea; Follow-up#1	313	2206	Safety Report	
52,003	Certican®	06/28/2004	Dr. George Demetri: Dyspnoea, ascites, disease progression, drug ineffective.	312	2206	Safety Report	
52,003	Certican®	06/16/2004	[BELGIUM] Dr. Van Oosterom: Gastritis haemorrhagic, right ventricular failure, pulmonary hypertension, anaemia, blood in stool, general physical health deterioration: Follow-up#2	311	2206	Safety Report	

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	06/14/2004	[BELGIUM] Dr. Van Oosterom: Gastritis haemorrhagic, right ventricular failure, pulmonary hypertension, anaemia, blood in stool, general physical health deterioration; Follow-up#1	310	2206	Safety Report
52,003	Certican®	06/10/2004	This Annual Report covers the period November 15, 2002 through November 14, 2003. Includes clinical/preclinical information and Foreign marketing developments.	309		Annual Report
52,003	Certican®	06/10/2004	[BELGIUM] Dr. Van Oosterom: Gastritis haemorrhagic, right ventricular failure, pulmonary hypertension, anaemia, blood in stool, general physical health deterioration.	308	2206	Safety Report
52,003	Certican®	06/03/2004	Howard A. Burris, III, MD; Epistaxis, platelet count decreased, bleeding time prolonged; Follow-up#1	307	2101	Safety Report
52,003	Certican®	05/24/2004	[SWITZERLAND] Prof. W. Kiowski: Pyrexia, C-reactive protein increased, red blood cell sedimentation rate increased; Follow-up#1	306	B253	Safety Report
52,003	Certican®	05/03/2004	Howard A. Burris, III, MD; Epistaxis, platelet count decreased, bleeding time prolonged.	305	2101	Safety Report
52,003	Certican®	04/07/2004	FAX from FDA containing comments from the reviewing medical officer, statistician and clinical pharmacologist on the February 27, 2004 protocol for Study A2411.			
52,003	Certican®	04/06/2004	[BELGIUM] Dr. Van Oosterom: Gastritis haemorrhagic, thrombocytopenia, anaemia, nausea, vomiting, melaena.	304	2206	Safety Report
52,003	Certican®	03/17/2004	Amendment No.1 and Amendmen No. 2 to Study No. RAD001 A2410.	303	A2410	Change In Protocol
52,003	Certican®	03/17/2004	Amendment No. 1 and Amendment No. 2 to Study No. RAD001 A2409.	302	A2409	Change In Protocol
52,003	Certican®	03/17/2004	Amendment No.1 and Amendment No. 2 to Study No. RAD001 A2408.	301	A2408	Change In Protocol
52,003	Certican®	03/15/2004	New protocol to Study No. A2409 entitled, "Open-label, two-period, single-sequence, crossover study to evaluate the influence of ketoconazole on the pharmacokinetics of everolimus in healthy subjects. Investigator: Dr. Magdy Shenouda, MD.	300	A2409	New Investigator New Protocol
52,003	Certican®	03/12/2004	New protocol to Study No. A2410 entitled, "A open-label, two-period, single-sequence, crossover study to evaluate the influence of verapamil on the pharmacokinetics of everolimus in healthy subjects. New investigator: Mark.J. Allison, MD.	299	A2410	New Investigator New Protocol
52,003	Certican®	03/11/2004	New protocol to Study No. A 2408 entitled, "Open-label, two-period, single-sequence, crossover study to evaluate the influence of erythromycin on the pharmacokinetics of everolimus in healthy subjects. Investigator: Dr. Magdy Shenouda, MD.	298	A2408	New Investigator New Protocol
52,003	Certican®	03/10/2004	FAX from FDA containing comments on the drug-drug interaction protocols submitted February 18, 2004, Serial No. 294)			
52,003	Certican®	03/05/2004	New Investigator to Study No. A 2401: Dr. Jeffrey Punch, MD.	297	A2401	New Investigator

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	02/27/2004	[FRANCE] Alexandre Karras; Histiocytosis haematophagic, human herpesvirus 6 infection, graft loss, lymphadenopathy, neurological symptom, gastrointestinal disorder, weight decreased, pyrexia, anaemia, haemoglobin decreased, white blood cell count decreased, platelet count decreased, liver function test abnormal, blood lactate dehydrogenase increased, blood triglycerides increased, serum ferritin increased, hyponatraemia, nephrectomy.	296			Safety Report
52,003	Certican®	02/27/2004	In response to the approvable letter for NDA 21-628 and subsequent interactions with the Division, this submission contains a revised study summary and protocol for a de novo heart transplantation study for review and comment prior to initiation.	295	A2411		Clinical Information Amendr Response to FDA Request
52,003	Certican®	02/18/2004	In response to a recommendation from the Division at the January 6, 2004 teleconference for drug interaction studies, this submission contains final protocols for each drug interaction study and a request for timely review comments.	294			
52,003	Certican®	02/13/2004	FAX from FDA containing comments on the protocol synopses for three drug-drug interaction studies submitted February 6, 2004.				
52,003	Certican®	02/03/2004	In response to a recommendation from the Division at the January 6, 2004 teleconference for drug interaction studies, this submission contains a study summary and assessment schedule for each drug interaction study	293			Response to FDA Request
52,003	Certican®	12/08/2003	This letter authorizes FDA to refer to this IND in support of an IND that will be filed by B. Kahan, MD.	291			General Correspondence
52,003	Certican®	11/03/2003	New protocol: Study No. CRAD001AUS09 entitled, "A prospective, multicenter, open label, randomized study of the safety, tolerability and efficacy of Certican (RAD001) with Simulect, corticosteroids and lower levels versus higher levels of tacrolimus in de novo renal transplant recipients.	290	US09		New Protocol
52,003	Certican®	10/01/2003	[SWEDEN] Gunnar Martensson: Respiratory failure, cardiac failure NOS, pneumonitis NOS, acute respiratory distress syndrome, coagulopathy, bronchial obstruction, asthma nos, hypoxia, lung infiltration NOS, alveolitis NOS, pulmonary haemorrhage, pulmonary oedema NOS, hypoperfusion, atelectasis, lung consolidation, dyspnoea, eosinophilia; Follow-up#4	289	B159		Safety Report
52,003	Certican®	09/26/2003	[SWEDEN] Gunnar Martensson: Respiratory failure, cardiac failure NOS, pneumonitis NOS, lung disorder NOS, coagulopathy, bronchial obstruction, asthma NOS, hypoxia, lung infiltration NOS, alveolitis NOS, pulmonary haemorrhage, lung consolidation, dyspnoea, eosinophilia; Follow-up#3.	288	B159		Safety Report
52,003	Certican®	09/15/2003	[AUSTRALIA] Dr. Scott Campbell; Optic neuropathy NOS, nuclear magnetic resonance imaging brain abnormal, vision blurred, visual acuity reduced; Follow-up#3	287	A2307		Safety Report
52,003	Certican®	09/12/2003	Minutes of the September 11 and 12, 2003, meeting to discuss the Pediatric Written Request.				FDA/Novartis Meeting Minu
52,003	Certican®	09/11/2003	TELECON with FDA to discuss Novartis' Request for a Type A Meeting on the Written Request and data exclusivity.				Memo of Record (telephone report)
52,003	Certican®	09/05/2003	FDA LETTER responding to the request for a meeting to discuss the pediatric Written Request.				
52,003	Certican®	08/21/2003	Request a Type A meeting to discuss the Written Request prior to the NDA action date of October 20, 2203 (NDAs 21-560 and 21-628).	286			Request for FDA Meeting

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	08/07/2003	TELECON with FDA regarding 24 month statistical analysis plan for Study No. B159 (Submitted July 9, 2003, Serial No. 285)				Memo of Record (telephone report)
52,003	Certican®	08/01/2003	TELECON with FDA to discuss the statistical proposals found acceptable for Study B159 24-month data analysis.				Memo of Record (telephone report)
52,003	Certican®	07/10/2003	In reference to the Pre-NDA meeting held on May 1, 2003, this amendment to Study B159 provides for a detailed statistical methodology for the 24-month data analysis.	285	B159		Change In Protocol
52,003	Certican®	05/27/2003	Submission of slides presented at pre-NDA meeting held on May 1, 2003, to discuss the use of Certican in lung transplantation.	284			General Correspondence
52,003	Certican®	05/05/2003	FAX from FDA containing attendance sheets for May 1, 2003 pre-NDA meeting.				
52,003	Certican®	05/01/2003	FDA minutes of the May 1, 2003 pre-NDA/Type B meeting. The purpose of the meeting was to obtain feedback from the Agency concerning the proposed NDA in lung transplantation.				FDA/Novartis Meeting Minu
52,003	Certican®	04/29/2003	FAX from FDA containing comments concerning pre-NDA background package (Serial No. 281)				
52,003	Certican®	04/25/2003	FAX from FDA containing comments concerning pre-NDA background package (Serial No. 281)				
52,003	Certican®	04/07/2003	FDA LETTER containing details of the Type B meeting scheduled for May 1, 2003, requested March 21, 2003.				
52,003	Certican®	04/03/2003	This Annual Report covers the period November 15, 2001 through November 14, 2002. Includes clinical and preclinical study/safety information.	283			Annual Report
52,003	Certican®	04/01/2003	Submission of additional desk copies of the Briefing Book dated March 21, 2003.	282			Response to FDA Request
52,003	Certican®	03/21/2003	This Briefing Book is being submitted in preparation for a pre-NDA (Type B) meeting scheduled May 1, 2003, to discuss submission proposals to support the use of Certican in lung transplantation. This Briefing Book replaces submission dated March 4, 2003 (Serial No. 279)	281			Briefing Book
52,003	Certican®	03/19/2003	[SWEDEN] Gunnar Martensson; Respiratory failure, cardiac failure NOS, pneumonitis NOS, bronchial obstruction, asthma NOS, hypoxia, lung infiltration NOS, alveolitis NOS, pulmonary haemorrhage, lung consolidation, dyspnoea NOS, eosinophilia; Follow-up#2	280	B159		Safety Report
52,003	Certican®	03/04/2003	Request for pre-NDA meeting (Type B) to discuss submission proposals in support of an NDA for the use of Certican in lung transplantation.	279			
52,003	Certican®	02/19/2003	[SWEDEN] Gunnar Martensson; Respiratory failure, cardiac failure NOS, pneumonitis NOS, bronchial obstruction, asthma NOS, hypoxia, lung infiltration NOS, alveolitis NOS, lung consolidation, dyspnoea NOS, eosinophilia; Follow-up#1	278	B159		Safety Report
52,003	Certican®	01/03/2003	[AUSTRALIA] Dr. Scott Campbell; Optic neuropathy NOS, nuclear magnetic resonance imaging brain abnormal, vision blurred, visual acuity reduced; Follow-up#2	277	2307		Safety Report
52,003	Certican®	12/24/2002	[AUSTRALIA] Dr. Scott Cambell; Optic neuropathy NOS, nuclear magnetic resonance imaging brain abnormal, vision blurred, visual acuity reduces; Follow-up#1	276	2307		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	11/19/2002	TELECON with FDA on November 18 and 19, 2002 to discuss tradename potential for similarity between Certican and Foradil Certihaler.			Memo of Record (telephone report)
52,003	Certican®	10/29/2002	TELECON with FDA regarding the SAS data transfer.			Memo of Record (telephone report)
52,003	Certican®	10/25/2002	Minutes of the October 25, 2003 meeting to discuss plans for submitting the statistical datasets for the upcoming NDAs.			FDA/Novartis Meeting Minu
52,003	Certican®	10/21/2002	FDA LETTER asking Novartis to determine if the new protocol submitted August 6, 2002, Serial No. 268, meets the requirements for listing in the Clinical Trials Data Bank.			
52,003	Certican®	10/17/2002	[Sweden] Gunnar Martensson; Pneumonitis NOS, bronchial obstruction, asthma NOS, Hypoxia, alveolitis NOS, respiratory failure, lungconsolidation, dyspnoea NOS, eosinophilia	274	B159	Safety Report
52,003	Certican®	10/15/2002	[France] Prof Bourbigot; Protocol No. CRAD001 A2307; renal impairment NOS, hepatitis acute, concomitant disease progression, blood creatinine increased, gamma-glutamyltransferase increased, aspartate aminotransferase increased, alanine aminotransferase increased; follow-up# 2	273	A2307	Safety Report
52,003	Certican®	09/20/2002	[Australia] Dr Scott Campbell; Optic neuropathy NOS, vision blurred, visual acuity reduced	272	A2307	Safety Report
52,003	Certican®	09/05/2002	TELECON from FDA assigning NDA Numbers and User Fee ID#.			Memo of Record (telephone report)
52,003	Certican®	09/04/2002	TELECON with FDA to discuss the submission of a new Oncology IND for RAD.			Memo of Record (telephone report)
52,003	Certican®	09/04/2002	A telecon is being requested to discuss a proposal for the transfer of SAS datasets and programs for Division review.	271		General Correspondence
52,003	Certican®	08/15/2002	This submission provides a copy of the communication received from the Data Safety Monitoring Board (DSMB) dated July 23, 2002 and the Novartis written notification to Study B253 investigators, dated July 26, 2002.	270		Clinical Information Amendr
52,003	Certican®	08/08/2002	n reference to a telephone conversation on August 5, 2002, regarding a GCP audit, this correspondence provides written notification to the file with a copy of the letter submitted on August 6, 2002, to the Division of Scientific Investigations.	269		General Correspondence
52,003	Certican®	08/06/2002	New protocol: Study No. US08 entitled, "Single center, prospective, single-arm, open-label trial of rapid steroid withdrawal in combination with Certican (RAD), Simulect, and Neoral for the prevention of acute rejection in de novo renal transplant recipients". Investigator: R. M. Ferguson, MD	268	US08	New Protocol
52,003	Certican®	08/05/2002	TELECON with FDA regarding the UCLA GCP audit findings and Novartis' intent to inform DSI.			Memo of Record (telephone report)
52,003	Certican®	08/05/2002	This letter authorizes FDA to refer to this IND in support of an IND filed by B. J. Hering, MD (BB-IND 8919).	267		General Correspondence
52,003	Certican®	07/17/2002	New investigator to Study No. 2307: M. L. Lorber, MD	266	2307	New Investigator
52,003	Certican®	07/12/2002	In reference to the pre-NDA meeting held on March 25, 2002, and to the FDA Meeting Minutes, this correspondence requests clarification on several issues raised in the minutes and contains revision to those minutes.	265		

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	07/11/2002	[France] Prof Bourbigot; Protocol No. CRAD001 A2307; renal impairment NOS, hepatitis acute, concomitant disease progression, blood creatinine increased, gamma-glutamyltransferase increased, aspartate aminotransferase increased, alanine aminotransferase increased; follow-up	264	A2307	Safety Report
52,003	Certican®	07/02/2002	FDA LETTER referencing the "Best Pharmaceuticals for Children Act" (BPCA) and serving as notification that the Written Request, originally issued on April 25, 2000, is considered to be reissued as of the date of this letter.			
52,003	Certican®	06/03/2002	Barry Donald Kahan, MD; Protocol No. FTY A2202; anasarca, disease progression NOS, oedema NOS, dyspnoea exertional, weight increased, blood creatinine increased	261	A2202	Safety Report
52,003	Certican®	05/29/2002	New investigators: Study No. 2306: Drs. J. Magee, P. Morissey; Study No. 2307: Drs. D. Norman, J. D. Scandling	260	2306 2307	New Investigator
52,003	Certican®	05/15/2002	New investigator to Study No. 2307: F. H. Wright, MD	259	2307	New Investigator
52,003	Certican®	05/01/2002	This Annual Report covers the period November 15, 2000, through November 14, 2001. Includes preclinical and clinical study/safety information, CMC changes, and a revised Investigator's Brochure dated June 29, 2001.	258		Annual Report
52,003	Certican®	04/30/2002	New investigators to Study No. 2306: D. Wombolt, MD; Study No. 2307: K. M. H. Butt, MD	257	2306,2307	New Investigator
52,003	Certican®	03/25/2002	FDA minutes of the pre-NDA/Type B meeting held March 25, 2002. regarding the renal and heart transplantation indications.			FDA/Novartis Meeting Minu
52,003	Certican®	03/22/2002	New investigator to Study No. 2306: T. Pruett, MD	255	2306	New Investigator
52,003	Certican®	03/21/2002	This submission is in response to an FDA request to provide 254 additional summary documentation (B201/B251 6 month amendments) to support the Division's review and proposals for the use of Certican in renal transplantation.			Response to FDA Request
52,003	Certican®	03/07/2002	FDA LETTER containing a meeting date in response to the February 14, 2002, correspondence requesting a meeting to discuss the proposal to submit a single NDA for two separate indications.			
52,003	Certican®	02/28/2002	TELECON with FDA to discuss pre-NDA meeting logistics and format.			Memo of Record (telephone report)
52,003	Certican®	02/22/2002	New investigators: Study No. 2306: Drs. P. R. Rajagopalan, T. R. Srinivas; Study No. 2307: Drs. J. D. Whelchel, J. Leone	250	2306 2307	New Investigator
52,003	Certican®	02/14/2002	This Briefing Book is being submitted in preparation for the pre-NDA being requested in this correspondence. The purpose of this meeting is to obtain FDA feedback and agreement on our proposal for submission of a single NDA containing two separate indications for use of Certican in heart and renal transplantation.	249		Briefing Book Request for FDA Meeting
52,003	Certican®	02/12/2002	TELECON with FDA to discuss the scheduling of the pre-NDA meeting.			Memo of Record (telephone report)
52,003	Certican®	12/21/2001	New investigators to Study No. A2202: Drs. L. Toselli, H. Tedesco, P. Neuhaus, R. J. Hene, S. Flechner	248		General Correspondence
52,003	Certican®	12/20/2001	Dr. Joshua Hare; Pulmonary fibrosis, cardiac failure congestive; Follow-up#2	247	B253	Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	12/11/2001	Dr. Vincent Valentine; Rhabdomyolysis, renal failure acute, renal failure chronic, hyperkalaemia, fluid overload, metabolic acidosis NOS, bradycardia NOS, liver function tests NOS abnormal; Follow-up#2	246	B159	Safety Report
52,003	Certican®	12/10/2001	New investigator to Study No. 2306: H. Shidban, MD	245	2306	New Investigator
52,003	Certican®	11/21/2001	Amendment No. 3 to Study No. B156; Amendment No. 2 to Study No. B157-E-01; Amendment No. 7 to Study No. B152	244	B156 B157-E-01 B152	Change In Protocol
52,003	Certican®	11/15/2001	New investigators to Study No. A2202: Drs. S. J. Tomlianovich, A. N. Langnas	243		General Correspondence
52,003	Certican®	10/31/2001	Amendment No. 4 to Study No. B251.	242	B251	Change In Protocol
52,003	Certican®	10/31/2001	TELECON to FDA regarding the delay in the NDA submission from November 2001 to June 2002. FDA also acknowledged that multiple indications can be submitted in the same application.			Memo of Record (telephone report)
52,003	Certican®	10/18/2001	Dr. Joshua Hare; Protocol No. CRAD0001 B253; pulmonary fibrosis; follow-up	241	B253	Safety Report
52,003	Certican®	10/15/2001	Extension 1 to Protocol No. A2202 titled, "Two-year extension of a one-year, multicenter, prospective, open-label study of the safety, tolerability and preliminary efficacy of oral FTY720 and RAD001 in de novo adult renal transplant recipients at increased risk of delayed graft function".	240		General Correspondence
52,003	Certican®	10/12/2001	Dr. Hall; Protocol No. CRAD0001 B253; pulmonary fibrosis	239	B253	Safety Report
52,003	Certican®	10/09/2001	New investigator to Study No. A2202: A. Humar, MD	238	A2202	New Investigator
52,003	Certican®	09/25/2001	This submission contains a draft protocol of a nonclinical study titled, "An oral neonatal and juvenile development study in rats with 13- and 26-week recovery period".	237		Preclinical Amendment
52,003	Certican®	09/13/2001	FAX from FDA containing comments from the reviewing statistician on protocols for Studies No. 2306 and 2307 (August 9, 2001).			
52,003	Certican®	09/05/2001	This Annual Report covers the period November 15, 1999 through November 14, 2000. Includes preclinical and clinical study information and CMC changes.	235		Annual Report
52,003	Certican®	09/05/2001	New investigator to Study A2202: R. Mendez, MD	236	A2202	New Investigator
52,003	Certican®	08/31/2001	This Annual Report covers the period November 15, 1998 to November 14, 1999. Includes preclinical and clinical study information, CMC changes, and an investigator's brochure dated November 26, 1999.	234		Annual Report
52,003	Certican®	08/16/2001	FAX from FDA containing comments from the reviewing clinical pharmacologist on the submission dated August 7, 2001, Serial No. 228.			
52,003	Certican®	08/15/2001	Dr. Vincent Valentine; Protocol No. B159. Rhabdomyolysis, renal failure acute, renal failure chronic, hyperkalaemia, fluid overload, metabolic acidosis NOS, bradycardia NOS, liver function tests NOS abnormal; follow-up	232	B159	Safety Report
52,003	Certican®	08/09/2001	New protocol: Study No. 2307 entitled, "A 1 year multicenter, randomized, open label, parallel group study of the safety, tolerability and efficacy of two doses (1.5 and 3 mg/day) of Certican (RAD001) with Simulect, corticosteroids and optimized administration of Neoral in de novo renal transplant recipients".	231	2307	New Protocol

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	08/09/2001	New protocol: Study No. 2306 entitled, "A 1 year multicenter, randomized, open label, parallel group study of the safety, tolerability and efficacy of two doses (1.5 and 3 mg/day) of Certican (RAD001) with steroids and optimized administration of Neoral in de novo renal transplant recipients".	230	2306	New Protocol
52,003	Certican®	08/09/2001	General correspondence. New investigator to FTY 720 Study No. A2202: P. R. Rajagopalan, MD	229	A2202	General Correspondence
52,003	Certican®	08/07/2001	This submission contains a list of proposed additional dissolution experiments to be performed on the 0.25 and 1 mg tablet.	228		CMC Amendment
52,003	Certican®	08/06/2001	[Canada] Dr. H. Ross; compassionate need patient; heart transplant rejection, drug ineffective, disease progression NOS, ventricular extrasystoles; follow-up	227		Safety Report
52,003	Certican®	08/03/2001	TELECON to FDA regarding the everolimus starting material, rapamycin, in reference to the upcoming submission of the NDA.			Memo of Record (telephone report)
52,003	Certican®	08/02/2001	Joseph P. Lynch, MD; Protocol No. B159; hypersensitivity NOS, throat oedema, dyspnoea NOS, hypertension NOS, face oedema	226	B159	Safety Report
52,003	Certican®	07/31/2001	TELECON with FDA to discuss the endocrine findings and proposals for study amendment in the clinical program.			Memo of Record (telephone report)
52,003	Certican®	07/30/2001	[Canada] Dr. H. Ross; compassionate need patient; heart transplant rejection, ventricular extrasystoles	225		Safety Report
52,003	Certican®	07/23/2001	FAX from FDA containing comments on amendments to Study No. 2407, Serial No. 219.		2407	
52,003	Certican®	07/19/2001	TELECON with FDA to discuss the April 17, 2001, fax from FDA that contained several questions regarding the justification of the dissolution method submitted December 21, 2000.			Memo of Record (telephone report)
52,003	Certican®	07/19/2001	TELECON with FDA to discuss the dissolution profile for the RAD001 tablets and Novartis' memorandum of April 17, 2001.			Memo of Record (telephone report)
52,003	Certican®	07/13/2001	Vincent Valentine, MD; Protocol No. AD001 B159; rhabdomyolysis, pyrexia, myalgia, weakness, liver function tests NOS abnormal; follow-up	224	B159	Safety Report
52,003	Certican®	07/12/2001	FDA LETTER indicating that the teleconference requested to discuss dissolution methodology for the dosage forms is a meeting type C. The date, time and CDER participants are given.			
52,003	Certican®	07/11/2001	TELECON to FDA regarding Novartis' reporting obligations for the close-out of a study site for GCP related issues.			Memo of Record (telephone report)
52,003	Certican®	07/10/2001	Dr. Vincent Valentine; Center 16. Rhabdomyolysis, renal failure acute, renal failure chronic, hyperkalaemia, fluid overload, metabolic acidosis NOS, bradycardia NOS, liver function tests NOS abnormal.	223	B159	Safety Report
52,003	Certican®	07/02/2001	This submission contains endocrine findings in specific clinical trials, overviews of preclinical safety findings, summaries of our discussions with endocrine consultants and proposals for FDA feedback. A list of tentative dates and participants for a meeting is also provided.	222		Clinical Information Amendr Request for FDA Meeting
52,003	Certican®	06/29/2001	Protocol A2202, Amendment No. 3.	221	A2202	Change In Protocol

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	06/28/2001	This correspondence notifies the FDA of Novartis' intent to import the material listed for further processing into a drug that will be exported from the US.				
52,003	Certican®	06/25/2001	TELECON FROM FDA requesting an overview of the planned submission of the endocrine package based on the recent endocrine findings from adult kidney studies and in view of the Rapamune FDA preclinical toxicology reviews. Discussed were contents/timelines and communication to NIH.				Memo of Record (telephone report)
52,003	Certican®	06/21/2001	TELECON TO FDA notifying the agency that a package is being prepared for submission to FDA containing endocrine findings based on results from adult kidney studies. Novartis would request a teleconference and provide tentative dates.				Memo of Record (telephone report)
52,003	Certican®	06/14/2001	FAX FROM FDA providing review comments on Protocol A2414 submitted on May 29, 2001 to NDA 50-716.		A2414		
52,003	Certican®	06/08/2001	Response to the medical review comments and requests regarding Amendment # 3 for Study B251, Serial # 211. Additional information is provided on the monitoring and timely review of acute rejection episodes in de novo renal transplant studies B201 and B251.		220		Response to FDA Request
52,003	Certican®	06/05/2001	As per the FDA April 17, 2001 FAX which included additional questions concerning the proposed dissolution methodology for the dosage form, Novartis is requesting a telephone conference between FDA clinical pharmacology representatives including the reviewing chemist and Novartis US and Basle representatives.		218		CMC Amendment General Correspondence
52,003	Certican®	06/05/2001	Vincent Valentine, MD. Rhabdomyolysis.		217	B159	Safety Report
52,003	Certican®	05/15/2001	Protocol A2202, Amendment 2.		216	A2202	Change In Protocol
52,003	Certican®	05/09/2001	Point-by-point response to FDA communication dated April 19, 2001 which provided medical review comments and requests for additional information on Amendment # 3 for Study B251, serial no. 211.		215	B251	Response to FDA Request
52,003	Certican®	04/17/2001	FDA FAX providing the comments from the reviewing clinical pharmacologist regarding CMC information amendments Serial Nos. 200 and 208.				
52,003	Certican®	03/23/2001	[Italy] Dr. Francis Cardelli. Center 18. Leukopenia NOS.		213	AIT01	Safety Report
52,003	Certican®	03/21/2001	TELECON WITH FDA regarding FDA's acceptance of cross referencing the new IND in oncology to IND 52,003. In order to avoid redundancy on all supporting documents intended for the submission of the NDA later in the year, Novartis made proposal as outlined. Acceptance of these proposals will be confirmed by the Medical Officers.				Memo of Record (telephone report)
52,003	Certican®	03/21/2001	New investigators to Protocol A2202: Drs. Douglas Norman, Clarence Foster.		212	A2202	New Investigator
52,003	Certican®	03/19/2001	Protocol B251, Amendment No. 3.		211	B251	Change In Protocol
52,003	Certican®	03/15/2001	New investigator to Protocol A2202: Ron Shapiro, MD.		210	A2202	New Investigator

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	03/12/2001	TELECON FROM FDA in response to a voice message left on March 9, 2001 by the Oncology TA. The Agency confirmed that it was acceptable for Novartis to cross-reference the upcoming RAD oncology IND to the transplant IND submitted earlier. The upcoming IND will be submitted to the Division of Oncologic Drug Products to support an indication in solid tumors. The agency re-confirmed that it was acceptable to cross-reference the CMC and toxicology section of the IND to the transplant				Memo of Record (telephone report)
52,003	Certican®	03/07/2001	[Spain] Dr. L. Pulpon. Centre 128. Rhabdomyolysis, renal failure acute, weakness, pain in limb, nausea.	209	B253		Safety Report
52,003	Certican®	03/05/2001	FDA FAX providing the minutes of the February 6, 2001 pe-NDA meeting (Type B) to reach FDA consensus on the NDA submission requirements for the 120-day safety update and to inform the agency of the major efficacy and safety results from the Phase III program.				FDA/Novartis Meeting Minu
52,003	Certican®	02/22/2001	At the request of the FDA, provided a legible replacement copy of CMC document - Drug product in vitro dissolution rate: justification of method, 15-Dec-00, which was included in the December 21, 2000 correspondence (serial no. 200).	208			CMC Amendment
52,003	Certican®	02/15/2001	Correspondence to document the Division's acceptance of Novartis' proposals included in the January 12, 2001 correspondence which provided statistical proposals to facilitate the timely and efficient transfer of SAS programs for the NDA reviewers. The proposals were accepted during a February 6, 2001 conversation with the FDA.	205			General Correspondence
52,003	Certican®	02/15/2001	New investigator for Protocol B253-E01: O.H. Frazier, MD.	207	B253-E01		New Investigator
52,003	Certican®	02/15/2001	New investigator for Protocol A2202: Marc I. Lorber, MD.	206	A2202		New Investigator
52,003	Certican®	02/06/2001	FDA FAX providing the attendance list for the pre-NDA meeting scheduled for February 6, 2001 and informing Novartis that the TELECON scheduled for February 7, 2001 is not needed.				
52,003	Certican®	01/23/2001	FDA LETTER referring to Novartis' December 13, 2000 correspondence requesting a meeting to discuss the final requirements for NDA submission. The meeting which the agency considers to be a type B, has been rescheduled for February 6, 2001.				
52,003	Certican®	01/23/2001	FDA FAX which provides comments from the reviewing medical officer and the statistician regarding the submission dated December 6, 2000, serial no. 191.				
52,003	Certican®	01/22/2001	Provided point-by-point response to medical/clinical pharmacology comments provided in FDA's communication dated January 9, 2001.	204			Response to FDA Request
52,003	Certican®	01/18/2001	Extension E-01 to Study B253, "A two-year extension of the two-year randomized, multicenter, double-blind study of the efficacy and safety of SDZ RAD versus azathioprine as part of a triple immunosuppressive therapy regimen in de novo heart transplant recipients". New investigators: Drs. Howard J. Eisen, James A. Hill, Paul J. Hauptman, Robert B. Love.	203	B253-E01		Clinical Information Amendr New Investigator
52,003	Certican®	01/17/2001	TELECON FROM FDA informing Novartis that the Division will have to reschedule the January 31 meeting. The new date is February 6, 2001. Novartis indicated that the cancellation is an inconvenience for the team but that the team members will be requested to confirm the new date.				Memo of Record (telephone report)

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	01/12/2001	Requested a teleconference with the FDA to facilitate the timely transfer of SAS programs for Division review. Included are Novartis' proposals for discussion with the statistical reviewers.	202			Request for FDA Meeting
52,003	Certican®	01/09/2001	FDA FAX which includes review comments from the medical officer and the clinical pharmacologist relating to the December 18, submission, serial no. 195.				
52,003	Certican®	01/08/2001	Submitted Novartis' proposals for the NDA 120-Day Safety Update. The proposals and related NDA issues will be discussed in a meeting on January 31, 2001.	201			General Correspondence
52,003	Certican®	12/22/2000	New investigators to Protocol A2202: Drs. Deise De boni Monteiro De Carvalho, Helio Tedesco Silva Junior (non-US investigators), Hans Sollinger (US investigator), Barry Kahan and Stephen Katz, (co investigators).	198	A2202		New Investigator
52,003	Certican®	12/22/2000	FDA LETTER noting that based on Novartis December 6, 2000 meeting request, the agency has determined that the meeting is a type B and it is scheduled for January 31, 2001.				
52,003	Certican®	12/21/2000	Provided a CD-ROM which contains a demonstration of the electronic submission in accordance with the FDA Guidance for industry for providing regulatory submissions in electronic format. Also provided is an NDA table of contents that itemizes contents available for paper and electronic archive.	199			
52,003	Certican®	12/21/2000	In response to FDA telefax dated June 27, 2000 expressing concern regarding the dissolution method used for Certican tablets, provided document entitled, "In vitro dissolution rate: Justification of method".	200			CMC Amendment
52,003	Certican®	12/20/2000	TELECON FROM FDA indicating that the agency will be ready to have a teleconference with Novartis on January 3, 2001 to discuss the proposed amendment and a face to face meeting on January 31, 2001 to discuss NDA submission requirements.				Memo of Record (telephone report)
52,003	Certican®	12/20/2000	TELECON TO FDA to confirm delivery of the electronic demo to the FDA Division of Special Pathogens and Immunologic Drug Products.				Memo of Record (telephone report)
52,003	Certican®	12/20/2000	New Protocol A2202, "A one-year, multicenter, prospective, open-label study of the safety, tolerability and preliminary efficacy of oral FTY720 and RAD001 in de novo adult renal transplant recipients at increased risk of delayed graft function". Also included is Amendment 1 to Protocol A2202.	197	A2202		New Protocol
52,003	Certican®	12/19/2000	In accordance with FDA request of October 24, 2000, provided a CD-ROM which contains two carcinogenicity studies: SPM/113, Oncogenicity study by oral gavage administration to rats for 104 weeks, and SPM/118, Oncogenicity study by oral gavage administration to mice for 104 weeks.	196			Response to FDA Request
52,003	Certican®	12/18/2000	Submitted draft Amendment to Study B251 for FDA comment and requesting feedback from the agency before January 4, 2001.	195	B251		
52,003	Certican®	12/15/2000	As requested by the FDA, provided additional summary statistics for creatinine clearance by Nankivell formula. This information is considered an amendment to the Briefing Book, Section 5.2, submitted December 6, 2000.	194			Response to FDA Request

REF	PRODOC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	12/12/2000	[Russian Federation] Dr. Alexander Sokolsky. Center 88. Cerebrovascular accident NOS, hypertension NOS, infection NOS, pyrexia, weakness, dyspnea NOS, hyperglycemia NOS, hypotension NOS, heart rate increased, hypoglycemia NOS, convulsions NOS, depressed level of consciousness, apnea, memory impairment, confusion, urinary incontinence, cerebral atrophy.	193	B201	Safety Report
52,003	Certican®	12/08/2000	FDA FAX providing statistical analysis issues relating to the April 17, 2000 submission, serial no. 154.			
52,003	Certican®	12/08/2000	TELECON TO FDA to reach agreement on the documentation to be submitted to both FTY720 and RAD001 INDs to support the clinical program which uses both investigational drugs (Protocol 2202, FTY 720). It was agreed that routine regulatory submissions would be made only to IND 57,293 with only a copy of the cover letter submitted to the RAD 001 IND indicating that attachments would be found in the FTY720 IND. The Division would like to see Novartis' proposals for safety reporting in writing.			Memo of Record (telephone report)
52,003	Certican®	12/07/2000	Provided information on an additional 0.75 mg tablet which is dose proportional to the current 0.5 and 1.0 mg dosage strengths. The following documents are included: composition, batch formula and method of preparation, drug product stability data/report, RAD001 0.75 mg tablets (KN 3749223.00.002 and 003) dated 23-Aug-2000.	192		CMC Amendment
52,003	Certican®	12/06/2000	Request for FDA teleconference/meeting in mid January 2001 to discuss the final requirements for the NDA submission. Also included is requested additional information on renal data from the ongoing Phase 3 kidney transplant studies.	191		Request for FDA Meeting
52,003	Certican®	11/17/2000	[Norway] Dr. S. Simonsen. Center 146. Alveolar proteinosis, dyspnoea NOS. Follow-up # 1.	190	B253	Safety Report
52,003	Certican®	11/08/2000	[Norway] Dr. S. Simonsen. Center 146. Alveolar proteinosis, dyspnoea NOS.	189	CRAD001B2	Safety Report
52,003	Certican®	11/08/2000	New investigator to Protocol IA06: Francis H. Wright, Jr., MD.	188	IA06	New Investigator
52,003	Certican®	10/05/2000	Dr. Paul Hauptman. Study CRAD001B253. Renal failure acute, thromboembolism NOS, pleural effusion, renal tubular necrosis, pericardial effusion. Follow-up # 2. The initial and first follow-up reports were submitted under case No. CRAD001/B253/0/16/6/1/USA.	186	CRAD001B2	Safety Report
52,003	Certican®	10/05/2000	Dr. Shamkant Mulgaonkar; Study CRAD001B251, Center 12. Hemolytic uremic syndrome, graft rejection, graft loss, drug ineffective, nephrectomy.	185	CRAD001B2	Safety Report
52,003	Certican®	10/02/2000	Provided information on new clinical materials consisting of 0.1 and 0.25 mg fast dispersible tablets differentiated by their appearance as they have an engraving on both sides. Included are the following documents: Drug product composition, site of manufacture, packaging and control, RAD001, 0.1 and 0.25, fast dispersible tablets, KN 374962.00.005 and KN 3745403.00.015, date 7-Mar 2000; Stability Report, 2U99 1895, date 16-Apr-1999.	184		CMC Amendment
52,003	Certican®	09/26/2000	Submitted first interpretable results for Studies B251 and 2304.	183	B251 2304	Clinical Information Amendr

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	09/21/2000	Request for a teleconference with the Division to discuss the summary findings from Novartis' pivotal trials in kidney transplantation. Included proposed agenda and list of Novartis participants.	182		
52,003	Certican®	09/18/2000	New investigators to conduct the following Protocols: Drs. Mark D. Pescovitz, Donald Hrick, John J. Curtis Study US01. Robert Naraghi, MD, Study IA06. Alan H. Wilkinson, MD, Studies IA11 and IA01.	181	US01 IA06 IA11 IA01	New Investigator
52,003	Certican®	08/24/2000	As requested during the pre-NDA meeting on December 3, 1999, provided 6 month first interpretable results for Studies CRAD B251 and CRAD B201. Additional analyses on creatinine values for each study is also included.	180		Response to FDA Request
52,003	Certican®	08/22/2000	Provided revised Chemistry Manufacturing and Controls information in support of a new clinical trial formulation consisting of 0.25, 0.5 and 1 mg tablets. The following documents are provided: drug product composition, manufacturing formula, stability data/report, date 7-Jun-2000	179		CMC Amendment
52,003	Certican®	08/17/2000	In reference to FDA communication of May 11, 2000 which requested Novartis to provide information regarding interaction between everolimus (formerly RAD001) and St. John's Wort, it is anticipated that everolimus will be recognized as a drug with a potential for interaction with St. John's Wort based on Novartis' evaluation of the potential for drug-drug interactions in the firm's Phase 3 renal transplant program. Accordingly, St. John's Wort will be mentioned in the proposed labeling. Also included for	178		Response to FDA Request
52,003	Certican®	08/15/2000	Provided for the followig new investigators: Dr. Stephen J. Tomlanovich for Protocol CRAD001 IA01 and IA11; Drs. John J. Curtis and Donald E. Hrick for Protocol CRAD001A US01; Dr. Robert Naraghi for Protocol CRAD001 IA06.	177	IA01 IA11 US01 IA06	New Investigator
52,003	Certican®	07/24/2000	FDA FAX providing the comments from the reviewing clinical pharmacologist regarding Point # 3 in Novartis' correspondence (Serial No. 159) responding to FDA's March 22, 2000 memorandum.			
52,003	Certican®	07/14/2000	New investigators for Protocol CRAD001 B351: Drs. Jacques Lemire, John D. Mahan, Robert Ettenger.	176	B351	New Investigator
52,003	Certican®	07/06/2000	Requested FDA approval for the use of the term "dispersible" for the drug product tablet and remove all references to speed at which the drug product disintegrates when placed in water. At the present time, there is a "normal" immediate release tablet and a "fast dispersible" tablet.	175		CMC Amendment General Correspondence
52,003	Certican®	07/06/2000	Nghiem, Dai Dao, MD. Arthralgia.	174	CRAD001B2	Safety Report
52,003	Certican®	06/30/2000	Amendment No. 1 to Protocol B351.	173	B351	Change In Protocol
52,003	Certican®	06/29/2000	[Italy] Dr. Fabio Vistoli. Hepatic failure, death.	172	CRAD001IA	Safety Report
52,003	Certican®	06/29/2000	In response to the April 5, 2000 FDA request, provided an electronic copy of two carcinogenicity studies in rats and mice, SPM/113 and SPM/118, initially submitted on February 24, 2000 as paper copies, Serial No. 133.	171		Preclinical Amendment Response to FDA Request
52,003	Certican®	06/28/2000	FDA FAX providing the comments of the reviewing Clinical Pharmacologist regarding response 1, 3, 4, 5 from the April 20, 2000 submission, serial no. 156, Study B258 (Protocol comment).		B258	

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	06/28/2000	Correspondence to document the June 29, 2000 telephone conversation with the FDA at which time the Regulatory Manager informed Novartis that the Office of Postmarketing Drug Risk Assessment has made a tentative decision to accept Novartis' proposed trademark Certican for IND 52,003.	170			General Correspondence
52,003	Certican®	06/27/2000	FDA FAX providing the comments of the Clinical Pharmacologist regarding response 1, 3, 4, 5 from the March 30, 2000 submission, serial no. 146 (dissolution issues).				
52,003	Certican®	06/27/2000	FDA FAX providing comments from the reviewing Clinical Pharmacologist regarding response 5 from the April 17 2000, submission, serial no. 152 (Protocol comment).				
52,003	Certican®	06/26/2000	New investigators for Protocol IA01: Drs. Janet L. Karlx and Richard Howard (co-principal) Allan M. Roza, Oleh Pankewycz, Jonathan Bromberg. New investigators for Prot. IA06: Drs. George Burke III, Jon Odorico. New investigators for Prot. IA11: Drs. Allan Roza, Jonathan Bromberg. New investigator for Prot. B159: Dr. Joseph P. Lynch.	169	IA01 IA06 IA11 B159		New Investigator
52,003	Certican®	06/26/2000	As requested by the FDA in the April 25, 2000 telex, provided clarification to clinical investigators participating in Study 258 regarding points in the Informed Consent form for the trial. Additionally, as requested by the Division, included is a letter informing the clinical trial investigators that Neoral is available free of charge to patients in the RAD clinical program.	168			Response to FDA Request
52,003	Certican®	06/21/2000	TELECON FROM FDA informing Novartis that the FDA Office of Postmarketing Drug Risk Assessment has tentatively approved the proposed trademark Certican for the drug product. A final decision on the trademark approval will be made after the NDA submission.				Memo of Record (telephone report)
52,003	Certican®	06/15/2000	Submitted revised CMC information to support the Fast Dispersible Tablet dosage form. Included are the following drug product documentation: Composition, manufacturing formula, specifications and control procedures, RAD001 01 and 0.25 mg fast dispersible tablets, KN 3749462.00.007, KN 3745403.00.018, dated May 8, 2000 and Stability Report for development batches, SR1895A, release date March 23, 2000.	167			CMC Amendment
52,003	Certican®	06/02/2000	New investigators: Luigi Bonomini, MD, for Protocol IA06; Jeffrey D. Hosenpud, MD, for Protocol B253; Steven Lobritto, MD, for Protocol B258.	165	IA06 B253 B258		New Investigator
52,003	Certican®	05/30/2000	As proposed in the teleconference of May 25, 2000 with the FDA, Novartis provided a summary of the clinical issues for discussion at the teleconference scheduled for June 2, 2000. The synopsis for Study B153 and the supporting literature is also included in this correspondence.	164	B153		Clinical Information Amendr
52,003	Certican®	05/25/2000	FDA LETTER which includes the comments from the reviewing clinical pharmacologist relating to Protocol US01 submitted on April 17, 2000, serial no. 153.				
52,003	Certican®	05/22/2000	Novartis provided its assessment of efficacy and contingency plans for the scenario of simultaneous equivalence and inferiority of RAD to MMF. FDA requested this information at the December 3, 1999 pre-NDA meeting. Novartis also clarified for the FDA the definition of rejection episodes discussed in Studies B251 and B201.	163			Clinical Information Amendr Response to Clinical Hold

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	05/19/2000	In response to FDA request of April 5, 2000, provided the following toxicology studies that evaluated the combination of RAD and cyclosporine: Report 203-461, "Toxicity study by oral gavage administration to Hanlbm Wistar rats for 4 weeks followed by a 2 week reversibility period". Report 203-080, "Combination of Sandimmun-Neoral and SDZ RAD 4-week oral (gavage) toxicity study in Cynomolgus monkeys". Complete submission in 5 vols.	161		Preclinical Amendment Response to FDA Request
52,003	Certican®	05/18/2000	Provided Study CRAD001 B257, Appendix 8.2, Pharmacokinetic evaluation, to support Novartis' position that the current (original protocol Study B258) blood-sampling schedule is appropriate for the study objectives.	162		Clinical Information Amendr
52,003	Certican®	05/18/2000	[France] Dr. Saliba; sudden death.	160	CRAD001B1	Safety Report
52,003	Certican®	05/12/2000	Provided a point-by-point response to FDA comments dated March 22, 2000 regarding Study IA04, serial no. 116.	159		Response to FDA Request
52,003	Certican®	05/08/2000	FDA LETTER which contains the review comments from the clinical pharmacologist concerning Protocol A2304, Serial No. 150.		A2304	
52,003	Certican®	05/08/2000	FDA LETTER providing the recommendations of the reviewing clinical pharmacologist regarding Protocol A2303, Serial No. 149.		A2303	
52,003	Certican®	05/02/2000	TELECON TO the FDA reviewing chemist concerning the status of the proposed stability protocols (RSP1870A and 2RSP99-1895) submitted on March 30, 2000. The agency has determined that the protocols are acceptable. Regarding the "name" (fast dispersible, etc.) issue for the dosage form, the FDA suggested that Novartis propose a list of "names" to the FDA for approval.			CMC Amendment Memo of Record (telephone report)
52,003	Certican®	04/26/2000	New investigator to Protocol B258: Jeffrey D. Punch, MD.	158	B258	New Investigator
52,003	Certican®	04/25/2000	FDA LETTER in reference to Novartis' proposed Pediatric Study Request submitted on October 29, 1999. To obtain needed pediatric information on the active moiety everolimus, FDA is making a formal Written Request for information from studies as listed. Included in the letter are agency recommendations regarding Novartis' request.			
52,003	Certican®	04/24/2000	FDA FAX providing requirements regarding the informed consent document that was received by the FDA on March 29, 2000 for Study B258, serial no. 134.			
52,003	Certican®	04/20/2000	Point-by-point response to FDA review comments communicated via facsimile on March 31, 2000 regarding Study B258.	156	B258	Response to FDA Request
52,003	Certican®	04/19/2000	FDA's minutes of the January 27, 2000 meeting with Novartis to discuss CMC issues related to the RAD001 development program which were not covered by the pre-NDA meeting of December 3, 1999.			CMC Amendment
52,003	Certican®	04/17/2000	Request for a Type B meeting to discuss Novartis' Phase 3 clinical program for the use of RAD001 in de novo liver transplantation. Supporting documentation and protocol summary for Study B252 is included.	155		Request for FDA Meeting
52,003	Certican®	04/17/2000	In response to FDA request for Division review communicated in the December 3, 1999 pre-NDA meeting, provided Novartis' proposal entitled, "Protocol analyses - Renal Indication".	154		Clinical Information Amendr

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	04/17/2000	New Protocol CRAD001A US01 entitled, "A multicenter, open-label, single-arm, exploratory study to assess the safety and tolerability of reduced-dose tacrolimus with RAD in maintenance renal transplant recipients with renal insufficiency". Study US01 will replace draft protocol for Study IA04 submitted on December 15, 1999 (serial no. 116). Also noted that Novartis is preparing a point-by-point response to the Division's clinical pharmacology review comments of March 22, 2000.	153	US01	New Protocol
52,003	Certican®	04/17/2000	Point-by-point response to the Division's facsimile communication of March 10, 2000 which provided medical and clinical pharmacology review comments on Study B351.	152	B351	
52,003	Certican®	04/17/2000	In response to FDA request of April 11, 2000, provided information to support Novartis' position that the data of Study B257 are considered acceptable for robust statistical evaluation and conclusions.	157		Response to FDA Request
52,003	Certican®	04/11/2000	[Germany] Dr. B. Nonnast-Daniel; Neuropathy, gout. Follow-up # 3.	151	CRAD001B2	Safety Report
52,003	Certican®	04/11/2000	TELECON FROM FDA requesting patient information enrolled in Pediatric Study B257. A formal recommendation will be made by the FDA after more information is received on patient enrollment in the study.			Memo of Record (telephone report)
52,003	Certican®	04/06/2000	New Protocol CRAD001A2304 entitled, "Determination of the effect of two cyclosporine formulations on the pharmacokinetics of single oral doses of RAD001 in healthy subjects using a randomized, two period, four sequence, crossover study design.	150	A2304	New Protocol
52,003	Certican®	04/06/2000	New Protocol CRAD001A2303 entitled, "An open-label, single-dose, case-control study to compare the pharmacokinetics of RAD001 in subjects with moderate hepatic impairment to matched healthy control subjects". New investigator, Kenneth C. Lasseter, MD.	149	A2303	New Investigator New Protocol
52,003	Certican®	04/06/2000	Pursuant to the agency's March 24, 2000 communication which provided clinical pharmacology comments regarding bioequivalence issues for RAD001, provided a summary synopsis and assessment schedule for Study A2301 entitled, "A randomized, open-label, four-way crossover study to evaluate the bioequivalence of a single 1mg dose of RAD001 administered as a 0.25mg market formulation (MF) tablet, a 0.5 mg (MF) tablet, a 0.25mg Final Market image (MFI) tablet and a 1 mg FMI tablet to healthy	148	A2301	Clinical Information Amendr
52,003	Certican®	04/03/2000	As per the request that was made during the pre-NDA meeting between FDA and Novartis, an example of the packaged (CR-blister) placebo for RAD001 Tablets is provided to the reviewing chemist.			CMC Amendment
52,003	Certican®	04/03/2000	New investigator, Protocol B258: Harvey L. Sharp, MD.	147	B258	New Investigator
52,003	Certican®	03/31/2000	FDA LETTER providing the comments from the reviewing medical officer and the clinical pharmacologist concerning Protocol B258, Serial No. 134.			
52,003	Certican®	03/30/2000	As requested by the agency during the January 27, 2000 pre-NDA meeting, Novartis provided information concerning stability issues discussed at the meeting. Additionally, as requested in the February 3, 2000 telefax, information is provided regarding dissolution questions outlined in the telefax. Included: RAD001 0.1, 0.25 mg Fast Dispersible Tablets, 2U99 1895 Stability Report dated 16-Apr-99.	146		CMC Amendment Response to FDA Request

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	03/28/2000	[Germany] Dr. Kehle; edema legs. Follow-up # 2.	145	CRAD001B2	Safety Report
52,003	Certican®	03/24/2000	[Germany] Dr. Nonnast-Daniel; neuropathy, gout. Follow-up # 2.	144	CRAD001B2	Safety Report
52,003	Certican®	03/24/2000	[Germany] Dr. Kehle; edema legs. Follow-up # 1.	143	CRAD001B2	Safety Report
52,003	Certican®	03/24/2000	TELECON from FDA requesting information to address the reviewing clinical pharmacologist's comments regarding bioequivalence issues, bio-link between market formulation and final market image tablets.			Memo of Record (telephone report)
52,003	Certican®	03/22/2000	FDA LETTER providing the comments of the reviewing clinical pharmacologist with regard to Study IA04, Serial No. 116.		IA04	
52,003	Certican®	03/20/2000	Submitted the following two new protocols: Study IA01 entitled, "A 1 year multicenter, randomized, open label, parallel group pilot study of the efficacy and safety of RAD with early versus possibly delayed initiation of Neoral in de novo renal transplant recipients at increased risk of delayed graft function". Study IA11 entitled, "A 1 year multicenter, single arm, open label, pilot study of the efficacy and safety of RAD in de novo renal transplant recipients at immunological high risk of rejection".	142	IA01/IA11	New Protocol
52,003	Certican®	03/13/2000	New investigator to Protocol B351: Mark I. Menster, MD.	141	B351	New Investigator
52,003	Certican®	03/10/2000	FDA LETTER responding to Novartis' February 1, 2000 correspondence which requested a teleconference to discuss the impact of different cyclosporine products on the RAD development program. The agency categorized the meeting to be a type C and scheduled it for March 15, 2000.			
52,003	Certican®	03/10/2000	FDA FAX providing comments from the clinical pharmacologist and the reviewing medical officer regarding Study B351.		B351	
52,003	Certican®	03/10/2000	TELECON FROM FDA providing comments on Pediatric Protocol B351. Novartis' suggestion that the response to the requests might be best addressed in the final reports was acceptable by the agency.		B351	Memo of Record (telephone report)
52,003	Certican®	03/10/2000	FDA FAX providing the minutes of the pre-NDA meeting with Novartis held on December 3, 1999.			FDA/Novartis Meeting Minu
52,003	Certican®	03/10/2000	New investigator to Protocol IA06: Gary A. Wilson, MD.	140	IA06	New Investigator
52,003	Certican®	03/06/2000	[Belgium] Dr. Maimone; hepatitis cholestatic, hepatic function abnormal, fever, asthenia, follow-up # 3.	139	CRAD001B2	Safety Report
52,003	Certican®	03/06/2000	In follow-up to a telephone conversation on March 1, 2000 regarding Study B351, provided additional comments on dose justification and pharmacokinetic data availability to support initiation of the trial.	138	B351	Clinical Information Amendr
52,003	Certican®	03/01/2000	TELECON WITH FDA soliciting FDA comment on the pediatric de novo kidney protocol B351, submitted on February 4, 2000. The protocol is still in the process of being discussed by the Division and a decision to request a teleconference has not yet been made. Novartis will obtain additional information to address the Clinical Pharmacology reviewer's comments on the study communicated to Novartis during the teleconference.			Memo of Record (telephone report)
52,003	Certican®	02/28/2000	Point by point response to FDA comments communicated to Novartis on February 16, 2000 relating to Study IA06.	137	IA06	Response to FDA Request

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	02/28/2000	TELECON WITH FDA to confirm Novartis' request for a teleconference to discuss an amendment to RAD transplant studies to avoid confusing results in cases where patients are switched to an alternate cyclosporine product during the RAD registration program. The FDA suggested a teleconference on March 15, 2000.				Memo of Record (telephone report)
52,003	Certican®	02/25/2000	[Australia]; Dr. R. Rigby; hemolysis. Follow-up # 2.	136	CRAD001B2		Safety Report
52,003	Certican®	02/24/2000	Provided the FDA with Novartis' minutes of the pre-NDA Chemistry Manufacturing and Controls meeting that took place on January 27, 2000 with the FDA.	135			FDA/Novartis Meeting Minu
52,003	Certican®	02/24/2000	New Protocol, Study B258 entitled, "Multicenter, open-label, single oral dose pharmacokinetic, safety and tolerability study of RAD001 in pediatric stable liver transplant patients". New investigator: Estella M. Alonso, MD.	134	B258		New Investigator New Protocol
52,003	Certican®	02/24/2000	In response to the Pharmacology-Toxicology reviewer's questions with regard to the dose selection for the RAD carcinogenicity studies in rats and mice, provided the following documents: Summary discussion on dose justification; Report 973228, "SDZ RAD-Oncogenicity study by oral gavage administration to Hanibm Wistar rats for 104 weeks"; Report 973229, "SDZ RAD-Oncogenicity study by oral gavage administration to CD-1 mice for 104 weeks". Complete submission in 12 volumes.	133			Preclinical Amendment
52,003	Certican®	02/16/2000	[Spain]; Dr. Segovia; renal failure acute, follow-up # 2.	132	CRAD001B2		Safety Report
52,003	Certican®	02/16/2000	FAX FROM FDA providing comments relating to Study IA06, Serial No. 118.		IA06		
52,003	Certican®	02/10/2000	In response to FDA request to obtain information to evaluate interethnic variability regarding pharmacokinetics in the Hispanic population of Study B251, Novartis requested the study coordinators to confirm the ethnicity of Hispanic patients in Study B251.	131			Clinical Information Amendr
52,003	Certican®	02/07/2000	Point-by-point response to FDA facsimile dated December 16, 1999 which contained requests from the clinical pharmacologist. The response provided information on synopsis for Study W301 and PK data and information on RAD food effect to be evaluated in Study W302 and B201.	130			Response to FDA Request
52,003	Certican®	02/07/2000	Amendment 1 to Protocol CRAD001 0101. Additionally, included is available information to provide justification for the participation of liver transplant patients in Study 0101	129	0101		Change In Protocol
52,003	Certican®	02/07/2000	FDA FAX which includes the names of the Novartis and FDA representatives who will attend the January 27, 2000 meeting to discuss the stability protocols for RAD001.				
52,003	Certican®	02/06/2000	TELECON FROM FDA in follow-up to Novartis' request for authorization to use the trademark Certican for RAD. The agency outlined the current FDA process for nomenclature review and approval.				Memo of Record (telephone report)
52,003	Certican®	02/04/2000	New Protocol, Study CRAD001 B351, "Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients". Also included is Study CRAD001 B257, "Multicenter, open-label, single-oral dose pharmacokinetic, safety and tolerability study of RAD001 in pediatric stable renal transplant patients", Interim pharmacokinetic report. Additionally, requested is a written response to Novartis' submission of October 29,	128	B351B257		New Protocol

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	02/03/2000	FAX from FDA requesting information relating to the dissolution data submitted in the pre-NDA briefing package of November 1, 1999, Serial No. 104.				
52,003	Certican®	02/01/2000	In follow-up to the Division's concerns regarding interactions between RAD and different cyclosporine formulations expressed during the December 3, 1999 pre-NDA meeting, Novartis requested a teleconference with the Division to agree on the necessary protocol amendments to ensure that the RAD registration database and FDA's review of it are not compromised if multiple cyclosporine products with different bioavailability profiles are co-administered with RAD during the clinical program.	127			
52,003	Certican®	02/01/2000	[Belgium]; Dr. Maimone; hepatitis cholestatic, hepatic function abnormal, fever, anemia, follow-up #2	126	CRAD001B2	Safety Report	
52,003	Certican®	01/31/2000	Provided additional information requested by the FDA for review of Novartis' request for confirmation for the use of the proprietary tradename Certican. A letter from the European Agency for the Evaluation of Medicinal Products authorizing the use of the proposed tradename Certican is also included in the submission.	125			Response to FDA Request
52,003	Certican®	01/27/2000	Minutes from the January 27, 2000 CMC pre-NDA meeting with the FDA.				FDA/Novartis Meeting Minu
52,003	Certican®	01/19/2000	[CANADA]; hepatic function abnormal, follow-up 3.	124	CRAD001B2	Safety Report	
52,003	Certican®	01/18/2000	Documentation which provides for a new process for the stabilization of RAD 001 drug substance. This submission also provides information on new clinical materials of RAD 001, 0.25, 0.5 and 1 mg tablets. Updated documents include: drug product composition, manufacturing formula and method of preparation and stability data, dated 8-Jun-99.	123			CMC Amendment
52,003	Certican®	01/14/2000	New investigator to Protocol 251: James R. Thistlethwaite, Jr. MD, PhD. Also delete Dr. E Steve Woodle, principal investigator for Protocol 251.	121	B251		New Investigator
52,003	Certican®	01/14/2000	[GERMANY]; Neuropathy, follow-up 1.	122	CRAD001B2	Safety Report	
52,003	Certican®	01/12/2000	Novartis requested confirmation from the Division regarding the acceptance for use of the proprietary tradename Certican. Also included in the correspondence is an acknowledgment letter from the director, USAN Program, indicating that the USAN Council adopted "everolimus" as the US Adopted Name (USAN) for Novartis' immunosuppressant RAD001.	120			
52,003	Certican®	01/10/2000	Briefing book provided to the FDA in preparation for the meeting scheduled for 27-Jan-2000 to discuss CMC issues.	119			Briefing Book
52,003	Certican®	01/07/2000	New Protocol IA06 entitled, "A multi-center, open label, exploratory study to assess the safety and tolerability of Simulect, Neoral, RAD and steroids for the prevention of acute rejection in diabetic patients undergoing simultaneous pancreas-kidney transplantation".	118	IA06		New Protocol
52,003	Certican®	12/23/99	Novartis' minutes of the 12/3/99 pre-NDA meeting with the FDA for RAD001 for the indication of prevention of rejection in solid organ transplantation.	117			General Correspondence
52,003	Certican®	12/21/99	TELECON WITH FDA to discuss the RAD compassionate need protocol 0101 (ser. no. 108). The agency expressed concerns with the inclusion criteria and the dose justification for liver patients. Additional information is requested.				Memo of Record (telephone report)

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	12/16/99	TELECON FROM FDA requesting Novartis' availability for a meeting on January 27, 2000 to discuss the stability program and protocol for RAD. Novartis would like to discuss additional CMC questions at the meeting.			Memo of Record (telephone report)
52,003	Certican®	12/16/99	FDA FAX which includes requests from the reviewing clinical pharmacologist related to the December 3, 1999 pre-NDA meeting for RAD001.			
52,003	Certican®	12/15/99	Requested a teleconference with the FDA to discuss the following new protocol, Study CRAD001 IA04, "A multi-center, open label, single arm, exploratory study to assess the safety and tolerability of reduced-dose tacrolimus with RAD001 in maintenance renal transplant recipients with renal insufficiency".	116	IA04	
52,003	Certican®	12/03/99	[Belgium] Dr. Maimone; hepatitis cholestatic, hepatic function abnormal, fever, asthenia, follow-up.	115	CRAD001B2	Safety Report
52,003	Certican®	12/02/99	[Spain] Dr. Javier Segovia; renal failure acute, follow-up.	114	CRAD001B2	Safety Report
52,003	Certican®	11/30/99	Novartis provided an alternate proposal for discussion at the pre-NDA meeting scheduled for December 3, 1999.	113		Other
52,003	Certican®	11/23/99	[Canada] Site 84; hepatic function abnormal, follow-up.	111	CRAD001B2	Safety Report
52,003	Certican®	11/23/99	[Germany] Dr. B. Nonnast-Daniel; neuropathy.	112	CRAD001B2	Safety Report
52,003	Certican®	11/17/99	Submitted the following new investigator to Protocol No. 159; Kenneth R. McCurry, MD.	110	159	New Investigator
52,003	Certican®	11/12/99	New Protocol CRAD001 0101 entitled, "Compassionate use of RAD prior to registration in heart, kidney, liver and lung transplant patients".	108	0101	New Protocol
52,003	Certican®	11/12/99	[Belgium] Dr. Maimone; hepatitis cholestatic, hepatic function abnormal, fever, asthenia.	109		Safety Report
52,003	Certican®	11/12/99	[Canada] Site 84; hepatic functional abnormal, follow-up.	107		Safety Report
52,003	Certican®	11/12/99	Baz, Maher, MD; haemolysis, follow-up.	106		Safety Report
52,003	Certican®	11/03/99	[Canada] Site 84; hepatic function abnormal.	105		Safety Report
52,003	Certican®	11/01/99	As requested in the FDA letter dated 10/12/99 acknowledging Novartis' pre-NDA meeting request, provided pre-NDA briefing book which contains background information included in 2 volumes.	104		Briefing Book
52,003	Certican®	10/29/99	Submitted documentation to provide a Proposed Pediatric Study Request for RAD001 and to request the issuance of a Written Request. The enclosed information consists of proposed pediatric program, study synopses and examples of formatted reports.	103		
52,003	Certican®	10/28/99	[Canada] Houde, Isabelle, MD; NPN increased, drug-drug interaction (symptom specified), epididymitis, drug level increased, follow-up.	102		Safety Report
52,003	Certican®	10/21/99	Valantine, Hannah, MD; hepatic function abnormal, hyperlipaemia, drug level increased, graft rejection, cardiac failure left.	101		Safety Report
52,003	Certican®	10/12/99	[Argentina] Kaplinsky, Edgardo, MD; hepatic function abnormal, renal failure acute, tremor, follow-up.	100		Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	10/12/99	FDA LETTER responding to Novartis' 9/27/99 correspondence requesting a pre-NDA meeting. The FDA indicated that the meeting has been scheduled for December 3, 1999. If the background information for this meeting is not received by the agency one month prior to the meeting, rescheduling of the meeting may be necessary.				
52,003	Certican®	10/07/99	TELECON from FDA informing Novartis that the Pre-NDA meeting will be held on December 3, 1999. It was also noted that a separate meeting for the CMC issues might be requested.				Memo of Record (telephone report)
52,003	Certican®	10/06/99	[Australia] Dr. Josette Eris; hepatic function abnormal.	099			Safety Report
52,003	Certican®	10/04/99	A point by point response is provided to the Division on additional information requested for Serial No. 048 (15-day report for CRAD001/B158/0/102/2/1/D).	098			
52,003	Certican®	10/01/99	Gonwa, Thomas, MD; purpura thrombocytopenic, graft rejection, renal tubular necrosis, hypertension, glomerulonephritis.	097			Safety Report
52,003	Certican®	09/27/99	Burdick, James, MD; cardiomyopathy, cardiac failure, oedema generalised, pleural effusion, myocardial ischaemia, hepatic function abnormal, follow-up.	096			Safety Report
52,003	Certican®	09/27/99	This submission requests a Pre-NDA meeting to discuss the content and format requirements for the RAD001 Tablet NDA. A table of contents from the briefing book currently in preparation is included.	095			Request for FDA Meeting
52,003	Certican®	09/21/99	FAX from FDA containing comments from the reviewing clinical pharmacologist on amendment to protocol B257 (Serial No. 077).		B257		
52,003	Certican®	09/20/99	[Germany] Prof. Neubaus; face oedema, follow-up.	094			Safety Report
52,003	Certican®	09/17/99	[Germany] Dr. Budde; renal failure acute, nephropathy toxic.	093			Safety Report
52,003	Certican®	09/15/99	Langas, Alan, DO; chest pain, hypertension pulmonary, renal failure acute, anaemia haemolytic, emphysema, pleural effusion, atrial flutter, cardiac arrest.	091			Safety Report
52,003	Certican®	09/14/99	[Spain] Dr. Javier Segovia; renal failure acute.	090			Safety Report
52,003	Certican®	09/14/99	[Canada] Houde, Isabelle, MD; NPN increased, drug-drug interaction (symptom specified), epididymitis, drug level increased, follow-up.	089			Safety Report
52,003	Certican®	09/14/99	[Canada] Houde, Isabelle, MD; NPN increased, drug-drug interaction (symptom specified), epididymitis, drug level increased, follow-up.	088			
52,003	Certican®	09/10/99	Baz, Maher, MD; haemolysis.	087			Safety Report
52,003	Certican®	09/08/99	New investigator for Protocol 156: Alan H. Wilkinson, MD. Also provided for Charlotte M. McKee, new investigator for Protocol 159, and for Drs. Roberts Ettenger and Jacques Lemire, new investigators for Protocol 257.	086	156/159/257		New Investigator
52,003	Certican®	09/02/99	Rajagopalan, P.R., MD; gastritis, thrombocytopenia, weight decrease, follow-up.	085			Safety Report
52,003	Certican®	09/02/99	[Argentina] Kaplinski, Edgardo, MD; hepatic functional abnormal, renal failure acute, tremor.	084			Safety Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	09/02/99	[Canada] Houde, Isabelle, MD; NPN increased, drug-drug interaction (symptom specified), epididymitis, drug level increased, follow-up (MedWatch).				Safety Report
52,003	Certican®	09/01/99	[Germany] Prof. Neubas; face oedema.	083			Safety Report
52,003	Certican®	08/27/99	[Australia] hepatic functional abnormal, follow-up.	082			Safety Report
52,003	Certican®	08/24/99	[France] Thubanroyn Danielen; haemolytic, follow-up.	081			Safety Report
52,003	Certican®	08/17/99	[France] Thubanroyn Danielen; haemolysis, follow-up.	080			Safety Report
52,003	Certican®	08/12/99	[France] Thubanroyn Danielen; haemolysis.	079			Safety Report
52,003	Certican®	08/12/99	[Canada] Houde, Isabelle, MD; NPN increased, drug-drug interaction (symptom specified), epididymitis, Drug level increased.	078			Safety Report
52,003	Certican®	08/12/99	Submitted change to Protocol B257 entitled: Amendment No.1.	077	B257		Change In Protocol
52,003	Certican®	08/11/99	[Australia] Dr. Josette Eris; hepatic functional abnormal.	076			Safety Report
52,003	Certican®	08/10/99	New subinvestigators for , Protocol B158 investigator. Also Hans Sollinger, MD, PhD has been added as a new investigator for Protocol B156 and John Mahan, MD has been added as a new investigator for Protocol B257.	074	B158/B156/E		New Investigator
52,003	Certican®	08/10/99	[Australia] Dr. R. Rigby; haemolysis, follow-up.	075			Safety Report
52,003	Certican®	08/05/99	FDA LETTER providing comments of Novartis' response to comment 3 (distribution of patients in each age strata) included in FDA fax of 6/25/99 regarding Protocol B257.		B257		
52,003	Certican®	07/22/99	TELECON TO FDA to obtain feedback on Novartis' response dated 7/9/99 to FDA questions faxed 6/25/99 regarding pediatric Protocol B257.		B257		Memo of Record (telephone report)
52,003	Certican®	07/19/99	Hauptman, Paul, MD; renal failure acute, renal tubular necrosis, embolism - blood clot, pericardial effusion, pleural effusion, follow-up.	073			Safety Report
52,003	Certican®	07/16/99	New investigators: P. R. Rajagopalan, MD; for Protocol B156; S. Forrest Dodson, MD; and Russell Wiesner, MD for Protocol B158; Stacy F. Davis for Protocol B253.	072	156/158/253		New Investigator
52,003	Certican®	07/15/99	Point by point response to the 5/24/99 teleconference minutes provided in the FDA communication dated 6/21/99. Novartis also requested written comments from the FDA on proposals for study B159.	071	B159		
52,003	Certican®	07/09/99	Point by point response to the FDA review comments to Protocol B257 included in the 6/25/99 communication.	070	B257		
52,003	Certican®	07/07/99	[Germany] Dr. Kehle; lymphoedema, oedema legs.	068			Safety Report
52,003	Certican®	07/07/99	[Australia] Dr. R. Rigby; haemolysis.	069	B257		Safety Report
52,003	Certican®	07/06/99	[France] Prof. Nourad; haemolysis, nephropathy toxic.	067			Safety Report
52,003	Certican®	07/01/99	Annual report covering the period from 15-Nov-97 through 14-Nov-98. Includes Preclinical, Clinical, CMC, information as well as a new General Investigational Plan For The Coming Year.	066			Annual Report

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	06/30/99	Valentine, V.; sepsis, renal failure acute, respiratory insufficiency, dyspnoea, thrombocytopenia, GI Haemorrhage, drug level increased, hyperglycaemia, death, follow-up.	065		Safety Report
52,003	Certican®	06/23/99	Also provided new investigator Barry D. Kahan, MD to Protocol 156.	064	156	New Investigator
52,003	Certican®	06/21/99	Valentine, V.; respiratory insufficiency, dyspnoea, renal failure acute, thrombocytopenia, GI haemorrhage, nephropathy toxic.	063		Safety Report
52,003	Certican®	06/17/99	In response to FDA request communicated in the 6/1/99 teleconference, provided additional clarification to the submission of Amendment 1 for study 156, Serial No. 052.	062	156	Other
52,003	Certican®	06/03/99	In response to FDA request of 6/2/99, provided desk copies of Protocol B257, submission dated 5/24/99.	060	B257	Other
52,003	Certican®	06/03/99	TELECON FROM FDA requesting additional copies of pediatric protocol 257.			Memo of Record (telephone report)
52,003	Certican®	06/02/99	Registration Stability Protocol RAD001A (SDZ RAD) 0.25mg, 0.5mg, 1mg tablets, 1RSP98 1870, 9-Nov-98.	058		CMC Amendment
52,003	Certican®	05/24/99	Study CRAD001 B257 new protocol. Also includes CMC information amendment providing information on the new RAD001 0.1 and 0.25mg fast dispersible tablets-pediatric formulation. (PS)	056		CMC Amendment New Protocol
52,003	Certican®	05/21/99	Initial report CRAD001B158010221D (PS)	055		Safety Report
52,003	Certican®	05/14/99	Response to FDA request for copies of published literature cited in our submission dated April 14, 1999 SN049. (PS)	054		Response to FDA Request
52,003	Certican®	05/13/99	Studies RADB 152, RADB 253 new investigator (PS).	053		New Investigator
52,003	Certican®	04/29/99	Study RADB 156 change in protocol, amendment 1. (PS)	052		Change In Protocol
52,003	Certican®	04/26/99	Novartis requests confirmation from FDA regarding the acceptance for use of the trademark Certican. (PS)	051		Other
52,003	Certican®	04/23/99	Amendment 1 to Protocol RADB 251.	050	251	Clinical Information Amendr
52,003	Certican®	04/14/99	Response to FDA correspondence dated 11/24/98 which raised several medical and statistical issues regarding Study B 159.	049	B 159	Clinical Information Amendr
52,003	Certican®	04/09/99	Also provided for Dr. Nghiem.	047	B 251	New Investigator
52,003	Certican®	04/09/99	Also provided for Dr. Freeman, new investigator for Protocol RADB 158.	047	B 158	New Investigator
52,003	Certican®	04/09/99	Also provided for Dr. McCurry.	047	B 253	New Investigator
52,003	Certican®	04/09/99	Also provided for Dr. Kinkhabwala.	047	B 251	New Investigator
52,003	Certican®	04/09/99	Also provided for Dr. Kaplan, new investigator for Protocol RADB 156.	047	B 156	New Investigator
52,003	Certican®	04/09/99	Submitted the following new investigators to Protocol RADB 251: Drs. Cohen, Nghiem and Kinkhabwala.	047	B 251	New Investigator
52,003	Certican®	04/09/99	Also submitted the following new investigators to Protocol RADB 253: Dr. Kobashigawa and McCurry.	047	B253	New Investigator
52,003	Certican®	04/05/99	Point by point response to FDA letter dated 1/20/98 which raised several statistical issues regarding Study RADB 156.	046	B 156	Clinical Information Amendr

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	03/30/99	Burdick, J.; cardiomyopathy, cardiac failure, pleural effusion, oedema generalised, hepatic function abnormal, myocardial ischaemia.	045	B251	Safety Report
52,003	Certican®	03/11/99	Study RADB 158 change in protocol, amendment 1. Study RADB 159 change in protocol, amendment 1. Study RADB253 change in protocol amendment 1 and 2. (PS)	044		Change In Protocol
52,003	Certican®	03/08/99	Submitted the following new investigator to Protocol RADB 159: Dr. Lawrence.	043	RADB159	New Investigator
52,003	Certican®	03/04/99	Submitted the following new investigator to Protocol RADB 159: Dr. Davis.	042	RADB159	New Investigator
52,003	Certican®	03/04/99	Also submitted the following new investigators to Protocol RADB 251: Drs. Leichtman, Harland, Thompson and Johnson.	042	RADB251	New Investigator
52,003	Certican®	03/04/99	Also provided for Dr. Johnson.	042	RADB251	New Investigator
52,003	Certican®	03/04/99	Also provided for Dr. Thompson.	042	RADB251	New Investigator
52,003	Certican®	03/04/99	Also submitted the following new investigator to Protocol RADB 253: Dr. Hill.	042	RADB253	New Investigator
52,003	Certican®	03/02/99	Submitted the following technical documentation: Drug product manufacture, MANU_CP_967_1 and Drug product composition and container, COMP_CP_967_1, dated 9-Apr-98: KN 3845403.00.005, 0.25 mg tablets; KN 3749215.00.002, 0.5 mg tablets; KN 3745411.00.005, 1 mg tablets.	041		CMC Amendment
52,003	Certican®	03/02/99	Also included Stability Report SDZ RAD solid dispersion, 5U97 1769, dated 7-Jan-98. **SDZ RAD 0.25mg, 0.5mg, 1mg, 5mg, 10mg and placebo tablets, Stability Report for development batches, 5U98 1800, dated 24-Apr-98.	041		CMC Amendment
52,003	Certican®	02/10/99	Submitted the following co-investigators for Protocol RADB 251: Wilkinson and Danovitch.	039	B251	New Investigator
52,003	Certican®	02/10/99	Also provided for Dr. Danovitch.	039	B251	New Investigator
52,003	Certican®	02/10/99	Also provided for Dr. Orens.	040	B 159	New Investigator
52,003	Certican®	02/10/99	Also provided for Drs. Woodle and Neylan, Protocol B251 investigators.	040	B 251	New Investigator
52,003	Certican®	02/10/99	Also provided for Dr. Neylan.	040	B 251	New Investigator
52,003	Certican®	02/10/99	Also provided for Drs. Andrew L. Smith and Lindenfeld, Protocol B253 investigators.	040	B 253	New Investigator
52,003	Certican®	02/10/99	New investigator for Protocol RADB 158: Dr. Abecassis.	040	B 158	New Investigator
52,003	Certican®	02/10/99	Also provided for Drs. Valentine and Orens, new investigators for Protocol B159.	040	B 159	New Investigator
52,003	Certican®	02/10/99	Also provided for Dr. Lindenfeld.	040	B 253	New Investigator
52,003	Certican®	01/14/99	Submitted the following new investigators to Protocol RADB 159: Drs. Rosengard and Loyd.	038	RADB 159	New Investigator
52,003	Certican®	01/14/99	Also submitted the following new investigator to Protocol RADB 253: Dr. Hare.	038	RADB 253	New Investigator
52,003	Certican®	01/14/99	Also provided for Dr. Loyd.	038	RADB 159	New Investigator

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	12/14/98	New protocol RADB 156, "A 3 year, multicenter, randomized, open label, parallel group study of the efficacy and safety of RAD tablets given in conjunction with Simulect, corticosteroids and either full or reduced dose Neoral in de novo renal transplant recipients". Also provided for Dr. Curtis.	036	B156	Clinical Information Amendr New Investigator New Protocol
52,003	Certican®	11/20/98	Also provided for Dr. Van Buren.	035	251	New Investigator
52,003	Certican®	11/20/98	Also provided for Dr. Hauptman.	035	253	New Investigator
52,003	Certican®	11/20/98	Also provided for Dr. Miller.	035	253	New Investigator
52,003	Certican®	11/20/98	Also provided for Dr. Aris.	035	159	New Investigator
52,003	Certican®	11/20/98	Also submitted the following new investigators to Protocol RADB 253: Drs. Frazier, Hauptman, Miller.	035	253	New Investigator
52,003	Certican®	11/20/98	Submitted the following new investigators to Protocol RADB 159: Drs. Frost, Mullett, Aris.	035	159	New Investigator
52,003	Certican®	10/27/98	Also provided for Dr. Wombolt.	034	251	New Investigator
52,003	Certican®	10/27/98	Also provided for Dr. Lorber.	034	251	New Investigator
52,003	Certican®	10/27/98	Also provided for Dr. Ouseph (co-investigator).	034	251	New Investigator
52,003	Certican®	10/27/98	Also provided for Dr. Burrows.	034	251	New Investigator
52,003	Certican®	10/27/98	Also submitted the following new investigator for Protocol RADB 159: Dr. Maurer.	034	159	New Investigator
52,003	Certican®	10/27/98	Also provided for Dr. Mancini.	034	253	New Investigator
52,003	Certican®	10/27/98	Also provided for Dr. Hricik.	034	251	New Investigator
52,003	Certican®	10/27/98	Also provided for Dr. Renlund.	034	253	New Investigator
52,003	Certican®	10/27/98	Submitted the following new investigator to Protocol RADB 157: Dr. Min (who replaces Dr. Elkhammas).	034	157	New Investigator
52,003	Certican®	10/27/98	Also submitted the following investigators to Protocol RADB 251: Drs. Farney, Hricik, Lorber, Burrows, Wombolt, and Jones and Ouseph (co-investigators).	034	251	New Investigator
52,003	Certican®	10/13/98	Also submitted the following new investigators to Protocol RADB 159: Drs. Garrity, McGiffin (co- investigator), and Young (co-investigator).	033	159	New Investigator
52,003	Certican®	10/13/98	Also provided for Dr. Matas.	033	251	New Investigator
52,003	Certican®	10/13/98	Also provided for Dr. Starling.	033	253	New Investigator
52,003	Certican®	10/13/98	Also submitted the following new investigators to Protocol RADB 251: Drs. Dunn, Matas.	033	251	New Investigator
52,003	Certican®	10/13/98	Also provided for Dr. Young.	033	159	New Investigator
52,003	Certican®	10/13/98	Submitted the following new investigator to Protocol RADB 152: Dr. Rosengard.	033	152	New Investigator
52,003	Certican®	09/25/98	Annual Report covering the period November 15, 1996 to November 14, 1997 (PS).	031		Annual Report
52,003	Certican®	09/25/98	Also submitted the following new investigators to Protocol RADB 158: Drs. Langnas, Merion.	032	158	New Investigator
52,003	Certican®	09/25/98	Also provided for Dr. Trulock.	032	159	New Investigator

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	09/25/98	Also provided for Dr. Merlon.	032	158	New Investigator
52,003	Certican®	09/25/98	Also provided for Dr. Pruett.	032	251	New Investigator
52,003	Certican®	09/25/98	Also provided for Dr. Doyle.	032	159	New Investigator
52,003	Certican®	09/25/98	Also submitted the following new investigators to Protocol RADB 251: Drs. Barone, Conti, Elkhammas, Pollack, Pruett, Burdick, Kahan.	032	251	New Investigator
52,003	Certican®	09/25/98	Also provided for Dr. Conti.	032	251	New Investigator
52,003	Certican®	09/25/98	Also provided for Dr. Elkhammas.	032	251	New Investigator
52,003	Certican®	09/25/98	Also provided for Dr. Baz.	032	159	New Investigator
52,003	Certican®	09/25/98	Also provided for Dr. Kahan.	032	251	New Investigator
52,003	Certican®	09/25/98	Also submitted the following new investigators to Protocol RADB 159: Drs. Hertz, Doyle, Trulock, Baz.	032	159	New Investigator
52,003	Certican®	09/25/98	Submitted the following new investigator to Protocol RADB 152: Dr. McCurry.	032	152	New Investigator
52,003	Certican®	09/10/98	Fax from Dr. Self, UK, providing DRA with a copy of the MCA CTX approval letters for studies RADB 201-E-00 and 159.			
52,003	Certican®	08/27/98	Studies RADB151, RADB152, RADB157, RADB159, RADB251 new investigator (PS).	030		New Investigator
52,003	Certican®	08/27/98	Novartis telecon meeting minutes from meeting held with FDA on August 25, 1998 to discuss points of clarification to the FDA communication dated August 20, 1998. (PS)	030		FDA/Novartis Meeting Minu
52,003	Certican®	08/25/98	Studies RADB151, RADB152, RADB157, RADB159, RADB251 new investigator (PS).	029		New Investigator
52,003	Certican®	08/19/98	Study RADB 253 new protocol (PS).	028		New Protocol
52,003	Certican®	08/12/98	Study RADB158 new protocol. (PS)	027		New Protocol
52,003	Certican®	08/09/98	Study RADB 251 new protocol (PS)	023		New Protocol
52,003	Certican®	08/04/98	Communication to FDA regarding 52-week oral (gavage) toxicity study 1463-045 in the cynomolgus monkey. (PS)	026		Preclinical Amendment
52,003	Certican®	07/24/98	Study RADB 159 new protocol (PS).	025		New Protocol
52,003	Certican®	07/09/98	Also submitted the following new investigator to Protocol RADB 157: Dr. Tomlanovich.	024	157	New Investigator
52,003	Certican®	07/09/98	Also provided for Dr. Davis.	024	152	New Investigator
52,003	Certican®	07/09/98	Submitted the following new investigators to Protocol RADB 152: Drs. Garrity, Davis.	024	152	New Investigator
52,003	Certican®	07/07/98	Novartis requested the FDA to accept the firm's rationale for the termination of study 1463-045, a 52 week oral (gavage) toxicity study in the cynomolgus monkey, being conducted at Covance Laboratories GmbH, Germany. The study was terminated at week 39 due to the observed tolerability problems in several dose groups.			Preclinical Amendment
52,003	Certican®	06/08/98	Submitted an overview of safety reporting in Phase 2-3 RAD 022 trials per request by the Division at a March 11, 1998 meeting.	022		Clinical Information Amendr

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION	TYPE
52,003	Certican®	05/20/98	Study RADB 152, RADB 157 new investigator (PS)	020			New Investigator
52,003	Certican®	05/01/98	Submitted per request at the 3/11/98 meeting with the FDA the following carcinogenicity protocols for review: SDZ RAD: Oncogenicity Study By Oral Gavage Administration To Hanibm Wistar Rats for 104 Weeks (Doc. No. 203-069) and Amendments 1-9 and SDZ RAD: Oncogenicity Study By Oral Gavage Administration to CD-1 Mice for 90 Weeks (Doc. No. 203-082) and Amendments 1-7.	019			Preclinical Amendment
52,003	Certican®	04/22/98	Document 203-082 range finding toxicity study by oral gavage administration to CD-1 mice for 13 weeks. (PS)	018			Preclinical Amendment
52,003	Certican®	04/17/98	Study RADB 152 new investigator (PS)	017			New Investigator
52,003	Certican®	03/27/98	Submitted a summary of the discussion and agreements of the meeting held on March 11, 1998 between Novartis, consultants and the FDA to discuss the clinical development program for RAD.				Clinical Information Amendr
52,003	Certican®	03/02/98	FDA FAX: Review of the End-of-Phase 2 Meeting Request Package and comments and recommendations that the Division would like Novartis to be prepared to discuss at the March 11, 1998 meeting.				
52,003	Certican®	02/18/98	Study RADB 157 change in protocol. (PS)	015			Change in Protocol
52,003	Certican®	02/18/98	New Protocol RADB 152 entitled "A One Year Randomized, Multicenter, Open-Label, Parallel, Group Study of the Efficacy and Safety of SDZ RAD Tablets Versus Antilymphocyte Globulin and Azathioprine in Lung or Heart/Lung Transplant Receipients with Bronchiolitis Obliterans Syndrome." Also submitted Amendment Nos. 1 and 2.	016	RADB 152		Clinical Information Amendr New Protocol
52,003	Certican®	02/02/98	Letter requesting an End-of-Phase 2 meeting to present the clinical development program. Also submitted was a comprehensive Briefing Book.	014			Briefing Book Request for FDA Meeting
52,003	Certican®	01/26/98	An Information Amendment submitting complete reproductive toxicology reports (please note that an "R" is placed prior to the submissions that contain full reports, all other studies are summary reports). Document Nos.: *203-069, *203-072, *203-077, *203-074, *203-073, *203-076, 203-068, 203-070, 203-461, 203-071, 203-062, 203-063, 203-067, 203-037, 203-036, 203-078, 203-075.	013			Preclinical Amendment
52,003	Certican®	01/20/98	FDA FAX providing the statisticians review comments on Protocol for Study RADB 156.				
52,003	Certican®	01/16/98	Submitted new protocol: Protocol RADB 157-E-00, A One-Year, Multicenter, Randomized, Double-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SDZ RAD in De Novo Renal Transplant Recipients.	012	RADB157-E-		Clinical Information Amendr New Protocol
52,003	Certican®	01/16/98	Also submitted Amendment No. 1 to Protocol RADB 157. Also the following new investigator: Dr. Elkhammas.	012	RADB 157		Clinical Information Amendr New Investigator
52,003	Certican®	01/16/98	Also included the following stability reports: RAD Solid Dispersion, Stability Report 3U96 1769, dated 15-Nov-96. **RAD Tablets, 0.25 mg, 1 mg, 5 mg, 10 mg, Stability Report 1U97 1800, dated 8-Feb-97.	012			CMC Amendment

REF	PRODUC	DATE	DESCRIPTION	SERI	PROTOCOL	SUBMISSION TYPE
52,003	Certican®	01/16/98	Also provided documentation to support the following formulations: Description of the Manufacturing and Packaging: KN3745346.00.001, 2% RAD solid dispersion, KN 3744448.00.002, 9.09% RAD solid dispersion, KN 3745403.00.002, 0.25 mg tablet, KN 3745411.00.002, 1 mg tablet, KN 3745429.00.002, 5 mg tablet, KN 3745437.00.002, 10 mg tablet. Also included placebo drug product information.	012		CMC Amendment
52,003	Certican®	09/25/97	Study RADB 151 new investigator (PS).	011		New Investigator
52,003	Certican®	09/04/97	Follow-up safety report RADW1020641N (PS)	010		Safety Report
52,003	Certican®	03/21/97	Response to FDA correspondence dated February 3, 1997 which provided IND review comments and requests for additional information. (PS)	007		Response to FDA Request
52,003	Certican®	03/03/97	Study RADB 151 new investigator (PS).	006		New Investigator
52,003	Certican®	02/12/97	Change in Company Name To Novartis (PS).	005		Other
52,003	Certican®	01/31/97	Study RADB 202 change in protocol, amendment 1. (PS)	002		Change In Protocol
52,003	Certican®	01/31/97	Study RADB 154 change in protocol, amendment 1. (PS)	003		Change In Protocol
52,003	Certican®	01/31/97	Study RADB 151 change in protocol, amendment 1. (PS)	004		Change In Protocol
52,003	Certican®	01/28/97	Update Form 1572 to add New Clinical Lab Facility for Study B154. (PS)	001		Clinical Information Amendr
52,003	Certican®	11/25/96	Acknowledge receipt of original IND for prophylaxis of organ rejection.			Other
52,003	Certican®	11/15/96	Submission of Original IND for prophylaxis of organ rejection. (PS)	000		Original IND



UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 24 2009

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

The attached application for patent term extension of U.S. Patent No. 5,665,772 was filed on May 18, 2009, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application, AFINITOR® (everolimus), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period beginning on the date the product was approved.¹ Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

¹The filing of the application on May 18, 2009, was timely, given the NDA approval date of March 30, 2009. Applicant, however, misidentified at section 5 on page 3 of the application the last day the application may be submitted as May 29, 2009, pursuant to 37 C.F.R. § 1.740(a)(5). Under both 35 U.S.C. § 156(d)(1) and 37 C.F.R. § 1.720(f), a PTE applicant has sixty days to submit a PTE application, with the first day of that sixty-day period beginning on the FDA approval date. The absolute deadline for filing the present PTE Application is thus May 28, 2009, or sixty days from March 30, 2009, starting the count of the sixty-day period on March 30, 2009. The Federal Circuit in *Unimed, Inc. v. Quigg*, 12 USPQ2d 1644, 1646, made clear that "section 156(d)(1) admits of no other meaning than that the sixty-day period begins on the FDA approval date."

U.S. Patent No. 5,665,772

Page 2

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).



Mary C. Till

Legal Advisor

Office of Patent Legal Administration

Office of the Deputy Commissioner

for Patent Examination Policy

cc: Gregory C. Houghton
Novartis Pharmaceuticals corp.
Patents Pharma
One Health Plaza, Bldg. 101
East Hanover, NJ 07936-1080



DEPARTMENT OF HEALTH & HUMAN SERVICES

SEP - 2 2009

Food and Drug Administration
Rockville MD 20857

Re: Afinitor
Docket No. FDA-2009-E-0413

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 5,665,772 filed by Novartis AG, under 35 U.S.C. § 156. The human drug product claimed by the patent is Afinitor (everolimus), which was assigned new drug application (NDA) No. 22-334.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1).

The NDA was approved on March 30, 2009, which makes the submission of the patent term extension application on May 18, 2009, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

Dudas - Afinitor
Patent No. 5,665,772
Page 2

cc: Gregory C. Houghton
Novartis Pharmaceuticals Corp
Patents Pharma
One Health Plaza, Bldg. 101
East Hanover, NJ 07936-1080



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

NOV 25 2009

Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 5,665,772. The application was filed on May 18, 2009, under 35 U.S.C. § 156.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Gregory C. Houghton
Novartis Pharmaceuticals corp.
Patents Pharma
One Health Plaza, Bldg. 101
East Hanover, NJ 07936-1080

RE: AFINTOR® (everolimus)
Docket No. FDA-2009-E-0413



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

MAR 24 2010

Re: Afinitor
Docket No.: FDA-2009-E-0413

The Honorable David J. Kappos
Undersecretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director-Kappos:

This is in regard to the application for patent term extension for U.S. Patent No. 5,665,772, filed by Novartis AG, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Afinitor (everolimus), the human drug product claimed by the patent.

The total length of the regulatory review period for Afinitor (everolimus) is 4,486 days. Of this time, 4,212 days occurred during the testing phase and 274 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: December 19, 1996.

FDA has verified the applicant's claim that the date the investigational new drug application became effective was on December 19, 1996.

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: June 30, 2008.

FDA has verified the applicant's claim that the new drug application (NDA) 22-334 was submitted on June 30, 2008.

3. The date the application was approved: March 30, 2009.


FDA has verified the applicant's claim that NDA 22-334 was approved on March 30, 2009.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Kappos - Afinitor
Patent No. 5,665,772
Page 2

Please let me know if we can be of further assistance.

Sincerely yours,



Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Gregory C. Houghton
Novartis Pharmaceuticals Corp
Patents Pharma
One Health Plaza, Bldg. 101
East Hanover, NJ 07936-1080

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN¹

Food Code Survey	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
Respondents	75	4	300	1	300

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

This estimate is based on FDA's experience and the number of updates received in the past 3 years. FDA estimates that 75 respondents will provide four quarterly updates each, resulting in an estimated 300 total annual responses. The agency estimates that each quarterly update will take about 1 hour. Of the 75 respondents, those who amend their regulations with changes unrelated to the risk factors and interventions, and those who are not adopting model FDA Food Code provisions, but are incorporating certain Conference for Food Protection recommendations only, will likely need only annual contact.

Dated: April 9, 2010.

Leslie Kux,

Acting Assistant Commissioner for Policy.

[FR Doc. 2010-8510 Filed 4-13-10; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-E-0413]

Determination of Regulatory Review Period for Purposes of Patent Extension; AFINITOR

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for AFINITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. **ADDRESSES:** Submit written comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.regulations.gov>.

FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration,

10903 New Hampshire Ave., Bldg. 51, rm. 6222, Silver Spring, MD 20993-0002, 301-796-3602.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product AFINITOR (everolimus). AFINITOR is indicated for treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for AFINITOR (U.S. Patent No. 5,665,772) from Novartis AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated September 2, 2009, FDA

advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of AFINITOR represented the first permitted commercial marketing or use of the product. Thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for AFINITOR is 4,486 days. Of this time, 4,212 days occurred during the testing phase of the regulatory review period, while 274 days occurred during the approval phase. These periods of time were derived from the following dates:

1. *The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) became effective:* December 19, 1996. FDA has verified the applicant's claim that the date the investigational new drug application became effective was on December 19, 1996.

2. *The date the application was initially submitted with respect to the human drug product under section 505(b) of the act:* June 30, 2008. FDA has verified the applicant's claim that the new drug application (NDA) 22-334 was submitted on June 30, 2008.

3. *The date the application was approved:* March 30, 2009. FDA has verified the applicant's claim that NDA 22-334 was approved on March 30, 2009.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,826 days of patent term extension.

Anyone with knowledge that any of the dates as published are incorrect may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments and ask for a redetermination by June 14, 2010. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by October 12, 2010. To meet its burden,

the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41–42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Division of Dockets Management. Three copies of any mailed information are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated: March 22, 2010.

Jane A. Axelrad,

Associate Director for Policy, Center for Drug Evaluation and Research.

[FR Doc. 2010-8443 Filed 4-13-10; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2009-E-0230 and FDA-2009-E-0231]

Determination of Regulatory Review Period for Purposes of Patent Extension; SAVELLA

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for SAVELLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.

ADDRESSES: Submit written comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.regulations.gov>.

FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6222, Silver Spring, MD 20993-0002, 301-796-3602.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and

Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product SAVELLA (milnacipran hydrochloride). SAVELLA is indicated for the management of fibromyalgia. Subsequent to this approval, the Patent and Trademark Office received patent term restoration applications for SAVELLA (U.S. Patent Nos. 6,602,911 and 6,992,110) from Cypress Bioscience, Inc., and the Patent and Trademark Office requested FDA's assistance in determining the patents' eligibility for patent term restoration. In a letter dated September 29, 2009, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of SAVELLA represented the first permitted commercial marketing or use of the product. Thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for SAVELLA is 2,571 days. Of this time, 2,177 days occurred during the testing phase of the regulatory review period, while 394 days occurred during the

approval phase. These periods of time were derived from the following dates:

1. *The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) became effective:* January 2, 2002. FDA has verified the applicant's claim that the date the investigational new drug application became effective was on January 2, 2002.

2. *The date the application was initially submitted with respect to the human drug product under section 505(b) of the act:* December 18, 2007. FDA has verified the applicant's claim that the new drug application (NDA) 22-256 was submitted on December 18, 2007.

3. *The date the application was approved:* January 14, 2009. FDA has verified the applicant's claim that NDA 22-256 was approved on January 14, 2009.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its applications for patent extension, this applicant seeks 435 days of patent term extension.

Anyone with knowledge that any of the dates as published are incorrect may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments and ask for a redetermination by June 14, 2010. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by October 12, 2010. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41–42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Division of Dockets Management. Three copies of any mailed information are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated: March 22, 2010.

Jane A. Axelrad,

Associate Director for Policy, Center for Drug Evaluation and Research.

[FR Doc. 2010-8518 Filed 4-13-10; 8:45 am]

BILLING CODE 4160-01-S



FEB 17 2011

Food and Drug Administration
Rockville, MD 20857

Re: Afinitor
Docket No. FDA-2009-E-0413

The Honorable David J. Kappos
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the patent term extension application for U.S. Patent No. 5,665,772 filed by Novartis AG under 35 U.S.C. § 156. The patent claims Afinitor (everolimus), new drug application (NDA) 22-334.

In the April 14, 2010, issue of the Federal Register (75 Fed. Reg. 19406), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before October 12, 2010, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Gregory C. Houghton
Novartis Pharmaceuticals Corp
Patents Pharma
One Health Plaza, Bldg. 101
East Hanover, NJ 07936-1080



MAY 31 2011

Gregory C. Houghton
Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Bldg. 101
East Hanover, NJ 07936-1080

In Re: Patent Term Extension
Application for
U.S. Patent No. 5,665,772

NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 5,665,772, claims of which cover the human drug product AFINITOR® (everolimus), is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be 5 years.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Director will issue a certificate of extension, under seal, for a period of 5 years.

The period of extension, if calculated using the Food and Drug Administration determination of the length of the regulatory review period published in the Federal Register of April 14, 2010 (75 Fed. Reg. 19406), would be 2,248 days. Under 35 U.S.C. § 156(c):

$$\begin{aligned}
\text{Period of Extension} &= \text{RRP} - \text{PGRRP} - \text{DD} - \frac{1}{2} (\text{TP} - \text{PGTP})^1 \\
&= 4,486 - 265 - 0 - \frac{1}{2} (4,212 - 265) \\
&= 2,248 \text{ days (6.2 years)}
\end{aligned}$$

Since the regulatory review period began December 19, 1996, before the patent issued (September 9, 1997), only that portion of the regulatory review period occurring after the date the patent issued has been considered in the above determination of the length of the extension period 35 U.S.C. § 156(c). (From December 19, 1996, to and including September 9, 1997, is 265 days; this period is subtracted for the number of days occurring in the testing phase according to the FDA determination of the length of the regulatory review period.) No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

However, the five year limitation of 35 U.S.C. § 156(g)(6)(A) applies in the present situation,

¹ Consistent with 35 U.S.C. § 156(c), "RRP" is the total number of days in the regulatory review period, "PGRRP" is the number of days of the RRP which were on and before the date on which the patent issued, "DD" is the number of days of the RRP that the applicant did not act with due diligence, "TP" is the testing phase period described in paragraphs (1)(B)(i), (2)(B)(i), (3)(B)(i), (4)(B)(i), and (5)(B)(i) of subsection (g) of 35 U.S.C. § 156, and "PGTP" is the number of days of the TP which were on and before the date on which the patent issued, wherein half days are ignored for purposes of the subtraction of 1/2 (TP - PGTP).

because the patent was issued after the date of enactment of 35 U.S.C. § 156. Since the period of extension calculated under 35 U.S.C. § 156(c) for the patent cannot exceed five years under 35 U.S.C. § 156(g)(6)(A), the period of extension will be for five years.

The 14 year limitation of 35 U.S.C. § 156(c)(3) does not operate to further reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.:	5,665,772
Granted:	September 9, 1997
Original Expiration Date ² :	September 9, 2014
Applicant:	Sylvain Cottens et al.
Owner of Record:	Novartis AG
Title:	O-Alkylated Rapamycin Derivatives and Their Use, Particularly as Immunosuppressants
Product Trade Name:	AFINITOR® (everolimus)
Term Extended:	5 years
Expiration Date of Extension:	September 9, 2019.


²Subject to the provisions of 35 U.S.C. § 41(b).

Any correspondence with respect to this matter should be addressed as follows:

By mail: Mail Stop Hatch-Waxman PTE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450.

By FAX: (571) 273-7755

Telephone inquiries related to this determination should be directed to Mary Till at (571) 272-7755.



Mary C. Till
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: AFINITOR® (everolimus)
Docket No.: FDA-2009-E-0413

Attention: Beverly Friedman



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

MAR - 6 2012

Gregory C. Houghton
Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Bldg. 101
East Hanover, NJ 07936-1080

In Re: Patent Term Extension
Application for
U.S. Patent No. 5,665,772

Dear Mr. Houghton:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 5,665,772 for a period of 5 years. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website:

<http://www.fda.gov/opacom/morechoices/fdaforms/default.html>
(<http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf>).

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at mary.till@uspto.gov.

Mary C. Till
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: AFINITOR® (everolimus)
Docket No.: FDA-2009-E-0413

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

(68) PATENT NO. : 5,665,772
(45) ISSUED : September 9, 1997
(75) INVENTOR : Sylvain Cottens et al.
(73) PATENT OWNER : Novartis AG
(95) PRODUCT : AFINITOR® (everolimus)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 5,665,772 based upon the regulatory review of the product AFINITOR® (everolimus) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 5 years

from September 9, 2014, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156.



I have caused the seal of the United States Patent and Trademark Office to be affixed this 1st day of March 2012.

David J. Kappos

David J. Kappos
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PATENT OF

Cottens, Sylvain et al.

U.S. PATENT NO: 5665772

ISSUED: September 09, 1997

FOR: O-ALKYLATED RAPAMYCIN DERIVATIVES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Request for Certificate of Correction under 37 CFR § 1.322

Sir:

Pursuant to 37 CFR 1.322, it is hereby respectfully requested that a Certificate of Correction be issued for United States Patent 5665772 containing the corrections set forth on the appended Form PTO 1050.

The structural formula presented in claim 1 depicts a bond between C3 and C35 and no such bond was intended and is an error in printing. The claimed formula has a methyl group bound to the C35 position.

The error is believed to be attributable to the Patent and Trademark Office as is evident from the following table:

<u>Location and/or Error in Printed Patent</u>	<u>Location of Support in Specification or Amendment</u>
Claim 1, lines 15-30, formula.	<p>On page 3, last line of the application, and in claim 10 as corrected by the certificate of correction, the compound name for everolimus (40-O-(2-hydroxyethyl)-rapamycin) is set forth which is the formula in claim 1 wherein R₁ is hydroxyl(C₁₋₆)alkyl and there is no bond between C3 and C35 in everolimus.</p> <p>Additionally, the structures on page 2 of the application, and in application claim 10 of the October 15, 1996 Amendment, which issued as claim 1, shows that there is no bond between C3 and C35.</p>

Attached is a duplicate of Form PTO 1050, with at least one copy being suitable for printing.

Since the above error is not ascribable to the patentee, no fee is believed to be necessitated by this Request for Certificate of Correction. However, in the event that a fee is required, the Commissioner is hereby authorized to charge said fee to Deposit Account No. 19-0134 in the name of Novartis

Please send the Certificate of Correction to the address currently associated with Customer No. 001095, viz:

Novartis Pharmaceuticals Corporation
 One Health Plaza, Bldg. 433
 East Hanover, NJ 07936

Respectfully submitted,

/Gregory Ferraro/

Gregory Ferraro
 Attorney for Applicant
 Reg. No. 36,134

Novartis Pharmaceuticals Corporation
 One Health Plaza, Bldg. 101
 East Hanover, NJ 07936
 +18627787831

Date: August 25, 2014


Encis.: Form PTO1050 (2)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 5665772
DATED: : September 09, 1997
INVENTOR(S) : Cottens, Sylvain et al.

It is certified that there is/are an error(s) in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 1, lines 15-30, delete the formula and replace it with



MAILING ADDRESS OF SENDER:
Gregory Ferraro
Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
+18627787831

PATENT NO. 5665772


Form PTO-1050

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 5665772
DATED : September 09, 1997
INVENTOR(S) : Cottens, Sylvain et al.

It is certified that there is/are an error(s) in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 1, lines 15-30, delete the formula and replace it with



MAILING ADDRESS OF SENDER:
Gregory Ferraro
Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
+18627787831

PATENT NO. 5665772

Form PTO-1080

Electronic Acknowledgement Receipt

EFS ID:	19967698
Application Number:	08416673
International Application Number:	
Confirmation Number:	9777
Title of Invention:	O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS
First Named Inventor/Applicant Name:	SYLVAIN COTTENS
Customer Number:	1095
Filer:	Gregory David Ferraro./Cindy Klepacky
Filer Authorized By:	Gregory David Ferraro.
Attorney Docket Number:	100-7932
Receipt Date:	26-AUG-2014
Filing Date:	07-APR-1995
Time Stamp:	14:36:09
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Certificate of Correction	PAT100_7932_US_PCT_Certificate_Correction.pdf	637113 <small>9fbed054c4dc3a044c3e571db8cc437c26c21363</small>	no	4

Warnings:

Information:

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

AO 120 (Rev. 08/10)

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	---

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court _____ for the District of Delaware _____ on the following

Trademarks or Patents. (the patent action involves 35 U.S.C. § 292.):

DOCKET NO.	DATE FILED 9/16/2014	U.S. DISTRICT COURT for the District of Delaware
PLAINTIFF NOVARTIS PHARMACEUTICALS CORPORATION and NOVARTIS AG		DEFENDANT ROXANE LABORATORIES, INC. and BOEHRINGER INGELHEIM ROXANE, INC.
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 5,665,772	September 9, 1997	Novartis AG
2 6,004,973	December 21, 1999	Novartis AG
3 6,239,124	May 29, 2001	Novartis AG
4 6,455,518	September 24, 2002	Novartis AG
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading		
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK	
1			
2			
3			
4			
5			

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK	(BY) DEPUTY CLERK	DATE
-------	-------------------	------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

AO 120 (Rev. 08/10)

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	--

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court _____ for the District of Delaware _____ on the following
 Trademarks or Patents. (the patent action involves 35 U.S.C. § 292.);

DOCKET NO.	DATE FILED 10/10/2014	U.S. DISTRICT COURT for the District of Delaware
PLAINTIFF NOVARTIS PHARMACEUTICALS CORPORATION and NOVARTIS AG		DEFENDANT PAR PHARMACEUTICAL, INC.
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 5,665,772	September 9, 1997	Novartis AG
2 6,004,973	December 21, 1999	Novartis AG
3 6,455,518	September 24, 2002	Novartis AG
4		
5		

In the above--entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above--entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK	(BY) DEPUTY CLERK	DATE
-------	-------------------	------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
 Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

AO 120 (Rev. 08/10)

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	--

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court FOR THE SOUTHERN DISTRICT OF OHIO on the following

Trademarks or Patents. (the patent action involves 35 U.S.C. § 292.):

DOCKET NO. 2:14-cv-1602	DATE FILED 9/17/2014	U.S. DISTRICT COURT FOR THE SOUTHERN DISTRICT OF OHIO
PLAINTIFF NOVARTIS PHARMACEUTICALS CORPORATION and NOVARTIS AG		DEFENDANT ROXANE LABORATORIES, INC. and BOEHRINGER INGELHEIM ROXANE, INC.
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 5,665,772	9/9/1997	NOVARTIS AG
2 6,004,973	12/21/1999	NOVARTIS AG
3 6,239,124	5/29/2001	NOVARTIS AG
4 6,455,518	9/24/2002	NOVARTIS AG
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading		
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK	
1			
2			
3			
4			
5			

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK	(BY) DEPUTY CLERK	DATE
-------	-------------------	------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
 Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

AO 120 (Rev. 08/10)

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	---

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court **FOR THE SOUTHERN DISTRICT OF OHIO** on the following

Trademarks or Patents. (the patent action involves 35 U.S.C. § 292.):

DOCKET NO. 2:14-cv-1602	DATE FILED 9/17/2014	U.S. DISTRICT COURT FOR THE SOUTHERN DISTRICT OF OHIO
PLAINTIFF NOVARTIS PHARMACEUTICALS CORPORATION and NOVARTIS AG		DEFENDANT ROXANE LABORATORIES, INC. and BOEHRINGER INGELHEIM ROXANE, INC.
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 5,665,772	9/9/1997	NOVARTIS AG
2 6,004,973	12/21/1999	NOVARTIS AG
3 6,239,124	5/29/2001	NOVARTIS AG
4 6,455,518	9/24/2002	NOVARTIS AG
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

The motion to dismiss is hereby GRANTED. This action is hereby DISMISSED WITHOUT PREJUDICE pursuant to Rule 41(a)(2).

CLERK John P. Hehman	(BY) DEPUTY CLERK <i>Kristen Keppeler</i>	DATE 11/7/2014
-------------------------	--	-------------------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
 Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

**IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF OHIO
EASTERN DIVISION**

<hr/>)
NOVARTIS PHARMACEUTICALS))
CORPORATION and NOVARTIS AG,)	Case No. 2:14-cv-1602-GLF
))
Plaintiffs,)	Judge Frost
))
v.)	Magistrate Judge Deavers
))
ROXANE LABORATORIES, INC. and))
BOEHRINGER INGELHEIM ROXANE,))
INC.,))
))
Defendants.))
<hr/>)

ORDER OF DISMISSAL WITHOUT PREJUDICE

This matter is before the Court on the Plaintiffs' Notice and Motion for Order of Dismissal Without Prejudice Under Federal Rule of Civil Procedure 41(a)(2).

The motion is hereby GRANTED. This action is hereby DISMISSED WITHOUT PREJUDICE pursuant to Rule 41(a)(2).



Gregory L. Frost
United States District Court Judge

AO 120 (Rev. 08/10)

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	---

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court _____ for the District of Delaware _____ on the following
 Trademarks or Patents. (the patent action involves 35 U.S.C. § 292.):

DOCKET NO.	DATE FILED 12/18/2014	U.S. DISTRICT COURT for the District of Delaware
PLAINTIFF NOVARTIS PHARMACEUTICALS CORPORATION and NOVARTIS AG		DEFENDANT PAR PHARMACEUTICAL, INC.
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 5,665,772	September 9, 1997	Novartis AG
2 7,297,703	November 20, 2007	Novartis AG
3 7,741,338	June 22, 2010	Novartis AG
4		
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading		
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK	
1			
2			
3			
4			
5			

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK	(BY) DEPUTY CLERK	DATE
-------	-------------------	------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
 Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PATENT OF
Cottens, Sylvain et al.
U.S. PATENT NO: 5665772
ISSUED: September 09, 1997
FOR: O-ALKYLATED RAPAMYCIN DERIVATIVES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Request for Certificate of Correction under 37 CFR § 1.322

Sir:

Pursuant to 37 CFR 1.322, it is hereby respectfully requested that a Certificate of Correction be issued for United States Patent 5665772 containing the correction set forth on the appended Form PTO 1050.

The error is believed to be attributable to Applicants. The mistake is of a clerical, typographical nature and does not involve changes which would constitute new matter or require reexamination. In claim 9, line 27 contains a typographical error wherein the word "allograft" is misspelled as "allograph."

Attached is a duplicate of Form PTO 1050, with at least one copy being suitable for printing.

Since the above error is ascribable to the patentee, please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$100 for payment of the fee required by 37 C.F.R. § 1.20.

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge the above mentioned \$100 fee and any additional fees which may be required to Deposit Account No. 19-0134 in the name of Novartis.

Please send the Certificate of Correction to the address currently associated with Customer
No. 001095, viz:

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 433
East Hanover, NJ 07936

Respectfully submitted,

/Gregory Ferraro/

Gregory Ferraro
Attorney for Applicant
Reg. No. 36,134

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
+18627787831

Date: March 11, 2015

Encls.: Form PTO1050 (2)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 5665772
DATED: : September 09, 1997
INVENTOR(S) : Cottens, Sylvain, et al.

It is certified that there is/are an error(s) in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 9, line 27, "allograph" should be changed to --allograft--.

MAILING ADDRESS OF SENDER: PATENT NO. 5665772
Gregory Ferraro
Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
+18627787831

FORM PTO-1050

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 5665772
DATED: : September 09, 1997
INVENTOR(S) : Cottens, Sylvain, et al.

It is certified that there is/are an error(s) in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 9, line 27, "allograph" should be changed to --allograft--.

MAILING ADDRESS OF SENDER:
Gregory Ferraro
Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
+18627787831

PATENT NO. 5665772

FORM PTO-1050

Electronic Patent Application Fee Transmittal

Application Number:	08416673			
Filing Date:	07-Apr-1995			
Title of Invention:	O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS			
First Named Inventor/Applicant Name:	SYLVAIN COTTENS			
Filer:	Gregory David Ferraro./Cindy Klepacky			
Attorney Docket Number:	100-7932			
Filed as Large Entity				
Filing Fees for U.S. National Stage under 35 USC 371				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Certificate of Correction	1811	1	100	100

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				100

Electronic Acknowledgement Receipt

EFS ID:	21739648
Application Number:	08416673
International Application Number:	
Confirmation Number:	9777
Title of Invention:	O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS
First Named Inventor/Applicant Name:	SYLVAIN COTTENS
Customer Number:	1095
Filer:	Gregory David Ferraro./Cindy Klepacky
Filer Authorized By:	Gregory David Ferraro.
Attorney Docket Number:	100-7932
Receipt Date:	11-MAR-2015
Filing Date:	07-APR-1995
Time Stamp:	15:30:39
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$100
RAM confirmation Number	1788
Deposit Account	190134
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Certificate of Correction	PAT100_7932_US_PCT_2015_Mar11_Certificate_Correction.pdf	52014 0d9ed4c62fc65e0315a5aefcc9e4c8acdfaa31a	no	4

Warnings:

The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	30569 0bc02b67771339e248318b154c33d3aa57385af	no	2
---	----------------------	--------------	--	----	---

Warnings:

Information:

Total Files Size (in bytes):	82583
-------------------------------------	-------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

AO 120 (Rev. 08/10)

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	--

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court _____ for the District of Delaware _____ on the following
 Trademarks or Patents. (the patent action involves 35 U.S.C. § 292.):

DOCKET NO.	DATE FILED 1/23/2015	U.S. DISTRICT COURT for the District of Delaware
PLAINTIFF NOVARTIS PHARMACEUTICALS CORPORATION and NOVARTIS AG		DEFENDANT PAR PHARMACEUTICAL, INC.
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 5,665,772	September 9, 1997	Novartis AG
2 7,297,703	November 20, 2007	Novartis AG
3 7,741,338	June 22, 2010	Novartis AG
4		
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK	(BY) DEPUTY CLERK	DATE
-------	-------------------	------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
 Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,665,772
APPLICATION NO. : 08/416673
DATED : September 9, 1997
INVENTOR(S) : Cottens et al.


Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

Claim 9, line 27, "allograph" should be changed to --allograft--.

Signed and Sealed this
Second Day of June, 2015



Michelle K. Lee
Director of the United States Patent and Trademark Office